Famotidine	Chemical
-associated	O
delirium	Disease
.	O
A	O
series	O
of	O
six	O
cases.	O
Famotidine	Chemical
is	O
a	O
histamine	O
H2-receptor	O
antagonist	O
used	O
in	O
inpatient	O
settings	O
for	O
prevention	O
of	O
stress	O
ulcers	Disease
and	O
is	O
showing	O
increasing	O
popularity	O
because	O
of	O
its	O
low	O
cost.	O
Although	O
all	O
of	O
the	O
currently	O
available	O
H2-receptor	O
antagonists	O
have	O
shown	O
the	O
propensity	O
to	O
cause	O
delirium	Disease
,	O
only	O
two	O
previously	O
reported	O
cases	O
have	O
been	O
associated	O
with	O
famotidine	Chemical
.	O
The	O
authors	O
report	O
on	O
six	O
cases	O
of	O
famotidine	Chemical
-associated	O
delirium	Disease
in	O
hospitalized	O
patients	O
who	O
cleared	O
completely	O
upon	O
removal	O
of	O
famotidine	Chemical
.	O
The	O
pharmacokinetics	O
of	O
famotidine	Chemical
are	O
reviewed,	O
with	O
no	O
change	O
in	O
its	O
metabolism	O
in	O
the	O
elderly	O
population	O
seen.	O
The	O
implications	O
of	O
using	O
famotidine	Chemical


Indomethacin	Chemical
induced	O
hypotension	Disease
in	O
sodium	Chemical
and	O
volume	O
depleted	O
rats.	O
After	O
a	O
single	O
oral	O
dose	O
of	O
4	O
mg/kg	O
indomethacin	Chemical
(	O
IDM	Chemical
)	O
to	O
sodium	Chemical
and	O
volume	O
depleted	O
rats	O
plasma	O
renin	O
activity	O
(PRA)	O
and	O
systolic	O
blood	O
pressure	O
fell	O
significantly	O
within	O
four	O
hours.	O
In	O
sodium	Chemical
repleted	O
animals	O
indomethacin	Chemical
did	O
not	O
change	O
systolic	O
blood	O
pressure	O
(BP)	O
although	O
plasma	O
renin	O
activity	O
was	O
decreased.	O
Thus,	O
indomethacin	Chemical
by	O
inhibition	O
of	O
prostaglandin	Chemical
synthesis	O
may	O
diminish	O
the	O
blood	O
pressure	O
maintaining	O
effect	O
of	O
the	O
stimulated	O
renin-	O
angiotensin	Chemical
system	O
in	O
sodium	Chemical

Late-onset	O
scleroderma	Disease
renal	Disease
crisis	Disease
induced	O
by	O
tacrolimus	Chemical
and	O
prednisolone	Chemical
:	O
a	O
case	O
report.	O
Scleroderma	Disease
renal	Disease
crisis	Disease
(	O
SRC	Disease
)	O
is	O
a	O
rare	O
complication	O
of	O
systemic	Disease
sclerosis	Disease
(	O
SSc	Disease
)	O
but	O
can	O
be	O
severe	O
enough	O
to	O
require	O
temporary	O
or	O
permanent	O
renal	O
replacement	O
therapy.	O
Moderate	O
to	O
high	O
dose	O
corticosteroid	Chemical
use	O
is	O
recognized	O
as	O
a	O
major	O
risk	O
factor	O
for	O
SRC	Disease
.	O
Furthermore,	O
there	O
have	O
been	O
reports	O
of	O
thrombotic	Disease
microangiopathy	Disease
precipitated	O
by	O
cyclosporine	Chemical
in	O
patients	O
with	O
SSc	Disease
.	O
In	O
this	O
article,	O
we	O
report	O
a	O
patient	O
with	O
SRC	Disease
induced	O
by	O
tacrolimus	Chemical
and	O
corticosteroids	Chemical
.	O
The	O
aim	O
of	O
this	O
work	O
is	O
to	O
call	O
attention	O
to	O
the	O
risk	O
of	O
tacrolimus	Chemical
use	O
in	O
patients	O
with	O
SSc	Disease

The	O
risk	O
and	O
associated	O
factors	O
of	O
methamphetamine	Chemical
	O
psychosis	Disease
in	O
methamphetamine	Chemical
-dependent	O
patients	O
in	O
Malaysia.	O
OBJECTIVE:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
risk	O
of	O
lifetime	O
and	O
current	O
methamphetamine	Chemical
-induced	O
psychosis	Disease
in	O
patients	O
with	O
methamphetamine	Chemical
dependence.	O
The	O
association	O
between	O
psychiatric	O
co-morbidity	O
and	O
methamphetamine	Chemical
-induced	O
psychosis	Disease
was	O
also	O
studied.	O
METHODS:	O
This	O
was	O
a	O
cross-sectional	O
study	O
conducted	O
concurrently	O
at	O
a	O
teaching	O
hospital	O
and	O
a	O
drug	O
rehabilitation	O
center	O
in	O
Malaysia.	O
Patients	O
with	O
the	O
diagnosis	O
of	O
methamphetamine	Chemical
based	O
on	O
DSM-IV	O
were	O
interviewed	O
using	O
the	O
Mini	O
International	O
Neuropsychiatric	O
Interview	O
(M.I.N.I.)	O
for	O
methamphetamine	Chemical
-induced	O
psychosis	Disease
and	O
other	O
Axis	O
I	O
psychiatric	Disease
disorders	Disease
.	O
The	O
information	O
on	O
sociodemographic	O
background	O
and	O
drug	O
use	O
history	O
was	O
obtained	O
from	O
interview	O
or	O
medical	O
records.	O
RESULTS:	O
Of	O
292	O
subjects,	O
47.9%	O
of	O
the	O
subjects	O
had	O
a	O
past	O
history	O
of	O
psychotic	Disease
symptoms	Disease
and	O
13.0%	O
of	O
the	O
patients	O
were	O
having	O
current	O
psychotic	Disease
symptoms	Disease
.	O
Co-morbid	O
major	O
depressive	Disease
disorder	Disease
(OR=7.18,	O
95	O
CI=2.612-19.708),	O
bipolar	Disease
disorder	Disease
(OR=13.807,	O
95	O
CI=5.194-36.706),	O
antisocial	Disease
personality	Disease
disorder	Disease
(OR=12.619,	O
95	O
CI=6.702-23.759)	O
and	O
heavy	O
methamphetamine	Chemical
uses	O
were	O
significantly	O
associated	O
with	O
lifetime	O
methamphetamine	Chemical
-induced	O
psychosis	Disease
after	O
adjusted	O
for	O
other	O
factors.	O
Major	Disease
depressive	Disease
disorder	Disease
(OR=2.870,	O
CI=1.154-7.142)	O
and	O
antisocial	Disease
personality	Disease
disorder	Disease
(OR=3.299,	O
95	O
CI=1.375-7.914)	O
were	O
the	O
only	O
factors	O
associated	O
with	O
current	O
psychosis	Disease
.	O
CONCLUSION:	O
There	O
was	O
a	O
high	O
risk	O
of	O
psychosis	Disease
in	O
patients	O
with	O
methamphetamine	Chemical
dependence.	O
It	O
was	O
associated	O
with	O
co-morbid	O
affective	Disease
disorder	Disease
,	O
antisocial	Disease
personality	Disease
,	O
and	O
heavy	O
methamphetamine	Chemical
use.	O
It	O
is	O
recommended	O
that	O
all	O
cases	O
of	O
methamphetamine	Chemical
dependence	O
should	O
be	O
screened	O
for	O
psychotic	Disease
symptoms	Disease

Cerebellar	O
sensory	O
processing	O
alterations	O
impact	O
motor	O
cortical	O
plasticity	O
in	O
Parkinson's	Disease
disease	Disease
:	O
clues	O
from	O
dyskinetic	Disease
patients.	O
The	O
plasticity	O
of	O
primary	O
motor	O
cortex	O
(M1)	O
in	O
patients	O
with	O
Parkinson's	Disease
disease	Disease
(	O
PD	Disease
)	O
and	O
levodopa	Chemical
-induced	O
dyskinesias	Disease
(	O
LIDs	Disease
)	O
is	O
severely	O
impaired.	O
We	O
recently	O
reported	O
in	O
young	O
healthy	O
subjects	O
that	O
inhibitory	O
cerebellar	O
stimulation	O
enhanced	O
the	O
sensorimotor	O
plasticity	O
of	O
M1	O
that	O
was	O
induced	O
by	O
paired	O
associative	O
stimulation	O
(PAS).	O
This	O
study	O
demonstrates	O
that	O
the	O
deficient	O
sensorimotor	O
M1	O
plasticity	O
in	O
16	O
patients	O
with	O
LIDs	Disease
could	O
be	O
reinstated	O
by	O
a	O
single	O
session	O
of	O
real	O
inhibitory	O
cerebellar	O
stimulation	O
but	O
not	O
sham	O
stimulation.	O
This	O
was	O
evident	O
only	O
when	O
a	O
sensory	O
component	O
was	O
involved	O
in	O
the	O
induction	O
of	O
plasticity,	O
indicating	O
that	O
cerebellar	O
sensory	O
processing	O
function	O
is	O
involved	O
in	O
the	O
resurgence	O
of	O
M1	O
plasticity.	O
The	O
benefit	O
of	O
inhibitory	O
cerebellar	O
stimulation	O
on	O
LIDs	Disease
is	O
known.	O
To	O
explore	O
whether	O
this	O
benefit	O
is	O
linked	O
to	O
the	O
restoration	O
of	O
sensorimotor	O
plasticity	O
of	O
M1,	O
we	O
conducted	O
an	O
additional	O
study	O
looking	O
at	O
changes	O
in	O
LIDs	Disease
and	O
PAS-induced	O
plasticity	O
after	O
10	O
sessions	O
of	O
either	O
bilateral,	O
real	O
inhibitory	O
cerebellar	O
stimulation	O
or	O
sham	O
stimulation.	O
Only	O
real	O
and	O
not	O
sham	O
stimulation	O
had	O
an	O
antidyskinetic	O
effect	O
and	O
it	O
was	O
paralleled	O
by	O
a	O
resurgence	O
in	O
the	O
sensorimotor	O
plasticity	O
of	O
M1.	O
These	O
results	O
suggest	O
that	O
alterations	O
in	O
cerebellar	O
sensory	O
processing	O
function,	O
occurring	O
secondary	O
to	O
abnormal	O
basal	O
ganglia	O
signals	O
reaching	O
it,	O
may	O
be	O
an	O
important	O
element	O
contributing	O
to	O
the	O
maladaptive	O
sensorimotor	O
plasticity	O
of	O
M1	O
and	O
the	O
emergence	O
of	O
abnormal	Disease
involuntary	Disease
movements	Disease

The	O
function	O
of	O
P2X3	O
receptor	O
and	O
NK1	O
receptor	O
antagonists	O
on	O
cyclophosphamide	Chemical
-induced	O
cystitis	Disease
in	O
rats.	O
PURPOSE:	O
The	O
purpose	O
of	O
the	O
study	O
is	O
to	O
explore	O
the	O
function	O
of	O
P2X3	O
and	O
NK1	O
receptors	O
antagonists	O
on	O
cyclophosphamide	Chemical
(	O
CYP	Chemical
)-induced	O
cystitis	Disease
in	O
rats.	O
METHODS:	O
Sixty	O
female	O
Sprague-Dawley	O
(SD)	O
rats	O
were	O
randomly	O
divided	O
into	O
three	O
groups.	O
The	O
rats	O
in	O
the	O
control	O
group	O
were	O
intraperitoneally	O
(i.p.)	O
injected	O
with	O
0.9%	O
saline	O
(4	O
ml/kg);	O
the	O
rats	O
in	O
the	O
model	O
group	O
were	O
i.p.	O
injected	O
with	O
CYP	Chemical
(150	O
mg/kg);	O
and	O
the	O
rats	O
in	O
the	O
intervention	O
group	O
were	O
i.p.	O
injected	O
with	O
CYP	Chemical
with	O
subsequently	O
perfusion	O
of	O
bladder	O
with	O
P2X3	O
and	O
NK1	O
receptors'	O
antagonists,	O
Suramin	Chemical
and	O
GR	Chemical
82334	Chemical
.	O
Spontaneous	O
pain	Disease
behaviors	O
following	O
the	O
administration	O
of	O
CYP	Chemical
were	O
observed.	O
Urodynamic	O
parameters,	O
bladder	O
pressure-volume	O
curve,	O
maximum	O
voiding	O
pressure	O
(MVP),	O
and	O
maximum	O
cystometric	O
capacity	O
(MCC),	O
were	O
recorded.	O
Pathological	O
changes	O
in	O
bladder	O
tissue	O
were	O
observed.	O
Immunofluorescence	O
was	O
used	O
to	O
detect	O
the	O
expression	O
of	O
P2X3	O
and	O
NK1	O
receptors	O
in	O
bladder.	O
RESULTS:	O
Cyclophosphamide	Chemical
treatment	O
increased	O
the	O
spontaneous	O
pain	Disease
behaviors	O
scores.	O
The	O
incidence	O
of	O
bladder	O
instability	O
during	O
urine	O
storage	O
period	O
of	O
model	O
group	O
was	O
significantly	O
higher	O
than	O
intervention	O
group	O
(X(2)	O
=	O
7.619,	O
P	O
=	O
0.007)	O
and	O
control	O
group	O
(X(2)	O
=	O
13.755,	O
P	O
=	O
0.000).	O
MCC	O
in	O
the	O
model	O
group	O
was	O
lower	O
than	O
the	O
control	O
and	O
intervention	O
groups	O
(P	O
<	O
0.01).	O
Histological	O
changes	O
evident	O
in	O
model	O
and	O
intervention	O
groups	O
rats'	O
bladder	O
included	O
edema	Disease
,	O
vasodilation,	O
and	O
infiltration	O
of	O
inflammatory	O
cells.	O
In	O
model	O
group,	O
the	O
expression	O
of	O
P2X3	O
receptor	O
increased	O
in	O
urothelium	O
and	O
suburothelium,	O
and	O
NK1	O
receptor	O
increased	O
in	O
suburothelium,	O
while	O
the	O
expression	O
of	O
them	O
in	O
intervention	O
group	O
was	O
lower.	O
CONCLUSIONS:	O
In	O
CYP	Chemical
-induced	O
cystitis	Disease

Acute	O
hepatitis	Disease
associated	O
with	O
clopidogrel	Chemical
:	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature.	O
Drug-induced	O
hepatotoxicity	Disease
is	O
a	O
common	O
cause	O
of	O
acute	O
hepatitis	Disease
,	O
and	O
the	O
recognition	O
of	O
the	O
responsible	O
drug	O
may	O
be	O
difficult.	O
We	O
describe	O
a	O
case	O
of	O
clopidogrel	Chemical
-related	O
acute	O
hepatitis	Disease
.	O
The	O
diagnosis	O
is	O
strongly	O
suggested	O
by	O
an	O
accurate	O
medical	O
history	O
and	O
liver	O
biopsy.	O
Reports	O
about	O
cases	O
of	O
hepatotoxicity	Disease
due	O
to	O
clopidogrel	Chemical
are	O
increasing	O
in	O
the	O
last	O
few	O
years,	O
after	O
the	O
increased	O
use	O
of	O
this	O
drug.	O
In	O
conclusion,	O
we	O
believe	O
that	O
physicians	O
should	O
carefully	O
consider	O
the	O
risk	O
of	O
drug-induced	O
hepatic	Disease
injury	Disease
when	O
clopidogrel	Chemical

Bortezomib	Chemical
and	O
dexamethasone	Chemical
as	O
salvage	O
therapy	O
in	O
patients	O
with	O
relapsed/refractory	O
multiple	Disease
myeloma	Disease
:	O
analysis	O
of	O
long-term	O
clinical	O
outcomes.	O
Bortezomib	Chemical
(	O
bort	Chemical
)-	O
dexamethasone	Chemical
(	O
dex	Chemical
)	O
is	O
an	O
effective	O
therapy	O
for	O
relapsed/refractory	O
(R/R)	O
multiple	Disease
myeloma	Disease
(	O
MM	Disease
).	O
This	O
retrospective	O
study	O
investigated	O
the	O
combination	O
of	O
bort	Chemical
(1.3	O
mg/m(2)	O
on	O
days	O
1,	O
4,	O
8,	O
and	O
11	O
every	O
3	O
weeks)	O
and	O
dex	Chemical
(20	O
mg	O
on	O
the	O
day	O
of	O
and	O
the	O
day	O
after	O
bort	Chemical
)	O
as	O
salvage	O
treatment	O
in	O
85	O
patients	O
with	O
R/R	O
MM	Disease
after	O
prior	O
autologous	O
stem	O
cell	O
transplantation	O
or	O
conventional	O
chemotherapy.	O
The	O
median	O
number	O
of	O
prior	O
lines	O
of	O
therapy	O
was	O
2.	O
Eighty-seven	O
percent	O
of	O
the	O
patients	O
had	O
received	O
immunomodulatory	O
drugs	O
included	O
in	O
some	O
line	O
of	O
therapy	O
before	O
bort	Chemical
-	O
dex	Chemical
.	O
The	O
median	O
number	O
of	O
bort	Chemical
-	O
dex	Chemical
cycles	O
was	O
6,	O
up	O
to	O
a	O
maximum	O
of	O
12	O
cycles.	O
On	O
an	O
intention-to-treat	O
basis,	O
55	O
%	O
of	O
the	O
patients	O
achieved	O
at	O
least	O
partial	O
response,	O
including	O
19	O
%	O
CR	O
and	O
35	O
%	O
achieved	O
at	O
least	O
very	O
good	O
partial	O
response.	O
Median	O
durations	O
of	O
response,	O
time	O
to	O
next	O
therapy	O
and	O
treatment-free	O
interval	O
were	O
8,	O
11.2,	O
and	O
5.1	O
months,	O
respectively.	O
The	O
most	O
relevant	O
adverse	O
event	O
was	O
peripheral	Disease
neuropathy	Disease
,	O
which	O
occurred	O
in	O
78	O
%	O
of	O
the	O
patients	O
(grade	O
II,	O
38	O
%;	O
grade	O
III,	O
21	O
%)	O
and	O
led	O
to	O
treatment	O
discontinuation	O
in	O
6	O
%.	O
With	O
a	O
median	O
follow	O
up	O
of	O
22	O
months,	O
median	O
time	O
to	O
progression,	O
progression-free	O
survival	O
(PFS)	O
and	O
overall	O
survival	O
(OS)	O
were	O
8.9,	O
8.7,	O
and	O
22	O
months,	O
respectively.	O
Prolonged	O
PFS	O
and	O
OS	O
were	O
observed	O
in	O
patients	O
achieving	O
CR	O
and	O
receiving	O
bort	Chemical
-	O
dex	Chemical
a	O
single	O
line	O
of	O
prior	O
therapy.	O
Bort	Chemical
-	O
dex	Chemical
was	O
an	O
effective	O
salvage	O
treatment	O
for	O
MM	Disease

Pubertal	O
exposure	O
to	O
Bisphenol	Chemical
A	Chemical
increases	O
anxiety	Disease
-like	O
behavior	O
and	O
decreases	O
acetylcholinesterase	O
activity	O
of	O
hippocampus	O
in	O
adult	O
male	O
mice.	O
The	O
negative	O
effects	O
of	O
Bisphenol	Chemical
A	Chemical
(	O
BPA	Chemical
)	O
on	O
neurodevelopment	O
and	O
behaviors	O
have	O
been	O
well	O
established.	O
Acetylcholinesterase	O
(AChE)	O
is	O
a	O
regulatory	O
enzyme	O
which	O
is	O
involved	O
in	O
anxiety	Disease
-like	O
behavior.	O
This	O
study	O
investigated	O
behavioral	O
phenotypes	O
and	O
AChE	O
activity	O
in	O
male	O
mice	O
following	O
BPA	Chemical
exposure	O
during	O
puberty.	O
On	O
postnatal	O
day	O
(PND)	O
35,	O
male	O
mice	O
were	O
exposed	O
to	O
50mg	O
BPA	Chemical
/kg	O
diet	O
per	O
day	O
for	O
a	O
period	O
of	O
35	O
days.	O
On	O
PND71,	O
a	O
behavioral	O
assay	O
was	O
performed	O
using	O
the	O
elevated	O
plus	O
maze	O
(EPM)	O
and	O
the	O
light/dark	O
test.	O
In	O
addition,	O
AChE	O
activity	O
was	O
measured	O
in	O
the	O
prefrontal	O
cortex,	O
hypothalamus,	O
cerebellum	O
and	O
hippocampus.	O
Results	O
from	O
our	O
behavioral	O
phenotyping	O
indicated	O
that	O
anxiety	Disease
-like	O
behavior	O
was	O
increased	O
in	O
mice	O
exposed	O
to	O
BPA	Chemical
.	O
AChE	O
activity	O
was	O
significantly	O
decreased	O
in	O
the	O
hippocampus	O
of	O
mice	O
with	O
BPA	Chemical
compared	O
to	O
control	O
mice,	O
whereas	O
no	O
difference	O
was	O
found	O
in	O
the	O
prefrontal	O
cortex,	O
hypothalamus	O
and	O
cerebellum.	O
Our	O
findings	O
showed	O
that	O
pubertal	O
BPA	Chemical
exposure	O
increased	O
anxiety	Disease
-like	O
behavior,	O
which	O
may	O
be	O
associated	O
with	O
decreased	O
AChE	O
activity	O
of	O
the	O
hippocampus	O
in	O
adult	O
male	O
mice.	O
Further	O
studies	O
are	O
necessary	O
to	O
investigate	O
the	O
cholinergic	O
signaling	O
of	O
the	O
hippocampus	O
in	O
PBE	O
induced	O
anxiety	Disease

Biochemical	O
effects	O
of	O
Solidago	O
virgaurea	O
extract	O
on	O
experimental	O
cardiotoxicity	Disease
.	O
Cardiovascular	Disease
diseases	Disease
(	O
CVDs	Disease
)	O
are	O
the	O
major	O
health	O
problem	O
of	O
advanced	O
as	O
well	O
as	O
developing	O
countries	O
of	O
the	O
world.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
protective	O
effect	O
of	O
the	O
Solidago	O
virgaurea	O
extract	O
on	O
isoproterenol	Chemical
-induced	O
cardiotoxicity	Disease
in	O
rats.	O
The	O
subcutaneous	O
injection	O
of	O
isoproterenol	Chemical
(30	O
mg/kg)	O
into	O
rats	O
twice	O
at	O
an	O
interval	O
of	O
24	O
h,	O
for	O
two	O
consecutive	O
days,	O
led	O
to	O
a	O
significant	O
increase	O
in	O
serum	O
lactate	Chemical
dehydrogenase,	O
creatine	Chemical
phosphokinase,	O
alanine	Chemical
transaminase,	O
aspartate	Chemical
transaminase,	O
and	O
angiotensin	Chemical
-converting	O
enzyme	O
activities,	O
total	O
cholesterol	Chemical
,	O
triglycerides	Chemical
,	O
free	O
serum	O
fatty	Chemical
acid	Chemical
,	O
cardiac	O
tissue	O
malondialdehyde	Chemical
(	O
MDA	Chemical
),	O
and	O
nitric	Chemical
oxide	Chemical
levels	O
and	O
a	O
significant	O
decrease	O
in	O
levels	O
of	O
glutathione	Chemical
and	O
superoxide	Chemical
dismutase	O
in	O
cardiac	O
tissue	O
as	O
compared	O
to	O
the	O
normal	O
control	O
group	O
(P	O
<	O
0.05).	O
Pretreatment	O
with	O
S.	O
virgaurea	O
extract	O
for	O
5	O
weeks	O
at	O
a	O
dose	O
of	O
250	O
mg/kg	O
followed	O
by	O
isoproterenol	Chemical
injection	O
significantly	O
prevented	O
the	O
observed	O
alterations.	O
Captopril	Chemical
(50	O
mg/kg/day,	O
given	O
orally),	O
an	O
inhibitor	O
of	O
angiotensin	Chemical
-converting	O
enzyme	O
used	O
as	O
a	O
standard	O
cardioprotective	O
drug,	O
was	O
used	O
as	O
a	O
positive	O
control	O
in	O
this	O
study.	O
The	O
data	O
of	O
the	O
present	O
study	O
suggest	O
that	O
S.	O
virgaurea	O
extract	O
exerts	O
its	O
protective	O
effect	O
by	O
decreasing	O
MDA	Chemical
level	O
and	O
increasing	O
the	O
antioxidant	O
status	O
in	O
isoproterenol	Chemical

"Real-world"	O
data	O
on	O
the	O
efficacy	O
and	O
safety	O
of	O
lenalidomide	Chemical
and	O
dexamethasone	Chemical
in	O
patients	O
with	O
relapsed/refractory	O
multiple	Disease
myeloma	Disease
who	O
were	O
treated	O
according	O
to	O
the	O
standard	O
clinical	O
practice:	O
a	O
study	O
of	O
the	O
Greek	O
Myeloma	Disease
Study	O
Group.	O
Lenalidomide	Chemical
and	O
dexamethasone	Chemical
(	O
RD	Chemical
)	O
is	O
a	O
standard	O
of	O
care	O
for	O
relapsed/refractory	O
multiple	Disease
myeloma	Disease
(	O
RRMM	Disease
),	O
but	O
there	O
is	O
limited	O
published	O
data	O
on	O
its	O
efficacy	O
and	O
safety	O
in	O
the	O
"real	O
world"	O
(RW),	O
according	O
to	O
the	O
International	O
Society	O
of	O
Pharmacoeconomics	O
and	O
Outcomes	O
Research	O
definition.	O
We	O
studied	O
212	O
RRMM	Disease
patients	O
who	O
received	O
RD	Chemical
in	O
RW.	O
Objective	O
response	O
(>PR	O
(partial	O
response))	O
rate	O
was	O
77.4	O
%	O
(complete	O
response	O
(CR),	O
20.2	O
%).	O
Median	O
time	O
to	O
first	O
and	O
best	O
response	O
was	O
2	O
and	O
5	O
months,	O
respectively.	O
Median	O
time	O
to	O
CR	O
when	O
RD	Chemical
was	O
given	O
as	O
2nd	O
or	O
>2(nd)-line	O
treatment	O
at	O
4	O
and	O
11	O
months,	O
respectively.	O
Quality	O
of	O
response	O
was	O
independent	O
of	O
previous	O
lines	O
of	O
therapies	O
or	O
previous	O
exposure	O
to	O
thalidomide	Chemical
or	O
bortezomib	Chemical
.	O
Median	O
duration	O
of	O
response	O
was	O
34.4	O
months,	O
and	O
it	O
was	O
higher	O
in	O
patients	O
who	O
received	O
RD	Chemical
until	O
progression	O
(not	O
reached	O
versus	O
19	O
months,	O
p	O
<	O
0.001).	O
Improvement	O
of	O
humoral	O
immunity	O
occurred	O
in	O
60	O
%	O
of	O
responders	O
(p	O
<	O
0.001)	O
and	O
in	O
the	O
majority	O
of	O
patients	O
who	O
achieved	O
stable	O
disease.	O
Adverse	O
events	O
were	O
reported	O
in	O
68.9	O
%	O
of	O
patients	O
(	O
myelosuppression	Disease
in	O
49.4	O
%)	O
and	O
12.7	O
%	O
of	O
patients	O
needed	O
hospitalization.	O
Peripheral	Disease
neuropathy	Disease
was	O
observed	O
only	O
in	O
2.5	O
%	O
of	O
patients	O
and	O
deep	Disease
vein	Disease
thrombosis	Disease
in	O
5.7	O
%.	O
Dose	O
reductions	O
were	O
needed	O
in	O
31	O
%	O
of	O
patients	O
and	O
permanent	O
discontinuation	O
in	O
38.9	O
%.	O
Median	O
time	O
to	O
treatment	O
discontinuation	O
was	O
16.8	O
months.	O
Performance	O
status	O
(PS)	O
and	O
initial	O
lenalidomide	Chemical
dose	O
predicted	O
for	O
treatment	O
discontinuation.	O
Extra-medullary	O
relapses	O
occurred	O
in	O
3.8	O
%	O
of	O
patients.	O
Our	O
study	O
confirms	O
that	O
RD	Chemical
is	O
effective	O
and	O
safe	O
in	O
RRMM	Disease

The	O
cytogenetic	O
action	O
of	O
ifosfamide	Chemical
,	O
mesna	Chemical
,	O
and	O
their	O
combination	O
on	O
peripheral	O
rabbit	O
lymphocytes:	O
an	O
in	O
vivo/in	O
vitro	O
cytogenetic	O
study.	O
Ifosfamide	Chemical
(	O
IFO	Chemical
)	O
is	O
an	O
alkylating	O
nitrogen	Chemical
mustard,	O
administrated	O
as	O
an	O
antineoplasmic	O
agent.	O
It	O
is	O
characterized	O
by	O
its	O
intense	O
urotoxic	O
action,	O
leading	O
to	O
hemorrhagic	Disease
cystitis	Disease
.	O
This	O
side	O
effect	O
of	O
IFO	Chemical
raises	O
the	O
requirement	O
for	O
the	O
co-administration	O
with	O
sodium	Chemical
2-sulfanylethanesulfonate	Chemical
(	O
Mesna	Chemical
)	O
aiming	O
to	O
avoid	O
or	O
minimize	O
this	O
effect.	O
IFO	Chemical
and	O
Mesna	Chemical
were	O
administrated	O
separately	O
on	O
rabbit's	O
lymphocytes	O
in	O
vivo,	O
which	O
were	O
later	O
developed	O
in	O
vitro.	O
Cytogenetic	O
markers	O
for	O
sister	O
chromatid	O
exchanges	O
(SCEs),	O
proliferation	O
rate	O
index	O
(PRI)	O
and	O
Mitotic	O
Index	O
were	O
recorded.	O
Mesna	Chemical
's	O
action,	O
in	O
conjunction	O
with	O
IFO	Chemical
reduces	O
the	O
frequency	O
of	O
SCEs,	O
in	O
comparison	O
with	O
the	O
SCEs	O
recordings	O
obtained	O
when	O
IFO	Chemical
is	O
administered	O
alone.	O
In	O
addition	O
to	O
this,	O
when	O
high	O
concentrations	O
of	O
Mesna	Chemical
were	O
administered	O
alone	O
significant	O
reductions	O
of	O
the	O
PRI	O
were	O
noted,	O
than	O
with	O
IFO	Chemical
acting	O
at	O
the	O
same	O
concentration	O
on	O
the	O
lymphocytes.	O
Mesna	Chemical
significantly	O
reduces	O
IFO	Chemical
's	O
genotoxicity	Disease

Risk	O
factors	O
and	O
predictors	O
of	O
levodopa	Chemical
-induced	O
dyskinesia	Disease
among	O
multiethnic	O
Malaysians	O
with	O
Parkinson's	Disease
disease	Disease
.	O
Chronic	O
pulsatile	O
levodopa	Chemical
therapy	O
for	O
Parkinson's	Disease
disease	Disease
(	O
PD	Disease
)	O
leads	O
to	O
the	O
development	O
of	O
motor	O
fluctuations	O
and	O
dyskinesia	Disease
.	O
We	O
studied	O
the	O
prevalence	O
and	O
predictors	O
of	O
levodopa	Chemical
-induced	O
dyskinesia	Disease
among	O
multiethnic	O
Malaysian	O
patients	O
with	O
PD	Disease
.	O
METHODS:	O
This	O
is	O
a	O
cross-sectional	O
study	O
involving	O
95	O
patients	O
with	O
PD	Disease
on	O
uninterrupted	O
levodopa	Chemical
therapy	O
for	O
at	O
least	O
6	O
months.	O
The	O
instrument	O
used	O
was	O
the	O
UPDRS	O
questionnaires.	O
The	O
predictors	O
of	O
dyskinesia	Disease
were	O
determined	O
using	O
multivariate	O
logistic	O
regression	O
analysis.	O
RESULTS:	O
The	O
mean	O
age	O
was	O
65.6	O
+	O
8.5	O
years.	O
The	O
mean	O
onset	O
age	O
was	O
58.5	O
+	O
9.8	O
years.	O
The	O
median	O
disease	O
duration	O
was	O
6	O
(7)	O
years.	O
Dyskinesia	Disease
was	O
present	O
in	O
44%	O
(n	O
=	O
42)	O
with	O
median	O
levodopa	Chemical
therapy	O
of	O
3	O
years.	O
There	O
were	O
64.3%	O
Chinese,	O
31%	O
Malays,	O
and	O
3.7%	O
Indians	O
and	O
other	O
ethnic	O
groups.	O
Eighty-one	O
percent	O
of	O
patients	O
with	O
dyskinesia	Disease
had	O
clinical	O
fluctuations.	O
Patients	O
with	O
dyskinesia	Disease
had	O
lower	O
onset	O
age	O
(	O
p	O
<	O
0.001),	O
longer	O
duration	O
of	O
levodopa	Chemical
therapy	O
(	O
p	O
<	O
0.001),	O
longer	O
disease	O
duration	O
(	O
p	O
<	O
0.001),	O
higher	O
total	O
daily	O
levodopa	Chemical
dose	O
(	O
p	O
<	O
0.001),	O
and	O
higher	O
total	O
UPDRS	O
scores	O
(	O
p	O
=	O
0.005)	O
than	O
patients	O
without	O
dyskinesia	Disease
.	O
The	O
three	O
significant	O
predictors	O
of	O
dyskinesia	Disease
were	O
duration	O
of	O
levodopa	Chemical
therapy,	O
onset	O
age,	O
and	O
total	O
daily	O
levodopa	Chemical
dose.	O
CONCLUSIONS:	O
The	O
prevalence	O
of	O
levodopa	Chemical
-induced	O
dyskinesia	Disease
in	O
our	O
patients	O
was	O
44%.	O
The	O
most	O
significant	O
predictors	O
were	O
duration	O
of	O
levodopa	Chemical
therapy,	O
total	O
daily	O
levodopa	Chemical

An	O
unexpected	O
diagnosis	O
in	O
a	O
renal-transplant	O
patient	O
with	O
proteinuria	Disease
treated	O
with	O
everolimus	Chemical
:	O
AL	Disease
	O
amyloidosis	Disease
.	O
Proteinuria	Disease
is	O
an	O
expected	O
complication	O
in	O
transplant	O
patients	O
treated	O
with	O
mammalian	O
target	O
of	O
rapamycin	Chemical
inhibitors	O
(mTOR-i).	O
However,	O
clinical	O
suspicion	O
should	O
always	O
be	O
supported	O
by	O
histological	O
evidence	O
in	O
order	O
to	O
investigate	O
potential	O
alternate	O
diagnoses	O
such	O
as	O
acute	O
or	O
chronic	O
rejection,	O
interstitial	O
fibrosis	Disease
and	O
tubular	O
atrophy	Disease
,	O
or	O
recurrent	O
or	O
de	O
novo	O
glomerulopathy	Disease
.	O
In	O
this	O
case	O
we	O
report	O
the	O
unexpected	O
diagnosis	O
of	O
amyloidosis	Disease
in	O
a	O
renal-transplant	O
patient	O
with	O
pre-transplant	O
monoclonal	O
gammapathy	O
of	O
undetermined	O
significance	O
who	O
developed	O
proteinuria	Disease
after	O
conversion	O
from	O
tacrolimus	Chemical
to	O
everolimus	Chemical

An	O
investigation	O
of	O
the	O
pattern	O
of	O
kidney	Disease
injury	Disease
in	O
HIV-positive	O
persons	O
exposed	O
to	O
tenofovir	Chemical
disoproxil	Chemical
fumarate	Chemical
:	O
an	O
examination	O
of	O
a	O
large	O
population	O
database	O
(MHRA	O
database).	O
The	O
potential	O
for	O
tenofovir	Chemical
to	O
cause	O
a	O
range	O
of	O
kidney	O
syndromes	O
has	O
been	O
established	O
from	O
mechanistic	O
and	O
randomised	O
clinical	O
trials.	O
However,	O
the	O
exact	O
pattern	O
of	O
kidney	O
involvement	O
is	O
still	O
uncertain.	O
We	O
undertook	O
a	O
descriptive	O
analysis	O
of	O
Yellow	O
Card	O
records	O
of	O
407	O
HIV-positive	O
persons	O
taking	O
tenofovir	Chemical
disoproxil	Chemical
fumarate	Chemical
(	O
TDF	Chemical
)	O
as	O
part	O
of	O
their	O
antiretroviral	O
therapy	O
regimen	O
and	O
submitted	O
to	O
the	O
Medicines	O
and	O
Healthcare	O
Products	O
Regulatory	O
Agency	O
(MHRA)	O
with	O
suspected	O
kidney	O
adverse	O
effects.	O
Reports	O
that	O
satisfy	O
defined	O
criteria	O
were	O
classified	O
as	O
acute	Disease
kidney	Disease
injury	Disease
,	O
kidney	Disease
tubular	Disease
dysfunction	Disease
and	O
Fanconi	Disease
syndrome	Disease
.	O
Of	O
the	O
407	O
Yellow	O
Card	O
records	O
analysed,	O
106	O
satisfied	O
criteria	O
for	O
TDF	Chemical
-related	O
kidney	Disease
disease	Disease
,	O
of	O
which	O
53	O
(50%)	O
had	O
features	O
of	O
kidney	Disease
tubular	Disease
dysfunction	Disease
,	O
35	O
(33%)	O
were	O
found	O
to	O
have	O
features	O
of	O
glomerular	Disease
dysfunction	Disease
and	O
18	O
(17%)	O
had	O
Fanconi	Disease
syndrome	Disease
.	O
The	O
median	O
TDF	Chemical
exposure	O
was	O
316	O
days	O
(interquartile	O
range	O
120-740).	O
The	O
incidence	O
of	O
hospitalisation	O
for	O
TDF	Chemical
kidney	O
adverse	O
effects	O
was	O
high,	O
particularly	O
amongst	O
patients	O
with	O
features	O
of	O
Fanconi	Disease
syndrome	Disease
.	O
The	O
pattern	O
of	O
kidney	O
syndromes	O
in	O
this	O
population	O
series	O
mirrors	O
that	O
reported	O
in	O
randomised	O
clinical	O
trials.	O
Cessation	O
of	O
TDF	Chemical

Incidence	O
of	O
postoperative	Disease
delirium	Disease
is	O
high	O
even	O
in	O
a	O
population	O
without	O
known	O
risk	O
factors.	O
PURPOSE:	O
Postoperative	Disease
delirium	Disease
is	O
a	O
recognized	O
complication	O
in	O
populations	O
at	O
risk.	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
assess	O
the	O
prevalence	O
of	O
early	O
postoperative	Disease
delirium	Disease
in	O
a	O
population	O
without	O
known	O
risk	O
factors	O
admitted	O
to	O
the	O
ICU	O
for	O
postoperative	O
monitoring	O
after	O
elective	O
major	O
surgery.	O
The	O
secondary	O
outcome	O
investigated	O
is	O
to	O
identify	O
eventual	O
independent	O
risk	O
factors	O
among	O
demographic	O
data	O
and	O
anesthetic	O
drugs	O
used.	O
METHODS:	O
An	O
observational,	O
prospective	O
study	O
was	O
conducted	O
on	O
a	O
consecutive	O
cohort	O
of	O
patients	O
admitted	O
to	O
our	O
ICU	O
within	O
and	O
for	O
at	O
least	O
24	O
h	O
after	O
major	O
surgical	O
procedures.	O
Exclusion	O
criteria	O
were	O
any	O
preexisting	O
predisposing	O
factor	O
for	O
delirium	Disease
or	O
other	O
potentially	O
confounding	O
neurological	Disease
dysfunctions	Disease
.	O
Patients	O
were	O
assessed	O
daily	O
using	O
the	O
confusion	Disease
assessment	O
method	O
for	O
the	O
ICU	O
scale	O
for	O
3	O
days	O
after	O
the	O
surgical	O
procedure.	O
Early	O
postoperative	Disease
delirium	Disease
incidence	O
risk	O
factors	O
were	O
then	O
assessed	O
through	O
three	O
different	O
multiple	O
regression	O
models.	O
RESULTS:	O
According	O
to	O
the	O
confusion	O
assessment	O
method	O
for	O
the	O
ICU	O
scale,	O
28	O
%	O
of	O
patients	O
were	O
diagnosed	O
with	O
early	O
postoperative	Disease
delirium	Disease
.	O
The	O
use	O
of	O
thiopentone	Chemical
was	O
significantly	O
associated	O
with	O
an	O
eight-fold-higher	O
risk	O
for	O
delirium	Disease
compared	O
to	O
propofol	Chemical
(57.1%	O
vs.	O
7.1%,	O
RR	O
=	O
8.0,	O
X2	O
=	O
4.256;	O
df	O
=	O
1;	O
0.05	O
<	O
p	O
<	O
0.02).	O
CONCLUSION:	O
In	O
this	O
study	O
early	O
postoperative	Disease
delirium	Disease
was	O
found	O
to	O
be	O
a	O
very	O
common	O
complication	O
after	O
major	O
surgery,	O
even	O
in	O
a	O
population	O
without	O
known	O
risk	O
factors.	O
Thiopentone	Chemical

A	O
single	O
neurotoxic	Disease
dose	O
of	O
methamphetamine	Chemical
induces	O
a	O
long-lasting	O
depressive	Disease
-like	O
behaviour	O
in	O
mice.	O
Methamphetamine	Chemical
(	O
METH	Chemical
)	O
triggers	O
a	O
disruption	O
of	O
the	O
monoaminergic	O
system	O
and	O
METH	Chemical
abuse	O
leads	O
to	O
negative	O
emotional	O
states	O
including	O
depressive	Disease
symptoms	Disease
during	O
drug	O
withdrawal.	O
However,	O
it	O
is	O
currently	O
unknown	O
if	O
the	O
acute	O
toxic	O
dosage	O
of	O
METH	Chemical
also	O
causes	O
a	O
long-lasting	O
depressive	Disease
phenotype	O
and	O
persistent	O
monoaminergic	O
deficits.	O
Thus,	O
we	O
now	O
assessed	O
the	O
depressive	Disease
-like	O
behaviour	O
in	O
mice	O
at	O
early	O
and	O
long-term	O
periods	O
following	O
a	O
single	O
high	O
METH	Chemical
dose	O
(30	O
mg/kg,	O
i.p.).	O
METH	Chemical
did	O
not	O
alter	O
the	O
motor	O
function	O
and	O
procedural	O
memory	O
of	O
mice	O
as	O
assessed	O
by	O
swimming	O
speed	O
and	O
escape	O
latency	O
to	O
find	O
the	O
platform	O
in	O
a	O
cued	O
version	O
of	O
the	O
water	O
maze	O
task.	O
However,	O
METH	Chemical
significantly	O
increased	O
the	O
immobility	O
time	O
in	O
the	O
tail	O
suspension	O
test	O
at	O
3	O
and	O
49	O
days	O
post-administration.	O
This	O
depressive	Disease
-like	O
profile	O
induced	O
by	O
METH	Chemical
was	O
accompanied	O
by	O
a	O
marked	O
depletion	O
of	O
frontostriatal	O
dopaminergic	O
and	O
serotonergic	O
neurotransmission,	O
indicated	O
by	O
a	O
reduction	O
in	O
the	O
levels	O
of	O
dopamine	Chemical
,	O
DOPAC	Chemical
and	O
HVA	Chemical
,	O
tyrosine	Chemical
hydroxylase	O
and	O
serotonin	Chemical
,	O
observed	O
at	O
both	O
3	O
and	O
49	O
days	O
post-administration.	O
In	O
parallel,	O
another	O
neurochemical	O
feature	O
of	O
depression	Disease
--astroglial	O
dysfunction--was	O
unaffected	O
in	O
the	O
cortex	O
and	O
the	O
striatal	O
levels	O
of	O
the	O
astrocytic	O
protein	O
marker,	O
glial	O
fibrillary	O
acidic	O
protein,	O
were	O
only	O
transiently	O
increased	O
at	O
3	O
days.	O
These	O
findings	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
a	O
single	O
high	O
dose	O
of	O
METH	Chemical
induces	O
long-lasting	O
depressive	Disease

Linezolid	Chemical
-induced	O
optic	Disease
neuropathy	Disease
.	O
Many	O
systemic	O
antimicrobials	O
have	O
been	O
implicated	O
to	O
cause	O
ocular	O
adverse	O
effects.	O
This	O
is	O
especially	O
relevant	O
in	O
multidrug	O
therapy	O
where	O
more	O
than	O
one	O
drug	O
can	O
cause	O
a	O
similar	O
ocular	O
adverse	O
effect.	O
We	O
describe	O
a	O
case	O
of	O
progressive	O
loss	Disease
of	Disease
vision	Disease
associated	O
with	O
linezolid	Chemical
therapy.	O
A	O
45-year-old	O
male	O
patient	O
who	O
was	O
on	O
treatment	O
with	O
multiple	O
second-line	O
anti-tuberculous	O
drugs	O
including	O
linezolid	Chemical
and	O
ethambutol	Chemical
for	O
extensively	Disease
drug-resistant	Disease
tuberculosis	Disease
(	O
XDR-TB	Disease
)	O
presented	O
to	O
us	O
with	O
painless	O
progressive	O
loss	Disease
of	Disease
vision	Disease
in	O
both	O
eyes.	O
Color	O
vision	O
was	O
defective	O
and	O
fundus	O
examination	O
revealed	O
optic	Disease
disc	Disease
edema	Disease
in	O
both	O
eyes.	O
Ethambutol	Chemical
-induced	O
toxic	Disease
optic	Disease
neuropathy	Disease
was	O
suspected	O
and	O
tablet	O
ethambutol	Chemical
was	O
withdrawn.	O
Deterioration	Disease
of	Disease
vision	Disease
occurred	O
despite	O
withdrawal	O
of	O
ethambutol	Chemical
.	O
Discontinuation	O
of	O
linezolid	Chemical
resulted	O
in	O
marked	O
improvement	O
of	O
vision.	O
Our	O
report	O
emphasizes	O
the	O
need	O
for	O
monitoring	O
of	O
visual	O
function	O
in	O
patients	O
on	O
long-term	O
linezolid	Chemical

Resuscitation	O
with	O
lipid,	O
epinephrine	Chemical
,	O
or	O
both	O
in	O
levobupivacaine	Chemical
-induced	O
cardiac	Disease
toxicity	Disease
in	O
newborn	O
piglets.	O
BACKGROUND:	O
The	O
optimal	O
dosing	O
regimens	O
of	O
lipid	O
emulsion,	O
epinephrine	Chemical
,	O
or	O
both	O
are	O
not	O
yet	O
determined	O
in	O
neonates	O
in	O
cases	O
of	O
local	O
anaesthetic	O
systemic	O
toxicity	Disease
(LAST).	O
METHODS:	O
Newborn	O
piglets	O
received	O
levobupivacaine	Chemical
until	O
cardiovascular	Disease
collapse	Disease
occurred.	O
Standard	O
cardiopulmonary	O
resuscitation	O
was	O
started	O
and	O
electrocardiogram	O
(ECG)	O
was	O
monitored	O
for	O
ventricular	Disease
tachycardia	Disease
,	O
fibrillation	Disease
,	O
or	O
QRS	O
prolongation.	O
Piglets	O
were	O
then	O
randomly	O
allocated	O
to	O
four	O
groups:	O
control	O
(saline),	O
Intralipid(	O
)	O
alone,	O
epinephrine	Chemical
alone,	O
or	O
a	O
combination	O
of	O
Intralipd	O
plus	O
epinephrine	Chemical
.	O
Resuscitation	O
continued	O
for	O
30	O
min	O
or	O
until	O
there	O
was	O
a	O
return	O
of	O
spontaneous	O
circulation	O
(ROSC)	O
accompanied	O
by	O
a	O
mean	O
arterial	O
pressure	O
at	O
or	O
superior	O
to	O
the	O
baseline	O
pressure	O
and	O
normal	O
sinus	O
rhythm	O
for	O
a	O
period	O
of	O
30	O
min.	O
RESULTS:	O
ROSC	O
was	O
achieved	O
in	O
only	O
one	O
of	O
the	O
control	O
piglets	O
compared	O
with	O
most	O
of	O
the	O
treated	O
piglets.	O
Mortality	O
was	O
not	O
significantly	O
different	O
between	O
the	O
three	O
treatment	O
groups,	O
but	O
was	O
significantly	O
lower	O
in	O
all	O
the	O
treatment	O
groups	O
compared	O
with	O
control.	O
The	O
number	O
of	O
ECG	O
abnormalities	O
was	O
zero	O
in	O
the	O
Intralipid	O
only	O
group,	O
but	O
14	O
and	O
17,	O
respectively,	O
in	O
the	O
epinephrine	Chemical
and	O
epinephrine	Chemical
plus	O
lipid	O
groups	O
(P<0.05).	O
CONCLUSIONS:	O
Lipid	O
emulsion	O
with	O
or	O
without	O
epinephrine	Chemical
,	O
or	O
epinephrine	Chemical
alone	O
were	O
equally	O
effective	O
in	O
achieving	O
a	O
return	O
to	O
spontaneous	O
circulation	O
in	O
this	O
model	O
of	O
LAST.	O
Epinephrine	Chemical

Incidence	O
of	O
heparin	Chemical
-induced	O
thrombocytopenia	Disease
type	Disease
II	Disease
and	O
postoperative	O
recovery	O
of	O
platelet	O
count	O
in	O
liver	O
graft	O
recipients:	O
a	O
retrospective	O
cohort	O
analysis.	O
BACKGROUND:	O
Thrombocytopenia	Disease
in	O
patients	O
with	O
end-stage	Disease
liver	Disease
disease	Disease
is	O
a	O
common	O
disorder	O
caused	O
mainly	O
by	O
portal	Disease
hypertension	Disease
,	O
low	O
levels	O
of	O
thrombopoetin,	O
and	O
endotoxemia	Disease
.	O
The	O
impact	O
of	O
immune-mediated	O
heparin	Chemical
-induced	O
thrombocytopenia	Disease
type	Disease
II	Disease
(	O
HIT	Disease
type	Disease
II	Disease
)	O
as	O
a	O
cause	O
of	O
thrombocytopenia	Disease
after	O
liver	O
transplantation	O
is	O
not	O
yet	O
understood,	O
with	O
few	O
literature	O
citations	O
reporting	O
contradictory	O
results.	O
The	O
aim	O
of	O
our	O
study	O
was	O
to	O
demonstrate	O
the	O
perioperative	O
course	O
of	O
thrombocytopenia	Disease
after	O
liver	O
transplantation	O
and	O
determine	O
the	O
occurrence	O
of	O
clinical	O
HIT	Disease
type	Disease
II	Disease
.	O
METHOD:	O
We	O
retrospectively	O
evaluated	O
the	O
medical	O
records	O
of	O
205	O
consecutive	O
adult	O
patients	O
who	O
underwent	O
full-size	O
liver	O
transplantation	O
between	O
January	O
2006	O
and	O
December	O
2010	O
due	O
to	O
end-stage	Disease
or	Disease
malignant	Disease
liver	Disease
disease	Disease
.	O
Preoperative	O
platelet	O
count,	O
postoperative	O
course	O
of	O
platelets,	O
and	O
clinical	O
signs	O
of	O
HIT	Disease
type	Disease
II	Disease
were	O
analyzed.	O
RESULTS:	O
A	O
total	O
of	O
155	O
(75.6%)	O
of	O
205	O
patients	O
had	O
thrombocytopenia	Disease
before	O
transplantation,	O
significantly	O
influenced	O
by	O
Model	O
of	O
End-Stage	Disease
Liver	Disease
Disease	Disease
score	O
and	O
liver	Disease
cirrhosis	Disease
.	O
The	O
platelet	O
count	O
exceeded	O
100,000/uL	O
in	O
most	O
of	O
the	O
patients	O
(n	O
=	O
193)	O
at	O
a	O
medium	O
of	O
7	O
d.	O
Regarding	O
HIT	Disease
II	Disease
,	O
there	O
were	O
four	O
(1.95%)	O
patients	O
with	O
a	O
background	O
of	O
HIT	Disease
type	Disease
II	Disease
.	O
CONCLUSIONS:	O
The	O
incidence	O
of	O
HIT	Disease
in	O
patients	O
with	O
end-stage	Disease
hepatic	Disease
failure	Disease
is,	O
with	O
about	O
1.95%,	O
rare.	O
For	O
further	O
reduction	O
of	O
HIT	Disease
type	Disease
II	Disease
,	O
the	O
use	O
of	O
intravenous	O
heparin	Chemical
should	O
be	O
avoided	O
and	O
the	O
prophylactic	O
anticoagulation	O
should	O
be	O
performed	O
with	O
low-molecular-weight	O
heparin	Chemical

Takotsubo	Disease
syndrome	Disease
(or	O
apical	Disease
ballooning	Disease
syndrome	Disease
)	O
secondary	O
to	O
Zolmitriptan	Chemical
.	O
Takotsubo	Disease
syndrome	Disease
(	O
TS	Disease
),	O
also	O
known	O
as	O
broken	Disease
heart	Disease
syndrome	Disease
,	O
is	O
characterized	O
by	O
left	O
ventricle	O
apical	O
ballooning	O
with	O
elevated	O
cardiac	O
biomarkers	O
and	O
electrocardiographic	O
changes	O
suggestive	O
of	O
an	O
acute	Disease
coronary	Disease
syndrome	Disease
(ie,	O
ST-segment	O
elevation,	O
T	O
wave	O
inversions,	O
and	O
pathologic	O
Q	O
waves).	O
We	O
report	O
a	O
case	O
of	O
54-year-old	O
woman	O
with	O
medical	O
history	O
of	O
mitral	Disease
valve	Disease
prolapse	Disease
and	O
migraines	Disease
,	O
who	O
was	O
admitted	O
to	O
the	O
hospital	O
for	O
substernal	O
chest	Disease
pain	Disease
and	O
electrocardiogram	O
demonstrated	O
1/2	O
mm	O
ST-segment	O
elevation	O
in	O
leads	O
II,	O
III,	O
aVF,	O
V5,	O
and	O
V6	O
and	O
positive	O
troponin	O
I.	O
Emergent	O
coronary	O
angiogram	O
revealed	O
normal	O
coronary	O
arteries	O
with	O
moderately	O
reduced	O
left	O
ventricular	O
ejection	O
fraction	O
with	O
wall	O
motion	O
abnormalities	O
consistent	O
with	O
TS	Disease
.	O
Detailed	O
history	O
obtained	O
retrospectively	O
revealed	O
that	O
the	O
patient	O
took	O
zolmitriptan	Chemical
sparingly	O
only	O
when	O
she	O
had	O
migraines	Disease
.	O
But	O
before	O
this	O
event,	O
she	O
was	O
taking	O
zolmitriptan	Chemical
2-3	O
times	O
daily	O
for	O
several	O
days	O
because	O
of	O
a	O
persistent	O
migraine	Disease
headache	Disease
.	O
She	O
otherwise	O
reported	O
that	O
she	O
is	O
quite	O
active,	O
rides	O
horses,	O
and	O
does	O
show	O
jumping	O
without	O
any	O
limitations	O
in	O
her	O
physical	O
activity.	O
There	O
was	O
no	O
evidence	O
of	O
any	O
recent	O
stress	O
or	O
status	Disease
migrainosus	Disease
.	O
Extensive	O
literature	O
search	O
revealed	O
multiple	O
cases	O
of	O
coronary	Disease
artery	Disease
vasospasm	Disease
secondary	O
to	O
zolmitriptan	Chemical
,	O
but	O
none	O
of	O
the	O
cases	O
were	O
associated	O
with	O
TS	Disease

Depression	Disease
,	O
impulsiveness	Disease
,	O
sleep,	O
and	O
memory	O
in	O
past	O
and	O
present	O
polydrug	O
users	O
of	O
3,4-methylenedioxymethamphetamine	Chemical
(	O
MDMA	Chemical
,	O
ecstasy	Chemical
).	O
RATIONALE:	O
Ecstasy	Chemical
(	O
3,4-methylenedioxymethamphetamine	Chemical
,	O
MDMA	Chemical
)	O
is	O
a	O
worldwide	O
recreational	O
drug	O
of	O
abuse.	O
Unfortunately,	O
the	O
results	O
from	O
human	O
research	O
investigating	O
its	O
psychological	O
effects	O
have	O
been	O
inconsistent.	O
OBJECTIVES:	O
The	O
present	O
study	O
aimed	O
to	O
be	O
the	O
largest	O
to	O
date	O
in	O
sample	O
size	O
and	O
5HT-related	O
behaviors;	O
the	O
first	O
to	O
compare	O
present	O
ecstasy	Chemical
users	O
with	O
past	O
users	O
after	O
an	O
abstinence	O
of	O
4	O
or	O
more	O
years,	O
and	O
the	O
first	O
to	O
include	O
robust	O
controls	O
for	O
other	O
recreational	O
substances.	O
METHODS:	O
A	O
sample	O
of	O
997	O
participants	O
(52	O
%	O
male)	O
was	O
recruited	O
to	O
four	O
control	O
groups	O
(non-drug	O
(ND),	O
alcohol	Chemical
/	O
nicotine	Chemical
(	O
AN	Chemical
),	O
cannabis	Chemical
/	O
alcohol	Chemical
/	O
nicotine	Chemical
(	O
CAN	Chemical
),	O
non-	O
ecstasy	Chemical
polydrug	O
(PD)),	O
and	O
two	O
ecstasy	Chemical
polydrug	O
groups	O
(present	O
(	O
MDMA	Chemical
)	O
and	O
past	O
users	O
(EX-	O
MDMA	Chemical
).	O
Participants	O
completed	O
a	O
drug	O
history	O
questionnaire,	O
Beck	O
Depression	Disease
Inventory,	O
Barratt	O
Impulsiveness	Disease
Scale,	O
Pittsburgh	O
Sleep	O
Quality	O
Index,	O
and	O
Wechsler	O
Memory	O
Scale-Revised	O
which,	O
in	O
total,	O
provided	O
13	O
psychometric	O
measures.	O
RESULTS:	O
While	O
the	O
CAN	Chemical
and	O
PD	O
groups	O
tended	O
to	O
record	O
greater	O
deficits	O
than	O
the	O
non-drug	O
controls,	O
the	O
MDMA	Chemical
and	O
EX-	O
MDMA	Chemical
groups	O
recorded	O
greater	O
deficits	O
than	O
all	O
the	O
control	O
groups	O
on	O
ten	O
of	O
the	O
13	O
psychometric	O
measures.	O
Strikingly,	O
despite	O
prolonged	O
abstinence	O
(mean,	O
4.98;	O
range,	O
4-9	O
years),	O
past	O
ecstasy	Chemical
users	O
showed	O
few	O
signs	O
of	O
recovery.	O
Compared	O
with	O
present	O
ecstasy	Chemical
users,	O
the	O
past	O
users	O
showed	O
no	O
change	O
for	O
ten	O
measures,	O
increased	O
impairment	O
for	O
two	O
measures,	O
and	O
improvement	O
on	O
just	O
one	O
measure.	O
CONCLUSIONS:	O
Given	O
this	O
record	O
of	O
impaired	Disease
memory	Disease
and	O
clinically	O
significant	O
levels	O
of	O
depression	Disease
,	O
impulsiveness	Disease
,	O
and	O
sleep	Disease
disturbance	Disease
,	O
the	O
prognosis	O
for	O
the	O
current	O
generation	O
of	O
ecstasy	Chemical

Association	O
of	O
common	O
genetic	O
variants	O
of	O
HOMER1	O
gene	O
with	O
levodopa	Chemical
adverse	O
effects	O
in	O
Parkinson's	Disease
disease	Disease
patients.	O
Levodopa	Chemical
is	O
the	O
most	O
effective	O
symptomatic	O
therapy	O
for	O
Parkinson's	Disease
disease	Disease
,	O
but	O
its	O
chronic	O
use	O
could	O
lead	O
to	O
chronic	O
adverse	O
outcomes,	O
such	O
as	O
motor	O
fluctuations,	O
dyskinesia	Disease
and	O
visual	Disease
hallucinations	Disease
.	O
HOMER1	O
is	O
a	O
protein	O
with	O
pivotal	O
function	O
in	O
glutamate	Chemical
transmission,	O
which	O
has	O
been	O
related	O
to	O
the	O
pathogenesis	O
of	O
these	O
complications.	O
This	O
study	O
investigates	O
whether	O
polymorphisms	O
in	O
the	O
HOMER1	O
gene	O
promoter	O
region	O
are	O
associated	O
with	O
the	O
occurrence	O
of	O
the	O
chronic	O
complications	O
of	O
levodopa	Chemical
therapy.	O
A	O
total	O
of	O
205	O
patients	O
with	O
idiopathic	Disease
Parkinson's	Disease
disease	Disease
were	O
investigated.	O
Patients	O
were	O
genotyped	O
for	O
rs4704559,	O
rs10942891	O
and	O
rs4704560	O
by	O
allelic	O
discrimination	O
with	O
Taqman	O
assays.	O
The	O
rs4704559	O
G	O
allele	O
was	O
associated	O
with	O
a	O
lower	O
prevalence	O
of	O
dyskinesia	Disease
(prevalence	O
ratio	O
(PR)=0.615,	O
95%	O
confidence	O
interval	O
(CI)	O
0.426-0.887,	O
P=0.009)	O
and	O
visual	Disease
hallucinations	Disease
(PR=0.515,	O
95%	O
CI	O
0.295-0.899,	O
P=0.020).	O
Our	O
data	O
suggest	O
that	O
HOMER1	O
rs4704559	O
G	O
allele	O
has	O
a	O
protective	O
role	O
for	O
the	O
development	O
of	O
levodopa	Chemical

Crocin	Chemical
improves	O
lipid	O
dysregulation	O
in	O
subacute	O
diazinon	Chemical
exposure	O
through	O
ERK1/2	O
pathway	O
in	O
rat	O
liver.	O
INTRODUCTION:	O
Diazinon	Chemical
Yis	O
one	O
of	O
the	O
most	O
broadly	O
used	O
organophosphorus	Chemical
insecticides	O
in	O
agriculture.	O
It	O
has	O
been	O
shown	O
that	O
exposure	O
to	O
diazinon	Chemical
may	O
interfere	O
with	O
lipid	O
metabolism.	O
Moreover,	O
the	O
hypolipidemic	O
effect	O
of	O
crocin	Chemical
has	O
been	O
established.	O
Earlier	O
studies	O
revealed	O
the	O
major	O
role	O
of	O
Extracellular	O
signal-regulated	O
kinase	O
(ERK)	O
pathways	O
in	O
low-density	O
lipoprotein	O
receptor	O
(LDLr)	O
expression.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
changes	O
in	O
the	O
regulation	O
of	O
lipid	O
metabolism,	O
ERK	O
and	O
LDLr	O
expression	O
in	O
the	O
liver	O
of	O
rats	O
exposed	O
to	O
subacute	O
diazinon	Chemical
.	O
Furthermore	O
ameliorating	O
effect	O
of	O
crocin	Chemical
on	O
diazinon	Chemical
induced	O
disturbed	O
cholesterol	Chemical
homeostasis	O
was	O
studied.	O
METHODS:	O
24	O
Rats	O
were	O
divided	O
into	O
4	O
groups	O
and	O
received	O
following	O
treatments	O
for	O
4	O
weeks;	O
Corn	O
oil	O
(control),	O
diazinon	Chemical
(15mg/kg	O
per	O
day,	O
orally)	O
and	O
crocin	Chemical
(12.5	O
and	O
25mg/kg	O
per	O
day,	O
intraperitoneally)	O
in	O
combination	O
with	O
diazinon	Chemical
(15	O
mg/kg).	O
The	O
levels	O
of	O
cholesterol	Chemical
,	O
triglyceride	Chemical
and	O
LDL	O
in	O
blood	O
of	O
rats	O
were	O
analyzed.	O
Moreover	O
mRNA	O
levels	O
of	O
LDLr	O
and	O
ERK1/2	O
as	O
well	O
as	O
protein	O
levels	O
of	O
total	O
and	O
activated	O
forms	O
of	O
ERK1/2	O
in	O
rat	O
liver	O
were	O
evaluated	O
by	O
Western	O
blotting	O
and	O
quantitative	O
real	O
time	O
polymerase	O
chain	O
reaction	O
analysis.	O
RESULTS:	O
Our	O
data	O
showed	O
that	O
subacute	O
exposure	O
to	O
diazinon	Chemical
significantly	O
increased	O
concentrations	O
of	O
cholesterol	Chemical
,	O
triglyceride	Chemical
and	O
LDL.	O
Moreover	O
diazinon	Chemical
decreased	O
ERK1/2	O
protein	O
phosphorylation	O
and	O
LDLr	O
transcript.	O
Crocin	Chemical
reduced	O
inhibition	O
of	O
ERK	O
activation	O
and	O
diazinon	Chemical
-induced	O
hyperlipemia	Disease
and	O
increased	O
levels	O
of	O
LDLr	O
transcript.	O
CONCLUSIONS:	O
Crocin	Chemical
may	O
be	O
considered	O
as	O
a	O
novel	O
protective	O
agent	O
in	O
diazinon	Chemical
-induced	O
hyperlipemia	Disease

GEM	Chemical
-P	O
chemotherapy	O
is	O
active	O
in	O
the	O
treatment	O
of	O
relapsed	O
Hodgkin	Disease
lymphoma	Disease
.	O
Hodgkin	Disease
lymphoma	Disease
(	O
HL	Disease
)	O
is	O
a	O
relatively	O
chemosensitive	O
malignancy	Disease
.	O
However,	O
for	O
those	O
who	O
relapse,	O
high-dose	O
chemotherapy	O
with	O
autologous	O
stem	O
cell	O
transplant	O
is	O
the	O
treatment	O
of	O
choice	O
which	O
relies	O
on	O
adequate	O
disease	O
control	O
with	O
salvage	O
chemotherapy.	O
Regimens	O
commonly	O
used	O
often	O
require	O
inpatient	O
administration	O
and	O
can	O
be	O
difficult	O
to	O
deliver	O
due	O
to	O
toxicity	Disease
.	O
Gemcitabine	Chemical
and	O
cisplatin	Chemical
have	O
activity	O
in	O
HL	Disease
,	O
non-overlapping	O
toxicity	Disease
with	O
first-line	O
chemotherapeutics,	O
and	O
may	O
be	O
delivered	O
in	O
an	O
outpatient	O
setting.	O
In	O
this	O
retrospective	O
single-centre	O
analysis,	O
patients	O
with	O
relapsed	O
or	O
refractory	O
HL	Disease
treated	O
with	O
gemcitabine	Chemical
1,000	O
mg/m(2)	O
day	O
(D)1,	O
D8	O
and	O
D15;	O
methylprednisolone	Chemical
1,000	O
mg	O
D1-5;	O
and	O
cisplatin	Chemical
100	O
mg/m(2)	O
D15,	O
every	O
28	O
days	O
(	O
GEM	Chemical
-P)	O
were	O
included.	O
Demographic,	O
survival,	O
response	O
and	O
toxicity	Disease
data	O
were	O
recorded.	O
Forty-one	O
eligible	O
patients	O
were	O
identified:	O
median	O
age	O
27.	O
One	O
hundred	O
and	O
twenty-two	O
cycles	O
of	O
GEM	Chemical
-P	O
were	O
administered	O
in	O
total	O
(median	O
3	O
cycles;	O
range	O
1-6).	O
Twenty	O
of	O
41	O
(48	O
%)	O
patients	O
received	O
GEM	Chemical
-P	O
as	O
second-line	O
treatment	O
and	O
11/41	O
(27	O
%)	O
as	O
third-line	O
therapy.	O
Overall	O
response	O
rate	O
(ORR)	O
to	O
GEM	Chemical
-P	O
in	O
the	O
entire	O
cohort	O
was	O
80	O
%	O
(complete	O
response	O
(CR)	O
37	O
%,	O
partial	O
response	O
44	O
%)	O
with	O
14/15	O
CR	O
confirmed	O
as	O
a	O
metabolic	O
CR	O
on	O
PET	O
and	O
ORR	O
of	O
85	O
%	O
in	O
the	O
20	O
second-line	O
patients.	O
The	O
most	O
common	O
grade	O
3/4	O
toxicities	Disease
were	O
haematological:	O
neutropenia	Disease
54	O
%	O
and	O
thrombocytopenia	Disease
51	O
%.	O
Median	O
follow-up	O
from	O
the	O
start	O
of	O
GEM	Chemical
-P	O
was	O
4.5	O
years.	O
Following	O
GEM	Chemical
-P,	O
5-year	O
progression-free	O
survival	O
was	O
46	O
%	O
(95	O
%	O
confidence	O
interval	O
(CI),	O
30-62	O
%)	O
and	O
5-year	O
overall	O
survival	O
was	O
59	O
%	O
(95	O
%	O
CI,	O
43-74	O
%).	O
Fourteen	O
of	O
41	O
patients	O
proceeded	O
directly	O
to	O
autologous	O
transplant.	O
GEM	Chemical
-P	O
is	O
a	O
salvage	O
chemotherapy	O
with	O
relatively	O
high	O
response	O
rates,	O
leading	O
to	O
successful	O
transplantation	O
in	O
appropriate	O
patients,	O
in	O
the	O
treatment	O
of	O
relapsed	O
or	O
refractory	O
HL	Disease

Basal	O
functioning	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
(HPA)	O
axis	O
and	O
psychological	O
distress	O
in	O
recreational	O
ecstasy	Chemical
polydrug	O
users.	O
RATIONALE:	O
Ecstasy	Chemical
(	O
MDMA	Chemical
)	O
is	O
a	O
psychostimulant	O
drug	O
which	O
is	O
increasingly	O
associated	O
with	O
psychobiological	Disease
dysfunction	Disease
.	O
While	O
some	O
recent	O
studies	O
suggest	O
acute	O
changes	O
in	O
neuroendocrine	O
function,	O
less	O
is	O
known	O
about	O
long-term	O
changes	O
in	O
HPA	O
functionality	O
in	O
recreational	O
users.	O
OBJECTIVES:	O
The	O
current	O
study	O
is	O
the	O
first	O
to	O
explore	O
the	O
effects	O
of	O
ecstasy	Chemical
-polydrug	O
use	O
on	O
psychological	O
distress	O
and	O
basal	O
functioning	O
of	O
the	O
HPA	O
axis	O
through	O
assessing	O
the	O
secretion	O
of	O
cortisol	Chemical
across	O
the	O
diurnal	O
period.	O
METHOD:	O
Seventy-six	O
participants	O
(21	O
nonusers,	O
29	O
light	O
ecstasy	Chemical
-polydrug	O
users,	O
26	O
heavy	O
ecstasy	Chemical
-polydrug	O
users)	O
completed	O
a	O
substance	O
use	O
inventory	O
and	O
measures	O
of	O
psychological	O
distress	O
at	O
baseline,	O
then	O
two	O
consecutive	O
days	O
of	O
cortisol	Chemical
sampling	O
(on	O
awakening,	O
30	O
min	O
post	O
awakening,	O
between	O
1400	O
and	O
1600	O
hours	O
and	O
pre	O
bedtime).	O
On	O
day	O
2,	O
participants	O
also	O
attended	O
the	O
laboratory	O
to	O
complete	O
a	O
20-min	O
multitasking	O
stressor.	O
RESULTS:	O
Both	O
user	O
groups	O
exhibited	O
significantly	O
greater	O
levels	O
of	O
anxiety	Disease
and	O
depression	Disease
than	O
nonusers.	O
On	O
day	O
1,	O
all	O
participants	O
exhibited	O
a	O
typical	O
cortisol	Chemical
profile,	O
though	O
light	O
users	O
had	O
significantly	O
elevated	O
levels	O
pre-bed.	O
On	O
day	O
2,	O
heavy	O
users	O
demonstrated	O
elevated	O
levels	O
upon	O
awakening	O
and	O
all	O
ecstasy	Chemical
-polydrug	O
users	O
demonstrated	O
elevated	O
pre-bed	O
levels	O
compared	O
to	O
non-users.	O
Significant	O
between	O
group	O
differences	O
were	O
also	O
observed	O
in	O
afternoon	O
cortisol	Chemical
levels	O
and	O
in	O
overall	O
cortisol	Chemical
secretion	O
across	O
the	O
day.	O
CONCLUSIONS:	O
The	O
increases	O
in	O
anxiety	Disease
and	O
depression	Disease
are	O
in	O
line	O
with	O
previous	O
observations	O
in	O
recreational	O
ecstasy	Chemical
-polydrug	O
users.	O
Dysregulated	O
diurnal	O
cortisol	Chemical
may	O
be	O
indicative	O
of	O
inappropriate	O
anticipation	O
of	O
forthcoming	O
demands	O
and	O
hypersecretion	O
may	O
lead	O
to	O
the	O
increased	O
psychological	O
and	O
physical	O
morbidity	O
associated	O
with	O
heavy	O
recreational	O
use	O
of	O
ecstasy	Chemical

Ifosfamide	Chemical
related	O
encephalopathy	Disease
:	O
the	O
need	O
for	O
a	O
timely	O
EEG	O
evaluation.	O
BACKGROUND:	O
Ifosfamide	Chemical
is	O
an	O
alkylating	O
agent	O
useful	O
in	O
the	O
treatment	O
of	O
a	O
wide	O
range	O
of	O
cancers	Disease
including	O
sarcomas	Disease
,	O
lymphoma	Disease
,	O
gynecologic	Disease
and	Disease
testicular	Disease
cancers	Disease
.	O
Encephalopathy	Disease
has	O
been	O
reported	O
in	O
10-40%	O
of	O
patients	O
receiving	O
high-dose	O
IV	O
ifosfamide	Chemical
.	O
OBJECTIVE:	O
To	O
highlight	O
the	O
role	O
of	O
electroencephalogram	O
(EEG)	O
in	O
the	O
early	O
detection	O
and	O
management	O
of	O
ifosfamide	Chemical
related	O
encephalopathy	Disease
.	O
METHODS:	O
Retrospective	O
chart	O
review	O
including	O
clinical	O
data	O
and	O
EEG	O
recordings	O
was	O
done	O
on	O
five	O
patients,	O
admitted	O
to	O
MD	O
Anderson	O
Cancer	Disease
Center	O
between	O
years	O
2009	O
and	O
2012,	O
who	O
developed	O
ifosfamide	Chemical
related	O
acute	O
encephalopathy	Disease
.	O
RESULTS:	O
All	O
five	O
patients	O
experienced	O
symptoms	O
of	O
encephalopathy	Disease
soon	O
after	O
(within	O
12	O
h-2	O
days)	O
receiving	O
ifosfamide	Chemical
.	O
Two	O
patients	O
developed	O
generalized	O
convulsions	Disease
while	O
one	O
patient	O
developed	O
continuous	O
non-convulsive	Disease
status	Disease
epilepticus	Disease
(	O
NCSE	Disease
)	O
that	O
required	O
ICU	O
admission	O
and	O
intubation.	O
Initial	O
EEG	O
showed	O
epileptiform	O
discharges	O
in	O
three	O
patients;	O
run	O
of	O
triphasic	O
waves	O
in	O
one	O
patient	O
and	O
moderate	O
degree	O
diffuse	O
generalized	O
slowing.	O
Mixed	O
pattern	O
with	O
the	O
presence	O
of	O
both	O
sharps	O
and	O
triphasic	O
waves	O
were	O
also	O
noted.	O
Repeat	O
EEGs	O
within	O
24_h	O
of	O
symptom	O
onset	O
showed	O
marked	O
improvement	O
that	O
was	O
correlated	O
with	O
clinical	O
improvement.	O
CONCLUSIONS:	O
Severity	O
of	O
ifosfamide	Chemical
related	O
encephalopathy	Disease
correlates	O
with	O
EEG	O
changes.	O
We	O
suggest	O
a	O
timely	O
EEG	O
evaluation	O
for	O
patients	O
receiving	O
ifosfamide	Chemical
who	O
develop	O
features	O
of	O
encephalopathy	Disease

Incidence	O
of	O
contrast	Chemical
-induced	O
nephropathy	Disease
in	O
hospitalised	O
patients	O
with	O
cancer	Disease
.	O
OBJECTIVES:	O
To	O
determine	O
the	O
frequency	O
of	O
and	O
possible	O
factors	O
related	O
to	O
contrast	Chemical
-induced	O
nephropathy	Disease
(CIN)	O
in	O
hospitalised	O
patients	O
with	O
cancer	Disease
.	O
METHODS:	O
Ninety	O
adult	O
patients	O
were	O
enrolled.	O
Patients	O
with	O
risk	O
factors	O
for	O
acute	Disease
renal	Disease
failure	Disease
were	O
excluded.	O
Blood	O
samples	O
were	O
examined	O
the	O
day	O
before	O
contrast	Chemical
-enhanced	O
computed	O
tomography	O
(CT)	O
and	O
serially	O
for	O
3	O
days	O
thereafter.	O
CIN	O
was	O
defined	O
as	O
an	O
increase	O
in	O
serum	O
creatinine	Chemical
(	O
Cr	Chemical
)	O
of	O
0.5	O
mg/dl	O
or	O
more,	O
or	O
elevation	O
of	O
Cr	Chemical
to	O
25	O
%	O
over	O
baseline.	O
Relationships	O
between	O
CIN	O
and	O
possible	O
risk	O
factors	O
were	O
investigated.	O
RESULTS:	O
CIN	O
was	O
detected	O
in	O
18/90	O
(20	O
%)	O
patients.	O
CIN	O
developed	O
in	O
25.5	O
%	O
patients	O
who	O
underwent	O
chemotherapy	O
and	O
in	O
11	O
%	O
patients	O
who	O
did	O
not	O
(P	O
=	O
0.1).	O
CIN	O
more	O
frequently	O
developed	O
in	O
patients	O
who	O
had	O
undergone	O
CT	O
within	O
45	O
days	O
after	O
the	O
last	O
chemotherapy	O
(P	O
=	O
0.005);	O
it	O
was	O
also	O
an	O
independent	O
risk	O
factor	O
(P	O
=	O
0.017).	O
CIN	O
was	O
significantly	O
more	O
after	O
treatment	O
with	O
bevacizumab	Chemical
/	O
irinotecan	Chemical
(P	O
=	O
0.021)	O
and	O
in	O
patients	O
with	O
hypertension	Disease
(P	O
=	O
0.044).	O
CONCLUSIONS:	O
The	O
incidence	O
of	O
CIN	O
after	O
CT	O
in	O
hospitalised	O
oncological	O
patients	O
was	O
20	O
%.	O
CIN	O
developed	O
4.5-times	O
more	O
frequently	O
in	O
patients	O
with	O
cancer	Disease
who	O
had	O
undergone	O
recent	O
chemotherapy.	O
Hypertension	Disease
and	O
the	O
combination	O
of	O
bevacizumab	Chemical
/	O
irinotecan	Chemical
may	O
be	O
additional	O
risk	O
factors	O
for	O
CIN	O
development.	O
KEY	O
POINTS:	O
.	O
Contrast	Chemical
-induced	O
nephropathy	Disease
(CIN)	O
is	O
a	O
concern	O
for	O
oncological	O
patients	O
undergoing	O
CT.	O
.	O
CIN	O
occurs	O
more	O
often	O
when	O
CT	O
is	O
performed	O
<45	O
days	O
after	O
chemotherapy.	O
.	O
Hypertension	Disease
and	O
treatment	O
with	O
bevacizumab	Chemical

Syndrome	Disease
of	Disease
inappropriate	Disease
antidiuretic	Disease
hormone	Disease
secretion	O
associated	O
with	O
desvenlafaxine	Chemical
.	O
OBJECTIVE:	O
To	O
report	O
a	O
case	O
of	O
syndrome	Disease
of	Disease
inappropriate	Disease
anti-diuretic	Disease
hormone	Disease
(	O
SIADH	Disease
)	O
secretion	O
associated	O
with	O
desvenlafaxine	Chemical
.	O
CASE	O
SUMMARY:	O
A	O
57-year	O
old	O
female	O
with	O
hyponatraemia	Disease
.	O
Her	O
medications	O
included	O
desvenlafaxine	Chemical
,	O
and	O
symptoms	O
included	O
nausea	Disease
,	O
anxiety	Disease
and	O
confusion	Disease
.	O
The	O
serum	O
sodium	Chemical
at	O
this	O
time	O
was	O
120	O
mmol/L,	O
serum	O
osmolality	O
was	O
263	O
mosmol/kg,	O
urine	O
osmolality	O
410	O
mosmol/kg	O
and	O
urine	O
sodium	Chemical
63	O
mmol/L,	O
consistent	O
with	O
a	O
diagnosis	O
of	O
SIADH	Disease
.	O
Desvenlafaxine	Chemical
was	O
ceased	O
and	O
fluid	O
restriction	O
implemented.	O
After	O
4	O
days	O
the	O
sodium	Chemical
increased	O
to	O
128	O
mmol/L	O
and	O
fluid	O
restriction	O
was	O
relaxed.	O
During	O
her	O
further	O
3	O
weeks	O
inpatient	O
admission	O
the	O
serum	O
sodium	Chemical
ranged	O
from	O
134	O
to	O
137	O
mmol/L	O
during	O
treatment	O
with	O
mirtazapine	Chemical
.	O
DISCUSSION:	O
SIADH	Disease
has	O
been	O
widely	O
reported	O
with	O
a	O
range	O
of	O
antidepressants.	O
This	O
case	O
report	O
suggests	O
that	O
desvenlafaxine	Chemical
might	O
cause	O
clinically	O
significant	O
hyponatremia	Disease
.	O
CONCLUSIONS:	O
Clinicians	O
should	O
be	O
aware	O
of	O
the	O
potential	O
for	O
antidepressants	O
to	O
cause	O
hyponatremia	Disease

Oxidative	O
stress	O
on	O
cardiotoxicity	Disease
after	O
treatment	O
with	O
single	O
and	O
multiple	O
doses	O
of	O
doxorubicin	Chemical
.	O
The	O
mechanism	O
of	O
doxorubicin	Chemical
(	O
DOX	Chemical
)-induced	O
cardiotoxicity	Disease
remains	O
controversial.	O
Wistar	O
rats	O
(n	O
=	O
66)	O
received	O
DOX	Chemical
injections	O
intraperitoneally	O
and	O
were	O
randomly	O
assigned	O
to	O
2	O
experimental	O
protocols:	O
(1)	O
rats	O
were	O
killed	O
before	O
(-24	O
h,	O
n	O
=	O
8)	O
and	O
24	O
h	O
after	O
(+24	O
h,	O
n	O
=	O
8)	O
a	O
single	O
dose	O
of	O
DOX	Chemical
(4	O
mg/kg	O
body	O
weight)	O
to	O
determine	O
the	O
DOX	Chemical
acute	O
effect	O
and	O
(2)	O
rats	O
(n	O
=	O
58)	O
received	O
4	O
injections	O
of	O
DOX	Chemical
(4	O
mg/kg	O
body	O
weight/week)	O
and	O
were	O
killed	O
before	O
the	O
first	O
injection	O
(M0)	O
and	O
1	O
week	O
after	O
each	O
injection	O
(M1,	O
M2,	O
M3,	O
and	O
M4)	O
to	O
determine	O
the	O
chronological	O
effects.	O
Animals	O
used	O
at	O
M0	O
(n	O
=	O
8)	O
were	O
also	O
used	O
at	O
moment	O
-24	O
h	O
of	O
acute	O
study.	O
Cardiac	O
total	O
antioxidant	O
performance	O
(TAP),	O
DNA	O
damage,	O
and	O
morphology	O
analyses	O
were	O
carried	O
out	O
at	O
each	O
time	O
point.	O
Single	O
dose	O
of	O
DOX	Chemical
was	O
associated	O
with	O
increased	O
cardiac	Disease
disarrangement	Disease
,	O
necrosis	Disease
,	O
and	O
DNA	O
damage	O
(strand	O
breaks	O
(SBs)	O
and	O
oxidized	O
pyrimidines)	O
and	O
decreased	O
TAP.	O
The	O
chronological	O
study	O
showed	O
an	O
effect	O
of	O
a	O
cumulative	O
dose	O
on	O
body	O
weight	O
(R	O
=	O
-0.99,	O
p	O
=	O
0.011),	O
necrosis	Disease
(R	O
=	O
1.00,	O
p	O
=	O
0.004),	O
TAP	O
(R	O
=	O
0.95,	O
p	O
=	O
0.049),	O
and	O
DNA	O
SBs	O
(R	O
=	O
-0.95,	O
p	O
=	O
0.049).	O
DNA	O
SBs	O
damage	O
was	O
negatively	O
associated	O
with	O
TAP	O
(R	O
=	O
-0.98,	O
p	O
=	O
0.018),	O
and	O
necrosis	Disease
(R	O
=	O
-0.97,	O
p	O
=	O
0.027).	O
Our	O
results	O
suggest	O
that	O
oxidative	O
damage	O
is	O
associated	O
with	O
acute	O
cardiotoxicity	Disease
induced	O
by	O
a	O
single	O
dose	O
of	O
DOX	Chemical
only.	O
Increased	O
resistance	O
to	O
the	O
oxidative	O
stress	O
is	O
plausible	O
for	O
the	O
multiple	O
dose	O
of	O
DOX	Chemical
.	O
Thus,	O
different	O
mechanisms	O
may	O
be	O
involved	O
in	O
acute	O
toxicity	Disease
versus	O
chronic	O
toxicity	Disease

Tacrolimus	Chemical
-related	O
seizure	Disease
after	O
pediatric	O
liver	O
transplantation--a	O
single-center	O
experience.	O
To	O
identify	O
the	O
risk	O
factors	O
for	O
new-onset	O
seizures	Disease
after	O
pediatric	O
LT	O
and	O
to	O
assess	O
their	O
clinical	O
implications	O
and	O
long-term	O
prognosis.	O
The	O
clinical	O
and	O
laboratory	O
data	O
of	O
27	O
consecutive	O
children	O
who	O
underwent	O
LT	O
from	O
January	O
2007	O
to	O
December	O
2010	O
in	O
our	O
center	O
were	O
analyzed	O
retrospectively.	O
Patients	O
were	O
divided	O
into	O
seizures	Disease
group	O
and	O
a	O
non-	O
seizures	Disease
group.	O
Pre-operative,	O
intra-operative,	O
and	O
post-operative	O
data	O
were	O
collected.	O
Seizures	Disease
occurred	O
in	O
four	O
children,	O
an	O
incidence	O
of	O
14.8%.	O
All	O
exhibited	O
generalized	O
tonic-clonic	Disease
seizures	Disease
within	O
the	O
first	O
two	O
wk	O
after	O
LT.	O
Univariate	O
analysis	O
showed	O
that	O
the	O
risk	O
factors	O
associated	O
with	O
seizures	Disease
after	O
pediatric	O
LT	O
included	O
gender,	O
pediatric	O
end-stage	Disease
liver	Disease
disease	Disease
score	O
before	O
surgery,	O
Child-Pugh	O
score	O
before	O
surgery,	O
serum	O
total	O
bilirubin	Chemical
after	O
surgery,	O
and	O
trough	O
TAC	Chemical
level.	O
Multivariate	O
analysis	O
showed	O
that	O
trough	O
TAC	Chemical
level	O
was	O
the	O
only	O
independent	O
risk	O
factor	O
associated	O
with	O
the	O
seizures	Disease
.	O
All	O
children	O
who	O
experienced	O
seizures	Disease
survived	O
with	O
good	O
graft	O
function	O
and	O
remained	O
seizure	Disease
-free	O
without	O
anti-	O
epileptic	Disease
drugs	O
over	O
a	O
mean	O
follow-up	O
period	O
of	O
33.7	O
+	O
14.6	O
months.	O
High	O
trough	O
TAC	Chemical
level	O
was	O
the	O
predominant	O
factor	O
that	O
contributed	O
to	O
seizures	Disease
in	O
the	O
early	O
post-operative	O
period	O
after	O
pediatric	O
LT.	O
High	O
PELD	O
and	O
Child-Pugh	O
scores	O
before	O
LT	O
and	O
high	O
post-operative	O
serum	O
Tbil	O
may	O
be	O
contributory	O
risk	O
factors	O
for	O
TAC	Chemical
-related	O
seizures	Disease

The	O
flavonoid	Chemical
	O
apigenin	Chemical
delays	O
forgetting	O
of	O
passive	O
avoidance	O
conditioning	O
in	O
rats.	O
The	O
present	O
experiments	O
were	O
performed	O
to	O
study	O
the	O
effect	O
of	O
the	O
flavonoid	Chemical
	O
apigenin	Chemical
(20	O
mg/kg	O
intraperitoneally	O
(i.p.),	O
1	O
h	O
before	O
acquisition),	O
on	O
24	O
h	O
retention	O
performance	O
and	O
forgetting	O
of	O
a	O
step-through	O
passive	O
avoidance	O
task,	O
in	O
young	O
male	O
Wistar	O
rats.	O
There	O
were	O
no	O
differences	O
between	O
saline-	O
and	O
apigenin	Chemical
-treated	O
groups	O
in	O
the	O
24	O
h	O
retention	O
trial.	O
Furthermore,	O
apigenin	Chemical
did	O
not	O
prevent	O
the	O
amnesia	Disease
induced	O
by	O
scopolamine	Chemical
(1mg/kg,	O
i.p.,	O
30	O
min	O
before	O
the	O
acquisition).	O
The	O
saline-	O
and	O
apigenin	Chemical
-treated	O
rats	O
that	O
did	O
not	O
step	O
through	O
into	O
the	O
dark	O
compartment	O
during	O
the	O
cut-off	O
time	O
(540	O
s)	O
were	O
retested	O
weekly	O
for	O
up	O
to	O
eight	O
weeks.	O
In	O
the	O
saline	O
treated	O
group,	O
the	O
first	O
significant	O
decline	O
in	O
passive	O
avoidance	O
response	O
was	O
observed	O
at	O
four	O
weeks,	O
and	O
complete	O
memory	Disease
loss	Disease
was	O
found	O
five	O
weeks	O
after	O
the	O
acquisition	O
of	O
the	O
passive	O
avoidance	O
task.	O
At	O
the	O
end	O
of	O
the	O
experimental	O
period,	O
60%	O
of	O
the	O
animals	O
treated	O
with	O
apigenin	Chemical
still	O
did	O
not	O
step	O
through.	O
These	O
data	O
suggest	O
that	O
1)	O
apigenin	Chemical
delays	O
the	O
long-term	O
forgetting	O
but	O
did	O
not	O
modulate	O
the	O
24	O
h	O
retention	O
of	O
fear	O
memory	O
and	O
2)	O
the	O
obtained	O
beneficial	O
effect	O
of	O
apigenin	Chemical

Cholecystokinin-octapeptide	Chemical
restored	O
morphine	Chemical
-induced	O
hippocampal	O
long-term	O
potentiation	O
impairment	O
in	O
rats.	O
Cholecystokinin-octapeptide	Chemical
(	O
CCK-8	Chemical
),	O
which	O
is	O
a	O
typical	O
brain-gut	O
peptide,	O
exerts	O
a	O
wide	O
range	O
of	O
biological	O
activities	O
on	O
the	O
central	O
nervous	O
system.	O
We	O
have	O
previously	O
reported	O
that	O
CCK-8	Chemical
significantly	O
alleviated	O
morphine	Chemical
-induced	O
amnesia	Disease
and	O
reversed	O
spine	O
density	O
decreases	O
in	O
the	O
CA1	O
region	O
of	O
the	O
hippocampus	O
in	O
morphine	Chemical
-treated	O
animals.	O
Here,	O
we	O
investigated	O
the	O
effects	O
of	O
CCK-8	Chemical
on	O
long-term	O
potentiation	O
(LTP)	O
in	O
the	O
lateral	O
perforant	O
path	O
(LPP)-granule	O
cell	O
synapse	O
of	O
rat	O
dentate	O
gyrus	O
(DG)	O
in	O
acute	O
saline	O
or	O
morphine	Chemical
-treated	O
rats.	O
Population	O
spikes	O
(PS),	O
which	O
were	O
evoked	O
by	O
stimulation	O
of	O
the	O
LPP,	O
were	O
recorded	O
in	O
the	O
DG	O
region.	O
Acute	O
morphine	Chemical
(30mg/kg,	O
s.c.)	O
treatment	O
significantly	O
attenuated	O
hippocampal	O
LTP	O
and	O
CCK-8	Chemical
(1ug,	O
i.c.v.)	O
restored	O
the	O
amplitude	O
of	O
PS	O
that	O
was	O
attenuated	O
by	O
morphine	Chemical
injection.	O
Furthermore,	O
microinjection	O
of	O
CCK-8	Chemical
(0.1	O
and	O
1ug,	O
i.c.v.)	O
also	O
significantly	O
augmented	O
hippocampal	O
LTP	O
in	O
saline-treated	O
(1ml/kg,	O
s.c.)	O
rats.	O
Pre-treatment	O
of	O
the	O
CCK2	O
receptor	O
antagonist	O
L-365,260	O
(10ug,	O
i.c.v)	O
reversed	O
the	O
effects	O
of	O
CCK-8	Chemical
,	O
but	O
the	O
CCK1	O
receptor	O
antagonist	O
L-364,718	O
(10ug,	O
i.c.v)	O
did	O
not.	O
The	O
present	O
results	O
demonstrate	O
that	O
CCK-8	Chemical
attenuates	O
the	O
effect	O
of	O
morphine	Chemical
on	O
hippocampal	O
LTP	O
through	O
CCK2	O
receptors	O
and	O
suggest	O
an	O
ameliorative	O
function	O
of	O
CCK-8	Chemical
on	O
morphine	Chemical
-induced	O
memory	Disease
impairment	Disease

Glial	O
activation	O
and	O
post-synaptic	O
neurotoxicity	Disease
:	O
the	O
key	O
events	O
in	O
Streptozotocin	Chemical
(ICV)	O
induced	O
memory	Disease
impairment	Disease
in	O
rats.	O
In	O
the	O
present	O
study	O
the	O
role	O
of	O
glial	O
activation	O
and	O
post	O
synaptic	O
toxicity	Disease
in	O
ICV	O
Streptozotocin	Chemical
(	O
STZ	Chemical
)	O
induced	O
memory	Disease
impaired	Disease
rats	O
was	O
explored.	O
In	O
experiment	O
set	O
up	O
1:	O
Memory	Disease
deficit	Disease
was	O
found	O
in	O
Morris	O
water	O
maze	O
test	O
on	O
14-16	O
days	O
after	O
STZ	Chemical
(ICV;	O
3mg/Kg)	O
administration.	O
STZ	Chemical
causes	O
increased	O
expression	O
of	O
GFAP,	O
CD11b	O
and	O
TNF-a	O
indicating	O
glial	O
activation	O
and	O
neuroinflammation	Disease
.	O
STZ	Chemical
also	O
significantly	O
increased	O
the	O
level	O
of	O
ROS,	O
nitrite	Chemical
,	O
Ca	Chemical
(2+)	O
and	O
reduced	O
the	O
mitochondrial	O
activity	O
in	O
synaptosomal	O
preparation	O
illustrating	O
free	O
radical	O
generation	O
and	O
excitotoxicity	Disease
.	O
Increased	O
expression	O
and	O
activity	O
of	O
Caspase-3	O
was	O
also	O
observed	O
in	O
STZ	Chemical
treated	O
rat	O
which	O
specify	O
apoptotic	O
cell	O
death	O
in	O
hippocampus	O
and	O
cortex.	O
STZ	Chemical
treatment	O
showed	O
decrease	O
expression	O
of	O
post	O
synaptic	O
markers	O
CaMKIIa	O
and	O
PSD-95,	O
while,	O
expression	O
of	O
pre	O
synaptic	O
markers	O
(synaptophysin	O
and	O
SNAP-25)	O
remains	O
unaltered	O
indicating	O
selective	O
post	O
synaptic	O
neurotoxicity	Disease
.	O
Oral	O
treatment	O
with	O
Memantine	Chemical
(10mg/kg)	O
and	O
Ibuprofen	Chemical
(50	O
mg/kg)	O
daily	O
for	O
13	O
days	O
attenuated	O
STZ	Chemical
induced	O
glial	O
activation,	O
apoptotic	O
cell	O
death	O
and	O
post	O
synaptic	O
neurotoxicity	Disease
in	O
rat	O
brain.	O
Further,	O
in	O
experiment	O
set	O
up	O
2:	O
where	O
memory	O
function	O
was	O
not	O
affected	O
i.e.	O
7-9	O
days	O
after	O
STZ	Chemical
treatment.	O
The	O
level	O
of	O
GFAP,	O
CD11b,	O
TNF-a,	O
ROS	O
and	O
nitrite	Chemical
levels	O
were	O
increased.	O
On	O
the	O
other	O
hand,	O
apoptotic	O
marker,	O
synaptic	O
markers,	O
mitochondrial	O
activity	O
and	O
Ca	Chemical
(2+)	O
levels	O
remained	O
unaffected.	O
Collective	O
data	O
indicates	O
that	O
neuroinflammatory	Disease
process	O
and	O
oxidative	O
stress	O
occurs	O
earlier	O
to	O
apoptosis	O
and	O
does	O
not	O
affect	O
memory	O
function.	O
Present	O
study	O
clearly	O
suggests	O
that	O
glial	O
activation	O
and	O
post	O
synaptic	O
neurotoxicity	Disease
are	O
the	O
key	O
factors	O
in	O
STZ	Chemical
induced	O
memory	Disease
impairment	Disease

Comparison	O
of	O
effects	O
of	O
isotonic	O
sodium	Chemical
chloride	Chemical
with	O
diltiazem	Chemical
in	O
prevention	O
of	O
contrast	Chemical
-induced	O
nephropathy	Disease
.	O
INTRODUCTION	O
AND	O
OBJECTIVE:	O
Contrast	Chemical
-induced	O
nephropathy	Disease
(CIN)	O
significantly	O
increases	O
the	O
morbidity	O
and	O
mortality	O
of	O
patients.	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
and	O
compare	O
the	O
protective	O
effects	O
of	O
isotonic	O
sodium	Chemical
chloride	Chemical
with	O
sodium	Chemical
bicarbonate	Chemical
infusion	O
and	O
isotonic	O
sodium	Chemical
chloride	Chemical
infusion	O
with	O
diltiazem	Chemical
,	O
a	O
calcium	Chemical
channel	O
blocker,	O
in	O
preventing	O
CIN.	O
MATERIALS	O
AND	O
METHODS:	O
Our	O
study	O
included	O
patients	O
who	O
were	O
administered	O
30-60	O
mL	O
of	O
iodinated	O
contrast	Chemical
agent	O
for	O
percutaneous	O
coronary	O
angiography	O
(PCAG),	O
all	O
with	O
creatinine	Chemical
values	O
between	O
1.1	O
and	O
3.1	O
mg/dL.	O
Patients	O
were	O
divided	O
into	O
three	O
groups	O
and	O
each	O
group	O
had	O
20	O
patients.	O
The	O
first	O
group	O
of	O
patients	O
was	O
administered	O
isotonic	O
sodium	Chemical
chloride	Chemical
;	O
the	O
second	O
group	O
was	O
administered	O
a	O
solution	O
that	O
of	O
5%	O
dextrose	Chemical
and	O
sodium	Chemical
bicarbonate	Chemical
,	O
while	O
the	O
third	O
group	O
was	O
administered	O
isotonic	O
sodium	Chemical
chloride	Chemical
before	O
and	O
after	O
the	O
contrast	Chemical
injection.	O
The	O
third	O
group	O
received	O
an	O
additional	O
injection	O
of	O
diltiazem	Chemical
the	O
day	O
before	O
and	O
first	O
2	O
days	O
after	O
the	O
contrast	Chemical
injection.	O
All	O
of	O
the	O
patients'	O
plasma	O
blood	Chemical
urea	Chemical
nitrogen	Chemical
(	O
BUN	Chemical
)	O
and	O
creatinine	Chemical
levels	O
were	O
measured	O
on	O
the	O
second	O
and	O
seventh	O
day	O
after	O
the	O
administration	O
of	O
intravenous	O
contrast	Chemical
material.	O
RESULTS:	O
The	O
basal	O
creatinine	Chemical
levels	O
were	O
similar	O
for	O
all	O
three	O
groups	O
(p	O
>	O
0.05).	O
Among	O
a	O
total	O
of	O
60	O
patients	O
included	O
in	O
the	O
study,	O
16	O
patients	O
developed	O
acute	Disease
renal	Disease
failure	Disease
(	O
ARF	Disease
)	O
on	O
the	O
second	O
day	O
after	O
contrast	Chemical
material	O
was	O
injected	O
(26.6%).	O
The	O
number	O
of	O
patients	O
who	O
developed	O
ARF	Disease
on	O
the	O
second	O
day	O
after	O
the	O
injection	O
in	O
the	O
first	O
group	O
was	O
five	O
(25%),	O
in	O
the	O
second	O
group	O
was	O
six	O
(30%)	O
and	O
the	O
third	O
group	O
was	O
five	O
(25%)	O
(p	O
>	O
0.05).	O
CONCLUSION:	O
There	O
was	O
no	O
significant	O
difference	O
between	O
isotonic	O
sodium	Chemical
chloride	Chemical
,	O
sodium	Chemical
bicarbonate	Chemical
and	O
isotonic	O
sodium	Chemical
chloride	Chemical
with	O
diltiazem	Chemical

Neurocognitive	O
and	O
neuroradiologic	O
central	O
nervous	O
system	O
late	O
effects	O
in	O
children	O
treated	O
on	O
Pediatric	O
Oncology	O
Group	O
(POG)	O
P9605	O
(standard	O
risk)	O
and	O
P9201	O
(lesser	O
risk)	O
acute	Disease
lymphoblastic	Disease
leukemia	Disease
protocols	O
(ACCL0131):	O
a	O
methotrexate	Chemical
consequence?	O
A	O
report	O
from	O
the	O
Children's	O
Oncology	O
Group.	O
Concerns	O
about	O
long-term	O
methotrexate	Chemical
(	O
MTX	Chemical
)	O
neurotoxicity	Disease
in	O
the	O
1990s	O
led	O
to	O
modifications	O
in	O
intrathecal	O
(IT)	O
therapy,	O
leucovorin	O
rescue,	O
and	O
frequency	O
of	O
systemic	O
MTX	Chemical
administration	O
in	O
children	O
with	O
acute	Disease
lymphoblastic	Disease
leukemia	Disease
.	O
In	O
this	O
study,	O
neurocognitive	O
outcomes	O
and	O
neuroradiologic	O
evidence	O
of	O
leukoencephalopathy	Disease
were	O
compared	O
in	O
children	O
treated	O
with	O
intense	O
central	O
nervous	O
system	O
(CNS)-directed	O
therapy	O
(P9605)	O
versus	O
those	O
receiving	O
fewer	O
CNS-directed	O
treatment	O
days	O
during	O
intensive	O
consolidation	O
(P9201).	O
A	O
total	O
of	O
66	O
children	O
from	O
16	O
Pediatric	O
Oncology	O
Group	O
institutions	O
with	O
"standard-risk"	O
acute	Disease
lymphoblastic	Disease
leukemia	Disease
,	O
1.00	O
to	O
9.99	O
years	O
at	O
diagnosis,	O
without	O
evidence	O
of	O
CNS	O
leukemia	Disease
at	O
diagnosis	O
were	O
enrolled	O
on	O
ACCL0131:	O
28	O
from	O
P9201	O
and	O
38	O
from	O
P9605.	O
Magnetic	O
resonance	O
imaging	O
scans	O
and	O
standard	O
neuropsychological	O
tests	O
were	O
performed	O
>2.6	O
years	O
after	O
the	O
end	O
of	O
treatment.	O
Significantly	O
more	O
P9605	O
patients	O
developed	O
leukoencephalopathy	Disease
compared	O
with	O
P9201	O
patients	O
(68%,	O
95%	O
confidence	O
interval	O
49%-83%	O
vs.	O
22%,	O
95%	O
confidence	O
interval	O
5%-44%;	O
P=0.001)	O
identified	O
as	O
late	O
as	O
7.7	O
years	O
after	O
the	O
end	O
of	O
treatment.	O
Overall,	O
40%	O
of	O
patients	O
scored	O
<85	O
on	O
either	O
Verbal	O
or	O
Performance	O
IQ.	O
Children	O
on	O
both	O
studies	O
had	O
significant	O
attention	Disease
problems	Disease
,	O
but	O
P9605	O
children	O
scored	O
below	O
average	O
on	O
more	O
neurocognitive	O
measures	O
than	O
those	O
treated	O
on	O
P9201	O
(82%,	O
14/17	O
measures	O
vs.	O
24%,	O
4/17	O
measures).	O
This	O
supports	O
ongoing	O
concerns	O
about	O
intensive	O
MTX	Chemical

Tranexamic	Chemical
acid	Chemical
overdosage-induced	O
generalized	O
seizure	Disease
in	O
renal	Disease
failure	Disease
.	O
We	O
report	O
a	O
45-year-old	O
lady	O
with	O
chronic	Disease
kidney	Disease
disease	Disease
stage	O
4	O
due	O
to	O
chronic	O
tubulointerstial	Disease
disease	Disease
.	O
She	O
was	O
admitted	O
to	O
our	O
center	O
for	O
severe	O
anemia	Disease
due	O
to	O
menorrhagia	Disease
and	O
deterioration	Disease
of	Disease
renal	Disease
function	Disease
.	O
She	O
was	O
infused	O
three	O
units	O
of	O
packed	O
cells	O
during	O
a	O
session	O
of	O
hemodialysis.	O
Tranexamic	Chemical
acid	Chemical
(	O
TNA	Chemical
)	O
1	O
g	O
8-hourly	O
was	O
administered	O
to	O
her	O
to	O
control	O
bleeding	Disease
per	O
vaginum.	O
Two	O
hours	O
after	O
the	O
sixth	O
dose	O
of	O
TNA	Chemical
,	O
she	O
had	O
an	O
episode	O
of	O
generalized	O
tonic	Disease
clonic	Disease
convulsions	Disease
.	O
TNA	Chemical
was	O
discontinued.	O
Investigations	O
of	O
the	O
patient	O
revealed	O
no	O
biochemical	O
or	O
structural	O
central	O
nervous	Disease
system	Disease
abnormalities	Disease
that	O
could	O
have	O
provoked	O
the	O
convulsions	Disease
.	O
She	O
did	O
not	O
require	O
any	O
further	O
dialytic	O
support.	O
She	O
had	O
no	O
further	O
episodes	O
of	O
convulsion	Disease
till	O
dis-charge	O
and	O
during	O
the	O
two	O
months	O
of	O
follow-up.	O
Thus,	O
the	O
precipitating	O
cause	O
of	O
convulsions	Disease
was	O
believed	O
to	O
be	O
an	O
overdose	Disease
of	O
TNA	Chemical

Pre-treatment	O
of	O
bupivacaine	Chemical
-induced	O
cardiovascular	Disease
depression	Disease
using	O
different	O
lipid	O
formulations	O
of	O
propofol	Chemical
.	O
BACKGROUND:	O
Pre-treatment	O
with	O
lipid	O
emulsions	O
has	O
been	O
shown	O
to	O
increase	O
lethal	O
doses	O
of	O
bupivacaine	Chemical
,	O
and	O
the	O
lipid	O
content	O
of	O
propofol	Chemical
may	O
alleviate	O
bupivacaine	Chemical
-induced	O
cardiotoxicity	Disease
.	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
the	O
effects	O
of	O
propofol	Chemical
in	O
intralipid	O
or	O
medialipid	O
emulsions	O
on	O
bupivacaine	Chemical
-induced	O
cardiotoxicity	Disease
.	O
METHODS:	O
Rats	O
were	O
anaesthetised	O
with	O
ketamine	Chemical
and	O
were	O
given	O
0.5	O
mg/kg/min	O
propofol	Chemical
in	O
intralipid	O
(Group	O
P),	O
propofol	Chemical
in	O
medialipid	O
(Group	O
L),	O
or	O
saline	O
(Group	O
C)	O
over	O
20	O
min.	O
Thereafter,	O
2	O
mg/kg/min	O
bupivacaine	Chemical
0.5%	O
was	O
infused.	O
We	O
recorded	O
time	O
to	O
first	O
dysrhythmia	Disease
occurrence,	O
respective	O
times	O
to	O
25%	O
and	O
50%	O
reduction	O
of	O
the	O
heart	O
rate	O
(HR)	O
and	O
mean	O
arterial	O
pressure,	O
and	O
time	O
to	O
asystole	Disease
and	O
total	O
amount	O
of	O
bupivacaine	Chemical
consumption.	O
Blood	O
and	O
tissue	O
samples	O
were	O
collected	O
following	O
asystole	Disease
.	O
RESULTS:	O
The	O
time	O
to	O
first	O
dysrhythmia	Disease
occurrence,	O
time	O
to	O
25%	O
and	O
50%	O
reductions	O
in	O
HR,	O
and	O
time	O
to	O
asystole	Disease
were	O
longer	O
in	O
Group	O
P	O
than	O
the	O
other	O
groups.	O
The	O
cumulative	O
bupivacaine	Chemical
dose	O
given	O
at	O
those	O
time	O
points	O
was	O
higher	O
in	O
Group	O
P.	O
Plasma	O
bupivacaine	Chemical
levels	O
were	O
significantly	O
lower	O
in	O
Group	O
P	O
than	O
in	O
Group	O
C.	O
Bupivacaine	Chemical
levels	O
in	O
the	O
brain	O
and	O
heart	O
were	O
significantly	O
lower	O
in	O
Group	O
P	O
and	O
Group	O
L	O
than	O
in	O
Group	O
C.	O
CONCLUSION:	O
We	O
conclude	O
that	O
pre-treatment	O
with	O
propofol	Chemical
in	O
intralipid,	O
compared	O
with	O
propofol	Chemical
in	O
medialipid	O
or	O
saline,	O
delayed	O
the	O
onset	O
of	O
bupivacaine	Chemical
-induced	O
cardiotoxic	Disease
effects	O
as	O
well	O
as	O
reduced	O
plasma	O
bupivacaine	Chemical
levels.	O
Further	O
studies	O
are	O
needed	O
to	O
explore	O
tissue	O
bupivacaine	Chemical
levels	O
of	O
propofol	Chemical

Drug-Induced	Disease
Acute	Disease
Liver	Disease
Injury	Disease
Within	O
12	O
Hours	O
After	O
Fluvastatin	Chemical
Therapy.	O
Although	O
statins	Chemical
are	O
generally	O
well-tolerated	O
drugs,	O
recent	O
cases	O
of	O
drug-induced	Disease
liver	Disease
injury	Disease
associated	O
with	O
their	O
use	O
have	O
been	O
reported.	O
A	O
52-year-old	O
Chinese	O
man	O
reported	O
with	O
liver	Disease
damage	Disease
,	O
which	O
appeared	O
12	O
hours	O
after	O
beginning	O
treatment	O
with	O
fluvastatin	Chemical
.	O
Patient	O
presented	O
with	O
complaints	O
of	O
increasing	O
nausea	Disease
,	O
anorexia	Disease
,	O
and	O
upper	O
abdominal	Disease
pain	Disease
.	O
His	O
laboratory	O
values	O
showed	O
elevated	O
creatine	Chemical
kinase	O
and	O
transaminases.	O
Testing	O
for	O
autoantibodies	O
was	O
also	O
negative.	O
The	O
liver	O
biochemistries	O
eventually	O
normalized	O
within	O
3	O
weeks	O
of	O
stopping	O
the	O
fluvastatin	Chemical
.	O
Therefore,	O
when	O
prescribing	O
statins,	O
the	O
possibility	O
of	O
hepatic	Disease
damage	Disease

Fluconazole	Chemical
associated	O
agranulocytosis	Disease
and	O
thrombocytopenia	Disease
.	O
CASE:	O
We	O
describe	O
a	O
second	O
case	O
of	O
fluconazole	Chemical
associated	O
agranulocytosis	Disease
with	O
thrombocytopenia	Disease
and	O
recovery	O
upon	O
discontinuation	O
of	O
therapy.	O
The	O
patient	O
began	O
to	O
have	O
changes	O
in	O
white	O
blood	O
cells	O
and	O
platelets	O
within	O
48	O
h	O
of	O
administration	O
of	O
fluconazole	Chemical
and	O
began	O
to	O
recover	O
with	O
48	O
h	O
of	O
discontinuation.	O
This	O
case	O
highlights	O
that	O
drug-induced	O
blood	Disease
dyscrasias	Disease
can	O
occur	O
unexpectedly	O
as	O
a	O
result	O
of	O
treatment	O
with	O
a	O
commonly	O
used	O
drug	O
thought	O
to	O
be	O
"safe".	O
CONCLUSION:	O
According	O
to	O
Naranjo's	O
algorithm	O
the	O
likelihood	O
that	O
our	O
patient's	O
agranulocytosis	Disease
and	O
thrombocytopenia	Disease
occurred	O
as	O
a	O
result	O
of	O
therapy	O
with	O
fluconazole	Chemical
is	O
probable,	O
with	O
a	O
total	O
of	O
six	O
points.	O
We	O
feel	O
that	O
the	O
weight	O
of	O
the	O
overall	O
evidence	O
of	O
this	O
evidence	O
is	O
strong.	O
In	O
particular	O
the	O
temporal	O
relationship	O
of	O
bone	Disease
marrow	Disease
suppression	Disease
to	O
the	O
initiation	O
of	O
fluconazole	Chemical

Two-dimensional	O
speckle	O
tracking	O
echocardiography	O
combined	O
with	O
high-sensitive	O
cardiac	O
troponin	O
T	O
in	O
early	O
detection	O
and	O
prediction	O
of	O
cardiotoxicity	Disease
during	O
epirubicine	Chemical
-based	O
chemotherapy.	O
AIMS:	O
To	O
investigate	O
whether	O
alterations	O
of	O
myocardial	Disease
strain	Disease
and	O
high-sensitive	O
cardiac	O
troponin	O
T	O
(cTnT)	O
could	O
predict	O
future	O
cardiac	Disease
dysfunction	Disease
in	O
patients	O
after	O
epirubicin	Chemical
exposure.	O
METHODS:	O
Seventy-five	O
patients	O
with	O
non-Hodgkin	Disease
lymphoma	Disease
treated	O
with	O
epirubicin	Chemical
were	O
studied.	O
Blood	O
collection	O
and	O
echocardiography	O
were	O
performed	O
at	O
baseline,	O
1	O
day	O
after	O
the	O
third	O
cycle,	O
and	O
1	O
day	O
after	O
completion	O
of	O
chemotherapy.	O
Patients	O
were	O
studied	O
using	O
echocardiography	O
during	O
follow-up.	O
Global	O
longitudinal	O
(GLS),	O
circumferential	O
(GCS),	O
and	O
radial	O
strain	O
(GRS)	O
were	O
calculated	O
using	O
speckle	O
tracking	O
echocardiography.	O
Left	O
ventricular	O
ejection	O
fraction	O
was	O
analysed	O
by	O
real-time	O
3D	O
echocardiography.	O
Cardiotoxicity	Disease
was	O
defined	O
as	O
a	O
reduction	O
of	O
the	O
LVEF	O
of	O
>5%	O
to	O
<55%	O
with	O
symptoms	O
of	O
heart	Disease
failure	Disease
or	O
an	O
asymptomatic	O
reduction	O
of	O
the	O
LVEF	O
of	O
>10%	O
to	O
<55%.	O
RESULTS:	O
Fourteen	O
patients	O
(18.67%)	O
developed	O
cardiotoxicity	Disease
after	O
treatment.	O
GLS	O
(-18.48	O
+	O
1.72%	O
vs.	O
-15.96	O
+	O
1.6%),	O
GCS	O
(-20.93	O
+	O
2.86%	O
vs.	O
-19.20	O
+	O
3.21%),	O
and	O
GRS	O
(39.23	O
+	O
6.44%	O
vs.	O
34.98	O
+	O
6.2%)	O
were	O
markedly	O
reduced	O
and	O
cTnT	O
was	O
elevated	O
from	O
0.0010	O
+	O
0.0020	O
to	O
0.0073	O
+	O
0.0038	O
ng/mL	O
(P	O
all	O
<	O
0.01)	O
at	O
the	O
completion	O
of	O
chemotherapy	O
compared	O
with	O
baseline	O
values.	O
A	O
>15.9%	O
decrease	O
in	O
GLS	O
[sensitivity,	O
86%;	O
specificity,	O
75%;	O
area	O
under	O
the	O
curve	O
(AUC)	O
=	O
0.815;	O
P	O
=	O
0.001]	O
and	O
a	O
>0.004	O
ng/mL	O
elevation	O
in	O
cTnT	O
(sensitivity,	O
79%;	O
specificity,	O
64%;	O
AUC	O
=	O
0.757;	O
P	O
=	O
0.005)	O
from	O
baseline	O
to	O
the	O
third	O
cycle	O
of	O
chemotherapy	O
predicted	O
later	O
cardiotoxicity	Disease
.	O
The	O
decrease	O
in	O
GLS	O
remained	O
the	O
only	O
independent	O
predictor	O
of	O
cardiotoxicity	Disease
(P	O
=	O
0.000).	O
CONCLUSIONS:	O
GLS	O
combined	O
with	O
cTnT	O
may	O
provide	O
a	O
reliable	O
and	O
non-invasive	O
method	O
to	O
predict	O
cardiac	Disease
dysfunction	Disease
in	O
patients	O
receiving	O
anthracycline	Chemical

Prevention	O
of	O
etomidate	Chemical
-induced	O
myoclonus	Disease
:	O
which	O
is	O
superior:	O
Fentanyl	Chemical
,	O
midazolam	Chemical
,	O
or	O
a	O
combination?	O
A	O
Retrospective	O
comparative	O
study.	O
BACKGROUND:	O
In	O
this	O
retrospective	O
comparative	O
study,	O
we	O
aimed	O
to	O
compare	O
the	O
effectiveness	O
of	O
fentanyl	Chemical
,	O
midazolam	Chemical
,	O
and	O
a	O
combination	O
of	O
fentanyl	Chemical
and	O
midazolam	Chemical
to	O
prevent	O
etomidate	Chemical
-induced	O
myoclonus	Disease
.	O
MATERIAL	O
AND	O
METHODS:	O
This	O
study	O
was	O
performed	O
based	O
on	O
anesthesia	O
records.	O
Depending	O
on	O
the	O
drugs	O
that	O
would	O
be	O
given	O
before	O
the	O
induction	O
of	O
anesthesia	O
with	O
etomidate	Chemical
,	O
the	O
patients	O
were	O
separated	O
into	O
4	O
groups:	O
no	O
pretreatment	O
(Group	O
NP),	O
fentanyl	Chemical
1	O
ug.kg-1	O
(Group	O
F),	O
midazolam	Chemical
0.03	O
mg.kg-1	O
(Group	O
M),	O
and	O
midazolam	Chemical
0.015	O
mg.kg-1	O
+	O
fentanyl	Chemical
0.5	O
ug.kg-1	O
(Group	O
FM).	O
Patients	O
who	O
received	O
the	O
same	O
anesthetic	O
procedure	O
were	O
selected:	O
2	O
minutes	O
after	O
intravenous	O
injections	O
of	O
the	O
pretreatment	O
drugs,	O
anesthesia	O
is	O
induced	O
with	O
0.3	O
mg.kg-1	O
etomidate	Chemical
injected	O
intravenously	O
over	O
a	O
period	O
of	O
20-30	O
seconds.	O
Myoclonic	Disease
movements	Disease
are	O
evaluated,	O
which	O
were	O
observed	O
and	O
graded	O
according	O
to	O
clinical	O
severity	O
during	O
the	O
2	O
minutes	O
after	O
etomidate	Chemical
injection.	O
The	O
severity	O
of	O
pain	Disease
due	O
to	O
etomidate	Chemical
injection,	O
mean	O
arterial	O
pressure,	O
heart	O
rate,	O
and	O
adverse	O
effects	O
were	O
also	O
evaluated.	O
RESULTS:	O
Study	O
results	O
showed	O
that	O
myoclonus	Disease
incidence	O
was	O
85%,	O
40%,	O
70%,	O
and	O
25%	O
in	O
Group	O
NP,	O
Group	O
F,	O
Group	O
M,	O
and	O
Group	O
FM,	O
respectively,	O
and	O
were	O
significantly	O
lower	O
in	O
Group	O
F	O
and	O
Group	O
FM.	O
CONCLUSIONS:	O
We	O
conclude	O
that	O
pretreatment	O
with	O
fentanyl	Chemical
or	O
combination	O
of	O
fentanyl	Chemical
and	O
midazolam	Chemical
was	O
effective	O
in	O
preventing	O
etomidate	Chemical
-induced	O
myoclonus	Disease

Cholestatic	Disease
presentation	O
of	O
yellow	O
phosphorus	Chemical
	O
poisoning	Disease
.	O
Yellow	O
phosphorus	Chemical
,	O
a	O
component	O
of	O
certain	O
pesticide	O
pastes	O
and	O
fireworks,	O
is	O
well	O
known	O
to	O
cause	O
hepatotoxicity	Disease
.	O
Poisoning	Disease
with	O
yellow	O
phosphorus	Chemical
classically	O
manifests	O
with	O
acute	Disease
hepatitis	Disease
leading	O
to	O
acute	Disease
liver	Disease
failure	Disease
which	O
may	O
need	O
liver	O
transplantation.	O
We	O
present	O
a	O
case	O
of	O
yellow	O
phosphorus	Chemical
	O
poisoning	Disease
in	O
which	O
a	O
patient	O
presented	O
with	O
florid	O
clinical	O
features	O
of	O
cholestasis	Disease
highlighting	O
the	O
fact	O
that	O
cholestasis	Disease
can	O
rarely	O
be	O
a	O
presenting	O
feature	O
of	O
yellow	O
phosphorus	Chemical
	O
hepatotoxicity	Disease

Vasovagal	Disease
syncope	Disease
and	O
severe	O
bradycardia	Disease
following	O
intranasal	O
dexmedetomidine	Chemical
for	O
pediatric	O
procedural	O
sedation.	O
We	O
report	O
syncope	Disease
and	O
bradycardia	Disease
in	O
an	O
11-year-old	O
girl	O
following	O
administration	O
of	O
intranasal	O
dexmedetomidine	Chemical
for	O
sedation	O
for	O
a	O
voiding	O
cystourethrogram.	O
Following	O
successful	O
completion	O
of	O
VCUG	O
and	O
a	O
60-min	O
recovery	O
period,	O
the	O
patient's	O
level	O
of	O
consciousness	O
and	O
vital	O
signs	O
returned	O
to	O
presedation	O
levels.	O
Upon	O
leaving	O
the	O
sedation	O
area,	O
the	O
patient	O
collapsed,	O
with	O
no	O
apparent	O
inciting	O
event.	O
The	O
patient	O
quickly	O
regained	O
consciousness	O
and	O
no	O
injury	O
occurred.	O
The	O
primary	O
abnormality	O
found	O
was	O
persistent	O
bradycardia	Disease
,	O
and	O
she	O
was	O
admitted	O
to	O
the	O
hospital	O
for	O
telemetric	O
observation.	O
The	O
bradycardia	Disease

Paradoxical	O
severe	O
agitation	Disease
induced	O
by	O
add-on	O
high-doses	O
quetiapine	Chemical
in	O
schizo-affective	Disease
disorder	Disease
.	O
We	O
report	O
the	O
case	O
of	O
a	O
35-year-old	O
patient	O
suffering	O
from	O
schizo-affective	Disease
disorder	Disease
since	O
the	O
age	O
of	O
19	O
years,	O
treated	O
by	O
a	O
combination	O
of	O
first-generation	O
antipsychotics,	O
zuclopenthixol	Chemical
(100	O
mg/day)	O
and	O
lithium	Chemical
(1200	O
mg/day)	O
(serum	O
lithium	Chemical
=0.85	O
mEq/l).	O
This	O
patient	O
had	O
no	O
associated	O
personality	Disease
disorder	Disease
(particularly	O
no	O
antisocial	Disease
disorder	Disease
)	O
and	O
no	O
substance	Disease
abuse	Disease
disorder	Disease
.	O
Within	O
the	O
48	O
h	O
following	O
the	O
gradual	O
introduction	O
of	O
quetiapine	Chemical
(up	O
to	O
600	O
mg/day),	O
the	O
patient	O
presented	O
severe	O
agitation	Disease
without	O
an	O
environmental	O
explanation,	O
contrasting	O
with	O
the	O
absence	O
of	O
a	O
history	O
of	O
aggressiveness	Disease
or	O
personality	Disease
disorder	Disease
.	O
The	O
diagnoses	O
of	O
manic	Disease
shift	O
and	O
akathisia	Disease
were	O
dismissed.	O
The	O
withdrawal	O
and	O
the	O
gradual	O
reintroduction	O
of	O
quetiapine	Chemical
2	O
weeks	O
later,	O
which	O
led	O
to	O
another	O
severe	O
agitation	Disease
,	O
enabled	O
us	O
to	O
attribute	O
the	O
agitation	Disease
specifically	O
to	O
quetiapine	Chemical

Antioxidant	O
effects	O
of	O
bovine	O
lactoferrin	O
on	O
dexamethasone	Chemical
-induced	O
hypertension	Disease
in	O
rat.	O
Dexamethasone	Chemical
-	O
(	O
Dex	Chemical
-)	O
induced	O
hypertension	Disease
is	O
associated	O
with	O
enhanced	O
oxidative	O
stress.	O
Lactoferrin	O
(LF)	O
is	O
an	O
iron	Chemical
-binding	O
glycoprotein	O
with	O
antihypertensive	O
properties.	O
In	O
this	O
study,	O
we	O
investigated	O
the	O
effect	O
of	O
chronic	O
administration	O
of	O
LF	O
on	O
oxidative	O
stress	O
and	O
hypertension	Disease
upon	O
Dex	Chemical
administration.	O
Male	O
Wistar	O
rats	O
were	O
treated	O
by	O
Dex	Chemical
(30	O
	O
u	O
g/kg/day	O
subcutaneously)	O
or	O
saline	O
for	O
14	O
days.	O
Oral	O
bovine	O
LF	O
(30,	O
100,	O
300	O
mg/kg)	O
was	O
given	O
from	O
day	O
8	O
to	O
14	O
in	O
a	O
reversal	O
study.	O
In	O
a	O
prevention	O
study,	O
rats	O
received	O
4	O
days	O
of	O
LF	O
treatment	O
followed	O
by	O
Dex	Chemical
and	O
continued	O
during	O
the	O
test	O
period.	O
Systolic	O
blood	O
pressure	O
(SBP)	O
was	O
measured	O
using	O
tail-cuff	O
method.	O
Thymus	O
weight	O
was	O
used	O
as	O
a	O
marker	O
of	O
glucocorticoid	O
activity.	O
Plasma	O
hydrogen	Chemical
peroxide	Chemical
(	O
H2O2	Chemical
)	O
concentration	O
and	O
ferric	O
reducing	O
antioxidant	O
power	O
(FRAP)	O
value	O
were	O
determined.	O
Dexamethasone	Chemical
significantly	O
increased	O
SBP	O
and	O
plasma	O
H2O2	Chemical
level	O
and	O
decreased	O
thymus	O
and	O
body	O
weights.	O
LF	O
lowered	O
(P	O
<	O
0.01)	O
and	O
dose	O
dependently	O
prevented	O
(P	O
<	O
0.001)	O
Dex	Chemical
-induced	O
hypertension	Disease
.	O
LF	O
prevented	O
body	O
weight	Disease
loss	Disease
and	O
significantly	O
reduced	O
the	O
elevated	O
plasma	O
H2O2	Chemical
and	O
increased	O
FRAP	O
values.	O
Chronic	O
administration	O
of	O
LF	O
strongly	O
reduced	O
the	O
blood	O
pressure	O
and	O
production	O
of	O
ROS	O
and	O
improved	O
antioxidant	O
capacity	O
in	O
Dex	Chemical
-induced	O
hypertension	Disease

The	O
association	O
between	O
tranexamic	Chemical
acid	Chemical
and	O
convulsive	Disease
	O
seizures	Disease
after	O
cardiac	O
surgery:	O
a	O
multivariate	O
analysis	O
in	O
11	O
529	O
patients.	O
Because	O
of	O
a	O
lack	O
of	O
contemporary	O
data	O
regarding	O
seizures	Disease
after	O
cardiac	O
surgery,	O
we	O
undertook	O
a	O
retrospective	O
analysis	O
of	O
prospectively	O
collected	O
data	O
from	O
11	O
529	O
patients	O
in	O
whom	O
cardiopulmonary	O
bypass	O
was	O
used	O
from	O
January	O
2004	O
to	O
December	O
2010.	O
A	O
convulsive	Disease
	O
seizure	Disease
was	O
defined	O
as	O
a	O
transient	O
episode	O
of	O
disturbed	O
brain	O
function	O
characterised	O
by	O
abnormal	Disease
involuntary	Disease
motor	Disease
movements	Disease
.	O
Multivariate	O
regression	O
analysis	O
was	O
performed	O
to	O
identify	O
independent	O
predictors	O
of	O
postoperative	O
seizures	Disease
.	O
A	O
total	O
of	O
100	O
(0.9%)	O
patients	O
developed	O
postoperative	O
convulsive	Disease
	O
seizures	Disease
.	O
Generalised	Disease
and	Disease
focal	Disease
seizures	Disease
were	O
identified	O
in	O
68	O
and	O
32	O
patients,	O
respectively.	O
The	O
median	O
(IQR	O
[range])	O
time	O
after	O
surgery	O
when	O
the	O
seizure	Disease
occurred	O
was	O
7	O
(6-12	O
[1-216])	O
h	O
and	O
8	O
(6-11	O
[4-18])	O
h,	O
respectively.	O
Epileptiform	O
findings	O
on	O
electroencephalography	O
were	O
seen	O
in	O
19	O
patients.	O
Independent	O
predictors	O
of	O
postoperative	O
seizures	Disease
included	O
age,	O
female	O
sex,	O
redo	O
cardiac	O
surgery,	O
calcification	O
of	O
ascending	O
aorta,	O
congestive	Disease
heart	Disease
failure	Disease
,	O
deep	O
hypothermic	Disease
circulatory	O
arrest,	O
duration	O
of	O
aortic	O
cross-clamp	O
and	O
tranexamic	Chemical
acid	Chemical
.	O
When	O
tested	O
in	O
a	O
multivariate	O
regression	O
analysis,	O
tranexamic	Chemical
acid	Chemical
was	O
a	O
strong	O
independent	O
predictor	O
of	O
seizures	Disease
(OR	O
14.3,	O
95%	O
CI	O
5.5-36.7;	O
p	O
<	O
0.001).	O
Patients	O
with	O
convulsive	Disease
	O
seizures	Disease
had	O
2.5	O
times	O
higher	O
in-hospital	O
mortality	O
rates	O
and	O
twice	O
the	O
length	O
of	O
hospital	O
stay	O
compared	O
with	O
patients	O
without	O
convulsive	Disease
	O
seizures	Disease
.	O
Mean	O
(IQR	O
[range])	O
length	O
of	O
stay	O
in	O
the	O
intensive	O
care	O
unit	O
was	O
115	O
(49-228	O
[32-481])	O
h	O
in	O
patients	O
with	O
convulsive	Disease
	O
seizures	Disease
compared	O
with	O
26	O
(22-69	O
[14-1080])	O
h	O
in	O
patients	O
without	O
seizures	Disease
(p	O
<	O
0.001).	O
Convulsive	Disease
	O
seizures	Disease
are	O
a	O
serious	O
postoperative	Disease
complication	Disease
after	O
cardiac	O
surgery.	O
As	O
tranexamic	Chemical
acid	Chemical
is	O
the	O
only	O
modifiable	O
factor,	O
its	O
administration,	O
particularly	O
in	O
doses	O
exceeding	O
80	O
mg.kg(-1),	O
should	O
be	O
weighed	O
against	O
the	O
risk	O
of	O
postoperative	O
seizures	Disease

Dysfunctional	Disease
overnight	Disease
memory	Disease
consolidation	O
in	O
ecstasy	Chemical
users.	O
Sleep	O
plays	O
an	O
important	O
role	O
in	O
the	O
consolidation	O
and	O
integration	O
of	O
memory	O
in	O
a	O
process	O
called	O
overnight	O
memory	O
consolidation.	O
Previous	O
studies	O
indicate	O
that	O
ecstasy	Chemical
users	O
have	O
marked	O
and	O
persistent	O
neurocognitive	O
and	O
sleep-related	Disease
impairments	Disease
.	O
We	O
extend	O
past	O
research	O
by	O
examining	O
overnight	O
memory	O
consolidation	O
among	O
regular	O
ecstasy	Chemical
users	O
(n=12)	O
and	O
drug	O
naive	O
healthy	O
controls	O
(n=26).	O
Memory	O
recall	O
of	O
word	O
pairs	O
was	O
evaluated	O
before	O
and	O
after	O
a	O
period	O
of	O
sleep,	O
with	O
and	O
without	O
interference	O
prior	O
to	O
testing.	O
In	O
addition,	O
we	O
assessed	O
neurocognitive	O
performances	O
across	O
tasks	O
of	O
learning,	O
memory	O
and	O
executive	O
functioning.	O
Ecstasy	Chemical
users	O
demonstrated	O
impaired	Disease
overnight	Disease
memory	Disease
consolidation,	O
a	O
finding	O
that	O
was	O
more	O
pronounced	O
following	O
associative	O
interference.	O
Additionally,	O
ecstasy	Chemical
users	O
demonstrated	O
impairments	O
on	O
tasks	O
recruiting	O
frontostriatal	O
and	O
hippocampal	O
neural	O
circuitry,	O
in	O
the	O
domains	O
of	O
proactive	O
interference	O
memory,	O
long-term	O
memory,	O
encoding,	O
working	O
memory	O
and	O
complex	O
planning.	O
We	O
suggest	O
that	O
ecstasy	Chemical
-associated	O
dysfunction	O
in	O
fronto-temporal	O
circuitry	O
may	O
underlie	O
overnight	O
consolidation	O
memory	Disease
impairments	Disease
in	O
regular	O
ecstasy	Chemical

Normoammonemic	O
encephalopathy	Disease
:	O
solely	O
valproate	Chemical
induced	O
or	O
multiple	O
mechanisms?	O
A	O
77-year-old	O
woman	O
presented	O
with	O
subacute	O
onset	O
progressive	O
confusion	Disease
,	O
aggression	Disease
,	O
auditory	Disease
hallucinations	Disease
and	O
delusions	Disease
.	O
In	O
the	O
preceding	O
months,	O
the	O
patient	O
had	O
a	O
number	O
of	O
admissions	O
with	O
transient	O
unilateral	O
hemiparesis	Disease
with	O
facial	O
droop,	O
and	O
had	O
been	O
started	O
on	O
valproate	Chemical
for	O
presumed	O
hemiplegic	Disease
migraine	Disease
.	O
Valproate	Chemical
was	O
withdrawn	O
soon	O
after	O
admission	O
and	O
her	O
cognitive	O
abilities	O
have	O
gradually	O
improved	O
over	O
3	O
months	O
of	O
follow-up.	O
Valproate	Chemical
levels	O
taken	O
prior	O
to	O
withdrawal	O
were	O
subtherapeutic	O
and	O
the	O
patient	O
was	O
normoammonaemic.	O
EEG	O
undertaken	O
during	O
inpatient	O
stay	O
showed	O
changes	O
consistent	O
with	O
encephalopathy	Disease
,	O
and	O
low	O
titre	O
N-methyl-D-aspartate	Chemical
(	O
NMDA	Chemical
)	O
receptor	O
antibodies	O
were	O
present	O
in	O
this	O
patient.	O
The	O
possible	O
aetiologies	O
of	O
valproate	Chemical
-induced	O
encephalopathy	Disease
and	O
NMDA	Chemical
receptor-associated	O
encephalitis	Disease

Cerebellar	Disease
and	Disease
oculomotor	Disease
dysfunction	Disease
induced	O
by	O
rapid	O
infusion	O
of	O
pethidine	Chemical
.	O
Pethidine	Chemical
is	O
an	O
opioid	O
that	O
gains	O
its	O
popularity	O
for	O
the	O
effective	O
pain	Disease
control	O
through	O
acting	O
on	O
the	O
opioid-receptors.	O
However,	O
rapid	O
pain	Disease
relief	O
sometimes	O
brings	O
about	O
unfavourable	O
side	O
effects	O
that	O
largely	O
limit	O
its	O
clinical	O
utility.	O
Common	O
side	O
effects	O
include	O
nausea	Disease
,	O
vomiting	Disease
and	O
hypotension	Disease
.	O
In	O
patients	O
with	O
impaired	Disease
renal	Disease
and	Disease
liver	Disease
function	Disease
,	O
and	O
those	O
who	O
need	O
long-term	O
pain	Disease
control,	O
pethidine	Chemical
may	O
cause	O
excitatory	O
central	O
nervous	O
system	O
(CNS)	O
effects	O
through	O
its	O
neurotoxic	Disease
metabolite,	O
norpethidine	Chemical
,	O
resulting	O
in	O
irritability	Disease
and	O
seizure	Disease
attack.	O
On	O
the	O
contrary,	O
though	O
not	O
clinically	O
apparent,	O
pethidine	Chemical
potentially	O
causes	O
inhibitory	O
impacts	O
on	O
the	O
CNS	O
and	O
impairs	O
normal	O
cerebellar	O
and	O
oculomotor	O
function	O
in	O
the	O
short	O
term.	O
In	O
this	O
case	O
report,	O
we	O
highlight	O
opioid's	O
inhibitory	O
side	O
effects	O
on	O
the	O
cerebellar	O
structure	O
that	O
causes	O
dysmetria	Disease
,	O
dysarthria	Disease

Baboon	Disease
syndrome	Disease
induced	O
by	O
ketoconazole	Chemical
.	O
A	O
27-year-old	O
male	O
patient	O
presented	O
with	O
a	O
maculopapular	Disease
eruption	Disease
on	O
the	O
flexural	O
areas	O
and	O
buttocks	O
after	O
using	O
oral	O
ketoconazole	Chemical
.	O
The	O
patient	O
was	O
diagnosed	O
with	O
drug-induced	O
baboon	Disease
syndrome	Disease
based	O
on	O
his	O
history,	O
which	O
included	O
prior	O
sensitivity	O
to	O
topical	O
ketoconazole	Chemical
,	O
a	O
physical	O
examination,	O
and	O
histopathological	O
findings.	O
Baboon	Disease
syndrome	Disease
is	O
a	O
drug-	O
or	O
contact	O
allergen-related	O
maculopapular	Disease
eruption	Disease
that	O
typically	O
involves	O
the	O
flexural	O
and	O
gluteal	O
areas.	O
To	O
the	O
best	O
of	O
our	O
knowledge,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
ketoconazole	Chemical
-induced	O
baboon	Disease
syndrome	Disease

A	O
Case	O
of	O
Sudden	Disease
Cardiac	Disease
Death	Disease
due	O
to	O
Pilsicainide	Chemical
-Induced	O
Torsades	Disease
de	Disease
Pointes	Disease
.	O
An	O
84-year-old	O
male	O
received	O
oral	O
pilsicainide	Chemical
,	O
a	O
pure	O
sodium	Chemical
channel	O
blocker	O
with	O
slow	O
recovery	O
kinetics,	O
to	O
convert	O
his	O
paroxysmal	O
atrial	Disease
fibrillation	Disease
to	O
a	O
sinus	O
rhythm;	O
the	O
patient	O
developed	O
sudden	Disease
cardiac	Disease
death	Disease
two	O
days	O
later.	O
The	O
Holter	O
electrocardiogram,	O
which	O
was	O
worn	O
by	O
chance,	O
revealed	O
torsade	Disease
de	Disease
pointes	Disease
with	O
gradually	O
prolonged	O
QT	O
intervals.	O
This	O
drug	O
is	O
rapidly	O
absorbed	O
from	O
the	O
gastrointestinal	O
tract,	O
and	O
most	O
of	O
it	O
is	O
excreted	O
from	O
the	O
kidney.	O
Although	O
the	O
patient's	O
renal	O
function	O
was	O
not	O
highly	O
impaired	O
and	O
the	O
dose	O
of	O
pilsicainide	Chemical
was	O
low,	O
the	O
plasma	O
concentration	O
of	O
pilsicainide	Chemical
may	O
have	O
been	O
high,	O
which	O
can	O
produce	O
torsades	Disease
de	Disease
pointes	Disease
in	O
the	O
octogenarian.	O
Although	O
the	O
oral	O
administration	O
of	O
class	O
IC	O
drugs,	O
including	O
pilsicainide	Chemical
,	O
is	O
effective	O
to	O
terminate	O
atrial	Disease
fibrillation	Disease

All-trans	Chemical
retinoic	Chemical
acid	Chemical
-induced	O
inflammatory	O
myositis	Disease
in	O
a	O
patient	O
with	O
acute	Disease
promyelocytic	Disease
leukemia	Disease
.	O
All-trans	Chemical
retinoic	Chemical
acid	Chemical
(	O
ATRA	Chemical
),	O
a	O
component	O
of	O
standard	O
therapy	O
for	O
acute	Disease
promyelocytic	Disease
leukemia	Disease
(	O
APL	Disease
),	O
is	O
associated	O
with	O
potentially	O
serious	O
but	O
treatable	O
adverse	O
effects	O
involving	O
numerous	O
organ	O
systems,	O
including	O
rare	O
skeletal	O
muscle	O
involvement.	O
Only	O
a	O
handful	O
of	O
cases	O
of	O
ATRA	Chemical
-induced	O
myositis	Disease
in	O
children	O
have	O
been	O
reported,	O
and	O
none	O
in	O
the	O
radiology	O
literature.	O
We	O
present	O
such	O
a	O
case	O
in	O
a	O
15-year-old	O
boy	O
with	O
APL	Disease

Tolerability	O
of	O
lomustine	Chemical
in	O
combination	O
with	O
cyclophosphamide	Chemical
in	O
dogs	O
with	O
lymphoma	Disease
.	O
This	O
retrospective	O
study	O
describes	O
toxicity	Disease
associated	O
with	O
a	O
protocol	O
of	O
lomustine	Chemical
(	O
CCNU	Chemical
)	O
and	O
cyclophosphamide	Chemical
(	O
CTX	Chemical
)	O
in	O
dogs	O
with	O
lymphoma	Disease
.	O
CCNU	Chemical
was	O
administered	O
per	O
os	O
(PO)	O
at	O
a	O
targeted	O
dosage	O
of	O
60	O
mg/m(2)	O
body	O
surface	O
area	O
on	O
day	O
0,	O
CTX	Chemical
was	O
administered	O
PO	O
at	O
a	O
targeted	O
dosage	O
of	O
250	O
mg/m(2)	O
divided	O
over	O
days	O
0	O
through	O
4,	O
and	O
all	O
dogs	O
received	O
prophylactic	O
antibiotics.	O
Ninety	O
treatments	O
were	O
given	O
to	O
the	O
57	O
dogs	O
included	O
in	O
the	O
study.	O
Neutropenia	Disease
was	O
the	O
principal	O
toxic	O
effect,	O
and	O
the	O
overall	O
frequency	O
of	O
grade	O
4	O
neutropenia	Disease
after	O
the	O
first	O
treatment	O
of	O
CCNU	Chemical
/	O
CTX	Chemical
was	O
30%	O
(95%	O
confidence	O
interval,	O
19-43%).	O
The	O
mean	O
body	O
weight	O
of	O
dogs	O
with	O
grade	O
4	O
neutropenia	Disease
(19.7	O
kg	O
+	O
13.4	O
kg)	O
was	O
significantly	O
less	O
than	O
the	O
mean	O
body	O
weight	O
of	O
dogs	O
that	O
did	O
not	O
develop	O
grade	O
4	O
neutropenia	Disease
(31.7	O
kg	O
+	O
12.4	O
kg;	O
P	O
=	O
.005).	O
One	O
dog	O
(3%)	O
developed	O
hematologic	O
changes	O
suggestive	O
of	O
hepatotoxicity	Disease
.	O
No	O
dogs	O
had	O
evidence	O
of	O
either	O
renal	Disease
toxicity	Disease
or	O
hemorrhagic	Disease
cystitis	Disease
.	O
Adverse	O
gastrointestinal	O
effects	O
were	O
uncommon.	O
On	O
the	O
basis	O
of	O
the	O
findings	O
reported	O
herein,	O
a	O
dose	O
of	O
60	O
mg/m(2)	O
of	O
CCNU	Chemical
combined	O
with	O
250	O
mg/m(2)	O
of	O
CTX	Chemical
(divided	O
over	O
5	O
days)	O
q	O
4	O
wk	O
is	O
tolerable	O
in	O
tumor	Disease

Nelarabine	Chemical
	O
neurotoxicity	Disease
with	O
concurrent	O
intrathecal	O
chemotherapy:	O
Case	O
report	O
and	O
review	O
of	O
literature.	O
Severe	O
nelarabine	Chemical
	O
neurotoxicity	Disease
in	O
a	O
patient	O
who	O
received	O
concurrent	O
intrathecal	O
(IT)	O
chemotherapy	O
is	O
reported.	O
A	O
37-year-old	O
Caucasian	O
woman	O
with	O
a	O
history	O
of	O
T-cell	Disease
lymphoblastic	Disease
lymphoma	Disease
was	O
admitted	O
for	O
relapsed	O
disease.	O
She	O
was	O
originally	O
treated	O
with	O
induction	O
chemotherapy	O
followed	O
by	O
an	O
autologous	O
transplant.	O
She	O
developed	O
relapsed	O
disease	O
10	O
months	O
later	O
with	O
leukemic	Disease
involvement.	O
She	O
was	O
re-induced	O
with	O
nelarabine	Chemical
1500	O
mg/m(2)	O
on	O
days	O
1,	O
3,	O
and	O
5	O
with	O
1	O
dose	O
of	O
IT	O
cytarabine	Chemical
100	O
mg	O
on	O
day	O
2	O
as	O
central	O
nervous	O
system	O
(CNS)	O
prophylaxis.	O
At	O
the	O
time	O
of	O
treatment,	O
she	O
was	O
on	O
continuous	O
renal	O
replacement	O
therapy	O
due	O
to	O
sequelae	O
of	O
tumor	Disease
lysis	Disease
syndrome	Disease
(	O
TLS	Disease
).	O
She	O
tolerated	O
therapy	O
well,	O
entered	O
a	O
complete	O
remission,	O
and	O
recovered	O
her	O
renal	O
function.	O
She	O
received	O
a	O
second	O
cycle	O
of	O
nelarabine	Chemical
without	O
additional	O
IT	O
prophylaxis	O
one	O
month	O
later.	O
A	O
week	O
after	O
this	O
second	O
cycle,	O
she	O
noted	O
numbness	O
in	O
her	O
lower	O
extremities.	O
Predominantly	O
sensory,	O
though	O
also	O
motor	O
and	O
autonomic,	O
peripheral	Disease
neuropathy	Disease
started	O
in	O
her	O
feet,	O
ascended	O
proximally	O
to	O
the	O
mid-thoracic	O
region,	O
and	O
eventually	O
included	O
her	O
distal	O
upper	O
extremities.	O
A	O
magnetic	O
resonance	O
imaging	O
(MRI)	O
of	O
her	O
spine	O
demonstrated	O
changes	O
from	O
C2	O
to	O
C6	O
consistent	O
with	O
subacute	O
combined	O
degeneration.	O
Nelarabine	Chemical
was	O
felt	O
to	O
be	O
the	O
cause	O
of	O
her	O
symptoms.	O
Her	O
neuropathy	Disease
stabilized	O
and	O
showed	O
slight	O
improvement	O
and	O
ultimately	O
received	O
an	O
unrelated,	O
reduced-intensity	O
allogeneic	O
transplant	O
while	O
in	O
complete	O
remission,	O
but	O
relapsed	O
disease	O
10	O
weeks	O
later.	O
She	O
is	O
currently	O
being	O
treated	O
with	O
best	O
supportive	O
care.	O
To	O
our	O
knowledge,	O
this	O
is	O
the	O
first	O
published	O
case	O
report	O
of	O
severe	O
neurotoxicity	Disease
caused	O
by	O
nelarabine	Chemical

Valproate	Chemical
-induced	O
hyperammonemic	Disease
	O
encephalopathy	Disease
in	O
a	O
renal	O
transplanted	O
patient.	O
Neurological	Disease
complications	Disease
after	O
renal	O
transplantation	O
constitute	O
an	O
important	O
cause	O
of	O
morbidity	O
and	O
mortality.	O
Their	O
differential	O
diagnosis	O
is	O
difficult	O
and	O
essential	O
for	O
subsequent	O
patient's	O
management.	O
Valproate	Chemical
-induced	O
hyperammonemic	Disease
	O
encephalopathy	Disease
is	O
an	O
uncommon	O
but	O
serious	O
effect	O
of	O
valproate	Chemical
treatment.	O
Here,	O
we	O
describe	O
the	O
case	O
of	O
a	O
15-year-old	O
girl	O
who	O
was	O
on	O
a	O
long-term	O
therapy	O
with	O
valproate	Chemical
due	O
to	O
epilepsy	Disease
and	O
revealed	O
impaired	Disease
consciousness	Disease
with	O
hyperammonemia	Disease
12	O
days	O
after	O
renal	O
transplantation.	O
After	O
withdraw	O
of	O
valproate	Chemical
,	O
patients'	O
symptoms	O
resolved	O
within	O
24	O
h.	O
Clinicians	O
should	O
increase	O
their	O
awareness	O
for	O
potential	O
complication	O
of	O
valproate	Chemical

Necrotising	Disease
fasciitis	Disease
after	O
bortezomib	Chemical
and	O
dexamethasone	Chemical
-containing	O
regimen	O
in	O
an	O
elderly	O
patient	O
of	O
Waldenstrom	Disease
macroglobulinaemia	Disease
.	O
Bortezomib	Chemical
and	O
high-dose	O
dexamethasone	Chemical
-containing	O
regimens	O
are	O
considered	O
to	O
be	O
generally	O
tolerable	O
with	O
few	O
severe	O
bacterial	Disease
infections	Disease
in	O
patients	O
with	O
B-cell	O
malignancies	Disease
.	O
However,	O
information	O
is	O
limited	O
concerning	O
the	O
safety	O
of	O
the	O
regimen	O
in	O
elderly	O
patients.	O
We	O
report	O
a	O
case	O
of	O
a	O
76-year-old	O
man	O
with	O
Waldenstrom	Disease
macroglobulinaemia	Disease
who	O
suffered	O
necrotising	Disease
fasciitis	Disease
without	O
neutropenia	Disease
after	O
the	O
combination	O
treatment	O
with	O
bortezomib	Chemical
,	O
high-dose	O
dexamethasone	Chemical
and	O
rituximab.	O
Despite	O
immediate	O
intravenous	O
antimicrobial	O
therapy,	O
he	O
succumbed	O
23	O
h	O
after	O
the	O
onset.	O
Physicians	O
should	O
recognise	O
the	O
possibility	O
of	O
fatal	O
bacterial	Disease
infections	Disease
related	O
to	O
bortezomib	Chemical
plus	O
high-dose	O
dexamethasone	Chemical

An	O
integrated	O
characterization	O
of	O
serological,	O
pathological,	O
and	O
functional	O
events	O
in	O
doxorubicin	Chemical
-induced	O
cardiotoxicity	Disease
.	O
Many	O
efficacious	O
cancer	Disease
treatments	O
cause	O
significant	O
cardiac	O
morbidity,	O
yet	O
biomarkers	O
or	O
functional	O
indices	O
of	O
early	O
damage,	O
which	O
would	O
allow	O
monitoring	O
and	O
intervention,	O
are	O
lacking.	O
In	O
this	O
study,	O
we	O
have	O
utilized	O
a	O
rat	O
model	O
of	O
progressive	O
doxorubicin	Chemical
(	O
DOX	Chemical
)-induced	O
cardiomyopathy	Disease
,	O
applying	O
multiple	O
approaches,	O
including	O
cardiac	O
magnetic	O
resonance	O
imaging	O
(MRI),	O
to	O
provide	O
the	O
most	O
comprehensive	O
characterization	O
to	O
date	O
of	O
the	O
timecourse	O
of	O
serological,	O
pathological,	O
and	O
functional	O
events	O
underlying	O
this	O
toxicity	Disease
.	O
Hannover	O
Wistar	O
rats	O
were	O
dosed	O
with	O
1.25	O
mg/kg	O
DOX	Chemical
weekly	O
for	O
8	O
weeks	O
followed	O
by	O
a	O
4	O
week	O
off-dosing	O
"recovery"	O
period.	O
Electron	O
microscopy	O
of	O
the	O
myocardium	O
revealed	O
subcellular	Disease
degeneration	Disease
and	O
marked	O
mitochondrial	O
changes	O
after	O
a	O
single	O
dose.	O
Histopathological	O
analysis	O
revealed	O
progressive	O
cardiomyocyte	Disease
degeneration	Disease
,	O
hypertrophy	Disease
/cytomegaly,	O
and	O
extensive	O
vacuolation	O
after	O
two	O
doses.	O
Extensive	O
replacement	O
fibrosis	Disease
(quantified	O
by	O
Sirius	O
red	O
staining)	O
developed	O
during	O
the	O
off-dosing	O
period.	O
Functional	O
indices	O
assessed	O
by	O
cardiac	O
MRI	O
(including	O
left	O
ventricular	O
ejection	O
fraction	O
(LVEF),	O
cardiac	O
output,	O
and	O
E/A	O
ratio)	O
declined	O
progressively,	O
reaching	O
statistical	O
significance	O
after	O
two	O
doses	O
and	O
culminating	O
in	O
"clinical"	O
LV	Disease
dysfunction	Disease
by	O
12	O
weeks.	O
Significant	O
increases	O
in	O
peak	O
myocardial	O
contrast	O
enhancement	O
and	O
serological	O
cardiac	O
troponin	O
I	O
(cTnI)	O
emerged	O
after	O
eight	O
doses,	O
importantly	O
preceding	O
the	O
LVEF	O
decline	O
to	O
<50%.	O
Troponin	O
I	O
levels	O
positively	O
correlated	O
with	O
delayed	O
and	O
peak	O
gadolinium	Chemical
contrast	O
enhancement,	O
histopathological	O
grading,	O
and	O
diastolic	Disease
dysfunction	Disease
.	O
In	O
summary,	O
subcellular	O
cardiomyocyte	Disease
degeneration	Disease
was	O
the	O
earliest	O
marker,	O
followed	O
by	O
progressive	O
functional	O
decline	O
and	O
histopathological	O
manifestations.	O
Myocardial	O
contrast	O
enhancement	O
and	O
elevations	O
in	O
cTnI	O
occurred	O
later.	O
However,	O
all	O
indices	O
predated	O
"clinical"	O
LV	Disease
dysfunction	Disease

Intradermal	O
glutamate	Chemical
and	O
capsaicin	Chemical
injections:	O
intra-	O
and	O
interindividual	O
variability	O
of	O
provoked	O
hyperalgesia	Disease
and	O
allodynia	Disease
.	O
Intradermal	O
injections	O
of	O
glutamate	Chemical
and	O
capsaicin	Chemical
are	O
attractive	O
to	O
use	O
in	O
human	O
experimental	O
pain	Disease
models	O
because	O
hyperalgesia	Disease
and	O
allodynia	Disease
mimic	O
isolated	O
aspects	O
of	O
clinical	O
pain	Disease
disorders	Disease
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
reproducibility	O
of	O
these	O
models.	O
Twenty	O
healthy	O
male	O
volunteers	O
(mean	O
age	O
24	O
years;	O
range	O
18-38	O
years)	O
received	O
intradermal	O
injections	O
of	O
glutamate	Chemical
and	O
capsaicin	Chemical
in	O
the	O
volar	O
forearm.	O
Magnitudes	O
of	O
secondary	O
pinprick	O
hyperalgesia	Disease
and	O
brush-evoked	O
allodynia	Disease
were	O
investigated	O
using	O
von	O
Frey	O
filaments	O
(gauges	O
10,	O
15,	O
60	O
and	O
100	O
g)	O
and	O
brush	O
strokes.	O
Areas	O
of	O
secondary	Disease
hyperalgesia	Disease
and	O
allodynia	Disease
were	O
quantified	O
immediately	O
after	O
injection	O
and	O
after	O
15,	O
30	O
and	O
60	O
min.	O
Two	O
identical	O
experiments	O
separated	O
by	O
at	O
least	O
7	O
days	O
were	O
performed.	O
Reproducibility	O
across	O
and	O
within	O
volunteers	O
(inter-	O
and	O
intra-individual	O
variation,	O
respectively)	O
was	O
assessed	O
using	O
intraclass	O
correlation	O
coefficient	O
(ICC)	O
and	O
coefficient	O
of	O
variation	O
(CV).	O
Secondary	O
pinprick	O
hyperalgesia	Disease
was	O
observed	O
as	O
a	O
marked	O
increase	O
in	O
the	O
visual	O
analogue	O
scale	O
(VAS)	O
response	O
to	O
von	O
Frey	O
gauges	O
60	O
and	O
100	O
g	O
(P	O
<	O
0.001)	O
after	O
glutamate	Chemical
injection.	O
For	O
capsaicin	Chemical
,	O
secondary	O
pinprick	O
hyperalgesia	Disease
was	O
detected	O
with	O
all	O
von	O
Frey	O
gauges	O
(P	O
<	O
0.001).	O
Glutamate	Chemical
evoked	O
reproducible	O
VAS	O
response	O
to	O
all	O
von	O
Frey	O
gauges	O
(ICC	O
>	O
0.60)	O
and	O
brush	O
strokes	O
(ICC	O
>	O
0.83).	O
Capsaicin	Chemical
injection	O
was	O
reproducible	O
for	O
secondary	Disease
hyperalgesia	Disease
(ICC	O
>	O
0.70)	O
and	O
allodynia	Disease
(ICC	O
>	O
0.71).	O
Intra-individual	O
variability	O
was	O
generally	O
lower	O
for	O
the	O
VAS	O
response	O
to	O
von	O
Frey	O
and	O
brush	O
compared	O
with	O
areas	O
of	O
secondary	Disease
hyperalgesia	Disease
and	O
allodynia	Disease
.	O
In	O
conclusion,	O
glutamate	Chemical
and	O
capsaicin	Chemical
yield	O
reproducible	O
hyperalgesic	Disease
and	O
allodynic	Disease

Ocular-specific	O
ER	O
stress	O
reduction	O
rescues	O
glaucoma	Disease
in	O
murine	O
glucocorticoid-induced	O
glaucoma	Disease
.	O
Administration	O
of	O
glucocorticoids	O
induces	O
ocular	Disease
hypertension	Disease
in	O
some	O
patients.	O
If	O
untreated,	O
these	O
patients	O
can	O
develop	O
a	O
secondary	O
glaucoma	Disease
that	O
resembles	O
primary	Disease
open-angle	Disease
glaucoma	Disease
(	O
POAG	Disease
).	O
The	O
underlying	O
pathology	O
of	O
glucocorticoid-induced	O
glaucoma	Disease
is	O
not	O
fully	O
understood,	O
due	O
in	O
part	O
to	O
lack	O
of	O
an	O
appropriate	O
animal	O
model.	O
Here,	O
we	O
developed	O
a	O
murine	O
model	O
of	O
glucocorticoid-induced	O
glaucoma	Disease
that	O
exhibits	O
glaucoma	Disease
features	O
that	O
are	O
observed	O
in	O
patients.	O
Treatment	O
of	O
WT	O
mice	O
with	O
topical	O
ocular	O
0.1%	O
dexamethasone	Chemical
led	O
to	O
elevation	O
of	O
intraocular	O
pressure	O
(IOP),	O
functional	O
and	O
structural	O
loss	O
of	O
retinal	Disease
ganglion	Disease
cells,	O
and	O
axonal	Disease
degeneration	Disease
,	O
resembling	O
glucocorticoid-induced	O
glaucoma	Disease
in	O
human	O
patients.	O
Furthermore,	O
dexamethasone	Chemical
-induced	O
ocular	Disease
hypertension	Disease
was	O
associated	O
with	O
chronic	O
ER	O
stress	O
of	O
the	O
trabecular	O
meshwork	O
(TM).	O
Similar	O
to	O
patients,	O
withdrawal	O
of	O
dexamethasone	Chemical
treatment	O
reduced	O
elevated	O
IOP	O
and	O
ER	O
stress	O
in	O
this	O
animal	O
model.	O
Dexamethasone	Chemical
induced	O
the	O
transcriptional	O
factor	O
CHOP,	O
a	O
marker	O
for	O
chronic	O
ER	O
stress,	O
in	O
the	O
anterior	O
segment	O
tissues,	O
and	O
Chop	O
deletion	O
reduced	O
ER	O
stress	O
in	O
these	O
tissues	O
and	O
prevented	O
dexamethasone	Chemical
-induced	O
ocular	Disease
hypertension	Disease
.	O
Furthermore,	O
reduction	O
of	O
ER	O
stress	O
in	O
the	O
TM	O
with	O
sodium	Chemical
4-phenylbutyrate	Chemical
prevented	O
dexamethasone	Chemical
-induced	O
ocular	Disease
hypertension	Disease
in	O
WT	O
mice.	O
Our	O
data	O
indicate	O
that	O
ER	O
stress	O
contributes	O
to	O
glucocorticoid-induced	O
ocular	Disease
hypertension	Disease
and	O
suggest	O
that	O
reducing	O
ER	O
stress	O
has	O
potential	O
as	O
a	O
therapeutic	O
strategy	O
for	O
treating	O
glucocorticoid-induced	O
glaucoma	Disease

Effects	O
of	O
ginsenosides	Chemical
on	O
opioid-induced	O
hyperalgesia	Disease
in	O
mice.	O
Opioid-induced	O
hyperalgesia	Disease
(	O
OIH	Disease
)	O
is	O
characterized	O
by	O
nociceptive	O
sensitization	O
caused	O
by	O
the	O
cessation	O
of	O
chronic	O
opioid	O
use.	O
OIH	Disease
can	O
limit	O
the	O
clinical	O
use	O
of	O
opioid	O
analgesics	O
and	O
complicate	O
withdrawal	O
from	O
opioid	Disease
addiction	Disease
.	O
In	O
this	O
study,	O
we	O
investigated	O
the	O
effects	O
of	O
Re,	Chemical
Rg1,	Chemical
and	Chemical
Rb1	Chemical
ginsenosides	Chemical
,	O
the	O
bioactive	O
components	O
of	O
ginseng,	O
on	O
OIH	Disease
.	O
OIH	Disease
was	O
achieved	O
in	O
mice	O
after	O
subcutaneous	O
administration	O
of	O
morphine	Chemical
for	O
7	O
consecutive	O
days	O
three	O
times	O
per	O
day.	O
During	O
withdrawal	O
(days	O
8	O
and	O
9),	O
these	O
mice	O
were	O
administered	O
Re	Chemical
,	O
Rg1	Chemical
,	O
or	O
Rb1	Chemical
intragastrically	O
two	O
times	O
per	O
day.	O
On	O
the	O
test	O
day	O
(day	O
10),	O
mice	O
were	O
subjected	O
to	O
the	O
thermal	O
sensitivity	O
test	O
and	O
the	O
acetic	Chemical
acid	Chemical
-induced	O
writhing	O
test.	O
Re	Chemical
(300	O
mg/kg)	O
inhibited	O
OIH	Disease
in	O
both	O
the	O
thermal	O
sensitivity	O
test	O
and	O
the	O
acetic	Chemical
acid	Chemical
-induced	O
writhing	O
test.	O
However,	O
the	O
Rg1	Chemical
and	Chemical
Rb1	Chemical
ginsenosides	Chemical
failed	O
to	O
prevent	O
OIH	Disease
in	O
either	O
test.	O
Furthermore,	O
Rg1	Chemical
showed	O
a	O
tendency	O
to	O
aggravate	O
OIH	Disease
in	O
the	O
acetic	Chemical
acid	Chemical
-induced	O
writhing	O
test.	O
Our	O
data	O
suggested	O
that	O
the	O
ginsenoside	Chemical
Re	Chemical
,	O
but	O
not	O
Rg1	Chemical
or	O
Rb1	Chemical
,	O
may	O
contribute	O
toward	O
reversal	O
of	O
OIH	Disease

A	O
comparison	O
of	O
severe	O
hemodynamic	O
disturbances	O
between	O
dexmedetomidine	Chemical
and	O
propofol	Chemical
for	O
sedation	O
in	O
neurocritical	O
care	O
patients.	O
OBJECTIVE:	O
Dexmedetomidine	Chemical
and	O
propofol	Chemical
are	O
commonly	O
used	O
sedatives	O
in	O
neurocritical	O
care	O
as	O
they	O
allow	O
for	O
frequent	O
neurologic	O
examinations.	O
However,	O
both	O
agents	O
are	O
associated	O
with	O
significant	O
hemodynamic	O
side	O
effects.	O
The	O
primary	O
objective	O
of	O
this	O
study	O
is	O
to	O
compare	O
the	O
prevalence	O
of	O
severe	O
hemodynamic	O
effects	O
in	O
neurocritical	O
care	O
patients	O
receiving	O
dexmedetomidine	Chemical
and	O
propofol	Chemical
.	O
DESIGN:	O
Multicenter,	O
retrospective,	O
propensity-matched	O
cohort	O
study.	O
SETTING:	O
Neurocritical	O
care	O
units	O
at	O
two	O
academic	O
medical	O
centers	O
with	O
dedicated	O
neurocritical	O
care	O
teams	O
and	O
board-certified	O
neurointensivists.	O
PATIENTS:	O
Neurocritical	O
care	O
patients	O
admitted	O
between	O
July	O
2009	O
and	O
September	O
2012	O
were	O
evaluated	O
and	O
then	O
matched	O
1:1	O
based	O
on	O
propensity	O
scoring	O
of	O
baseline	O
characteristics.	O
INTERVENTIONS:	O
Continuous	O
sedation	O
with	O
dexmedetomidine	Chemical
or	O
propofol	Chemical
.	O
MEASUREMENTS	O
AND	O
MAIN	O
RESULTS:	O
A	O
total	O
of	O
342	O
patients	O
(105	O
dexmedetomidine	Chemical
and	O
237	O
propofol	Chemical
)	O
were	O
included	O
in	O
the	O
analysis,	O
with	O
190	O
matched	O
(95	O
in	O
each	O
group)	O
by	O
propensity	O
score.	O
The	O
primary	O
outcome	O
of	O
this	O
study	O
was	O
a	O
composite	O
of	O
severe	O
hypotension	Disease
(mean	O
arterial	O
pressure	O
<	O
60	O
mm	O
Hg)	O
and	O
bradycardia	Disease
(heart	O
rate	O
<	O
50	O
beats/min)	O
during	O
sedative	O
infusion.	O
No	O
difference	O
in	O
the	O
primary	O
composite	O
outcome	O
in	O
both	O
the	O
unmatched	O
(30%	O
vs	O
30%,	O
p	O
=	O
0.94)	O
or	O
matched	O
cohorts	O
(28%	O
vs	O
34%,	O
p	O
=	O
0.35)	O
could	O
be	O
found.	O
When	O
analyzed	O
separately,	O
no	O
differences	O
could	O
be	O
found	O
in	O
the	O
prevalence	O
of	O
severe	O
hypotension	Disease
or	O
bradycardia	Disease
in	O
either	O
the	O
unmatched	O
or	O
matched	O
cohorts.	O
CONCLUSIONS:	O
Severe	O
hypotension	Disease
and	O
bradycardia	Disease
occur	O
at	O
similar	O
prevalence	O
in	O
neurocritical	O
care	O
patients	O
who	O
receive	O
dexmedetomidine	Chemical
or	O
propofol	Chemical
.	O
Providers	O
should	O
similarly	O
consider	O
the	O
likelihood	O
of	O
hypotension	Disease
or	O
bradycardia	Disease

Hydroxytyrosol	Chemical
ameliorates	O
oxidative	O
stress	O
and	O
mitochondrial	Disease
dysfunction	Disease
in	O
doxorubicin	Chemical
-induced	O
cardiotoxicity	Disease
in	O
rats	O
with	O
breast	Disease
cancer	Disease
.	O
Oxidative	O
stress	O
is	O
involved	O
in	O
several	O
processes	O
including	O
cancer	Disease
,	O
aging	O
and	O
cardiovascular	Disease
disease	Disease
,	O
and	O
has	O
been	O
shown	O
to	O
potentiate	O
the	O
therapeutic	O
effect	O
of	O
drugs	O
such	O
as	O
doxorubicin	Chemical
.	O
Doxorubicin	Chemical
causes	O
significant	O
cardiotoxicity	Disease
characterized	O
by	O
marked	O
increases	O
in	O
oxidative	O
stress	O
and	O
mitochondrial	Disease
dysfunction	Disease
.	O
Herein,	O
we	O
investigate	O
whether	O
doxorubicin	Chemical
-associated	O
chronic	O
cardiac	Disease
toxicity	Disease
can	O
be	O
ameliorated	O
with	O
the	O
antioxidant	O
hydroxytyrosol	Chemical
in	O
rats	O
with	O
breast	Disease
cancer	Disease
.	O
Thirty-six	O
rats	O
bearing	O
breast	Disease
tumors	Disease
induced	O
chemically	O
were	O
divided	O
into	O
4	O
groups:	O
control,	O
hydroxytyrosol	Chemical
(0.5mg/kg,	O
5days/week),	O
doxorubicin	Chemical
(1mg/kg/week),	O
and	O
doxorubicin	Chemical
plus	O
hydroxytyrosol	Chemical
.	O
Cardiac	Disease
disturbances	Disease
at	O
the	O
cellular	O
and	O
mitochondrial	O
level,	O
mitochondrial	O
electron	O
transport	O
chain	O
complexes	O
I-IV	O
and	O
apoptosis-inducing	O
factor,	O
and	O
oxidative	O
stress	O
markers	O
have	O
been	O
analyzed.	O
Hydroxytyrosol	Chemical
improved	O
the	O
cardiac	Disease
disturbances	Disease
enhanced	O
by	O
doxorubicin	Chemical
by	O
significantly	O
reducing	O
the	O
percentage	O
of	O
altered	O
mitochondria	O
and	O
oxidative	O
damage.	O
These	O
results	O
suggest	O
that	O
hydroxytyrosol	Chemical
improve	O
the	O
mitochondrial	O
electron	O
transport	O
chain.	O
This	O
study	O
demonstrates	O
that	O
hydroxytyrosol	Chemical
protect	O
rat	O
heart	Disease
damage	Disease
provoked	O
by	O
doxorubicin	Chemical

Amiodarone	Chemical
-induced	O
myxoedema	Disease
coma	Disease
.	O
A	O
62-year-old	O
man	O
was	O
found	O
to	O
have	O
bradycardia	Disease
,	O
hypothermia	Disease
and	O
respiratory	Disease
failure	Disease
3	O
weeks	O
after	O
initiation	O
of	O
amiodarone	Chemical
therapy	O
for	O
atrial	Disease
fibrillation	Disease
.	O
Thyroid-stimulating	O
hormone	O
was	O
found	O
to	O
be	O
168	O
uIU/mL	O
(nl.	O
0.3-5	O
uIU/mL)	O
and	O
free	O
thyroxine	Chemical
(FT4)	O
was	O
<0.2	O
ng/dL	O
(nl.	O
0.8-1.8	O
ng/dL).	O
He	O
received	O
intravenous	O
fluids,	O
vasopressor	O
therapy	O
and	O
stress	O
dose	O
steroids	Chemical
;	O
he	O
was	O
intubated	O
and	O
admitted	O
to	O
the	O
intensive	O
care	O
unit.	O
He	O
received	O
500	O
ug	O
of	O
intravenous	O
levothyroxine	Chemical
in	O
the	O
first	O
18	O
h	O
of	O
therapy,	O
and	O
150	O
ug	O
intravenous	O
daily	O
thereafter.	O
Haemodynamic	O
improvement,	O
along	O
with	O
complete	O
recovery	O
of	O
mental	O
status,	O
occurred	O
after	O
48	O
h.	O
Twelve	O
hours	O
after	O
the	O
initiation	O
of	O
therapy,	O
FT4	O
was	O
0.96	O
ng/dL.	O
The	O
patient	O
was	O
maintained	O
on	O
levothyroxine	Chemical
175	O
(g	O
POorally	O
daily.	O
A	O
thyroid	O
ultrasound	O
showed	O
diffuse	O
heterogeneity.	O
The	O
24	O
hour	O
excretion	O
of	O
iodine	Chemical
was	O
3657	O
(mcg	O
(25-756	O
(	O
mcg).	O
The	O
only	O
two	O
cases	O
of	O
amiodarone	Chemical
-induced	O
myxoedema	Disease
coma	Disease
in	O
the	O
literature	O
report	O
patient	O
death	O
despite	O
supportive	O
therapy	O
and	O
thyroid	O
hormone	O
replacement.	O
This	O
case	O
represents	O
the	O
most	O
thoroughly	O
investigated	O
case	O
of	O
amiodarone	Chemical
-induced	O
myxoedema	Disease
coma	Disease
with	O
a	O
history	O
significant	O
for	O
subclinical	O
thyroid	Disease
disease	Disease

Use	O
of	O
argatroban	Chemical
and	O
catheter-directed	O
thrombolysis	Disease
with	O
alteplase	O
in	O
an	O
oncology	O
patient	O
with	O
heparin	Chemical
-induced	O
thrombocytopenia	Disease
with	O
thrombosis	Disease
.	O
PURPOSE:	O
The	O
case	O
of	O
an	O
oncology	O
patient	O
who	O
developed	O
heparin	Chemical
-induced	O
thrombocytopenia	Disease
with	O
thrombosis	Disease
(	O
HITT	Disease
)	O
and	O
was	O
treated	O
with	O
argatroban	Chemical
plus	O
catheter-directed	O
thrombolysis	Disease
(CDT)	O
with	O
alteplase	O
is	O
presented.	O
SUMMARY:	O
A	O
63-year-old	O
Caucasian	O
man	O
with	O
renal	O
amyloidosis	Disease
undergoing	O
peripheral	O
blood	O
stem	O
cell	O
collection	O
for	O
an	O
autologous	O
stem	O
cell	O
transplant	O
developed	O
extensive	O
bilateral	O
upper-extremity	Disease
deep	Disease
venous	Disease
thrombosis	Disease
(	O
DVT	Disease
)	O
and	O
pulmonary	Disease
embolism	Disease
secondary	O
to	O
heparin	Chemical
-induced	O
thrombocytopenia	Disease
.	O
A	O
continuous	O
i.v.	O
infusion	O
of	O
argatroban	Chemical
was	O
initiated,	O
and	O
the	O
patient	O
was	O
managed	O
on	O
the	O
general	O
medical	O
floor.	O
After	O
one	O
week	O
of	O
therapy,	O
he	O
was	O
transferred	O
to	O
the	O
intensive	O
care	O
unit	O
with	O
cardiopulmonary	O
compromise	O
related	O
to	O
superior	Disease
vena	Disease
cava	Disease
(SVC)	Disease
syndrome	Disease
.	O
A	O
percutaneous	O
mechanical	O
thrombectomy	O
and	O
CDT	O
with	O
alteplase	O
were	O
attempted,	O
but	O
the	O
procedure	O
was	O
aborted	O
due	O
to	O
epistaxis	Disease
.	O
The	O
epistaxis	Disease
resolved	O
the	O
next	O
day,	O
and	O
the	O
patient	O
was	O
restarted	O
on	O
argatroban	Chemical
.	O
A	O
second	O
percutaneous	O
mechanical	O
thrombectomy	O
was	O
performed	O
six	O
days	O
later	O
and	O
resulted	O
in	O
partial	O
revascularization	O
of	O
the	O
SVC	O
and	O
central	O
veins.	O
Postthrombectomy	O
continuous	O
CDT	O
with	O
alteplase	O
was	O
commenced	O
while	O
argatroban	Chemical
was	O
withheld,	O
and	O
complete	O
patency	O
of	O
the	O
SVC	O
and	O
central	O
veins	O
was	O
achieved	O
after	O
three	O
days	O
of	O
therapy.	O
Alteplase	O
was	O
discontinued,	O
and	O
the	O
patient	O
was	O
reinitiated	O
on	O
argatroban	Chemical
;	O
ultimately,	O
he	O
was	O
transitioned	O
to	O
warfarin	Chemical
for	O
long-term	O
anticoagulation.	O
Although	O
the	O
patient	O
recovered,	O
he	O
experienced	O
permanent	O
vision	Disease
and	Disease
hearing	Disease
loss	Disease
,	O
as	O
well	O
as	O
end-stage	Disease
renal	Disease
disease	Disease
.	O
CONCLUSION:	O
A	O
63-year-old	O
man	O
with	O
renal	O
amyloidosis	Disease
and	O
SVC	Disease
syndrome	Disease
secondary	O
to	O
HITT	Disease
was	O
successfully	O
treated	O
with	O
argatroban	Chemical

Effects	O
of	O
dehydroepiandrosterone	Chemical
in	O
amphetamine	Chemical
-induced	O
schizophrenia	Disease
models	O
in	O
mice.	O
OBJECTIVE:	O
To	O
examine	O
the	O
effects	O
of	O
dehydroepiandrosterone	Chemical
(	O
DHEA	Chemical
)	O
on	O
animal	O
models	O
of	O
schizophrenia	Disease
.	O
METHODS:	O
Seventy	O
Swiss	O
albino	O
female	O
mice	O
(25-35	O
g)	O
were	O
divided	O
into	O
4	O
groups:	O
amphetamine	Chemical
-free	O
(control),	O
amphetamine	Chemical
,	O
50,	O
and	O
100	O
mg/kg	O
DHEA	Chemical
.	O
The	O
DHEA	Chemical
was	O
administered	O
intraperitoneally	O
(ip)	O
for	O
5	O
days.	O
Amphetamine	Chemical
(3	O
mg/kg	O
ip)	O
induced	O
hyper	Disease
locomotion,	O
apomorphine	Chemical
(1.5	O
mg/kg	O
subcutaneously	O
[sc])	O
induced	O
climbing,	O
and	O
haloperidol	Chemical
(1.5	O
mg/kg	O
sc)	O
induced	O
catalepsy	Disease
tests	O
were	O
used	O
as	O
animal	O
models	O
of	O
schizophrenia	Disease
.	O
The	O
study	O
was	O
conducted	O
at	O
the	O
Animal	O
Experiment	O
Laboratories,	O
Department	O
of	O
Pharmacology,	O
Medical	O
School,	O
Eskisehir	O
Osmangazi	O
University,	O
Eskisehir,	O
Turkey	O
between	O
March	O
and	O
May	O
2012.	O
Statistical	O
analysis	O
was	O
carried	O
out	O
using	O
Kruskal-Wallis	O
test	O
for	O
hyper	Disease
locomotion,	O
and	O
one-way	O
ANOVA	O
for	O
climbing	O
and	O
catalepsy	Disease
tests.	O
RESULTS:	O
In	O
the	O
amphetamine	Chemical
-induced	O
locomotion	O
test,	O
there	O
were	O
significant	O
increases	O
in	O
all	O
movements	O
compared	O
with	O
the	O
amphetamine	Chemical
-free	O
group.	O
Both	O
DHEA	Chemical
50	O
mg/kg	O
(p<0.05),	O
and	O
100	O
mg/kg	O
(p<0.01)	O
significantly	O
decreased	O
all	O
movements	O
compared	O
with	O
the	O
amphetamine	Chemical
-induced	O
locomotion	O
group.	O
There	O
was	O
a	O
significant	O
difference	O
between	O
groups	O
in	O
the	O
haloperidol	Chemical
-induced	O
catalepsy	Disease
test	O
(p<0.05).	O
There	O
was	O
no	O
significant	O
difference	O
between	O
groups	O
in	O
terms	O
of	O
total	O
climbing	O
time	O
in	O
the	O
apomorphine	Chemical
-induced	O
climbing	O
test	O
(p>0.05).	O
CONCLUSION:	O
We	O
observed	O
that	O
DHEA	Chemical
reduced	O
locomotor	O
activity	O
and	O
increased	O
catalepsy	Disease
at	O
both	O
doses,	O
while	O
it	O
had	O
no	O
effect	O
on	O
climbing	O
behavior.	O
We	O
suggest	O
that	O
DHEA	Chemical
displays	O
typical	O
neuroleptic-like	O
effects,	O
and	O
may	O
be	O
used	O
in	O
the	O
treatment	O
of	O
schizophrenia	Disease

Availability	O
of	O
human	O
induced	O
pluripotent	O
stem	O
cell-derived	O
cardiomyocytes	O
in	O
assessment	O
of	O
drug	O
potential	O
for	O
QT	Disease
prolongation	Disease
.	O
Field	O
potential	O
duration	O
(FPD)	O
in	O
human-induced	O
pluripotent	O
stem	O
cell-derived	O
cardiomyocytes	O
(hiPS-CMs),	O
which	O
can	O
express	O
QT	O
interval	O
in	O
an	O
electrocardiogram,	O
is	O
reported	O
to	O
be	O
a	O
useful	O
tool	O
to	O
predict	O
K	Chemical
(+)	O
channel	O
and	O
Ca	Chemical
(2+)	O
channel	O
blocker	O
effects	O
on	O
QT	O
interval.	O
However,	O
there	O
is	O
no	O
report	O
showing	O
that	O
this	O
technique	O
can	O
be	O
used	O
to	O
predict	O
multichannel	O
blocker	O
potential	O
for	O
QT	Disease
prolongation	Disease
.	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
show	O
that	O
FPD	O
from	O
MEA	O
(Multielectrode	O
array)	O
of	O
hiPS-CMs	O
can	O
detect	O
QT	Disease
prolongation	Disease
induced	O
by	O
multichannel	O
blockers.	O
hiPS-CMs	O
were	O
seeded	O
onto	O
MEA	O
and	O
FPD	O
was	O
measured	O
for	O
2min	O
every	O
10min	O
for	O
30min	O
after	O
drug	O
exposure	O
for	O
the	O
vehicle	O
and	O
each	O
drug	O
concentration.	O
IKr	O
and	O
IKs	O
blockers	O
concentration-dependently	O
prolonged	O
corrected	O
FPD	O
(FPDc),	O
whereas	O
Ca	Chemical
(2+)	O
channel	O
blockers	O
concentration-dependently	O
shortened	O
FPDc.	O
Also,	O
the	O
multichannel	O
blockers	O
Amiodarone	Chemical
,	O
Paroxetine	Chemical
,	O
Terfenadine	Chemical
and	O
Citalopram	Chemical
prolonged	O
FPDc	O
in	O
a	O
concentration	O
dependent	O
manner.	O
Finally,	O
the	O
IKr	O
blockers,	O
Terfenadine	Chemical
and	O
Citalopram	Chemical
,	O
which	O
are	O
reported	O
to	O
cause	O
Torsade	Disease
de	Disease
Pointes	Disease
(	O
TdP	Disease
)	O
in	O
clinical	O
practice,	O
produced	O
early	O
afterdepolarization	O
(EAD).	O
hiPS-CMs	O
using	O
MEA	O
system	O
and	O
FPDc	O
can	O
predict	O
the	O
effects	O
of	O
drug	O
candidates	O
on	O
QT	O
interval.	O
This	O
study	O
also	O
shows	O
that	O
this	O
assay	O
can	O
help	O
detect	O
EAD	O
for	O
drugs	O
with	O
TdP	Disease

Dermal	O
developmental	O
toxicity	Disease
of	O
N-phenylimide	O
herbicides	O
in	O
rats.	O
BACKGROUND:	O
S-53482	Chemical
and	O
S-23121	Chemical
are	O
N-phenylimide	O
herbicides	O
and	O
produced	O
embryolethality	Disease
,	O
teratogenicity	Disease
(mainly	O
ventricular	Disease
septal	Disease
defects	Disease
and	O
wavy	O
ribs),	O
and	O
growth	Disease
retardation	Disease
in	O
rats	O
in	O
conventional	O
oral	O
developmental	O
toxicity	Disease
studies.	O
Our	O
objective	O
in	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
the	O
compounds	O
induce	O
developmental	O
toxicity	Disease
via	O
the	O
dermal	O
route,	O
which	O
is	O
more	O
relevant	O
to	O
occupational	O
exposure,	O
hence	O
better	O
addressing	O
human	O
health	O
risks.	O
METHODS:	O
S-53482	Chemical
was	O
administered	O
dermally	O
to	O
rats	O
at	O
30,	O
100,	O
and	O
300	O
mg/kg	O
during	O
organogenesis,	O
and	O
S-23121	Chemical
was	O
administered	O
at	O
200,	O
400,	O
and	O
800	O
mg/kg	O
(the	O
maximum	O
applicable	O
dose	O
level).	O
Fetuses	O
were	O
obtained	O
by	O
a	O
Cesarean	O
section	O
and	O
examined	O
for	O
external,	O
visceral,	O
and	O
skeletal	O
alterations.	O
RESULTS:	O
Dermal	O
exposure	O
of	O
rats	O
to	O
S-53482	Chemical
at	O
300	O
mg/kg	O
produced	O
patterns	O
of	O
developmental	O
toxicity	Disease
similar	O
to	O
those	O
resulting	O
from	O
oral	O
exposure.	O
Toxicity	Disease
included	O
embryolethality	Disease
,	O
teratogenicity	Disease
,	O
and	O
growth	Disease
retardation	Disease
.	O
Dermal	O
administration	O
of	O
S-23121	Chemical
at	O
800	O
mg/kg	O
resulted	O
in	O
an	O
increased	O
incidence	O
of	O
embryonic	Disease
death	Disease
and	O
ventricular	Disease
septal	Disease
defect	Disease
,	O
but	O
retarded	O
fetal	O
growth	O
was	O
not	O
observed	O
as	O
it	O
was	O
following	O
oral	O
exposure	O
to	O
S-23121	Chemical
.	O
CONCLUSIONS:	O
Based	O
on	O
the	O
results,	O
S-53482	Chemical
and	O
S-23121	Chemical
were	O
teratogenic	Disease

Rates	O
of	O
Renal	Disease
Toxicity	Disease
in	O
Cancer	Disease
Patients	O
Receiving	O
Cisplatin	Chemical
With	O
and	O
Without	O
Mannitol	Chemical
.	O
BACKGROUND:	O
Cisplatin	Chemical
is	O
a	O
widely	O
used	O
antineoplastic.	O
One	O
of	O
the	O
major	O
complications	O
of	O
cisplatin	Chemical
use	O
is	O
dose-limiting	O
nephrotoxicity	Disease
.	O
There	O
are	O
many	O
strategies	O
to	O
prevent	O
this	O
toxicity	Disease
,	O
including	O
the	O
use	O
of	O
mannitol	Chemical
as	O
a	O
nephroprotectant	O
in	O
combination	O
with	O
hydration.	O
OBJECTIVE:	O
We	O
aimed	O
to	O
evaluate	O
the	O
rates	O
of	O
cisplatin	Chemical
-induced	O
nephrotoxicity	Disease
in	O
cancer	Disease
patients	O
receiving	O
single-agent	O
cisplatin	Chemical
with	O
and	O
without	O
mannitol	Chemical
.	O
METHODS:	O
This	O
single-center	O
retrospective	O
analysis	O
was	O
a	O
quasi	O
experiment	O
created	O
by	O
the	O
national	O
mannitol	Chemical
shortage.	O
Data	O
were	O
collected	O
on	O
adult	O
cancer	Disease
patients	O
receiving	O
single-agent	O
cisplatin	Chemical
as	O
an	O
outpatient	O
from	O
January	O
2011	O
to	O
September	O
2012.	O
The	O
primary	O
outcome	O
was	O
acute	Disease
kidney	Disease
injury	Disease
(	O
AKI	Disease
).	O
RESULTS:	O
We	O
evaluated	O
143	O
patients	O
who	O
received	O
single-agent	O
cisplatin	Chemical
;	O
97.2%	O
of	O
patients	O
had	O
head	Disease
and	Disease
neck	Disease
cancer	Disease
as	O
their	O
primary	O
malignancy	Disease
.	O
Patients	O
who	O
did	O
not	O
receive	O
mannitol	Chemical
were	O
more	O
likely	O
to	O
develop	O
nephrotoxicity	Disease
:	O
odds	O
ratio	O
[OR]	O
=	O
2.646	O
(95%	O
CI	O
=	O
1.008,	O
6.944;	O
P	O
=	O
0.048).	O
Patients	O
who	O
received	O
the	O
100	O
mg/m(2)	O
dosing	O
and	O
patients	O
who	O
had	O
a	O
history	O
of	O
hypertension	Disease
also	O
had	O
a	O
higher	O
likelihood	O
of	O
developing	O
nephrotoxicity	Disease
:	O
OR	O
=	O
11.494	O
(95%	O
CI	O
=	O
4.149,	O
32.258;	O
P	O
<	O
0.0001)	O
and	O
OR	O
=	O
3.219	O
(95%	O
CI	O
=	O
1.228,	O
8.439;	O
P	O
=	O
0.017),	O
respectively.	O
CONCLUSIONS:	O
When	O
limited	O
quantities	O
of	O
mannitol	Chemical
are	O
available,	O
it	O
should	O
preferentially	O
be	O
given	O
to	O
patients	O
at	O
particularly	O
high	O
risk	O
of	O
nephrotoxicity	Disease
.	O
Our	O
analysis	O
suggests	O
that	O
those	O
patients	O
receiving	O
the	O
dosing	O
schedule	O
of	O
100	O
mg/m(2)	O
cisplatin	Chemical
every	O
3	O
weeks	O
and	O
those	O
with	O
hypertension	Disease
are	O
at	O
the	O
greatest	O
risk	O
of	O
nephrotoxicity	Disease
and	O
would	O
benefit	O
from	O
the	O
addition	O
of	O
mannitol	Chemical

Metformin	Chemical
protects	O
against	O
seizures	Disease
,	O
learning	Disease
and	Disease
memory	Disease
impairments	Disease
and	O
oxidative	O
damage	O
induced	O
by	O
pentylenetetrazole	Chemical
-induced	O
kindling	O
in	O
mice.	O
Cognitive	Disease
impairment	Disease
,	O
the	O
most	O
common	O
and	O
severe	O
comorbidity	O
of	O
epilepsy	Disease
,	O
greatly	O
diminishes	O
the	O
quality	O
of	O
life.	O
However,	O
current	O
therapeutic	O
interventions	O
for	O
epilepsy	Disease
can	O
also	O
cause	O
untoward	O
cognitive	O
effects.	O
Thus,	O
there	O
is	O
an	O
urgent	O
need	O
for	O
new	O
kinds	O
of	O
agents	O
targeting	O
both	O
seizures	Disease
and	O
cognition	Disease
deficits	Disease
.	O
Oxidative	O
stress	O
is	O
considered	O
to	O
play	O
an	O
important	O
role	O
in	O
epileptogenesis	O
and	O
cognitive	Disease
deficits	Disease
,	O
and	O
antioxidants	O
have	O
a	O
putative	O
antiepileptic	O
potential.	O
Metformin	Chemical
,	O
the	O
most	O
commonly	O
prescribed	O
antidiabetic	O
oral	O
drug,	O
has	O
antioxidant	O
properties.	O
This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
ameliorative	O
effects	O
of	O
metformin	Chemical
on	O
seizures	Disease
,	O
cognitive	Disease
impairment	Disease
and	O
brain	O
oxidative	O
stress	O
markers	O
observed	O
in	O
pentylenetetrazole	Chemical
-induced	O
kindling	O
animals.	O
Male	O
C57BL/6	O
mice	O
were	O
administered	O
with	O
subconvulsive	O
dose	O
of	O
pentylenetetrazole	Chemical
(37	O
mg/kg,	O
i.p.)	O
every	O
other	O
day	O
for	O
14	O
injections.	O
Metformin	Chemical
was	O
injected	O
intraperitoneally	O
in	O
dose	O
of	O
200mg/kg	O
along	O
with	O
alternate-day	O
PTZ	Chemical
.	O
We	O
found	O
that	O
metformin	Chemical
suppressed	O
the	O
progression	O
of	O
kindling,	O
ameliorated	O
the	O
cognitive	Disease
impairment	Disease
and	O
decreased	O
brain	O
oxidative	O
stress.	O
Thus	O
the	O
present	O
study	O
concluded	O
that	O
metformin	Chemical
may	O
be	O
a	O
potential	O
agent	O
for	O
the	O
treatment	O
of	O
epilepsy	Disease
as	O
well	O
as	O
a	O
protective	O
medicine	O
against	O
cognitive	Disease
impairment	Disease
induced	O
by	O
seizures	Disease

P53	O
inhibition	O
exacerbates	O
late-stage	O
anthracycline	Chemical
	O
cardiotoxicity	Disease
.	O
AIMS:	O
Doxorubicin	Chemical
(	O
DOX	Chemical
)	O
is	O
an	O
effective	O
anti-	O
cancer	Disease
therapeutic,	O
but	O
is	O
associated	O
with	O
both	O
acute	O
and	O
late-stage	O
cardiotoxicity	Disease
.	O
Children	O
are	O
particularly	O
sensitive	O
to	O
DOX	Chemical
-induced	O
heart	Disease
failure	Disease
.	O
Here,	O
the	O
impact	O
of	O
p53	O
inhibition	O
on	O
acute	O
vs.	O
late-stage	O
DOX	Chemical
	O
cardiotoxicity	Disease
was	O
examined	O
in	O
a	O
juvenile	O
model.	O
METHODS	O
AND	O
RESULTS:	O
Two-week-old	O
MHC-CB7	O
mice	O
(which	O
express	O
dominant-interfering	O
p53	O
in	O
cardiomyocytes)	O
and	O
their	O
non-transgenic	O
(NON-TXG)	O
littermates	O
received	O
weekly	O
DOX	Chemical
injections	O
for	O
5	O
weeks	O
(25	O
mg/kg	O
cumulative	O
dose).	O
One	O
week	O
after	O
the	O
last	O
DOX	Chemical
treatment	O
(acute	O
stage),	O
MHC-CB7	O
mice	O
exhibited	O
improved	O
cardiac	O
function	O
and	O
lower	O
levels	O
of	O
cardiomyocyte	O
apoptosis	O
when	O
compared	O
with	O
the	O
NON-TXG	O
mice.	O
Surprisingly,	O
by	O
13	O
weeks	O
following	O
the	O
last	O
DOX	Chemical
treatment	O
(late	O
stage),	O
MHC-CB7	O
exhibited	O
a	O
progressive	O
decrease	O
in	O
cardiac	O
function	O
and	O
higher	O
rates	O
of	O
cardiomyocyte	O
apoptosis	O
when	O
compared	O
with	O
NON-TXG	O
mice.	O
p53	O
inhibition	O
blocked	O
transient	O
DOX	Chemical
-induced	O
STAT3	O
activation	O
in	O
MHC-CB7	O
mice,	O
which	O
was	O
associated	O
with	O
enhanced	O
induction	O
of	O
the	O
DNA	O
repair	O
proteins	O
Ku70	O
and	O
Ku80.	O
Mice	O
with	O
cardiomyocyte-restricted	O
deletion	O
of	O
STAT3	O
exhibited	O
worse	O
cardiac	O
function,	O
higher	O
levels	O
of	O
cardiomyocyte	O
apoptosis,	O
and	O
a	O
greater	O
induction	O
of	O
Ku70	O
and	O
Ku80	O
in	O
response	O
to	O
DOX	Chemical
treatment	O
during	O
the	O
acute	O
stage	O
when	O
compared	O
with	O
control	O
animals.	O
CONCLUSION:	O
These	O
data	O
support	O
a	O
model	O
wherein	O
a	O
p53-dependent	O
cardioprotective	O
pathway,	O
mediated	O
via	O
STAT3	O
activation,	O
mitigates	O
DOX	Chemical
-induced	O
myocardial	O
stress	O
during	O
drug	O
delivery.	O
Furthermore,	O
these	O
data	O
suggest	O
an	O
explanation	O
as	O
to	O
how	O
p53	O
inhibition	O
can	O
result	O
in	O
cardioprotection	O
during	O
drug	O
treatment	O
and,	O
paradoxically,	O
enhanced	O
cardiotoxicity	Disease

Metronidazole	Chemical
-induced	O
encephalopathy	Disease
:	O
an	O
uncommon	O
scenario.	O
Metronidazole	Chemical
can	O
produce	O
neurological	O
complications	O
although	O
it	O
is	O
not	O
a	O
common	O
scenario.	O
We	O
present	O
a	O
case	O
where	O
a	O
patient	O
developed	O
features	O
of	O
encephalopathy	Disease
following	O
prolonged	O
metronidazole	Chemical
intake.	O
Magnetic	O
resonance	O
imaging	O
(MRI)	O
brain	O
showed	O
abnormal	O
signal	O
intensity	O
involving	O
both	O
dentate	O
nuclei	O
of	O
cerebellum	O
and	O
splenium	O
of	O
corpus	O
callosum.	O
The	O
diagnosis	O
of	O
metronidazole	Chemical
	O
toxicity	Disease

Aconitine	Chemical
-induced	O
Ca	Chemical
2+	O
overload	O
causes	O
arrhythmia	Disease
and	O
triggers	O
apoptosis	O
through	O
p38	O
MAPK	O
signaling	O
pathway	O
in	O
rats.	O
Aconitine	Chemical
is	O
a	O
major	O
bioactive	O
diterpenoid	O
alkaloid	O
with	O
high	O
content	O
derived	O
from	O
herbal	O
aconitum	O
plants.	O
Emerging	O
evidence	O
indicates	O
that	O
voltage-dependent	O
Na	Chemical
(+)	O
channels	O
have	O
pivotal	O
roles	O
in	O
the	O
cardiotoxicity	Disease
of	O
aconitine	Chemical
.	O
However,	O
no	O
reports	O
are	O
available	O
on	O
the	O
role	O
of	O
Ca	Chemical
(2+)	O
in	O
aconitine	Chemical
	O
poisoning	Disease
.	O
In	O
this	O
study,	O
we	O
explored	O
the	O
importance	O
of	O
pathological	O
Ca	Chemical
(2+)	O
signaling	O
in	O
aconitine	Chemical
	O
poisoning	Disease
in	O
vitro	O
and	O
in	O
vivo.	O
We	O
found	O
that	O
Ca	Chemical
(2+)	O
overload	O
lead	O
to	O
accelerated	O
beating	O
rhythm	O
in	O
adult	O
rat	O
ventricular	O
myocytes	O
and	O
caused	O
arrhythmia	Disease
in	O
conscious	O
freely	O
moving	O
rats.	O
To	O
investigate	O
effects	O
of	O
aconitine	Chemical
on	O
myocardial	Disease
injury	Disease
,	O
we	O
performed	O
cytotoxicity	Disease
assay	O
in	O
neonatal	O
rat	O
ventricular	O
myocytes	O
(NRVMs),	O
as	O
well	O
as	O
measured	O
lactate	Chemical
dehydrogenase	O
level	O
in	O
the	O
culture	O
medium	O
of	O
NRVMs	O
and	O
activities	O
of	O
serum	O
cardiac	O
enzymes	O
in	O
rats.	O
The	O
results	O
showed	O
that	O
aconitine	Chemical
resulted	O
in	O
myocardial	Disease
injury	Disease
and	O
reduced	O
NRVMs	O
viability	O
dose-dependently.	O
To	O
confirm	O
the	O
pro-apoptotic	O
effects,	O
we	O
performed	O
flow	O
cytometric	O
detection,	O
cardiac	O
histology,	O
transmission	O
electron	O
microscopy	O
and	O
terminal	O
deoxynucleotidyl	O
transferase-mediated	O
dUTP	Chemical
-	O
biotin	Chemical
nick	O
end	O
labeling	O
assay.	O
The	O
results	O
showed	O
that	O
aconitine	Chemical
stimulated	O
apoptosis	O
time-dependently.	O
The	O
expression	O
analysis	O
of	O
Ca	Chemical
(2+)	O
handling	O
proteins	O
demonstrated	O
that	O
aconitine	Chemical
promoted	O
Ca	Chemical
(2+)	O
overload	O
through	O
the	O
expression	O
regulation	O
of	O
Ca	Chemical
(2+)	O
handling	O
proteins.	O
The	O
expression	O
analysis	O
of	O
apoptosis-related	O
proteins	O
revealed	O
that	O
pro-apoptotic	O
protein	O
expression	O
was	O
upregulated,	O
and	O
anti-apoptotic	O
protein	O
BCL-2	O
expression	O
was	O
downregulated.	O
Furthermore,	O
increased	O
phosphorylation	O
of	O
MAPK	O
family	O
members,	O
especially	O
the	O
P-P38/P38	O
ratio	O
was	O
found	O
in	O
cardiac	O
tissues.	O
Hence,	O
our	O
results	O
suggest	O
that	O
aconitine	Chemical
significantly	O
aggravates	O
Ca	Chemical
(2+)	O
overload	O
and	O
causes	O
arrhythmia	Disease

Chronic	O
treatment	O
with	O
metformin	Chemical
suppresses	O
toll-like	O
receptor	O
4	O
signaling	O
and	O
attenuates	O
left	Disease
ventricular	Disease
dysfunction	Disease
following	O
myocardial	Disease
infarction	Disease
.	O
Acute	O
treatment	O
with	O
metformin	Chemical
has	O
a	O
protective	O
effect	O
in	O
myocardial	Disease
infarction	Disease
by	O
suppression	O
of	O
inflammatory	O
responses	O
due	O
to	O
activation	O
of	O
AMP	Chemical
-activated	O
protein	O
kinase	O
(AMPK).	O
In	O
the	O
present	O
study,	O
the	O
effect	O
of	O
chronic	O
pre-treatment	O
with	O
metformin	Chemical
on	O
cardiac	Disease
dysfunction	Disease
and	O
toll-like	O
receptor	O
4	O
(TLR4)	O
activities	O
following	O
myocardial	Disease
infarction	Disease
and	O
their	O
relation	O
with	O
AMPK	O
were	O
assessed.	O
Male	O
Wistar	O
rats	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
5	O
groups	O
(n=6):	O
normal	O
control	O
and	O
groups	O
were	O
injected	O
isoproterenol	Chemical
after	O
chronic	O
pre-treatment	O
with	O
0,	O
25,	O
50,	O
or	O
100mg/kg	O
of	O
metformin	Chemical
twice	O
daily	O
for	O
14	O
days.	O
Isoproterenol	Chemical
(100mg/kg)	O
was	O
injected	O
subcutaneously	O
on	O
the	O
13th	O
and	O
14th	O
days	O
to	O
induce	O
acute	Disease
myocardial	Disease
infarction	Disease
.	O
Isoproterenol	Chemical
alone	O
decreased	O
left	O
ventricular	O
systolic	O
pressure	O
and	O
myocardial	O
contractility	O
indexed	O
as	O
LVdp/dtmax	O
and	O
LVdp/dtmin.	O
The	O
left	Disease
ventricular	Disease
dysfunction	Disease
was	O
significantly	O
lower	O
in	O
the	O
groups	O
treated	O
with	O
25	O
and	O
50mg/kg	O
of	O
metformin	Chemical
.	O
Metfromin	O
markedly	O
lowered	O
isoproterenol	Chemical
-induced	O
elevation	O
in	O
the	O
levels	O
of	O
TLR4	O
mRNA,	O
myeloid	O
differentiation	O
protein	O
88	O
(MyD88),	O
tumor	Disease
	O
necrosis	Disease
factor-alpha	O
(TNF-a),	O
and	O
interleukin	O
6	O
(IL-6)	O
in	O
the	O
heart	O
tissues.	O
Similar	O
changes	O
were	O
also	O
seen	O
in	O
the	O
serum	O
levels	O
of	O
TNF-a	O
and	O
IL-6.	O
However,	O
the	O
lower	O
doses	O
of	O
25	O
and	O
50mg/kg	O
were	O
more	O
effective	O
than	O
100mg/kg.	O
Phosphorylated	O
AMPKa	O
(p-AMPK)	O
in	O
the	O
myocardium	O
was	O
significantly	O
elevated	O
by	O
25mg/kg	O
of	O
metformin	Chemical
,	O
slightly	O
by	O
50mg/kg,	O
but	O
not	O
by	O
100mg/kg.	O
Chronic	O
pre-treatment	O
with	O
metformin	Chemical
reduces	O
post-	O
myocardial	Disease
infarction	Disease

Neuroleptic	Disease
malignant	Disease
syndrome	Disease
induced	O
by	O
combination	O
therapy	O
with	O
tetrabenazine	Chemical
and	O
tiapride	Chemical
in	O
a	O
Japanese	O
patient	O
with	O
Huntington's	Disease
disease	Disease
at	O
the	O
terminal	O
stage	O
of	O
recurrent	O
breast	Disease
cancer	Disease
.	O
We	O
herein	O
describe	O
the	O
case	O
of	O
an	O
81-year-old	O
Japanese	O
woman	O
with	O
neuroleptic	Disease
malignant	Disease
syndrome	Disease
that	O
occurred	O
36	O
days	O
after	O
the	O
initiation	O
of	O
combination	O
therapy	O
with	O
tiapride	Chemical
(75	O
mg/day)	O
and	O
tetrabenazine	Chemical
(12.5	O
mg/day)	O
for	O
Huntington's	Disease
disease	Disease
.	O
The	O
patient	O
had	O
been	O
treated	O
with	O
tiapride	Chemical
or	O
tetrabenazine	Chemical
alone	O
without	O
any	O
adverse	O
effects	O
before	O
the	O
administration	O
of	O
the	O
combination	O
therapy.	O
She	O
also	O
had	O
advanced	O
breast	Disease
cancer	Disease
when	O
the	O
combination	O
therapy	O
was	O
initiated.	O
To	O
the	O
best	O
of	O
our	O
knowledge,	O
the	O
occurrence	O
of	O
neuroleptic	Disease
malignant	Disease
syndrome	Disease
due	O
to	O
combination	O
therapy	O
with	O
tetrabenazine	Chemical
and	O
tiapride	Chemical
has	O
not	O
been	O
previously	O
reported.	O
Tetrabenazine	Chemical
should	O
be	O
administered	O
very	O
carefully	O
in	O
combination	O
with	O
other	O
neuroleptic	Chemical
drugs	Chemical

A	O
metoprolol	Chemical
-	O
terbinafine	Chemical
combination	O
induced	O
bradycardia	Disease
.	O
To	O
report	O
a	O
sinus	Disease
bradycardia	Disease
induced	O
by	O
metoprolol	Chemical
and	O
terbinafine	Chemical
drug-drug	O
interaction	O
and	O
its	O
management.	O
A	O
63	O
year-old	O
Caucasian	O
man	O
on	O
metoprolol	Chemical
200	O
mg/day	O
for	O
stable	O
coronary	Disease
artery	Disease
disease	Disease
was	O
prescribed	O
a	O
90-day	O
course	O
of	O
oral	O
terbinafine	Chemical
250	O
mg/day	O
for	O
onychomycosis	Disease
.	O
On	O
the	O
49th	O
day	O
of	O
terbinafine	Chemical
therapy,	O
he	O
was	O
brought	O
to	O
the	O
emergency	O
room	O
for	O
a	O
decrease	O
of	O
his	O
global	O
health	O
status,	O
confusion	Disease
and	O
falls.	O
The	O
electrocardiogram	O
revealed	O
a	O
37	O
beats/min	O
sinus	Disease
bradycardia	Disease
.	O
A	O
score	O
of	O
7	O
on	O
the	O
Naranjo	O
adverse	Disease
drug	Disease
reaction	Disease
probability	O
scale	O
indicates	O
a	O
probable	O
relationship	O
between	O
the	O
patient's	O
sinus	Disease
bradycardia	Disease
and	O
the	O
drug	O
interaction	O
between	O
metoprolol	Chemical
and	O
terbinafine	Chemical
.	O
The	O
heart	O
rate	O
ameliorated	O
first	O
with	O
a	O
decrease	O
in	O
the	O
dose	O
of	O
metoprolol	Chemical
.	O
It	O
was	O
subsequently	O
changed	O
to	O
bisoprolol	Chemical
and	O
the	O
heart	O
rate	O
remained	O
normal.	O
By	O
inhibiting	O
the	O
cytochrome	O
P450	O
2D6,	O
terbinafine	Chemical
had	O
decreased	O
metoprolol	Chemical
's	O
clearance,	O
leading	O
in	O
metoprolol	Chemical
accumulation	O
which	O
has	O
resulted	O
in	O
clinically	O
significant	O
sinus	Disease
bradycardia	Disease

Optochiasmatic	O
and	O
peripheral	Disease
neuropathy	Disease
due	O
to	O
ethambutol	Chemical
overtreatment.	O
Ethambutol	Chemical
is	O
known	O
to	O
cause	O
optic	Disease
neuropathy	Disease
and,	O
more	O
rarely,	O
axonal	O
polyneuropathy	Disease
.	O
We	O
characterize	O
the	O
clinical,	O
neurophysiological,	O
and	O
neuroimaging	O
findings	O
in	O
a	O
72-year-old	O
man	O
who	O
developed	O
visual	Disease
loss	Disease
and	O
paresthesias	Disease
after	O
11	O
weeks	O
of	O
exposure	O
to	O
a	O
supratherapeutic	O
dose	O
of	O
ethambutol	Chemical
.	O
This	O
case	O
demonstrates	O
the	O
selective	O
vulnerability	O
of	O
the	O
anterior	O
visual	O
pathways	O
and	O
peripheral	O
nerves	O
to	O
ethambutol	Chemical
	O
toxicity	Disease

Testosterone	Chemical
ameliorates	O
streptozotocin	Chemical
-induced	O
memory	Disease
impairment	Disease
in	O
male	O
rats.	O
AIM:	O
To	O
study	O
the	O
effects	O
of	O
testosterone	Chemical
on	O
streptozotocin	Chemical
(	O
STZ	Chemical
)-induced	O
memory	Disease
impairment	Disease
in	O
male	O
rats.	O
METHODS:	O
Adult	O
male	O
Wistar	O
rats	O
were	O
intracerebroventricularly	O
(icv)	O
infused	O
with	O
STZ	Chemical
(750	O
ug)	O
on	O
d	O
1	O
and	O
d	O
3,	O
and	O
a	O
passive	O
avoidance	O
task	O
was	O
assessed	O
2	O
weeks	O
after	O
the	O
first	O
injection	O
of	O
STZ	Chemical
.	O
Castration	O
surgery	O
was	O
performed	O
in	O
another	O
group	O
of	O
rats,	O
and	O
the	O
passive	O
avoidance	O
task	O
was	O
assessed	O
4	O
weeks	O
after	O
the	O
operation.	O
Testosterone	Chemical
(1	O
mg.kg(-1).d(-1),	O
sc),	O
the	O
androgen	Chemical
receptor	O
antagonist	O
flutamide	Chemical
(10	O
mg.kg(-1).d(-1),	O
ip),	O
the	O
estrogen	Chemical
receptor	O
antagonist	O
tamoxifen	Chemical
(1	O
mg.kg(-1).d(-1),	O
ip)	O
or	O
the	O
aromatase	O
inhibitor	O
letrozole	Chemical
(4	O
mg.kg(-1).d(-1),	O
ip)	O
were	O
administered	O
for	O
6	O
d	O
after	O
the	O
first	O
injection	O
of	O
STZ	Chemical
.	O
RESULTS:	O
STZ	Chemical
administration	O
and	O
castration	O
markedly	O
decreased	O
both	O
STL1	O
(the	O
short	O
memory)	O
and	O
STL2	O
(the	O
long	O
memory)	O
in	O
passive	O
avoidance	O
tests.	O
Testosterone	Chemical
replacement	O
almost	O
restored	O
the	O
STL1	O
and	O
STL2	O
in	O
castrated	O
rats,	O
and	O
significantly	O
prolonged	O
the	O
STL1	O
and	O
STL2	O
in	O
STZ	Chemical
-treated	O
rats.	O
Administration	O
of	O
flutamide	Chemical
,	O
letrozole	Chemical
or	O
tamoxifen	Chemical
significantly	O
impaired	Disease
the	Disease
memory	Disease
in	O
intact	O
rats,	O
and	O
significantly	O
attenuated	O
the	O
testosterone	Chemical
replacement	O
in	O
improving	O
STZ	Chemical
-	O
and	O
castration-induced	O
memory	Disease
impairment	Disease
.	O
CONCLUSION:	O
Testosterone	Chemical
administration	O
ameliorates	O
STZ	Chemical
-	O
and	O
castration-induced	O
memory	Disease
impairment	Disease

Behavioral	O
and	O
neurochemical	O
studies	O
in	O
mice	O
pretreated	O
with	O
garcinielliptone	Chemical
FC	Chemical
in	O
pilocarpine	Chemical
-induced	O
seizures	Disease
.	O
Garcinielliptone	Chemical
FC	Chemical
(	O
GFC	Chemical
)	O
isolated	O
from	O
hexanic	O
fraction	O
seed	O
extract	O
of	O
species	O
Platonia	O
insignis	O
Mart.	O
It	O
is	O
widely	O
used	O
in	O
folk	O
medicine	O
to	O
treat	O
skin	Disease
diseases	Disease
in	O
both	O
humans	O
and	O
animals	O
as	O
well	O
as	O
the	O
seed	O
decoction	O
has	O
been	O
used	O
to	O
treat	O
diarrheas	Disease
and	O
inflammatory	Disease
diseases	Disease
.	O
However,	O
there	O
is	O
no	O
research	O
on	O
GFC	Chemical
effects	O
in	O
the	O
central	O
nervous	O
system	O
of	O
rodents.	O
The	O
present	O
study	O
aimed	O
to	O
evaluate	O
the	O
GFC	Chemical
effects	O
at	O
doses	O
of	O
25,	O
50	O
or	O
75	O
mg/kg	O
on	O
seizure	Disease
parameters	O
to	O
determine	O
their	O
anticonvulsant	O
activity	O
and	O
its	O
effects	O
on	O
amino	Chemical
acid	Chemical
(	O
r-aminobutyric	Chemical
acid	Chemical
(	O
GABA	Chemical
),	O
glutamine	Chemical
,	O
aspartate	Chemical
and	O
glutathione	Chemical
)	O
levels	O
as	O
well	O
as	O
on	O
acetylcholinesterase	O
(AChE)	O
activity	O
in	O
mice	O
hippocampus	O
after	O
seizures	Disease
.	O
GFC	Chemical
produced	O
an	O
increased	O
latency	O
to	O
first	O
seizure	Disease
,	O
at	O
doses	O
25mg/kg	O
(20.12	O
+	O
2.20	O
min),	O
50mg/kg	O
(20.95	O
+	O
2.21	O
min)	O
or	O
75	O
mg/kg	O
(23.43	O
+	O
1.99	O
min)	O
when	O
compared	O
with	O
seized	O
mice.	O
In	O
addition,	O
GABA	Chemical
content	O
of	O
mice	O
hippocampus	O
treated	O
with	O
GFC75	O
plus	O
P400	O
showed	O
an	O
increase	O
of	O
46.90%	O
when	O
compared	O
with	O
seized	O
mice.	O
In	O
aspartate	Chemical
,	O
glutamine	Chemical
and	O
glutamate	Chemical
levels	O
detected	O
a	O
decrease	O
of	O
5.21%,	O
13.55%	O
and	O
21.80%,	O
respectively	O
in	O
mice	O
hippocampus	O
treated	O
with	O
GFC75	O
plus	O
P400	O
when	O
compared	O
with	O
seized	O
mice.	O
Hippocampus	O
mice	O
treated	O
with	O
GFC75	O
plus	O
P400	O
showed	O
an	O
increase	O
in	O
AChE	O
activity	O
(63.30%)	O
when	O
compared	O
with	O
seized	O
mice.	O
The	O
results	O
indicate	O
that	O
GFC	Chemical
can	O
exert	O
anticonvulsant	O
activity	O
and	O
reduce	O
the	O
frequency	O
of	O
installation	O
of	O
pilocarpine	Chemical
-induced	O
status	Disease
epilepticus	Disease
,	O
as	O
demonstrated	O
by	O
increase	O
in	O
latency	O
to	O
first	O
seizure	Disease
and	O
decrease	O
in	O
mortality	O
rate	O
of	O
animals.	O
In	O
conclusion,	O
our	O
data	O
suggest	O
that	O
GFC	Chemical
may	O
influence	O
in	O
epileptogenesis	O
and	O
promote	O
anticonvulsant	O
actions	O
in	O
pilocarpine	Chemical
model	O
by	O
modulating	O
the	O
GABA	Chemical
and	O
glutamate	Chemical

Standard	O
operating	O
procedures	O
for	O
antibiotic	O
therapy	O
and	O
the	O
occurrence	O
of	O
acute	Disease
kidney	Disease
injury	Disease
:	O
a	O
prospective,	O
clinical,	O
non-interventional,	O
observational	O
study.	O
INTRODUCTION:	O
Acute	Disease
kidney	Disease
injury	Disease
(	O
AKI	Disease
)	O
occurs	O
in	O
7%	O
of	O
hospitalized	O
and	O
66%	O
of	O
Intensive	O
Care	O
Unit	O
(ICU)	O
patients.	O
It	O
increases	O
mortality,	O
hospital	O
length	O
of	O
stay,	O
and	O
costs.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate,	O
whether	O
there	O
is	O
an	O
association	O
between	O
adherence	O
to	O
guidelines	O
(standard	O
operating	O
procedures	O
(SOP))	O
for	O
potentially	O
nephrotoxic	Disease
antibiotics	O
and	O
the	O
occurrence	O
of	O
AKI	Disease
.	O
METHODS:	O
This	O
study	O
was	O
carried	O
out	O
as	O
a	O
prospective,	O
clinical,	O
non-interventional,	O
observational	O
study.	O
Data	O
collection	O
was	O
performed	O
over	O
a	O
total	O
of	O
170	O
days	O
in	O
three	O
ICUs	O
at	O
Charite	O
-	O
Universitaetsmedizin	O
Berlin.	O
A	O
total	O
of	O
675	O
patients	O
were	O
included;	O
163	O
of	O
these	O
had	O
therapy	O
with	O
vancomycin	Chemical
,	O
gentamicin	Chemical
,	O
or	O
tobramycin	Chemical
;	O
were	O
>18	O
years;	O
and	O
treated	O
in	O
the	O
ICU	O
for	O
>24	O
hours.	O
Patients	O
with	O
an	O
adherence	O
to	O
SOP	O
>70%	O
were	O
classified	O
into	O
the	O
high	O
adherence	O
group	O
(HAG)	O
and	O
patients	O
with	O
an	O
adherence	O
of	O
<70%	O
into	O
the	O
low	O
adherence	O
group	O
(LAG).	O
AKI	Disease
was	O
defined	O
according	O
to	O
RIFLE	O
criteria.	O
Adherence	O
to	O
SOPs	O
was	O
evaluated	O
by	O
retrospective	O
expert	O
audit.	O
Development	O
of	O
AKI	Disease
was	O
compared	O
between	O
groups	O
with	O
exact	O
Chi2-test	O
and	O
multivariate	O
logistic	O
regression	O
analysis	O
(two-sided	O
P	O
<0.05).	O
RESULTS:	O
LAG	O
consisted	O
of	O
75	O
patients	O
(46%)	O
versus	O
88	O
HAG	O
patients	O
(54%).	O
AKI	Disease
occurred	O
significantly	O
more	O
often	O
in	O
LAG	O
with	O
36%	O
versus	O
21%	O
in	O
HAG	O
(P	O
=	O
0.035).	O
Basic	O
characteristics	O
were	O
comparable,	O
except	O
an	O
increased	O
rate	O
of	O
soft	O
tissue	O
infections	Disease
in	O
LAG.	O
Multivariate	O
analysis	O
revealed	O
an	O
odds	O
ratio	O
of	O
2.5-fold	O
for	O
LAG	O
to	O
develop	O
AKI	Disease
compared	O
with	O
HAG	O
(95%	O
confidence	O
interval	O
1.195	O
to	O
5.124,	O
P	O
=	O
0.039).	O
CONCLUSION:	O
Low	O
adherence	O
to	O
SOPs	O
for	O
potentially	O
nephrotoxic	Disease
antibiotics	O
was	O
associated	O
with	O
a	O
higher	O
occurrence	O
of	O
AKI	Disease

Rhabdomyolysis	Disease
in	O
a	O
hepatitis	Disease
C	Disease
virus	Disease
infected	Disease
patient	O
treated	O
with	O
telaprevir	Chemical
and	O
simvastatin	Chemical
.	O
A	O
46-year	O
old	O
man	O
with	O
a	O
chronic	O
hepatitis	Disease
C	Disease
virus	Disease
infection	Disease
received	O
triple	O
therapy	O
with	O
ribavirin	Chemical
,	O
pegylated	Chemical
interferon	Chemical
and	O
telaprevir	Chemical
.	O
The	O
patient	O
also	O
received	O
simvastatin	Chemical
.	O
One	O
month	O
after	O
starting	O
the	O
antiviral	O
therapy,	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
hospital	O
because	O
he	O
developed	O
rhabdomyolysis	Disease
.	O
At	O
admission	O
simvastatin	Chemical
and	O
all	O
antiviral	O
drugs	O
were	O
discontinued	O
because	O
toxicity	Disease
due	O
to	O
a	O
drug-drug	O
interaction	O
was	O
suspected.	O
The	O
creatine	Chemical
kinase	O
peaked	O
at	O
62,246	O
IU/L	O
and	O
the	O
patient	O
was	O
treated	O
with	O
intravenous	O
normal	O
saline.	O
The	O
patient's	O
renal	O
function	O
remained	O
unaffected.	O
Fourteen	O
days	O
after	O
hospitalization,	O
creatine	Chemical
kinase	O
level	O
had	O
returned	O
to	O
230	O
IU/L	O
and	O
the	O
patient	O
was	O
discharged.	O
Telaprevir	Chemical
was	O
considered	O
the	O
probable	O
causative	O
agent	O
of	O
an	O
interaction	O
with	O
simvastatin	Chemical
according	O
to	O
the	O
Drug	O
Interaction	O
Probability	O
Scale.	O
The	O
interaction	O
is	O
due	O
to	O
inhibition	O
of	O
CYP3A4-mediated	O
simvastatin	Chemical
clearance.	O
Simvastatin	Chemical
plasma	O
concentration	O
increased	O
30	O
times	O
in	O
this	O
patient	O
and	O
statin	Chemical
induced	O
muscle	Disease
toxicity	Disease
is	O
related	O
to	O
the	O
concentration	O
of	O
the	O
statin	Chemical
in	O
blood.	O
In	O
conclusion,	O
with	O
this	O
case	O
we	O
illustrate	O
that	O
telaprevir	Chemical
as	O
well	O
as	O
statins	Chemical

Combination	O
of	O
bortezomib	Chemical
,	O
thalidomide	Chemical
,	O
and	O
dexamethasone	Chemical
(VTD)	O
as	O
a	O
consolidation	O
therapy	O
after	O
autologous	O
stem	O
cell	O
transplantation	O
for	O
symptomatic	O
multiple	Disease
myeloma	Disease
in	O
Japanese	O
patients.	O
Consolidation	O
therapy	O
for	O
patients	O
with	O
multiple	Disease
myeloma	Disease
(	O
MM	Disease
)	O
has	O
been	O
widely	O
adopted	O
to	O
improve	O
treatment	O
response	O
following	O
autologous	O
stem	O
cell	O
transplantation.	O
In	O
this	O
study,	O
we	O
retrospectively	O
analyzed	O
the	O
safety	O
and	O
efficacy	O
of	O
combination	O
regimen	O
of	O
bortezomib	Chemical
,	O
thalidomide	Chemical
,	O
and	O
dexamethasone	Chemical
(VTD)	O
as	O
consolidation	O
therapy	O
in	O
24	O
Japanese	O
patients	O
with	O
newly	O
diagnosed	O
MM	Disease
.	O
VTD	O
consisted	O
of	O
bortezomib	Chemical
at	O
a	O
dose	O
of	O
1.3	O
mg/m(2)	O
and	O
dexamethasone	Chemical
at	O
a	O
dose	O
of	O
40	O
mg/day	O
on	O
days	O
1,	O
8,	O
15,	O
and	O
22	O
of	O
a	O
35-day	O
cycle,	O
with	O
daily	O
oral	O
thalidomide	Chemical
at	O
a	O
dose	O
of	O
100	O
mg/day.	O
Grade	O
3-4	O
neutropenia	Disease
and	O
thrombocytopenia	Disease
were	O
documented	O
in	O
four	O
and	O
three	O
patients	O
(17	O
and	O
13	O
%),	O
respectively,	O
but	O
drug	O
dose	O
reduction	O
due	O
to	O
cytopenia	Disease
was	O
not	O
required	O
in	O
any	O
case.	O
Peripheral	Disease
neuropathy	Disease
was	O
common	O
(63	O
%),	O
but	O
severe	O
grade	O
3-4	O
peripheral	Disease
neuropathy	Disease

Conversion	O
to	O
sirolimus	Chemical
ameliorates	O
cyclosporine	Chemical
-induced	O
nephropathy	Disease
in	O
the	O
rat:	O
focus	O
on	O
serum,	O
urine,	O
gene,	O
and	O
protein	O
renal	O
expression	O
biomarkers.	O
Protocols	O
of	O
conversion	O
from	O
cyclosporin	Chemical
A	Chemical
(	O
CsA	Chemical
)	O
to	O
sirolimus	Chemical
(	O
SRL	Chemical
)	O
have	O
been	O
widely	O
used	O
in	O
immunotherapy	O
after	O
transplantation	O
to	O
prevent	O
CsA	Chemical
-induced	O
nephropathy	Disease
,	O
but	O
the	O
molecular	O
mechanisms	O
underlying	O
these	O
protocols	O
remain	O
nuclear.	O
This	O
study	O
aimed	O
to	O
identify	O
the	O
molecular	O
pathways	O
and	O
putative	O
biomarkers	O
of	O
CsA	Chemical
-to-	O
SRL	Chemical
conversion	O
in	O
a	O
rat	O
model.	O
Four	O
animal	O
groups	O
(n	O
=	O
6)	O
were	O
tested	O
during	O
9	O
weeks:	O
control,	O
CsA	Chemical
,	O
SRL	Chemical
,	O
and	O
conversion	O
(	O
CsA	Chemical
for	O
3	O
weeks	O
followed	O
by	O
SRL	Chemical
for	O
6	O
weeks).	O
Classical	O
and	O
emergent	O
serum,	O
urinary,	O
and	O
kidney	O
tissue	O
(gene	O
and	O
protein	O
expression)	O
markers	O
were	O
assessed.	O
Renal	Disease
lesions	Disease
were	O
analyzed	O
in	O
hematoxylin	Chemical
and	O
eosin	Chemical
,	O
periodic	O
acid-Schiff,	O
and	O
Masson's	O
trichrome	O
stains.	O
SRL	Chemical
-treated	O
rats	O
presented	O
proteinuria	Disease
and	O
NGAL	O
(serum	O
and	O
urinary)	O
as	O
the	O
best	O
markers	O
of	O
renal	Disease
impairment	Disease
.	O
Short	O
CsA	Chemical
treatment	O
presented	O
slight	O
or	O
even	O
absent	O
kidney	Disease
lesions	Disease
and	O
TGF-b,	O
NF-	O
kb,	O
mTOR,	O
PCNA,	O
TP53,	O
KIM-1,	O
and	O
CTGF	O
as	O
relevant	O
gene	O
and	O
protein	O
changes.	O
Prolonged	O
CsA	Chemical
exposure	O
aggravated	O
renal	Disease
damage	Disease
,	O
without	O
clear	O
changes	O
on	O
the	O
traditional	O
markers,	O
but	O
with	O
changes	O
in	O
serums	O
TGF-	O
b	O
and	O
IL-7,	O
TBARs	O
clearance,	O
and	O
kidney	O
TGF-b	O
and	O
mTOR.	O
Conversion	O
to	O
SRL	Chemical
prevented	O
CsA	Chemical
-induced	O
renal	Disease
damage	Disease
evolution	O
(absent/mild	O
grade	O
lesions),	O
while	O
NGAL	O
(serum	O
versus	O
urine)	O
seems	O
to	O
be	O
a	O
feasible	O
biomarker	O
of	O
CsA	Chemical
replacement	O
to	O
SRL	Chemical

Kinin	O
B2	O
receptor	O
deletion	O
and	O
blockage	O
ameliorates	O
cisplatin	Chemical
-induced	O
acute	Disease
renal	Disease
injury	Disease
.	O
Cisplatin	Chemical
treatment	O
has	O
been	O
adopted	O
in	O
some	O
chemotherapies;	O
however,	O
this	O
drug	O
can	O
induce	O
acute	Disease
kidney	Disease
injury	Disease
due	O
its	O
ability	O
to	O
negatively	O
affect	O
renal	O
function,	O
augment	O
serum	O
levels	O
of	O
creatinine	Chemical
and	O
urea	Chemical
,	O
increase	O
the	O
acute	Disease
tubular	Disease
necrosis	Disease
score	O
and	O
up-regulate	O
cytokines	O
(e.g.,	O
IL-1b	O
and	O
TNF-a).	O
The	O
kinin	O
B2	O
receptor	O
has	O
been	O
associated	O
with	O
the	O
inflammation	Disease
process,	O
as	O
well	O
as	O
the	O
regulation	O
of	O
cytokine	O
expression,	O
and	O
its	O
deletion	O
resulted	O
in	O
an	O
improvement	O
in	O
the	O
diabetic	Disease
nephropathy	Disease
status.	O
To	O
examine	O
the	O
role	O
of	O
the	O
kinin	O
B2	O
receptor	O
in	O
cisplatin	Chemical
-induced	O
acute	Disease
kidney	Disease
injury	Disease
,	O
kinin	O
B2	O
receptor	O
knockout	O
mice	O
were	O
challenged	O
with	O
cisplatin	Chemical
.	O
Additionally,	O
WT	O
mice	O
were	O
treated	O
with	O
a	O
B2	O
receptor	O
antagonist	O
after	O
cisplatin	Chemical
administration.	O
B2	O
receptor-deficient	O
mice	O
were	O
less	O
sensitive	O
to	O
this	O
drug	O
than	O
the	O
WT	O
mice,	O
as	O
shown	O
by	O
reduced	O
weight	Disease
loss	Disease
,	O
better	O
preservation	O
of	O
kidney	O
function,	O
down	O
regulation	O
of	O
inflammatory	O
cytokines	O
and	O
less	O
acute	Disease
tubular	Disease
necrosis	Disease
.	O
Moreover,	O
treatment	O
with	O
the	O
kinin	O
B2	O
receptor	O
antagonist	O
effectively	O
reduced	O
the	O
levels	O
of	O
serum	O
creatinine	Chemical
and	O
blood	O
urea	Chemical
after	O
cisplatin	Chemical
administration.	O
Thus,	O
our	O
data	O
suggest	O
that	O
the	O
kinin	O
B2	O
receptor	O
is	O
involved	O
in	O
cisplatin	Chemical
-induced	O
acute	Disease
kidney	Disease
injury	Disease
by	O
mediating	O
the	O
necrotic	Disease
process	O
and	O
the	O
expression	O
of	O
inflammatory	O
cytokines,	O
thus	O
resulting	O
in	O
declined	O
renal	O
function.	O
These	O
results	O
highlight	O
the	O
kinin	O
B2	O
receptor	O
antagonist	O
treatment	O
in	O
amelioration	O
of	O
nephrotoxicity	Disease
induced	O
by	O
cisplatin	Chemical

Safety	O
and	O
efficacy	O
of	O
fluocinolone	Chemical
acetonide	Chemical
intravitreal	O
implant	O
(0.59	O
mg)	O
in	O
birdshot	Disease
retinochoroidopathy	Disease
.	O
PURPOSE:	O
To	O
report	O
the	O
treatment	O
outcomes	O
of	O
the	O
fluocinolone	Chemical
acetonide	Chemical
intravitreal	O
implant	O
(0.59	O
mg)	O
in	O
patients	O
with	O
birdshot	Disease
retinochoroidopathy	Disease
whose	O
disease	O
is	O
refractory	O
or	O
intolerant	O
to	O
conventional	O
immunomodulatory	O
therapy.	O
METHODS:	O
A	O
retrospective	O
case	O
series	O
involving	O
11	O
birdshot	Disease
retinochoroidopathy	Disease
patients	O
(11	O
eyes).	O
Eleven	O
patients	O
(11	O
eyes)	O
underwent	O
surgery	O
for	O
fluocinolone	Chemical
acetonide	Chemical
implant	O
(0.59	O
mg).	O
Treatment	O
outcomes	O
of	O
interest	O
were	O
noted	O
at	O
baseline,	O
before	O
fluocinolone	Chemical
acetonide	Chemical
implant,	O
and	O
then	O
at	O
6	O
months,	O
1	O
year,	O
2	O
years,	O
3	O
years,	O
and	O
beyond	O
3	O
years.	O
Disease	O
activity	O
markers,	O
including	O
signs	O
of	O
ocular	O
inflammation	Disease
,	O
evidence	O
of	O
retinal	Disease
vasculitis	Disease
,	O
Swedish	O
interactive	O
threshold	O
algorithm-short	O
wavelength	O
automated	O
perimetry	O
Humphrey	O
visual	O
field	O
analysis,	O
electroretinographic	O
parameters,	O
and	O
optical	O
coherence	O
tomography	O
were	O
recorded.	O
Data	O
on	O
occurrence	O
of	O
cataract	Disease
and	O
raised	Disease
intraocular	Disease
pressure	Disease
were	O
collected	O
in	O
all	O
eyes.	O
RESULTS:	O
Intraocular	O
inflammation	Disease
was	O
present	O
in	O
54.5,	O
9.9,	O
11.1,	O
and	O
0%	O
of	O
patients	O
at	O
baseline,	O
6	O
months,	O
1	O
year,	O
2	O
years,	O
3	O
years,	O
and	O
beyond	O
3	O
years	O
after	O
receiving	O
the	O
implant,	O
respectively.	O
Active	O
vasculitis	Disease
was	O
noted	O
in	O
36.3%	O
patients	O
at	O
baseline	O
and	O
0%	O
at	O
3	O
years	O
of	O
follow-up.	O
More	O
than	O
20%	O
(47.61-67.2%)	O
reduction	O
in	O
central	O
retinal	O
thickness	O
was	O
noted	O
in	O
all	O
patients	O
with	O
cystoid	Disease
macular	Disease
edema	Disease
at	O
6	O
months,	O
1	O
year,	O
2	O
years,	O
and	O
3	O
years	O
postimplant.	O
At	O
baseline,	O
54.5%	O
patients	O
were	O
on	O
immunomodulatory	O
agents.	O
This	O
percentage	O
decreased	O
to	O
45.45,	O
44.4,	O
and	O
14.28%	O
at	O
1	O
year,	O
2	O
years,	O
and	O
3	O
years	O
postimplant,	O
respectively.	O
Adverse	O
events	O
included	O
increased	Disease
intraocular	Disease
pressure	Disease
(54.5%)	O
and	O
cataract	Disease
formation	O
(100%).	O
CONCLUSION:	O
The	O
data	O
suggest	O
that	O
fluocinolone	Chemical
acetonide	Chemical
implant	O
(0.59	O
mg)	O
helps	O
to	O
control	O
inflammation	Disease
in	O
otherwise	O
treatment-refractory	O
cases	O
of	O
birdshot	Disease
retinochoroidopathy	Disease
.	O
It	O
is	O
associated	O
with	O
significant	O
side	O
effects	O
of	O
cataract	Disease
and	O
ocular	Disease
hypertension	Disease

Optimal	O
precurarizing	O
dose	O
of	O
rocuronium	Chemical
to	O
decrease	O
fasciculation	Disease
and	O
myalgia	Disease
following	O
succinylcholine	Chemical
administration.	O
BACKGROUND:	O
Succinylcholine	Chemical
commonly	O
produces	O
frequent	O
adverse	O
effects,	O
including	O
muscle	Disease
fasciculation	Disease
and	O
myalgia	Disease
.	O
The	O
current	O
study	O
identified	O
the	O
optimal	O
dose	O
of	O
rocuronium	Chemical
to	O
prevent	O
succinylcholine	Chemical
-induced	O
fasciculation	Disease
and	O
myalgia	Disease
and	O
evaluated	O
the	O
influence	O
of	O
rocuronium	Chemical
on	O
the	O
speed	O
of	O
onset	O
produced	O
by	O
succinylcholine	Chemical
.	O
METHODS:	O
This	O
randomized,	O
double-blinded	O
study	O
was	O
conducted	O
in	O
100	O
patients	O
randomly	O
allocated	O
into	O
five	O
groups	O
of	O
20	O
patients	O
each.	O
Patients	O
were	O
randomized	O
to	O
receive	O
0.02,	O
0.03,	O
0.04,	O
0.05	O
and	O
0.06	O
mg/kg	O
rocuronium	Chemical
as	O
a	O
precurarizing	O
dose.	O
Neuromuscular	O
monitoring	O
after	O
each	O
precurarizing	O
dose	O
was	O
recorded	O
from	O
the	O
adductor	O
pollicis	O
muscle	O
using	O
acceleromyography	O
with	O
train-of-four	O
stimulation	O
of	O
the	O
ulnar	O
nerve.	O
All	O
patients	O
received	O
succinylcholine	Chemical
1.5	O
mg/kg	O
at	O
2	O
minutes	O
after	O
the	O
precurarization,	O
and	O
were	O
assessed	O
the	O
incidence	O
and	O
severity	O
of	O
fasciculations	Disease
,	O
while	O
myalgia	Disease
was	O
assessed	O
at	O
24	O
hours	O
after	O
surgery.	O
RESULTS:	O
The	O
incidence	O
and	O
severity	O
of	O
visible	O
muscle	Disease
fasciculation	Disease
was	O
significantly	O
less	O
with	O
increasing	O
the	O
amount	O
of	O
precurarizing	O
dose	O
of	O
rocuronium	Chemical
(P	O
<	O
0.001).	O
Those	O
of	O
myalgia	Disease
tend	O
to	O
decrease	O
according	O
to	O
increasing	O
the	O
amount	O
of	O
precurarizing	O
dose	O
of	O
rocuronium	Chemical
,	O
but	O
there	O
was	O
no	O
significance	O
(P	O
=	O
0.072).	O
The	O
onset	O
time	O
of	O
succinylcholine	Chemical
was	O
significantly	O
longer	O
with	O
increasing	O
the	O
amount	O
of	O
precurarizing	O
dose	O
of	O
rocuronium	Chemical
(P	O
<	O
0.001).	O
CONCLUSIONS:	O
Precurarization	O
with	O
0.04	O
mg/kg	O
rocuronium	Chemical
was	O
the	O
optimal	O
dose	O
considering	O
the	O
reduction	O
in	O
the	O
incidence	O
and	O
severity	O
of	O
fasciculation	Disease
and	O
myalgia	Disease

Absence	O
of	O
PKC-alpha	O
attenuates	O
lithium	Chemical
-induced	O
nephrogenic	Disease
diabetes	Disease
insipidus	Disease
.	O
Lithium	Chemical
,	O
an	O
effective	O
antipsychotic,	O
induces	O
nephrogenic	Disease
diabetes	Disease
insipidus	Disease
(	O
NDI	Disease
)	O
in	O
	O
40%	O
of	O
patients.	O
The	O
decreased	O
capacity	O
to	O
concentrate	O
urine	O
is	O
likely	O
due	O
to	O
lithium	Chemical
acutely	O
disrupting	O
the	O
cAMP	Chemical
pathway	O
and	O
chronically	O
reducing	O
urea	Chemical
transporter	O
(UT-A1)	O
and	O
water	O
channel	O
(AQP2)	O
expression	O
in	O
the	O
inner	O
medulla.	O
Targeting	O
an	O
alternative	O
signaling	O
pathway,	O
such	O
as	O
PKC-mediated	O
signaling,	O
may	O
be	O
an	O
effective	O
method	O
of	O
treating	O
lithium	Chemical
-induced	O
polyuria	Disease
.	O
PKC-alpha	O
null	O
mice	O
(PKCa	O
KO)	O
and	O
strain-matched	O
wild	O
type	O
(WT)	O
controls	O
were	O
treated	O
with	O
lithium	Chemical
for	O
0,	O
3	O
or	O
5	O
days.	O
WT	O
mice	O
had	O
increased	O
urine	O
output	O
and	O
lowered	O
urine	O
osmolality	O
after	O
3	O
and	O
5	O
days	O
of	O
treatment	O
whereas	O
PKCa	O
KO	O
mice	O
had	O
no	O
change	O
in	O
urine	O
output	O
or	O
concentration.	O
Western	O
blot	O
analysis	O
revealed	O
that	O
AQP2	O
expression	O
in	O
medullary	O
tissues	O
was	O
lowered	O
after	O
3	O
and	O
5	O
days	O
in	O
WT	O
mice;	O
however,	O
AQP2	O
was	O
unchanged	O
in	O
PKCa	O
KO.	O
Similar	O
results	O
were	O
observed	O
with	O
UT-A1	O
expression.	O
Animals	O
were	O
also	O
treated	O
with	O
lithium	Chemical
for	O
6	O
weeks.	O
Lithium	Chemical
-treated	O
WT	O
mice	O
had	O
19-fold	O
increased	O
urine	O
output	O
whereas	O
treated	O
PKCa	O
KO	O
animals	O
had	O
a	O
4-fold	O
increase	O
in	O
output.	O
AQP2	O
and	O
UT-A1	O
expression	O
was	O
lowered	O
in	O
6	O
week	O
lithium	Chemical
-treated	O
WT	O
animals	O
whereas	O
in	O
treated	O
PKCa	O
KO	O
mice,	O
AQP2	O
was	O
only	O
reduced	O
by	O
2-fold	O
and	O
UT-A1	O
expression	O
was	O
unaffected.	O
Urinary	O
sodium	Chemical
,	O
potassium	Chemical
and	O
calcium	Chemical
were	O
elevated	O
in	O
lithium	Chemical
-fed	O
WT	O
but	O
not	O
in	O
lithium	Chemical
-fed	O
PKCa	O
KO	O
mice.	O
Our	O
data	O
show	O
that	O
ablation	O
of	O
PKCa	O
preserves	O
AQP2	O
and	O
UT-A1	O
protein	O
expression	O
and	O
localization	O
in	O
lithium	Chemical
-induced	O
NDI	Disease
,	O
and	O
prevents	O
the	O
development	O
of	O
the	O
severe	O
polyuria	Disease
associated	O
with	O
lithium	Chemical

Is	O
Dysguesia	Disease
Going	O
to	O
be	O
a	O
Rare	O
or	O
a	O
Common	O
Side-effect	O
of	O
Amlodipine	Chemical
?	O
A	O
very	O
rare	O
side-effect	O
of	O
amlodipine	Chemical
is	O
dysguesia	Disease
.	O
A	O
review	O
of	O
the	O
literature	O
produced	O
only	O
one	O
case.	O
We	O
report	O
a	O
case	O
about	O
a	O
female	O
with	O
essential	O
hypertension	Disease
on	O
drug	O
treatment	O
with	O
amlodipine	Chemical
developed	O
loss	Disease
of	Disease
taste	Disease
sensation	Disease
.	O
Condition	O
moderately	O
improved	O
on	O
stoppage	O
of	O
the	O
drug	O
for	O
25	O
days.	O
We	O
conclude	O
that	O
amlodipine	Chemical
can	O
cause	O
dysguesia	Disease
.	O
Here,	O
we	O
describe	O
the	O
clinical	O
presentation	O
and	O
review	O
the	O
relevant	O
literature	O
on	O
amlodipine	Chemical
and	O
dysguesia	Disease

Rhabdomyolysis	Disease
in	O
association	O
with	O
simvastatin	Chemical
and	O
dosage	O
increment	O
in	O
clarithromycin	Chemical
.	O
Clarithromycin	Chemical
is	O
the	O
most	O
documented	O
cytochrome	O
P450	O
3A4	O
(CYP3A4)	O
inhibitor	O
to	O
cause	O
an	O
adverse	O
interaction	O
with	O
simvastatin	Chemical
.	O
This	O
particular	O
case	O
is	O
of	O
interest	O
as	O
rhabdomyolysis	Disease
only	O
occurred	O
after	O
an	O
increase	O
in	O
the	O
dose	O
of	O
clarithromycin	Chemical
.	O
The	O
patient	O
developed	O
raised	O
cardiac	O
biomarkers	O
without	O
any	O
obvious	O
cardiac	O
issues,	O
a	O
phenomenon	O
that	O
has	O
been	O
linked	O
to	O
rhabdomyolysis	Disease
previously.	O
To	O
date,	O
there	O
has	O
been	O
no	O
reported	O
effect	O
of	O
rhabdomyolysis	Disease
on	O
the	O
structure	O
and	O
function	O
of	O
cardiac	O
muscle.	O
Clinicians	O
need	O
to	O
be	O
aware	O
of	O
prescribing	O
concomitant	O
medications	O
that	O
increase	O
the	O
risk	O
of	O
myopathy	Disease
or	O
inhibit	O
the	O
CYP3A4	O
enzyme.	O
Our	O
case	O
suggests	O
that	O
troponin	O
elevation	O
could	O
be	O
associated	O
with	O
statin	Chemical
induced	O
rhabdomyolysis	Disease

Characterization	O
of	O
a	O
novel	O
BCHE	O
"silent"	O
allele:	O
point	O
mutation	O
(p.Val204Asp)	O
causes	O
loss	O
of	O
activity	O
and	O
prolonged	O
apnea	Disease
with	O
suxamethonium	Chemical
.	O
Butyrylcholinesterase	Disease
deficiency	Disease
is	O
characterized	O
by	O
prolonged	O
apnea	Disease
after	O
the	O
use	O
of	O
muscle	O
relaxants	O
(	O
suxamethonium	Chemical
or	O
mivacurium	Chemical
)	O
in	O
patients	O
who	O
have	O
mutations	O
in	O
the	O
BCHE	O
gene.	O
Here,	O
we	O
report	O
a	O
case	O
of	O
prolonged	O
neuromuscular	O
block	O
after	O
administration	O
of	O
suxamethonium	Chemical
leading	O
to	O
the	O
discovery	O
of	O
a	O
novel	O
BCHE	O
variant	O
(c.695T>A,	O
p.Val204Asp).	O
Inhibition	O
studies,	O
kinetic	O
analysis	O
and	O
molecular	O
dynamics	O
were	O
undertaken	O
to	O
understand	O
how	O
this	O
mutation	O
disrupts	O
the	O
catalytic	O
triad	O
and	O
determines	O
a	O
"silent"	O
phenotype.	O
Low	O
activity	O
of	O
patient	O
plasma	O
butyrylcholinesterase	O
with	O
butyrylthiocholine	Chemical
(	O
BTC	Chemical
)	O
and	O
benzoylcholine	Chemical
,	O
and	O
values	O
of	O
dibucaine	Chemical
and	O
fluoride	Chemical
numbers	O
fit	O
with	O
heterozygous	O
atypical	O
silent	O
genotype.	O
Electrophoretic	O
analysis	O
of	O
plasma	O
BChE	O
of	O
the	O
proband	O
and	O
his	O
mother	O
showed	O
that	O
patient	O
has	O
a	O
reduced	O
amount	O
of	O
tetrameric	O
enzyme	O
in	O
plasma	O
and	O
that	O
minor	O
fast-moving	O
BChE	O
components:	O
monomer,	O
dimer,	O
and	O
monomer-albumin	O
conjugate	O
are	O
missing.	O
Kinetic	O
analysis	O
showed	O
that	O
the	O
p.Val204Asp/p.Asp70Gly-p.Ala539Thr	O
BChE	O
displays	O
a	O
pure	O
Michaelian	O
behavior	O
with	O
BTC	Chemical
as	O
the	O
substrate.	O
Both	O
catalytic	O
parameters	O
Km	O
=	O
265	O
uM	O
for	O
BTC	Chemical
,	O
two	O
times	O
higher	O
than	O
that	O
of	O
the	O
atypical	O
enzyme,	O
and	O
a	O
low	O
Vmax	O
are	O
consistent	O
with	O
the	O
absence	O
of	O
activity	O
against	O
suxamethonium	Chemical
.	O
Molecular	O
dynamic	O
(MD)	O
simulations	O
showed	O
that	O
the	O
overall	O
effect	O
of	O
the	O
mutation	O
p.Val204Asp	O
is	O
disruption	O
of	O
hydrogen	Chemical

Delayed	O
anemia	Disease
after	O
treatment	O
with	O
injectable	O
artesunate	Chemical
in	O
the	O
Democratic	O
Republic	O
of	O
the	O
Congo:	O
a	O
manageable	O
issue.	O
Cases	O
of	O
delayed	O
hemolytic	Disease
anemia	Disease
have	O
been	O
described	O
after	O
treatment	O
with	O
injectable	O
artesunate	Chemical
,	O
the	O
current	O
World	O
Health	O
Organization	O
(WHO)-recommended	O
first-line	O
drug	O
for	O
the	O
treatment	O
of	O
severe	O
malaria	Disease
.	O
A	O
total	O
of	O
350	O
patients	O
(215	O
[61.4%]	O
<	O
5	O
years	O
of	O
age	O
and	O
135	O
[38.6%]	O
>	O
5	O
years	O
of	O
age)	O
were	O
followed-up	O
after	O
treatment	O
with	O
injectable	O
artesunate	Chemical
for	O
severe	O
malaria	Disease
in	O
hospitals	O
and	O
health	O
centers	O
of	O
the	O
Democratic	O
Republic	O
of	O
the	O
Congo.	O
Complete	O
series	O
of	O
hemoglobin	O
(Hb)	O
measurements	O
were	O
available	O
for	O
201	O
patients.	O
A	O
decrease	O
in	O
Hb	O
levels	O
between	O
2	O
and	O
5	O
g/dL	O
was	O
detected	O
in	O
23	O
(11.4%)	O
patients	O
during	O
the	O
follow-up	O
period.	O
For	O
five	O
patients,	O
Hb	O
levels	O
decreased	O
below	O
5	O
g/dL	O
during	O
at	O
least	O
one	O
follow-up	O
visit.	O
All	O
cases	O
of	O
delayed	O
anemia	Disease

Regulation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
and	O
apoptotic	O
pathways	O
by	O
betaine	Chemical
attenuates	O
isoproterenol	Chemical
-induced	O
acute	O
myocardial	Disease
injury	Disease
in	O
rats.	O
The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
cardioprotective	O
effects	O
of	O
betaine	Chemical
on	O
acute	O
myocardial	Disease
ischemia	Disease
induced	O
experimentally	O
in	O
rats	O
focusing	O
on	O
regulation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
(STAT3)	O
and	O
apoptotic	O
pathways	O
as	O
the	O
potential	O
mechanism	O
underlying	O
the	O
drug	O
effect.	O
Male	O
Sprague	O
Dawley	O
rats	O
were	O
treated	O
with	O
betaine	Chemical
(100,	O
200,	O
and	O
400	O
mg/kg)	O
orally	O
for	O
40	O
days.	O
Acute	O
myocardial	Disease
ischemic	Disease
injury	Disease
was	O
induced	O
in	O
rats	O
by	O
subcutaneous	O
injection	O
of	O
isoproterenol	Chemical
(85	O
mg/kg),	O
for	O
two	O
consecutive	O
days.	O
Serum	O
cardiac	O
marker	O
enzyme,	O
histopathological	O
variables	O
and	O
expression	O
of	O
protein	O
levels	O
were	O
analyzed.	O
Oral	O
administration	O
of	O
betaine	Chemical
(200	O
and	O
400	O
mg/kg)	O
significantly	O
reduced	O
the	O
level	O
of	O
cardiac	O
marker	O
enzyme	O
in	O
the	O
serum	O
and	O
prevented	O
left	O
ventricular	Disease
remodeling	Disease
.	O
Western	O
blot	O
analysis	O
showed	O
that	O
isoproterenol	Chemical
-induced	O
phosphorylation	O
of	O
STAT3	O
was	O
maintained	O
or	O
further	O
enhanced	O
by	O
betaine	Chemical
treatment	O
in	O
myocardium.	O
Furthermore,	O
betaine	Chemical
(200	O
and	O
400	O
mg/kg)	O
treatment	O
increased	O
the	O
ventricular	O
expression	O
of	O
Bcl-2	O
and	O
reduced	O
the	O
level	O
of	O
Bax,	O
therefore	O
causing	O
a	O
significant	O
increase	O
in	O
the	O
ratio	O
of	O
Bcl-2/Bax.	O
The	O
protective	O
role	O
of	O
betaine	Chemical
on	O
myocardial	Disease
damage	Disease
was	O
further	O
confirmed	O
by	O
histopathological	O
examination.	O
In	O
summary,	O
our	O
results	O
showed	O
that	O
betaine	Chemical
pretreatment	O
attenuated	O
isoproterenol	Chemical
-induced	O
acute	O
myocardial	Disease
ischemia	Disease

Quetiapine	Chemical
-induced	O
neutropenia	Disease
in	O
a	O
bipolar	Disease
patient	O
with	O
hepatocellular	Disease
carcinoma	Disease
.	O
OBJECTIVE:	O
Quetiapine	Chemical
is	O
a	O
dibenzothiazepine	O
derivative,	O
similar	O
to	O
clozapine	Chemical
,	O
which	O
has	O
the	O
highest	O
risk	O
of	O
causing	O
blood	Disease
dyscrasias	Disease
,	O
especially	O
neutropenia	Disease
.	O
There	O
are	O
some	O
case	O
reports	O
about	O
this	O
side	O
effect	O
of	O
quetiapine	Chemical
,	O
but	O
possible	O
risk	O
factors	O
are	O
seldom	O
discussed	O
and	O
identified.	O
A	O
case	O
of	O
a	O
patient	O
with	O
hepatocellular	Disease
carcinoma	Disease
that	O
developed	O
neutropenia	Disease
after	O
treatment	O
with	O
quetiapine	Chemical
is	O
described	O
here.	O
CASE	O
REPORT:	O
A	O
62-year-old	O
Taiwanese	O
widow	O
with	O
bipolar	Disease
disorder	Disease
was	O
diagnosed	O
with	O
hepatocellular	Disease
carcinoma	Disease
at	O
age	O
60.	O
She	O
developed	O
leucopenia	Disease
after	O
being	O
treated	O
with	O
quetiapine	Chemical
.	O
After	O
quetiapine	Chemical
was	O
discontinued,	O
her	O
white	O
blood	O
cell	O
count	O
returned	O
to	O
normal.	O
CONCLUSIONS:	O
Although	O
neutropenia	Disease
is	O
not	O
a	O
common	O
side	O
effect	O
of	O
quetiapine	Chemical
,	O
physicians	O
should	O
be	O
cautious	O
about	O
its	O
presentation	O
and	O
associated	O
risk	O
factors.	O
Hepatic	Disease
dysfunction	Disease
may	O
be	O
one	O
of	O
the	O
possible	O
risk	O
factors,	O
and	O
concomitant	O
fever	Disease
may	O
be	O
a	O
diagnostic	O
marker	O
for	O
adverse	O
reaction	O
to	O
quetiapine	Chemical

Lateral	O
antebrachial	O
cutaneous	O
neuropathy	Disease
after	O
steroid	Chemical
injection	O
at	O
lateral	O
epicondyle.	O
BACKGROUND	O
AND	O
OBJECTIVES:	O
This	O
report	O
aimed	O
to	O
present	O
a	O
case	O
of	O
lateral	O
antebrachial	O
cutaneous	O
neuropathy	Disease
(LACNP)	O
that	O
occurred	O
after	O
a	O
steroid	Chemical
injection	O
in	O
the	O
lateral	O
epicondyle	O
to	O
treat	O
lateral	Disease
epicondylitis	Disease
in	O
a	O
40-year-old	O
woman.	O
MATERIAL	O
AND	O
METHOD:	O
A	O
40-year-old	O
woman	O
presented	O
with	O
decreased	O
sensation	O
and	O
paresthesia	Disease
over	O
her	O
right	O
lateral	O
forearm;	O
the	O
paresthesia	Disease
had	O
occurred	O
after	O
a	O
steroid	Chemical
injection	O
in	O
the	O
right	O
lateral	O
epicondyle	O
3	O
months	O
before.	O
Her	O
sensation	O
of	O
light	O
touch	O
and	O
pain	Disease
was	O
diminished	O
over	O
the	O
lateral	O
side	O
of	O
the	O
right	O
forearm	O
and	O
wrist	O
area.	O
RESULTS:	O
The	O
sensory	O
action	O
potential	O
amplitude	O
of	O
the	O
right	O
lateral	O
antebrachial	O
cutaneous	O
nerve	O
(LACN)	O
(6.2	O
uV)	O
was	O
lower	O
than	O
that	O
of	O
the	O
left	O
(13.1	O
uV).	O
The	O
difference	O
of	O
amplitude	O
between	O
both	O
sides	O
was	O
significant	O
because	O
there	O
was	O
more	O
than	O
a	O
50%	O
reduction.	O
She	O
was	O
diagnosed	O
with	O
right	O
LACNP	O
(mainly	O
axonal	O
involvement)	O
on	O
the	O
basis	O
of	O
the	O
clinical	O
manifestation	O
and	O
the	O
electrodiagnostic	O
findings.	O
Her	O
symptoms	O
improved	O
through	O
physical	O
therapy	O
but	O
persisted	O
to	O
some	O
degree.	O
CONCLUSION:	O
This	O
report	O
describes	O
the	O
case	O
of	O
a	O
woman	O
with	O
LACNP	O
that	O
developed	O
after	O
a	O
steroid	Chemical
injection	O
for	O
the	O
treatment	O
of	O
lateral	Disease
epicondylitis	Disease

Curcumin	Chemical
prevents	O
maleate	Chemical
-induced	O
nephrotoxicity	Disease
:	O
relation	O
to	O
hemodynamic	O
alterations,	O
oxidative	O
stress,	O
mitochondrial	O
oxygen	Chemical
consumption	O
and	O
activity	O
of	O
respiratory	O
complex	O
I.	O
The	O
potential	O
protective	O
effect	O
of	O
the	O
dietary	O
antioxidant	O
curcumin	Chemical
(120	O
mg/Kg/day	O
for	O
6	O
days)	O
against	O
the	O
renal	Disease
injury	Disease
induced	O
by	O
maleate	Chemical
was	O
evaluated.	O
Tubular	O
proteinuria	Disease
and	O
oxidative	O
stress	O
were	O
induced	O
by	O
a	O
single	O
injection	O
of	O
maleate	Chemical
(400	O
mg/kg)	O
in	O
rats.	O
Maleate	Chemical
-induced	O
renal	Disease
injury	Disease
included	O
increase	O
in	O
renal	O
vascular	O
resistance	O
and	O
in	O
the	O
urinary	O
excretion	O
of	O
total	O
protein,	O
glucose	Chemical
,	O
sodium	Chemical
,	O
neutrophil	O
gelatinase-associated	O
lipocalin	O
(NGAL)	O
and	O
N-acetyl	O
b-D-glucosaminidase	O
(NAG),	O
upregulation	O
of	O
kidney	Disease
injury	Disease
molecule	O
(KIM)-1,	O
decrease	O
in	O
renal	O
blood	O
flow	O
and	O
claudin-2	O
expression	O
besides	O
of	O
necrosis	Disease
and	O
apoptosis	O
of	O
tubular	O
cells	O
on	O
24	O
h.	O
Oxidative	O
stress	O
was	O
determined	O
by	O
measuring	O
the	O
oxidation	O
of	O
lipids	O
and	O
proteins	O
and	O
diminution	O
in	O
renal	O
Nrf2	O
levels.	O
Studies	O
were	O
also	O
conducted	O
in	O
renal	O
epithelial	O
LLC-PK1	O
cells	O
and	O
in	O
mitochondria	O
isolated	O
from	O
kidneys	O
of	O
all	O
the	O
experimental	O
groups.	O
Maleate	Chemical
induced	O
cell	O
damage	O
and	O
reactive	O
oxygen	Chemical
species	O
(ROS)	O
production	O
in	O
LLC-PK1	O
cells	O
in	O
culture.	O
In	O
addition,	O
maleate	Chemical
treatment	O
reduced	O
oxygen	Chemical
consumption	O
in	O
ADP	Chemical
-stimulated	O
mitochondria	O
and	O
diminished	O
respiratory	O
control	O
index	O
when	O
using	O
malate	Chemical
/	O
glutamate	Chemical
as	O
substrate.	O
The	O
activities	O
of	O
both	O
complex	O
I	O
and	O
aconitase	O
were	O
also	O
diminished.	O
All	O
the	O
above-described	O
alterations	O
were	O
prevented	O
by	O
curcumin	Chemical
.	O
It	O
is	O
concluded	O
that	O
curcumin	Chemical
is	O
able	O
to	O
attenuate	O
in	O
vivo	O
maleate	Chemical
-induced	O
nephropathy	Disease
and	O
in	O
vitro	O
cell	O
damage.	O
The	O
in	O
vivo	O
protection	O
was	O
associated	O
to	O
the	O
prevention	O
of	O
oxidative	O
stress	O
and	O
preservation	O
of	O
mitochondrial	O
oxygen	Chemical

Incidence	O
of	O
solid	O
tumours	Disease
among	O
pesticide	O
applicators	O
exposed	O
to	O
the	O
organophosphate	Chemical
insecticide	O
diazinon	Chemical
in	O
the	O
Agricultural	O
Health	O
Study:	O
an	O
updated	O
analysis.	O
OBJECTIVE:	O
Diazinon	Chemical
,	O
a	O
common	O
organophosphate	Chemical
insecticide	O
with	O
genotoxic	O
properties,	O
was	O
previously	O
associated	O
with	O
lung	Disease
cancer	Disease
in	O
the	O
Agricultural	O
Health	O
Study	O
(AHS)	O
cohort,	O
but	O
few	O
other	O
epidemiological	O
studies	O
have	O
examined	O
diazinon	Chemical
-associated	O
cancer	Disease
risk.	O
We	O
used	O
updated	O
diazinon	Chemical
exposure	O
and	O
cancer	Disease
incidence	O
information	O
to	O
evaluate	O
solid	O
tumour	Disease
risk	O
in	O
the	O
AHS.	O
METHODS:	O
Male	O
pesticide	O
applicators	O
in	O
Iowa	O
and	O
North	O
Carolina	O
reported	O
lifetime	O
diazinon	Chemical
use	O
at	O
enrolment	O
(1993-1997)	O
and	O
follow-up	O
(1998-2005);	O
cancer	Disease
incidence	O
was	O
assessed	O
through	O
2010(North	O
Carolina)/2011(Iowa).	O
Among	O
applicators	O
with	O
usage	O
information	O
sufficient	O
to	O
evaluate	O
exposure-response	O
patterns,	O
we	O
used	O
Poisson	O
regression	O
to	O
estimate	O
adjusted	O
rate	O
ratios	O
(RRs)	O
and	O
95%	O
CI	O
for	O
cancer	Disease
sites	O
with	O
>10	O
exposed	O
cases	O
for	O
both	O
lifetime	O
(LT)	O
exposure	O
days	O
and	O
intensity-weighted	O
(IW)	O
lifetime	O
exposure	O
days	O
(accounting	O
for	O
factors	O
impacting	O
exposure).	O
RESULTS:	O
We	O
observed	O
elevated	O
lung	Disease
cancer	Disease
risks	O
(N=283)	O
among	O
applicators	O
with	O
the	O
greatest	O
number	O
of	O
LT	O
(RR=1.60;	O
95%	O
CI	O
1.11	O
to	O
2.31;	O
Ptrend=0.02)	O
and	O
IW	O
days	O
of	O
diazinon	Chemical
use	O
(RR=1.41;	O
95%	O
CI	O
0.98	O
to	O
2.04;	O
Ptrend=0.08).	O
Kidney	Disease
cancer	Disease
(N=94)	O
risks	O
were	O
non-significantly	O
elevated	O
(RRLT	O
days=1.77;	O
95%	O
CI	O
0.90	O
to	O
3.51;	O
Ptrend=0.09;	O
RRIW	O
days	O
1.37;	O
95%	O
CI	O
0.64	O
to	O
2.92;	O
Ptrend=0.50),	O
as	O
were	O
risks	O
for	O
aggressive	O
prostate	Disease
cancer	Disease
(N=656).	O
CONCLUSIONS:	O
Our	O
updated	O
evaluation	O
of	O
diazinon	Chemical
provides	O
additional	O
evidence	O
of	O
an	O
association	O
with	O
lung	Disease
cancer	Disease
risk.	O
Newly	O
identified	O
links	O
to	O
kidney	Disease
cancer	Disease
and	O
associations	O
with	O
aggressive	O
prostate	Disease
cancer	Disease

Associations	O
of	O
Ozone	Chemical
and	O
PM2.5	O
Concentrations	O
With	O
Parkinson's	Disease
Disease	Disease
Among	O
Participants	O
in	O
the	O
Agricultural	O
Health	O
Study.	O
OBJECTIVE:	O
This	O
study	O
describes	O
associations	O
of	O
ozone	Chemical
and	O
fine	O
particulate	Chemical
matter	Chemical
with	O
Parkinson's	Disease
disease	Disease
observed	O
among	O
farmers	O
in	O
North	O
Carolina	O
and	O
Iowa.	O
METHODS:	O
We	O
used	O
logistic	O
regression	O
to	O
determine	O
the	O
associations	O
of	O
these	O
pollutants	O
with	O
self-reported,	O
doctor-diagnosed	O
Parkinson's	Disease
disease	Disease
.	O
Daily	O
predicted	O
pollutant	O
concentrations	O
were	O
used	O
to	O
derive	O
surrogates	O
of	O
long-term	O
exposure	O
and	O
link	O
them	O
to	O
study	O
participants'	O
geocoded	O
addresses.	O
RESULTS:	O
We	O
observed	O
positive	O
associations	O
of	O
Parkinson's	Disease
disease	Disease
with	O
ozone	Chemical
(odds	O
ratio	O
=	O
1.39;	O
95%	O
CI:	O
0.98	O
to	O
1.98)	O
and	O
fine	O
particulate	Chemical
matter	Chemical
(odds	O
ratio	O
=	O
1.34;	O
95%	O
CI:	O
0.93	O
to	O
1.93)	O
in	O
North	O
Carolina	O
but	O
not	O
in	O
Iowa.	O
CONCLUSIONS:	O
The	O
plausibility	O
of	O
an	O
effect	O
of	O
ambient	O
concentrations	O
of	O
these	O
pollutants	O
on	O
Parkinson's	Disease
disease	Disease

Low	O
functional	O
programming	O
of	O
renal	O
AT2R	O
mediates	O
the	O
developmental	O
origin	O
of	O
glomerulosclerosis	Disease
in	O
adult	O
offspring	O
induced	O
by	O
prenatal	O
caffeine	Chemical
exposure.	O
UNASSIGNED:	O
Our	O
previous	O
study	O
has	O
indicated	O
that	O
prenatal	O
caffeine	Chemical
exposure	O
(PCE)	O
could	O
induce	O
intrauterine	Disease
growth	Disease
retardation	Disease
(	O
IUGR	Disease
)	O
of	O
offspring.	O
Recent	O
research	O
suggested	O
that	O
IUGR	Disease
is	O
a	O
risk	O
factor	O
for	O
glomerulosclerosis	Disease
.	O
However,	O
whether	O
PCE	O
could	O
induce	O
glomerulosclerosis	Disease
and	O
its	O
underlying	O
mechanisms	O
remain	O
unknown.	O
This	O
study	O
aimed	O
to	O
demonstrate	O
the	O
induction	O
to	O
glomerulosclerosis	Disease
in	O
adult	O
offspring	O
by	O
PCE	O
and	O
its	O
intrauterine	O
programming	O
mechanisms.	O
A	O
rat	O
model	O
of	O
IUGR	Disease
was	O
established	O
by	O
PCE,	O
male	O
fetuses	O
and	O
adult	O
offspring	O
at	O
the	O
age	O
of	O
postnatal	O
week	O
24	O
were	O
euthanized.	O
The	O
results	O
revealed	O
that	O
the	O
adult	O
offspring	O
kidneys	O
in	O
the	O
PCE	O
group	O
exhibited	O
glomerulosclerosis	Disease
as	O
well	O
as	O
interstitial	Disease
fibrosis	Disease
,	O
accompanied	O
by	O
elevated	O
levels	O
of	O
serum	O
creatinine	Chemical
and	O
urine	O
protein.	O
Renal	O
angiotensin	Chemical
II	Chemical
receptor	O
type	O
2	O
(AT2R)	O
gene	O
expression	O
in	O
adult	O
offspring	O
was	O
reduced	O
by	O
PCE,	O
whereas	O
the	O
renal	O
angiotensin	Chemical
II	Chemical
receptor	O
type	O
1a	O
(AT1aR)/AT2R	O
expression	O
ratio	O
was	O
increased.	O
The	O
fetal	O
kidneys	O
in	O
the	O
PCE	O
group	O
displayed	O
an	O
enlarged	O
Bowman's	O
space	O
and	O
a	O
shrunken	O
glomerular	O
tuft,	O
accompanied	O
by	O
a	O
reduced	O
cortex	O
width	O
and	O
an	O
increase	O
in	O
the	O
nephrogenic	O
zone/cortical	O
zone	O
ratio.	O
Observation	O
by	O
electronic	O
microscope	O
revealed	O
structural	O
damage	O
of	O
podocytes;	O
the	O
reduced	O
expression	O
level	O
of	O
podocyte	O
marker	O
genes,	O
nephrin	O
and	O
podocin,	O
was	O
also	O
detected	O
by	O
q-PCR.	O
Moreover,	O
AT2R	O
gene	O
and	O
protein	O
expressions	O
in	O
fetal	O
kidneys	O
were	O
inhibited	O
by	O
PCE,	O
associated	O
with	O
the	O
repression	O
of	O
the	O
gene	O
expression	O
of	O
glial-cell-line-derived	O
neurotrophic	O
factor	O
(GDNF)/	O
tyrosine	Chemical
kinase	O
receptor	O
(c-Ret)	O
signaling	O
pathway.	O
These	O
results	O
demonstrated	O
that	O
PCE	O
could	O
induce	O
dysplasia	Disease
of	Disease
fetal	Disease
kidneys	Disease
as	O
well	O
as	O
glomerulosclerosis	Disease
of	O
adult	O
offspring,	O
and	O
the	O
low	O
functional	O
programming	O
of	O
renal	O
AT2R	O
might	O
mediate	O
the	O
developmental	O
origin	O
of	O
adult	O
glomerulosclerosis	Disease

1,3-Butadiene	Chemical
,	O
CML	Disease
and	O
the	O
t(9:22)	O
translocation:	O
A	O
reality	O
check.	O
UNASSIGNED:	O
Epidemiological	O
studies	O
of	O
1,3-butadiene	Chemical
have	O
suggest	O
that	O
exposures	O
to	O
humans	O
are	O
associated	O
with	O
chronic	Disease
myeloid	Disease
leukemia	Disease
(	O
CML	Disease
).	O
CML	Disease
has	O
a	O
well-documented	O
association	O
with	O
ionizing	O
radiation,	O
but	O
reports	O
of	O
associations	O
with	O
chemical	O
exposures	O
have	O
been	O
questioned.	O
Ionizing	O
radiation	O
is	O
capable	O
of	O
inducing	O
the	O
requisite	O
CML	Disease
-associated	O
t(9:22)	O
translocation	O
(	O
Philadelphia	Disease
chromosome	Disease
)	O
in	O
appropriate	O
cells	O
in	O
vitro	O
but,	O
thus	O
far,	O
chemicals	O
have	O
not	O
shown	O
this	O
capacity.	O
We	O
have	O
proposed	O
that	O
1,3-butadiene	Chemical
metabolites	O
be	O
so	O
tested	O
as	O
a	O
reality	O
check	O
on	O
the	O
epidemiological	O
reports.	O
In	O
order	O
to	O
conduct	O
reliable	O
testing	O
in	O
this	O
regard,	O
it	O
is	O
essential	O
that	O
a	O
positive	O
control	O
for	O
induction	O
be	O
available.	O
We	O
have	O
used	O
ionizing	O
radiation	O
to	O
develop	O
such	O
a	O
control.	O
Results	O
described	O
here	O
demonstrate	O
that	O
this	O
agent	O
does	O
in	O
fact	O
induce	O
pathogenic	O
t(9:22)	O
translocations	O
in	O
a	O
human	O
myeloid	O
cell	O
line	O
in	O
vitro,	O
but	O
does	O
so	O
at	O
low	O
frequencies.	O
Conditions	O
that	O
will	O
be	O
required	O
for	O
studies	O
of	O
1,3-butadiene	Chemical

Cancer	Disease
incidence	O
and	O
metolachlor	Chemical
use	O
in	O
the	O
Agricultural	O
Health	O
Study:	O
An	O
update.	O
UNASSIGNED:	O
Metolachlor	Chemical
,	O
a	O
widely	O
used	O
herbicide,	O
is	O
classified	O
as	O
a	O
Group	O
C	O
carcinogen	O
by	O
the	O
U.S.	O
Environmental	O
Protection	O
Agency	O
based	O
on	O
increased	O
liver	Disease
neoplasms	Disease
in	O
female	O
rats.	O
Epidemiologic	O
studies	O
of	O
the	O
health	O
effects	O
of	O
metolachlor	Chemical
have	O
been	O
limited.	O
The	O
Agricultural	O
Health	O
Study	O
(AHS)	O
is	O
a	O
prospective	O
cohort	O
study	O
including	O
licensed	O
private	O
and	O
commercial	O
pesticide	O
applicators	O
in	O
Iowa	O
and	O
North	O
Carolina	O
enrolled	O
1993-1997.	O
We	O
evaluated	O
cancer	Disease
incidence	O
through	O
2010/2011	O
(NC/IA)	O
for	O
49,616	O
applicators,	O
53%	O
of	O
whom	O
reported	O
ever	O
using	O
metolachlor	Chemical
.	O
We	O
used	O
Poisson	O
regression	O
to	O
evaluate	O
relations	O
between	O
two	O
metrics	O
of	O
metolachlor	Chemical
use	O
(lifetime	O
days,	O
intensity-weighted	O
lifetime	O
days)	O
and	O
cancer	Disease
incidence.	O
We	O
saw	O
no	O
association	O
between	O
metolachlor	Chemical
use	O
and	O
incidence	O
of	O
all	O
cancers	Disease
combined	O
(n	O
=	O
5,701	O
with	O
a	O
5-year	O
lag)	O
or	O
most	O
site-specific	O
cancers	Disease
.	O
For	O
liver	Disease
cancer	Disease
,	O
in	O
analyses	O
restricted	O
to	O
exposed	O
workers,	O
elevations	O
observed	O
at	O
higher	O
categories	O
of	O
use	O
were	O
not	O
statistically	O
significant.	O
However,	O
trends	O
for	O
both	O
lifetime	O
and	O
intensity-weighted	O
lifetime	O
days	O
of	O
metolachor	Chemical
use	O
were	O
positive	O
and	O
statistically	O
significant	O
with	O
an	O
unexposed	O
reference	O
group.	O
A	O
similar	O
pattern	O
was	O
observed	O
for	O
follicular	Disease
cell	Disease
lymphoma	Disease
,	O
but	O
no	O
other	O
lymphoma	Disease
subtypes.	O
An	O
earlier	O
suggestion	O
of	O
increased	O
lung	Disease
cancer	Disease
risk	O
at	O
high	O
levels	O
of	O
metolachlor	Chemical
use	O
in	O
this	O
cohort	O
was	O
not	O
confirmed	O
in	O
this	O
update.	O
This	O
suggestion	O
of	O
an	O
association	O
between	O
metolachlor	Chemical
and	O
liver	Disease
cancer	Disease
among	O
pesticide	O
applicators	O
is	O
a	O
novel	O
finding	O
and	O
echoes	O
observation	O
of	O
increased	O
liver	Disease
neoplasms	Disease
in	O
some	O
animal	O
studies.	O
However,	O
our	O
findings	O
for	O
both	O
liver	Disease
cancer	Disease
and	O
follicular	O
cell	O
lymphoma	Disease
warrant	O
follow-up	O
to	O
better	O
differentiate	O
effects	O
of	O
metolachlor	Chemical

Mechanisms	O
Underlying	O
Latent	O
Disease	O
Risk	O
Associated	O
with	O
Early-Life	O
Arsenic	Chemical
Exposure:	O
Current	O
Research	O
Trends	O
and	O
Scientific	O
Gaps.	O
BACKGROUND:	O
Millions	O
of	O
individuals	O
worldwide,	O
particularly	O
those	O
living	O
in	O
rural	O
and	O
developing	O
areas,	O
are	O
exposed	O
to	O
harmful	O
levels	O
of	O
inorganic	Chemical
arsenic	Chemical
(	O
iAs	Chemical
)	O
in	O
their	O
drinking	O
water.	O
Inorganic	Chemical
As	Chemical
exposure	O
during	O
key	O
developmental	O
periods	O
is	O
associated	O
with	O
a	O
variety	O
of	O
adverse	O
health	O
effects	O
including	O
those	O
that	O
are	O
evident	O
in	O
adulthood.	O
There	O
is	O
considerable	O
interest	O
in	O
identifying	O
the	O
molecular	O
mechanisms	O
that	O
relate	O
early-life	O
iAs	Chemical
exposure	O
to	O
the	O
development	O
of	O
these	O
latent	O
diseases,	O
particularly	O
in	O
relationship	O
to	O
cancer	Disease
.	O
OBJECTIVES:	O
This	O
work	O
summarizes	O
research	O
on	O
the	O
molecular	O
mechanisms	O
that	O
underlie	O
the	O
increased	O
risk	O
of	O
cancer	Disease
development	O
in	O
adulthood	O
that	O
is	O
associated	O
with	O
early-life	O
iAs	Chemical
exposure.	O
DISCUSSION:	O
Epigenetic	O
reprogramming	O
that	O
imparts	O
functional	O
changes	O
in	O
gene	O
expression,	O
the	O
development	O
of	O
cancer	Disease
stem	O
cells,	O
and	O
immunomodulation	O
are	O
plausible	O
underlying	O
mechanisms	O
by	O
which	O
early-life	O
iAs	Chemical
exposure	O
elicits	O
latent	O
carcinogenic	O
effects.	O
CONCLUSIONS:	O
Evidence	O
is	O
mounting	O
that	O
relates	O
early-life	O
iAs	Chemical
exposure	O
and	O
cancer	Disease

On	O
the	O
antiarrhythmic	O
activity	O
of	O
one	O
N-substituted	O
piperazine	Chemical
derivative	O
of	O
trans-2-amino-3-hydroxy-1,	Chemical
2,	Chemical
3,	Chemical
4-tetrahydroanaphthalene	Chemical
.	O
The	O
antiarrhythmic	O
activity	O
of	O
the	O
compound	O
N-(trans-3-hydroxy-1,2,3,4-tetrahydro-2-naphthyl)-N-(3-oxo-3-phenyl-2-methylpropyl)-piperazine	Chemical
hydrochloride	Chemical
,	O
referred	O
to	O
as	O
P11	Chemical
,	O
is	O
studied	O
on	O
anaesthesized	O
cats	O
and	O
Wistar	O
albino	O
rats,	O
as	O
well	O
as	O
on	O
non-anaesthesized	O
rabbits.	O
Four	O
types	O
of	O
experimental	O
arrhythmia	Disease
are	O
used--with	O
BaCl2	Chemical
,	O
with	O
chloroform	Chemical
-	O
adrenaline	Chemical
,	O
with	O
strophantine	Chemical
G	Chemical
and	O
with	O
aconitine	Chemical
.	O
The	O
compound	O
P11	Chemical
is	O
introduced	O
in	O
doses	O
of	O
0.25	O
and	O
0.50	O
mg/kg	O
intravenously	O
and	O
10	O
mg/kg	O
orally.	O
The	O
compound	O
manifests	O
antiarrhythmic	O
activity	O
in	O
all	O
models	O
of	O
experimental	O
arrhythmia	Disease
used,	O
causing	O
greatest	O
inhibition	O
on	O
the	O
arrhythmia	Disease
induced	O
by	O
chloroform	Chemical
-	O
adrenaline	Chemical
(in	O
90	O
per	O
cent)	O
and	O
with	O
BaCl2	Chemical

Experimental	O
progressive	O
muscular	Disease
dystrophy	Disease
and	O
its	O
treatment	O
with	O
high	O
doses	O
anabolizing	O
agents.	O
We	O
are	O
still	O
a	O
long	O
way	O
from	O
discovering	O
an	O
unequivocal	O
pathogenetic	O
interpretation	O
of	O
progressive	O
muscular	Disease
dystrophy	Disease
in	O
man.	O
Noteworthy	O
efforts	O
have	O
been	O
made	O
in	O
the	O
experimental	O
field;	O
a	O
recessive	O
autosomic	O
form	O
found	O
in	O
the	O
mouse	O
seems	O
to	O
bear	O
the	O
closest	O
resemblance	O
to	O
the	O
human	O
form	O
from	O
the	O
genetic	O
point	O
of	O
view.	O
Myopathy	Disease
due	O
to	O
lack	O
of	O
vitamin	Chemical
E	Chemical
and	O
myopathy	Disease
induced	O
by	O
certain	O
viruses	O
have	O
much	O
in	O
common	O
anatomically	O
and	O
pathologically	O
with	O
the	O
human	O
form.	O
The	O
authors	O
induced	O
myodystrophy	Disease
in	O
the	O
rat	O
by	O
giving	O
it	O
a	O
diet	O
lacking	O
in	O
vitamin	Chemical
E	Chemical
.	O
The	O
pharmacological	O
characteristics	O
of	O
vitamin	Chemical
E	Chemical
and	O
the	O
degenerative	O
changes	O
brought	O
about	O
by	O
its	O
deficiency,	O
especially	O
in	O
the	O
muscles,	O
are	O
illustrated.	O
It	O
is	O
thus	O
confirmed	O
that	O
the	O
histological	O
characteristics	O
of	O
myopathic	Disease
rat	O
muscle	O
induced	O
experimentally	O
are	O
extraordinarily	O
similar	O
to	O
those	O
of	O
human	O
myopathy	Disease
as	O
confirmed	O
during	O
biopsies	O
performed	O
at	O
the	O
Orthopaedic	O
Traumatological	O
Centre,	O
Florence.	O
The	O
encouraging	O
results	O
obtained	O
in	O
various	O
authoratative	O
departments	O
in	O
myopathic	Disease
patients	O
by	O
using	O
anabolizing	O
steroids	Chemical
have	O
encouraged	O
the	O
authors	O
to	O
investigate	O
the	O
beneficial	O
effects	O
of	O
one	O
anabolizing	O
agent	O
(	O
Dianabol	Chemical
,	O
CIBA	Chemical
)	O
at	O
high	O
doses	O
in	O
rats	O
rendered	O
myopathic	Disease
by	O
a	O
diet	O
deficient	O
in	O
vitamin	Chemical
E	Chemical
.	O
In	O
this	O
way	O
they	O
obtained	O
appreciable	O
changes	O
in	O
body	O
weight	O
(increased	O
from	O
50	O
to	O
70	O
g	O
after	O
forty	O
days	O
at	O
a	O
dose	O
of	O
5	O
mg	O
per	O
day	O
of	O
anabolizing	O
agent),	O
but	O
most	O
of	O
all	O
they	O
found	O
histological	O
changes	O
due	O
to	O
"regenerative"	O
changes	O
in	O
the	O
muscle	O
tissue,	O
which	O
however	O
maintained	O
its	O
myopathic	Disease
characteristics	O
in	O
the	O
control	O
animals	O
that	O
were	O
not	O
treated	O
with	O
the	O
anabolizing	O
agent.	O
The	O
authors	O
conclude	O
by	O
affirming	O
the	O
undoubted	O
efficacy	O
of	O
the	O
anabolizing	O
steroids	Chemical
in	O
experimental	O
myopathic	Disease
disease	Disease
,	O
but	O
they	O
have	O
reservations	O
as	O
to	O
the	O
transfer	O
of	O
the	O
results	O
into	O
the	O
human	O
field,	O
where	O
high	O
dosage	O
cannot	O
be	O
carried	O
out	O
continuously	O
because	O
of	O
the	O
effects	O
of	O
the	O
drug	O
on	O
virility;	O
because	O
the	O
tissue	O
injury	O
too	O
often	O
occurs	O
at	O
an	O
irreversible	O
stage	O
vis-a-vis	O
the	O
"regeneration"	O
of	O
the	O
muscle	O
tissue;	O
and	O
finally	O
because	O
the	O
dystrophic	O
injurious	O
agent	O
is	O
certainly	O
not	O
the	O
lack	O
of	O
vitamin	Chemical
E	Chemical

Fetal	O
risks	O
due	O
to	O
warfarin	Chemical
therapy	O
during	O
pregnancy.	O
Two	O
mothers	O
with	O
heart	O
valve	O
prosthesis	O
were	O
treated	O
with	O
warfarin	Chemical
during	O
pregnancy.	O
In	O
the	O
first	O
case	O
a	O
caesarean	O
section	O
was	O
done	O
one	O
week	O
after	O
replacement	O
of	O
warfarin	Chemical
with	O
heparin	Chemical
.	O
The	O
baby	O
died	O
of	O
cerebral	Disease
and	Disease
pulmonary	Disease
hemorrhage	Disease
.	O
The	O
second	O
mother	O
had	O
a	O
male	O
infant	O
by	O
caesarean	O
section.	O
The	O
baby	O
showed	O
warfarin	Chemical
-induced	O
embryopathy	Disease
with	O
nasal	Disease
hypoplasia	Disease
and	O
stippled	Disease
epiphyses	Disease
(	O
chondrodysplasia	Disease
punctata	Disease
).	O
Nasal	Disease
hypoplasia	Disease
with	O
or	O
without	O
stippled	Disease
epiphyses	Disease
has	O
now	O
been	O
reported	O
in	O
11	O
infants	O
born	O
to	O
mothers	O
treated	O
with	O
warfarin	Chemical

Isradipine	Chemical
treatment	O
for	O
hypertension	Disease
in	O
general	O
practice	O
in	O
Hong	O
Kong.	O
A	O
6-week	O
open	O
study	O
of	O
the	O
introduction	O
of	O
isradipine	Chemical
treatment	O
was	O
conducted	O
in	O
general	O
practice	O
in	O
Hong	O
Kong.	O
303	O
Chinese	O
patients	O
with	O
mild	O
to	O
moderate	O
hypertension	Disease
entered	O
the	O
study.	O
Side	O
effects	O
were	O
reported	O
in	O
21%	O
of	O
patients	O
and	O
caused	O
withdrawal	O
from	O
the	O
study	O
in	O
3	O
patients.	O
The	O
main	O
side-effects	O
were	O
headache	Disease
,	O
dizziness	Disease
,	O
palpitation	Disease
and	O
flushing	Disease
and	O
these	O
were	O
not	O
more	O
frequent	O
than	O
reported	O
in	O
other	O
studies	O
with	O
isradipine	Chemical
or	O
with	O
placebo.	O
Supine	O
blood	O
pressure	O
was	O
reduced	O
(P	O
less	O
than	O
0.01)	O
from	O
170	O
+/-	O
20/102	O
+/-	O
6	O
mmHg	O
to	O
153	O
+/-	O
19/92	O
+/-	O
8,	O
147	O
+/-	O
18/88	O
+/-	O
7	O
and	O
144	O
+/-	O
14/87	O
+/-	O
6	O
mmHg	O
at	O
2,	O
4	O
and	O
6	O
weeks	O
respectively	O
in	O
evaluable	O
patients.	O
Similar	O
reductions	O
occurred	O
in	O
standing	O
blood	O
pressure	O
and	O
there	O
was	O
no	O
evidence	O
of	O
postural	Disease
hypotension	Disease

Tachyphylaxis	O
to	O
systemic	O
but	O
not	O
to	O
airway	O
responses	O
during	O
prolonged	O
therapy	O
with	O
high	O
dose	O
inhaled	O
salbutamol	Chemical
in	O
asthmatics	Disease
.	O
High	O
doses	O
of	O
inhaled	O
salbutamol	Chemical
produce	O
substantial	O
improvements	O
in	O
airway	O
response	O
in	O
patients	O
with	O
asthma	Disease
,	O
and	O
are	O
associated	O
with	O
dose-dependent	O
systemic	O
beta-adrenoceptor	O
responses.	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
whether	O
tachyphylaxis	O
occurs	O
during	O
prolonged	O
treatment	O
with	O
high	O
dose	O
inhaled	O
salbutamol	Chemical
.	O
Twelve	O
asthmatic	Disease
patients	O
(FEV1,	O
81	O
+/-	O
4%	O
predicted),	O
requiring	O
only	O
occasional	O
inhaled	O
beta-agonists	O
as	O
their	O
sole	O
therapy,	O
were	O
given	O
a	O
14-day	O
treatment	O
with	O
high	O
dose	O
inhaled	O
salbutamol	Chemical
(HDS),	O
4,000	O
micrograms	O
daily,	O
low	O
dose	O
inhaled	O
salbutamol	Chemical
(LDS),	O
800	O
micrograms	O
daily,	O
or	O
placebo	O
(PI)	O
by	O
metered-dose	O
inhaler	O
in	O
a	O
double-blind,	O
randomized	O
crossover	O
design.	O
During	O
the	O
14-day	O
run-in	O
and	O
during	O
washout	O
periods,	O
inhaled	O
beta-agonists	O
were	O
withheld	O
and	O
ipratropium	Chemical
bromide	Chemical
was	O
substituted	O
for	O
rescue	O
purposes.	O
At	O
the	O
end	O
of	O
each	O
14-day	O
treatment,	O
a	O
dose-response	O
curve	O
(DRC)	O
was	O
performed,	O
and	O
airway	O
(FEV1,	O
FEF25-75)	O
chronotropic	O
(HR),	O
tremor	Disease
,	O
and	O
metabolic	O
(	O
K	Chemical
,	O
Glu	Chemical
)	O
responses	O
were	O
measured	O
at	O
each	O
step	O
(from	O
100	O
to	O
4,000	O
micrograms).	O
Treatment	O
had	O
no	O
significant	O
effect	O
on	O
baseline	O
values.	O
There	O
were	O
dose-dependent	O
increases	O
in	O
FEV1	O
and	O
FEF25-75	O
(p	O
less	O
than	O
0.001),	O
and	O
pretreatment	O
with	O
HDS	O
did	O
not	O
displace	O
the	O
DRC	O
to	O
the	O
right.	O
DRC	O
for	O
HR	O
(p	O
less	O
than	O
0.001),	O
K	Chemical
(p	O
less	O
than	O
0.001),	O
and	O
Glu	Chemical
(p	O
less	O
than	O
0.005)	O
were	O
attenuated	O
after	O
treatment	O
with	O
HDS	O
compared	O
with	O
PI.	O
There	O
were	O
also	O
differences	O
between	O
HDS	O
and	O
LDS	O
for	O
HR	O
(p	O
less	O
than	O
0.001)	O
and	O
Glu	Chemical
(p	O
less	O
than	O
0.05)	O
responses.	O
Frequency	O
and	O
severity	O
of	O
subjective	O
adverse	O
effects	O
were	O
also	O
reduced	O
after	O
HDS:	O
tremor	Disease
(p	O
less	O
than	O
0.001),	O
palpitations	Disease

Increased	O
anxiogenic	O
effects	O
of	O
caffeine	Chemical
in	O
panic	Disease
disorders	Disease
.	O
The	O
effects	O
of	O
oral	O
administration	O
of	O
caffeine	Chemical
(10	O
mg/kg)	O
on	O
behavioral	O
ratings,	O
somatic	O
symptoms,	O
blood	O
pressure	O
and	O
plasma	O
levels	O
of	O
3-methoxy-4-hydroxyphenethyleneglycol	Chemical
(	O
MHPG	Chemical
)	O
and	O
cortisol	Chemical
were	O
determined	O
in	O
17	O
healthy	O
subjects	O
and	O
21	O
patients	O
meeting	O
DSM-III	O
criteria	O
for	O
agoraphobia	Disease
with	O
panic	Disease
attacks	Disease
or	O
panic	Disease
disorder	Disease
.	O
Caffeine	Chemical
produced	O
significantly	O
greater	O
increases	O
in	O
subject-rated	O
anxiety	Disease
,	O
nervousness,	O
fear,	O
nausea	Disease
,	O
palpitations	Disease
,	O
restlessness	Disease
,	O
and	O
tremors	Disease
in	O
the	O
patients	O
compared	O
with	O
healthy	O
subjects.	O
In	O
the	O
patients,	O
but	O
not	O
the	O
healthy	O
subjects,	O
these	O
symptoms	O
were	O
significantly	O
correlated	O
with	O
plasma	O
caffeine	Chemical
levels.	O
Seventy-one	O
percent	O
of	O
the	O
patients	O
reported	O
that	O
the	O
behavioral	O
effects	O
of	O
caffeine	Chemical
were	O
similar	O
to	O
those	O
experienced	O
during	O
panic	Disease
attacks	Disease
.	O
Caffeine	Chemical
did	O
not	O
alter	O
plasma	O
MHPG	Chemical
levels	O
in	O
either	O
the	O
healthy	O
subjects	O
or	O
patients.	O
Caffeine	Chemical
increased	O
plasma	O
cortisol	Chemical
levels	O
equally	O
in	O
the	O
patient	O
and	O
healthy	O
groups.	O
Because	O
caffeine	Chemical
is	O
an	O
adenosine	Chemical
receptor	O
antagonist,	O
these	O
results	O
suggest	O
that	O
some	O
panic	Disease
disorder	Disease
patients	O
may	O
have	O
abnormalities	Disease
in	Disease
neuronal	Disease
systems	Disease
involving	O
adenosine	Chemical
.	O
Patients	O
with	O
anxiety	Disease
disorders	Disease
may	O
benefit	O
by	O
avoiding	O
caffeine	Chemical

Human	O
and	O
canine	O
ventricular	O
vasoactive	O
intestinal	O
polypeptide:	O
decrease	O
with	O
heart	Disease
failure	Disease
.	O
Vasoactive	O
intestinal	O
polypeptide	O
(VIP)	O
is	O
a	O
systemic	O
and	O
coronary	O
vasodilator	O
that	O
may	O
have	O
positive	O
inotropic	O
properties.	O
Myocardial	O
levels	O
of	O
VIP	O
were	O
assayed	O
before	O
and	O
after	O
the	O
development	O
of	O
heart	Disease
failure	Disease
in	O
two	O
canine	O
models.	O
In	O
the	O
first,	O
cobalt	Chemical
	O
cardiomyopathy	Disease
was	O
induced	O
in	O
eight	O
dogs;	O
VIP	O
(by	O
radioimmunoassay)	O
decreased	O
from	O
35	O
+/-	O
11	O
pg/mg	O
protein	O
(mean	O
+/-	O
SD)	O
to	O
5	O
+/-	O
4	O
pg/mg	O
protein	O
(P	O
less	O
than	O
0.05).	O
In	O
six	O
dogs	O
with	O
doxorubicin	Chemical
-induced	O
heart	Disease
failure	Disease
,	O
VIP	O
decreased	O
from	O
31	O
+/-	O
7	O
to	O
11	O
+/-	O
4	O
pg/mg	O
protein	O
(P	O
less	O
than	O
0.05).	O
In	O
addition,	O
VIP	O
content	O
of	O
left	O
ventricular	O
muscle	O
of	O
resected	O
failing	O
hearts	O
in	O
10	O
patients	O
receiving	O
a	O
heart	O
transplant	O
was	O
compared	O
with	O
the	O
papillary	O
muscles	O
in	O
14	O
patients	O
(five	O
with	O
rheumatic	Disease
disease	Disease
,	O
nine	O
with	O
myxomatous	Disease
degeneration	Disease
)	O
receiving	O
mitral	O
valve	O
prostheses.	O
The	O
lowest	O
myocardial	O
VIP	O
concentration	O
was	O
found	O
in	O
the	O
hearts	O
of	O
patients	O
with	O
coronary	Disease
disease	Disease
(one	O
patient	O
receiving	O
a	O
transplant	O
and	O
three	O
receiving	O
mitral	O
prostheses)	O
(6.3	O
+/-	O
1.9	O
pg/mg	O
protein).	O
The	O
other	O
patients	O
undergoing	O
transplantation	O
had	O
an	O
average	O
ejection	O
fraction	O
of	O
17%	O
+/-	O
6%	O
and	O
a	O
VIP	O
level	O
of	O
8.8	O
+/-	O
3.9	O
pg/mg	O
protein.	O
The	O
hearts	O
without	O
coronary	Disease
artery	Disease
disease	Disease
(average	O
ejection	O
fraction	O
of	O
this	O
group	O
62%	O
+/-	O
10%)	O
had	O
a	O
VIP	O
concentration	O
of	O
14.1	O
+/-	O
7.9	O
pg/mg	O
protein,	O
and	O
this	O
was	O
greater	O
than	O
in	O
hearts	O
of	O
the	O
patients	O
with	O
coronary	Disease
disease	Disease
and	O
the	O
hearts	O
of	O
patients	O
receiving	O
a	O
transplant	O
(P	O
less	O
than	O
0.05).	O
Myocardial	O
catecholamines	Chemical
were	O
also	O
determined	O
in	O
14	O
subjects;	O
a	O
weak	O
correlation	O
(r	O
=	O
0.57,	O
P	O
less	O
than	O
0.05)	O
between	O
the	O
tissue	O
concentrations	O
of	O
VIP	O
and	O
norepinephrine	Chemical

Interstrain	O
variation	O
in	O
acute	O
toxic	O
response	O
to	O
caffeine	Chemical
among	O
inbred	O
mice.	O
Acute	O
toxic	O
dosage-dependent	O
behavioral	O
effects	O
of	O
caffeine	Chemical
were	O
compared	O
in	O
adult	O
males	O
from	O
seven	O
inbred	O
mouse	O
strains	O
(A/J,	O
BALB/cJ,	O
CBA/J,	O
C3H/HeJ,	O
C57BL/6J,	O
DBA/2J,	O
SWR/J).	O
C57BL/6J,	O
chosen	O
as	O
a	O
"prototypic"	O
mouse	O
strain,	O
was	O
used	O
to	O
determine	O
behavioral	O
responses	O
to	O
a	O
broad	O
range	O
(5-500	O
mg/kg)	O
of	O
caffeine	Chemical
doses.	O
Five	O
phenotypic	O
characteristics--locomotor	O
activity,	O
righting	O
ability,	O
clonic	Disease
seizure	Disease
induction,	O
stress-induced	O
lethality,	O
death	O
without	O
external	O
stress--were	O
scored	O
at	O
various	O
caffeine	Chemical
doses	O
in	O
drug-naive	O
animals	O
under	O
empirically	O
optimized,	O
rigidly	O
constant	O
experimental	O
conditions.	O
Mice	O
(n	O
=	O
12	O
for	O
each	O
point)	O
received	O
single	O
IP	O
injections	O
of	O
a	O
fixed	O
volume/g	O
body	O
weight	O
of	O
physiological	O
saline	O
carrier	O
with	O
or	O
without	O
caffeine	Chemical
in	O
doses	O
ranging	O
from	O
125-500	O
mg/kg.	O
Loss	O
of	O
righting	O
ability	O
was	O
scored	O
at	O
1,	O
3,	O
5	O
min	O
post	O
dosing	O
and	O
at	O
5	O
min	O
intervals	O
thereafter	O
for	O
20	O
min.	O
In	O
the	O
same	O
animals	O
the	O
occurrence	O
of	O
clonic	Disease
seizures	Disease
was	O
scored	O
as	O
to	O
time	O
of	O
onset	O
and	O
severity	O
for	O
20	O
min	O
after	O
drug	O
administration.	O
When	O
these	O
proceeded	O
to	O
tonic	Disease
seizures	Disease
,	O
death	O
occurred	O
in	O
less	O
than	O
20	O
min.	O
Animals	O
surviving	O
for	O
20	O
min	O
were	O
immediately	O
stressed	O
by	O
a	O
swim	O
test	O
in	O
25	O
degrees	O
C	O
water,	O
and	O
death-producing	O
tonic	Disease
seizures	Disease
were	O
scored	O
for	O
2	O
min.	O
In	O
other	O
animals	O
locomotor	O
activity	O
was	O
measured	O
15	O
or	O
60	O
min	O
after	O
caffeine	Chemical
administration.	O
By	O
any	O
single	O
behavioral	O
criterion	O
or	O
a	O
combination	O
of	O
these	O
criteria,	O
marked	O
differences	O
in	O
response	O
to	O
toxic	O
caffeine	Chemical
doses	O
were	O
observed	O
between	O
strains.	O
These	O
results	O
indicate	O
that	O
behavioral	O
toxicity	Disease
testing	O
of	O
alkylxanthines	Chemical

Invasive	O
carcinoma	Disease
of	Disease
the	Disease
renal	Disease
pelvis	Disease
following	O
cyclophosphamide	Chemical
therapy	O
for	O
nonmalignant	O
disease.	O
A	O
47-year-old	O
woman	O
with	O
right	O
hydroureteronephrosis	Disease
due	O
to	O
ureterovesical	O
junction	O
obstruction	O
had	O
gross	O
hematuria	Disease
after	O
being	O
treated	O
for	O
five	O
years	O
wtih	O
cyclophosphamide	Chemical
for	O
cerebral	Disease
vasculitis	Disease
.	O
A	O
right	O
nephroureterectomy	O
was	O
required	O
for	O
control	O
of	O
bleeding	Disease
.	O
The	O
pathology	O
specimen	O
contained	O
clinically	O
occult	O
invasive	O
carcinoma	Disease
of	Disease
the	Disease
renal	Disease
pelvis	Disease
.	O
Although	O
the	O
ability	O
of	O
cyclophosphamide	Chemical
to	O
cause	O
hemorrhagic	Disease
cystitis	Disease
and	O
urine	O
cytologic	O
abnormalities	O
indistinguishable	O
from	O
high	O
grade	O
carcinoma	Disease
is	O
well	O
known,	O
it	O
is	O
less	O
widely	O
appreciated	O
that	O
it	O
is	O
also	O
associated	O
with	O
carcinoma	Disease
of	Disease
the	Disease
urinary	Disease
tract	Disease
.	O
Twenty	O
carcinomas	Disease
of	Disease
the	Disease
urinary	Disease
bladder	Disease
and	O
one	O
carcinoma	Disease
of	Disease
the	Disease
prostate	Disease
have	O
been	O
reported	O
in	O
association	O
with	O
its	O
use.	O
The	O
present	O
case	O
is	O
the	O
first	O
carcinoma	Disease
of	Disease
the	Disease
renal	Disease
pelvis	Disease
reported	O
in	O
association	O
with	O
cyclophosphamide	Chemical
treatment.	O
It	O
is	O
the	O
third	O
urinary	Disease
tract	Disease
cancer	Disease
reported	O
in	O
association	O
with	O
cyclophosphamide	Chemical
treatment	O
for	O
nonmalignant	O
disease.	O
The	O
association	O
of	O
the	O
tumor	Disease
with	O
preexisting	O
hydroureteronephrosis	Disease
suggests	O
that	O
stasis	O
prolonged	O
and	O
intensified	O
exposure	O
of	O
upper	O
urinary	O
tract	O
epithelium	O
to	O
cyclophosphamide	Chemical
.	O
Patients	O
who	O
are	O
candidates	O
for	O
long-term	O
cyclophosphamide	Chemical
treatment	O
should	O
be	O
routinely	O
evaluated	O
for	O
obstructive	Disease
uropathy	Disease

Ascending	O
dose	O
tolerance	O
study	O
of	O
intramuscular	O
carbetocin	Chemical
administered	O
after	O
normal	O
vaginal	O
birth.	O
OBJECTIVE:	O
To	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(MTD)	O
of	O
carbetocin	Chemical
(a	O
long-acting	O
synthetic	O
analogue	O
of	O
oxytocin	Chemical
),	O
when	O
administered	O
immediately	O
after	O
vaginal	O
delivery	O
at	O
term.	O
MATERIALS	O
AND	O
METHODS:	O
Carbetocin	Chemical
was	O
given	O
as	O
an	O
intramuscular	O
injection	O
immediately	O
after	O
the	O
birth	O
of	O
the	O
infant	O
in	O
45	O
healthy	O
women	O
with	O
normal	O
singleton	O
pregnancies	O
who	O
delivered	O
vaginally	O
at	O
term.	O
Dosage	O
groups	O
of	O
15,	O
30,	O
50,	O
75,	O
100,	O
125,	O
150,	O
175	O
or	O
200	O
microg	O
carbetocin	Chemical
were	O
assigned	O
to	O
blocks	O
of	O
three	O
women	O
according	O
to	O
the	O
continual	O
reassessment	O
method	O
(CRM).	O
RESULTS:	O
All	O
dosage	O
groups	O
consisted	O
of	O
three	O
women,	O
except	O
those	O
with	O
100	O
microg	O
(n=6)	O
and	O
200	O
microg	O
(n=18).	O
Recorded	O
were	O
dose-limiting	O
adverse	O
events:	O
hyper-	Disease
or	Disease
hypotension	Disease
(three),	O
severe	O
abdominal	Disease
pain	Disease
(0),	O
vomiting	Disease
(0)	O
and	O
retained	Disease
placenta	Disease
(four).	O
Serious	O
adverse	O
events	O
occurred	O
in	O
seven	O
women:	O
six	O
cases	O
with	O
blood	Disease
loss	Disease
>	O
or	O
=	O
1000	O
ml,	O
four	O
cases	O
of	O
manual	O
placenta	O
removal,	O
five	O
cases	O
of	O
additional	O
oxytocics	O
administration	O
and	O
five	O
cases	O
of	O
blood	O
transfusion.	O
Maximum	O
blood	Disease
loss	Disease
was	O
greatest	O
at	O
the	O
upper	O
and	O
lower	O
dose	O
levels,	O
and	O
lowest	O
in	O
the	O
70-125	O
microg	O
dose	O
range.	O
Four	O
out	O
of	O
six	O
cases	O
with	O
blood	Disease
loss	Disease
>	O
or	O
=	O
1000	O
ml	O
occurred	O
in	O
the	O
200	O
microg	O
group.	O
The	O
majority	O
of	O
additional	O
administration	O
of	O
oxytocics	O
(4/5)	O
and	O
blood	O
transfusion	O
(3/5)	O
occurred	O
in	O
the	O
dose	O
groups	O
of	O
200	O
microg.	O
All	O
retained	O
placentae	O
were	O
found	O
in	O
the	O
group	O
of	O
200	O
microg.	O
CONCLUSION:	O
The	O
MTD	O
was	O
calculated	O
to	O
be	O
at	O
200	O
microg	O
carbetocin	Chemical

A	O
pilot	O
study	O
to	O
assess	O
the	O
safety	O
of	O
dobutamine	Chemical
stress	O
echocardiography	O
in	O
the	O
emergency	O
department	O
evaluation	O
of	O
cocaine	Chemical
-associated	O
chest	Disease
pain	Disease
.	O
STUDY	O
OBJECTIVE:	O
Chest	Disease
pain	Disease
in	O
the	O
setting	O
of	O
cocaine	Chemical
use	O
poses	O
a	O
diagnostic	O
dilemma.	O
Dobutamine	Chemical
stress	O
echocardiography	O
(DSE)	O
is	O
a	O
widely	O
available	O
and	O
sensitive	O
test	O
for	O
evaluating	O
cardiac	O
ischemia	Disease
.	O
Because	O
of	O
the	O
theoretical	O
concern	O
regarding	O
administration	O
of	O
dobutamine	Chemical
in	O
the	O
setting	O
of	O
cocaine	Chemical
use,	O
we	O
conducted	O
a	O
pilot	O
study	O
to	O
assess	O
the	O
safety	O
of	O
DSE	O
in	O
emergency	O
department	O
patients	O
with	O
cocaine	Chemical
-associated	O
chest	Disease
pain	Disease
.	O
METHODS:	O
A	O
prospective	O
case	O
series	O
was	O
conducted	O
in	O
the	O
intensive	O
diagnostic	O
and	O
treatment	O
unit	O
in	O
the	O
ED	O
of	O
an	O
urban	O
tertiary-care	O
teaching	O
hospital.	O
Patients	O
were	O
eligible	O
for	O
DSE	O
if	O
they	O
had	O
used	O
cocaine	Chemical
within	O
24	O
hours	O
preceding	O
the	O
onset	O
of	O
chest	Disease
pain	Disease
and	O
had	O
a	O
normal	O
ECG	O
and	O
tropinin	O
I	O
level.	O
Patients	O
exhibiting	O
signs	O
of	O
continuing	O
cocaine	Chemical
	O
toxicity	Disease
were	O
excluded	O
from	O
the	O
study.	O
All	O
patients	O
were	O
admitted	O
to	O
the	O
hospital	O
for	O
serial	O
testing	O
after	O
the	O
DSE	O
testing	O
in	O
the	O
intensive	O
diagnostic	O
and	O
treatment	O
unit.	O
RESULTS:	O
Twenty-four	O
patients	O
were	O
enrolled.	O
Two	O
patients	O
had	O
inadequate	O
resting	O
images,	O
one	O
DSE	O
was	O
terminated	O
because	O
of	O
inferior	O
hypokinesis	Disease
,	O
another	O
DSE	O
was	O
terminated	O
because	O
of	O
a	O
rate-related	O
atrial	O
conduction	O
deficit,	O
and	O
1	O
patient	O
did	O
not	O
reach	O
the	O
target	O
heart	O
rate.	O
Thus,	O
19	O
patients	O
completed	O
a	O
DSE	O
and	O
reached	O
their	O
target	O
heart	O
rates.	O
None	O
of	O
the	O
patients	O
experienced	O
signs	O
of	O
exaggerated	O
adrenergic	O
response,	O
which	O
was	O
defined	O
as	O
a	O
systolic	O
blood	O
pressure	O
of	O
greater	O
than	O
200	O
mm	O
Hg	O
or	O
the	O
occurrence	O
of	O
tachydysrhythmias	Disease
(excluding	O
sinus	Disease
tachycardia	Disease
).	O
Further	O
suggesting	O
lack	O
of	O
exaggerated	O
adrenergic	O
response,	O
13	O
(65%)	O
of	O
20	O
patients	O
required	O
supplemental	O
atropine	Chemical
to	O
reach	O
their	O
target	O
heart	O
rates.	O
CONCLUSION:	O
No	O
exaggerated	O
adrenergic	O
response	O
was	O
detected	O
when	O
dobutamine	Chemical
was	O
administered	O
to	O
patients	O
with	O
cocaine	Chemical
-related	O
chest	Disease
pain	Disease

Amiodarone	Chemical
-induced	O
torsade	Disease
de	Disease
pointes	Disease
during	O
bladder	O
irrigation:	O
an	O
unusual	O
presentation--a	O
case	O
report.	O
The	O
authors	O
present	O
a	O
case	O
of	O
early	O
(within	O
4	O
days)	O
development	O
of	O
torsade	Disease
de	Disease
pointes	Disease
(	O
TdP	Disease
)	O
associated	O
with	O
oral	O
amiodarone	Chemical
therapy.	O
Consistent	O
with	O
other	O
reports	O
this	O
case	O
of	O
TdP	Disease
occurred	O
in	O
the	O
context	O
of	O
multiple	O
exacerbating	O
factors	O
including	O
hypokalemia	Disease
and	O
digoxin	Chemical
excess.	O
Transient	O
prolongation	O
of	O
the	O
QT	O
during	O
bladder	O
irrigation	O
prompted	O
the	O
episode	O
of	O
TdP	Disease
.	O
It	O
is	O
well	O
known	O
that	O
bradycardia	Disease
exacerbates	O
acquired	O
TdP	Disease
.	O
The	O
authors	O
speculate	O
that	O
the	O
increased	O
vagal	O
tone	O
during	O
bladder	O
irrigation,	O
a	O
vagal	O
maneuver,	O
in	O
the	O
context	O
of	O
amiodarone	Chemical
therapy	O
resulted	O
in	O
amiodarone	Chemical
-induced	O
proarrhythmia	Disease
.	O
In	O
the	O
absence	O
of	O
amiodarone	Chemical
therapy,	O
a	O
second	O
bladder	O
irrigation	O
did	O
not	O
induce	O
TdP	Disease
despite	O
hypokalemia	Disease
and	O
hypomagnesemia	Disease

Acute	Disease
renal	Disease
insufficiency	Disease
after	O
high-dose	O
melphalan	Chemical
in	O
patients	O
with	O
primary	Disease
systemic	Disease
amyloidosis	Disease
during	O
stem	O
cell	O
transplantation.	O
BACKGROUND:	O
Patients	O
with	O
primary	Disease
systemic	Disease
amyloidosis	Disease
(	O
AL	Disease
)	O
have	O
a	O
poor	O
prognosis.	O
Median	O
survival	O
time	O
from	O
standard	O
treatments	O
is	O
only	O
17	O
months.	O
High-dose	O
intravenous	O
melphalan	Chemical
followed	O
by	O
peripheral	O
blood	O
stem	O
cell	O
transplant	O
(PBSCT)	O
appears	O
to	O
be	O
the	O
most	O
promising	O
therapy,	O
but	O
treatment	O
mortality	O
can	O
be	O
high.	O
The	O
authors	O
have	O
noted	O
the	O
development	O
of	O
acute	Disease
renal	Disease
insufficiency	Disease
immediately	O
after	O
melphalan	Chemical
conditioning.	O
This	O
study	O
was	O
undertaken	O
to	O
further	O
examine	O
its	O
risk	O
factors	O
and	O
impact	O
on	O
posttransplant	O
mortality.	O
METHODS:	O
Consecutive	O
AL	Disease
patients	O
who	O
underwent	O
PBSCT	O
were	O
studied	O
retrospectively.	O
Acute	Disease
renal	Disease
insufficiency	Disease
(	O
ARI	Disease
)	O
after	O
high-dose	O
melphalan	Chemical
was	O
defined	O
by	O
a	O
minimum	O
increase	O
of	O
0.5	O
mg/dL	O
(44	O
micromol/L)	O
in	O
the	O
serum	O
creatinine	Chemical
level	O
that	O
is	O
greater	O
than	O
50%	O
of	O
baseline	O
immediately	O
after	O
conditioning.	O
Urine	O
sediment	O
score	O
was	O
the	O
sum	O
of	O
the	O
individual	O
types	O
of	O
sediment	O
identified	O
on	O
urine	O
microscopy.	O
RESULTS:	O
Of	O
the	O
80	O
patients	O
studied,	O
ARI	Disease
developed	O
in	O
18.8%	O
of	O
the	O
patients	O
after	O
high-dose	O
melphalan	Chemical
.	O
Univariate	O
analysis	O
identified	O
age,	O
hypoalbuminemia	Disease
,	O
heavy	O
proteinuria	Disease
,	O
diuretic	O
use,	O
and	O
urine	O
sediment	O
score	O
(>3)	O
as	O
risk	O
factors.	O
Age	O
and	O
urine	O
sediment	O
score	O
remained	O
independently	O
significant	O
risk	O
factors	O
in	O
the	O
multivariate	O
analysis.	O
Patients	O
who	O
had	O
ARI	Disease
after	O
high-dose	O
melphalan	Chemical
underwent	O
dialysis	O
more	O
often	O
(P	O
=	O
0.007),	O
and	O
had	O
a	O
worse	O
1-year	O
survival	O
(P	O
=	O
0.03).	O
CONCLUSION:	O
The	O
timing	O
of	O
renal	Disease
injury	Disease
strongly	O
suggests	O
melphalan	Chemical
as	O
the	O
causative	O
agent.	O
Ongoing	O
tubular	Disease
injury	Disease
may	O
be	O
a	O
prerequisite	O
for	O
renal	Disease
injury	Disease
by	O
melphalan	Chemical
as	O
evidenced	O
by	O
the	O
active	O
urinary	O
sediment.	O
Development	O
of	O
ARI	Disease
adversely	O
affected	O
the	O
outcome	O
after	O
PBSCT.	O
Effective	O
preventive	O
measures	O
may	O
help	O
decrease	O
the	O
treatment	O
mortality	O
of	O
PBSCT	O
in	O
AL	Disease

Impaired	Disease
fear	Disease
recognition	Disease
in	O
regular	O
recreational	O
cocaine	Chemical
users.	O
INTRODUCTION:	O
The	O
ability	O
to	O
read	O
facial	O
expressions	O
is	O
essential	O
for	O
normal	O
human	O
social	O
interaction.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
conduct	O
the	O
first	O
investigation	O
of	O
facial	O
expression	O
recognition	O
performance	O
in	O
recreational	O
cocaine	Chemical
users.	O
MATERIALS	O
AND	O
METHODS:	O
Three	O
groups,	O
comprised	O
of	O
21	O
cocaine	Chemical
naive	O
participants	O
(CN),	O
	O
30	O
occasional	O
cocaine	Chemical
(OC),	O
and	O
48	O
regular	O
recreational	O
cocaine	Chemical
(RC)	O
users,	O
were	O
compared.	O
An	O
emotional	O
facial	O
expression	O
(EFE)	O
task	O
consisting	O
of	O
a	O
male	O
and	O
female	O
face	O
expressing	O
six	O
basic	O
emotions	O
(happiness,	O
surprise,	O
sadness,	O
anger,	O
fear,	O
and	O
disgust)	O
was	O
administered.	O
Mean	O
percent	O
accuracy	O
and	O
latencies	O
for	O
correct	O
responses	O
across	O
eight	O
presentations	O
of	O
each	O
basic	O
emotion	O
were	O
derived.	O
Participants	O
were	O
also	O
assessed	O
with	O
the	O
"Eyes	O
task"	O
to	O
investigate	O
their	O
ability	O
to	O
recognize	O
more	O
complex	O
emotional	O
states	O
and	O
the	O
Symptom	O
CheckList-90-Revised	O
to	O
measure	O
psychopathology.	O
RESULTS:	O
There	O
were	O
no	O
group	O
differences	O
in	O
psychopathology	O
or	O
"eyes	O
task"	O
performance,	O
but	O
the	O
RC	O
group,	O
who	O
otherwise	O
had	O
similar	O
illicit	O
substance	O
use	O
histories	O
to	O
the	O
OC	O
group,	O
exhibited	O
impaired	Disease
fear	Disease
recognition	Disease
accuracy	O
compared	O
to	O
the	O
OC	O
and	O
CN	O
groups.	O
The	O
RC	O
group	O
also	O
correctly	O
identified	O
anger,	O
fear,	O
happiness,	O
and	O
surprise,	O
more	O
slowly	O
than	O
CN,	O
but	O
not	O
OC	O
participants.	O
The	O
OC	O
group	O
was	O
slower	O
than	O
CN	O
when	O
correctly	O
identifying	O
disgust.	O
The	O
selective	O
deficit	Disease
in	Disease
fear	Disease
recognition	Disease
accuracy	O
manifested	O
by	O
the	O
RC	O
group	O
cannot	O
be	O
explained	O
by	O
the	O
subacute	O
effects	O
of	O
cocaine	Chemical
,	O
or	O
ecstasy	Chemical
,	O
because	O
recent	O
and	O
less	O
recent	O
users	O
of	O
these	O
drugs	O
within	O
this	O
group	O
were	O
similarly	O
impaired.	O
Possible	O
parallels	O
between	O
RC	O
users	O
and	O
psychopaths	Disease
with	O
respect	O
to	O
impaired	Disease
fear	Disease
recognition	Disease
,	O
amygdala	Disease
dysfunction	Disease

Corneal	Disease
ulcers	Disease
associated	O
with	O
aerosolized	O
crack	Chemical
cocaine	Chemical
use.	O
PURPOSE:	O
We	O
report	O
4	O
cases	O
of	O
corneal	Disease
ulcers	Disease
associated	O
with	O
drug	Disease
abuse	Disease
.	O
The	O
pathogenesis	O
of	O
these	O
ulcers	Disease
and	O
management	O
of	O
these	O
patients	O
are	O
also	O
reviewed.	O
METHODS:	O
Review	O
of	O
all	O
cases	O
of	O
corneal	Disease
ulcers	Disease
associated	O
with	O
drug	Disease
abuse	Disease
seen	O
at	O
our	O
institution	O
from	O
July	O
2006	O
to	O
December	O
2006.	O
RESULTS:	O
Four	O
patients	O
with	O
corneal	Disease
ulcers	Disease
associated	O
with	O
crack	Chemical
cocaine	Chemical
use	O
were	O
reviewed.	O
All	O
corneal	Disease
ulcers	Disease
were	O
cultured,	O
and	O
the	O
patients	O
were	O
admitted	O
to	O
the	O
hospital	O
for	O
intensive	O
topical	O
antibiotic	O
treatment.	O
Each	O
patient	O
received	O
comprehensive	O
health	O
care,	O
including	O
medical	O
and	O
substance	Disease
abuse	Disease
consultations.	O
Streptococcal	O
organisms	O
were	O
found	O
in	O
3	O
cases	O
and	O
Capnocytophaga	O
and	O
Brevibacterium	O
casei	O
in	O
1	O
patient.	O
The	O
infections	Disease
responded	O
to	O
antibiotic	O
treatment.	O
Two	O
patients	O
needed	O
a	O
lateral	O
tarsorrhaphy	O
for	O
persistent	O
epithelial	Disease
defects	Disease
.	O
CONCLUSIONS:	O
Aerosolized	O
crack	Chemical
cocaine	Chemical
use	O
can	O
be	O
associated	O
with	O
the	O
development	O
of	O
corneal	Disease
ulcers	Disease
.	O
Drug	Disease
abuse	Disease
provides	O
additional	O
challenges	O
for	O
management.	O
Not	O
only	O
treatment	O
of	O
their	O
infections	Disease
but	O
also	O
the	O
overall	O
poor	O
health	O
of	O
the	O
patients	O
and	O
increased	O
risk	O
of	O
noncompliance	O
need	O
to	O
be	O
addressed.	O
Comprehensive	O
care	O
may	O
provide	O
the	O
patient	O
the	O
opportunity	O
to	O
discontinue	O
their	O
substance	Disease
abuse	Disease

Levetiracetam	Chemical
as	O
an	O
adjunct	O
to	O
phenobarbital	Chemical
treatment	O
in	O
cats	O
with	O
suspected	O
idiopathic	Disease
epilepsy	Disease
.	O
OBJECTIVE:	O
To	O
assess	O
pharmacokinetics,	O
efficacy,	O
and	O
tolerability	O
of	O
oral	O
levetiracetam	Chemical
administered	O
as	O
an	O
adjunct	O
to	O
phenobarbital	Chemical
treatment	O
in	O
cats	O
with	O
poorly	O
controlled	O
suspected	O
idiopathic	Disease
epilepsy	Disease
.	O
DESIGN-Open-label,	O
noncomparative	O
clinical	O
trial.	O
ANIMALS:	O
12	O
cats	O
suspected	O
to	O
have	O
idiopathic	Disease
epilepsy	Disease
that	O
was	O
poorly	O
controlled	O
with	O
phenobarbital	Chemical
or	O
that	O
had	O
unacceptable	O
adverse	O
effects	O
when	O
treated	O
with	O
phenobarbital	Chemical
.	O
PROCEDURES:	O
Cats	O
were	O
treated	O
with	O
levetiracetam	Chemical
(20	O
mg/kg	O
[9.1	O
mg/lb],	O
PO,	O
q	O
8	O
h).	O
After	O
a	O
minimum	O
of	O
1	O
week	O
of	O
treatment,	O
serum	O
levetiracetam	Chemical
concentrations	O
were	O
measured	O
before	O
and	O
2,	O
4,	O
and	O
6	O
hours	O
after	O
drug	O
administration,	O
and	O
maximum	O
and	O
minimum	O
serum	O
concentrations	O
and	O
elimination	O
half-life	O
were	O
calculated.	O
Seizure	Disease
frequencies	O
before	O
and	O
after	O
initiation	O
of	O
levetiracetam	Chemical
treatment	O
were	O
compared,	O
and	O
adverse	O
effects	O
were	O
recorded.	O
RESULTS:	O
Median	O
maximum	O
serum	O
levetiracetam	Chemical
concentration	O
was	O
25.5	O
microg/mL,	O
median	O
minimum	O
serum	O
levetiracetam	Chemical
concentration	O
was	O
8.3	O
microg/mL,	O
and	O
median	O
elimination	O
half-life	O
was	O
2.9	O
hours.	O
Median	O
seizure	Disease
frequency	O
prior	O
to	O
treatment	O
with	O
levetiracetam	Chemical
(2.1	O
seizures	Disease
/mo)	O
was	O
significantly	O
higher	O
than	O
median	O
seizure	Disease
frequency	O
after	O
initiation	O
of	O
levetiracetam	Chemical
treatment	O
(0.42	O
seizures	Disease
/mo),	O
and	O
7	O
of	O
10	O
cats	O
were	O
classified	O
as	O
having	O
responded	O
to	O
levetiracetam	Chemical
treatment	O
(ie,	O
reduction	O
in	O
seizure	Disease
frequency	O
of	O
>or=50%).	O
Two	O
cats	O
had	O
transient	O
lethargy	Disease
and	O
inappetence	Disease
.	O
CONCLUSIONS	O
AND	O
CLINICAL	O
RELEVANCE:	O
Results	O
suggested	O
that	O
levetiracetam	Chemical
is	O
well	O
tolerated	O
in	O
cats	O
and	O
may	O
be	O
useful	O
as	O
an	O
adjunct	O
to	O
phenobarbital	Chemical
treatment	O
in	O
cats	O
with	O
idiopathic	Disease
epilepsy	Disease

Bilateral	O
haemorrhagic	Disease
infarction	Disease
of	Disease
the	Disease
globus	Disease
pallidus	Disease
after	O
cocaine	Chemical
and	O
alcohol	Chemical
intoxication.	O
Cocaine	Chemical
is	O
a	O
risk	O
factor	O
for	O
both	O
ischemic	Disease
and	Disease
haemorrhagic	Disease
stroke	Disease
.	O
We	O
present	O
the	O
case	O
of	O
a	O
31-year-old	O
man	O
with	O
bilateral	O
ischemia	Disease
of	Disease
the	Disease
globus	Disease
pallidus	Disease
after	O
excessive	O
alcohol	Chemical
and	O
intranasal	O
cocaine	Chemical
use.	O
Drug-related	O
globus	Disease
pallidus	Disease
infarctions	Disease
are	O
most	O
often	O
associated	O
with	O
heroin	Chemical
.	O
Bilateral	O
basal	Disease
ganglia	Disease
infarcts	Disease
after	O
the	O
use	O
of	O
cocaine	Chemical
,	O
without	O
concurrent	O
heroin	Chemical
use,	O
have	O
never	O
been	O
reported.	O
In	O
our	O
patient,	O
transient	O
cardiac	Disease
arrhythmia	Disease
or	O
respiratory	Disease
dysfunction	Disease
related	O
to	O
cocaine	Chemical
and/or	O
ethanol	Chemical
use	O
were	O
the	O
most	O
likely	O
causes	O
of	O
cerebral	Disease
hypoperfusion	Disease

Acute	Disease
renal	Disease
failure	Disease
after	O
high-dose	O
methotrexate	Chemical
therapy	O
in	O
a	O
patient	O
with	O
ileostomy.	O
High-dose	O
methotrexate	Chemical
(HD-	O
MTX	Chemical
)	O
is	O
an	O
important	O
treatment	O
for	O
Burkitt	Disease
lymphoma	Disease
,	O
but	O
can	O
cause	O
hepatic	Disease
and	Disease
renal	Disease
toxicity	Disease
when	O
its	O
clearance	O
is	O
delayed.	O
We	O
report	O
a	O
case	O
of	O
acute	Disease
renal	Disease
failure	Disease
after	O
HD-	O
MTX	Chemical
therapy	O
in	O
a	O
patient	O
with	O
ileostomy,	O
The	O
patient	O
was	O
a	O
3-year-old	O
boy	O
who	O
had	O
received	O
a	O
living-related	O
liver	O
transplantation	O
for	O
congenital	O
biliary	Disease
atresia	Disease
.	O
At	O
day	O
833	O
after	O
the	O
transplantation,	O
he	O
was	O
diagnosed	O
with	O
PTLD	Disease
(	O
post-transplantation	Disease
lymphoproliferative	Disease
disorder	Disease
,	O
Burkitt-type	Disease
malignant	Disease
lymphoma	Disease
).	O
During	O
induction	O
therapy,	O
he	O
suffered	O
ileal	O
perforation	O
and	O
ileostomy	O
was	O
performed.	O
Subsequent	O
HD-	O
MTX	Chemical
therapy	O
caused	O
acute	Disease
renal	Disease
failure	Disease
that	O
required	O
continuous	O
hemodialysis.	O
We	O
supposed	O
that	O
intravascular	O
hypovolemia	Disease
due	O
to	O
substantial	O
drainage	O
from	O
the	O
ileostoma	O
caused	O
acute	Disease
prerenal	Disease
failure	Disease
.	O
After	O
recovery	O
of	O
his	O
renal	O
function,	O
we	O
could	O
safely	O
treat	O
the	O
patient	O
with	O
HD-	O
MTX	Chemical

Antithrombotic	O
drug	O
use,	O
cerebral	Disease
microbleeds	Disease
,	O
and	O
intracerebral	Disease
hemorrhage	Disease
:	O
a	O
systematic	O
review	O
of	O
published	O
and	O
unpublished	O
studies.	O
BACKGROUND	O
AND	O
PURPOSE:	O
Cerebral	Disease
microbleeds	Disease
(	O
MB	Disease
)	O
are	O
potential	O
risk	O
factors	O
for	O
intracerebral	Disease
hemorrhage	Disease
(	O
ICH	Disease
),	O
but	O
it	O
is	O
unclear	O
if	O
they	O
are	O
a	O
contraindication	O
to	O
using	O
antithrombotic	O
drugs.	O
Insights	O
could	O
be	O
gained	O
by	O
pooling	O
data	O
on	O
MB	Disease
frequency	O
stratified	O
by	O
antithrombotic	O
use	O
in	O
cohorts	O
with	O
ICH	Disease
and	O
ischemic	Disease
stroke	Disease
(	O
IS	Disease
)/	O
transient	Disease
ischemic	Disease
attack	Disease
(	O
TIA	Disease
).	O
METHODS:	O
We	O
performed	O
a	O
systematic	O
review	O
of	O
published	O
and	O
unpublished	O
data	O
from	O
cohorts	O
with	O
stroke	Disease
or	O
TIA	Disease
to	O
compare	O
the	O
presence	O
of	O
MB	Disease
in:	O
(1)	O
antithrombotic	O
users	O
vs	O
nonantithrombotic	O
users	O
with	O
ICH	Disease
;	O
(2)	O
antithrombotic	O
users	O
vs	O
nonusers	O
with	O
IS	Disease
/	O
TIA	Disease
;	O
and	O
(3)	O
ICH	Disease
vs	O
ischemic	Disease
events	O
stratified	O
by	O
antithrombotic	O
use.	O
We	O
also	O
analyzed	O
published	O
and	O
unpublished	O
follow-up	O
data	O
to	O
determine	O
the	O
risk	O
of	O
ICH	Disease
in	O
antithrombotic	O
users	O
with	O
MB	Disease
.	O
RESULTS:	O
In	O
a	O
pooled	O
analysis	O
of	O
1460	O
ICH	Disease
and	O
3817	O
IS	Disease
/	O
TIA	Disease
,	O
MB	Disease
were	O
more	O
frequent	O
in	O
ICH	Disease
vs	O
IS	Disease
/	O
TIA	Disease
in	O
all	O
treatment	O
groups,	O
but	O
the	O
excess	O
increased	O
from	O
2.8	O
(odds	O
ratio;	O
range,	O
2.3-3.5)	O
in	O
nonantithrombotic	O
users	O
to	O
5.7	O
(range,	O
3.4-9.7)	O
in	O
antiplatelet	O
users	O
and	O
8.0	O
(range,	O
3.5-17.8)	O
in	O
warfarin	Chemical
users	O
(P	O
difference=0.01).	O
There	O
was	O
also	O
an	O
excess	O
of	O
MB	Disease
in	O
warfarin	Chemical
users	O
vs	O
nonusers	O
with	O
ICH	Disease
(OR,	O
2.7;	O
95%	O
CI,	O
1.6-4.4;	O
P<0.001)	O
but	O
none	O
in	O
warfarin	Chemical
users	O
with	O
IS	Disease
/	O
TIA	Disease
(OR,	O
1.3;	O
95%	O
CI,	O
0.9-1.7;	O
P=0.33;	O
P	O
difference=0.01).	O
There	O
was	O
a	O
smaller	O
excess	O
of	O
MB	Disease
in	O
antiplatelet	O
users	O
vs	O
nonusers	O
with	O
ICH	Disease
(OR,	O
1.7;	O
95%	O
CI,	O
1.3-2.3;	O
P<0.001),	O
but	O
findings	O
were	O
similar	O
for	O
antiplatelet	O
users	O
with	O
IS	Disease
/	O
TIA	Disease
(OR,	O
1.4;	O
95%	O
CI,	O
1.2-1.7;	O
P<0.001;	O
P	O
difference=0.25).	O
In	O
pooled	O
follow-up	O
data	O
for	O
768	O
antithrombotic	O
users,	O
presence	O
of	O
MB	Disease
at	O
baseline	O
was	O
associated	O
with	O
a	O
substantially	O
increased	O
risk	O
of	O
subsequent	O
ICH	Disease
(OR,	O
12.1;	O
95%	O
CI,	O
3.4-42.5;	O
P<0.001).	O
CONCLUSIONS:	O
The	O
excess	O
of	O
MB	Disease
in	O
warfarin	Chemical
users	O
with	O
ICH	Disease
compared	O
to	O
other	O
groups	O
suggests	O
that	O
MB	Disease
increase	O
the	O
risk	O
of	O
warfarin	Chemical
-associated	O
ICH	Disease

Verapamil	Chemical
stimulation	O
test	O
in	O
hyperprolactinemia	Disease
:	O
loss	O
of	O
prolactin	O
response	O
in	O
anatomic	O
or	O
functional	O
stalk	O
effect.	O
AIM:	O
Verapamil	Chemical
stimulation	O
test	O
was	O
previously	O
investigated	O
as	O
a	O
tool	O
for	O
differential	O
diagnosis	O
of	O
hyperprolactinemia	Disease
,	O
but	O
with	O
conflicting	O
results.	O
Macroprolactinemia	Disease
was	O
never	O
considered	O
in	O
those	O
previous	O
studies.	O
Here,	O
we	O
aimed	O
to	O
re-investigate	O
the	O
diagnostic	O
value	O
of	O
verapamil	Chemical
in	O
a	O
population	O
who	O
were	O
all	O
screened	O
for	O
macroprolactinemia	Disease
.	O
Prolactin	O
responses	O
to	O
verapamil	Chemical
in	O
65	O
female	O
patients	O
(age:	O
29.9	O
+/-	O
8.1	O
years)	O
with	O
hyperprolactinemia	Disease
were	O
tested	O
in	O
a	O
descriptive,	O
matched	O
case-control	O
study.	O
METHODS:	O
Verapamil	Chemical
80	O
mg,	O
p.o.	O
was	O
administered,	O
and	O
then	O
PRL	O
levels	O
were	O
measured	O
at	O
8th	O
and	O
16th	O
hours,	O
by	O
immunometric	O
chemiluminescence.	O
Verapamil	Chemical
responsiveness	O
was	O
determined	O
by	O
peak	O
percent	O
change	O
in	O
basal	O
prolactin	O
levels	O
(PRL).	O
RESULTS:	O
Verapamil	Chemical
significantly	O
increased	O
PRL	O
levels	O
in	O
healthy	O
controls	O
(N.	O
8,	O
PRL:	O
183%),	O
macroprolactinoma	Disease
(N.	O
8,	O
PRL:	O
7%),	O
microprolactinoma	Disease
(N.	O
19,	O
PRL:	O
21%),	O
macroprolactinemia	Disease
(N.	O
23,	O
PRL:	O
126%),	O
but	O
not	O
in	O
pseudoprolactinoma	Disease
(N.	O
8,	O
PRL:	O
0.8%),	O
and	O
risperidone	Chemical
-induced	O
hyperprolactinemia	Disease
(N.	O
7,	O
PRL:	O
3%).	O
ROC	O
curve	O
analysis	O
revealed	O
that	O
unresponsiveness	O
to	O
verapamil	Chemical
defined	O
as	O
PRL	O
<7%,	O
discriminated	O
anatomical	O
or	O
functional	O
stalk	O
effect	O
(sensitivity:	O
74%,	O
specificity:	O
73%,	O
AUC:	O
0.855+/-0.04,	O
P	O
<0.001,	O
CI:	O
0.768-0.942)	O
associated	O
with	O
pseudoprolactinoma	Disease
or	O
risperidone	Chemical
-induced	O
hyperprolactinemia	Disease
,	O
respectively.	O
CONCLUSION:	O
Verapamil	Chemical
responsiveness	O
is	O
not	O
a	O
reliable	O
finding	O
for	O
the	O
differential	O
diagnosis	O
of	O
hyperprolactinemia	Disease
.	O
However,	O
verapamil	Chemical
unresponsiveness	O
discriminates	O
stalk	O
effect	O
(i.e.,	O
anatomically	O
or	O
functionally	O
inhibited	O
dopaminergic	O
tonus)	O
from	O
other	O
causes	O
of	O
hyperprolactinemia	Disease

Central	O
action	O
of	O
narcotic	O
analgesics.	O
Part	O
IV.	O
Noradrenergic	O
influences	O
on	O
the	O
activity	O
of	O
analgesics	O
in	O
rats.	O
The	O
effect	O
of	O
clonidine	Chemical
,	O
naphazoline	Chemical
and	O
xylometazoline	Chemical
on	O
analgesia	O
induced	O
by	O
morphine	Chemical
,	O
codeine	Chemical
,	O
fentanyl	Chemical
and	O
pentazocine	Chemical
,	O
and	O
on	O
cataleptic	Disease
effect	O
of	O
morphine	Chemical
,	O
codine	Chemical
and	O
fentanyl	Chemical
was	O
studied	O
in	O
rats.	O
The	O
biochemical	O
assays	O
on	O
the	O
influence	O
of	O
four	O
analgesics	O
on	O
the	O
brain	O
concentration	O
and	O
turnover	O
of	O
noradrenaline	Chemical
(	O
NA	Chemical
)	O
were	O
also	O
performed.	O
It	O
was	O
found	O
that	O
three	O
drugs	O
stimulating	O
central	O
NA	Chemical
receptors	O
failed	O
to	O
affect	O
the	O
analgesic	O
ED50	O
of	O
all	O
antinociceptive	O
agents	O
and	O
they	O
enhanced	O
catalepsy	Disease
induced	O
by	O
morphine	Chemical
and	O
fentanyl	Chemical
.	O
Codeine	Chemical
	O
catalepsy	Disease
was	O
increased	O
by	O
clonidine	Chemical
and	O
decreased	O
by	O
naphazoline	Chemical
and	O
xylometazoline	Chemical
.	O
The	O
brain	O
concentration	O
of	O
NA	Chemical
was	O
not	O
changed	O
by	O
morphine	Chemical
and	O
fentanyl	Chemical
,	O
but	O
one	O
of	O
the	O
doses	O
of	O
codeine	Chemical
(45	O
mg/kg)	O
slightly	O
enhanced	O
it.	O
Pentazocine	Chemical
dose-dependently	O
decreased	O
the	O
brain	O
level	O
of	O
NA	Chemical
.	O
The	O
rate	O
of	O
NA	Chemical
turnover	O
was	O
not	O
altered	O
by	O
analgesics	O
except	O
for	O
the	O
higher	O
dose	O
of	O
fentanyl	Chemical
(0.2	O
mg/kg)	O
following	O
which	O
the	O
disappearance	O
of	O
NA	Chemical
from	O
the	O
brain	O
was	O
diminished.	O
The	O
results	O
are	O
discussed	O
in	O
the	O
light	O
of	O
various	O
and	O
non-uniform	O
data	O
from	O
the	O
literature.	O
It	O
is	O
suggested	O
that	O
in	O
rats	O
the	O
brain	O
NA	Chemical
plays	O
a	O
less	O
important	O
function	O
than	O
the	O
other	O
monoamines	Chemical

Modification	O
by	O
propranolol	Chemical
of	O
cardiovascular	O
effects	O
of	O
induced	O
hypoglycaemia	Disease
.	O
The	O
cardiovascular	O
effects	O
of	O
hypoglycaemia	Disease
,	O
with	O
and	O
without	O
beta-blockade,	O
were	O
compared	O
in	O
fourteen	O
healthy	O
men.	O
Eight	O
received	O
insulin	O
alone,	O
and	O
eight,	O
including	O
two	O
of	O
the	O
original	O
insulin-only	O
group,	O
were	O
given	O
propranolol	Chemical
and	O
insulin.	O
In	O
the	O
insulin-group	O
the	O
period	O
of	O
hypoglycaemia	Disease
was	O
associated	O
with	O
an	O
increase	O
in	O
heart-rate	O
and	O
a	O
fall	O
in	O
diastolic	O
blood-pressure.	O
In	O
the	O
propranolol	Chemical
-insulin	O
group	O
there	O
was	O
a	O
significant	O
fall	O
in	O
heart-rate	O
in	O
most	O
subjects	O
and	O
an	O
increase	O
in	O
diastolic	O
pressure.	O
Typical	O
S-T/T	O
changes	O
occurred	O
in	O
the	O
insulin-group	O
but	O
in	O
none	O
of	O
the	O
propranolol	Chemical
-insulin	O
group.	O
Hypertension	Disease
in	O
diabetics	Disease
prone	O
to	O
hypoglycaemia	Disease

Prevention	O
and	O
treatment	O
of	O
endometrial	Disease
disease	Disease
in	O
climacteric	O
women	O
receiving	O
oestrogen	Chemical
therapy.	O
The	O
treatment	O
regimens	O
are	O
described	O
in	O
74	O
patients	O
with	O
endometrial	Disease
disease	Disease
among	O
850	O
climacteric	O
women	O
receiving	O
oestrogen	Chemical
therapy.	O
Cystic	O
hyperplasia	Disease
was	O
associated	O
with	O
unopposed	O
oestrogen	Chemical
therapy	O
without	O
progestagen	Chemical
.	O
Two	O
courses	O
of	O
21	O
days	O
of	O
5	O
mg	O
norethisterone	Chemical
daily	O
caused	O
reversion	O
to	O
normal	O
in	O
all	O
57	O
cases	O
of	O
cystic	O
hyperplasia	Disease
and	O
6	O
of	O
the	O
8	O
cases	O
of	O
atypical	O
hyperplasia	Disease
.	O
4	O
cases	O
of	O
endometrial	Disease
carcinoma	Disease
referred	O
from	O
elsewhere	O
demonstrated	O
the	O
problems	O
of	O
inappropriate	O
and	O
unsupervised	O
unopposed	O
oestrogen	Chemical
therapy	O
and	O
the	O
difficulty	O
in	O
distinguishing	O
severe	O
hyperplasia	Disease
from	O
malignancy	Disease
.	O
Cyclical	O
low-dose	O
oestrogen	Chemical
therapy	O
with	O
7--13	O
days	O
of	O
progestagen	Chemical
does	O
not	O
seem	O
to	O
increase	O
the	O
risk	O
of	O
endometrial	Disease
hyperplasia	Disease
or	O
carcinoma	Disease

Pure	Disease
red	Disease
cell	Disease
aplasia	Disease
,	O
toxic	Disease
dermatitis	Disease
and	O
lymphadenopathy	Disease
in	O
a	O
patient	O
taking	O
diphenylhydantoin	Chemical
.	O
A	O
patient	O
taking	O
diphenylhydantoin	Chemical
for	O
3	O
weeks	O
developed	O
a	O
generalized	O
skin	Disease
rash	Disease
,	O
lymphadenopathy	Disease
and	O
pure	Disease
red	Disease
cell	Disease
aplasia	Disease
.	O
After	O
withdrawal	O
of	O
the	O
pharmacon	O
all	O
symptoms	O
disappeared	O
spontaneously.	O
Skin	Disease
rash	Disease
is	O
a	O
well-known	O
complication	O
of	O
diphenylhydantoin	Chemical
treatment	O
as	O
is	O
benign	O
and	O
malignant	O
lymphadenopathy	Disease
.	O
Pure	Disease
red	Disease
cell	Disease
aplasia	Disease
associated	O
with	O
diphenylhydantoin	Chemical
medication	O
has	O
been	O
reported	O
in	O
3	O
patients.	O
The	O
exact	O
mechanism	O
by	O
which	O
diphenylhydantoin	Chemical
exerts	O
its	O
toxic	O
effects	O
is	O
not	O
known.	O
In	O
this	O
patient	O
the	O
time	O
relation	O
between	O
the	O
ingestion	O
of	O
diphenylhydantoin	Chemical
and	O
the	O
occurrence	O
of	O
the	O
skin	Disease
rash	Disease
,	O
lymphadenopathy	Disease
and	O
pure	Disease
red	Disease
cell	Disease
aplasia	Disease

Continuous	O
infusion	O
tobramycin	Chemical
combined	O
with	O
carbenicillin	Chemical
for	O
infections	Disease
in	O
cancer	Disease
patients.	O
The	O
cure	O
rate	O
of	O
infections	Disease
in	O
cancer	Disease
patients	O
is	O
adversely	O
affected	O
by	O
neutropenia	Disease
(less	O
than	O
1,000/mm3).	O
In	O
particular,	O
patients	O
with	O
severe	O
neutropenia	Disease
(less	O
than	O
100/mm3)	O
have	O
shown	O
a	O
poor	O
response	O
to	O
antibiotics.	O
To	O
overcome	O
the	O
adverse	O
effects	O
of	O
neutropenia	Disease
,	O
tobramycin	Chemical
was	O
given	O
by	O
continuous	O
infusion	O
and	O
combined	O
with	O
intermittent	O
carbenicillin	Chemical
.	O
Tobramycin	Chemical
was	O
given	O
to	O
a	O
total	O
daily	O
dose	O
of	O
300	O
mg/m2	O
and	O
carbenicillin	Chemical
was	O
given	O
at	O
a	O
dose	O
of	O
5	O
gm	O
every	O
four	O
hours.	O
There	O
were	O
125	O
infectious	O
episodes	O
in	O
116	O
cancer	Disease
patients	O
receiving	O
myelosuppressive	O
chemotherapy.	O
The	O
overall	O
cure	O
rate	O
was	O
70%.	O
Pneumonia	Disease
was	O
the	O
most	O
common	O
infection	Disease
and	O
61%	O
of	O
59	O
episodes	O
were	O
cured.	O
Gram-negative	O
bacilli	O
were	O
the	O
most	O
common	O
causative	O
organisms	O
and	O
69%	O
of	O
these	O
infections	Disease
were	O
cured.	O
The	O
most	O
common	O
pathogen	O
was	O
Klebsiella	O
pneumoniae	Disease
and	O
this,	O
together	O
with	O
Escherichia	O
coli	O
and	O
Pseudomonas	O
aeruginosa,	O
accounted	O
for	O
74%	O
of	O
all	O
gram-negative	Disease
bacillary	Disease
infections	Disease
.	O
Response	O
was	O
not	O
influenced	O
by	O
the	O
initial	O
neutrophil	O
count,	O
with	O
a	O
62%	O
cure	O
rate	O
for	O
39	O
episodes	O
associated	O
with	O
severe	O
neutropenia	Disease
.	O
However,	O
failure	O
of	O
the	O
neutrophil	O
count	O
to	O
increase	O
during	O
therapy	O
adversely	O
affected	O
response.	O
Azotemia	Disease
was	O
the	O
major	O
side	O
effect	O
recognized,	O
and	O
it	O
occurred	O
in	O
11%	O
of	O
episodes.	O
Major	O
azotemia	Disease
(serum	O
creatinine	Chemical
greater	O
than	O
2.5	O
mg/dl	O
or	O
BUN	O
greater	O
than	O
50	O
mg/dl)	O
occurred	O
in	O
only	O
2%.	O
Azotemia	Disease
was	O
not	O
related	O
to	O
duration	O
of	O
therapy	O
or	O
serum	O
tobramycin	Chemical
concentration.	O
This	O
antibiotic	O
regimen	O
showed	O
both	O
therapeutic	O
efficacy	O
and	O
acceptable	O
renal	Disease
toxicity	Disease

Recurrent	O
subarachnoid	Disease
hemorrhage	Disease
associated	O
with	O
aminocaproic	Chemical
acid	Chemical
therapy	O
and	O
acute	Disease
renal	Disease
artery	Disease
thrombosis	Disease
.	O
Case	O
report.	O
Epsilon	Chemical
aminocaproic	Chemical
acid	Chemical
(	O
EACA	Chemical
)	O
has	O
been	O
used	O
to	O
prevent	O
rebleeding	O
in	O
patients	O
with	O
subarachnoid	Disease
hemorrhage	Disease
(	O
SAH	Disease
).	O
Although	O
this	O
agent	O
does	O
decrease	O
the	O
frequency	O
of	O
rebleeding,	O
several	O
reports	O
have	O
described	O
thrombotic	Disease
complications	O
of	O
EACA	Chemical
therapy.	O
These	O
complications	O
have	O
included	O
clinical	O
deterioration	O
and	O
intracranial	Disease
vascular	Disease
thrombosis	Disease
in	O
patients	O
with	O
SAH	Disease
,	O
arteriolar	O
and	O
capillary	O
fibrin	O
thrombi	Disease
in	O
patients	O
with	O
fibrinolytic	O
syndromes	O
treated	O
with	O
EACA	Chemical
,	O
or	O
other	O
thromboembolic	Disease
phenomena	Disease
.	O
Since	O
intravascular	O
fibrin	O
thrombi	Disease
are	O
often	O
observed	O
in	O
patients	O
with	O
fibrinolytic	O
disorders,	O
EACA	Chemical
should	O
not	O
be	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
fibrin	O
thrombi	Disease
in	O
patients	O
with	O
disseminated	Disease
intravascular	Disease
coagulation	Disease
or	O
other	O
"	O
consumption	Disease
coagulopathies	Disease
."	O
This	O
report	O
describes	O
subtotal	O
infarction	Disease
of	O
the	O
kidney	O
due	O
to	O
thrombosis	Disease
of	Disease
a	Disease
normal	Disease
renal	Disease
artery	Disease
.	O
This	O
occlusion	O
occurred	O
after	O
EACA	Chemical
therapy	O
in	O
a	O
patient	O
with	O
SAH	Disease
and	O
histopathological	O
documentation	O
of	O
recurrent	O
SAH	Disease
.	O
The	O
corresponding	O
clinical	O
event	O
was	O
characterized	O
by	O
marked	O
hypertension	Disease

Long-term	O
propranolol	Chemical
therapy	O
in	O
pregnancy:	O
maternal	O
and	O
fetal	O
outcome.	O
Propranolol	Chemical
,	O
a	O
beta-adrenergic	O
blocking	O
agent,	O
has	O
found	O
an	O
important	O
position	O
in	O
the	O
practice	O
of	O
medicine.	O
Its	O
use	O
in	O
pregnancy,	O
however,	O
is	O
an	O
open	O
question	O
as	O
a	O
number	O
of	O
detrimental	O
side	O
effects	O
have	O
been	O
reported	O
in	O
the	O
fetus	O
and	O
neonate.	O
Ten	O
patients	O
and	O
12	O
pregnancies	O
are	O
reported	O
where	O
chronic	O
propranolol	Chemical
has	O
been	O
administered.	O
Five	O
patients	O
with	O
serial	O
pregnancies	O
with	O
and	O
without	O
propranolol	Chemical
therapy	O
are	O
also	O
examined.	O
Maternal,	O
fetal,	O
and	O
neonatal	O
complications	O
are	O
examined.	O
An	O
attempt	O
is	O
made	O
to	O
differentiate	O
drug-related	O
complications	O
from	O
maternal	O
disease--related	O
complications.	O
We	O
conclude	O
that	O
previously	O
reported	O
hypoglycemia	Disease
,	O
hyperbilirubinemia	Disease
,	O
polycythemia	Disease
,	O
neonatal	Disease
apnea	Disease
,	O
and	O
bradycardia	Disease
are	O
not	O
invariable	O
and	O
cannot	O
be	O
statistically	O
correlated	O
with	O
chronic	O
propranolol	Chemical
therapy.	O
Growth	Disease
retardation	Disease

Use	O
of	O
propranolol	Chemical
in	O
the	O
treatment	O
of	O
idiopathic	Disease
orthostatic	Disease
hypotension	Disease
.	O
Five	O
patients	O
with	O
idiopathic	Disease
orthostatic	Disease
hypotension	Disease
who	O
had	O
physiologic	O
and	O
biochemical	O
evidence	O
of	O
severe	O
autonomic	O
dysfunction	O
were	O
included	O
in	O
the	O
study.	O
They	O
all	O
exhibited	O
markedly	O
reduced	O
plasma	O
catecholamines	Chemical
and	O
plasma	O
renin	O
activity	O
in	O
both	O
recumbent	O
and	O
upright	O
positions	O
and	O
had	O
marked	O
hypersensitivity	Disease
to	O
the	O
pressor	O
effects	O
of	O
infused	O
norepinephrine	Chemical
.	O
Treatment	O
with	O
propanolol	Chemical
administered	O
intravenously	O
(1-5	O
mg)	O
produced	O
increases	O
in	O
supine	O
and	O
upright	O
blood	O
pressure	O
in	O
4	O
of	O
the	O
5	O
individuals	O
with	O
rises	O
ranging	O
from	O
11/6	O
to	O
22/11	O
mmHg.	O
Chronic	O
oral	O
administration	O
of	O
propranolol	Chemical
(40-160	O
mg/day)	O
also	O
elevated	O
the	O
blood	O
pressures	O
of	O
these	O
individuals	O
with	O
increases	O
in	O
the	O
order	O
of	O
20-35/15-25	O
mmg	O
being	O
observed.	O
In	O
1	O
patient,	O
marked	O
hypertension	Disease
was	O
induced	O
by	O
propranolol	Chemical
and	O
the	O
drug	O
had	O
to	O
be	O
withdrawn.	O
It	O
otherwise	O
was	O
well	O
tolerated	O
and	O
no	O
important	O
side	O
effects	O
were	O
observed.	O
Treatment	O
has	O
been	O
continued	O
in	O
3	O
individuals	O
for	O
6-13	O
months	O
with	O
persistence	O
of	O
the	O
pressor	O
effect,	O
although	O
there	O
appears	O
to	O
have	O
been	O
some	O
decrease	O
in	O
the	O
degree	O
of	O
response	O
with	O
time.	O
Hemodynamic	O
measurements	O
in	O
1	O
of	O
the	O
patients	O
demonstrated	O
an	O
increase	O
in	O
total	O
peripheral	O
resistance	O
and	O
essentially	O
no	O
change	O
in	O
cardiac	O
output	O
following	O
propranolol	Chemical
therapy.	O
The	O
studies	O
suggest	O
that	O
propranolol	Chemical
is	O
a	O
useful	O
drug	O
in	O
selected	O
patients	O
with	O
severe	O
idiopathic	Disease
orthostatic	Disease
hypotension	Disease

Total	O
intravenous	O
anesthesia	O
with	O
etomidate	Chemical
.	O
III.	O
Some	O
observations	O
in	O
adults.	O
An	O
investigation	O
was	O
undertaken	O
to	O
determine	O
the	O
dosage	O
of	O
etomidate	Chemical
required	O
to	O
maintain	O
sleep	O
in	O
adults	O
undergoing	O
surgery	O
under	O
regional	O
local	O
anesthesia.	O
Premedication	O
of	O
diazepam	Chemical
10	O
mg	O
and	O
atropine	Chemical
0.5	O
mg	O
was	O
given,	O
and	O
sleep	O
was	O
induced	O
and	O
maintained	O
by	O
intermittent	O
intravenous	O
injections	O
of	O
etomidate	Chemical
0.1/mg/kg,	O
given	O
whenever	O
the	O
patient	O
would	O
open	O
his	O
eyes	O
on	O
request.	O
A	O
mean	O
overall	O
dose	O
of	O
etomidate	Chemical
17.4	O
microgram/kg/min.	O
was	O
required	O
to	O
maintain	O
sleep,	O
but	O
great	O
individual	O
variation	O
occurred,	O
with	O
older	O
patients	O
requiring	O
less	O
drug.	O
The	O
investigation	O
was	O
discontinued	O
after	O
18	O
patients	O
because	O
of	O
the	O
frequency	O
and	O
intensity	O
of	O
side-effects,	O
particularly	O
pain	Disease
and	O
myoclonia	Disease
,	O
which	O
caused	O
the	O
technique	O
to	O
be	O
abandoned	O
in	O
two	O
cases.	O
It	O
is	O
considered	O
unlikely	O
that	O
etomidate	Chemical
will	O
prove	O
to	O
be	O
the	O
hypnotic	O
of	O
choice	O
for	O
a	O
totally	O
intravenous	O
anesthetic	O
technique	O
in	O
adults	O
because	O
of	O
the	O
high	O
incidence	O
of	O
myoclonia	Disease

A	O
method	O
for	O
the	O
measurement	O
of	O
tremor	Disease
,	O
and	O
a	O
comparison	O
of	O
the	O
effects	O
of	O
tocolytic	O
beta-mimetics.	O
A	O
method	O
permitting	O
measurement	O
of	O
finger	O
tremor	Disease
as	O
a	O
displacement-time	O
curve	O
is	O
described,	O
using	O
a	O
test	O
system	O
with	O
simple	O
amplitude	O
calibration.	O
The	O
coordinates	O
of	O
the	O
inversion	O
points	O
of	O
the	O
displacement-time	O
curves	O
were	O
transferred	O
through	O
graphical	O
input	O
equipment	O
to	O
punched	O
tape.	O
By	O
means	O
of	O
a	O
computer	O
program,	O
periods	O
and	O
amplitudes	O
of	O
tremor	Disease
oscillations	O
were	O
calculated	O
and	O
classified.	O
The	O
event	O
frequency	O
for	O
each	O
class	O
of	O
periods	O
and	O
amplitudes	O
was	O
determined.	O
The	O
actions	O
of	O
fenoterol-hydrobromide	Chemical
,	O
ritodrin-HCl	Chemical
and	O
placebo	O
given	O
to	O
10	O
healthy	O
subjects	O
by	O
intravenous	O
infusion	O
in	O
a	O
double-blind	O
crossover	O
study	O
were	O
tested	O
by	O
this	O
method.	O
At	O
therapeutic	O
doses	O
both	O
substances	O
raised	O
the	O
mean	O
tremor	Disease
amplitude	O
to	O
about	O
three	O
times	O
the	O
control	O
level.	O
At	O
the	O
same	O
time,	O
the	O
mean	O
period	O
within	O
each	O
class	O
of	O
amplitudes	O
shortened	O
by	O
10--20	O
ms,	O
whereas	O
the	O
mean	O
periods	O
calculated	O
from	O
all	O
oscillations	O
together	O
did	O
not	O
change	O
significantly.	O
After	O
the	O
end	O
of	O
fenoterol-hydrobromide	Chemical
infusion,	O
tremor	Disease
amplitudes	O
decreased	O
significantly	O
faster	O
than	O
those	O
following	O
ritodrin-HCl	Chemical

Bilateral	O
retinal	Disease
artery	Disease
and	Disease
choriocapillaris	Disease
occlusion	Disease
following	O
the	O
injection	O
of	O
long-acting	O
corticosteroid	Chemical
suspensions	O
in	O
combination	O
with	O
other	O
drugs:	O
I.	O
Clinical	O
studies.	O
Two	O
well-documented	O
cases	O
of	O
bilateral	O
retinal	Disease
artery	Disease
and	Disease
choriocapillaris	Disease
occlusions	Disease
with	O
blindness	Disease
following	O
head	O
and	O
neck	O
soft-tissue	O
injection	O
with	O
methylprednisolone	Chemical
acetate	Chemical
in	O
combination	O
with	O
lidocaine	Chemical
,	O
epinephrine	Chemical
,	O
or	O
penicillin	Chemical
are	O
reported.	O
One	O
case	O
had	O
only	O
a	O
unilateral	O
injection.	O
The	O
acute	O
observations	O
included	O
hazy	O
sensorium,	O
superior	O
gaze	O
palsy	Disease
,	O
pupillary	Disease
abnormalities	Disease
,	O
and	O
conjunctival	O
hemorrhages	Disease
with	O
edema	Disease
.	O
Follow-up	O
changes	O
showed	O
marked	O
visual	Disease
loss	Disease
,	O
constricted	O
visual	O
fields,	O
optic	O
nerve	O
pallor,	O
vascular	O
attenuation,	O
and	O
chorioretinal	Disease
atrophy	Disease

Cephalothin	Chemical
-induced	O
immune	O
hemolytic	Disease
anemia	Disease
.	O
A	O
patient	O
with	O
renal	Disease
disease	Disease
developed	O
Coombs-positive	O
hemolytic	Disease
anemia	Disease
while	O
receiving	O
cephalothin	Chemical
therapy.	O
An	O
anti-	O
cephalothin	Chemical
IgG	O
antibody	O
was	O
detected	O
in	O
the	O
patient's	O
serum	O
and	O
in	O
the	O
eluates	O
from	O
her	O
erythrocytes.	O
In	O
addition,	O
nonimmunologic	O
binding	O
of	O
normal	O
and	O
patient's	O
serum	O
proteins	O
to	O
her	O
own	O
and	O
cephalothin	Chemical
-coated	O
normal	O
red	O
cells	O
was	O
demonstrated.	O
Skin	O
tests	O
and	O
in	O
vitro	O
lymphocyte	O
stimulation	O
revealed	O
that	O
the	O
patient	O
was	O
sensitized	O
to	O
cephalothin	Chemical
and	O
also	O
to	O
ampicillin	Chemical
.	O
Careful	O
investigation	O
of	O
drug-induced	O
hemolytic	Disease
anemias	Disease

Kaliuretic	O
effect	O
of	O
L-dopa	Chemical
treatment	O
in	O
parkinsonian	Disease
patients.	O
Hypokalemia	Disease
,	O
sometimes	O
severe,	O
was	O
observed	O
in	O
some	O
L-dopa	Chemical
-treated	O
parkinsonian	Disease
patients.	O
The	O
influence	O
of	O
L-dopa	Chemical
on	O
the	O
renal	O
excretion	O
of	O
potassium	Chemical
was	O
studied	O
in	O
3	O
patients	O
with	O
hypokalemia	Disease
and	O
in	O
5	O
normokalemic	O
patients	O
by	O
determination	O
of	O
renal	O
plasma	O
flow,	O
glomerular	O
filtration	O
rate,	O
plasma	O
concentration	O
of	O
potassium	Chemical
and	O
sodium	Chemical
as	O
well	O
as	O
urinary	O
excretion	O
of	O
potassium	Chemical
,	O
sodium	Chemical
and	O
aldosterone	Chemical
.	O
L-Dopa	Chemical
intake	O
was	O
found	O
to	O
cause	O
an	O
increased	O
excretion	O
of	O
potassium	Chemical
,	O
and	O
sometimes	O
also	O
of	O
sodium	Chemical
,	O
in	O
the	O
hypokalemic	O
but	O
not	O
in	O
the	O
normokalemic	O
patients.	O
This	O
effect	O
on	O
the	O
renal	O
function	O
could	O
be	O
prohibited	O
by	O
the	O
administration	O
of	O
a	O
peripheral	O
dopa	O
decarbodylase	O
inhibitor.	O
It	O
is	O
not	O
known	O
why	O
this	O
effect	O
occurred	O
in	O
some	O
individuals	O
but	O
not	O
in	O
others,	O
but	O
our	O
results	O
indicate	O
a	O
correlation	O
between	O
aldosterone	Chemical
production	O
and	O
this	O
renal	O
effect	O
of	O
L-dopa	Chemical

Phenytoin	Chemical
	O
encephalopathy	Disease
as	O
probable	O
idiosyncratic	O
reaction:	O
case	O
report.	O
A	O
case	O
of	O
phenytoin	Chemical
(	O
DPH	Chemical
)	O
encephalopathy	Disease
with	O
increasing	O
seizures	Disease
and	O
EEG	O
and	O
mental	O
changes	O
is	O
described.	O
Despite	O
adequate	O
oral	O
dosage	O
of	O
DPH	Chemical
(5	O
mg/kg/daily)	O
the	O
plasma	O
level	O
was	O
very	O
low	O
(2.8	O
microgramg/ml).	O
The	O
encephalopathy	Disease
was	O
probably	O
an	O
idiosyncratic	O
and	O
not	O
toxic	O
or	O
allergic	O
reaction.	O
In	O
fact	O
the	O
concentration	O
of	O
free	O
DPH	Chemical
was	O
normal,	O
the	O
patient	O
presented	O
a	O
retarded	O
morbilliform	O
rash	Disease
during	O
DPH	Chemical
treatment,	O
the	O
protidogram	O
was	O
normal,	O
and	O
an	O
intradermic	O
DPH	Chemical
injection	O
had	O
no	O
local	O
effect.	O
The	O
authors	O
conclude	O
that	O
in	O
a	O
patient	O
starting	O
DPH	Chemical
treatment	O
an	O
unexpected	O
increase	O
in	O
seizures	Disease
,	O
with	O
EEG	O
and	O
mental	O
changes	O
occurring	O
simultaneously,	O
should	O
alert	O
the	O
physician	O
to	O
the	O
possible	O
need	O
for	O
eliminating	O
DPH	Chemical

Effects	O
of	O
exercise	O
on	O
the	O
severity	O
of	O
isoproterenol	Chemical
-induced	O
myocardial	Disease
infarction	Disease
.	O
The	O
effect	O
of	O
exercise	O
on	O
the	O
severity	O
of	O
isoproterenol	Chemical
-induced	O
myocardial	Disease
infarction	Disease
was	O
studied	O
in	O
male	O
rats.	O
Ninety-three	O
rats	O
were	O
randomly	O
divided	O
into	O
three	O
groups.	O
The	O
exercise-	O
isoproterenol	Chemical
(E-1)	O
and	O
exercise	O
control	O
(EC)	O
groups	O
exercised	O
daily	O
for	O
thirty	O
days	O
on	O
a	O
treadmill	O
at	O
1	O
mph,	O
2%	O
grade	O
while	O
animals	O
of	O
the	O
sedentary-	O
isoproterenol	Chemical
(S-I)	O
group	O
remained	O
sedentary.	O
Eight	O
animals	O
were	O
assigned	O
to	O
the	O
sedentary	O
control	O
(SC)	O
group	O
which	O
remained	O
sedentary	O
throughout	O
the	O
experimental	O
period.	O
Forty-eight	O
hours	O
after	O
the	O
final	O
exercise	O
period,	O
S-I	O
and	O
E-I	O
animals	O
received	O
a	O
single	O
subcutaneous	O
injection	O
of	O
isoproterenol	Chemical
(250	O
mg/kg	O
body	O
weight).	O
Animals	O
of	O
the	O
S-I	O
group	O
exhibited	O
significantly	O
(Pp	O
less	O
than	O
0.05)	O
greater	O
mortality	O
from	O
the	O
effects	O
of	O
isoproterenol	Chemical
than	O
animals	O
of	O
the	O
E-I	O
group.	O
Serum	O
CPK	O
activity	O
for	O
E-I	O
animals	O
was	O
significantly	O
(p	O
less	O
than	O
0.05)	O
greater	O
than	O
for	O
animals	O
in	O
the	O
S-I	O
and	O
EC	O
groups	O
twenty	O
hours	O
following	O
isoproterenol	Chemical
injection.	O
No	O
statistically	O
significant	O
differences	O
were	O
observed	O
between	O
the	O
two	O
isoproterenol	Chemical
treated	O
groups	O
for	O
severity	O
of	O
the	O
induced	O
lesions,	O
changes	O
in	O
heart	O
weight,	O
or	O
heart	O
weight	O
to	O
body	O
weight	O
ratios.	O
The	O
results	O
indicated	O
that	O
exercise	O
reduced	O
the	O
mortality	O
associated	O
with	O
the	O
effects	O
of	O
large	O
dosages	O
of	O
isoproterenol	Chemical
but	O
had	O
little	O
on	O
the	O
severity	O
of	O
the	O
infarction	Disease

Effect	O
of	O
D-Glucarates	Chemical
on	O
basic	O
antibiotic-induced	O
renal	Disease
damage	Disease
in	O
rats.	O
Dehydrated	Disease
rats	O
regularly	O
develop	O
acute	Disease
renal	Disease
failure	Disease
following	O
single	O
injection	O
of	O
aminoglycoside	Chemical
antibiotics	O
combined	O
with	O
dextran	O
or	O
of	O
antibiotics	O
only.	O
Oral	O
administration	O
of	O
2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone	Chemical
protected	O
rats	O
against	O
renal	Disease
failure	Disease
induced	O
by	O
kanamycin	Chemical
-dextran.	O
The	O
protective	O
effect	O
was	O
prevalent	O
among	O
D-glucarates	Chemical
,	O
and	O
also	O
to	O
other	O
saccharic	Chemical
acid	Chemical
,	O
hexauronic	Chemical
acids	Chemical
and	O
hexaaldonic	Chemical
acids	Chemical
,	O
although	O
to	O
a	O
lesser	O
degree,	O
but	O
not	O
to	O
a	O
hexaaldose,	O
sugar	Chemical
alcohols	Chemical
,	O
substances	O
inthe	O
TCA	Chemical
cycle	O
and	O
other	O
acidic	O
compounds.	O
D-Glucarates	Chemical
were	O
effective	O
against	O
renal	Disease
damage	Disease
induced	O
by	O
peptide	O
antibiotics	O
as	O
well	O
as	O
various	O
aminoglycoside	Chemical
antibitocis.	O
Dose-responses	O
were	O
observed	O
in	O
the	O
protective	O
effect	O
of	O
D-Glucarates	Chemical
.	O
With	O
a	O
D-glucarate	Chemical
of	O
a	O
fixed	O
size	O
of	O
dose,	O
approximately	O
the	O
same	O
degree	O
of	O
protection	O
was	O
obtained	O
against	O
renal	Disease
damages	Disease
induced	O
by	O
different	O
basic	O
antibiotics	O
despite	O
large	O
disparities	O
in	O
administration	O
doses	O
of	O
different	O
antibiotics.	O
D-Glucarates	Chemical
had	O
the	O
ability	O
to	O
prevent	O
renal	Disease
damage	Disease
but	O
not	O
to	O
cure	O
it.	O
Rats	O
excreted	O
acidic	O
urine	O
when	O
they	O
were	O
spared	O
from	O
renal	Disease
lesions	Disease
by	O
monosaccharides	Chemical
.	O
The	O
reduction	O
effect	O
of	O
D-glucarates	Chemical
against	O
nephrotoxicity	Disease

Paraplegia	Disease
following	O
intrathecal	O
methotrexate	Chemical
:	O
report	O
of	O
a	O
case	O
and	O
review	O
of	O
the	O
literature.	O
A	O
patient	O
who	O
developed	O
paraplegia	Disease
following	O
the	O
intrathecal	O
instillation	O
of	O
methotrexate	Chemical
is	O
discribed.	O
The	O
ten	O
previously	O
reported	O
cases	O
of	O
this	O
unusual	O
complication	O
are	O
reviewed.	O
The	O
following	O
factors	O
appear	O
to	O
predispose	O
to	O
the	O
development	O
of	O
this	O
complication:	O
abnormal	O
cerebrospinal	O
dynamics	O
related	O
to	O
the	O
presence	O
of	O
central	Disease
nervous	Disease
system	Disease
leukemia	Disease
,	O
and	O
epidural	O
cerebrospinal	O
leakage;	O
elevated	O
cerebrospinal	O
fluid	O
methothexate	Chemical
concentration	O
related	O
to	O
abnormal	O
cerebrospinal	O
fluid	O
dynamics	O
and	O
to	O
inappropriately	O
high	O
methotrexate	Chemical
doses	O
based	O
on	O
body	O
surface	O
area	O
calculations	O
in	O
older	O
children	O
and	O
adults;	O
the	O
presence	O
of	O
neurotoxic	Disease
preservatives	O
in	O
commercially	O
available	O
methotrexate	Chemical
preparations	O
and	O
diluents;	O
and	O
the	O
use	O
of	O
methotrexate	Chemical
diluents	O
of	O
unphysiologic	O
pH,	O
ionic	O
content	O
and	O
osmolarity.	O
The	O
role	O
of	O
methotrexate	Chemical
contaminants,	O
local	O
folate	Disease
deficiency	Disease
,	O
and	O
cranial	O
irradiation	O
in	O
the	O
pathogenesis	O
of	O
intrathecal	O
methotrexate	Chemical
	O
toxicity	Disease
is	O
unclear.	O
The	O
incidence	O
of	O
neurotoxicity	Disease
may	O
be	O
reduced	O
by	O
employing	O
lower	O
doses	O
of	O
methotrexate	Chemical
in	O
the	O
presence	O
of	O
central	Disease
nervous	Disease
system	Disease
leukemia	Disease
,	O
in	O
older	O
children	O
and	O
adults,	O
and	O
in	O
the	O
presence	O
of	O
epidural	O
leakage.	O
Only	O
preservative-free	O
methotrexate	Chemical
in	O
Elliott's	O
B	O
Solution	O
at	O
a	O
concentration	O
of	O
not	O
more	O
than	O
1	O
mg/ml	O
should	O
be	O
used	O
for	O
intrathecal	O
administration.	O
Periodic	O
monitoring	O
of	O
cerebruspinal	O
fluid	O
methotrexate	Chemical
levels	O
may	O
be	O
predictive	O
of	O
the	O
development	O
of	O
serious	O
neurotoxicity	Disease

Centrally	O
mediated	O
cardiovascular	O
effects	O
of	O
intracisternal	O
application	O
of	O
carbachol	Chemical
in	O
anesthetized	O
rats.	O
The	O
pressor	O
response	O
to	O
the	O
intracisternal	O
(i.c.)	O
injection	O
of	O
carbachol	Chemical
(1	O
mug)	O
in	O
anesthetized	O
rats	O
was	O
analyzed.	O
This	O
response	O
was	O
significantly	O
reduced	O
by	O
the	O
intravenous	O
(i.v.)	O
injection	O
of	O
guanethidine	Chemical
(5	O
mg),	O
hexamethonium	Chemical
(10	O
mg)	O
or	O
phentolamine	Chemical
(5	O
mg),	O
and	O
conversely,	O
potentiated	O
by	O
i.v.	O
desmethylimipramine	Chemical
(0.3	O
mg),	O
while	O
propranolol	Chemical
(0.5	O
mg)	O
i.v.	O
selectively	O
inhibited	O
the	O
enlargement	Disease
of	Disease
pulse	Disease
pressure	Disease
and	O
the	O
tachycardia	Disease
following	O
i.c.	O
carbachol	Chemical
(1	O
mug).	O
On	O
the	O
other	O
hand,	O
the	O
pressor	O
response	O
to	O
i.c.	O
carbachol	Chemical
(1	O
mug)	O
was	O
almost	O
completely	O
blocked	O
by	O
i.c.	O
atropine	Chemical
(3	O
mug)	O
or	O
hexamethonium	Chemical
(500	O
mug),	O
and	O
significantly	O
reduced	O
by	O
i.c.	O
chlorpromazine	Chemical
(50	O
mug)	O
but	O
significantly	O
potentiated	O
by	O
i.c.	O
desmethylimipramine	Chemical
(30	O
mug).	O
The	O
pressor	O
response	O
to	O
i.c.	O
carbachol	Chemical
(1	O
mug)	O
remained	O
unchanged	O
after	O
sectioning	O
of	O
the	O
bilateral	O
cervical	O
vagal	O
nerves	O
but	O
disappeared	O
after	O
sectioning	O
of	O
the	O
spinal	O
cord	O
(C7-C8).	O
From	O
the	O
above	O
result	O
it	O
is	O
suggested	O
that	O
the	O
pressor	O
response	O
to	O
i.c.	O
carbachol	Chemical

Hyperglycemic	Disease
effect	O
of	O
amino	Chemical
compounds	O
structurally	O
related	O
to	O
caproate	Chemical
in	O
rats.	O
The	O
chronic	O
feeding	O
of	O
small	O
amounts	O
(0.3-3%	O
of	O
diet	O
weight)	O
of	O
certain	O
amino	Chemical
derivatives	O
of	O
caproate	Chemical
resulted	O
in	O
hyperglycemia	Disease
,	O
an	O
elevated	O
glucose	Chemical
tolerance	O
curve	O
and,	O
occasionally,	O
glucosuria	Disease
.	O
Effective	O
compounds	O
included	O
norleucine	Chemical
,	O
norvaline	Chemical
,	O
glutamate	Chemical
,	O
epsilon-aminocaproate	Chemical
,	O
methionine	Chemical
,	O
and	O
leucine	Chemical

Fatty	Disease
liver	Disease
induced	O
by	O
tetracycline	Chemical
in	O
the	O
rat.	O
Dose-response	O
relationships	O
and	O
effect	O
of	O
sex.	O
Dose-response	O
relationships,	O
biochemical	O
mechanisms,	O
and	O
sex	O
differences	O
in	O
the	O
experimental	O
fatty	Disease
liver	Disease
induced	O
by	O
tetracycline	Chemical
were	O
studied	O
in	O
the	O
intact	O
rat	O
and	O
with	O
the	O
isolated	O
perfused	O
rat	O
liver	O
in	O
vitro.	O
In	O
the	O
intact	O
male	O
and	O
female	O
rat,	O
no	O
direct	O
relationship	O
was	O
observed	O
between	O
dose	O
of	O
tetracycline	Chemical
and	O
hepatic	O
accumulation	O
of	O
triglyceride	Chemical
.	O
With	O
provision	O
of	O
adequate	O
oleic	Chemical
acid	Chemical
as	O
a	O
substrate	O
for	O
the	O
isolated	O
perfused	O
liver,	O
a	O
direct	O
relationship	O
was	O
observed	O
between	O
dose	O
of	O
tetracycline	Chemical
and	O
both	O
accumulation	O
of	O
triglyceride	Chemical
in	O
the	O
liver	O
and	O
depression	Disease
of	O
output	O
of	O
triglyceride	Chemical
by	O
livers	O
from	O
male	O
and	O
female	O
rats.	O
Marked	O
differences	O
were	O
observed	O
between	O
female	O
and	O
male	O
rats	O
with	O
regard	O
to	O
base	O
line	O
(control)	O
hepatic	O
concentration	O
of	O
triglyceride	Chemical
and	O
output	O
of	O
triglyceride	Chemical
.	O
Accumulation	O
of	O
hepatic	O
triglyceride	Chemical
,	O
as	O
a	O
per	O
cent	O
of	O
control	O
values,	O
in	O
response	O
to	O
graded	O
doses	O
of	O
tetracycline	Chemical
,	O
did	O
not	O
differ	O
significantly	O
between	O
male,	O
female	O
and	O
pregnant	O
rat	O
livers.	O
However,	O
livers	O
from	O
female,	O
and	O
especially	O
pregnant	O
female	O
rats,	O
were	O
strikingly	O
resistant	O
to	O
the	O
effects	O
of	O
tetracycline	Chemical
on	O
depression	Disease
of	O
output	O
of	O
triglyceride	Chemical
under	O
these	O
experimental	O
conditions.	O
These	O
differences	O
between	O
the	O
sexes	O
could	O
not	O
be	O
related	O
to	O
altered	O
disposition	O
of	O
tetracycline	Chemical
or	O
altered	O
uptake	O
of	O
oleic	Chemical
acid	Chemical
.	O
Depressed	O
hepatic	O
secretion	O
of	O
triglyceride	Chemical
accounted	O
only	O
for	O
30	O
to	O
50%	O
of	O
accumulated	O
hepatic	O
triglyceride	Chemical
,	O
indicating	O
that	O
additional	O
mechanisms	O
must	O
be	O
involved	O
in	O
the	O
production	O
of	O
the	O
triglyceride	Chemical
-rich	O
fatty	Disease
liver	Disease
in	O
response	O
to	O
tetracycline	Chemical

Fatal	O
myeloencephalopathy	Disease
due	O
to	O
intrathecal	O
vincristine	Chemical
administration.	O
Vincristine	Chemical
was	O
accidentally	O
given	O
intrathecally	O
to	O
a	O
child	O
with	O
leukaemia	Disease
,	O
producing	O
sensory	Disease
and	Disease
motor	Disease
dysfunction	Disease
followed	O
by	O
encephalopathy	Disease
and	O
death.	O
Separate	O
times	O
for	O
administering	O
vincristine	Chemical

Progesterone	Chemical
potentiation	O
of	O
bupivacaine	Chemical
arrhythmogenicity	O
in	O
pentobarbital	Chemical
-anesthetized	O
rats	O
and	O
beating	O
rat	O
heart	O
cell	O
cultures.	O
The	O
effects	O
of	O
progesterone	Chemical
treatment	O
on	O
bupivacaine	Chemical
arrhythmogenicity	O
in	O
beating	O
rat	O
heart	O
myocyte	O
cultures	O
and	O
on	O
anesthetized	O
rats	O
were	O
determined.	O
After	O
determining	O
the	O
bupivacaine	Chemical
AD50	O
(the	O
concentration	O
of	O
bupivacaine	Chemical
that	O
caused	O
50%	O
of	O
all	O
beating	O
rat	O
heart	O
myocyte	O
cultures	O
to	O
become	O
arrhythmic	Disease
),	O
we	O
determined	O
the	O
effect	O
of	O
1-hour	O
progesterone	Chemical
	O
HCl	Chemical
exposure	O
on	O
myocyte	O
contractile	O
rhythm.	O
Each	O
concentration	O
of	O
progesterone	Chemical
(6.25,	O
12.5,	O
25,	O
and	O
50	O
micrograms/ml)	O
caused	O
a	O
significant	O
and	O
concentration-dependent	O
reduction	O
in	O
the	O
AD50	O
for	O
bupivacaine	Chemical
.	O
Estradiol	Chemical
treatment	O
also	O
increased	O
the	O
arrhythmogenicity	O
of	O
bupivacaine	Chemical
in	O
myocyte	O
cultures,	O
but	O
was	O
only	O
one	O
fourth	O
as	O
potent	O
as	O
progesterone	Chemical
.	O
Neither	O
progesterone	Chemical
nor	O
estradiol	Chemical
effects	O
on	O
bupivacaine	Chemical
arrhythmogenicity	O
were	O
potentiated	O
by	O
epinephrine	Chemical
.	O
Chronic	O
progesterone	Chemical
pretreatment	O
(5	O
mg/kg/day	O
for	O
21	O
days)	O
caused	O
a	O
significant	O
increase	O
in	O
bupivacaine	Chemical
arrhythmogenicity	O
in	O
intact	O
pentobarbital	Chemical
-anesthetized	O
rats.	O
There	O
was	O
a	O
significant	O
decrease	O
in	O
the	O
time	O
to	O
onset	O
of	O
arrhythmia	Disease
as	O
compared	O
with	O
control	O
nonprogesterone-treated	O
rats	O
(6.2	O
+/-	O
1.3	O
vs.	O
30.8	O
+/-	O
2.5	O
min,	O
mean	O
+/-	O
SE).	O
The	O
results	O
of	O
this	O
study	O
indicate	O
that	O
progesterone	Chemical
can	O
potentiate	O
bupivacaine	Chemical
arrhythmogenicity	O
both	O
in	O
vivo	O
and	O
in	O
vitro.	O
Potentiation	O
of	O
bupivacaine	Chemical
	O
arrhythmia	Disease

Acute	Disease
renal	Disease
failure	Disease
occurring	O
during	O
intravenous	O
desferrioxamine	Chemical
therapy:	O
recovery	O
after	O
haemodialysis.	O
A	O
patient	O
with	O
transfusion-dependent	O
thalassemia	Disease
was	O
undergoing	O
home	O
intravenous	O
desferrioxamine	Chemical
(	O
DFX	Chemical
)	O
treatment	O
by	O
means	O
of	O
a	O
totally	O
implanted	O
system	O
because	O
of	O
his	O
poor	O
compliance	O
with	O
the	O
nightly	O
subcutaneous	O
therapy.	O
Due	O
to	O
an	O
accidental	O
malfunctioning	O
of	O
the	O
infusion	O
pump,	O
the	O
patient	O
was	O
inadvertently	O
administered	O
a	O
toxic	O
dosage	O
of	O
the	O
drug	O
which	O
caused	O
renal	Disease
insufficiency	Disease
.	O
Given	O
the	O
progressive	O
deterioration	O
of	O
the	O
symptoms	O
and	O
of	O
the	O
laboratory	O
values,	O
despite	O
adequate	O
medical	O
treatment,	O
a	O
decision	O
was	O
made	O
to	O
introduce	O
haemodialytical	O
therapy	O
in	O
order	O
to	O
remove	O
the	O
drug	O
and	O
therapy	O
reduce	O
the	O
nephrotoxicity	Disease
.	O
From	O
the	O
results	O
obtained,	O
haemodialysis	O
can	O
therefore	O
be	O
suggested	O
as	O
a	O
useful	O
therapy	O
in	O
rare	O
cases	O
of	O
progressive	O
acute	Disease
renal	Disease
failure	Disease
caused	O
by	O
desferrioxamine	Chemical

Neuroleptic	Chemical
-associated	O
hyperprolactinemia	Disease
.	O
Can	O
it	O
be	O
treated	O
with	O
bromocriptine	Chemical
?	O
Six	O
stable	O
psychiatric	O
outpatients	O
with	O
hyperprolactinemia	Disease
and	O
amenorrhea	Disease
/	O
oligomenorrhea	Disease
associated	O
with	O
their	O
neuroleptic	Chemical
medications	Chemical
were	O
treated	O
with	O
bromocriptine	Chemical
.	O
Daily	O
dosages	O
of	O
5-10	O
mg	O
corrected	O
the	O
hyperprolactinemia	Disease
and	O
restored	O
menstruation	O
in	O
four	O
of	O
the	O
six	O
patients.	O
One	O
woman,	O
however,	O
developed	O
worsened	O
psychiatric	Disease
symptoms	Disease
while	O
taking	O
bromocriptine	Chemical
,	O
and	O
it	O
was	O
discontinued.	O
Thus,	O
three	O
of	O
six	O
patients	O
had	O
their	O
menstrual	O
irregularity	O
successfully	O
corrected	O
with	O
bromocriptine	Chemical
.	O
This	O
suggests	O
that	O
bromocriptine	Chemical
should	O
be	O
further	O
evaluated	O
as	O
potential	O
therapy	O
for	O
neuroleptic	Chemical
-associated	O
hyperprolactinemia	Disease
and	O
amenorrhea	Disease
/	O
galactorrhea	Disease

Ethacrynic	Chemical
acid	Chemical
-induced	O
convulsions	Disease
and	O
brain	O
neurotransmitters	O
in	O
mice.	O
Intracerebroventricular	O
injection	O
of	O
ethacrynic	Chemical
acid	Chemical
(50%	O
convulsive	Disease
dose;	O
50	O
micrograms/mouse)	O
accelerated	O
the	O
synthesis/turnover	O
of	O
5-hydroxytryptamine	Chemical
(	O
5-HT	Chemical
)	O
but	O
suppressed	O
the	O
synthesis	O
of	O
gamma-aminobutyric	Chemical
acid	Chemical
and	O
acetylcholine	Chemical
in	O
mouse	O
brain.	O
These	O
effects	O
were	O
completely	O
antagonized	O
by	O
pretreatment	O
with	O
a	O
glutamate	Chemical
/	O
N-methyl-D-aspartate	Chemical
antagonist,	O
aminophosphonovaleric	Chemical
acid	Chemical
.	O
In	O
ethacrynic	Chemical
acid	Chemical
-induced	O
convulsions	Disease

Pharmacology	O
of	O
gamma-aminobutyric	Chemical
acid	Chemical
A	O
receptor	O
complex	O
after	O
the	O
in	O
vivo	O
administration	O
of	O
the	O
anxioselective	O
and	O
anticonvulsant	O
beta-carboline	Chemical
derivative	O
abecarnil	Chemical
.	O
In	O
rodents,	O
the	O
effect	O
of	O
the	O
beta-carboline	Chemical
derivative	O
isopropyl-6-	Chemical
benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylate	Chemical
(	O
abecarrnil	Chemical
),	O
a	O
new	O
ligand	O
for	O
benzodiazepine	Chemical
receptors	O
possessing	O
anxiolytic	O
and	O
anticonvulsant	O
properties,	O
was	O
evaluated	O
on	O
the	O
function	O
of	O
central	O
gamma-aminobutyric	Chemical
acid	Chemical
(	O
GABA	Chemical
)A	O
receptor	O
complex,	O
both	O
in	O
vitro	O
and	O
in	O
vivo.	O
Added	O
in	O
vitro	O
to	O
rat	O
cortical	O
membrane	O
preparation,	O
abecarnil	Chemical
increased	O
[3H]	O
GABA	Chemical
binding,	O
enhanced	O
muscimol	Chemical
-stimulated	O
36Cl-	O
uptake	O
and	O
reduced	O
the	O
binding	O
of	O
t-[35S]butylbicyclophosphorothionate	Chemical
(	O
[35S]TBPS	Chemical
).	O
These	O
effects	O
were	O
similar	O
to	O
those	O
induced	O
by	O
diazepam	Chemical
,	O
whereas	O
the	O
partial	O
agonist	O
Ro	Chemical
16-6028	Chemical
(	O
tert-butyl-(S)-8-bromo-11,12,13,13a-tetrahydro-9-oxo-9H-	Chemical
imidazo[1,5-a]-pyrrolo-[2,1-c][1,4]benzodiazepine-1-carboxylate	Chemical
)	O
showed	O
very	O
weak	O
efficacy	O
in	O
these	O
biochemical	O
tests.	O
After	O
i.p.	O
injection	O
to	O
rats,	O
abecarnil	Chemical
and	O
diazepam	Chemical
decreased	O
in	O
a	O
time-dependent	O
and	O
dose-related	O
(0.25-20	O
mg/kg	O
i.p.)	O
manner	O
[35S]TBPS	Chemical
binding	O
measured	O
ex	O
vivo	O
in	O
the	O
cerebral	O
cortex.	O
Moreover,	O
both	O
drugs	O
at	O
the	O
dose	O
of	O
0.5	O
mg/kg	O
antagonized	O
completely	O
the	O
convulsant	O
activity	O
and	O
the	O
increase	O
of	O
[35S]TBPS	Chemical
binding	O
induced	O
by	O
isoniazide	Chemical
(350	O
mg/kg	O
s.c.)	O
as	O
well	O
as	O
the	O
increase	O
of	O
[35S]TBPS	Chemical
binding	O
induced	O
by	O
foot-shock	O
stress.	O
To	O
better	O
correlate	O
the	O
biochemical	O
and	O
the	O
pharmacological	O
effects,	O
we	O
studied	O
the	O
action	O
of	O
abecarnil	Chemical
on	O
[35S]TBPS	Chemical
binding,	O
exploratory	O
motility	O
and	O
on	O
isoniazid	Chemical
-induced	O
biochemical	O
and	O
pharmacological	O
effects	O
in	O
mice.	O
In	O
these	O
animals,	O
abecarnil	Chemical
produced	O
a	O
paralleled	O
dose-dependent	O
(0.05-1	O
mg/kg	O
i.p.)	O
reduction	O
of	O
both	O
motor	O
behavior	O
and	O
cortical	O
[35S]TBPS	O
binding.	O
Moreover,	O
0.05	O
mg/kg	O
of	O
this	O
beta-carboline	Chemical
reduced	O
markedly	O
the	O
increase	O
of	O
[35S]TBPS	Chemical
binding	O
and	O
the	O
convulsions	Disease
induced	O
by	O
isoniazid	Chemical

Recurrent	O
myocardial	Disease
infarction	Disease
in	O
a	O
postpartum	O
patient	O
receiving	O
bromocriptine	Chemical
.	O
Myocardial	Disease
infarction	Disease
in	O
puerperium	O
is	O
infrequently	O
reported.	O
Spasm	Disease
,	O
coronary	O
dissection,	O
or	O
atheromatous	O
etiology	O
has	O
been	O
described.	O
Bromocriptine	Chemical
has	O
been	O
implicated	O
in	O
several	O
previous	O
case	O
reports	O
of	O
myocardial	Disease
infarction	Disease
in	O
the	O
puerperium.	O
Our	O
case	O
(including	O
an	O
inadvertent	O
rechallenge)	O
suggests	O
such	O
a	O
relationship.	O
Although	O
generally	O
regarded	O
as	O
"safe,"	O
possible	O
serious	O
cardiac	O
effects	O
of	O
bromocriptine	Chemical

Asterixis	Disease
induced	O
by	O
carbamazepine	Chemical
therapy.	O
There	O
are	O
very	O
few	O
reports	O
about	O
asterixis	Disease
as	O
a	O
side	O
effect	O
of	O
treatment	O
with	O
psychopharmacologic	O
agents.	O
In	O
this	O
report	O
we	O
present	O
four	O
patients	O
treated	O
with	O
a	O
combination	O
of	O
different	O
psychotropic	O
drugs,	O
in	O
whom	O
asterixis	Disease
was	O
triggered	O
either	O
by	O
adding	O
carbamazepine	Chemical
(	O
CBZ	Chemical
)	O
to	O
a	O
treatment	O
regimen,	O
or	O
by	O
increasing	O
its	O
dosage.	O
Neither	O
dosage	O
nor	O
serum	O
levels	O
of	O
CBZ	Chemical
were	O
in	O
a	O
higher	O
range.	O
We	O
consider	O
asterixis	Disease
to	O
be	O
an	O
easily	O
overlooked	O
sign	O
of	O
neurotoxicity	Disease
,	O
which	O
may	O
occur	O
even	O
at	O
low	O
or	O
moderate	O
dosage	O
levels,	O
if	O
certain	O
drugs	O
as	O
lithium	Chemical
or	O
clozapine	Chemical
are	O
used	O
in	O
combination	O
with	O
CBZ	Chemical

Pharmacodynamics	O
of	O
the	O
hypotensive	Disease
effect	O
of	O
levodopa	Chemical
in	O
parkinsonian	Disease
patients.	O
Blood	O
pressure	O
effects	O
of	O
i.v.	O
levodopa	Chemical
were	O
examined	O
in	O
parkinsonian	Disease
patients	O
with	O
stable	O
and	O
fluctuating	O
responses	O
to	O
levodopa	Chemical
.	O
The	O
magnitude	O
of	O
the	O
hypotensive	Disease
effect	O
of	O
levodopa	Chemical
was	O
concentration	O
dependent	O
and	O
was	O
fit	O
to	O
an	O
Emax	O
model	O
in	O
fluctuating	O
responders.	O
Stable	O
responders	O
demonstrated	O
a	O
small	O
hypotensive	Disease
response.	O
Baseline	O
blood	O
pressures	O
were	O
higher	O
in	O
fluctuating	O
patients;	O
a	O
higher	O
baseline	O
blood	O
pressure	O
correlated	O
with	O
greater	O
hypotensive	Disease
effects.	O
Antiparkinsonian	O
effects	O
of	O
levodopa	Chemical
temporally	O
correlated	O
with	O
blood	O
pressure	O
changes.	O
Phenylalanine	Chemical
,	O
a	O
large	O
neutral	O
amino	Chemical
acid	Chemical
(LNAA)	O
competing	O
with	O
levodopa	Chemical
for	O
transport	O
across	O
the	O
blood-brain	O
barrier,	O
reduced	O
the	O
hypotensive	Disease
and	O
antiparkinsonian	O
effects	O
of	O
levodopa	Chemical
.	O
We	O
conclude	O
that	O
levodopa	Chemical
has	O
a	O
central	O
hypotensive	Disease
action	O
that	O
parallels	O
the	O
motor	O
effects	O
in	O
fluctuating	O
patients.	O
The	O
hypotensive	Disease

Syndrome	Disease
of	Disease
inappropriate	Disease
secretion	Disease
of	Disease
antidiuretic	Disease
hormone	Disease
after	O
infusional	O
vincristine	Chemical
.	O
A	O
77-year-old	O
woman	O
with	O
refractory	O
multiple	Disease
myeloma	Disease
was	O
treated	O
with	O
a	O
4-day	O
continuous	O
intravenous	O
infusion	O
of	O
vincristine	Chemical
and	O
doxorubicin	Chemical
and	O
4	O
days	O
of	O
oral	O
dexamethasone	Chemical
.	O
Nine	O
days	O
after	O
her	O
second	O
cycle	O
she	O
presented	O
with	O
lethargy	Disease
and	O
weakness	Disease
associated	O
with	O
hyponatremia	Disease
.	O
Evaluation	O
revealed	O
the	O
syndrome	Disease
of	Disease
inappropriate	Disease
secretion	Disease
of	Disease
antidiuretic	Disease
hormone	Disease
,	O
which	O
was	O
attributed	O
to	O
the	O
vincristine	Chemical
infusion.	O
After	O
normal	O
serum	O
sodium	Chemical
levels	O
returned,	O
further	O
doxorubicin	Chemical
and	O
dexamethasone	Chemical
chemotherapy	O
without	O
vincristine	Chemical

Heart	Disease
failure	Disease
:	O
to	O
digitalise	O
or	O
not?	O
The	O
view	O
against.	O
Despite	O
extensive	O
clinical	O
experience	O
the	O
role	O
of	O
digoxin	Chemical
is	O
still	O
not	O
well	O
defined.	O
In	O
patients	O
with	O
atrial	Disease
fibrillation	Disease
	O
digoxin	Chemical
is	O
beneficial	O
for	O
ventricular	O
rate	O
control.	O
For	O
patients	O
in	O
sinus	O
rhythm	O
and	O
heart	Disease
failure	Disease
the	O
situation	O
is	O
less	O
clear.	O
Digoxin	Chemical
has	O
a	O
narrow	O
therapeutic:toxic	O
ratio	O
and	O
concentrations	O
are	O
affected	O
by	O
a	O
number	O
of	O
drugs.	O
Also,	O
digoxin	Chemical
has	O
undesirable	O
effects	O
such	O
as	O
increasing	O
peripheral	O
resistance	O
and	O
myocardial	O
demands,	O
and	O
causing	O
arrhythmias	Disease
.	O
There	O
is	O
a	O
paucity	O
of	O
data	O
from	O
well-designed	O
trials.	O
The	O
trials	O
that	O
are	O
available	O
are	O
generally	O
small	O
with	O
limitations	O
in	O
design	O
and	O
these	O
show	O
variation	O
in	O
patient	O
benefit.	O
More	O
convincing	O
evidence	O
is	O
required	O
showing	O
that	O
digoxin	Chemical
improves	O
symptoms	O
or	O
exercise	O
capacity.	O
Furthermore,	O
no	O
trial	O
has	O
had	O
sufficient	O
power	O
to	O
evaluate	O
mortality.	O
Pooled	O
analysis	O
of	O
the	O
effects	O
of	O
other	O
inotropic	O
drugs	O
shows	O
an	O
excess	O
mortality	O
and	O
there	O
is	O
a	O
possibility	O
that	O
digoxin	Chemical
may	O
increase	O
mortality	O
after	O
myocardial	Disease
infarction	Disease
(	O
MI	Disease
).	O
Angiotensin	Chemical
-converting	O
enzyme	O
(ACE)	O
inhibitors	O
should	O
be	O
used	O
first	O
as	O
they	O
are	O
safer,	O
do	O
not	O
require	O
blood	O
level	O
monitoring,	O
modify	O
progression	O
of	O
disease,	O
relieve	O
symptoms,	O
improve	O
exercise	O
tolerance	O
and	O
reduce	O
mortality.	O
Caution	O
should	O
be	O
exercised	O
in	O
using	O
digoxin	Chemical
until	O
large	O
mortality	O
trials	O
are	O
completed	O
showing	O
either	O
benefit	O
or	O
harm.	O
Until	O
then	O
digoxin	Chemical

Intravascular	O
hemolysis	Disease
and	O
acute	Disease
renal	Disease
failure	Disease
following	O
intermittent	O
rifampin	Chemical
therapy.	O
Renal	Disease
failure	Disease
is	O
a	O
rare	O
complication	O
associated	O
with	O
the	O
use	O
of	O
rifampin	Chemical
.	O
Intravascular	O
hemolysis	Disease
leading	O
to	O
acute	Disease
renal	Disease
failure	Disease
following	O
rifampin	Chemical
therapy	O
is	O
extremely	O
rare.	O
Two	O
patients	O
with	O
leprosy	Disease
who	O
developed	O
hemolysis	Disease
and	O
acute	Disease
renal	Disease
failure	Disease
following	O
rifampin	Chemical

Zidovudine	Chemical
-induced	O
hepatitis	Disease
.	O
A	O
case	O
of	O
acute	O
hepatitis	Disease
induced	O
by	O
zidovudine	Chemical
in	O
a	O
38-year-old	O
patient	O
with	O
AIDS	Disease
is	O
presented.	O
The	O
mechanism	O
whereby	O
the	O
hepatitis	Disease
was	O
induced	O
is	O
not	O
known.	O
However,	O
the	O
patient	O
tolerated	O
well	O
an	O
alternative	O
reverse	O
transcriptase	O
inhibitor,	O
2'3'	Chemical
dideoxyinosine	Chemical
.	O
Physicians	O
caring	O
for	O
patients	O
with	O
AIDS	Disease

Thoracic	Disease
hematomyelia	Disease
secondary	O
to	O
coumadin	Chemical
anticoagulant	O
therapy:	O
a	O
case	O
report.	O
A	O
case	O
of	O
thoracic	Disease
hematomyelia	Disease

Mania	Disease
associated	O
with	O
fluoxetine	Chemical
treatment	O
in	O
adolescents.	O
Fluoxetine	Chemical
,	O
a	O
selective	O
serotonin	Chemical
reuptake	O
inhibitor,	O
is	O
gaining	O
increased	O
acceptance	O
in	O
the	O
treatment	O
of	O
adolescent	O
depression	Disease
.	O
Generally	O
safe	O
and	O
well	O
tolerated	O
by	O
adults,	O
fluoxetine	Chemical
has	O
been	O
reported	O
to	O
induce	O
mania	Disease
.	O
The	O
cases	O
of	O
five	O
depressed	Disease
adolescents,	O
14-16	O
years	O
of	O
age,	O
who	O
developed	O
mania	Disease
during	O
pharmacotherapy	O
with	O
fluoxetine	Chemical
,	O
are	O
reported	O
here.	O
Apparent	O
risk	O
factors	O
for	O
the	O
development	O
of	O
mania	Disease
or	O
hypomania	Disease
during	O
fluoxetine	Chemical
pharmacotherapy	O
in	O
this	O
population	O
were	O
the	O
combination	O
of	O
attention-deficit	Disease
hyperactivity	Disease
disorder	Disease
and	O
affective	O
instability;	O
major	O
depression	Disease
with	O
psychotic	Disease
features;	O
a	O
family	O
history	O
of	O
affective	Disease
disorder	Disease
,	O
especially	O
bipolar	Disease
disorder	Disease
;	O
and	O
a	O
diagnosis	O
of	O
bipolar	Disease
disorder	Disease
.	O
Further	O
study	O
is	O
needed	O
to	O
determine	O
the	O
optimal	O
dosage	O
and	O
to	O
identify	O
risk	O
factors	O
that	O
increase	O
individual	O
vulnerability	O
to	O
fluoxetine	Chemical
induced	O
mania	Disease

Gemfibrozil	Chemical
-	O
lovastatin	Chemical
therapy	O
for	O
primary	O
hyperlipoproteinemias	Disease
.	O
The	O
specific	O
aim	O
of	O
this	O
retrospective,	O
observational	O
study	O
was	O
to	O
assess	O
safety	O
and	O
efficacy	O
of	O
long-term	O
(21	O
months/patient),	O
open-label,	O
gemfibrozil	Chemical
-	O
lovastatin	Chemical
treatment	O
in	O
80	O
patients	O
with	O
primary	O
mixed	O
hyperlipidemia	Disease
(68%	O
of	O
whom	O
had	O
atherosclerotic	Disease
vascular	Disease
disease	Disease
).	O
Because	O
ideal	O
lipid	O
targets	O
were	O
not	O
reached	O
(low-density	O
lipoprotein	O
(LDL)	O
cholesterol	Chemical
less	O
than	O
130	O
mg/dl,	O
high-density	O
lipoprotein	O
(HDL)	O
cholesterol	Chemical
greater	O
than	O
35	O
mg/dl,	O
or	O
total	O
cholesterol	Chemical
/HDL	O
cholesterol	Chemical
less	O
than	O
4.5	O
mg/dl)	O
with	O
diet	O
plus	O
a	O
single	O
drug,	O
gemfibrozil	Chemical
(1.2	O
g/day)-	O
lovastatin	Chemical
(primarily	O
20	O
or	O
40	O
mg)	O
treatment	O
was	O
given.	O
Follow-up	O
visits	O
were	O
scheduled	O
with	O
2-drug	O
therapy	O
every	O
6	O
to	O
8	O
weeks,	O
an	O
average	O
of	O
10.3	O
visits	O
per	O
patient,	O
with	O
741	O
batteries	O
of	O
6	O
liver	O
function	O
tests	O
and	O
714	O
creatine	Chemical
phosphokinase	O
levels	O
measured.	O
Only	O
1	O
of	O
the	O
4,446	O
liver	O
function	O
tests	O
(0.02%),	O
a	O
gamma	O
glutamyl	O
transferase,	O
was	O
greater	O
than	O
or	O
equal	O
to	O
3	O
times	O
the	O
upper	O
normal	O
limit.	O
Of	O
the	O
714	O
creatine	Chemical
phosphokinase	O
levels,	O
9%	O
were	O
high;	O
only	O
1	O
(0.1%)	O
was	O
greater	O
than	O
or	O
equal	O
to	O
3	O
times	O
the	O
upper	O
normal	O
limit.	O
With	O
2-drug	O
therapy,	O
mean	O
total	O
cholesterol	Chemical
decreased	O
22%	O
from	O
255	O
to	O
200	O
mg/dl,	O
triglyceride	Chemical
levels	O
decreased	O
35%	O
from	O
236	O
to	O
154	O
mg/dl,	O
LDL	O
cholesterol	Chemical
decreased	O
26%	O
from	O
176	O
to	O
131	O
mg/dl,	O
and	O
the	O
total	O
cholesterol	Chemical
/HDL	O
cholesterol	Chemical
ratio	O
decreased	O
24%	O
from	O
7.1	O
to	O
5.4,	O
all	O
p	O
less	O
than	O
or	O
equal	O
to	O
0.0001.	O
Myositis	Disease
,	O
attributable	O
to	O
the	O
drug	O
combination	O
and	O
symptomatic	O
enough	O
to	O
discontinue	O
it,	O
occurred	O
in	O
3%	O
of	O
patients,	O
and	O
in	O
1%	O
with	O
concurrent	O
high	O
creatine	Chemical
phosphokinase	O
(769	O
U/liter);	O
no	O
patients	O
had	O
rhabdomyolysis	Disease
or	O
myoglobinuria	Disease

Hepatocellular	Disease
carcinoma	Disease
in	O
Fanconi's	Disease
anemia	Disease
treated	O
with	O
androgen	Chemical
and	O
corticosteroid	Chemical
.	O
The	O
case	O
of	O
an	O
11-year-old	O
boy	O
is	O
reported	O
who	O
was	O
known	O
to	O
have	O
Fanconi's	Disease
anemia	Disease
for	O
3	O
years	O
and	O
was	O
treated	O
with	O
androgens	Chemical
,	O
corticosteroids	Chemical
and	O
transfusions.	O
Two	O
weeks	O
before	O
his	O
death	O
he	O
was	O
readmitted	O
because	O
of	O
aplastic	O
crisis	O
with	O
septicemia	Disease
and	O
marked	O
abnormalities	O
in	O
liver	O
function	O
and	O
died	O
of	O
hemorrhagic	Disease
bronchopneumonia	Disease
.	O
At	O
autopsy	O
peliosis	Disease
and	O
multiple	O
hepatic	Disease
tumors	Disease
were	O
found	O
which	O
histologically	O
proved	O
to	O
be	O
well-differentiated	O
hepatocellular	Disease
carcinoma	Disease
.	O
This	O
case	O
contributes	O
to	O
the	O
previous	O
observations	O
that	O
non-metastasizing	O
hepatic	Disease
neoplasms	Disease
and	O
peliosis	Disease
can	O
develop	O
in	O
patients	O
with	O
androgen	Chemical
-	O
and	O
corticosteroid	Chemical
-treated	O
Fanconi's	Disease
anemia	Disease

Chronic	O
lesion	O
of	O
rostral	O
ventrolateral	O
medulla	O
in	O
spontaneously	O
hypertensive	Disease
rats.	O
We	O
studied	O
the	O
effects	O
of	O
chronic	O
selective	O
neuronal	O
lesion	O
of	O
rostral	O
ventrolateral	O
medulla	O
on	O
mean	O
arterial	O
pressure,	O
heart	O
rate,	O
and	O
neurogenic	O
tone	O
in	O
conscious,	O
unrestrained	O
spontaneously	O
hypertensive	Disease
rats.	O
The	O
lesions	O
were	O
placed	O
via	O
bilateral	O
microinjections	O
of	O
30	O
nmol/200	O
nl	O
N-methyl-D-aspartic	Chemical
acid	Chemical
.	O
The	O
restimulation	O
of	O
this	O
area	O
with	O
N-methyl-D-aspartic	Chemical
acid	Chemical
15	O
days	O
postlesion	O
failed	O
to	O
produce	O
a	O
pressor	O
response.	O
One	O
day	O
postlesion,	O
the	O
resting	O
mean	O
arterial	O
pressure	O
was	O
significantly	O
decreased	O
in	O
lesioned	O
rats	O
when	O
compared	O
with	O
sham	O
rats	O
(100	O
+/-	O
7	O
versus	O
173	O
+/-	O
4	O
mm	O
Hg,	O
p	O
less	O
than	O
0.05).	O
Fifteen	O
days	O
later,	O
the	O
lesioned	O
group	O
still	O
showed	O
values	O
significantly	O
lower	O
than	O
the	O
sham	O
group	O
(150	O
+/-	O
6	O
versus	O
167	O
+/-	O
5	O
mm	O
Hg,	O
p	O
less	O
than	O
0.05).	O
No	O
significant	O
heart	O
rate	O
differences	O
were	O
observed	O
between	O
the	O
sham	O
and	O
lesioned	O
groups.	O
The	O
ganglionic	O
blocker	O
trimethaphan	Chemical
(5	O
mg/kg	O
i.v.)	O
caused	O
similar	O
reductions	O
in	O
mean	O
arterial	O
pressure	O
in	O
both	O
lesioned	O
and	O
sham	O
groups.	O
The	O
trimethaphan	Chemical
-induced	O
hypotension	Disease
was	O
accompanied	O
by	O
a	O
significant	O
bradycardia	Disease
in	O
lesioned	O
rats	O
(-32	O
+/-	O
13	O
beats	O
per	O
minute)	O
but	O
a	O
tachycardia	Disease
in	O
sham	O
rats	O
(+33	O
+/-	O
12	O
beats	O
per	O
minute)	O
1	O
day	O
postlesion.	O
Therefore,	O
rostral	O
ventrolateral	O
medulla	O
neurons	O
appear	O
to	O
play	O
a	O
significant	O
role	O
in	O
maintaining	O
hypertension	Disease
in	O
conscious	O
spontaneously	O
hypertensive	Disease
rats.	O
Spinal	O
or	O
suprabulbar	O
structures	O
could	O
be	O
responsible	O
for	O
the	O
gradual	O
recovery	O
of	O
the	O
hypertension	Disease

Damage	Disease
of	Disease
substantia	Disease
nigra	Disease
pars	Disease
reticulata	Disease
during	O
pilocarpine	Chemical
-induced	O
status	Disease
epilepticus	Disease
in	O
the	O
rat:	O
immunohistochemical	O
study	O
of	O
neurons,	O
astrocytes	O
and	O
serum-protein	O
extravasation.	O
The	O
substantia	O
nigra	O
has	O
a	O
gating	O
function	O
controlling	O
the	O
spread	O
of	O
epileptic	Disease
seizure	Disease
activity.	O
Additionally,	O
in	O
models	O
of	O
prolonged	Disease
status	Disease
epilepticus	Disease
the	O
pars	O
reticulata	O
of	O
substantia	O
nigra	O
(SNR)	O
suffers	O
from	O
a	O
massive	O
lesion	O
which	O
may	O
arise	O
from	O
a	O
massive	O
metabolic	Disease
derangement	Disease
and	O
hyperexcitation	O
developing	O
in	O
the	O
activated	O
SNR.	O
In	O
this	O
study,	O
status	Disease
epilepticus	Disease
was	O
induced	O
by	O
systemic	O
injection	O
of	O
pilocarpine	Chemical
in	O
rats.	O
The	O
neuropathology	O
of	O
SNR	O
was	O
investigated	O
using	O
immunohistochemical	O
techniques	O
with	O
the	O
major	O
emphasis	O
on	O
the	O
time-course	O
of	O
changes	O
in	O
neurons	O
and	O
astrocytes.	O
Animals	O
surviving	O
20,	O
30,	O
40,	O
60	O
min,	O
2,	O
3,	O
6	O
hours,	O
1,	O
2,	O
and	O
3	O
days	O
after	O
induction	O
of	O
status	Disease
epilepticus	Disease
were	O
perfusion-fixed,	O
and	O
brains	O
processed	O
for	O
immunohistochemical	O
staining	O
of	O
SNR.	O
Nissl-staining	O
and	O
antibodies	O
against	O
the	O
neuron-specific	O
calcium	Chemical
-binding	O
protein,	O
parvalbumin,	O
served	O
to	O
detect	O
neuronal	Disease
damage	Disease
in	O
SNR.	O
Antibodies	O
against	O
the	O
astroglia-specific	O
cytoskeletal	O
protein,	O
glial	O
fibrillary	O
acidic	O
protein	O
(GFAP),	O
and	O
against	O
the	O
glial	O
calcium	Chemical
-binding	O
protein,	O
S-100	O
protein,	O
were	O
used	O
to	O
assess	O
the	O
status	O
of	O
astrocytes.	O
Immunohistochemical	O
staining	O
for	O
serum-albumin	O
and	O
immunoglobulins	O
in	O
brain	O
tissue	O
was	O
taken	O
as	O
indicator	O
of	O
blood-brain	O
barrier	O
disturbances	O
and	O
vasogenic	Disease
edema	Disease
formation.	O
Immunohistochemical	O
staining	O
indicated	O
loss	O
of	O
GFAP-staining	O
already	O
at	O
30	O
min	O
after	O
induction	O
of	O
seizures	Disease
in	O
an	O
oval	O
focus	O
situated	O
in	O
the	O
center	O
of	O
SNR	O
while	O
sparing	O
medial	O
and	O
lateral	O
aspects.	O
At	O
1	O
h	O
there	O
was	O
additional	O
vacuolation	O
in	O
S-100	O
protein	O
staining.	O
By	O
2	O
hours,	O
parvalbumin-staining	O
changed	O
in	O
the	O
central	O
SNR	O
indicating	O
neuronal	Disease
damage	Disease
,	O
and	O
Nissl-staining	O
visualized	O
some	O
neuronal	O
distortion.	O
Staining	O
for	O
serum-proteins	O
occurred	O
in	O
a	O
patchy	O
manner	O
throughout	O
the	O
forebrain	O
during	O
the	O
first	O
hours.	O
By	O
6	O
h,	O
vasogenic	Disease
edema	Disease
covered	O
the	O
lesioned	Disease
SNR	Disease
.	O
By	O
24	O
h,	O
glial	O
and	O
neuronal	O
markers	O
indicated	O
a	O
massive	O
lesion	O
in	O
the	O
center	O
of	O
SNR.	O
By	O
48-72	O
h,	O
astrocytes	O
surrounding	O
the	O
lesion	O
increased	O
in	O
size,	O
and	O
polymorphic	O
phagocytotic	O
cells	O
invaded	O
the	O
damaged	O
area.	O
In	O
a	O
further	O
group	O
of	O
animals	O
surviving	O
1	O
to	O
5	O
days,	O
conventional	O
paraffin-sections	O
confirmed	O
the	O
neuronal	O
and	O
glial	O
damage	Disease
of	Disease
SNR	Disease
.	O
Additional	O
pathology	O
of	O
similar	O
quality	O
was	O
found	O
in	O
the	O
globus	O
pallidus.	O
Since	O
astrocytes	O
were	O
always	O
damaged	O
in	O
parallel	O
with	O
neurons	O
in	O
SNR	O
it	O
is	O
proposed	O
that	O
the	O
anatomical	O
and	O
functional	O
interrelationship	O
between	O
neurons	O
and	O
astrocytes	O
is	O
particularly	O
tight	O
in	O
SNR.	O
Both	O
cell	O
elements	O
may	O
suffer	O
in	O
common	O
from	O
metabolic	O
disturbance	O
and	O
neurotransmitter	Disease
dysfunction	Disease
as	O
occur	O
during	O
massive	O
status	Disease
epilepticus	Disease

Reduced	O
cardiotoxicity	Disease
of	O
doxorubicin	Chemical
given	O
in	O
the	O
form	O
of	O
N-(2-hydroxypropyl)methacrylamide	Chemical
conjugates:	O
and	O
experimental	O
study	O
in	O
the	O
rat.	O
A	O
rat	O
model	O
was	O
used	O
to	O
evaluate	O
the	O
general	O
acute	O
toxicity	Disease
and	O
the	O
late	O
cardiotoxicity	Disease
of	O
4	O
mg/kg	O
doxorubicin	Chemical
(	O
DOX	Chemical
)	O
given	O
either	O
as	O
free	O
drug	O
or	O
in	O
the	O
form	O
of	O
three	O
N-(2-hydroxypropyl)methacrylamide	Chemical
(	O
HPMA	Chemical
)	O
copolymer	O
conjugates.	O
In	O
these	O
HPMA	Chemical
copolymers,	O
DOX	Chemical
was	O
covalently	O
bound	O
via	O
peptide	O
linkages	O
that	O
were	O
either	O
non-biodegradable	O
(Gly-Gly)	O
or	O
degradable	O
by	O
lysosomal	O
proteinases	O
(	O
Gly-Phe-Leu-Gly	Chemical
).	O
In	O
addition,	O
one	O
biodegradable	O
conjugate	O
containing	O
galactosamine	Chemical
was	O
used;	O
this	O
residue	O
was	O
targeted	O
to	O
the	O
liver.	O
Over	O
the	O
first	O
3	O
weeks	O
after	O
the	O
i.v.	O
administration	O
of	O
free	O
and	O
polymer-bound	O
DOX	Chemical
,	O
all	O
animals	O
showed	O
a	O
transient	O
reduction	O
in	O
body	O
weight.	O
However,	O
the	O
maximal	O
reduction	O
in	O
body	O
weight	O
seen	O
in	O
animals	O
that	O
received	O
polymer-bound	O
DOX	Chemical
(4	O
mg/kg)	O
was	O
significantly	O
lower	O
than	O
that	O
observed	O
in	O
those	O
that	O
received	O
free	O
DOX	Chemical
(4	O
mg/kg)	O
or	O
a	O
mixture	O
of	O
the	O
unmodified	O
parent	O
HPMA	Chemical
copolymer	O
and	O
free	O
DOX	Chemical
(4	O
mg/kg;	O
P	O
less	O
than	O
0.01).	O
Throughout	O
the	O
study	O
(20	O
weeks),	O
deaths	O
related	O
to	O
cardiotoxicity	Disease
were	O
observed	O
only	O
in	O
animals	O
that	O
received	O
either	O
free	O
DOX	Chemical
or	O
the	O
mixture	O
of	O
HPMA	Chemical
copolymer	O
and	O
free	O
DOX	Chemical
;	O
in	O
these	O
cases,	O
histological	O
investigations	O
revealed	O
marked	O
changes	O
in	O
the	O
heart	O
that	O
were	O
consistent	O
with	O
DOX	Chemical
-induced	O
cardiotoxicity	Disease
.	O
Sequential	O
measurements	O
of	O
cardiac	O
output	O
in	O
surviving	O
animals	O
that	O
received	O
either	O
free	O
DOX	Chemical
or	O
the	O
mixture	O
of	O
HPMA	Chemical
copolymer	O
and	O
free	O
DOX	Chemical
showed	O
a	O
reduction	O
of	O
approximately	O
30%	O
in	O
function	O
beginning	O
at	O
the	O
4th	O
week	O
after	O
drug	O
administration.	O
The	O
heart	O
rate	O
in	O
these	O
animals	O
was	O
approximately	O
12%	O
lower	O
than	O
that	O
measured	O
in	O
age-matched	O
control	O
rats	O
(P	O
less	O
than	O
0.05).	O
Animals	O
that	O
were	O
given	O
the	O
HPMA	Chemical
copolymer	O
conjugates	O
containing	O
DOX	Chemical
exhibited	O
no	O
significant	O
change	O
in	O
cardiac	O
output	O
throughout	O
the	O
study	O
(P	O
less	O
than	O
0.05).	O
In	O
addition,	O
no	O
significant	O
histological	O
change	O
was	O
observed	O
in	O
the	O
heart	O
of	O
animals	O
that	O
received	O
DOX	Chemical
in	O
the	O
form	O
of	O
HPMA	Chemical

Topical	O
0.025%	O
capsaicin	Chemical
in	O
chronic	O
post-herpetic	Disease
neuralgia	Disease
:	O
efficacy,	O
predictors	O
of	O
response	O
and	O
long-term	O
course.	O
In	O
order	O
to	O
evaluate	O
the	O
efficacy,	O
time-course	O
of	O
action	O
and	O
predictors	O
of	O
response	O
to	O
topical	O
capsaicin	Chemical
,	O
39	O
patients	O
with	O
chronic	O
post-herpetic	Disease
neuralgia	Disease
(	O
PHN	Disease
),	O
median	O
duration	O
24	O
months,	O
were	O
treated	O
with	O
0.025%	O
capsaicin	Chemical
cream	O
for	O
8	O
weeks.	O
During	O
therapy	O
the	O
patients	O
rated	O
their	O
pain	Disease
on	O
a	O
visual	O
analogue	O
scale	O
(VAS)	O
and	O
a	O
verbal	O
outcome	O
scale.	O
A	O
follow-up	O
investigation	O
was	O
performed	O
10-12	O
months	O
after	O
study	O
onset	O
on	O
the	O
patients	O
who	O
had	O
improved.	O
Nineteen	O
patients	O
(48.7%)	O
substantially	O
improved	O
after	O
the	O
8-week	O
trial;	O
5	O
(12.8%)	O
discontinued	O
therapy	O
due	O
to	O
side-effects	O
such	O
as	O
intolerable	O
capsaicin	Chemical
-induced	O
burning	O
sensations	O
(4)	O
or	O
mastitis	Disease
(1);	O
15	O
(38.5%)	O
reported	O
no	O
benefit.	O
The	O
decrease	O
in	O
VAS	O
ratings	O
was	O
significant	O
after	O
2	O
weeks	O
of	O
continuous	O
application.	O
Of	O
the	O
responders	O
72.2%	O
were	O
still	O
improved	O
at	O
the	O
follow-up;	O
only	O
one-third	O
of	O
them	O
had	O
continued	O
application	O
irregularly.	O
Treatment	O
effect	O
was	O
not	O
dependent	O
on	O
patient's	O
age,	O
duration	O
or	O
localization	O
of	O
PHN	Disease
(trigeminal	O
involvement	O
was	O
excluded),	O
sensory	Disease
disturbance	Disease
or	O
pain	Disease
character.	O
Treatment	O
response	O
was	O
not	O
correlated	O
with	O
the	O
incidence,	O
time-course	O
or	O
severity	O
of	O
capsaicin	Chemical
-induced	O
burning.	O
If	O
confirmed	O
in	O
controlled	O
trials,	O
the	O
long-term	O
results	O
of	O
this	O
open,	O
non-randomized	O
study	O
might	O
indicate	O
that	O
the	O
analgesic	O
effect	O
of	O
capsaicin	Chemical
in	O
PHN	Disease

Serotonin	Chemical
reuptake	O
inhibitors,	O
paranoia	Disease
,	O
and	O
the	O
ventral	O
basal	O
ganglia.	O
Antidepressants	O
have	O
previously	O
been	O
associated	O
with	O
paranoid	Disease
reactions	O
in	O
psychiatric	O
patients.	O
Five	O
cases	O
of	O
paranoid	Disease
exacerbation	O
with	O
the	O
serotonin	Chemical
reuptake	O
inhibitors	O
fluoxetine	Chemical
and	O
amitriptyline	Chemical
are	O
reported	O
here.	O
Elements	O
common	O
to	O
these	O
cases	O
included	O
a	O
history	O
of	O
paranoid	Disease
symptomatology	O
and	O
the	O
concomitant	O
occurrence	O
of	O
depressive	Disease
and	Disease
psychotic	Disease
symptoms	Disease
.	O
Complicated	O
depressive	Disease
disorders	Disease
(including	O
atypicality	O
of	O
course	O
and	O
symptomatology,	O
chronicity,	O
psychosis	Disease
,	O
bipolarity,	O
and	O
secondary	O
onset	O
in	O
the	O
course	O
of	O
a	O
primary	O
psychosis	Disease
)	O
may	O
present	O
particular	O
vulnerability	O
to	O
paranoid	Disease
exacerbations	O
associated	O
with	O
serotonin	Chemical
reuptake	O
inhibitors.	O
Although	O
the	O
pharmacology	O
and	O
neurobiology	O
of	O
paranoia	Disease
remain	O
cryptic,	O
several	O
mechanisms,	O
including	O
5HT3	O
receptor-mediated	O
dopamine	Chemical
release,	O
beta-noradrenergic	O
receptor	O
downregulation,	O
or	O
GABAB	O
receptor	O
upregulation	O
acting	O
in	O
the	O
vicinity	O
of	O
the	O
ventral	O
basal	O
ganglia	O
(possibly	O
in	O
lateral	O
orbitofrontal	O
or	O
anterior	O
cingulate	O
circuits),	O
might	O
apply	O
to	O
this	O
phenomenon.	O
These	O
cases	O
call	O
attention	O
to	O
possible	O
paranoid	Disease
exacerbations	O
with	O
serotonin	Chemical
reuptake	O
blockers	O
in	O
select	O
patients	O
and	O
raise	O
neurobiological	O
considerations	O
regarding	O
paranoia	Disease

Five	O
cases	O
of	O
encephalitis	Disease
during	O
treatment	O
of	O
loiasis	Disease
with	O
diethylcarbamazine	Chemical
.	O
Five	O
cases	O
of	O
encephalitis	Disease
following	O
treatment	O
with	O
diethylcarbamazine	Chemical
(	O
DEC	Chemical
)	O
were	O
observed	O
in	O
Congolese	O
patients	O
with	O
Loa	O
loa	O
filariasis	Disease
.	O
Two	O
cases	O
had	O
a	O
fatal	O
outcome	O
and	O
one	O
resulted	O
in	O
severe	O
sequelae.	O
The	O
notable	O
fact	O
was	O
that	O
this	O
complication	O
occurred	O
in	O
three	O
patients	O
hospitalized	O
before	O
treatment	O
began,	O
with	O
whom	O
particularly	O
strict	O
therapeutic	O
precautions	O
were	O
taken,	O
i.e.,	O
initial	O
dose	O
less	O
than	O
10	O
mg	O
of	O
DEC	Chemical
,	O
very	O
gradual	O
dose	O
increases,	O
and	O
associated	O
anti-allergic	O
treatment.	O
This	O
type	O
of	O
drug-induced	O
complication	O
may	O
not	O
be	O
that	O
uncommon	O
in	O
highly	O
endemic	O
regions.	O
It	O
occurs	O
primarily,	O
but	O
not	O
exclusively,	O
in	O
subjects	O
presenting	O
with	O
a	O
high	O
microfilarial	O
load.	O
The	O
relationship	O
between	O
the	O
occurrence	O
of	O
encephalitis	Disease
and	O
the	O
decrease	O
in	O
microfilaremia	Disease

Delirium	Disease
in	O
an	O
elderly	O
woman	O
possibly	O
associated	O
with	O
administration	O
of	O
misoprostol	Chemical
.	O
Misoprostol	Chemical
has	O
been	O
associated	O
with	O
adverse	O
reactions,	O
including	O
gastrointestinal	O
symptoms,	O
gynecologic	O
problems,	O
and	O
headache	Disease
.	O
Changes	O
in	O
mental	O
status,	O
however,	O
have	O
not	O
been	O
reported.	O
We	O
present	O
a	O
case	O
in	O
which	O
an	O
89-year-old	O
woman	O
in	O
a	O
long-term	O
care	O
facility	O
became	O
confused	O
after	O
the	O
initiation	O
of	O
misoprostol	Chemical
therapy.	O
The	O
patient's	O
change	O
in	O
mental	O
status	O
was	O
first	O
reported	O
nine	O
days	O
after	O
the	O
initiation	O
of	O
therapy.	O
Her	O
delirium	Disease
significantly	O
improved	O
after	O
misoprostol	Chemical
was	O
discontinued	O
and	O
her	O
mental	O
status	O
returned	O
to	O
normal	O
within	O
a	O
week.	O
Because	O
no	O
other	O
factors	O
related	O
to	O
this	O
patient	O
changed	O
significantly,	O
the	O
delirium	Disease
experienced	O
by	O
this	O
patient	O
possibly	O
resulted	O
from	O
misoprostol	Chemical

Hepatocellular	O
oxidant	O
stress	O
following	O
intestinal	O
ischemia	Disease
-	O
reperfusion	Disease
injury	Disease
.	O
Reperfusion	O
of	O
ischemic	Disease
intestine	O
results	O
in	O
acute	O
liver	Disease
dysfunction	Disease
characterized	O
by	O
hepatocellular	O
enzyme	O
release	O
into	O
plasma,	O
reduction	O
in	O
bile	O
flow	O
rate,	O
and	O
neutrophil	O
sequestration	O
within	O
the	O
liver.	O
The	O
pathophysiology	O
underlying	O
this	O
acute	O
hepatic	Disease
injury	Disease
is	O
unknown.	O
This	O
study	O
was	O
undertaken	O
to	O
determine	O
whether	O
oxidants	O
are	O
associated	O
with	O
the	O
hepatic	Disease
injury	Disease
and	O
to	O
determine	O
the	O
relative	O
value	O
of	O
several	O
indirect	O
methods	O
of	O
assessing	O
oxidant	O
exposure	O
in	O
vivo.	O
Rats	O
were	O
subjected	O
to	O
a	O
standardized	O
intestinal	O
ischemia	Disease
-	O
reperfusion	Disease
injury	Disease
.	O
Hepatic	O
tissue	O
was	O
assayed	O
for	O
lipid	O
peroxidation	O
products	O
and	O
oxidized	Chemical
and	Chemical
reduced	Chemical
glutathione	Chemical
.	O
There	O
was	O
no	O
change	O
in	O
hepatic	O
tissue	O
total	O
glutathione	Chemical
following	O
intestinal	O
ischemia	Disease
-	O
reperfusion	Disease
injury	Disease
.	O
Oxidized	Chemical
glutathione	Chemical
(	O
GSSG	Chemical
)	O
increased	O
significantly	O
following	O
30	O
and	O
60	O
min	O
of	O
reperfusion.	O
There	O
was	O
no	O
increase	O
in	O
any	O
of	O
the	O
products	O
of	O
lipid	O
peroxidation	O
associated	O
with	O
this	O
injury.	O
An	O
increase	O
in	O
GSSG	Chemical
within	O
hepatic	O
tissue	O
during	O
intestinal	O
reperfusion	O
suggests	O
exposure	O
of	O
hepatocytes	O
to	O
an	O
oxidant	O
stress.	O
The	O
lack	O
of	O
a	O
significant	O
increase	O
in	O
products	O
of	O
lipid	O
peroxidation	O
suggests	O
that	O
the	O
oxidant	O
stress	O
is	O
of	O
insufficient	O
magnitude	O
to	O
result	O
in	O
irreversible	O
injury	O
to	O
hepatocyte	O
cell	O
membranes.	O
These	O
data	O
also	O
suggest	O
that	O
the	O
measurement	O
of	O
tissue	O
GSSG	Chemical

Diphenhydramine	Chemical
prevents	O
the	O
haemodynamic	O
changes	O
of	O
cimetidine	Chemical
in	O
ICU	O
patients.	O
Cimetidine	Chemical
,	O
a	O
histamine	Chemical
2	O
(H2)	O
antagonist,	O
produces	O
a	O
decrease	O
in	O
arterial	O
pressure	O
due	O
to	O
vasodilatation,	O
especially	O
in	O
critically	O
ill	O
patients.	O
This	O
may	O
be	O
because	O
cimetidine	Chemical
acts	O
as	O
a	O
histamine	Chemical
agonist.	O
We,	O
therefore,	O
investigated	O
the	O
effects	O
of	O
the	O
histamine	Chemical
1(H1)	O
receptor	O
antagonist,	O
diphenhydramine	Chemical
,	O
on	O
the	O
haemodynamic	O
changes	O
observed	O
after	O
cimetidine	Chemical
in	O
ICU	O
patients.	O
Each	O
patient	O
was	O
studied	O
on	O
two	O
separate	O
days.	O
In	O
a	O
random	O
fashion,	O
they	O
received	O
cimetidine	Chemical
200	O
mg	O
iv	O
on	O
one	O
day,	O
and	O
on	O
the	O
other,	O
a	O
pretreatment	O
of	O
diphenhydramine	Chemical
40	O
mg	O
iv	O
with	O
cimetidine	Chemical
200	O
mg	O
iv.	O
In	O
the	O
non-pretreatment	O
group,	O
mean	O
arterial	O
pressure	O
(MAP)	O
decreased	O
from	O
107.4	O
+/-	O
8.4	O
mmHg	O
to	O
86.7	O
+/-	O
11.4	O
mmHg	O
(P	O
less	O
than	O
0.01)	O
two	O
minutes	O
after	O
cimetidine	Chemical
.	O
Also,	O
systemic	O
vascular	O
resistance	O
(SVR)	O
decreased	O
during	O
the	O
eight-minute	O
observation	O
period	O
(P	O
less	O
than	O
0.01).	O
In	O
contrast,	O
in	O
the	O
pretreatment	O
group,	O
little	O
haemodynamic	O
change	O
was	O
seen.	O
We	O
conclude	O
that	O
an	O
H1	O
antagonist	O
may	O
be	O
useful	O
in	O
preventing	O
hypotension	Disease
caused	O
by	O
iv	O
cimetidine	Chemical
,	O
since	O
the	O
vasodilating	O
activity	O
of	O
cimetidine	Chemical

Acute	Disease
renal	Disease
failure	Disease
due	O
to	O
rifampicin	Chemical
.	O
A	O
23-year-old	O
male	O
patient	O
with	O
bacteriologically	O
proven	O
pulmonary	Disease
tuberculosis	Disease
was	O
treated	O
with	O
the	O
various	O
regimens	O
of	O
antituberculosis	O
drugs	O
for	O
nearly	O
15	O
months.	O
Rifampicin	Chemical
was	O
administered	O
thrice	O
as	O
one	O
of	O
the	O
3-4	O
drug	O
regimen	O
and	O
each	O
time	O
he	O
developed	O
untoward	O
side	O
effects	O
like	O
nausea	Disease
,	O
vomiting	Disease
and	O
fever	Disease

Severe	O
polyneuropathy	Disease
and	O
motor	O
loss	O
after	O
intrathecal	O
thiotepa	Chemical
combination	O
chemotherapy:	O
description	O
of	O
two	O
cases.	O
Two	O
cases	O
of	O
severe	O
delayed	O
neurologic	Disease
toxicity	Disease
related	O
to	O
the	O
administration	O
of	O
intrathecal	O
(IT)	O
combination	O
chemotherapy	O
including	O
thiotepa	Chemical
(	O
TSPA	Chemical
)	O
are	O
presented.	O
Both	O
cases	O
developed	O
axonal	Disease
neuropathy	Disease
with	O
motor	O
predominance	O
in	O
the	O
lower	O
extremities	O
1	O
and	O
6	O
months	O
after	O
IT	O
chemotherapy	O
was	O
administered.	O
Neurologic	Disease
toxicities	Disease
have	O
been	O
described	O
with	O
IT-	O
methotrexate	Chemical
,	O
IT-	O
cytosine	Chemical
arabinoside	Chemical
and	O
IT-	O
TSPA	Chemical
.	O
To	O
our	O
knowledge,	O
however,	O
axonal	Disease
neuropathy	Disease
following	O
administration	O
of	O
these	O
three	O
agents	O
has	O
not	O
been	O
previously	O
described.	O
In	O
spite	O
of	O
the	O
fact	O
that	O
TSPA	Chemical
is	O
a	O
useful	O
IT	O
agent,	O
its	O
combination	O
with	O
MTX	Chemical
,	O
ara-C	Chemical
and	O
radiotherapy	O
could	O
cause	O
severe	O
neurotoxicity	Disease
.	O
This	O
unexpected	O
complication	O
indicates	O
the	O
need	O
for	O
further	O
toxicology	O
research	O
on	O
IT-	O
TSPA	Chemical

Effects	O
of	O
cromakalim	Chemical
and	O
pinacidil	Chemical
on	O
large	O
epicardial	O
and	O
small	O
coronary	O
arteries	O
in	O
conscious	O
dogs.	O
The	O
effects	O
of	O
i.v.	O
bolus	O
administration	O
of	O
cromakalim	Chemical
(1-10	O
micrograms/kg)	O
and	O
pinacidil	Chemical
(3-100	O
micrograms/kg)	O
on	O
large	O
(circumflex	O
artery)	O
and	O
small	O
coronary	O
arteries	O
and	O
on	O
systemic	O
hemodynamics	O
were	O
investigated	O
in	O
chronically	O
instrumented	O
conscious	O
dogs	O
and	O
compared	O
to	O
those	O
of	O
nitroglycerin	Chemical
(0.03-10	O
micrograms/kg).	O
Nitroglycerin	Chemical
,	O
up	O
to	O
0.3	O
micrograms/kg,	O
selectively	O
increased	O
circumflex	O
artery	O
diameter	O
(CxAD)	O
without	O
simultaneously	O
affecting	O
any	O
other	O
cardiac	O
or	O
systemic	O
hemodynamic	O
parameter.	O
In	O
contrast,	O
cromakalim	Chemical
and	O
pinacidil	Chemical
at	O
all	O
doses	O
and	O
nitroglycerin	Chemical
at	O
doses	O
higher	O
than	O
0.3	O
micrograms/kg	O
simultaneously	O
and	O
dose-dependently	O
increased	O
CxAD,	O
coronary	O
blood	O
flow	O
and	O
heart	O
rate	O
and	O
decreased	O
coronary	O
vascular	O
resistance	O
and	O
aortic	O
pressure.	O
Cromakalim	Chemical
was	O
approximately	O
8-	O
to	O
9.5-fold	O
more	O
potent	O
than	O
pinacidil	Chemical
in	O
increasing	O
CxAD.	O
Vasodilation	O
of	O
large	O
and	O
small	O
coronary	O
vessels	O
and	O
hypotension	Disease
induced	O
by	O
cromakalim	Chemical
and	O
pinacidil	Chemical
were	O
not	O
affected	O
by	O
prior	O
combined	O
beta	Chemical
adrenergic	Chemical
and	Chemical
muscarinic	Chemical
receptors	Chemical
blockade	Chemical
but	O
drug-induced	O
tachycardia	Disease
was	O
abolished.	O
When	O
circumflex	O
artery	O
blood	O
flow	O
was	O
maintained	O
constant,	O
the	O
increases	O
in	O
CxAD	O
induced	O
by	O
cromakalim	Chemical
(10	O
micrograms/kg),	O
pinacidil	Chemical
(30	O
micrograms/kg)	O
and	O
nitroglycerin	Chemical
(10	O
micrograms/kg)	O
were	O
reduced	O
by	O
68	O
+/-	O
7,	O
54	O
+/-	O
9	O
and	O
1	O
+/-	O
1%,	O
respectively.	O
Thus,	O
whereas	O
nitroglycerin	Chemical
preferentially	O
and	O
flow-independently	O
dilates	O
large	O
coronary	O
arteries,	O
cromakalim	Chemical
and	O
pinacidil	Chemical
dilate	O
both	O
large	O
and	O
small	O
coronary	O
arteries	O
and	O
this	O
effect	O
is	O
not	O
dependent	O
upon	O
the	O
simultaneous	O
beta	O
adrenoceptors-mediated	O
rise	O
in	O
myocardial	O
metabolic	O
demand.	O
Finally,	O
two	O
mechanisms	O
at	O
least,	O
direct	O
vasodilation	O
and	O
flow	O
dependency,	O
are	O
involved	O
in	O
the	O
cromakalim	Chemical
-	O
and	O
pinacidil	Chemical

Mefenamic	Chemical
acid	Chemical
-induced	O
neutropenia	Disease
and	O
renal	Disease
failure	Disease
in	O
elderly	O
females	O
with	O
hypothyroidism	Disease
.	O
We	O
report	O
mefenamic	Chemical
acid	Chemical
-induced	O
non-oliguric	O
renal	Disease
failure	Disease
and	O
severe	O
neutropenia	Disease
occurring	O
simultaneously	O
in	O
two	O
elderly	O
females.	O
The	O
neutropenia	Disease
was	O
due	O
to	O
maturation	O
arrest	O
of	O
the	O
myeloid	O
series	O
in	O
one	O
patient.	O
Both	O
patients	O
were	O
also	O
hypothyroid	Disease
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
this	O
was	O
a	O
predisposing	O
factor	O
to	O
the	O
development	O
of	O
these	O
adverse	O
reactions.	O
However,	O
it	O
would	O
seem	O
prudent	O
not	O
to	O
use	O
mefenamic	Chemical
acid	Chemical
in	O
hypothyroid	Disease
patients	O
until	O
the	O
hypothyroidism	Disease

Etiology	O
of	O
hypercalcemia	Disease
in	O
hemodialysis	O
patients	O
on	O
calcium	Chemical
carbonate	Chemical
therapy.	O
Fourteen	O
of	O
39	O
dialysis	O
patients	O
(36%)	O
became	O
hypercalcemic	Disease
after	O
switching	O
to	O
calcium	Chemical
carbonate	Chemical
as	O
their	O
principal	O
phosphate	Chemical
binder.	O
In	O
order	O
to	O
identify	O
risk	O
factors	O
associated	O
with	O
the	O
development	O
of	O
hypercalcemia	Disease
,	O
indirect	O
parameters	O
of	O
intestinal	O
calcium	Chemical
reabsorption	O
and	O
bone	O
turnover	O
rate	O
in	O
these	O
14	O
patients	O
were	O
compared	O
with	O
results	O
in	O
14	O
eucalcemic	O
patients	O
matched	O
for	O
age,	O
sex,	O
length	O
of	O
time	O
on	O
dialysis,	O
and	O
etiology	O
of	O
renal	Disease
disease	Disease
.	O
In	O
addition	O
to	O
experiencing	O
hypercalcemic	Disease
episodes	O
with	O
peak	O
calcium	Chemical
values	O
of	O
2.7	O
to	O
3.8	O
mmol/L	O
(10.7	O
to	O
15.0	O
mg/dL),	O
patients	O
in	O
the	O
hypercalcemic	Disease
group	O
exhibited	O
a	O
significant	O
increase	O
in	O
the	O
mean	O
calcium	Chemical
concentration	O
obtained	O
during	O
6	O
months	O
before	O
the	O
switch,	O
compared	O
with	O
the	O
mean	O
value	O
obtained	O
during	O
the	O
7	O
months	O
of	O
observation	O
after	O
the	O
switch	O
(2.4	O
+/-	O
0.03	O
to	O
2.5	O
+/-	O
0.03	O
mmol/L	O
[9.7	O
+/-	O
0.2	O
to	O
10.2	O
+/-	O
0.1	O
mg/dL],	O
P	O
=	O
0.006).	O
In	O
contrast,	O
eucalcemic	O
patients	O
exhibited	O
no	O
change	O
in	O
mean	O
calcium	Chemical
values	O
over	O
the	O
same	O
time	O
period	O
(2.3	O
+/-	O
0.05	O
to	O
2.3	O
+/-	O
0.05	O
mmol/L	O
[9.2	O
+/-	O
0.2	O
to	O
9.2	O
+/-	O
0.2	O
mg/dL]).	O
CaCO3	Chemical
dosage,	O
calculated	O
dietary	O
calcium	Chemical
intake,	O
and	O
circulating	O
levels	O
of	O
vitamin	Chemical
D	Chemical
metabolites	O
were	O
similar	O
in	O
both	O
groups.	O
Physical	O
activity	O
index	O
and	O
predialysis	O
serum	O
bicarbonate	Chemical

Methyldopa	Chemical
-induced	O
hemolytic	Disease
anemia	Disease
in	O
a	O
15	O
year	O
old	O
presenting	O
as	O
near-	O
syncope	Disease
.	O
Methyldopa	Chemical
is	O
an	O
antihypertensive	O
medication	O
which	O
is	O
available	O
generically	O
and	O
under	O
the	O
trade	O
name	O
Aldomet	Chemical
that	O
is	O
widely	O
prescribed	O
in	O
the	O
adult	O
population	O
and	O
infrequently	O
used	O
in	O
children.	O
Methyldopa	Chemical
causes	O
an	O
autoimmune	Disease
hemolytic	Disease
anemia	Disease
in	O
a	O
small	O
percentage	O
of	O
patients	O
who	O
take	O
the	O
drug.	O
We	O
report	O
a	O
case	O
of	O
methyldopa	Chemical
-induced	O
hemolytic	Disease
anemia	Disease
in	O
a	O
15-year-old	O
boy	O
who	O
presented	O
to	O
the	O
emergency	Disease
department	Disease
with	O
near-	O
syncope	Disease
.	O
The	O
boy	O
had	O
been	O
treated	O
with	O
intravenous	O
methyldopa	Chemical
during	O
a	O
trauma	Disease
admission	O
seven	O
weeks	O
prior	O
to	O
presentation.	O
Evaluation	O
revealed	O
a	O
hemoglobin	O
of	O
three	O
grams,	O
3+	O
Coombs'	O
test	O
with	O
polyspecific	O
anti-human	O
globulin	O
and	O
monospecific	O
IgG	O
reagents,	O
and	O
a	O
warm	O
reacting	O
autoantibody.	O
Transfusion	O
and	O
corticosteroid	Chemical
therapy	O
resulted	O
in	O
a	O
complete	O
recovery	O
of	O
the	O
patient.	O
Emergency	O
physicians	O
treating	O
children	O
must	O
be	O
aware	O
of	O
this	O
syndrome	O
in	O
order	O
to	O
diagnose	O
and	O
treat	O
it	O
correctly.	O
A	O
brief	O
review	O
of	O
autoimmune	O
and	O
drug-induced	O
hemolytic	Disease
anemias	Disease

The	O
long-term	O
safety	O
of	O
danazol	Chemical
in	O
women	O
with	O
hereditary	Disease
angioedema	Disease
.	O
Although	O
the	O
short-term	O
safety	O
(less	O
than	O
or	O
equal	O
to	O
6	O
months)	O
of	O
danazol	Chemical
has	O
been	O
established	O
in	O
a	O
variety	O
of	O
settings,	O
no	O
information	O
exists	O
as	O
to	O
its	O
long-term	O
safety.	O
We	O
therefore	O
investigated	O
the	O
long-term	O
safety	O
of	O
danazol	Chemical
by	O
performing	O
a	O
retrospective	O
chart	O
review	O
of	O
60	O
female	O
patients	O
with	O
hereditary	Disease
angioedema	Disease
treated	O
with	O
danazol	Chemical
for	O
a	O
continuous	O
period	O
of	O
6	O
months	O
or	O
longer.	O
The	O
mean	O
age	O
of	O
the	O
patients	O
was	O
35.2	O
years	O
and	O
the	O
mean	O
duration	O
of	O
therapy	O
was	O
59.7	O
months.	O
Virtually	O
all	O
patients	O
experienced	O
one	O
or	O
more	O
adverse	O
reactions.	O
Menstrual	Disease
abnormalities	Disease
(79%),	O
weight	Disease
gain	Disease
(60%),	O
muscle	Disease
cramps	Disease
/	O
myalgias	Disease
(40%),	O
and	O
transaminase	O
elevations	O
(40%)	O
were	O
the	O
most	O
common	O
adverse	O
reactions.	O
The	O
drug	O
was	O
discontinued	O
due	O
to	O
adverse	O
reactions	O
in	O
8	O
patients.	O
No	O
patient	O
has	O
died	O
or	O
suffered	O
any	O
apparent	O
long-term	O
sequelae	O
that	O
were	O
directly	O
attributable	O
to	O
the	O
drug.	O
We	O
conclude	O
that,	O
despite	O
a	O
relatively	O
high	O
incidence	O
of	O
adverse	O
reactions,	O
danazol	Chemical

Patient	O
tolerance	O
study	O
of	O
topical	O
chlorhexidine	Chemical
diphosphanilate	Chemical
:	O
a	O
new	O
topical	O
agent	O
for	O
burns	Disease
.	O
Effective	O
topical	O
antimicrobial	O
agents	O
decrease	O
infection	Disease
and	O
mortality	O
in	O
burn	Disease
patients.	O
Chlorhexidine	Chemical
phosphanilate	Chemical
(	O
CHP	Chemical
),	O
a	O
new	O
broad-spectrum	O
antimicrobial	O
agent,	O
has	O
been	O
evaluated	O
as	O
a	O
topical	O
burn	Disease
wound	O
dressing	O
in	O
cream	O
form,	O
but	O
preliminary	O
clinical	O
trials	O
reported	O
that	O
it	O
was	O
painful	O
upon	O
application.	O
This	O
study	O
compared	O
various	O
concentrations	O
of	O
CHP	Chemical
to	O
determine	O
if	O
a	O
tolerable	O
concentration	O
could	O
be	O
identified	O
with	O
retention	O
of	O
antimicrobial	O
efficacy.	O
Twenty-nine	O
burn	Disease
patients,	O
each	O
with	O
two	O
similar	O
burns	Disease
which	O
could	O
be	O
separately	O
treated,	O
were	O
given	O
pairs	O
of	O
treatments	O
at	O
successive	O
12-h	O
intervals	O
over	O
a	O
3-day	O
period.	O
One	O
burn	Disease
site	O
was	O
treated	O
with	O
each	O
of	O
four	O
different	O
CHP	Chemical
concentrations,	O
from	O
0.25	O
per	O
cent	O
to	O
2	O
per	O
cent,	O
their	O
vehicle,	O
and	O
1	O
per	O
cent	O
silver	Chemical
sulphadiazine	Chemical
(	O
AgSD	Chemical
)	O
cream,	O
an	O
antimicrobial	O
agent	O
frequently	O
used	O
for	O
topical	O
treatment	O
of	O
burn	Disease
wounds.	O
The	O
other	O
site	O
was	O
always	O
treated	O
with	O
AgSD	Chemical
cream.	O
There	O
was	O
a	O
direct	O
relationship	O
between	O
CHP	Chemical
concentration	O
and	O
patients'	O
ratings	O
of	O
pain	Disease
on	O
an	O
analogue	O
scale.	O
The	O
0.25	O
per	O
cent	O
CHP	Chemical
cream	O
was	O
closest	O
to	O
AgSD	Chemical
in	O
pain	Disease
tolerance;	O
however,	O
none	O
of	O
the	O
treatments	O
differed	O
statistically	O
from	O
AgSD	Chemical
or	O
from	O
each	O
other.	O
In	O
addition,	O
ease	O
of	O
application	O
of	O
CHP	Chemical
creams	O
was	O
less	O
satisfactory	O
than	O
that	O
of	O
AgSD	Chemical
.	O
It	O
was	O
concluded	O
that	O
formulations	O
at	O
or	O
below	O
0.5	O
per	O
cent	O
CHP	Chemical

Dose-dependent	O
neurotoxicity	Disease
of	O
high-dose	O
busulfan	Chemical
in	O
children:	O
a	O
clinical	O
and	O
pharmacological	O
study.	O
Busulfan	Chemical
is	O
known	O
to	O
be	O
neurotoxic	Disease
in	O
animals	O
and	O
humans,	O
but	O
its	O
acute	O
neurotoxicity	Disease
remains	O
poorly	O
characterized	O
in	O
children.	O
We	O
report	O
here	O
a	O
retrospective	O
study	O
of	O
123	O
children	O
(median	O
age,	O
6.5	O
years)	O
receiving	O
high-dose	O
busulfan	Chemical
in	O
combined	O
chemotherapy	O
before	O
bone	O
marrow	O
transplantation	O
for	O
malignant	O
solid	O
tumors	Disease
,	O
brain	Disease
tumors	Disease
excluded.	O
Busulfan	Chemical
was	O
given	O
p.o.,	O
every	O
6	O
hours	O
for	O
16	O
doses	O
over	O
4	O
days.	O
Two	O
total	O
doses	O
were	O
consecutively	O
used:	O
16	O
mg/kg,	O
then	O
600	O
mg/m2.	O
The	O
dose	O
calculation	O
on	O
the	O
basis	O
of	O
body	O
surface	O
area	O
results	O
in	O
higher	O
doses	O
in	O
young	O
children	O
than	O
in	O
older	O
patients	O
(16	O
to	O
28	O
mg/kg).	O
Ninety-six	O
patients	O
were	O
not	O
given	O
anticonvulsive	O
prophylaxis;	O
7	O
(7.5%)	O
developed	O
seizures	Disease
during	O
the	O
4	O
days	O
of	O
the	O
busulfan	Chemical
course	O
or	O
within	O
24	O
h	O
after	O
the	O
last	O
dosing.	O
When	O
the	O
total	O
busulfan	Chemical
dose	O
was	O
taken	O
into	O
account,	O
there	O
was	O
a	O
significant	O
difference	O
in	O
terms	O
of	O
neurotoxicity	Disease
incidence	O
among	O
patients	O
under	O
16	O
mg/kg	O
(1	O
of	O
57,	O
1.7%)	O
and	O
patients	O
under	O
600	O
mg/m2	O
(6	O
of	O
39,	O
15.4%)	O
(P	O
less	O
than	O
0.02).	O
Twenty-seven	O
patients	O
were	O
given	O
a	O
600-mg/m2	O
busulfan	Chemical
total	O
dose	O
with	O
continuous	O
i.v.	O
infusion	O
of	O
clonazepam	Chemical
;	O
none	O
had	O
any	O
neurological	Disease
symptoms	Disease
.	O
Busulfan	Chemical
levels	O
were	O
measured	O
by	O
a	O
gas	O
chromatographic-mass	O
spectrometry	O
assay	O
in	O
the	O
plasma	O
and	O
cerebrospinal	O
fluid	O
of	O
9	O
children	O
without	O
central	Disease
nervous	Disease
system	Disease
disease	Disease
under	O
600	O
mg/m2	O
busulfan	Chemical
with	O
clonazepam	Chemical
:	O
busulfan	Chemical
cerebrospinal	O
fluid:plasma	O
ratio	O
was	O
1.39.	O
This	O
was	O
significantly	O
different	O
(P	O
less	O
than	O
0.02)	O
from	O
the	O
cerebrospinal	O
fluid:plasma	O
ratio	O
previously	O
defined	O
in	O
children	O
receiving	O
a	O
16-mg/kg	O
total	O
dose	O
of	O
busulfan	Chemical
.	O
This	O
study	O
shows	O
that	O
busulfan	Chemical
	O
neurotoxicity	Disease
is	O
dose-dependent	O
in	O
children	O
and	O
efficiently	O
prevented	O
by	O
clonazepam	Chemical
.	O
A	O
busulfan	Chemical
dose	O
calculated	O
on	O
the	O
basis	O
of	O
body	O
surface	O
area,	O
resulting	O
in	O
higher	O
doses	O
in	O
young	O
children,	O
was	O
followed	O
by	O
increased	O
neurotoxicity	Disease
,	O
close	O
to	O
neurotoxicity	Disease
incidence	O
observed	O
in	O
adults.	O
Since	O
plasma	O
pharmacokinetic	O
studies	O
showed	O
a	O
faster	O
busulfan	Chemical
clearance	O
in	O
children	O
than	O
in	O
adults,	O
this	O
new	O
dose	O
may	O
approximate	O
more	O
closely	O
the	O
adult	O
systemic	O
exposure	O
obtained	O
after	O
the	O
usual	O
16-mg/kg	O
total	O
dose,	O
with	O
potential	O
inferences	O
in	O
terms	O
of	O
anticancer	O
or	O
myeloablative	O
effects.	O
The	O
busulfan	Chemical

Histamine	Chemical
antagonists	O
and	O
d-tubocurarine	Chemical
-induced	O
hypotension	Disease
in	O
cardiac	O
surgical	O
patients.	O
Hemodynamic	O
effects	O
and	O
histamine	Chemical
release	O
by	O
bolus	O
injection	O
of	O
0.35	O
mg/kg	O
of	O
d-tubocurarine	Chemical
were	O
studied	O
in	O
24	O
patients.	O
H1-	O
and	O
H2-	O
histamine	Chemical
antagonists	O
or	O
placebo	O
were	O
given	O
before	O
dosing	O
with	O
d-tubocurarine	Chemical
in	O
a	O
randomized	O
double-blind	O
fashion	O
to	O
four	O
groups:	O
group	O
1--placebo;	O
group	O
2--	O
cimetidine	Chemical
,	O
4	O
mg/kg,	O
plus	O
placebo;	O
group	O
3--	O
chlorpheniramine	Chemical
,	O
0.1	O
mg/kg,	O
plus	O
placebo;	O
and	O
group	O
4--	O
cimetidine	Chemical
plus	O
chlorpheniramine	Chemical
.	O
Histamine	Chemical
release	O
occurred	O
in	O
most	O
patients,	O
the	O
highest	O
level	O
2	O
minutes	O
after	O
d-tubocurarine	Chemical
dosing.	O
Group	O
1	O
had	O
a	O
moderate	O
negative	O
correlation	O
between	O
plasma	O
histamine	Chemical
change	O
and	O
systemic	O
vascular	O
resistance	O
(r	O
=	O
0.58;	O
P	O
less	O
than	O
0.05)	O
not	O
present	O
in	O
group	O
4.	O
Prior	O
dosing	O
with	O
antagonists	O
partially	O
prevented	O
the	O
fall	O
in	O
systemic	O
vascular	O
resistance.	O
These	O
data	O
demonstrate	O
that	O
the	O
hemodynamic	O
changes	O
associated	O
with	O
d-tubocurarine	Chemical
dosing	O
are	O
only	O
partially	O
explained	O
by	O
histamine	Chemical

Convulsant	O
effect	O
of	O
lindane	Chemical
and	O
regional	O
brain	O
concentration	O
of	O
GABA	Chemical
and	O
dopamine	Chemical
.	O
Lindane	Chemical
(	O
gamma-hexachlorocyclohexane	Chemical
)	O
is	O
an	O
organochlorine	O
insecticide	O
with	O
known	O
neurotoxic	Disease
effects.	O
Its	O
mechanism	O
of	O
action	O
is	O
not	O
well	O
understood	O
although	O
it	O
has	O
been	O
proposed	O
that	O
lindane	Chemical
acts	O
as	O
a	O
non-competitive	O
antagonist	O
at	O
the	O
gamma-aminobutyric	Chemical
acid	Chemical
(	O
GABA	Chemical
)-A	O
receptor.	O
We	O
studied	O
the	O
effect	O
of	O
lindane	Chemical
(150	O
mg/kg)	O
on	O
the	O
GABAergic	O
and	O
dopaminergic	O
systems	O
by	O
measuring	O
the	O
concentration	O
of	O
GABA	Chemical
,	O
dopamine	Chemical
and	O
its	O
metabolites	O
in	O
7	O
brain	O
areas	O
at	O
the	O
onset	O
of	O
seizures	Disease
.	O
All	O
animals	O
suffered	O
tonic	O
convulsions	Disease
at	O
18.3	O
+/-	O
1.4	O
min	O
after	O
lindane	Chemical
administration.	O
The	O
concentration	O
of	O
GABA	Chemical
was	O
only	O
slightly	O
but	O
significantly	O
decreased	O
in	O
the	O
colliculi	O
without	O
modifications	O
in	O
the	O
other	O
areas.	O
The	O
concentration	O
of	O
dopamine	Chemical
was	O
increased	O
in	O
the	O
mesencephalon	O
and	O
that	O
of	O
its	O
metabolite	O
DOPAC	Chemical

Unusual	O
complications	O
of	O
antithyroid	O
drug	O
therapy:	O
four	O
case	O
reports	O
and	O
review	O
of	O
literature.	O
Two	O
cases	O
of	O
propylthiouracil	Chemical
-associated	O
acute	O
hepatitis	Disease
,	O
one	O
case	O
of	O
fatal	O
methimazole	Chemical
-associated	O
hepatocellular	Disease
necrosis	Disease
and	O
one	O
case	O
of	O
propylthiouracil	Chemical
-associated	O
lupus-like	Disease
syndrome	Disease
are	O
described.	O
The	O
literature	O
related	O
to	O
antithyroid	O
drug	O
side	O
effects	O
and	O
the	O
mechanisms	O
for	O
their	O
occurrence	O
are	O
reviewed	O
and	O
the	O
efficacy	O
and	O
complications	O
of	O
thyroidectomy	O
and	O
radioiodine	O
compared	O
to	O
those	O
of	O
antithyroid	O
drugs.	O
It	O
is	O
concluded	O
that	O
in	O
most	O
circumstances	O
131I	O
is	O
the	O
therapy	O
of	O
choice	O
for	O
hyperthyroidism	Disease

Anticonvulsant	O
actions	O
of	O
MK-801	Chemical
on	O
the	O
lithium	Chemical
-	O
pilocarpine	Chemical
model	O
of	O
status	Disease
epilepticus	Disease
in	O
rats.	O
MK-801	Chemical
,	O
a	O
noncompetitive	O
N-methyl-D-aspartate	Chemical
(	O
NMDA	Chemical
)	O
receptor	O
antagonist,	O
was	O
tested	O
for	O
anticonvulsant	O
effects	O
in	O
rats	O
using	O
two	O
seizure	Disease
models,	O
coadministration	O
of	O
lithium	Chemical
and	O
pilocarpine	Chemical
and	O
administration	O
of	O
a	O
high	O
dose	O
of	O
pilocarpine	Chemical
alone.	O
Three	O
major	O
results	O
are	O
reported.	O
First,	O
pretreatment	O
with	O
MK-801	Chemical
produced	O
an	O
effective	O
and	O
dose-dependent	O
anticonvulsant	O
action	O
with	O
the	O
lithium	Chemical
-	O
pilocarpine	Chemical
model	O
but	O
not	O
with	O
rats	O
treated	O
with	O
pilocarpine	Chemical
alone,	O
suggesting	O
that	O
different	O
biochemical	O
mechanisms	O
control	O
seizures	Disease
in	O
these	O
two	O
models.	O
Second,	O
the	O
anticonvulsant	O
effect	O
of	O
MK-801	Chemical
in	O
the	O
lithium	Chemical
-	O
pilocarpine	Chemical
model	O
only	O
occurred	O
after	O
initial	O
periods	O
of	O
seizure	Disease
activity.	O
This	O
observation	O
is	O
suggested	O
to	O
be	O
an	O
in	O
vivo	O
demonstration	O
of	O
the	O
conclusion	O
derived	O
from	O
in	O
vitro	O
experiments	O
that	O
MK-801	Chemical
binding	O
requires	O
agonist-induced	O
opening	O
of	O
the	O
channel	O
sites	O
of	O
the	O
NMDA	Chemical
receptor.	O
Third,	O
although	O
it	O
is	O
relatively	O
easy	O
to	O
block	O
seizures	Disease
induced	O
by	O
lithium	Chemical
and	O
pilocarpine	Chemical
by	O
administration	O
of	O
anticonvulsants	O
prior	O
to	O
pilocarpine	Chemical
,	O
it	O
is	O
more	O
difficult	O
to	O
terminate	O
ongoing	O
status	Disease
epilepticus	Disease
and	O
block	O
the	O
lethality	O
of	O
the	O
seizures	Disease
.	O
Administration	O
of	O
MK-801	Chemical
30	O
or	O
60	O
min	O
after	O
pilocarpine	Chemical
,	O
i.e.,	O
during	O
status	Disease
epilepticus	Disease
,	O
gradually	O
reduced	O
electrical	O
and	O
behavioral	O
seizure	Disease
activity	O
and	O
greatly	O
enhanced	O
the	O
survival	O
rate.	O
These	O
results	O
suggest	O
that	O
activation	O
of	O
NMDA	Chemical
receptors	O
plays	O
an	O
important	O
role	O
in	O
status	Disease
epilepticus	Disease
and	O
brain	Disease
damage	Disease
in	O
the	O
lithium	Chemical
-	O
pilocarpine	Chemical
model.	O
This	O
was	O
further	O
supported	O
by	O
results	O
showing	O
that	O
nonconvulsive	O
doses	O
of	O
NMDA	Chemical
and	O
pilocarpine	Chemical
were	O
synergistic,	O
resulting	O
in	O
status	Disease
epilepticus	Disease

Nifedipine	Chemical
induced	O
bradycardia	Disease
in	O
a	O
patient	O
with	O
autonomic	Disease
neuropathy	Disease
.	O
An	O
80	O
year	O
old	O
diabetic	Disease
male	O
with	O
evidence	O
of	O
peripheral	Disease
and	Disease
autonomic	Disease
neuropathy	Disease
was	O
admitted	O
with	O
chest	Disease
pain	Disease
.	O
He	O
was	O
found	O
to	O
have	O
atrial	Disease
flutter	Disease
at	O
a	O
ventricular	O
rate	O
of	O
70/min	O
which	O
slowed	O
down	O
to	O
30-40/min	O
when	O
nifedipine	Chemical
(60	O
mg)	O
in	O
3	O
divided	O
doses,	O
during	O
which	O
he	O
was	O
paced	O
at	O
a	O
rate	O
of	O
70/min.	O
This	O
is	O
inconsistent	O
with	O
the	O
well-established	O
finding	O
that	O
nifedipine	Chemical
induces	O
tachycardia	Disease
in	O
normally	O
innervated	O
hearts.	O
However,	O
in	O
hearts	O
deprived	O
of	O
compensatory	O
sympathetic	O
drive,	O
it	O
may	O
lead	O
to	O
bradycardia	Disease

The	O
effect	O
of	O
haloperidol	Chemical
in	O
cocaine	Chemical
and	O
amphetamine	Chemical
intoxication.	O
The	O
effectiveness	O
of	O
haloperidol	Chemical
pretreatment	O
in	O
preventing	O
the	O
toxic	O
effects	O
of	O
high	O
doses	O
of	O
amphetamine	Chemical
and	O
cocaine	Chemical
was	O
studied	O
in	O
rats.	O
In	O
this	O
model,	O
toxic	O
effects	O
were	O
induced	O
by	O
intraperitoneal	O
(i.p.)	O
injection	O
of	O
amphetamine	Chemical
75	O
mg/kg	O
(100%	O
death	O
rate)	O
or	O
cocaine	Chemical
70	O
mg/kg	O
(82%	O
death	O
rate).	O
Haloperidol	Chemical
failed	O
to	O
prevent	O
amphetamine	Chemical
-induced	O
seizures	Disease
,	O
but	O
did	O
lower	O
the	O
mortality	O
rate	O
at	O
most	O
doses	O
tested.	O
Haloperidol	Chemical
decreased	O
the	O
incidence	O
of	O
cocaine	Chemical
-induced	O
seizures	Disease
at	O
the	O
two	O
highest	O
doses,	O
but	O
the	O
lowering	O
of	O
the	O
mortality	O
rate	O
did	O
not	O
reach	O
statistical	O
significance	O
at	O
any	O
dose.	O
These	O
data	O
suggest	O
a	O
protective	O
role	O
for	O
the	O
central	O
dopamine	Chemical
blocker	O
haloperidol	Chemical
against	O
death	O
from	O
high-dose	O
amphetamine	Chemical
exposure	O
without	O
reducing	O
the	O
incidence	O
of	O
seizures	Disease
.	O
In	O
contrast,	O
haloperidol	Chemical
demonstrated	O
an	O
ability	O
to	O
reduce	O
cocaine	Chemical
-induced	O
seizures	Disease

Autoradiographic	O
evidence	O
of	O
estrogen	Chemical
binding	O
sites	O
in	O
nuclei	O
of	O
diethylstilbesterol	Chemical
induced	O
hamster	O
renal	Disease
carcinomas	Disease
.	O
Estrogen	Chemical
binding	O
sites	O
were	O
demonstrated	O
by	O
autoradiography	O
in	O
one	O
transplantable	O
and	O
five	O
primary	O
diethylstilbesterol	Chemical
induced	O
renal	Disease
carcinomas	Disease
in	O
three	O
hamsters.	O
Radiolabelling,	O
following	O
the	O
in	O
vivo	O
injection	O
of	O
3H-17	O
beta	O
estradiol	Chemical
,	O
was	O
increased	O
only	O
over	O
the	O
nuclei	O
of	O
tumor	Disease
cells;	O
stereologic	O
analysis	O
revealed	O
a	O
4.5-	O
to	O
6.7-times	O
higher	O
concentration	O
of	O
reduced	O
silver	Chemical
grains	O
over	O
nuclei	O
than	O
cytoplasm	O
of	O
these	O
cells.	O
Despite	O
rapid	O
tubular	O
excretion	O
of	O
estradiol	Chemical
which	O
peaked	O
in	O
less	O
than	O
1	O
h,	O
the	O
normal	O
cells	O
did	O
not	O
appear	O
to	O
bind	O
the	O
ligand.	O
This	O
is	O
the	O
first	O
published	O
report	O
documenting	O
the	O
preferential	O
in	O
vivo	O
binding	O
of	O
estrogen	Chemical
to	O
nuclei	O
of	O
cells	O
in	O
estrogen	Chemical
induced	O
hamster	O
renal	Disease
carcinomas	Disease

Bradycardia	Disease
due	O
to	O
biperiden	Chemical
.	O
In	O
a	O
38-year-old	O
male	O
patient	O
suffering	O
from	O
a	O
severe	O
postzosteric	Disease
	O
trigeminal	Disease
neuralgia	Disease
,	O
intravenous	O
application	O
of	O
10	O
mg	O
biperiden	Chemical
lactate	Chemical
led	O
to	O
a	O
long-lasting	O
paradoxical	O
reaction	O
characterized	O
by	O
considerable	O
bradycardia	Disease
,	O
dysarthria	Disease
,	O
and	O
dysphagia	Disease
.	O
The	O
heart	O
rate	O
was	O
back	O
to	O
normal	O
within	O
12	O
hours	O
upon	O
administration	O
of	O
orciprenaline	Chemical
under	O
cardiac	O
monitoring	O
in	O
an	O
intensive	O
care	O
unit.	O
Bradycardia	Disease
induced	O
by	O
biperiden	Chemical
is	O
attributed	O
to	O
the	O
speed	O
of	O
injection	O
and	O
to	O
a	O
dose-related	O
dual	O
effect	O
of	O
atropine	Chemical
-like	O
drugs	O
on	O
muscarine	Chemical

Deliberate	O
hypotension	Disease
induced	O
by	O
labetalol	Chemical
with	O
halothane	Chemical
,	O
enflurane	Chemical
or	O
isoflurane	Chemical
for	O
middle-ear	O
surgery.	O
The	O
feasibility	O
of	O
using	O
labetalol	Chemical
,	O
an	O
alpha-	O
and	O
beta-adrenergic	O
blocking	O
agent,	O
as	O
a	O
hypotensive	Disease
agent	O
in	O
combination	O
with	O
inhalation	O
anaesthetics	O
(	O
halothane	Chemical
,	O
enflurane	Chemical
or	O
isoflurane	Chemical
)	O
was	O
studied	O
in	O
23	O
adult	O
patients	O
undergoing	O
middle-ear	O
surgery.	O
The	O
mean	O
arterial	O
pressure	O
was	O
decreased	O
from	O
86	O
+/-	O
5	O
(s.e.	O
mean)	O
mmHg	O
to	O
52	O
+/-	O
1	O
mmHg	O
(11.5	O
+/-	O
0.7	O
to	O
6.9	O
+/-	O
0.1	O
kPa)	O
for	O
98	O
+/-	O
10	O
min	O
in	O
the	O
halothane	Chemical
(	O
H	Chemical
)	O
group,	O
from	O
79	O
+/-	O
5	O
to	O
53	O
+/-	O
1	O
mmHg	O
(10.5	O
+/-	O
0.7	O
to	O
7.1	O
+/-	O
0.1	O
kPa)	O
for	O
129	O
+/-	O
11	O
min	O
in	O
the	O
enflurane	Chemical
(	O
E	Chemical
)	O
group,	O
and	O
from	O
80	O
+/-	O
4	O
to	O
49	O
+/-	O
1	O
mmHg	O
(10.7	O
+/-	O
0.5	O
to	O
6.5	O
+/-	O
0.1	O
kPa)	O
for	O
135	O
+/-	O
15	O
min	O
in	O
the	O
isoflurane	Chemical
(	O
I	Chemical
)	O
group.	O
The	O
mean	O
H	Chemical
concentration	O
during	O
hypotension	Disease
in	O
the	O
inspiratory	O
gas	O
was	O
0.7	O
+/-	O
0.1	O
vol%,	O
the	O
mean	O
E	Chemical
concentration	O
1.6	O
+/-	O
0.2	O
vol%,	O
and	O
the	O
mean	O
I	Chemical
concentration	O
1.0	O
+/-	O
0.1	O
vol%.	O
In	O
addition,	O
the	O
patients	O
received	O
fentanyl	Chemical
and	O
d-tubocurarine	Chemical
.	O
The	O
initial	O
dose	O
of	O
labetalol	Chemical
for	O
lowering	O
blood	O
pressure	O
was	O
similar,	O
0.52-0.59	O
mg/kg,	O
in	O
all	O
the	O
groups.	O
During	O
hypotension	Disease
,	O
the	O
heart	O
rate	O
was	O
stable	O
without	O
tachy-	Disease
or	Disease
bradycardia	Disease
.	O
The	O
operating	O
conditions	O
regarding	O
bleeding	Disease
were	O
estimated	O
in	O
a	O
double-blind	O
manner,	O
and	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
groups.	O
During	O
hypotension	Disease
,	O
the	O
serum	O
creatinine	Chemical
concentration	O
rose	O
significantly	O
in	O
all	O
groups	O
from	O
the	O
values	O
before	O
hypotension	Disease
and	O
returned	O
postoperatively	O
to	O
the	O
initial	O
level	O
in	O
the	O
other	O
groups,	O
except	O
the	O
isoflurane	Chemical
group.	O
After	O
hypotension	Disease
there	O
was	O
no	O
rebound	O
phenomenon	O
in	O
either	O
blood	O
pressure	O
or	O
heart	O
rate.	O
These	O
results	O
indicate	O
that	O
labetalol	Chemical
induces	O
easily	O
adjustable	O
hypotension	Disease
without	O
compensatory	O
tachycardia	Disease
and	O
rebound	O
hypertension	Disease

Convulsion	Disease
following	O
intravenous	O
fluorescein	Chemical
angiography.	O
Tonic-clonic	Disease
seizures	Disease
followed	O
intravenous	O
fluorescein	Chemical
injection	O
for	O
fundus	O
angiography	O
in	O
a	O
47-year-old	O
male.	O
Despite	O
precautions	O
this	O
adverse	O
reaction	O
recurred	O
on	O
re-exposure	O
to	O
intravenous	O
fluorescein	Chemical

Pharmacology	O
of	O
ACC-9653	Chemical
(	O
phenytoin	Chemical
prodrug).	O
ACC-9653	Chemical
,	O
the	O
disodium	Chemical
phosphate	Chemical
ester	Chemical
of	O
3-hydroxymethyl-5,5-diphenylhydantoin	Chemical
,	O
is	O
a	O
prodrug	O
of	O
phenytoin	Chemical
with	O
advantageous	O
physicochemical	O
properties.	O
ACC-9653	Chemical
is	O
rapidly	O
converted	O
enzymatically	O
to	O
phenytoin	Chemical
in	O
vivo.	O
ACC-9653	Chemical
and	O
phenytoin	Chemical
sodium	Chemical
have	O
equivalent	O
anticonvulsant	O
activity	O
against	O
seizures	Disease
induced	O
by	O
maximal	O
electroshock	O
(MES)	O
in	O
mice	O
following	O
i.p.,	O
oral,	O
or	O
i.v.	O
administration.	O
The	O
ED50	O
doses	O
were	O
16	O
mg/kg	O
for	O
i.v.	O
ACC-9653	Chemical
and	O
8	O
mg/kg	O
for	O
i.v.	O
phenytoin	Chemical
sodium	Chemical
.	O
ACC-9653	Chemical
and	O
phenytoin	Chemical
sodium	Chemical
have	O
similar	O
antiarrhythmic	O
activity	O
against	O
ouabain	Chemical
-induced	O
ventricular	Disease
tachycardia	Disease
in	O
anesthetized	O
dogs.	O
The	O
total	O
doses	O
of	O
ACC-9653	Chemical
or	O
phenytoin	Chemical
sodium	Chemical
necessary	O
to	O
convert	O
the	O
arrhythmia	Disease
to	O
a	O
normal	O
sinus	O
rhythm	O
were	O
24	O
+/-	O
6	O
and	O
14	O
+/-	O
3	O
mg/kg,	O
respectively.	O
Only	O
phenytoin	Chemical
sodium	Chemical
displayed	O
in	O
vitro	O
antiarrhythmic	O
activity	O
against	O
strophanthidin	Chemical
-induced	O
arrhythmias	Disease
in	O
guinea	O
pig	O
right	O
atria.	O
In	O
anesthetized	O
dogs,	O
a	O
high	O
dose	O
of	O
ACC-9653	Chemical
(31	O
mg/kg)	O
was	O
infused	O
over	O
15,	O
20,	O
and	O
30	O
min	O
and	O
the	O
responses	O
were	O
compared	O
to	O
an	O
equimolar	O
dose	O
of	O
phenytoin	Chemical
sodium	Chemical
(21	O
mg/kg).	O
The	O
ACC-9653	Chemical
and	O
phenytoin	Chemical
sodium	Chemical
treatments	O
produced	O
similar	O
marked	O
reductions	O
in	O
diastolic	O
blood	O
pressure	O
and	O
contractile	O
force	O
(LVdP/dt).	O
The	O
maximum	O
effects	O
of	O
each	O
treatment	O
occurred	O
at	O
the	O
time	O
of	O
maximum	O
phenytoin	Chemical
sodium	Chemical
levels.	O
Acute	O
toxicity	Disease
studies	O
of	O
ACC-9653	Chemical
and	O
phenytoin	Chemical
sodium	Chemical
were	O
carried	O
out	O
in	O
mice,	O
rats,	O
rabbits,	O
and	O
dogs	O
by	O
i.v.,	O
i.m.,	O
and	O
i.p.	O
routes	O
of	O
administration.	O
The	O
systemic	O
toxic	O
signs	O
of	O
both	O
agents	O
were	O
similar	O
and	O
occurred	O
at	O
approximately	O
equivalent	O
doses.	O
Importantly,	O
the	O
local	O
irritation	O
of	O
ACC-9653	Chemical
was	O
markedly	O
less	O
than	O
phenytoin	Chemical
sodium	Chemical

Phenytoin	Chemical
induced	O
fatal	O
hepatic	Disease
injury	Disease
.	O
A	O
61	O
year	O
old	O
female	O
developed	O
fatal	O
hepatic	Disease
failure	Disease
after	O
phenytoin	Chemical
administration.	O
A	O
typical	O
multisystem	O
clinical	O
pattern	O
precedes	O
the	O
manifestations	O
of	O
hepatic	Disease
injury	Disease
.	O
The	O
hematologic,	O
biochemical	O
and	O
pathologic	O
features	O
indicate	O
a	O
mixed	O
hepatocellular	Disease
damage	Disease
due	O
to	O
drug	Disease
hypersensitivity	Disease
.	O
In	O
a	O
patient	O
receiving	O
phenytoin	Chemical

Treatment	O
of	O
lethal	O
pertussis	Chemical
vaccine	Chemical
reaction	O
with	O
histamine	Chemical
H1	O
antagonists.	O
We	O
studied	O
mortality	O
after	O
pertussis	Disease
immunization	O
in	O
the	O
mouse.	O
Without	O
treatment,	O
73	O
of	O
92	O
animals	O
(80%)	O
died	O
after	O
injection	O
of	O
bovine	O
serum	O
albumin	O
(BSA)	O
on	O
day	O
+7	O
of	O
pertussis	Disease
immunization.	O
After	O
pretreatment	O
with	O
3	O
mg	O
of	O
cyproheptadine	Chemical
,	O
2	O
mg	O
mianserin	Chemical
,	O
or	O
2	O
mg	O
chlorpheniramine	Chemical
,	O
only	O
5	O
of	O
105	O
animals	O
(5%)	O
died	O
after	O
receiving	O
BSA	O
on	O
day	O
+7	O
(p	O
less	O
than	O
0.001).	O
Blockade	O
of	O
histamine	Chemical
H1	O
receptors	O
may	O
reduce	O
mortality	O
in	O
pertussis	Disease
immunization-induced	O
encephalopathy	Disease

Support	O
for	O
adrenaline	Chemical
-	O
hypertension	Disease
hypothesis:	O
18	O
hour	O
pressor	O
effect	O
after	O
6	O
hours	O
adrenaline	Chemical
infusion.	O
In	O
a	O
double	O
blind,	O
crossover	O
study	O
6	O
h	O
infusions	O
of	O
adrenaline	Chemical
(15	O
ng/kg/min;	O
1	O
ng	O
=	O
5.458	O
pmol),	O
noradrenaline	Chemical
(30	O
ng/kg/min;	O
1	O
ng	O
=	O
5.911	O
pmol),	O
and	O
a	O
5%	O
dextrose	Chemical
solution	O
(5.4	O
ml/h),	O
were	O
given	O
to	O
ten	O
healthy	O
volunteers	O
in	O
random	O
order	O
2	O
weeks	O
apart.	O
By	O
means	O
of	O
intra-arterial	O
ambulatory	O
monitoring	O
the	O
haemodynamic	O
effects	O
were	O
followed	O
for	O
18	O
h	O
after	O
the	O
infusions	O
were	O
stopped.	O
Adrenaline	Chemical
,	O
but	O
not	O
noradrenaline	Chemical
,	O
caused	O
a	O
delayed	O
and	O
protracted	O
pressor	O
effect.	O
Over	O
the	O
total	O
postinfusion	O
period	O
systolic	O
and	O
diastolic	O
arterial	O
pressure	O
were	O
6	O
(SEM	O
2)%	O
and	O
7	O
(2)%,	O
respectively,	O
higher	O
than	O
after	O
dextrose	Chemical
infusion	O
(ANOVA,	O
p	O
less	O
than	O
0.001).	O
Thus,	O
"stress"	O
levels	O
of	O
adrenaline	Chemical
(230	O
pg/ml)	O
for	O
6	O
h	O
cause	O
a	O
delayed	O
and	O
protracted	O
pressor	O
effect.	O
These	O
findings	O
are	O
strong	O
support	O
for	O
the	O
adrenaline	Chemical
-	O
hypertension	Disease

Effect	O
of	O
alkylxanthines	Chemical
on	O
gentamicin	Chemical
-induced	O
acute	Disease
renal	Disease
failure	Disease
in	O
the	O
rat.	O
Adenosine	Chemical
antagonists	O
have	O
been	O
previously	O
shown	O
to	O
be	O
of	O
benefit	O
in	O
some	O
ischaemic	Disease
and	O
nephrotoxic	Disease
models	O
of	O
acute	Disease
renal	Disease
failure	Disease
(	O
ARF	Disease
).	O
In	O
the	O
present	O
study,	O
the	O
effects	O
of	O
three	O
alkylxanthines	Chemical
with	O
different	O
potencies	O
as	O
adenosine	Chemical
antagonists	O
8-phenyltheophylline	Chemical
,	O
theophylline	Chemical
and	O
enprofylline	Chemical
,	O
were	O
examined	O
in	O
rats	O
developing	O
acute	Disease
renal	Disease
failure	Disease
after	O
4	O
daily	O
injections	O
of	O
gentamicin	Chemical
(200	O
mg	O
kg-1).	O
Renal	O
function	O
was	O
assessed	O
by	O
biochemical	O
(plasma	O
urea	Chemical
and	O
creatinine	Chemical
),	O
functional	O
(urine	O
analysis	O
and	O
[3H]inulin	O
and	O
[14C]	O
p-aminohippuric	Chemical
acid	Chemical
clearances)	O
and	O
morphological	O
(degree	O
of	O
necrosis	Disease
)	O
indices.	O
The	O
various	O
drug	O
treatments	O
produced	O
improvements	O
in	O
some,	O
but	O
not	O
all,	O
measurements	O
of	O
renal	O
function.	O
However,	O
any	O
improvement	O
produced	O
by	O
drug	O
treatment	O
was	O
largely	O
a	O
result	O
of	O
a	O
beneficial	O
effect	O
exerted	O
by	O
its	O
vehicle	O
(	O
polyethylene	Chemical
glycol	Chemical
and	O
NaOH	Chemical
).	O
The	O
lack	O
of	O
any	O
consistent	O
protective	O
effect	O
noted	O
with	O
the	O
alkylxanthines	Chemical
tested	O
in	O
the	O
present	O
study	O
indicates	O
that	O
adenosine	Chemical
plays	O
little,	O
if	O
any,	O
pathophysiological	O
role	O
in	O
gentamicin	Chemical
-induced	O
ARF	Disease

Adverse	O
ocular	O
reactions	O
possibly	O
associated	O
with	O
isotretinoin	Chemical
.	O
A	O
total	O
of	O
261	O
adverse	O
ocular	O
reactions	O
occurred	O
in	O
237	O
patients	O
who	O
received	O
isotretinoin	Chemical
,	O
a	O
commonly	O
used	O
drug	O
in	O
the	O
treatment	O
of	O
severe	O
cystic	O
acne	Disease
.	O
Blepharoconjunctivitis	Disease
,	O
subjective	O
complaints	O
of	O
dry	Disease
eyes	Disease
,	O
blurred	Disease
vision	Disease
,	O
contact	O
lens	O
intolerance,	O
and	O
photodermatitis	Disease
are	O
reversible	O
side	O
effects.	O
More	O
serious	O
ocular	O
adverse	O
reactions	O
include	O
papilledema	Disease
,	O
pseudotumor	Disease
cerebri	Disease
,	O
and	O
white	O
or	O
gray	O
subepithelial	O
corneal	Disease
opacities	Disease
;	O
all	O
of	O
these	O
are	O
reversible	O
if	O
the	O
drug	O
is	O
discontinued.	O
Reported	O
cases	O
of	O
decreased	O
dark	O
adaptation	O
are	O
under	O
investigation.	O
Isotretinoin	Chemical
is	O
contraindicated	O
in	O
pregnancy	O
because	O
of	O
the	O
many	O
reported	O
congenital	Disease
abnormalities	Disease
after	O
maternal	O
use	O
(including	O
microphthalmos	Disease
,	O
orbital	O
hypertelorism	Disease
,	O
and	O
optic	Disease
nerve	Disease
hypoplasia	Disease

Procaterol	Chemical
and	O
terbutaline	Chemical
in	O
bronchial	Disease
asthma	Disease
.	O
A	O
double-blind,	O
placebo-controlled,	O
cross-over	O
study.	O
Procaterol	Chemical
,	O
a	O
new	O
beta-2	O
adrenoceptor	O
stimulant,	O
was	O
studied	O
in	O
a	O
double-blind,	O
placebo-controlled,	O
cross-over	O
trial	O
in	O
patients	O
with	O
bronchial	Disease
asthma	Disease
.	O
Oral	O
procaterol	Chemical
50	O
micrograms	O
b.d.,	O
procaterol	Chemical
100	O
micrograms	O
b.d.,	O
and	O
terbutaline	Chemical
5	O
mg	O
t.i.d.,	O
were	O
compared	O
when	O
given	O
randomly	O
in	O
1-week	O
treatment	O
periods.	O
The	O
best	O
clinical	O
effect	O
was	O
found	O
with	O
terbutaline	Chemical
.	O
Both	O
anti-	O
asthmatic	Disease
and	O
tremorgenic	Disease
effects	O
of	O
procaterol	Chemical
were	O
dose-related.	O
Procaterol	Chemical

Subacute	O
effects	O
of	O
propranolol	Chemical
and	O
B	O
24/76	O
on	O
isoproterenol	Chemical
-induced	O
rat	O
heart	Disease
hypertrophy	Disease
in	O
correlation	O
with	O
blood	O
pressure.	O
We	O
compared	O
the	O
potential	O
beta-receptor	O
blocker,	O
B	O
24/76	O
i.e.	O
1-(2,4-dichlorophenoxy)-3[2-3,4-dimethoxyphenyl)ethanolamino]-prop	O
an-2-ol,	O
which	O
is	O
characterized	O
by	O
beta	O
1-adrenoceptor	O
blocking	O
and	O
beta	O
2-adrenoceptor	O
stimulating	O
properties	O
with	O
propranolol	Chemical
.	O
The	O
studies	O
were	O
performed	O
using	O
an	O
experimental	O
model	O
of	O
isoproterenol	Chemical
-induced	O
heart	Disease
hypertrophy	Disease
in	O
rats.	O
A	O
correlation	O
of	O
the	O
blood	O
pressure	O
was	O
neither	O
found	O
in	O
the	O
development	O
nor	O
in	O
the	O
attempt	O
to	O
suppress	O
the	O
development	O
of	O
heart	Disease
hypertrophy	Disease
with	O
the	O
two	O
beta-receptor	O
blockers.	O
Both	O
beta-blockers	O
influenced	O
the	O
development	O
of	O
hypertrophy	Disease
to	O
a	O
different,	O
but	O
not	O
reproducible	O
extent.	O
It	O
was	O
possible	O
to	O
suppress	O
the	O
increased	O
ornithine	Chemical
decarboxylase	O
activity	O
with	O
both	O
beta-blockers	O
in	O
hypertrophied	Disease
hearts	Disease
,	O
but	O
there	O
was	O
no	O
effect	O
on	O
the	O
heart	O
mass.	O
Neither	O
propranolol	Chemical
nor	O
B	O
24/76	O
could	O
stop	O
the	O
changes	O
in	O
the	O
characteristic	O
myosin	O
isoenzyme	O
pattern	O
of	O
the	O
hypertrophied	Disease
rat	O
heart.	O
Thus,	O
the	O
investigations	O
did	O
not	O
provide	O
any	O
evidence	O
that	O
the	O
beta-receptor	O
blockers	O
propranolol	Chemical
and	O
B	O
24/76	O
have	O
the	O
potency	O
to	O
prevent	O
isoproterenol	Chemical
from	O
producing	O
heart	Disease
hypertrophy	Disease

Comparison	O
of	O
the	O
effect	O
of	O
oxitropium	Chemical
bromide	Chemical
and	O
of	O
slow-release	O
theophylline	Chemical
on	O
nocturnal	O
asthma	Disease
.	O
The	O
effects	O
of	O
a	O
new	O
inhaled	O
antimuscarinic	O
drug,	O
oxitropium	Chemical
bromide	Chemical
,	O
and	O
of	O
a	O
slow-release	O
theophylline	Chemical
preparation	O
upon	O
nocturnal	O
asthma	Disease
were	O
compared	O
in	O
a	O
placebo-controlled	O
double-blind	O
study.	O
Two	O
samples	O
were	O
studied:	O
12	O
patients	O
received	O
oxitropium	Chemical
at	O
600	O
micrograms	O
(6	O
subjects)	O
or	O
at	O
400	O
micrograms	O
t.i.d.	O
(6	O
subjects)	O
whereas	O
11	O
received	O
theophylline	Chemical
at	O
300	O
mg	O
b.i.d.	O
Morning	O
dipping,	O
assessed	O
by	O
the	O
fall	O
in	O
peak	O
flow	O
overnight,	O
was	O
significantly	O
reduced	O
in	O
the	O
periods	O
when	O
either	O
active	O
drug	O
was	O
taken,	O
whereas	O
no	O
difference	O
was	O
noticed	O
during	O
the	O
placebo	O
administration.	O
No	O
significant	O
difference	O
was	O
noticed	O
between	O
results	O
obtained	O
with	O
either	O
active	O
drug,	O
as	O
well	O
as	O
with	O
either	O
dosage	O
of	O
oxitropium	Chemical
.	O
No	O
subject	O
reported	O
side	O
effects	O
of	O
oxitropium	Chemical
,	O
as	O
compared	O
to	O
three	O
subjects	O
reporting	O
nausea	Disease
,	O
vomiting	Disease
and	O
tremors	Disease
after	O
theophylline	Chemical
.	O
Oxitropium	Chemical
proves	O
to	O
be	O
a	O
valuable	O
alternative	O
to	O
theophylline	Chemical
in	O
nocturnal	O
asthma	Disease

Penicillin	Chemical
	O
anaphylaxis	Disease
.	O
A	O
case	O
of	O
oral	O
penicillin	Chemical
	O
anaphylaxis	Disease
is	O
described,	O
and	O
the	O
terminology,	O
occurrence,	O
clinical	O
manifestations,	O
pathogenesis,	O
prevention,	O
and	O
treatment	O
of	O
anaphylaxis	Disease
are	O
reviewed.	O
Emergency	O
physicians	O
should	O
be	O
aware	O
of	O
oral	O
penicillin	Chemical
	O
anaphylaxis	Disease

Reversible	O
valproic	Chemical
acid	Chemical
-induced	O
dementia	Disease
:	O
a	O
case	O
report.	O
Reversible	O
valproic	Chemical
acid	Chemical
-induced	O
dementia	Disease
was	O
documented	O
in	O
a	O
21-year-old	O
man	O
with	O
epilepsy	Disease
who	O
had	O
a	O
3-year	O
history	O
of	O
insidious	O
progressive	O
decline	O
in	O
global	O
cognitive	O
abilities	O
documented	O
by	O
serial	O
neuropsychological	O
studies.	O
Repeat	O
neuropsychological	O
testing	O
7	O
weeks	O
after	O
discontinuation	O
of	O
the	O
drug	O
revealed	O
dramatic	O
improvement	O
in	O
IQ,	O
memory,	O
naming,	O
and	O
other	O
tasks	O
commensurate	O
with	O
clinical	O
recovery	O
in	O
his	O
intellectual	O
capacity.	O
Possible	O
pathophysiological	O
mechanisms	O
which	O
may	O
have	O
been	O
operative	O
in	O
this	O
case	O
include:	O
a	O
direct	O
central	O
nervous	O
system	O
(CNS)	O
toxic	O
effect	O
of	O
valproic	Chemical
acid	Chemical
;	O
a	O
paradoxical	O
epileptogenic	O
effect	O
secondary	O
to	O
the	O
drug;	O
and	O
an	O
indirect	O
CNS	O
toxic	O
effect	O
mediated	O
through	O
valproic	Chemical
acid	Chemical
-induced	O
hyperammonemia	Disease

Reversal	O
of	O
scopolamine	Chemical
-induced	O
amnesia	Disease
of	O
passive	O
avoidance	O
by	O
pre-	O
and	O
post-training	O
naloxone	Chemical
.	O
In	O
a	O
series	O
of	O
five	O
experiments,	O
the	O
modulating	O
role	O
of	O
naloxone	Chemical
on	O
a	O
scopolamine	Chemical
-induced	O
retention	Disease
deficit	Disease
in	O
a	O
passive	O
avoidance	O
paradigm	O
was	O
investigated	O
in	O
mice.	O
Scopolamine	Chemical
,	O
but	O
not	O
methyl	Chemical
scopolamine	Chemical
(1	O
and	O
3	O
mg/kg),	O
induced	O
an	O
amnesia	Disease
as	O
measured	O
by	O
latency	O
and	O
duration	O
parameters.	O
Naloxone	Chemical
(0.3,	O
1,	O
3,	O
and	O
10	O
mg/kg)	O
injected	O
prior	O
to	O
training	O
attenuated	O
the	O
retention	Disease
deficit	Disease
with	O
a	O
peak	O
of	O
activity	O
at	O
3	O
mg/kg.	O
The	O
effect	O
of	O
naloxone	Chemical
could	O
be	O
antagonized	O
with	O
morphine	Chemical
(1,	O
3,	O
and	O
10	O
mg/kg),	O
demonstrating	O
the	O
opioid	O
specificity	O
of	O
the	O
naloxone	Chemical
effect.	O
Post-training	O
administration	O
of	O
naloxone	Chemical
(3	O
mg/kg)	O
as	O
a	O
single	O
or	O
as	O
a	O
split	O
dose	O
also	O
attenuated	O
the	O
scopolamine	Chemical
-induced	O
amnesia	Disease
.	O
Control	O
experiments	O
indicated	O
that	O
neither	O
an	O
increase	O
in	O
pain	Disease
sensitivity	O
(pre-training	O
naloxone	Chemical
)	O
nor	O
an	O
induced	O
aversive	O
state	O
(post-training	O
naloxone	Chemical
)	O
appear	O
to	O
be	O
responsible	O
for	O
the	O
influence	O
of	O
naloxone	Chemical
on	O
the	O
scopolamine	Chemical
-induced	O
retention	Disease
deficit	Disease

Electron	O
microscopic	O
investigations	O
of	O
the	O
cyclophosphamide	Chemical
-induced	O
lesions	Disease
of	Disease
the	Disease
urinary	Disease
bladder	Disease
of	O
the	O
rat	O
and	O
their	O
prevention	O
by	O
mesna	Chemical
.	O
Fully	O
developed	O
cyclophosphamide	Chemical
-induced	O
cystitis	Disease
is	O
characterized	O
by	O
nearly	O
complete	O
detachment	O
of	O
the	O
urothelium,	O
severe	O
submucosal	O
edema	Disease
owing	O
to	O
damage	O
to	O
the	O
microvascular	O
bed	O
and	O
focal	O
muscle	O
necroses	Disease
.	O
The	O
initial	O
response	O
to	O
the	O
primary	O
attack	O
by	O
the	O
cyclophosphamide	Chemical
metabolites	O
seems	O
to	O
be	O
fragmentation	O
of	O
the	O
luminal	Chemical
membrane.	O
This	O
damages	O
the	O
cellular	O
barrier	O
against	O
the	O
hypertonic	O
urine.	O
Subsequent	O
breaks	O
in	O
the	O
lateral	O
cell	O
membranes	O
of	O
the	O
superficial	O
cells	O
and	O
in	O
all	O
the	O
plasma	O
membranes	O
of	O
the	O
intermediate	O
and	O
basal	O
cells,	O
intercellular	O
and	O
intracellular	O
edema	Disease
and	O
disintegration	O
of	O
the	O
desmosomes	O
and	O
hemidesmosomes	O
lead	O
to	O
progressive	O
degeneration	O
and	O
detachment	O
of	O
the	O
epithelial	O
cells	O
with	O
exposure	O
and	O
splitting	O
of	O
the	O
basal	O
membrane.	O
The	O
morphological	O
changes	O
of	O
the	O
endothelial	O
cells,	O
which	O
become	O
more	O
pronounced	O
in	O
the	O
later	O
stages	O
of	O
the	O
experiment,	O
the	O
involvement	O
of	O
blood	O
vessels	O
regardless	O
of	O
their	O
diameter	O
and	O
the	O
location-dependent	O
extent	O
of	O
the	O
damage	O
indicate	O
a	O
direct	O
type	O
of	O
damage	O
which	O
is	O
preceded	O
by	O
a	O
mediator-induced	O
increase	O
in	O
permeability,	O
the	O
morphological	O
correlate	O
of	O
which	O
is	O
the	O
formation	O
of	O
gaps	O
in	O
the	O
interendothelial	O
cell	O
connections	O
on	O
the	O
venules.	O
These	O
changes	O
can	O
be	O
effectively	O
prevented	O
by	O
mesna	Chemical

Increase	O
in	O
intragastric	O
pressure	O
during	O
suxamethonium	Chemical
-induced	O
muscle	Disease
fasciculations	Disease
in	O
children:	O
inhibition	O
by	O
alfentanil	Chemical
.	O
Changes	O
in	O
intragastric	O
pressure	O
after	O
the	O
administration	O
of	O
suxamethonium	Chemical
1.5	O
mg	O
kg-1	O
i.v.	O
were	O
studied	O
in	O
32	O
children	O
(mean	O
age	O
6.9	O
yr)	O
pretreated	O
with	O
either	O
physiological	O
saline	O
or	O
alfentanil	Chemical
50	O
micrograms	O
kg-1.	O
Anaesthesia	O
was	O
induced	O
with	O
thiopentone	Chemical
5	O
mg	O
kg-1.	O
The	O
incidence	O
and	O
intensity	O
of	O
muscle	Disease
fasciculations	Disease
caused	O
by	O
suxamethonium	Chemical
were	O
significantly	O
greater	O
in	O
the	O
control	O
than	O
in	O
the	O
alfentanil	Chemical
group.	O
The	O
intragastric	O
pressure	O
during	O
muscle	Disease
fasciculations	Disease
was	O
significantly	O
higher	O
in	O
the	O
control	O
group	O
(16	O
+/-	O
0.7	O
(SEM)	O
cm	O
H2O	Chemical
)	O
than	O
in	O
the	O
alfentanil	Chemical
group	O
(7.7	O
+/-	O
1.5	O
(SEM)	O
cm	O
H2O	Chemical
).	O
The	O
increase	O
in	O
intragastric	O
pressure	O
was	O
directly	O
related	O
to	O
the	O
intensity	O
of	O
muscle	Disease
fasciculations	Disease
(regression	O
line:	O
y	O
=	O
0.5	O
+	O
4.78x	O
with	O
r	O
of	O
0.78).	O
It	O
is	O
concluded	O
that	O
intragastric	O
pressure	O
increases	O
significantly	O
during	O
muscle	Disease
fasciculations	Disease
caused	O
by	O
suxamethonium	Chemical
in	O
healthy	O
children.	O
Alfentanil	Chemical
50	O
micrograms	O
kg-1	O
effectively	O
inhibits	O
the	O
incidence	O
and	O
intensity	O
of	O
suxamethonium	Chemical
-induced	O
muscle	Disease
fasciculations	Disease

Acute	O
insulin	O
treatment	O
normalizes	O
the	O
resistance	O
to	O
the	O
cardiotoxic	Disease
effect	O
of	O
isoproterenol	Chemical
in	O
streptozotocin	Chemical
	O
diabetic	Disease
rats.	O
A	O
morphometric	O
study	O
of	O
isoproterenol	Chemical
induced	O
myocardial	O
fibrosis	Disease
.	O
The	O
acute	O
effect	O
of	O
insulin	O
treatment	O
on	O
the	O
earlier	O
reported	O
protective	O
effect	O
of	O
streptozotocin	Chemical
	O
diabetes	Disease
against	O
the	O
cardiotoxic	Disease
effect	O
of	O
high	O
doses	O
of	O
isoproterenol	Chemical
(	O
ISO	Chemical
)	O
was	O
investigated	O
in	O
rats.	O
Thirty	O
to	O
135	O
min	O
after	O
the	O
injection	O
of	O
crystalline	O
insulin,	O
ISO	Chemical
was	O
given	O
subcutaneously	O
and	O
when	O
ISO	Chemical
induced	O
fibrosis	Disease
in	O
the	O
myocardium	O
was	O
morphometrically	O
analyzed	O
7	O
days	O
later,	O
a	O
highly	O
significant	O
correlation	O
(r	O
=	O
0.83,	O
2	O
p	O
=	O
0.006)	O
to	O
the	O
slope	O
of	O
the	O
fall	O
in	O
blood	O
glucose	Chemical
after	O
insulin	O
treatment	O
appeared.	O
The	O
myocardial	O
content	O
of	O
catecholamines	Chemical
was	O
estimated	O
in	O
these	O
8	O
day	O
diabetic	Disease
rats.	O
The	O
norepinephrine	Chemical
content	O
was	O
significantly	O
increased	O
while	O
epinephrine	Chemical
remained	O
unchanged.	O
An	O
enhanced	O
sympathetic	O
nervous	O
system	O
activity	O
with	O
a	O
consequent	O
down	O
regulation	O
of	O
the	O
myocardial	O
beta-adrenergic	O
receptors	O
could,	O
therefore,	O
explain	O
this	O
catecholamine	Chemical
resistance.	O
The	O
rapid	O
reversion	O
after	O
insulin	O
treatment	O
excludes	O
the	O
possibility	O
that	O
streptozotocin	Chemical
in	O
itself	O
causes	O
the	O
ISO	Chemical
resistance	O
and	O
points	O
towards	O
a	O
direct	O
insulin	O
effect	O
on	O
myocardial	O
catecholamine	Chemical
sensitivity	O
in	O
diabetic	Disease
rats.	O
The	O
phenomenon	O
described	O
might	O
elucidate	O
pathogenetic	O
mechanisms	O
behind	O
toxic	O
myocardial	O
cell	O
degeneration	O
and	O
may	O
possibly	O
have	O
relevance	O
for	O
acute	O
cardiovascular	O
complications	O
in	O
diabetic	Disease

Differential	O
effects	O
of	O
non-steroidal	O
anti-inflammatory	O
drugs	O
on	O
seizures	Disease
produced	O
by	O
pilocarpine	Chemical
in	O
rats.	O
The	O
muscarinic	O
cholinergic	O
agonist	O
pilocarpine	Chemical
induces	O
in	O
rats	O
seizures	Disease
and	O
status	Disease
epilepticus	Disease
followed	O
by	O
widespread	O
damage	O
to	O
the	O
forebrain.	O
The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
effect	O
of	O
5	O
non-steroidal	O
anti-inflammatory	O
drugs,	O
sodium	Chemical
salicylate	Chemical
,	O
phenylbutazone	Chemical
,	O
indomethacin	Chemical
,	O
ibuprofen	Chemical
and	O
mefenamic	Chemical
acid	Chemical
,	O
on	O
seizures	Disease
produced	O
by	O
pilocarpine	Chemical
.	O
Pretreatment	O
of	O
rats	O
with	O
sodium	Chemical
salicylate	Chemical
,	O
ED50	O
103	O
mg/kg	O
(60-174),	O
and	O
phenylbutazone	Chemical
,	O
59	O
mg/kg	O
(50-70)	O
converted	O
the	O
non-convulsant	O
dose	O
of	O
pilocarpine	Chemical
,	O
200	O
mg/kg,	O
to	O
a	O
convulsant	O
one.	O
Indomethacin	Chemical
,	O
1-10	O
mg/kg,	O
and	O
ibuprofen	Chemical
,	O
10-100	O
mg/kg,	O
failed	O
to	O
modulate	O
seizures	Disease
produced	O
by	O
pilocarpine	Chemical
.	O
Mefenamic	Chemical
acid	Chemical
,	O
26	O
(22-30)	O
mg/kg,	O
prevented	O
seizures	Disease
and	O
protected	O
rats	O
from	O
seizure	Disease
-related	O
brain	Disease
damage	Disease
induced	O
by	O
pilocarpine	Chemical
,	O
380	O
mg/kg.	O
These	O
results	O
indicate	O
that	O
non-steroidal	O
anti-inflammatory	O
drugs	O
differentially	O
modulate	O
the	O
threshold	O
for	O
pilocarpine	Chemical
-induced	O
seizures	Disease

Acute	Disease
neurologic	Disease
dysfunction	Disease
after	O
high-dose	O
etoposide	Chemical
therapy	O
for	O
malignant	Disease
glioma	Disease
.	O
Etoposide	Chemical
(	O
VP-16-213	Chemical
)	O
has	O
been	O
used	O
in	O
the	O
treatment	O
of	O
many	O
solid	O
tumors	Disease
and	O
hematologic	Disease
malignancies	Disease
.	O
When	O
used	O
in	O
high	O
doses	O
and	O
in	O
conjunction	O
with	O
autologous	O
bone	O
marrow	O
transplantation,	O
this	O
agent	O
has	O
activity	O
against	O
several	O
treatment-resistant	O
cancers	Disease
including	O
malignant	Disease
glioma	Disease
.	O
In	O
six	O
of	O
eight	O
patients	O
(75%)	O
who	O
we	O
treated	O
for	O
recurrent	O
or	O
resistant	O
glioma	Disease
,	O
sudden	O
severe	O
neurologic	Disease
deterioration	Disease
occurred.	O
This	O
developed	O
a	O
median	O
of	O
9	O
days	O
after	O
initiation	O
of	O
high-dose	O
etoposide	Chemical
therapy.	O
Significant	O
clinical	O
manifestations	O
have	O
included	O
confusion	Disease
,	O
papilledema	Disease
,	O
somnolence	Disease
,	O
exacerbation	O
of	O
motor	Disease
deficits	Disease
,	O
and	O
sharp	O
increase	O
in	O
seizure	Disease
activity.	O
These	O
abnormalities	O
resolved	O
rapidly	O
after	O
initiation	O
of	O
high-dose	O
intravenous	O
dexamethasone	Chemical
therapy.	O
In	O
all	O
patients,	O
computerized	O
tomographic	O
(CT)	O
brain	O
scans	O
demonstrated	O
stability	O
in	O
tumor	Disease
size	O
and	O
peritumor	O
edema	Disease
when	O
compared	O
with	O
pretransplant	O
scans.	O
This	O
complication	O
appears	O
to	O
represent	O
a	O
significant	O
new	O
toxicity	Disease
of	O
high-dose	O
etoposide	Chemical
therapy	O
for	O
malignant	Disease
glioma	Disease

Progressive	O
bile	Disease
duct	Disease
injury	Disease
after	O
thiabendazole	Chemical
administration.	O
A	O
27-yr-old	O
man	O
developed	O
jaundice	Disease
2	O
wk	O
after	O
exposure	O
to	O
thiabendazole	Chemical
.	O
Cholestasis	Disease
persisted	O
for	O
3	O
yr,	O
at	O
which	O
time	O
a	O
liver	O
transplant	O
was	O
performed.	O
Two	O
liver	O
biopsy	O
specimens	O
and	O
the	O
hepatectomy	O
specimen	O
were	O
remarkable	O
for	O
almost	O
complete	O
disappearance	O
of	O
interlobular	O
bile	O
ducts.	O
Prominent	O
fibrosis	Disease
and	O
hepatocellular	O
regeneration	O
were	O
also	O
present;	O
however,	O
the	O
lobular	O
architecture	O
was	O
preserved.	O
This	O
case	O
represents	O
an	O
example	O
of	O
"idiosyncratic"	O
drug-induced	Disease
liver	Disease
damage	Disease
in	O
which	O
the	O
primary	O
target	O
of	O
injury	O
is	O
the	O
bile	O
duct.	O
An	O
autoimmune	O
pathogenesis	O
of	O
the	O
bile	Disease
duct	Disease
destruction	Disease

Differential	O
effects	O
of	O
1,4-dihydropyridine	Chemical
	O
calcium	Chemical
channel	Chemical
blockers	Chemical
:	O
therapeutic	O
implications.	O
Increasing	O
recognition	O
of	O
the	O
importance	O
of	O
calcium	Chemical
in	O
the	O
pathogenesis	O
of	O
cardiovascular	Disease
disease	Disease
has	O
stimulated	O
research	O
into	O
the	O
use	O
of	O
calcium	Chemical
channel	Chemical
blocking	Chemical
agents	Chemical
for	O
treatment	O
of	O
a	O
variety	O
of	O
cardiovascular	Disease
diseases	Disease
.	O
The	O
favorable	O
efficacy	O
and	O
tolerability	O
profiles	O
of	O
these	O
agents	O
make	O
them	O
attractive	O
therapeutic	O
modalities.	O
Clinical	O
applications	O
of	O
calcium	Chemical
channel	Chemical
blockers	Chemical
parallel	O
their	O
tissue	O
selectivity.	O
In	O
contrast	O
to	O
verapamil	Chemical
and	O
diltiazem	Chemical
,	O
which	O
are	O
roughly	O
equipotent	O
in	O
their	O
actions	O
on	O
the	O
heart	O
and	O
vascular	O
smooth	O
muscle,	O
the	O
dihydropyridine	Chemical
	O
calcium	Chemical
channel	Chemical
blockers	Chemical
are	O
a	O
group	O
of	O
potent	O
peripheral	O
vasodilator	O
agents	O
that	O
exert	O
minimal	O
electrophysiologic	O
effects	O
on	O
cardiac	O
nodal	O
or	O
conduction	O
tissue.	O
As	O
the	O
first	O
dihydropyridine	Chemical
available	O
for	O
use	O
in	O
the	O
United	O
States,	O
nifedipine	Chemical
controls	O
angina	Disease
and	O
hypertension	Disease
with	O
minimal	O
depression	O
of	O
cardiac	O
function.	O
Additional	O
members	O
of	O
this	O
group	O
of	O
calcium	Chemical
channel	Chemical
blockers	Chemical
have	O
been	O
studied	O
for	O
a	O
variety	O
of	O
indications	O
for	O
which	O
they	O
may	O
offer	O
advantages	O
over	O
current	O
therapy.	O
Once	O
or	O
twice	O
daily	O
dosage	O
possible	O
with	O
nitrendipine	Chemical
and	O
nisoldipine	Chemical
offers	O
a	O
convenient	O
administration	O
schedule,	O
which	O
encourages	O
patient	O
compliance	O
in	O
long-term	O
therapy	O
of	O
hypertension	Disease
.	O
The	O
coronary	O
vasodilating	O
properties	O
of	O
nisoldipine	Chemical
have	O
led	O
to	O
the	O
investigation	O
of	O
this	O
agent	O
for	O
use	O
in	O
angina	Disease
.	O
Selectivity	O
for	O
the	O
cerebrovascular	O
bed	O
makes	O
nimodipine	Chemical
potentially	O
useful	O
in	O
the	O
treatment	O
of	O
subarachnoid	Disease
hemorrhage	Disease
,	O
migraine	Disease
headache	Disease
,	O
dementia	Disease
,	O
and	O
stroke	Disease
.	O
In	O
general,	O
the	O
dihydropyridine	Chemical
	O
calcium	Chemical
channel	Chemical
blockers	Chemical
are	O
usually	O
well	O
tolerated,	O
with	O
headache	Disease
,	O
facial	O
flushing	Disease
,	O
palpitations	Disease
,	O
edema	Disease
,	O
nausea	Disease
,	O
anorexia	Disease
,	O
and	O
dizziness	Disease

The	O
enhancement	O
of	O
aminonucleoside	Chemical
	O
nephrosis	Disease
by	O
the	O
co-administration	O
of	O
protamine.	O
An	O
experimental	O
model	O
of	O
focal	Disease
segmental	Disease
glomerular	Disease
sclerosis	Disease
(	O
FSGS	Disease
)	O
was	O
developed	O
in	O
rats	O
by	O
the	O
combined	O
administration	O
of	O
puromycin-aminonucleoside	Chemical
(	O
AMNS	Chemical
)	O
and	O
protamine	Chemical
sulfate	Chemical
(	O
PS	Chemical
).	O
Male	O
Sprague-Dawley	O
rats,	O
uninephrectomized	O
three	O
weeks	O
before,	O
received	O
daily	O
injections	O
of	O
subcutaneous	O
AMNS	Chemical
(1	O
mg/100	O
g	O
body	O
wt)	O
and	O
intravenous	O
PS	Chemical
(2	O
separated	O
doses	O
of	O
2.5	O
mg/100	O
g	O
body	O
wt)	O
for	O
four	O
days.	O
The	O
series	O
of	O
injections	O
were	O
repeated	O
another	O
three	O
times	O
at	O
10	O
day	O
intervals.	O
The	O
animals	O
were	O
sacrificed	O
on	O
days	O
24,	O
52,	O
and	O
80.	O
They	O
developed	O
nephrotic	Disease
syndrome	Disease
and	O
finally	O
renal	Disease
failure	Disease
.	O
The	O
time-course	O
curve	O
of	O
creatinine	Chemical
clearance	O
dropped	O
and	O
showed	O
significant	O
difference	O
(P	O
less	O
than	O
0.01)	O
from	O
that	O
of	O
each	O
control	O
group,	O
such	O
as,	O
AMNS	Chemical
alone,	O
PS	Chemical
alone	O
or	O
saline	O
injected.	O
Their	O
glomeruli	O
showed	O
changes	O
of	O
progressive	O
FSGS	Disease
.	O
The	O
ultrastructural	O
studies	O
in	O
the	O
initial	O
stage	O
revealed	O
significant	O
lack	O
of	O
particles	O
of	O
perfused	O
ruthenium	Chemical
red	O
on	O
the	O
lamina	O
rara	O
externa	O
and	O
marked	O
changes	O
in	O
epithelial	O
cell	O
cytoplasm.	O
Therefore,	O
it	O
is	O
suggested	O
that	O
the	O
administration	O
of	O
PS	Chemical
enhances	O
the	O
toxicity	Disease
of	O
AMNS	Chemical
on	O
the	O
glomerulus	O
and	O
readily	O
produces	O
progressive	O
FSGS	Disease
in	O
rats	O
resulting	O
in	O
the	O
end-stage	Disease
renal	Disease
disease	Disease

Theophylline	Chemical
	O
neurotoxicity	Disease
in	O
pregnant	O
rats.	O
The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
determine	O
whether	O
the	O
neurotoxicity	Disease
of	O
theophylline	Chemical
is	O
altered	O
in	O
advanced	O
pregnancy.	O
Sprague-Dawley	O
rats	O
that	O
were	O
20	O
days	O
pregnant	O
and	O
nonpregnant	O
rats	O
of	O
the	O
same	O
age	O
and	O
strain	O
received	O
infusions	O
of	O
aminophylline	Chemical
until	O
onset	O
of	O
maximal	O
seizures	Disease
which	O
occurred	O
after	O
28	O
and	O
30	O
minutes	O
respectively.	O
Theophylline	Chemical
concentrations	O
at	O
this	O
endpoint	O
in	O
serum	O
(total)	O
and	O
CSF	O
were	O
similar	O
but	O
serum	O
(free)	O
and	O
brain	O
concentrations	O
were	O
slightly	O
different	O
in	O
pregnant	O
rats.	O
Theophylline	Chemical
serum	O
protein	O
binding	O
determined	O
by	O
equilibrium	O
dialysis	O
was	O
lower	O
in	O
pregnant	O
rats.	O
Fetal	O
serum	O
concentrations	O
at	O
onset	O
of	O
seizures	Disease
in	O
the	O
mother	O
were	O
similar	O
to	O
maternal	O
brain	O
and	O
CSF	O
concentrations	O
and	O
correlated	O
significantly	O
with	O
the	O
former.	O
It	O
is	O
concluded	O
that	O
advanced	O
pregnancy	O
has	O
a	O
negligible	O
effect	O
on	O
the	O
neurotoxic	Disease
response	O
to	O
theophylline	Chemical

Hyperkalemia	Disease
induced	O
by	O
indomethacin	Chemical
and	O
naproxen	Chemical
and	O
reversed	O
by	O
fludrocortisone	Chemical
.	O
We	O
have	O
described	O
a	O
patient	O
with	O
severe	O
rheumatoid	Disease
arthritis	Disease
and	O
a	O
history	O
of	O
mefenamic	Chemical
acid	Chemical
	O
nephropathy	Disease
in	O
whom	O
hyperkalemia	Disease
and	O
inappropriate	O
hypoaldosteronism	Disease
were	O
caused	O
by	O
both	O
indomethacin	Chemical
and	O
naproxen	Chemical
,	O
without	O
major	O
decline	O
in	O
renal	O
function.	O
It	O
is	O
likely	O
that	O
preexisting	O
renal	Disease
disease	Disease
predisposed	O
this	O
patient	O
to	O
type	Disease
IV	Disease
renal	Disease
tubular	Disease
acidosis	Disease
with	O
prostaglandin	Chemical
synthetase	O
inhibitors.	O
Because	O
he	O
was	O
unable	O
to	O
discontinue	O
nonsteroidal	O
anti-inflammatory	O
drug	O
therapy,	O
fludrocortisone	Chemical
was	O
added,	O
correcting	O
the	O
hyperkalemia	Disease
and	O
allowing	O
indomethacin	Chemical

Hypotension	Disease
as	O
a	O
manifestation	O
of	O
cardiotoxicity	Disease
in	O
three	O
patients	O
receiving	O
cisplatin	Chemical
and	O
5-fluorouracil	Chemical
.	O
Cardiac	O
symptoms,	O
including	O
hypotension	Disease
,	O
developed	O
in	O
three	O
patients	O
with	O
advanced	O
colorectal	Disease
carcinoma	Disease
while	O
being	O
treated	O
with	O
cisplatin	Chemical
(	O
CDDP	Chemical
)	O
and	O
5-fluorouracil	Chemical
(	O
5-FU	Chemical
).	O
In	O
two	O
patients,	O
hypotension	Disease
was	O
associated	O
with	O
severe	O
left	Disease
ventricular	Disease
dysfunction	Disease
.	O
All	O
three	O
patients	O
required	O
therapy	O
discontinuation.	O
Cardiac	O
enzymes	O
remained	O
normal	O
despite	O
transient	O
electrocardiographic	O
(EKG)	O
changes.	O
The	O
presentation	O
and	O
cardiac	O
evaluation	O
(hemodynamic,	O
echocardiographic,	O
and	O
scintigraphic)	O
of	O
these	O
patients	O
suggest	O
new	O
manifestations	O
of	O
5-FU	Chemical
	O
cardiotoxicity	Disease
that	O
may	O
be	O
influenced	O
by	O
CDDP	Chemical

Fatal	O
aplastic	Disease
anemia	Disease
in	O
a	O
patient	O
treated	O
with	O
carbamazepine	Chemical
.	O
A	O
case	O
of	O
fatal	O
aplastic	Disease
anemia	Disease
due	O
to	O
carbamazepine	Chemical
treatment	O
in	O
an	O
epileptic	Disease
woman	O
is	O
reported.	O
Despite	O
concerns	O
of	O
fatal	O
bone	Disease
marrow	Disease
toxicity	Disease
due	O
to	O
carbamazepine	Chemical
,	O
this	O
is	O
only	O
the	O
fourth	O
documented	O
and	O
published	O
report.	O
Carbamazepine	Chemical

Participation	O
of	O
a	O
bulbospinal	O
serotonergic	O
pathway	O
in	O
the	O
rat	O
brain	O
in	O
clonidine	Chemical
-induced	O
hypotension	Disease
and	O
bradycardia	Disease
.	O
The	O
effects	O
of	O
microinjection	O
of	O
clonidine	Chemical
(1-10	O
micrograms	O
in	O
1	O
microliter)	O
into	O
a	O
region	O
adjacent	O
to	O
the	O
ventrolateral	O
surface	O
of	O
the	O
medulla	O
oblongata	O
on	O
cardiovascular	O
function	O
were	O
assessed	O
in	O
urethane	Chemical
-anesthetized	O
rats.	O
Intramedullary	O
administration	O
of	O
clonidine	Chemical
,	O
but	O
not	O
saline	O
vehicle,	O
caused	O
a	O
dose-dependent	O
decrease	O
in	O
both	O
the	O
mean	O
arterial	O
pressure	O
and	O
the	O
heart	O
rate.	O
The	O
clonidine	Chemical
-induced	O
hypotension	Disease
was	O
antagonized	O
by	O
prior	O
spinal	O
transection,	O
but	O
not	O
bilateral	O
vagotomy.	O
On	O
the	O
other	O
hand,	O
the	O
clonidine	Chemical
-induced	O
bradycardia	Disease
was	O
antagonized	O
by	O
prior	O
bilateral	O
vagotomy,	O
but	O
not	O
spinal	O
transection.	O
Furthermore,	O
selective	O
destruction	O
of	O
the	O
spinal	O
5-HT	Chemical
nerves,	O
produced	O
by	O
bilateral	O
spinal	O
injection	O
of	O
5,7-dihydroxytryptamine	Chemical
,	O
reduced	O
the	O
magnitude	O
of	O
the	O
vasodepressor	O
or	O
the	O
bradycardiac	Disease
responses	O
to	O
clonidine	Chemical
microinjected	O
into	O
the	O
area	O
near	O
the	O
ventrolateral	O
surface	O
of	O
the	O
medulla	O
oblongata	O
in	O
rats.	O
The	O
data	O
indicate	O
that	O
a	O
bulbospinal	O
serotonergic	O
pathway	O
is	O
involved	O
in	O
development	O
of	O
clonidine	Chemical
-induced	O
hypotension	Disease
and	O
bradycardia	Disease
.	O
The	O
induced	O
hypotension	Disease
is	O
brought	O
about	O
by	O
a	O
decrease	O
in	O
sympathetic	O
efferent	O
activity,	O
whereas	O
the	O
induced	O
bradycardia	Disease

Hypertension	Disease
in	O
neuroblastoma	Disease
induced	O
by	O
imipramine	Chemical
.	O
Hypertension	Disease
is	O
a	O
well-known	O
finding	O
in	O
some	O
patients	O
with	O
neuroblastoma	Disease
.	O
However,	O
it	O
has	O
not	O
previously	O
been	O
described	O
in	O
association	O
with	O
the	O
use	O
of	O
Imipramine	Chemical
.	O
We	O
report	O
the	O
occurrence	O
of	O
severe	O
hypertension	Disease
(blood	O
pressure	O
190/160)	O
in	O
a	O
4-year-old	O
girl	O
with	O
neuroblastoma	Disease
who	O
was	O
given	O
Imipramine	Chemical
to	O
control	O
a	O
behavior	Disease
disorder	Disease
.	O
It	O
was	O
determined	O
later	O
that	O
this	O
patient's	O
tumor	Disease
was	O
recurring	O
at	O
the	O
time	O
of	O
her	O
hypertensive	Disease
episode.	O
Since	O
she	O
had	O
no	O
blood	O
pressure	O
elevation	O
at	O
initial	O
diagnosis	O
and	O
none	O
following	O
discontinuation	O
of	O
the	O
Imipramine	Chemical
(when	O
she	O
was	O
in	O
florid	O
relapse),	O
we	O
believe	O
that	O
this	O
drug	O
rather	O
than	O
her	O
underlying	O
disease	O
alone	O
caused	O
her	O
hypertension	Disease
.	O
The	O
mechanism	O
for	O
this	O
reaction	O
is	O
believed	O
to	O
be	O
increased	O
levels	O
of	O
vasoactive	O
catecholamines	Chemical
due	O
to	O
interference	O
of	O
their	O
physiologic	O
inactivation	O
by	O
Imipramine	Chemical
.	O
From	O
this	O
experience,	O
we	O
urge	O
extreme	O
caution	O
in	O
the	O
use	O
of	O
tricyclic	O
antidepressants	O
in	O
children	O
with	O
active	O
neuroblastoma	Disease

Rechallenge	O
of	O
patients	O
who	O
developed	O
oral	Disease
candidiasis	Disease
or	O
hoarseness	Disease
with	O
beclomethasone	Chemical
dipropionate	Chemical
.	O
Of	O
158	O
asthmatic	Disease
patients	O
who	O
were	O
placed	O
on	O
inhaled	O
beclomethasone	Chemical
,	O
15	O
(9.5%)	O
developed	O
either	O
hoarseness	Disease
(8),	O
oral	O
thrush	Disease
(6),	O
or	O
both	O
(1).	O
When	O
their	O
adverse	O
reactions	O
subsided,	O
seven	O
of	O
these	O
15	O
patients	O
were	O
rechallenged	O
with	O
inhaled	O
beclomethasone	Chemical
.	O
These	O
included	O
five	O
cases	O
who	O
developed	O
hoarseness	Disease
and	O
three	O
who	O
developed	O
Candidiasis	Disease
.	O
One	O
patient	O
had	O
both.	O
Oral	O
thrush	Disease
did	O
not	O
recur,	O
but	O
60%	O
(3/5)	O
of	O
patients	O
with	O
hoarseness	Disease
had	O
recurrence.	O
We	O
conclude	O
that	O
patients	O
may	O
be	O
restarted	O
on	O
inhaled	O
beclomethasone	Chemical
when	O
clinically	O
indicated;	O
however,	O
because	O
of	O
the	O
high	O
recurrence	O
rate,	O
patients	O
who	O
develop	O
hoarseness	Disease
should	O
not	O
be	O
re-challenged.	O
Concomitant	O
use	O
of	O
oral	O
prednisone	Chemical
and	O
topical	O
beclomethasone	Chemical
may	O
increase	O
the	O
risk	O
of	O
developing	O
hoarseness	Disease
or	O
candidiasis	Disease

Cyclophosphamide	Chemical
	O
cardiotoxicity	Disease
:	O
an	O
analysis	O
of	O
dosing	O
as	O
a	O
risk	O
factor.	O
Patients	O
who	O
undergo	O
bone	O
marrow	O
transplantation	O
are	O
generally	O
immunosuppressed	O
with	O
a	O
dose	O
of	O
cyclophosphamide	Chemical
(	O
CYA	Chemical
)	O
which	O
is	O
usually	O
calculated	O
based	O
on	O
the	O
patient's	O
weight.	O
At	O
these	O
high	O
doses	O
of	O
CYA	Chemical
,	O
serious	O
cardiotoxicity	Disease
may	O
occur,	O
but	O
definitive	O
risk	O
factors	O
for	O
the	O
development	O
of	O
such	O
cardiotoxicity	Disease
have	O
not	O
been	O
described.	O
Since	O
chemotherapeutic	O
agent	O
toxicity	Disease
generally	O
correlates	O
with	O
dose	O
per	O
body	O
surface	O
area,	O
we	O
retrospectively	O
calculated	O
the	O
dose	O
of	O
CYA	Chemical
in	O
patients	O
transplanted	O
at	O
our	O
institution	O
to	O
determine	O
whether	O
the	O
incidence	O
of	O
CYA	Chemical
	O
cardiotoxicity	Disease
correlated	O
with	O
the	O
dose	O
per	O
body	O
surface	O
area.	O
Eighty	O
patients	O
who	O
were	O
to	O
receive	O
CYA	Chemical
50	O
mg/kg/d	O
for	O
four	O
days	O
as	O
preparation	O
for	O
marrow	O
grafting	O
underwent	O
a	O
total	O
of	O
84	O
transplants	O
for	O
aplastic	Disease
anemia	Disease
,	O
Wiskott-Aldrich	Disease
syndrome	Disease
,	O
or	O
severe	Disease
combined	Disease
immunodeficiency	Disease
syndrome	Disease
.	O
Fourteen	O
of	O
84	O
(17%)	O
patients	O
had	O
symptoms	O
and	O
signs	O
consistent	O
with	O
CYA	Chemical
	O
cardiotoxicity	Disease
within	O
ten	O
days	O
of	O
receiving	O
1	O
to	O
4	O
doses	O
of	O
CYA	Chemical
.	O
Six	O
of	O
the	O
14	O
patients	O
died	O
with	O
congestive	Disease
heart	Disease
failure	Disease
.	O
The	O
dose	O
of	O
CYA	Chemical
per	O
body	O
surface	O
area	O
was	O
calculated	O
for	O
all	O
patients	O
and	O
the	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
based	O
on	O
daily	O
CYA	Chemical
dose:	O
Group	O
1,	O
CYA	Chemical
less	O
than	O
or	O
equal	O
to	O
1.55	O
g/m2/d;	O
Group	O
2,	O
CYA	Chemical
greater	O
than	O
1.55	O
g/m2/d.	O
Cardiotoxicity	Disease
that	O
was	O
thought	O
to	O
be	O
related	O
to	O
CYA	Chemical
occurred	O
in	O
1/32	O
(3%)	O
of	O
patients	O
in	O
Group	O
1	O
and	O
in	O
13/52	O
(25%)	O
patients	O
in	O
Group	O
2	O
(P	O
less	O
than	O
0.025).	O
Congestive	Disease
heart	Disease
failure	Disease
caused	O
or	O
contributed	O
to	O
death	O
in	O
0/32	O
patients	O
in	O
Group	O
1	O
v	O
6/52	O
(12%)	O
of	O
patients	O
in	O
Group	O
2	O
(P	O
less	O
than	O
0.25).	O
There	O
was	O
no	O
difference	O
in	O
the	O
rate	O
of	O
engraftment	O
of	O
evaluable	O
patients	O
in	O
the	O
two	O
groups	O
(P	O
greater	O
than	O
0.5).	O
We	O
conclude	O
that	O
the	O
CYA	Chemical
	O
cardiotoxicity	Disease
correlates	O
with	O
CYA	Chemical
dosage	O
as	O
calculated	O
by	O
body	O
surface	O
area,	O
and	O
that	O
patients	O
with	O
aplastic	Disease
anemia	Disease
and	O
immunodeficiencies	Disease
can	O
be	O
effectively	O
prepared	O
for	O
bone	O
marrow	O
grafting	O
at	O
a	O
CYA	Chemical
dose	O
of	O
1.55	O
g/m2/d	O
for	O
four	O
days	O
with	O
a	O
lower	O
incidence	O
of	O
cardiotoxicity	Disease
than	O
patients	O
whose	O
CYA	Chemical
dosage	O
is	O
calculated	O
based	O
on	O
weight.	O
This	O
study	O
reaffirms	O
the	O
principle	O
that	O
drug	O
toxicity	Disease

Studies	O
of	O
risk	O
factors	O
for	O
aminoglycoside	Chemical
	O
nephrotoxicity	Disease
.	O
The	O
epidemiology	O
of	O
aminoglycoside	Chemical
-induced	O
nephrotoxicity	Disease
is	O
not	O
fully	O
understood.	O
Experimental	O
studies	O
in	O
healthy	O
human	O
volunteers	O
indicate	O
aminoglycosides	Chemical
cause	O
proximal	O
tubular	O
damage	O
in	O
most	O
patients,	O
but	O
rarely,	O
if	O
ever,	O
cause	O
glomerular	Disease
or	Disease
tubular	Disease
dysfunction	Disease
.	O
Clinical	O
trials	O
of	O
aminoglycosides	Chemical
in	O
seriously	O
ill	O
patients	O
indicate	O
that	O
the	O
relative	O
risk	O
for	O
developing	O
acute	Disease
renal	Disease
failure	Disease
during	O
therapy	O
ranges	O
from	O
8	O
to	O
10	O
and	O
that	O
the	O
attributable	O
risk	O
is	O
70%	O
to	O
80%.	O
Further	O
analysis	O
of	O
these	O
data	O
suggests	O
that	O
the	O
duration	O
of	O
therapy,	O
plasma	O
aminoglycoside	Chemical
levels,	O
liver	Disease
disease	Disease
,	O
advanced	O
age,	O
high	O
initial	O
estimated	O
creatinine	Chemical
clearance	O
and,	O
possibly,	O
female	O
gender	O
all	O
increase	O
the	O
risk	O
for	O
nephrotoxicity	Disease
.	O
Other	O
causes	O
of	O
acute	Disease
renal	Disease
failure	Disease
,	O
such	O
as	O
shock	Disease
,	O
appear	O
to	O
have	O
an	O
additive	O
effect.	O
Predictive	O
models	O
have	O
been	O
developed	O
from	O
these	O
analyses	O
that	O
should	O
be	O
useful	O
for	O
identifying	O
patients	O
at	O
high	O
risk.	O
These	O
models	O
may	O
also	O
be	O
useful	O
in	O
developing	O
insights	O
into	O
the	O
pathophysiology	O
of	O
aminoglycoside	Chemical
-induced	O
nephrotoxicity	Disease

Flurothyl	Chemical
	O
seizure	Disease
thresholds	O
in	O
mice	O
treated	O
neonatally	O
with	O
a	O
single	O
injection	O
of	O
monosodium	Chemical
glutamate	Chemical
(	O
MSG	Chemical
):	O
evaluation	O
of	O
experimental	O
parameters	O
in	O
flurothyl	Chemical
	O
seizure	Disease
testing.	O
Monosodium	Chemical
glutamate	Chemical
(	O
MSG	Chemical
)	O
administration	O
to	O
neonatal	O
rodents	O
produces	O
convulsions	Disease
and	O
results	O
in	O
numerous	O
biochemical	O
and	O
behavioral	O
deficits.	O
These	O
studies	O
were	O
undertaken	O
to	O
determine	O
if	O
neonatal	O
administration	O
of	O
MSG	Chemical
produced	O
permanent	O
alterations	O
in	O
seizure	Disease
susceptibility,	O
since	O
previous	O
investigations	O
were	O
inconclusive.	O
A	O
flurothyl	Chemical
	O
ether	Chemical
	O
seizure	Disease
screening	O
technique	O
was	O
used	O
to	O
evaluate	O
seizure	Disease
susceptibility	O
in	O
adult	O
mice	O
that	O
received	O
neonatal	O
injections	O
of	O
MSG	Chemical
(4	O
mg/g	O
and	O
1	O
mg/g).	O
MSG	Chemical
treatment	O
resulted	O
in	O
significant	O
reductions	O
in	O
whole	O
brain	O
weight	O
but	O
did	O
not	O
alter	O
seizure	Disease
threshold.	O
A	O
naloxone	Chemical
(5	O
mg/kg)	O
challenge	O
was	O
also	O
ineffective	O
in	O
altering	O
the	O
seizure	Disease
thresholds	O
of	O
either	O
control	O
of	O
MSG	Chemical
-treated	O
mice.	O
Flurothyl	Chemical
	O
ether	Chemical
produced	O
hypothermia	Disease
which	O
was	O
correlated	O
with	O
the	O
duration	O
of	O
flurothyl	Chemical
exposure;	O
however,	O
the	O
relationship	O
of	O
hypothermia	Disease
to	O
seizure	Disease
induction	O
was	O
unclear.	O
Flurothyl	Chemical
	O
seizure	Disease
testing	O
proved	O
to	O
be	O
a	O
rapid	O
and	O
reliable	O
technique	O
with	O
which	O
to	O
evaluate	O
seizure	Disease

Susceptibility	O
to	O
seizures	Disease
produced	O
by	O
pilocarpine	Chemical
in	O
rats	O
after	O
microinjection	O
of	O
isoniazid	Chemical
or	O
gamma-vinyl-GABA	Chemical
into	O
the	O
substantia	O
nigra.	O
Pilocarpine	Chemical
,	O
given	O
intraperitoneally	O
to	O
rats,	O
reproduces	O
the	O
neuropathological	O
sequelae	O
of	O
temporal	Disease
lobe	Disease
epilepsy	Disease
and	O
provides	O
a	O
relevant	O
animal	O
model	O
for	O
studying	O
mechanisms	O
of	O
buildup	O
of	O
convulsive	Disease
activity	O
and	O
pathways	O
operative	O
in	O
the	O
generalization	O
and	O
propagation	O
of	O
seizures	Disease
within	O
the	O
forebrain.	O
In	O
the	O
present	O
study,	O
the	O
effects	O
of	O
manipulating	O
the	O
activity	O
of	O
the	O
gamma-aminobutyric	Chemical
acid	Chemical
(	O
GABA	Chemical
)-mediated	O
synaptic	O
inhibition	O
within	O
the	O
substantia	O
nigra	O
on	O
seizures	Disease
produced	O
by	O
pilocarpine	Chemical
in	O
rats,	O
were	O
investigated.	O
In	O
animals	O
pretreated	O
with	O
microinjections	O
of	O
isoniazid	Chemical
,	O
150	O
micrograms,	O
an	O
inhibitor	O
of	O
activity	O
of	O
the	O
GABA	Chemical
-synthesizing	O
enzyme,	O
L-glutamic	Chemical
acid	Chemical
decarboxylase,	O
into	O
the	O
substantia	O
nigra	O
pars	O
reticulata	O
(SNR),	O
bilaterally,	O
non-convulsant	O
doses	O
of	O
pilocarpine	Chemical
,	O
100	O
and	O
200	O
mg/kg,	O
resulted	O
in	O
severe	O
motor	O
limbic	O
seizures	Disease
and	O
status	Disease
epilepticus	Disease
.	O
Electroencephalographic	O
and	O
behavioral	O
monitoring	O
revealed	O
a	O
profound	O
reduction	O
of	O
the	O
threshold	O
for	O
pilocarpine	Chemical
-induced	O
convulsions	Disease
.	O
Morphological	O
analysis	O
of	O
frontal	O
forebrain	O
sections	O
with	O
light	O
microscopy	O
revealed	O
seizure	Disease
-related	O
damage	O
to	O
the	O
hippocampal	O
formation,	O
thalamus,	O
amygdala,	O
olfactory	O
cortex,	O
substantia	O
nigra	O
and	O
neocortex,	O
which	O
is	O
typically	O
observed	O
with	O
pilocarpine	Chemical
in	O
doses	O
exceeding	O
350	O
mg/kg.	O
Bilateral	O
intrastriatal	O
injections	O
of	O
isoniazid	Chemical
did	O
not	O
augment	O
seizures	Disease
produced	O
by	O
pilocarpine	Chemical
,	O
200	O
mg/kg.	O
Application	O
of	O
an	O
irreversible	O
inhibitor	O
of	O
GABA	Chemical
transaminase,	O
gamma-vinyl-GABA	Chemical
(	O
D,L-4-amino-hex-5-enoic	Chemical
acid	Chemical
),	O
5	O
micrograms,	O
into	O
the	O
SNR,	O
bilaterally,	O
suppressed	O
the	O
appearance	O
of	O
electrographic	O
and	O
behavioral	O
seizures	Disease
produced	O
by	O
pilocarpine	Chemical
,	O
380	O
mg/kg.	O
This	O
treatment	O
was	O
also	O
sufficient	O
to	O
protect	O
animals	O
from	O
the	O
occurrence	O
of	O
brain	Disease
damage	Disease
.	O
Microinjections	O
of	O
gamma-vinyl-GABA	Chemical
,	O
5	O
micrograms,	O
into	O
the	O
dorsal	O
striatum,	O
bilaterally,	O
failed	O
to	O
prevent	O
the	O
development	O
of	O
convulsions	Disease
produced	O
by	O
pilocarpine	Chemical
,	O
380	O
mg/kg.	O
The	O
results	O
demonstrate	O
that	O
the	O
threshold	O
for	O
pilocarpine	Chemical
-induced	O
seizures	Disease
in	O
rats	O
is	O
subjected	O
to	O
the	O
regulation	O
of	O
the	O
GABA	Chemical

Non-invasive	O
detection	O
of	O
coronary	Disease
artery	Disease
disease	Disease
by	O
body	O
surface	O
electrocardiographic	O
mapping	O
after	O
dipyridamole	Chemical
infusion.	O
Electrocardiographic	O
changes	O
after	O
dipyridamole	Chemical
infusion	O
(0.568	O
mg/kg/4	O
min)	O
were	O
studied	O
in	O
41	O
patients	O
with	O
coronary	Disease
artery	Disease
disease	Disease
and	O
compared	O
with	O
those	O
after	O
submaximal	O
treadmill	O
exercise	O
by	O
use	O
of	O
the	O
body	O
surface	O
mapping	O
technique.	O
Patients	O
were	O
divided	O
into	O
three	O
groups;	O
19	O
patients	O
without	O
myocardial	Disease
infarction	Disease
(non-	O
MI	Disease
group),	O
14	O
with	O
anterior	Disease
infarction	Disease
(	O
ANT-MI	Disease
)	O
and	O
eight	O
with	O
inferior	Disease
infarction	Disease
(	O
INF-MI	Disease
).	O
Eighty-seven	O
unipolar	O
electrocardiograms	O
(ECGs)	O
distributed	O
over	O
the	O
entire	O
thoracic	O
surface	O
were	O
simultaneously	O
recorded.	O
After	O
dipyridamole	Chemical
,	O
ischemic	Disease
ST-segment	O
depression	Disease
(0.05	O
mV	O
or	O
more)	O
was	O
observed	O
in	O
84%	O
of	O
the	O
non-	O
MI	Disease
group,	O
29%	O
of	O
the	O
ANT-MI	Disease
group,	O
63%	O
of	O
the	O
INF-MI	Disease
group	O
and	O
61%	O
of	O
the	O
total	O
population.	O
Exercise-induced	O
ST	O
depression	Disease
was	O
observed	O
in	O
84%	O
of	O
the	O
non-	O
MI	Disease
group,	O
43%	O
of	O
the	O
ANT-MI	Disease
group,	O
38%	O
of	O
the	O
INF-MI	Disease
group	O
and	O
61%	O
of	O
the	O
total.	O
For	O
individual	O
patients,	O
there	O
were	O
no	O
obvious	O
differences	O
between	O
the	O
body	O
surface	O
distribution	O
of	O
ST	O
depression	Disease
in	O
both	O
tests.	O
The	O
increase	O
in	O
pressure	O
rate	O
product	O
after	O
dipyridamole	Chemical
was	O
significantly	O
less	O
than	O
that	O
during	O
the	O
treadmill	O
exercise.	O
The	O
data	O
suggest	O
that	O
the	O
dipyridamole	Chemical
-induced	O
myocardial	Disease
ischemia	Disease
is	O
caused	O
by	O
the	O
inhomogenous	O
distribution	O
of	O
myocardial	O
blood	O
flow.	O
We	O
conclude	O
that	O
the	O
dipyridamole	Chemical
ECG	O
test	O
is	O
as	O
useful	O
as	O
the	O
exercise	O
ECG	O
test	O
for	O
the	O
assessment	O
of	O
coronary	Disease
artery	Disease
disease	Disease

Bradycardia	Disease
after	O
high-dose	O
intravenous	O
methylprednisolone	Chemical
therapy.	O
In	O
5	O
consecutive	O
patients	O
with	O
rheumatoid	Disease
arthritis	Disease
who	O
received	O
intravenous	O
high-dose	O
methylprednisolone	Chemical
(	O
MP	Chemical
)	O
therapy	O
(1	O
g	O
daily	O
for	O
2	O
or	O
3	O
consecutive	O
days),	O
a	O
decline	O
in	O
pulse	O
rate	O
was	O
observed,	O
most	O
pronounced	O
on	O
day	O
4.	O
In	O
one	O
of	O
the	O
5	O
patients	O
the	O
bradycardia	Disease
was	O
associated	O
with	O
complaints	O
of	O
substernal	O
pressure.	O
Reversal	O
to	O
normal	O
heart	O
rate	O
was	O
found	O
on	O
day	O
7.	O
Electrocardiographic	O
registrations	O
showed	O
sinus	Disease
bradycardia	Disease
in	O
all	O
cases.	O
No	O
significant	O
changes	O
in	O
plasma	O
concentrations	O
of	O
electrolytes	O
were	O
found.	O
Careful	O
observation	O
of	O
patients	O
receiving	O
high-dose	O
MP	Chemical
is	O
recommended.	O
High-dose	O
MP	Chemical
may	O
be	O
contraindicated	O
in	O
patients	O
with	O
known	O
heart	Disease
disease	Disease

Two	O
cases	O
of	O
downbeat	Disease
nystagmus	Disease
and	O
oscillopsia	Disease
associated	O
with	O
carbamazepine	Chemical
.	O
Downbeat	Disease
nystagmus	Disease
is	O
often	O
associated	O
with	O
structural	O
lesions	O
at	O
the	O
craniocervical	O
junction,	O
but	O
has	O
occasionally	O
been	O
reported	O
as	O
a	O
manifestation	O
of	O
metabolic	O
imbalance	O
or	O
drug	O
intoxication.	O
We	O
recorded	O
the	O
eye	O
movements	O
of	O
two	O
patients	O
with	O
reversible	O
downbeat	Disease
nystagmus	Disease
related	O
to	O
carbamazepine	Chemical
therapy.	O
The	O
nystagmus	Disease
of	O
both	O
patients	O
resolved	O
after	O
reduction	O
of	O
the	O
serum	O
carbamazepine	Chemical
levels.	O
Neuroradiologic	O
investigations	O
including	O
magnetic	O
resonance	O
imaging	O
scans	O
in	O
both	O
patients	O
showed	O
no	O
evidence	O
of	O
intracranial	O
abnormality.	O
In	O
patients	O
with	O
downbeat	Disease
nystagmus	Disease

Improvement	O
by	O
denopamine	Chemical
(	O
TA-064	Chemical
)	O
of	O
pentobarbital	Chemical
-induced	O
cardiac	Disease
failure	Disease
in	O
the	O
dog	O
heart-lung	O
preparation.	O
The	O
efficacy	O
of	O
denopamine	Chemical
,	O
an	O
orally	O
active	O
beta	O
1-adrenoceptor	O
agonist,	O
in	O
improving	O
cardiac	Disease
failure	Disease
was	O
assessed	O
in	O
dog	O
heart-lung	O
preparations.	O
Cardiac	O
functions	O
depressed	O
by	O
pentobarbital	Chemical
(118	O
+/-	O
28	O
mg;	O
mean	O
value	O
+/-	O
SD)	O
such	O
that	O
cardiac	O
output	O
and	O
maximum	O
rate	O
of	O
rise	O
of	O
left	O
ventricular	O
pressure	O
(LV	O
dP/dt	O
max)	O
had	O
been	O
reduced	O
by	O
about	O
35%	O
and	O
26%	O
of	O
the	O
respective	O
controls	O
were	O
improved	O
by	O
denopamine	Chemical
(10-300	O
micrograms)	O
in	O
a	O
dose-dependent	O
manner.	O
With	O
100	O
micrograms	O
denopamine	Chemical
,	O
almost	O
complete	O
restoration	O
of	O
cardiac	O
performance	O
was	O
attained,	O
associated	O
with	O
a	O
slight	O
increase	O
in	O
heart	O
rate.	O
No	O
arrhythmias	Disease
were	O
induced	O
by	O
these	O
doses	O
of	O
denopamine	Chemical
.	O
The	O
results	O
warrant	O
clinical	O
trials	O
of	O
denopamine	Chemical
in	O
the	O
treatment	O
of	O
cardiac	Disease
failure	Disease

Clonazepam	Chemical
monotherapy	O
for	O
epilepsy	Disease
in	O
childhood.	O
Sixty	O
patients	O
(age-range	O
one	O
month	O
to	O
14	O
years)	O
with	O
other	O
types	O
of	O
epilepsy	Disease
than	O
infantile	Disease
spasms	Disease
were	O
treated	O
with	O
clonazepam	Chemical
.	O
Disappearance	O
of	O
seizures	Disease
and	O
normalization	O
of	O
abnormal	O
EEG	O
with	O
disappearance	O
of	O
seizures	Disease
were	O
recognized	O
in	O
77%	O
and	O
50%,	O
respectively.	O
Seizures	Disease
disappeared	O
in	O
71%	O
of	O
the	O
patients	O
with	O
generalized	O
seizures	Disease
and	O
89%	O
of	O
partial	O
seizures	Disease
.	O
Improvement	O
of	O
abnormal	O
EEG	O
was	O
noticed	O
in	O
76%	O
of	O
diffuse	O
paroxysms	O
and	O
in	O
67%	O
of	O
focal	O
paroxysms.	O
In	O
excellent	O
cases,	O
mean	O
effective	O
dosages	O
were	O
0.086	O
+/-	O
0.021	O
mg/kg/day	O
in	O
infants	O
and	O
0.057	O
+/-	O
0.022	O
mg/kg/day	O
in	O
schoolchildren,	O
this	O
difference	O
was	O
statistically	O
significant	O
(p	O
less	O
than	O
0.005).	O
The	O
incidence	O
of	O
side	O
effects	O
such	O
as	O
drowsiness	Disease
and	O
ataxia	Disease

Postmarketing	O
study	O
of	O
timolol	Chemical
-	O
hydrochlorothiazide	Chemical
antihypertensive	O
therapy.	O
A	O
postmarketing	O
surveillance	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
safety	O
and	O
efficacy	O
of	O
a	O
fixed-ratio	O
combination	O
containing	O
10	O
mg	O
of	O
timolol	Chemical
maleate	Chemical
and	O
25	O
mg	O
of	O
hydrochlorothiazide	Chemical
,	O
administered	O
twice	O
daily	O
for	O
one	O
month	O
to	O
hypertensive	Disease
patients.	O
Data	O
on	O
9,037	O
patients	O
were	O
collected	O
by	O
1,455	O
participating	O
physicians.	O
Mean	O
systolic	O
blood	O
pressure	O
decreased	O
25	O
mmHg	O
and	O
mean	O
diastolic	O
blood	O
pressure	O
declined	O
15	O
mmHg	O
after	O
one	O
month	O
of	O
timolol	Chemical
-	O
hydrochlorothiazide	Chemical
therapy	O
(P	O
less	O
than	O
0.01,	O
both	O
comparisons).	O
Age,	O
race,	O
and	O
sex	O
appeared	O
to	O
have	O
no	O
influence	O
on	O
the	O
decrease	O
in	O
blood	O
pressure.	O
The	O
antihypertensive	O
effect	O
of	O
the	O
drug	O
was	O
greater	O
in	O
patients	O
with	O
more	O
severe	O
hypertension	Disease
.	O
Overall,	O
1,453	O
patients	O
experienced	O
a	O
total	O
of	O
2,658	O
adverse	O
events,	O
the	O
most	O
common	O
being	O
fatigue	Disease
,	O
dizziness	Disease
,	O
and	O
weakness	Disease

Salicylate	Chemical
	O
nephropathy	Disease
in	O
the	O
Gunn	O
rat:	O
potential	O
role	O
of	O
prostaglandins	Chemical
.	O
We	O
examined	O
the	O
potential	O
role	O
of	O
prostaglandins	Chemical
in	O
the	O
development	O
of	O
analgesic	O
nephropathy	Disease
in	O
the	O
Gunn	O
strain	O
of	O
rat.	O
The	O
homozygous	O
Gunn	O
rats	O
have	O
unconjugated	O
hyperbilirubinemia	Disease
due	O
to	O
the	O
absence	O
of	O
glucuronyl	Chemical
transferase,	O
leading	O
to	O
marked	O
bilirubin	Chemical
deposition	O
in	O
renal	O
medulla	O
and	O
papilla.	O
These	O
rats	O
are	O
also	O
highly	O
susceptible	O
to	O
develop	O
papillary	Disease
necrosis	Disease
with	O
analgesic	O
administration.	O
We	O
used	O
homozygous	O
(jj)	O
and	O
phenotypically	O
normal	O
heterozygous	O
(jJ)	O
animals.	O
Four	O
groups	O
of	O
rats	O
(n	O
=	O
7)	O
were	O
studied:	O
jj	O
and	O
jJ	O
rats	O
treated	O
either	O
with	O
aspirin	Chemical
300	O
mg/kg	O
every	O
other	O
day	O
or	O
sham-treated.	O
After	O
one	O
week,	O
slices	O
of	O
cortex,	O
outer	O
and	O
inner	O
medulla	O
from	O
one	O
kidney	O
were	O
incubated	O
in	O
buffer	O
and	O
prostaglandin	Chemical
synthesis	O
was	O
determined	O
by	O
radioimmunoassay.	O
The	O
other	O
kidney	O
was	O
examined	O
histologically.	O
A	O
marked	O
corticomedullary	O
gradient	O
of	O
prostaglandin	Chemical
synthesis	O
was	O
observed	O
in	O
all	O
groups.	O
PGE2	Chemical
synthesis	O
was	O
significantly	O
higher	O
in	O
outer	O
medulla,	O
but	O
not	O
cortex	O
or	O
inner	O
medulla,	O
of	O
jj	O
(38	O
+/-	O
6	O
ng/mg	O
prot)	O
than	O
jJ	O
rats	O
(15	O
+/-	O
3)	O
(p	O
less	O
than	O
0.01).	O
Aspirin	Chemical
treatment	O
reduced	O
PGE2	Chemical
synthesis	O
in	O
all	O
regions,	O
but	O
outer	O
medullary	O
PGE2	Chemical
remained	O
higher	O
in	O
jj	O
(18	O
+/-	O
3)	O
than	O
jJ	O
rats	O
(9	O
+/-	O
2)	O
(p	O
less	O
than	O
0.05).	O
PGF2	Chemical
alpha	Chemical
was	O
also	O
significantly	O
higher	O
in	O
the	O
outer	O
medulla	O
of	O
jj	O
rats	O
with	O
and	O
without	O
aspirin	Chemical
administration	O
(p	O
less	O
than	O
0.05).	O
The	O
changes	O
in	O
renal	O
prostaglandin	Chemical
synthesis	O
were	O
accompanied	O
by	O
evidence	O
of	O
renal	Disease
damage	Disease
in	O
aspirin	Chemical
-treated	O
jj	O
but	O
not	O
jJ	O
rats	O
as	O
evidenced	O
by:	O
increased	O
incidence	O
and	O
severity	O
of	O
hematuria	Disease
(p	O
less	O
than	O
0.01);	O
increased	O
serum	O
creatinine	Chemical
(p	O
less	O
than	O
0.05);	O
and	O
increase	O
in	O
outer	O
medullary	O
histopathologic	O
lesions	O
(p	O
less	O
than	O
0.005	O
compared	O
to	O
either	O
sham-treated	O
jj	O
or	O
aspirin	Chemical
-treated	O
jJ).	O
These	O
results	O
suggest	O
that	O
enhanced	O
prostaglandin	Chemical
synthesis	O
contributes	O
to	O
maintenance	O
of	O
renal	O
function	O
and	O
morphological	O
integrity,	O
and	O
that	O
inhibition	O
of	O
prostaglandin	Chemical
synthesis	O
may	O
lead	O
to	O
pathological	Disease
renal	Disease
medullary	Disease
lesions	Disease
and	O
deterioration	Disease
of	Disease
renal	Disease
function	Disease

Prophylactic	O
lidocaine	Chemical
in	O
the	O
early	O
phase	O
of	O
suspected	O
myocardial	Disease
infarction	Disease
.	O
Four	O
hundred	O
two	O
patients	O
with	O
suspected	O
myocardial	Disease
infarction	Disease
seen	O
within	O
6	O
hours	O
of	O
the	O
onset	O
of	O
symptoms	O
entered	O
a	O
double-blind	O
randomized	O
trial	O
of	O
lidocaine	Chemical
vs	O
placebo.	O
During	O
the	O
1	O
hour	O
after	O
administration	O
of	O
the	O
drug	O
the	O
incidence	O
of	O
ventricular	Disease
fibrillation	Disease
or	O
sustained	O
ventricular	Disease
tachycardia	Disease
among	O
the	O
204	O
patients	O
with	O
acute	O
myocardial	Disease
infarction	Disease
was	O
low,	O
1.5%.	O
Lidocaine	Chemical
,	O
given	O
in	O
a	O
300	O
mg	O
dose	O
intramuscularly	O
followed	O
by	O
100	O
mg	O
intravenously,	O
did	O
not	O
prevent	O
sustained	O
ventricular	Disease
tachycardia	Disease
,	O
although	O
there	O
was	O
a	O
significant	O
reduction	O
in	O
the	O
number	O
of	O
patients	O
with	O
warning	O
arrhythmias	Disease
between	O
15	O
and	O
45	O
minutes	O
after	O
the	O
administration	O
of	O
lidocaine	Chemical
(p	O
less	O
than	O
0.05).	O
The	O
average	O
plasma	O
lidocaine	Chemical
level	O
10	O
minutes	O
after	O
administration	O
for	O
patients	O
without	O
a	O
myocardial	Disease
infarction	Disease
was	O
significantly	O
higher	O
than	O
that	O
for	O
patients	O
with	O
an	O
acute	O
infarction	Disease
.	O
The	O
mean	O
plasma	O
lidocaine	Chemical
level	O
of	O
patients	O
on	O
beta-blocking	O
agents	O
was	O
no	O
different	O
from	O
that	O
in	O
patients	O
not	O
on	O
beta	O
blocking	O
agents.	O
During	O
the	O
1-hour	O
study	O
period,	O
the	O
incidence	O
of	O
central	O
nervous	O
system	O
side	O
effects	O
was	O
significantly	O
greater	O
in	O
the	O
lidocaine	Chemical
group,	O
hypotension	Disease
occurred	O
in	O
11	O
patients,	O
nine	O
of	O
whom	O
had	O
received	O
lidocaine	Chemical
,	O
and	O
four	O
patients	O
died	O
from	O
asystole	Disease
,	O
three	O
of	O
whom	O
had	O
had	O
lidocaine	Chemical
.	O
We	O
cannot	O
advocate	O
the	O
administration	O
of	O
lidocaine	Chemical
prophylactically	O
in	O
the	O
early	O
hours	O
of	O
suspected	O
myocardial	Disease
infarction	Disease

Evidence	O
for	O
a	O
cholinergic	O
role	O
in	O
haloperidol	Chemical
-induced	O
catalepsy	Disease
.	O
Experiments	O
in	O
mice	O
tested	O
previous	O
evidence	O
that	O
activation	O
of	O
cholinergic	O
systems	O
promotes	O
catalepsy	Disease
and	O
that	O
cholinergic	O
mechanisms	O
need	O
to	O
be	O
intact	O
for	O
full	O
expression	O
of	O
neuroleptic	Chemical
-induced	O
catalepsy	Disease
.	O
Large	O
doses	O
of	O
the	O
cholinomimetic,	O
pilocarpine	Chemical
,	O
could	O
induce	O
catalepsy	Disease
when	O
peripheral	O
cholinergic	O
receptors	O
were	O
blocked.	O
Low	O
doses	O
of	O
pilocarpine	Chemical
caused	O
a	O
pronounced	O
enhancement	O
of	O
the	O
catalepsy	Disease
that	O
was	O
induced	O
by	O
the	O
dopaminergic	O
blocker,	O
haloperidol	Chemical
.	O
A	O
muscarinic	O
receptor	O
blocker,	O
atropine	Chemical
,	O
disrupted	O
haloperidol	Chemical
-induced	O
catalepsy	Disease
.	O
Intracranial	O
injection	O
of	O
an	O
acetylcholine	Chemical
-synthesis	O
inhibitor,	O
hemicholinium	Chemical
,	O
prevented	O
the	O
catalepsy	Disease
that	O
is	O
usually	O
induced	O
by	O
haloperidol	Chemical
.	O
These	O
findings	O
suggest	O
the	O
hypothesis	O
that	O
the	O
catalepsy	Disease
that	O
is	O
produced	O
by	O
neuroleptics	Chemical
such	O
as	O
haloperidol	Chemical
is	O
actually	O
mediated	O
by	O
intrinsic	O
central	O
cholinergic	O
systems.	O
Alternatively,	O
activation	O
of	O
central	O
cholinergic	O
systems	O
could	O
promote	O
catalepsy	Disease

Cardiovascular	Disease
dysfunction	Disease
and	O
hypersensitivity	Disease
to	O
sodium	Chemical
pentobarbital	Chemical
induced	O
by	O
chronic	O
barium	Chemical
chloride	Chemical
ingestion.	O
Barium	Chemical
-supplemented	O
Long-Evans	O
hooded	O
rats	O
were	O
characterized	O
by	O
a	O
persistent	O
hypertension	Disease
that	O
was	O
evident	O
after	O
1	O
month	O
of	O
barium	Chemical
(100	O
micrograms/ml	O
mineral	O
fortified	O
water)	O
treatment.	O
Analysis	O
of	O
in	O
vivo	O
myocardial	O
excitability,	O
contractility,	O
and	O
metabolic	O
characteristics	O
at	O
16	O
months	O
revealed	O
other	O
significant	O
barium	Chemical
-induced	O
disturbances	Disease
within	Disease
the	Disease
cardiovascular	Disease
system	Disease
.	O
The	O
most	O
distinctive	O
aspect	O
of	O
the	O
barium	Chemical
effect	O
was	O
a	O
demonstrated	O
hypersensitivity	Disease
of	O
the	O
cardiovascular	O
system	O
to	O
sodium	Chemical
pentobarbital	Chemical
.	O
Under	O
barbiturate	Chemical
anesthesia,	O
virtually	O
all	O
of	O
the	O
myocardial	O
contractile	O
indices	O
were	O
depressed	O
significantly	O
in	O
barium	Chemical
-exposed	O
rats	O
relative	O
to	O
the	O
corresponding	O
control-fed	O
rats.	O
The	O
lack	O
of	O
a	O
similar	O
response	O
to	O
ketamine	Chemical
and	O
xylazine	Chemical
anesthesia	O
revealed	O
that	O
the	O
cardiovascular	O
actions	O
of	O
sodium	Chemical
pentobarbital	Chemical
in	O
barium	Chemical
-treated	O
rats	O
were	O
linked	O
specifically	O
to	O
this	O
anesthetic,	O
and	O
were	O
not	O
representative	O
of	O
a	O
generalized	O
anesthetic	O
response.	O
Other	O
myocardial	O
pathophysiologic	O
and	O
metabolic	O
changes	O
induced	O
by	O
barium	Chemical
were	O
manifest,	O
irrespective	O
of	O
the	O
anesthetic	O
employed.	O
The	O
contractile	O
element	O
shortening	O
velocity	O
of	O
the	O
cardiac	O
muscle	O
fibers	O
was	O
significantly	O
slower	O
in	O
both	O
groups	O
of	O
barium	Chemical
-treated	O
rats	O
relative	O
to	O
the	O
control	O
groups,	O
irrespective	O
of	O
the	O
anesthetic	O
regimen.	O
Similarly,	O
significant	O
disturbances	O
in	O
myocardial	O
energy	O
metabolism	O
were	O
detected	O
in	O
the	O
barium	Chemical
-exposed	O
rats	O
which	O
were	O
consistent	O
with	O
the	O
reduced	O
contractile	O
element	O
shortening	O
velocity.	O
In	O
addition,	O
the	O
excitability	O
of	O
the	O
cardiac	O
conduction	O
system	O
was	O
depressed	O
preferentially	O
in	O
the	O
atrioventricular	O
nodal	O
region	O
of	O
hearts	O
from	O
barium	Chemical
-exposed	O
rats.	O
Overall,	O
the	O
altered	O
cardiac	O
contractility	O
and	O
excitability	O
characteristics,	O
the	O
myocardial	O
metabolic	Disease
disturbances	Disease
,	O
and	O
the	O
hypersensitivity	Disease
of	O
the	O
cardiovascular	O
system	O
to	O
sodium	Chemical
pentobarbital	Chemical
suggest	O
the	O
existence	O
of	O
a	O
heretofore	O
undescribed	O
cardiomyopathic	Disease
disorder	Disease
induced	O
by	O
chronic	O
barium	Chemical
exposure.	O
These	O
experimental	O
findings	O
represent	O
the	O
first	O
indication	O
that	O
life-long	O
barium	Chemical

Propranolol	Chemical
antagonism	O
of	O
phenylpropanolamine	Chemical
-induced	O
hypertension	Disease
.	O
Phenylpropanolamine	Chemical
(	O
PPA	Chemical
)	O
overdose	Disease
can	O
cause	O
severe	O
hypertension	Disease
,	O
intracerebral	Disease
hemorrhage	Disease
,	O
and	O
death.	O
We	O
studied	O
the	O
efficacy	O
and	O
safety	O
of	O
propranolol	Chemical
in	O
the	O
treatment	O
of	O
PPA	Chemical
-induced	O
hypertension	Disease
.	O
Subjects	O
received	O
propranolol	Chemical
either	O
by	O
mouth	O
for	O
48	O
hours	O
before	O
PPA	Chemical
or	O
as	O
a	O
rapid	O
intravenous	O
infusion	O
after	O
PPA	Chemical
.	O
PPA	Chemical
,	O
75	O
mg	O
alone,	O
increased	O
blood	O
pressure	O
(31	O
+/-	O
14	O
mm	O
Hg	O
systolic,	O
20	O
+/-	O
5	O
mm	O
Hg	O
diastolic),	O
and	O
propranolol	Chemical
pretreatment	O
antagonized	O
this	O
increase	O
(12	O
+/-	O
10	O
mm	O
Hg	O
systolic,	O
10	O
+/-	O
7	O
mm	O
Hg	O
diastolic).	O
Intravenous	O
propranolol	Chemical
after	O
PPA	Chemical
also	O
decreased	O
blood	O
pressure.	O
Left	O
ventricular	O
function	O
(assessed	O
by	O
echocardiography)	O
showed	O
that	O
PPA	Chemical
increased	O
the	O
stroke	Disease
volume	O
30%	O
(from	O
62.5	O
+/-	O
20.9	O
to	O
80.8	O
+/-	O
22.4	O
ml),	O
the	O
ejection	O
fraction	O
9%	O
(from	O
64%	O
+/-	O
10%	O
to	O
70%	O
+/-	O
7%),	O
and	O
cardiac	O
output	O
14%	O
(from	O
3.6	O
+/-	O
0.6	O
to	O
4.1	O
+/-	O
1.0	O
L/min).	O
Intravenous	O
propranolol	Chemical
reversed	O
these	O
effects.	O
Systemic	O
vascular	O
resistance	O
was	O
increased	O
by	O
PPA	Chemical
28%	O
(from	O
1710	O
+/-	O
200	O
to	O
2190	O
+/-	O
700	O
dyne	O
X	O
sec/cm5)	O
and	O
was	O
further	O
increased	O
by	O
propranolol	Chemical
22%	O
(to	O
2660	O
+/-	O
1200	O
dyne	O
X	O
sec/cm5).	O
We	O
conclude	O
that	O
PPA	Chemical
increases	O
blood	O
pressure	O
by	O
increasing	O
systemic	O
vascular	O
resistance	O
and	O
cardiac	O
output,	O
and	O
that	O
propranolol	Chemical
antagonizes	O
this	O
increase	O
by	O
reversing	O
the	O
effect	O
of	O
PPA	Chemical
on	O
cardiac	O
output.	O
That	O
propranolol	Chemical
antagonizes	O
the	O
pressor	O
effect	O
of	O
PPA	Chemical
is	O
in	O
contrast	O
to	O
the	O
interaction	O
in	O
which	O
propranolol	Chemical
enhances	O
the	O
pressor	O
effect	O
of	O
norepinephrine	Chemical
.	O
This	O
is	O
probably	O
because	O
PPA	Chemical
has	O
less	O
beta	O
2	O
activity	O
than	O
does	O
norepinephrine	Chemical

Mesangial	O
function	O
and	O
glomerular	Disease
sclerosis	Disease
in	O
rats	O
with	O
aminonucleoside	Chemical
	O
nephrosis	Disease
.	O
The	O
possible	O
relationship	O
between	O
mesangial	Disease
dysfunction	Disease
and	O
development	O
of	O
glomerular	Disease
sclerosis	Disease
was	O
studied	O
in	O
the	O
puromycin	Chemical
aminonucleoside	Chemical
(	O
PAN	Chemical
)	O
model.	O
Five	O
male	O
Wistar	O
rats	O
received	O
repeated	O
subcutaneous	O
PAN	Chemical
injections;	O
five	O
controls	O
received	O
saline	O
only.	O
After	O
4	O
weeks	O
the	O
PAN	Chemical
rats	O
were	O
severely	O
proteinuric	Disease
(190	O
+/-	O
80	O
mg/24	O
hr),	O
and	O
all	O
rats	O
were	O
given	O
colloidal	O
carbon	Chemical
(CC)	O
intravenously.	O
At	O
5	O
months	O
glomerular	Disease
sclerosis	Disease
was	O
found	O
in	O
7.6	O
+/-	O
3.4%	O
of	O
the	O
glomeruli	O
of	O
PAN	Chemical
rats;	O
glomeruli	O
of	O
the	O
controls	O
were	O
normal.	O
Glomeruli	O
of	O
PAN	Chemical
rats	O
contained	O
significantly	O
more	O
CC	O
than	O
glomeruli	O
of	O
controls.	O
Glomeruli	O
with	O
sclerosis	Disease
contained	O
significantly	O
more	O
CC	O
than	O
non-sclerotic	O
glomeruli	O
in	O
the	O
same	O
kidneys.	O
CC	O
was	O
preferentially	O
localized	O
within	O
the	O
sclerotic	O
areas	O
of	O
the	O
affected	O
glomeruli.	O
Since	O
mesangial	O
CC	O
clearance	O
from	O
the	O
mesangium	O
did	O
not	O
change	O
during	O
chronic	O
PAN	Chemical
treatment,	O
we	O
conclude	O
that	O
this	O
preferential	O
CC	O
localization	O
within	O
the	O
lesions	O
is	O
caused	O
by	O
an	O
increased	O
CC	O
uptake	O
shortly	O
after	O
injection	O
in	O
apparent	O
vulnerable	O
areas	O
where	O
sclerosis	Disease
will	O
develop	O
subsequently.	O
Cluster	O
analysis	O
showed	O
a	O
random	O
distribution	O
of	O
lesions	O
in	O
the	O
PAN	Chemical
glomeruli	O
in	O
concordance	O
with	O
the	O
random	O
localization	O
of	O
mesangial	O
areas	O
with	O
dysfunction	O
in	O
this	O
model.	O
Similar	O
to	O
the	O
remnant	O
kidney	O
model	O
in	O
PAN	Chemical
	O
nephrosis	Disease
the	O
development	O
of	O
glomerular	Disease
sclerosis	Disease

Relationship	O
between	O
nicotine	Chemical
-induced	O
seizures	Disease
and	O
hippocampal	O
nicotinic	O
receptors.	O
A	O
controversy	O
has	O
existed	O
for	O
several	O
years	O
concerning	O
the	O
physiological	O
relevance	O
of	O
the	O
nicotinic	O
receptor	O
measured	O
by	O
alpha-bungarotoxin	O
binding.	O
Using	O
mice	O
derived	O
from	O
a	O
classical	O
F2	O
and	O
backcross	O
genetic	O
design,	O
a	O
relationship	O
between	O
nicotine	Chemical
-induced	O
seizures	Disease
and	O
alpha-bungarotoxin	O
nicotinic	O
receptor	O
concentration	O
was	O
found.	O
Mice	O
sensitive	O
to	O
the	O
convulsant	O
effects	O
of	O
nicotine	Chemical
had	O
greater	O
alpha-bungarotoxin	O
binding	O
in	O
the	O
hippocampus	O
than	O
seizure	Disease
insensitive	O
mice.	O
The	O
binding	O
sites	O
from	O
seizure	Disease
sensitive	O
and	O
resistant	O
mice	O
were	O
equally	O
affected	O
by	O
treatment	O
with	O
dithiothreitol	Chemical
,	O
trypsin	O
or	O
heat.	O
Thus	O
it	O
appears	O
that	O
the	O
difference	O
between	O
seizure	Disease

The	O
role	O
of	O
p-aminophenol	Chemical
in	O
acetaminophen	Chemical
-induced	O
nephrotoxicity	Disease
:	O
effect	O
of	O
bis(p-nitrophenyl)	Chemical
phosphate	Chemical
on	O
acetaminophen	Chemical
and	O
p-aminophenol	Chemical
	O
nephrotoxicity	Disease
and	O
metabolism	O
in	O
Fischer	O
344	O
rats.	O
Acetaminophen	Chemical
(	O
APAP	Chemical
)	O
produces	O
proximal	O
tubular	Disease
necrosis	Disease
in	O
Fischer	O
344	O
(F344)	O
rats.	O
Recently,	O
p-aminophenol	Chemical
(	O
PAP	Chemical
),	O
a	O
known	O
potent	O
nephrotoxicant,	O
was	O
identified	O
as	O
a	O
metabolite	O
of	O
APAP	Chemical
in	O
F344	O
rats.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
PAP	Chemical
formation	O
is	O
a	O
requisite	O
step	O
in	O
APAP	Chemical
-induced	O
nephrotoxicity	Disease
.	O
Therefore,	O
the	O
effect	O
of	O
bis(p-nitrophenyl)	Chemical
phosphate	Chemical
(	O
BNPP	Chemical
),	O
an	O
acylamidase	O
inhibitor,	O
on	O
APAP	Chemical
and	O
PAP	Chemical
	O
nephrotoxicity	Disease
and	O
metabolism	O
was	O
determined.	O
BNPP	Chemical
(1	O
to	O
8	O
mM)	O
reduced	O
APAP	Chemical
deacetylation	O
and	O
covalent	O
binding	O
in	O
F344	O
renal	O
cortical	O
homogenates	O
in	O
a	O
concentration-dependent	O
manner.	O
Pretreatment	O
of	O
animals	O
with	O
BNPP	Chemical
prior	O
to	O
APAP	Chemical
or	O
PAP	Chemical
administration	O
resulted	O
in	O
marked	O
reduction	O
of	O
APAP	Chemical
(900	O
mg/kg)	O
nephrotoxicity	Disease
but	O
not	O
PAP	Chemical
	O
nephrotoxicity	Disease
.	O
This	O
result	O
was	O
not	O
due	O
to	O
altered	O
disposition	O
of	O
either	O
APAP	Chemical
or	O
acetylated	O
metabolites	O
in	O
plasma	O
or	O
renal	O
cortical	O
and	O
hepatic	O
tissue.	O
Rather,	O
BNPP	Chemical
pretreatment	O
reduced	O
the	O
fraction	O
of	O
APAP	Chemical
excreted	O
as	O
PAP	Chemical
by	O
64	O
and	O
75%	O
after	O
APAP	Chemical
doses	O
of	O
750	O
and	O
900	O
mg/kg.	O
BNPP	Chemical
did	O
not	O
alter	O
the	O
excretion	O
of	O
APAP	Chemical
or	O
any	O
of	O
its	O
non-deacetylated	O
metabolites	O
nor	O
did	O
BNPP	Chemical
alter	O
excretion	O
of	O
PAP	Chemical
or	O
its	O
metabolites	O
after	O
PAP	Chemical
doses	O
of	O
150	O
and	O
300	O
mg/kg.	O
Therefore,	O
the	O
BNPP	Chemical
-induced	O
reduction	O
in	O
APAP	Chemical
-induced	O
nephrotoxicity	Disease
appears	O
to	O
be	O
due	O
to	O
inhibition	O
of	O
APAP	Chemical
deacetylation.	O
It	O
is	O
concluded	O
that	O
PAP	Chemical
formation,	O
in	O
vivo,	O
accounts,	O
at	O
least	O
in	O
part,	O
for	O
APAP	Chemical
-induced	O
renal	Disease
tubular	Disease
necrosis	Disease

Morphine	Chemical
-induced	O
seizures	Disease
in	O
newborn	O
infants.	O
Two	O
neonates	O
suffered	O
from	O
generalized	O
seizures	Disease
during	O
the	O
course	O
of	O
intravenous	O
morphine	Chemical
sulfate	Chemical
for	O
post-operative	O
analgesia.	O
They	O
received	O
morphine	Chemical
in	O
doses	O
of	O
32	O
micrograms/kg/hr	O
and	O
40	O
micrograms/kg/hr	O
larger	O
than	O
a	O
group	O
of	O
10	O
neonates	O
who	O
received	O
6-24	O
micrograms/kg/hr	O
and	O
had	O
no	O
seizures	Disease
.	O
Plasma	O
concentrations	O
of	O
morphine	Chemical
in	O
these	O
neonates	O
was	O
excessive	O
(60	O
and	O
90	O
mg/ml).	O
Other	O
known	O
reasons	O
for	O
seizures	Disease
were	O
ruled	O
out	O
and	O
the	O
convulsions	Disease
stopped	O
a	O
few	O
hours	O
after	O
cessation	O
of	O
morphine	Chemical
and	O
did	O
not	O
reoccur	O
in	O
the	O
subsequent	O
8	O
months.	O
It	O
is	O
suggested	O
that	O
post-operative	O
intravenous	O
morphine	Chemical

Effect	O
of	O
vincristine	Chemical
sulfate	Chemical
on	O
Pseudomonas	Disease
infections	Disease
in	O
monkeys.	O
In	O
rhesus	O
monkeys,	O
intravenous	O
challenge	O
with	O
0.6	O
x	O
10(10)	O
to	O
2.2	O
x	O
10(10)Pseudomonas	O
aeruginosa	O
organisms	O
caused	O
acute	O
illness	O
of	O
4	O
to	O
5	O
days'	O
duration	O
with	O
spontaneous	O
recovery	O
in	O
13	O
of	O
15	O
monkeys;	O
blood	O
cultures	O
became	O
negative	O
3	O
to	O
17	O
days	O
after	O
challenge.	O
Leukocytosis	Disease
was	O
observed	O
in	O
all	O
monkeys.	O
Intravenous	O
or	O
intratracheal	O
inoculation	O
of	O
2.0	O
to	O
2.5	O
mg	O
of	O
vincristine	Chemical
sulfate	Chemical
was	O
followed	O
by	O
leukopenia	Disease
in	O
4	O
to	O
5	O
days.	O
Intravenous	O
inoculation	O
of	O
4.2	O
x	O
10(10)	O
to	O
7.8	O
x	O
10(10)	O
pyocin	O
type	O
6	O
Pseudomonas	O
organisms	O
in	O
monkeys	O
given	O
vincristine	Chemical
sulfate	Chemical
4	O
days	O
previously	O
resulted	O
in	O
fatal	O
infection	Disease
in	O
11	O
of	O
14	O
monkeys,	O
whereas	O
none	O
of	O
four	O
receiving	O
Pseudomonas	O
alone	O
died.	O
These	O
studies	O
suggest	O
that	O
an	O
antimetabolite-induced	O
leukopenia	Disease
predisposes	O
to	O
severe	O
Pseudomonas	O
sepsis	Disease

Central	O
excitatory	O
actions	O
of	O
flurazepam	Chemical
.	O
Toxic	O
actions	O
of	O
flurazepam	Chemical
(	O
FZP	Chemical
)	O
were	O
studied	O
in	O
cats,	O
mice	O
and	O
rats.	O
High	O
doses	O
caused	O
an	O
apparent	O
central	O
excitation,	O
most	O
clearly	O
seen	O
as	O
clonic	O
convulsions	Disease
,	O
superimposed	O
on	O
general	O
depression	Disease
.	O
Following	O
a	O
lethal	O
dose,	O
death	O
was	O
always	O
associated	O
with	O
convulsions	Disease
.	O
Comparing	O
the	O
relative	O
sensitivity	O
to	O
central	O
depression	Disease
and	O
excitation	O
revealed	O
that	O
rats	O
were	O
least	O
likely	O
to	O
have	O
convulsions	Disease
at	O
doses	O
that	O
did	O
not	O
first	O
cause	O
loss	Disease
of	Disease
consciousness	Disease
,	O
while	O
cats	O
most	O
clearly	O
showed	O
marked	O
central	O
excitatory	O
actions.	O
Signs	O
of	O
FZP	Chemical
	O
toxocity	Disease
in	O
cats	O
included	O
excessive	O
salivation	Disease
,	O
extreme	O
apprehensive	O
behavior,	O
retching,	O
muscle	Disease
tremors	Disease
and	O
convulsions	Disease
.	O
An	O
interaction	O
between	O
FZP	Chemical
and	O
pentylenetetrazol	Chemical
(	O
PTZ	Chemical
)	O
was	O
shown	O
by	O
pretreating	O
mice	O
with	O
FZP	Chemical
before	O
PTZ	Chemical
challenge.	O
As	O
a	O
function	O
of	O
dose,	O
FZP	Chemical
first	O
protected	O
against	O
convulsions	Disease
and	O
death.	O
At	O
higher	O
doses,	O
however,	O
convulsions	Disease
again	O
emerged.	O
These	O
doses	O
of	O
FZP	Chemical
were	O
lower	O
than	O
those	O
that	O
would	O
alone	O
cause	O
convulsions	Disease
.	O
These	O
results	O
may	O
be	O
relevant	O
to	O
the	O
use	O
of	O
FZP	Chemical
in	O
clinical	O
situations	O
in	O
which	O
there	O
is	O
increased	O
neural	O
excitability,	O
such	O
as	O
epilepsy	Disease

Evidence	O
for	O
cardiac	O
beta	O
2-adrenoceptors	O
in	O
man.	O
We	O
compared	O
the	O
effects	O
of	O
single	O
doses	O
of	O
50	O
mg	O
atenolol	Chemical
(cardioselective),	O
40	O
mg	O
propranolol	Chemical
(nonselective),	O
and	O
placebo	O
on	O
both	O
exercise-	O
and	O
isoproterenol	Chemical
-induced	O
tachycardia	Disease
in	O
two	O
experiments	O
involving	O
nine	O
normal	O
subjects.	O
Maximal	O
exercise	O
heart	O
rate	O
was	O
reduced	O
from	O
187	O
+/-	O
4(SEM)	O
after	O
placebo	O
to	O
146	O
+/-	O
7	O
bpm	O
after	O
atenolol	Chemical
and	O
138	O
+/-	O
6	O
bpm	O
after	O
propranolol	Chemical
,	O
but	O
there	O
were	O
no	O
differences	O
between	O
the	O
drugs.	O
The	O
effects	O
on	O
isoproterenol	Chemical
	O
tachycardia	Disease
were	O
determined	O
before	O
and	O
after	O
atropine	Chemical
(0.04	O
mg/kg	O
IV).	O
Isoproterenol	Chemical
sensitivity	O
was	O
determined	O
as	O
the	O
intravenous	O
dose	O
that	O
increased	O
heart	O
rate	O
by	O
25	O
bpm	O
(CD25)	O
and	O
this	O
was	O
increased	O
from	O
1.8	O
+/-	O
0.3	O
micrograms	O
after	O
placebo	O
to	O
38.9	O
+/-	O
8.3	O
micrograms	O
after	O
propranolol	Chemical
and	O
8.3	O
+/-	O
1.7	O
micrograms	O
after	O
atenolol	Chemical
.	O
The	O
difference	O
in	O
the	O
effects	O
of	O
the	O
two	O
was	O
significant.	O
After	O
atropine	Chemical
the	O
CD25	O
was	O
unchanged	O
after	O
placebo	O
(2.3	O
+/-	O
0.3	O
micrograms)	O
and	O
atenolol	Chemical
(7.7	O
+/-	O
1.3	O
micrograms);	O
it	O
was	O
reduced	O
after	O
propranolol	Chemical
(24.8	O
+/-	O
5.0	O
micrograms),	O
but	O
remained	O
different	O
from	O
atenolol	Chemical
.	O
This	O
change	O
with	O
propranolol	Chemical
sensitivity	O
was	O
calculated	O
as	O
the	O
apparent	O
Ka,	O
this	O
was	O
unchanged	O
by	O
atropine	Chemical
(11.7	O
+/-	O
2.1	O
and	O
10.1	O
+/-	O
2.5	O
ml/ng).	O
These	O
data	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
exercise-induced	O
tachycardia	Disease
results	O
largely	O
from	O
beta	O
1-receptor	O
activation	O
that	O
is	O
blocked	O
by	O
both	O
cardioselective	O
and	O
nonselective	O
drugs,	O
whereas	O
isoproterenol	Chemical

Hormones	O
and	O
risk	O
of	O
breast	Disease
cancer	Disease
.	O
This	O
paper	O
reports	O
the	O
results	O
of	O
a	O
study	O
of	O
50	O
menopausal	O
women	O
receiving	O
hormonal	O
replacement	O
therapy.	O
The	O
majority	O
(29)	O
had	O
surgical	O
menopause;	O
their	O
mean	O
age	O
was	O
45.7	O
years.	O
It	O
was	O
hypothesized	O
that	O
progestins	Chemical
could	O
equilibrate	O
the	O
effects	O
of	O
the	O
estrogenic	O
stimulation	O
on	O
the	O
mammary	O
and	O
endometrial	O
target	O
tissues	O
of	O
women	O
on	O
hormonal	O
replacement	O
therapy.	O
The	O
treatment	O
schedule	O
consisted	O
of	O
conjugated	Chemical
estrogens	Chemical
(	O
Premarin	Chemical
)	O
1.25	O
mg/day	O
for	O
21	O
days	O
and	O
Medroxyprogesterone	Chemical
acetate	Chemical
10	O
mg/day	O
for	O
10	O
days	O
in	O
each	O
month.	O
The	O
mean	O
treatment	O
period	O
was	O
18	O
months.	O
During	O
the	O
follow-up	O
period,	O
attention	O
was	O
paid	O
to	O
breast	O
modifications	O
as	O
evidenced	O
by	O
symptomatology,	O
physical	O
examination,	O
and	O
plate	O
thermography.	O
Mastodynia	Disease
was	O
reported	O
by	O
21	O
patients,	O
and	O
physical	O
examination	O
revealed	O
a	O
light	O
increase	O
in	O
breast	O
firmness	O
in	O
12	O
women	O
and	O
a	O
moderate	O
increase	O
in	O
breast	O
nodularity	O
in	O
2	O
women.	O
Themography	O
confirmed	O
the	O
existence	O
of	O
an	O
excessive	O
breast	O
stimulation	O
in	O
1	O
women	O
who	O
complained	O
of	O
moderate	O
mastodynia	Disease
and	O
in	O
5	O
of	O
the	O
7	O
women	O
who	O
complained	O
of	O
severe	O
mastodynia	Disease
.	O
Normalization	O
was	O
obtained	O
by	O
halving	O
the	O
estrogen	Chemical

Early	O
infections	Disease
in	O
kidney,	O
heart,	O
and	O
liver	O
transplant	O
recipients	O
on	O
cyclosporine	Chemical
.	O
Eighty-one	O
renal,	O
seventeen	O
heart,	O
and	O
twenty-four	O
liver	O
transplant	O
patients	O
were	O
followed	O
for	O
infection	Disease
.	O
Seventeen	O
renal	O
patients	O
received	O
azathioprine	Chemical
(	O
Aza	Chemical
)	O
and	O
prednisone	Chemical
as	O
part	O
of	O
a	O
randomized	O
trial	O
of	O
immunosuppression	O
with	O
21	O
cyclosporine	Chemical
-and-	O
prednisone	Chemical
-treated	O
renal	O
transplant	O
patients.	O
All	O
others	O
received	O
cyclosporine	Chemical
and	O
prednisone	Chemical
.	O
The	O
randomized	O
Aza	Chemical
patients	O
had	O
more	O
overall	O
infections	Disease
(P	O
less	O
than	O
0.05)	O
and	O
more	O
nonviral	O
infections	Disease
(P	O
less	O
than	O
0.02)	O
than	O
the	O
randomized	O
cyclosporine	Chemical
patients.	O
Heart	O
and	O
liver	O
patients	O
had	O
more	O
infections	Disease
than	O
cyclosporine	Chemical
renal	O
patients	O
but	O
fewer	O
infections	Disease
than	O
the	O
Aza	Chemical
renal	O
patients.	O
There	O
were	O
no	O
infectious	O
deaths	O
in	O
renal	O
transplant	O
patients	O
on	O
cyclosporine	Chemical
or	O
Aza	Chemical
,	O
but	O
infection	Disease
played	O
a	O
major	O
role	O
in	O
3	O
out	O
of	O
6	O
cardiac	O
transplant	O
deaths	O
and	O
in	O
8	O
out	O
of	O
9	O
liver	O
transplant	O
deaths.	O
Renal	O
patients	O
on	O
cyclosporine	Chemical
had	O
the	O
fewest	O
bacteremias	Disease
.	O
Analysis	O
of	O
site	O
of	O
infection	Disease
showed	O
a	O
preponderance	O
of	O
abdominal	Disease
infections	Disease
in	O
liver	O
patients,	O
intrathoracic	O
infections	Disease
in	O
heart	O
patients,	O
and	O
urinary	Disease
tract	Disease
infections	Disease
in	O
renal	O
patients.	O
Pulmonary	O
infections	Disease
were	O
less	O
common	O
in	O
cyclosporine	Chemical
-treated	O
renal	O
patients	O
than	O
in	O
Aza	Chemical
-treated	O
patients	O
(P	O
less	O
than	O
0.05).	O
Aza	Chemical
patients	O
had	O
significantly	O
more	O
staphylococcal	Disease
infections	Disease
than	O
all	O
other	O
transplant	O
groups	O
(P	O
less	O
than	O
0.005),	O
and	O
systemic	O
fungal	Disease
infections	Disease
occurred	O
only	O
in	O
the	O
liver	O
transplant	O
group.	O
Cytomegalovirus	O
(CMV)	O
shedding	O
or	O
serological	O
rises	O
in	O
antibody	O
titer,	O
or	O
both	O
occurred	O
in	O
78%	O
of	O
cyclosporine	Chemical
patients	O
and	O
76%	O
of	O
Aza	Chemical
patients.	O
Of	O
the	O
cyclosporine	Chemical
patients,	O
15%	O
had	O
symptoms	O
related	O
to	O
CMV	Disease
infection	Disease
.	O
Serological	O
evidence	O
for	O
Epstein	Disease
Barr	Disease
Virus	Disease
infection	Disease
was	O
found	O
in	O
20%	O
of	O
65	O
cyclosporine	Chemical
patients	O
studied.	O
Three	O
had	O
associated	O
symptoms,	O
and	O
one	O
developed	O
a	O
lymphoma	Disease

Structure-activity	O
and	O
dose-effect	O
relationships	O
of	O
the	O
antagonism	O
of	O
picrotoxin	Chemical
-induced	O
seizures	Disease
by	O
cholecystokinin	Chemical
,	O
fragments	O
and	O
analogues	O
of	O
cholecystokinin	Chemical
in	O
mice.	O
Intraperitoneal	O
administration	O
of	O
cholecystokinin	Chemical
octapeptide	Chemical
sulphate	O
ester	O
(	O
CCK-8	Chemical
-SE)	O
and	O
nonsulphated	O
cholecystokinin	Chemical
octapeptide	Chemical
(	O
CCK-8	Chemical
-NS)	O
enhanced	O
the	O
latency	O
of	O
seizures	Disease
induced	O
by	O
picrotoxin	Chemical
in	O
mice.	O
Experiments	O
with	O
N-	O
and	O
C-terminal	O
fragments	O
revealed	O
that	O
the	O
C-terminal	O
tetrapeptide	O
(CCK-5-8)	O
was	O
the	O
active	O
centre	O
of	O
the	O
CCK	O
octapeptide	O
molecule.	O
The	O
analogues	O
CCK-8	Chemical
-SE	O
and	O
CCK-8	Chemical
-NS	O
(dose	O
range	O
0.2-6.4	O
mumol/kg)	O
and	O
caerulein	Chemical
dose	O
range	O
0.1-0.8	O
mumol/kg)	O
showed	O
bell-shaped	O
dose-effect	O
curves,	O
with	O
the	O
greatest	O
maximum	O
inhibition	O
for	O
CCK-8	Chemical
-NS.	O
The	O
peptide	O
CCK-5-8	O
had	O
weak	O
anticonvulsant	O
activity	O
in	O
comparison	O
to	O
the	O
octapeptides,	O
3.2	O
mumol/kg	O
and	O
larger	O
doses	O
of	O
the	O
reference	O
drug,	O
diazepam	Chemical
,	O
totally	O
prevented	O
picrotoxin	Chemical
-induced	O
seizures	Disease
and	O
mortality.	O
The	O
maximum	O
effect	O
of	O
the	O
peptides	O
tested	O
was	O
less	O
than	O
that	O
of	O
diazepam	Chemical
.	O
Experiments	O
with	O
analogues	O
and	O
derivatives	O
of	O
CCK-5-8	O
demonstrated	O
that	O
the	O
effectiveness	O
of	O
the	O
beta-alanyl	O
derivatives	O
of	O
CCK-5-8	O
were	O
enhanced	O
and	O
that	O
they	O
were	O
equipotent	O
with	O
CCK-8	Chemical
-SE.	O
Of	O
the	O
CCK-2-8	O
analogues,	O
Ser(SO3H)7-Ac-CCK-2-8-SE	O
and	O
Thr(SO3H)7-Ac-CCK-2-8-SE	O
and	O
Hyp(SO3H)-Ac-CCK-2-8-SE	O
were	O
slightly	O
more	O
active	O
than	O
CCK-8	Chemical

Vasopressin	Chemical
as	O
a	O
possible	O
contributor	O
to	O
hypertension	Disease
.	O
The	O
role	O
of	O
vasopressin	Chemical
as	O
a	O
pressor	O
agent	O
to	O
the	O
hypertensive	Disease
process	O
was	O
examined.	O
Vasopressin	Chemical
plays	O
a	O
major	O
role	O
in	O
the	O
pathogenesis	O
of	O
DOCA	Chemical
-salt	O
hypertension	Disease
,	O
since	O
the	O
elevation	O
of	O
blood	O
pressure	O
was	O
not	O
substantial	O
in	O
the	O
rats	O
with	O
lithium	Chemical
-treated	O
diabetes	Disease
insipidus	Disease
after	O
DOCA	Chemical
-salt	O
treatment.	O
Administration	O
of	O
DDAVP	Chemical
which	O
has	O
antidiuretic	O
action	O
but	O
minimal	O
vasopressor	O
effect	O
failed	O
to	O
increase	O
blood	O
pressure	O
to	O
the	O
levels	O
observed	O
after	O
administration	O
of	O
AVP.	O
Furthermore,	O
the	O
pressor	O
action	O
of	O
vasopressin	Chemical
appears	O
to	O
be	O
important	O
in	O
the	O
development	O
of	O
this	O
model	O
of	O
hypertension	Disease
,	O
since	O
the	O
enhanced	O
pressor	O
responsiveness	O
to	O
the	O
hormone	O
was	O
observed	O
in	O
the	O
initial	O
stage	O
of	O
hypertension	Disease
.	O
Increased	O
secretion	O
of	O
vasopressin	Chemical
from	O
neurohypophysis	O
also	O
promotes	O
the	O
function	O
of	O
the	O
hormone	O
as	O
a	O
pathogenetic	O
factor	O
in	O
hypertension	Disease
.	O
An	O
unproportional	O
release	O
of	O
vasopressin	Chemical
compared	O
to	O
plasma	O
osmolality	O
may	O
be	O
induced	O
by	O
the	O
absence	O
of	O
an	O
adjusting	O
control	O
of	O
angiotensin	Chemical
II	O
forming	O
and	O
receptor	O
binding	O
capacity	O
for	O
sodium	Chemical
balance	O
in	O
the	O
brain.	O
However,	O
the	O
role	O
of	O
vasopressin	Chemical
remains	O
to	O
be	O
determined	O
in	O
human	O
essential	O
hypertension	Disease

Toxic	Disease
hepatitis	Disease
induced	O
by	O
disulfiram	Chemical
in	O
a	O
non-alcoholic.	O
A	O
reversible	O
toxic	Disease
liver	Disease
damage	Disease
was	O
observed	O
in	O
a	O
non-alcoholic	O
woman	O
treated	O
with	O
disulfiram	Chemical

Atrial	Disease
thrombosis	Disease
involving	O
the	O
heart	O
of	O
F-344	O
rats	O
ingesting	O
quinacrine	Chemical
hydrochloride	Chemical
.	O
Quinacrine	Chemical
hydrochloride	Chemical
is	O
toxic	O
for	O
the	O
heart	O
of	O
F-344	O
rats.	O
Rats	O
treated	O
with	O
500	O
ppm	O
quinacrine	Chemical
hydrochloride	Chemical
in	O
the	O
diet	O
all	O
developed	O
a	O
high	O
incidence	O
of	O
left	O
atrial	Disease
thrombosis	Disease
.	O
The	O
lesion	O
was	O
associated	O
with	O
cardiac	Disease
hypertrophy	Disease
and	O
dilatation	O
and	O
focal	O
myocardial	Disease
degeneration	Disease
.	O
Rats	O
died	O
from	O
cardiac	Disease
hypertrophy	Disease
with	O
severe	O
acute	O
and	O
chronic	O
congestion	O
of	O
the	O
lungs,	O
liver,	O
and	O
other	O
organs.	O
Seventy	O
percent	O
of	O
rats	O
given	O
250	O
ppm	O
quinacrine	Chemical
hydrochloride	Chemical
and	O
1,000	O
ppm	O
sodium	Chemical
nitrite	Chemical
simultaneously	O
in	O
the	O
diet	O
had	O
thrombosis	Disease
of	O
the	O
atria	O
of	O
the	O
heart,	O
while	O
untreated	O
control	O
rats	O
in	O
this	O
laboratory	O
did	O
not	O
have	O
atrial	Disease
thrombosis	Disease
.	O
Sodium	Chemical
nitrite	Chemical
in	O
combination	O
with	O
quinacrine	Chemical
hydrochloride	Chemical

Alternating	Disease
sinus	Disease
rhythm	Disease
and	O
intermittent	O
sinoatrial	Disease
block	Disease
induced	O
by	O
propranolol	Chemical
.	O
Alternating	Disease
sinus	Disease
rhythm	Disease
and	O
intermittent	O
sinoatrial	Disease
(S-A)	Disease
block	Disease
was	O
observed	O
in	O
a	O
57-year-old	O
woman,	O
under	O
treatment	O
for	O
angina	Disease
with	O
80	O
mg	O
propranolol	Chemical
daily.	O
The	O
electrocardiogram	O
showed	O
alternation	O
of	O
long	O
and	O
short	O
P-P	O
intervals	O
and	O
occasional	O
pauses.	O
These	O
pauses	O
were	O
always	O
preceded	O
by	O
the	O
short	O
P-P	O
intervals	O
and	O
were	O
usually	O
followed	O
by	O
one	O
or	O
two	O
P-P	O
intervals	O
of	O
0.92-0.95	O
s	O
representing	O
the	O
basic	O
sinus	O
cycle.	O
Following	O
these	O
basic	O
sinus	O
cycles,	O
alternating	Disease
rhythm	Disease
started	O
with	O
the	O
longer	O
P-P	O
interval.	O
The	O
long	O
P-P	O
intervals	O
ranged	O
between	O
1.04-1.12	O
s	O
and	O
the	O
short	O
P-P	O
intervals	O
between	O
0.80-0.84	O
s,	O
respectively.	O
The	O
duration	O
of	O
the	O
pauses	O
were	O
equal	O
or	O
almost	O
equal	O
to	O
one	O
short	O
plus	O
one	O
long	O
P-P	O
interval	O
or	O
to	O
twice	O
the	O
basic	O
sinus	O
cycle.	O
In	O
one	O
recording	O
a	O
short	O
period	O
of	O
regular	O
sinus	O
rhythm	O
with	O
intermittent	O
2/1	O
S-A	Disease
block	Disease
was	O
observed.	O
This	O
short	O
period	O
of	O
sinus	O
rhythm	O
was	O
interrupted	O
by	O
sudden	O
prolongation	O
of	O
the	O
P-P	O
interval	O
starting	O
the	O
alternative	O
rhythm.	O
There	O
were	O
small	O
changes	O
in	O
the	O
shape	O
of	O
the	O
P	O
waves	O
and	O
P-R	O
intervals.	O
S-A	O
conduction	O
through	O
two	O
pathways,	O
the	O
first	O
with	O
2/1	O
block	O
the	O
second	O
having	O
0.12-0.14	O
s	O
longer	O
conduction	O
time	O
and	O
with	O
occasional	O
2/1	O
block	O
was	O
proposed	O
for	O
the	O
explanation	O
of	O
the	O
alternating	O
P-P	O
interval	O
and	O
other	O
electrocardiographic	O
features	O
seen.	O
Atropine	Chemical
1	O
mg	O
given	O
intravenously	O
resulted	O
in	O
shortening	O
of	O
all	O
P-P	O
intervals	O
without	O
changing	O
the	O
rhythm.	O
The	O
abnormal	O
rhythm	O
disappeared	O
with	O
the	O
withdrawal	O
of	O
propranolol	Chemical
and	O
when	O
the	O
drug	O
was	O
restarted	O
a	O
2/1	O
S-A	Disease
block	Disease
was	O
seen.	O
This	O
was	O
accepted	O
as	O
evidence	O
for	O
propranolol	Chemical
being	O
the	O
cause	O
of	O
this	O
conduction	Disease
disorder	Disease

Antitumor	O
effect,	O
cardiotoxicity	Disease
,	O
and	O
nephrotoxicity	Disease
of	O
doxorubicin	Chemical
in	O
the	O
IgM	O
solid	O
immunocytoma	Disease
-bearing	O
LOU/M/WSL	O
rat.	O
Antitumor	O
activity,	O
cardiotoxicity	Disease
,	O
and	O
nephrotoxicity	Disease
induced	O
by	O
doxorubicin	Chemical
were	O
studied	O
in	O
LOU/M/WSL	O
inbred	O
rats	O
each	O
bearing	O
a	O
transplantable	O
solid	O
IgM	O
immunocytoma	Disease
.	O
Animals	O
with	O
a	O
tumor	Disease
(diameter,	O
15.8	O
+/-	O
3.3	O
mm)	O
were	O
treated	O
with	O
iv	O
injections	O
of	O
doxorubicin	Chemical
on	O
5	O
consecutive	O
days,	O
followed	O
by	O
1	O
weekly	O
injection	O
for	O
7	O
weeks	O
(dose	O
range,	O
0.015-4.0	O
mg/kg	O
body	O
wt).	O
Tumor	Disease
regression	O
was	O
observed	O
with	O
0.5	O
mg	O
doxorubicin	Chemical
/kg.	O
Complete	O
disappearance	O
of	O
the	O
tumor	Disease
was	O
induced	O
with	O
1.0	O
mg	O
doxorubicin	Chemical
/kg.	O
Histologic	O
evidence	O
of	O
cardiotoxicity	Disease
scored	O
as	O
grade	O
III	O
was	O
only	O
observed	O
at	O
a	O
dose	O
of	O
1.0	O
mg	O
doxorubicin	Chemical
/kg.	O
Light	O
microscopic	O
evidence	O
of	O
renal	Disease
damage	Disease
was	O
seen	O
above	O
a	O
dose	O
of	O
0.5	O
mg	O
doxorubicin	Chemical
/kg,	O
which	O
resulted	O
in	O
albuminuria	Disease
and	O
very	O
low	O
serum	O
albumin	O
levels.	O
In	O
the	O
group	O
that	O
received	O
1.0	O
mg	O
doxorubicin	Chemical
/kg,	O
the	O
serum	O
albumin	O
level	O
decreased	O
from	O
33.6	O
+/-	O
4.1	O
to	O
1.5	O
+/-	O
0.5	O
g/liter.	O
Ascites	Disease
and	O
hydrothorax	Disease
were	O
observed	O
simultaneously.	O
The	O
same	O
experiments	O
were	O
performed	O
with	O
non-	O
tumor	Disease
-bearing	O
rats,	O
in	O
which	O
no	O
major	O
differences	O
were	O
observed.	O
In	O
conclusion,	O
antitumor	O
activity,	O
cardiotoxicity	Disease
,	O
and	O
nephrotoxicity	Disease
were	O
studied	O
simultaneously	O
in	O
the	O
same	O
LOU/M/WSL	O
rat.	O
Albuminuria	Disease
due	O
to	O
renal	Disease
damage	Disease
led	O
to	O
extremely	O
low	O
serum	O
albumin	O
levels,	O
so	O
ascites	Disease
and	O
hydrothorax	Disease
were	O
not	O
necessarily	O
a	O
consequence	O
of	O
the	O
observed	O
cardiomyopathy	Disease

Intraoperative	O
bradycardia	Disease
and	O
hypotension	Disease
associated	O
with	O
timolol	Chemical
and	O
pilocarpine	Chemical
eye	O
drops.	O
A	O
69-yr-old	O
man,	O
who	O
was	O
concurrently	O
being	O
treated	O
with	O
pilocarpine	Chemical
nitrate	Chemical
and	O
timolol	Chemical
maleate	Chemical
eye	O
drops,	O
developed	O
a	O
bradycardia	Disease
and	O
became	O
hypotensive	Disease
during	O
halothane	Chemical
anaesthesia.	O
Both	O
timolol	Chemical
and	O
pilocarpine	Chemical
were	O
subsequently	O
identified	O
in	O
a	O
24-h	O
collection	O
of	O
urine.	O
Timolol	Chemical
(but	O
not	O
pilocarpine	Chemical
)	O
was	O
detected	O
in	O
a	O
sample	O
of	O
plasma	O
removed	O
during	O
surgery;	O
the	O
plasma	O
concentration	O
of	O
timolol	Chemical
(2.6	O
ng	O
ml-1)	O
was	O
consistent	O
with	O
partial	O
beta-adrenoceptor	O
blockade.	O
It	O
is	O
postulated	O
that	O
this	O
action	O
may	O
have	O
been	O
enhanced	O
during	O
halothane	Chemical
anaesthesia	O
with	O
resultant	O
bradycardia	Disease
and	O
hypotension	Disease
.	O
Pilocarpine	Chemical

Succinylcholine	Chemical
	O
apnoea	Disease
:	O
attempted	O
reversal	O
with	O
anticholinesterases.	O
Anticholinesterases	O
were	O
administered	O
in	O
an	O
attempt	O
to	O
antagonize	O
prolonged	O
neuromuscular	Disease
blockade	Disease
following	O
the	O
administration	O
of	O
succinylcholine	Chemical
in	O
a	O
patient	O
later	O
found	O
to	O
be	O
homozygous	O
for	O
atypical	O
plasma	O
cholinesterase.	O
Edrophonium	Chemical
10	O
mg,	O
given	O
74	O
min	O
after	O
succinylcholine	Chemical
,	O
when	O
train-of-four	O
stimulation	O
was	O
characteristic	O
of	O
phase	O
II	O
block,	O
produced	O
partial	O
antagonism	O
which	O
was	O
not	O
sustained.	O
Repeated	O
doses	O
of	O
edrophonium	Chemical
to	O
70	O
mg	O
and	O
neostigmine	Chemical
to	O
2.5	O
mg	O
did	O
not	O
antagonize	O
or	O
augment	O
the	O
block.	O
Spontaneous	O
respiration	O
recommenced	O
200	O
min	O
after	O
succinylcholine	Chemical
administration.	O
It	O
is	O
concluded	O
that	O
anticholinesterases	O
are	O
only	O
partially	O
effective	O
in	O
restoring	O
neuromuscular	O
function	O
in	O
succinylcholine	Chemical
	O
apnoea	Disease

Effect	O
of	O
doxorubicin	Chemical
on	O
[omega-I-131]heptadecanoic	Chemical
acid	Chemical
myocardial	O
scintigraphy	O
and	O
echocardiography	O
in	O
dogs.	O
The	O
effects	O
of	O
serial	O
treatment	O
with	O
doxorubicin	Chemical
on	O
dynamic	O
myocardial	O
scintigraphy	O
with	O
[omega-I-131]heptadecanoic	Chemical
acid	Chemical
(	O
I-131	Chemical
HA	Chemical
),	O
and	O
on	O
global	O
left-ventricular	O
function	O
determined	O
echocardiographically,	O
were	O
studied	O
in	O
a	O
group	O
of	O
nine	O
mongrel	O
dogs.	O
Total	O
extractable	O
myocardial	O
lipid	O
was	O
compared	O
postmortem	O
between	O
a	O
group	O
of	O
control	O
dogs	O
and	O
doxorubicin	Chemical
-treated	O
dogs.	O
A	O
significant	O
and	O
then	O
progressive	O
fall	O
in	O
global	O
LV	O
function	O
was	O
observed	O
at	O
a	O
cumulative	O
doxorubicin	Chemical
dose	O
of	O
4	O
mg/kg.	O
A	O
significant	O
increase	O
in	O
the	O
myocardial	O
t1/2	O
of	O
the	O
I-131	Chemical
HA	Chemical
was	O
observed	O
only	O
at	O
a	O
higher	O
cumulative	O
dose,	O
10	O
mg/kg.	O
No	O
significant	O
alteration	O
in	O
total	O
extractable	O
myocardial	O
lipids	O
was	O
observed	O
between	O
control	O
dogs	O
and	O
those	O
treated	O
with	O
doxorubicin	Chemical
.	O
Our	O
findings	O
suggest	O
that	O
the	O
changes	O
leading	O
to	O
an	O
alteration	O
of	O
myocardial	O
dynamic	O
imaging	O
with	O
I-131	Chemical
HA	Chemical
are	O
not	O
the	O
initiating	O
factor	O
in	O
doxorubicin	Chemical
	O
cardiotoxicity	Disease

Hemodynamics	O
and	O
myocardial	O
metabolism	O
under	O
deliberate	O
hypotension	Disease
.	O
An	O
experimental	O
study	O
in	O
dogs.	O
Coronary	O
blood	O
flow,	O
cardiac	O
work	O
and	O
metabolism	O
were	O
studied	O
in	O
dogs	O
under	O
sodium	Chemical
nitroprusside	Chemical
(	O
SNP	Chemical
)	O
and	O
trimetaphan	Chemical
(	O
TMP	Chemical
)	O
deliberate	O
hypotension	Disease
(20%	O
and	O
40%	O
mean	O
pressure	O
decrease	O
from	O
baseline).	O
Regarding	O
the	O
effects	O
of	O
drug-induced	O
hypotension	Disease
on	O
coronary	O
blood	O
flow,	O
aortic	O
and	O
coronary	O
sinus	O
metabolic	O
data	O
(pH,	O
pO2,	O
pCO2)	O
we	O
could	O
confirm	O
that	O
nitroprusside	Chemical
	O
hypotension	Disease
could	O
be	O
safely	O
used	O
to	O
30%	O
mean	O
blood	O
pressure	O
decrease	O
from	O
control,	O
trimetaphan	Chemical
	O
hypotension	Disease
to	O
20%	O
mean	O
blood	O
pressure	O
decrease.	O
Cardiac	O
work	O
was	O
significantly	O
reduced	O
during	O
SNP	Chemical
	O
hypotension	Disease
.	O
Myocardial	O
O2	Chemical
consumption	O
and	O
O2	Chemical

Evidence	O
for	O
a	O
selective	O
brain	O
noradrenergic	O
involvement	O
in	O
the	O
locomotor	O
stimulant	O
effects	O
of	O
amphetamine	Chemical
in	O
the	O
rat.	O
Male	O
rats	O
received	O
the	O
noradrenaline	Chemical
neurotoxin	O
DSP4	Chemical
(50	O
mg/kg)	O
7	O
days	O
prior	O
to	O
injection	O
of	O
D-amphetamine	Chemical
(10	O
or	O
40	O
mumol/kg	O
i.p.).	O
The	O
hyperactivity	Disease
induced	O
by	O
D-amphetamine	Chemical
(10	O
mumol/kg)	O
was	O
significantly	O
reduced	O
by	O
DSP4	Chemical
pretreatment.	O
However,	O
the	O
increased	O
rearings	O
and	O
the	O
amphetamine	Chemical
-induced	O
stereotypies	Disease
were	O
not	O
blocked	O
by	O
pretreatment	O
with	O
DSP4	Chemical
.	O
The	O
reduction	O
of	O
amphetamine	Chemical
	O
hyperactivity	Disease
induced	O
by	O
DSP4	Chemical
was	O
blocked	O
by	O
pretreatment	O
with	O
the	O
noradrenaline	Chemical
-uptake	O
blocking	O
agent,	O
desipramine	Chemical
,	O
which	O
prevents	O
the	O
neurotoxic	Disease
action	O
of	O
DSP4	Chemical
.	O
The	O
present	O
results	O
suggest	O
a	O
selective	O
involvement	O
of	O
central	O
noradrenergic	O
neurones	O
in	O
the	O
locomotor	O
stimulant	O
effect	O
of	O
amphetamine	Chemical

Accelerated	Disease
junctional	Disease
rhythms	Disease
during	O
oral	O
verapamil	Chemical
therapy.	O
This	O
study	O
examined	O
the	O
frequency	O
of	O
atrioventricular	O
(AV)	O
dissociation	O
and	O
accelerated	Disease
junctional	Disease
rhythms	Disease
in	O
59	O
patients	O
receiving	O
oral	O
verapamil	Chemical
.	O
Accelerated	Disease
junctional	Disease
rhythms	Disease
and	O
AV	O
dissociation	O
were	O
frequent	O
in	O
patients	O
with	O
supraventricular	Disease
tachyarrhythmias	Disease
,	O
particularly	O
AV	O
nodal	O
reentry.	O
Verapamil	Chemical
administration	O
to	O
these	O
patients	O
led	O
to	O
an	O
asymptomatic	O
increase	O
in	O
activity	O
of	O
these	O
junctional	O
pacemakers.	O
In	O
patients	O
with	O
various	O
chest	Disease
pain	Disease
syndromes,	O
verapamil	Chemical

Treatment	O
of	O
ovarian	Disease
cancer	Disease
with	O
a	O
combination	O
of	O
cis-platinum	Chemical
,	O
adriamycin	Chemical
,	O
cyclophosphamide	Chemical
and	O
hexamethylmelamine	Chemical
.	O
During	O
the	O
last	O
2	O
1/2	O
years,	O
38	O
patients	O
with	O
ovarian	Disease
cancer	Disease
were	O
treated	O
with	O
a	O
combination	O
of	O
cisplatinum	Chemical
(	O
CPDD	Chemical
),	O
50	O
mg/m2,	O
adriamycin	Chemical
,	O
30	O
mg/m2,	O
cyclophosphamide	Chemical
,	O
300	O
mg/m2,	O
on	O
day	O
1;	O
and	O
hexamethylmelamine	Chemical
(	O
HMM	Chemical
),	O
6	O
mg/kg	O
daily,	O
for	O
14	O
days.	O
Each	O
course	O
was	O
repeated	O
monthly.	O
2	O
patients	O
had	O
stage	O
II,	O
14	O
stage	O
III	O
and	O
22	O
stage	O
IV	O
disease.	O
14	O
of	O
the	O
38	O
patients	O
were	O
previously	O
treated	O
with	O
chemotherapy,	O
1	O
with	O
radiation,	O
6	O
with	O
both	O
chemotherapy	O
and	O
radiation,	O
and	O
17	O
did	O
not	O
have	O
any	O
treatment	O
before	O
CPDD	Chemical
combination.	O
31	O
of	O
the	O
38	O
cases	O
(81.5%)	O
demonstrated	O
objective	O
responses	O
lasting	O
for	O
2	O
months	O
or	O
more.	O
These	O
responses	O
were	O
partial	O
in	O
19	O
and	O
complete	O
in	O
12	O
cases.	O
Hematologic	Disease
toxicity	Disease
was	O
moderate	O
and	O
with	O
reversible	O
anemia	Disease
developing	O
in	O
71%	O
of	O
patients.	O
Gastrointestinal	O
side	O
effects	O
from	O
CPDD	Chemical
were	O
universal.	O
HMM	Chemical
	O
gastrointestinal	Disease
toxicity	Disease
necessitated	O
discontinuation	O
of	O
the	O
drug	O
in	O
5	O
patients.	O
Severe	O
nephrotoxicity	Disease

Nontraumatic	O
dissecting	Disease
aneurysm	Disease
of	O
the	O
basilar	O
artery.	O
A	O
case	O
of	O
nontraumatic	O
dissecting	Disease
aneurysm	Disease
of	O
the	O
basilar	O
artery	O
in	O
association	O
with	O
hypertension	Disease
,	O
smoke,	O
and	O
oral	Chemical
contraceptives	Chemical
is	O
reported	O
in	O
a	O
young	O
female	O
patient	O
with	O
a	O
locked-in	Disease
syndrome	Disease

Propylthiouracil	Chemical
-induced	O
hepatic	Disease
damage	Disease
.	O
Two	O
cases	O
of	O
propylthiouracil	Chemical
-induced	O
liver	Disease
damage	Disease
have	O
been	O
observed.	O
The	O
first	O
case	O
is	O
of	O
an	O
acute	O
type	O
of	O
damage,	O
proven	O
by	O
rechallenge;	O
the	O
second	O
presents	O
a	O
clinical	O
and	O
histologic	O
picture	O
resembling	O
chronic	Disease
active	Disease
hepatitis	Disease

Studies	O
on	O
the	O
bradycardia	Disease
induced	O
by	O
bepridil	Chemical
.	O
Bepridil	Chemical
,	O
a	O
novel	O
active	O
compound	O
for	O
prophylactic	O
treatment	O
of	O
anginal	Disease
attacks	Disease
,	O
induced	O
persistent	O
bradycardia	Disease
and	O
a	O
non-specific	O
anti-	O
tachycardial	Disease
effect,	O
the	O
mechanisms	O
of	O
which	O
were	O
investigated	O
in	O
vitro	O
and	O
in	O
vivo.	O
In	O
vitro	O
perfusion	O
of	O
bepridil	Chemical
in	O
the	O
life-support	O
medium	O
for	O
isolated	O
sino-atrial	O
tissue	O
from	O
rabbit	O
heart,	O
caused	O
a	O
reduction	O
in	O
action	O
potential	O
(AP)	O
spike	O
frequency	O
(recorded	O
by	O
KCl	Chemical
microelectrodes)	O
starting	O
at	O
doses	O
of	O
5	O
X	O
10(-6)	O
M.	O
This	O
effect	O
was	O
dose-dependent	O
up	O
to	O
concentrations	O
of	O
5	O
X	O
10(-5)	O
M,	O
whereupon	O
blockade	O
of	O
sinus	O
activity	O
set	O
in.	O
Bepridil	Chemical
at	O
a	O
dose	O
of	O
5	O
X	O
10(-6)	O
M,	O
induced	O
a	O
concomitant	O
reduction	O
in	O
AP	O
amplitude	O
(falling	O
from	O
71	O
+/-	O
8	O
mV	O
to	O
47	O
+/-	O
6	O
mV),	O
maximum	O
systolic	O
depolarization	O
velocity	O
(phase	O
0)	O
which	O
fell	O
from	O
1.85	O
+/-	O
0.35	O
V/s	O
to	O
0.84	O
+/-	O
0.28	O
V/s,	O
together	O
with	O
maximum	O
diastolic	O
depolarization	O
velocity	O
(phase	O
4)	O
which	O
fell	O
from	O
38	O
+/-	O
3	O
mV/s	O
to	O
24	O
+/-	O
5	O
mV/s.	O
In	O
vivo	O
injection	O
of	O
bepridil	Chemical
at	O
a	O
dose	O
of	O
5	O
mg/kg	O
(i.v.)	O
into	O
6	O
anaesthetized	O
dogs	O
which	O
had	O
undergone	O
ablation	O
of	O
all	O
the	O
extrinsic	O
cardiac	O
afferent	O
nerve	O
supply,	O
together	O
with	O
a	O
bilateral	O
medullo-adrenalectomy,	O
caused	O
a	O
marked	O
reduction	O
in	O
heart	O
rate	O
which	O
fell	O
from	O
98.7	O
+/-	O
4.2	O
beats/min	O
to	O
76	O
+/-	O
5.3	O
beats/min	O
sustained	O
for	O
more	O
than	O
45	O
min.	O
It	O
is	O
concluded	O
that	O
bepridil	Chemical
reduces	O
heart	O
rate	O
by	O
acting	O
directly	O
on	O
the	O
sinus	O
node.	O
This	O
effect,	O
which	O
results	O
in	O
a	O
flattening	O
of	O
the	O
phase	O
0	O
and	O
phase	O
4	O
slope,	O
together	O
with	O
a	O
longer	O
AP	O
duration,	O
may	O
be	O
due	O
to	O
an	O
increase	O
in	O
the	O
time	O
constants	O
of	O
slow	O
inward	O
ionic	O
currents	O
(already	O
demonstrated	O
elsewhere),	O
but	O
also	O
to	O
an	O
increased	O
time	O
constant	O
for	O
deactivation	O
of	O
the	O
outward	O
potassium	Chemical

Hepatitis	Disease
and	O
renal	Disease
tubular	Disease
acidosis	Disease
after	O
anesthesia	O
with	O
methoxyflurane	Chemical
.	O
A	O
69-year-old	O
man	O
operated	O
for	O
acute	Disease
cholecystitis	Disease
under	O
methoxyflurane	Chemical
anesthesia	O
developed	O
postoperatively	O
a	O
hepatic	Disease
insufficiency	Disease
syndrome	Disease
and	O
renal	Disease
tubular	Disease
acidosis	Disease
.	O
Massive	O
bleeding	Disease

Pituitary	O
response	O
to	O
luteinizing	O
hormone-releasing	O
hormone	O
during	O
haloperidol	Chemical
-induced	O
hyperprolactinemia	Disease
.	O
The	O
effects	O
of	O
a	O
6-hour	O
infusion	O
with	O
haloperidol	Chemical
on	O
serum	O
prolactin	O
and	O
luteinizing	O
hormone	O
(LH)	O
levels	O
was	O
studied	O
in	O
a	O
group	O
of	O
male	O
subjects.	O
Five	O
hours	O
after	O
starting	O
the	O
infusions,	O
a	O
study	O
of	O
the	O
pituitary	O
responses	O
to	O
LH-releasing	O
hormone	O
(LH-RH)	O
was	O
carried	O
out.	O
Control	O
patients	O
received	O
infusions	O
of	O
0.9%	O
NaCl	Chemical
solution.	O
During	O
the	O
course	O
of	O
haloperidol	Chemical
infusions,	O
significant	O
hyperprolactinemia	Disease

Antirifampicin	O
antibodies	O
in	O
acute	O
rifampicin	Chemical
-associated	O
renal	Disease
failure	Disease
.	O
5	O
patients	O
with	O
acute	Disease
renal	Disease
failure	Disease
(3	O
with	O
thrombopenia	Disease
and	O
hemolysis	Disease
)	O
induced	O
by	O
the	O
reintroduction	O
of	O
rifampicin	Chemical
are	O
described.	O
No	O
correlation	O
was	O
found	O
between	O
the	O
severity	O
of	O
clinical	O
manifestations	O
and	O
the	O
total	O
dose	O
taken	O
by	O
the	O
patients.	O
In	O
all	O
but	O
1	O
patient,	O
antirifampicin	O
antibodies	O
were	O
detected.	O
Antibodies	O
suggested	O
to	O
be	O
of	O
the	O
IgM	O
class	O
were	O
detected	O
in	O
all	O
3	O
patients	O
with	O
hematological	Disease
disorders	Disease
.	O
The	O
pattern	O
of	O
non-specific	O
acute	Disease
tubular	Disease
necrosis	Disease

Cardiovascular	O
effects	O
of	O
hypotension	Disease
induced	O
by	O
adenosine	Chemical
triphosphate	Chemical
and	O
sodium	Chemical
nitroprusside	Chemical
on	O
dogs	O
with	O
denervated	O
hearts.	O
Adenosine	Chemical
triphosphate	Chemical
(	O
ATP	Chemical
)	O
and	O
sodium	Chemical
nitroprusside	Chemical
(	O
SNP	Chemical
)	O
are	O
administered	O
to	O
patients	O
to	O
induce	O
and	O
control	O
hypotension	Disease
during	O
anesthesia.	O
SNP	Chemical
is	O
authorized	O
for	O
clinical	O
use	O
in	O
USA	O
and	O
UK,	O
and	O
ATP	Chemical
is	O
clinically	O
used	O
in	O
other	O
countries	O
such	O
as	O
Japan.	O
We	O
investigated	O
how	O
these	O
two	O
drugs	O
act	O
on	O
the	O
cardiovascular	O
systems	O
of	O
20	O
dogs	O
whose	O
hearts	O
had	O
been	O
denervated	O
by	O
a	O
procedure	O
we	O
had	O
devised.	O
ATP	Chemical
(10	O
dogs)	O
or	O
SNP	Chemical
(10	O
dogs)	O
was	O
administered	O
to	O
reduce	O
mean	O
arterial	O
pressure	O
by	O
30%	O
to	O
70%	O
of	O
control.	O
Before,	O
during	O
and	O
after	O
induced	O
hypotension	Disease
,	O
we	O
measured	O
major	O
cardiovascular	O
parameters.	O
Hypotension	Disease
induced	O
by	O
ATP	Chemical
was	O
accompanied	O
by	O
significant	O
decreases	O
in	O
mean	O
pulmonary	O
arterial	O
pressure	O
(p	O
less	O
than	O
0.001),	O
central	O
venous	O
pressure	O
(p	O
less	O
than	O
0.001),	O
left	O
ventricular	O
end-diastolic	O
pressure	O
(p	O
less	O
than	O
0.001),	O
total	O
peripheral	O
resistance	O
(p	O
less	O
than	O
0.001),	O
rate	O
pressure	O
product	O
(p	O
less	O
than	O
0.001),	O
total	O
body	O
oxygen	Chemical
consumption	O
(p	O
less	O
than	O
0.05),	O
and	O
heart	O
rate	O
(p	O
less	O
than	O
0.001);	O
all	O
these	O
variables	O
returned	O
normal	O
within	O
30	O
min	O
after	O
ATP	Chemical
was	O
stopped.	O
Cardiac	O
output	O
did	O
not	O
change.	O
During	O
hypotension	Disease
produced	O
by	O
SNP	Chemical
similar	O
decreases	O
were	O
observed	O
in	O
mean	O
pulmonary	O
arterial	O
pressure	O
(p	O
less	O
than	O
0.01),	O
central	O
venous	O
pressure	O
(p	O
less	O
than	O
0.001),	O
left	O
ventricular	O
end-diastolic	O
pressure	O
(p	O
less	O
than	O
0.01),	O
total	O
peripheral	O
resistance	O
(p	O
less	O
than	O
0.001),	O
rate	O
pressure	O
product	O
(p	O
less	O
than	O
0.001),	O
and	O
oxygen	Chemical
content	O
difference	O
between	O
arterial	O
and	O
mixed	O
venous	O
blood	O
(p	O
less	O
than	O
0.05),	O
while	O
heart	O
rate	O
(p	O
less	O
than	O
0.001)	O
and	O
cardiac	O
output	O
(p	O
less	O
than	O
0.05)	O
were	O
increased.	O
Recoveries	O
of	O
heart	O
rate	O
and	O
left	O
ventricular	O
end-diastolic	O
pressure	O
were	O
not	O
shown	O
within	O
60	O
min	O
after	O
SNP	Chemical
had	O
been	O
stopped.	O
Both	O
ATP	Chemical
and	O
SNP	Chemical

Comparative	O
study:	O
Endografine	Chemical
(	O
diatrizoate	Chemical
),	O
Vasurix	Chemical
polyvidone	Chemical
(	O
acetrizoate	Chemical
),	O
Dimer-X	Chemical
(	O
iocarmate	Chemical
)	O
and	O
Hexabrix	Chemical
(	O
ioxaglate	Chemical
)	O
in	O
hysterosalpingography.	O
Side	O
effects	O
of	O
hysterosalpingography	O
with	O
Dimer-X	Chemical
,	O
Hexabrix	Chemical
,	O
Vasurix	Chemical
polyvidone	Chemical
and	O
Endografine	Chemical
in	O
142	O
consecutive	O
patients,	O
receiving	O
one	O
of	O
the	O
four	O
tested	O
media	O
were	O
evaluated	O
from	O
replies	O
to	O
postal	O
questionnaires.	O
The	O
Dimer-X	Chemical
group	O
had	O
a	O
higher	O
incidence	O
of	O
nausea	Disease
and	O
dizziness	Disease
.	O
The	O
Endografine	Chemical
group	O
had	O
a	O
higher	O
incidence	O
of	O
abdominal	Disease
pain	Disease
.	O
These	O
differences	O
occur	O
especially	O
in	O
the	O
age	O
groups	O
under	O
30	O
years.	O
Hexabrix	Chemical
and	O
Vasurix	Chemical
polyvidone	Chemical
are	O
considered	O
the	O
best	O
contrast	Chemical
media	Chemical
for	O
hysterosalpingography	O
and	O
perhaps	O
because	O
of	O
its	O
low	O
toxicity	Disease
	O
Hexabrix	Chemical

Post-	O
suxamethonium	Chemical
	O
pains	Disease
in	O
Nigerian	O
surgical	O
patients.	O
Contrary	O
to	O
an	O
earlier	O
report	O
by	O
Coxon,	O
scoline	Chemical
	O
pain	Disease
occurs	O
in	O
African	O
negroes.	O
Its	O
incidence	O
was	O
determined	O
in	O
a	O
prospective	O
study	O
involving	O
a	O
total	O
of	O
100	O
Nigerian	O
patients	O
(50	O
out-patients	O
and	O
50	O
in-patients).	O
About	O
62%	O
of	O
the	O
out-patients	O
developed	O
scoline	Chemical
	O
pain	Disease
as	O
compared	O
with	O
about	O
26%	O
among	O
the	O
in-patients.	O
The	O
abolition	O
of	O
muscle	O
fasciculations	Disease
(by	O
0.075mg/kg	O
dose	O
of	O
Fazadinium	Chemical
)	O
did	O
not	O
influence	O
the	O
occurrence	O
of	O
scoline	Chemical
	O
pain	Disease
.	O
Neither	O
the	O
type	O
of	O
induction	O
agent	O
(	O
Althesin	Chemical
or	O
Thiopentone	Chemical
)	O
nor	O
the	O
salt	O
preparation	O
of	O
suxamethonium	Chemical
used	O
(	O
chloride	Chemical
or	O
bromide	Chemical
),	O
affected	O
the	O
incidence	O
of	O
scoline	Chemical
	O
pain	Disease

Medial	O
changes	O
in	O
arterial	O
spasm	Disease
induced	O
by	O
L-norepinephrine	Chemical
.	O
In	O
normal	O
rats,	O
the	O
media	O
of	O
small	O
arteries	O
(0.4--0.2	O
mm	O
in	O
diameter)	O
previously	O
was	O
shown	O
to	O
contain	O
intracellular	O
vacuoles,	O
identified	O
ultrastructurally	O
as	O
herniations	O
of	O
one	O
smooth	O
muscle	O
cell	O
into	O
another.	O
The	O
hypothesis	O
that	O
intense	O
vasoconstriction	O
would	O
increase	O
the	O
number	O
of	O
such	O
vacuoles	O
has	O
been	O
tested.	O
In	O
the	O
media	O
of	O
the	O
saphenous	O
artery	O
and	O
its	O
distal	O
branch,	O
vasoconstriction	O
induced	O
by	O
L-norepinephrine	Chemical
produced	O
many	O
cell-to-cell	O
hernias	Disease
within	O
15	O
minutes.	O
At	O
1	O
day	O
their	O
number	O
was	O
reduced	O
to	O
about	O
1/10	O
of	O
the	O
original	O
number.	O
By	O
7	O
days	O
the	O
vessel	O
was	O
almost	O
restored	O
to	O
normal.	O
Triple	O
stimulation	O
over	O
1	O
day	O
induced	O
more	O
severe	O
changes	O
in	O
the	O
media.	O
These	O
findings	O
suggest	O
that	O
smooth	O
muscle	O
cells	O
are	O
susceptible	O
to	O
damage	O
in	O
the	O
course	O
of	O
their	O
specific	O
function.	O
The	O
experimental	O
data	O
are	O
discussed	O
in	O
relation	O
to	O
medial	O
changes	O
observed	O
in	O
other	O
instances	O
of	O
arterial	O
spasm	Disease

Abnormalities	O
of	O
the	O
pupil	O
and	O
visual-evoked	O
potential	O
in	O
quinine	Chemical
	O
amblyopia	Disease
.	O
Total	O
blindness	Disease
with	O
a	O
transient	O
tonic	Disease
pupillary	Disease
response,	O
denervation	O
supersensitivity,	O
and	O
abnormal	O
visual-evoked	O
potentials	O
developed	O
in	O
a	O
54-year-old	O
man	O
after	O
the	O
use	O
of	O
quinine	Chemical
sulfate	Chemical
for	O
leg	Disease
cramps	Disease
.	O
He	O
later	O
recovered	O
normal	O
visual	O
acuity.	O
A	O
transient	O
tonic	Disease
pupillary	Disease
response,	O
denervation	O
supersensitivity,	O
and	O
abnormal	O
visual-evoked	O
potentials	O
in	O
quinine	Chemical
	O
toxicity	Disease

Suxamethonium	Chemical
-induced	O
jaw	Disease
stiffness	Disease
and	O
myalgia	Disease
associated	O
with	O
atypical	O
cholinesterase:	O
case	O
report.	O
An	O
11-year-old	O
boy	O
was	O
given	O
halothane	Chemical
,	O
nitrous	Chemical
oxide	Chemical
and	O
oxygen	Chemical
,	O
pancuronium	Chemical
0.4	O
mg	O
and	O
suxamethonium	Chemical
100	O
mg	O
for	O
induction	O
of	O
anaesthesia.	O
In	O
response	O
to	O
this	O
a	O
marked	O
jaw	Disease
stiffness	Disease
occurred	O
which	O
lasted	O
for	O
two	O
minutes	O
and	O
the	O
anaesthesia	O
were	O
terminated.	O
Four	O
hours	O
of	O
apnoea	Disease
ensued	O
and	O
he	O
suffered	O
generalized	O
severe	O
myalgia	Disease
lasting	O
for	O
one	O
week.	O
He	O
was	O
found	O
to	O
have	O
atypical	O
plasma	O
cholinesterase	O
with	O
a	O
dibucaine	Chemical
number	O
of	O
12,	O
indicating	O
homozygocity.	O
This	O
was	O
verified	O
by	O
study	O
of	O
the	O
family.	O
The	O
case	O
shows	O
that	O
prolonged	Disease
jaw	Disease
rigidity	Disease
and	O
myalgia	Disease
may	O
occur	O
after	O
suxamethonium	Chemical
in	O
patients	O
with	O
atypical	O
cholinesterase	O
despite	O
pretreatment	O
with	O
pancuronium	Chemical

Indomethacin	Chemical
-induced	O
hyperkalemia	Disease
in	O
three	O
patients	O
with	O
gouty	Disease
arthritis	Disease
.	O
We	O
describe	O
three	O
patients	O
in	O
whom	O
severe,	O
life-threatening	O
hyperkalemia	Disease
and	O
renal	Disease
insufficiency	Disease
developed	O
after	O
treatment	O
of	O
acute	O
gouty	Disease
arthritis	Disease
with	O
indomethacin	Chemical
.	O
This	O
complication	O
may	O
result	O
from	O
an	O
inhibition	O
of	O
prostaglandin	Chemical
synthesis	O
and	O
consequent	O
hyporeninemic	Disease
hypoaidosteronism	Disease
.	O
Careful	O
attention	O
to	O
renal	O
function	O
and	O
potassium	Chemical
balance	O
in	O
patients	O
receiving	O
indomethacin	Chemical
or	O
other	O
nonsteroidal	O
anti-inflammatory	O
agents,	O
particularly	O
in	O
those	O
patients	O
with	O
diabetes	Disease
mellitus	Disease
or	O
preexisting	O
renal	Disease
disease	Disease

Etomidate	Chemical
:	O
a	O
foreshortened	O
clinical	O
trial.	O
A	O
clinical	O
evaluation	O
of	O
etomidate	Chemical
for	O
outpatient	O
cystoscopy	O
was	O
embarked	O
upon.	O
Unpremedicated	O
patients	O
were	O
given	O
fentanyl	Chemical
1	O
microgram/kg	O
followed	O
by	O
etomidate	Chemical
0.3	O
mg/kg.	O
Anaesthesia	O
was	O
maintained	O
with	O
intermittent	O
etomidate	Chemical
in	O
2-4	O
mg	O
doses.	O
Patients	O
were	O
interviewed	O
personally	O
later	O
the	O
same	O
day,	O
and	O
by	O
questionnaire	O
three	O
to	O
four	O
weeks	O
later.	O
The	O
trial	O
was	O
discontinued	O
after	O
20	O
cases	O
because	O
of	O
an	O
unacceptable	O
incidence	O
of	O
side	O
effects.	O
Venous	O
pain	Disease
occurred	O
in	O
68%	O
of	O
patients	O
and	O
50%	O
had	O
redness,	O
pain	Disease
or	O
swelling	Disease
related	O
to	O
the	O
injection	O
site,	O
in	O
some	O
cases	O
lasting	O
up	O
to	O
three	O
weeks	O
after	O
anaesthesia.	O
Skeletal	O
movements	O
occurred	O
in	O
50%	O
of	O
patients;	O
30%	O
experienced	O
respiratory	Disease
upset	Disease
,	O
one	O
sufficiently	O
severe	O
to	O
necessitate	O
abandoning	O
the	O
technique.	O
Nausea	Disease
and	O
vomiting	Disease
occurred	O
in	O
40%	O
and	O
25%	O
had	O
disturbing	O
emergence	O
psychoses	Disease

Levodopa	Chemical
-induced	O
dyskinesias	Disease
are	O
improved	O
by	O
fluoxetine	Chemical
.	O
We	O
evaluated	O
the	O
severity	O
of	O
motor	Disease
disability	Disease
and	O
dyskinesias	Disease
in	O
seven	O
levodopa	Chemical
-responsive	O
patients	O
with	O
Parkinson's	Disease
disease	Disease
after	O
an	O
acute	O
challenge	O
with	O
the	O
mixed	O
dopamine	Chemical
agonist,	O
apomorphine	Chemical
,	O
before	O
and	O
after	O
the	O
administration	O
of	O
fluoxetine	Chemical
(20	O
mg	O
twice	O
per	O
day)	O
for	O
11	O
+/-	O
1	O
days.	O
After	O
fluoxetine	Chemical
treatment,	O
there	O
was	O
a	O
significant	O
47%	O
improvement	O
(p	O
<	O
0.05)	O
of	O
apomorphine	Chemical
-induced	O
dyskinesias	Disease
without	O
modification	O
of	O
parkinsonian	Disease
	O
motor	Disease
disability	Disease
.	O
The	O
dyskinesias	Disease
were	O
reduced	O
predominantly	O
in	O
the	O
lower	O
limbs	O
during	O
the	O
onset	O
and	O
disappearance	O
of	O
dystonic	Disease
dyskinesias	Disease
(onset-	O
and	O
end-of-dose	O
dyskinesias	Disease
)	O
and	O
in	O
the	O
upper	O
limbs	O
during	O
choreic	Disease
mid-dose	Disease
dyskinesias	Disease
.	O
The	O
results	O
suggest	O
that	O
increased	O
brain	O
serotoninergic	O
transmission	O
with	O
fluoxetine	Chemical
may	O
reduce	O
levodopa	Chemical
-	O
or	O
dopamine	Chemical
agonist-induced	O
dyskinesias	Disease
without	O
aggravating	O
parkinsonian	Disease
	O
motor	Disease
disability	Disease

A	O
large	O
population-based	O
follow-up	O
study	O
of	O
trimethoprim-sulfamethoxazole	Chemical
,	O
trimethoprim	Chemical
,	O
and	O
cephalexin	Chemical
for	O
uncommon	O
serious	O
drug	Disease
toxicity	Disease
.	O
We	O
conducted	O
a	O
population-based	O
45-day	O
follow-up	O
study	O
of	O
232,390	O
people	O
who	O
were	O
prescribed	O
trimethoprim-sulfamethoxazole	Chemical
(	O
TMP-SMZ	Chemical
),	O
266,951	O
prescribed	O
trimethoprim	Chemical
alone,	O
and	O
196,397	O
prescribed	O
cephalexin	Chemical
,	O
to	O
estimate	O
the	O
risk	O
of	O
serious	O
liver,	Disease
blood,	Disease
skin,	Disease
and	Disease
renal	Disease
disorders	Disease
resulting	O
in	O
referral	O
or	O
hospitalization	O
associated	O
with	O
these	O
drugs.	O
The	O
results	O
were	O
based	O
on	O
information	O
recorded	O
on	O
office	O
computers	O
by	O
selected	O
general	O
practitioners	O
in	O
the	O
United	O
Kingdom,	O
together	O
with	O
a	O
review	O
of	O
clinical	O
records.	O
The	O
risk	O
of	O
clinically	O
important	O
idiopathic	O
liver	Disease
disease	Disease
was	O
similar	O
for	O
persons	O
prescribed	O
TMP-SMZ	Chemical
(5.2/100,000)	O
and	O
those	O
prescribed	O
trimethoprim	Chemical
alone	O
(3.8/100,000).	O
The	O
risk	O
for	O
those	O
prescribed	O
cephalexin	Chemical
was	O
somewhat	O
lower	O
(2.0/100,000).	O
Only	O
five	O
patients	O
experienced	O
blood	O
disorders,	O
one	O
of	O
whom	O
was	O
exposed	O
to	O
TMP-SMZ	Chemical
;	O
of	O
seven	O
with	O
erythema	Disease
multiforme	Disease
and	O
Stevens-Johnson	Disease
syndrome	Disease
,	O
four	O
were	O
exposed	O
to	O
TMP-SMZ	Chemical
.	O
The	O
one	O
case	O
of	O
toxic	Disease
epidermal	Disease
necrolysis	Disease
occurred	O
in	O
a	O
patient	O
who	O
took	O
cephalexin	Chemical
.	O
Finally,	O
only	O
five	O
cases	O
of	O
acute	O
parenchymal	O
renal	Disease
disease	Disease

Clinical	O
safety	O
of	O
lidocaine	Chemical
in	O
patients	O
with	O
cocaine	Chemical
-associated	O
myocardial	Disease
infarction	Disease
.	O
STUDY	O
OBJECTIVE:	O
To	O
evaluate	O
the	O
safety	O
of	O
lidocaine	Chemical
in	O
the	O
setting	O
of	O
cocaine	Chemical
-induced	O
myocardial	Disease
infarction	Disease
(	O
MI	Disease
).	O
DESIGN:	O
A	O
retrospective,	O
multicenter	O
study.	O
SETTING:	O
Twenty-nine	O
university,	O
university-affiliated,	O
or	O
community	O
hospitals	O
during	O
a	O
6-year	O
period	O
(total	O
of	O
117	O
cumulative	O
hospital-years).	O
PARTICIPANTS:	O
Patients	O
with	O
cocaine	Chemical
-associated	O
MI	Disease
who	O
received	O
lidocaine	Chemical
in	O
the	O
emergency	O
department.	O
RESULTS:	O
Of	O
29	O
patients	O
who	O
received	O
lidocaine	Chemical
in	O
the	O
setting	O
of	O
cocaine	Chemical
-associated	O
MI	Disease
,	O
no	O
patient	O
died;	O
exhibited	O
bradydysrhythmias	Disease
,	O
ventricular	Disease
tachycardia	Disease
,	O
or	O
ventricular	Disease
fibrillation	Disease
;	O
or	O
experienced	O
seizures	Disease
after	O
administration	O
of	O
lidocaine	Chemical
(95%	O
confidence	O
interval,	O
0%	O
to	O
11%).	O
CONCLUSION:	O
Despite	O
theoretical	O
concerns	O
that	O
lidocaine	Chemical
may	O
enhance	O
cocaine	Chemical
	O
toxicity	Disease
,	O
the	O
use	O
of	O
lidocaine	Chemical
in	O
patients	O
with	O
cocaine	Chemical
-associated	O
MI	Disease
was	O
not	O
associated	O
with	O
significant	O
cardiovascular	Disease
or	Disease
central	Disease
nervous	Disease
system	Disease
toxicity	Disease

Paclitaxel	Chemical
3-hour	O
infusion	O
given	O
alone	O
and	O
combined	O
with	O
carboplatin	Chemical
:	O
preliminary	O
results	O
of	O
dose-escalation	O
trials.	O
Paclitaxel	Chemical
(	O
Taxol	Chemical
;	O
Bristol-Myers	O
Squibb	O
Company,	O
Princeton,	O
NJ)	O
by	O
3-hour	O
infusion	O
was	O
combined	O
with	O
carboplatin	Chemical
in	O
a	O
phase	O
I/II	O
study	O
directed	O
to	O
patients	O
with	O
non-small	Disease
cell	Disease
lung	Disease
cancer	Disease
.	O
Carboplatin	Chemical
was	O
given	O
at	O
a	O
fixed	O
target	O
area	O
under	O
the	O
concentration-time	O
curve	O
of	O
6.0	O
by	O
the	O
Calvert	O
formula,	O
whereas	O
paclitaxel	Chemical
was	O
escalated	O
in	O
patient	O
cohorts	O
from	O
150	O
mg/m2	O
(dose	O
level	O
I)	O
to	O
175,	O
200,	O
225,	O
and	O
250	O
mg/m2.	O
The	O
225	O
mg/m2	O
level	O
was	O
expanded	O
for	O
the	O
phase	O
II	O
study	O
since	O
the	O
highest	O
level	O
achieved	O
(250	O
mg/m2)	O
required	O
modification	O
because	O
of	O
nonhematologic	O
toxicities	Disease
(	O
arthralgia	Disease
and	O
sensory	Disease
neuropathy	Disease
).	O
Therapeutic	O
effects	O
were	O
noted	O
at	O
all	O
dose	O
levels,	O
with	O
objective	O
responses	O
in	O
17	O
(two	O
complete	O
and	O
15	O
partial	O
regressions)	O
of	O
41	O
previously	O
untreated	O
patients.	O
Toxicities	Disease
were	O
compared	O
with	O
a	O
cohort	O
of	O
patients	O
in	O
a	O
phase	O
I	O
trial	O
of	O
paclitaxel	Chemical
alone	O
at	O
identical	O
dose	O
levels.	O
Carboplatin	Chemical
did	O
not	O
appear	O
to	O
add	O
to	O
the	O
hematologic	Disease
toxicities	Disease
observed,	O
and	O
the	O
paclitaxel	Chemical
/	O
carboplatin	Chemical

The	O
dose-dependent	O
effect	O
of	O
misoprostol	Chemical
on	O
indomethacin	Chemical
-induced	O
renal	Disease
dysfunction	Disease
in	O
well	O
compensated	O
cirrhosis	Disease
.	O
Misoprostol	Chemical
(200	O
micrograms)	O
has	O
been	O
shown	O
to	O
acutely	O
counteract	O
the	O
indomethacin	Chemical
-induced	O
renal	Disease
dysfunction	Disease
in	O
well	O
compensated	O
cirrhotic	Disease
patients.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
the	O
prophylactic	O
value	O
of	O
misoprostol	Chemical
was	O
dose-dependent.	O
Parameters	O
of	O
renal	O
hemodynamics	O
and	O
tubular	O
sodium	Chemical
and	O
water	O
handling	O
were	O
assessed	O
by	O
clearance	O
techniques	O
in	O
26	O
well	O
compensated	O
cirrhotic	Disease
patients	O
before	O
and	O
after	O
an	O
oral	O
combination	O
of	O
50	O
mg	O
of	O
indomethacin	Chemical
and	O
various	O
doses	O
of	O
misoprostol	Chemical
.	O
The	O
200-micrograms	O
dose	O
was	O
able	O
to	O
totally	O
abolish	O
the	O
deleterious	O
renal	O
effects	O
of	O
indomethacin	Chemical
,	O
whereas	O
the	O
800-micrograms	O
dose	O
resulted	O
in	O
significant	O
worsening	O
of	O
renal	O
hemodynamics	O
and	O
sodium	Chemical
retention.	O
These	O
changes	O
were	O
maximal	O
in	O
the	O
hour	O
immediately	O
after	O
medications	O
and	O
slowly	O
returned	O
toward	O
base-line	O
levels	O
thereafter.	O
These	O
results	O
suggest	O
that	O
the	O
renal	O
protective	O
effects	O
of	O
misoprostol	Chemical
is	O
dose-dependent.	O
However,	O
until	O
this	O
apparent	O
ability	O
of	O
200	O
micrograms	O
of	O
misoprostol	Chemical
to	O
prevent	O
the	O
adverse	O
effects	O
of	O
indomethacin	Chemical
on	O
renal	O
function	O
is	O
confirmed	O
with	O
chronic	O
frequent	O
dosing,	O
it	O
would	O
be	O
prudent	O
to	O
avoid	O
nonsteroidal	O
anti-inflammatory	O
therapy	O
in	O
patients	O
with	O
cirrhosis	Disease

Increased	O
frequency	O
and	O
severity	O
of	O
angio-oedema	Disease
related	O
to	O
long-term	O
therapy	O
with	O
angiotensin-converting	Chemical
enzyme	Chemical
inhibitor	Chemical
in	O
two	O
patients.	O
Adverse	O
reactions	O
to	O
drugs	O
are	O
well	O
recognized	O
as	O
a	O
cause	O
of	O
acute	O
or	O
chronic	O
urticaria	Disease
,	O
and	O
angio-oedema	Disease
.	O
Angiotensin-converting	Chemical
enzyme	Chemical
(ACE)	Chemical
inhibitors	Chemical
,	O
used	O
to	O
treat	O
hypertension	Disease
and	O
congestive	Disease
heart	Disease
failure	Disease
,	O
were	O
introduced	O
in	O
Europe	O
in	O
the	O
middle	O
of	O
the	O
eighties,	O
and	O
the	O
use	O
of	O
these	O
drugs	O
has	O
increased	O
progressively.	O
Soon	O
after	O
the	O
introduction	O
of	O
ACE	Chemical
inhibitors	Chemical
,	O
acute	O
bouts	O
of	O
angio-oedema	Disease
were	O
reported	O
in	O
association	O
with	O
the	O
use	O
of	O
these	O
drugs.	O
We	O
wish	O
to	O
draw	O
attention	O
to	O
the	O
possibility	O
of	O
adverse	O
reactions	O
to	O
ACE	Chemical
inhibitors	Chemical
after	O
long-term	O
use	O
and	O
in	O
patients	O
with	O
pre-existing	O
angio-oedema	Disease

Myoclonus	Disease
associated	O
with	O
lorazepam	Chemical
therapy	O
in	O
very-low-birth-weight	O
infants.	O
Lorazepam	Chemical
is	O
being	O
used	O
with	O
increasing	O
frequency	O
as	O
a	O
sedative	O
in	O
the	O
newborn	O
and	O
the	O
young	O
infant.	O
Concern	O
has	O
been	O
raised	O
with	O
regard	O
to	O
the	O
safety	O
of	O
lorazepam	Chemical
in	O
this	O
age	O
group,	O
especially	O
in	O
very-low-birth-weight	O
(VLBW;	O
<	O
1,500	O
g)	O
infants.	O
Three	O
young	O
infants,	O
all	O
of	O
birth	O
weight	O
<	O
1,500	O
g,	O
experienced	O
myoclonus	Disease
following	O
the	O
intravenous	O
administration	O
of	O
lorazepam	Chemical
.	O
The	O
potential	O
neurotoxic	Disease
effects	O
of	O
the	O
drug	O
(and	O
its	O
vehicle)	O
in	O
this	O
population	O
are	O
discussed.	O
Injectable	O
lorazepam	Chemical

Transvenous	O
right	O
ventricular	O
pacing	O
during	O
cardiopulmonary	O
resuscitation	O
of	O
pediatric	O
patients	O
with	O
acute	O
cardiomyopathy	Disease
.	O
We	O
describe	O
the	O
cardiopulmonary	O
resuscitation	O
efforts	O
on	O
five	O
patients	O
who	O
presented	O
in	O
acute	O
circulatory	Disease
failure	Disease
from	O
myocardial	Disease
dysfunction	Disease
.	O
Three	O
patients	O
had	O
acute	O
viral	O
myocarditis	Disease
,	O
one	O
had	O
a	O
carbamazepine	Chemical
-induced	O
acute	O
eosinophilic	Disease
myocarditis	Disease
,	O
and	O
one	O
had	O
cardiac	O
hemosiderosis	O
resulting	O
in	O
acute	O
cardiogenic	Disease
shock	Disease
.	O
All	O
patients	O
were	O
continuously	O
monitored	O
with	O
central	O
venous	O
and	O
arterial	O
catheters	O
in	O
addition	O
to	O
routine	O
noninvasive	O
monitoring.	O
An	O
introducer	O
sheath,	O
a	O
pacemaker,	O
and	O
sterile	O
pacing	O
wires	O
were	O
made	O
readily	O
available	O
for	O
the	O
patients,	O
should	O
the	O
need	O
arise	O
to	O
terminate	O
resistant	O
cardiac	O
dysrhythmias	Disease
.	O
All	O
patients	O
developed	O
cardiocirculatory	O
arrest	O
associated	O
with	O
extreme	O
hypotension	Disease
and	O
dysrhythmias	Disease
within	O
the	O
first	O
48	O
hours	O
of	O
their	O
admission	O
to	O
the	O
pediatric	O
intensive	O
care	O
unit	O
(PICU).	O
Right	O
ventricular	O
pacemaker	O
wires	O
were	O
inserted	O
in	O
all	O
of	O
them	O
during	O
cardiopulmonary	O
resuscitation	O
(CPR).	O
In	O
four	O
patients,	O
cardiac	O
pacing	O
was	O
used,	O
resulting	O
in	O
a	O
temporary	O
captured	O
rhythm	O
and	O
restoration	O
of	O
their	O
cardiac	O
output.	O
These	O
patients	O
had	O
a	O
second	O
event	O
of	O
cardiac	Disease
arrest	Disease
,	O
resulting	O
in	O
death,	O
within	O
10	O
to	O
60	O
minutes.	O
In	O
one	O
patient,	O
cardiac	O
pacing	O
was	O
not	O
used,	O
because	O
he	O
converted	O
to	O
normal	O
sinus	O
rhythm	O
by	O
electrical	O
defibrillation	O
within	O
three	O
minutes	O
of	O
initiating	O
CPR.	O
We	O
conclude	O
that	O
cardiac	O
pacing	O
during	O
resuscitative	O
efforts	O
in	O
pediatric	O
patients	O
suffering	O
from	O
acute	O
myocardial	Disease
dysfunction	Disease

Efficacy	O
and	O
safety	O
of	O
granisetron	Chemical
,	O
a	O
selective	O
5-hydroxytryptamine	Chemical
-3	O
receptor	O
antagonist,	O
in	O
the	O
prevention	O
of	O
nausea	Disease
and	O
vomiting	Disease
induced	O
by	O
high-dose	O
cisplatin	Chemical
.	O
PURPOSE:	O
To	O
assess	O
the	O
antiemetic	O
effects	O
and	O
safety	O
profile	O
of	O
four	O
different	O
doses	O
of	O
granisetron	Chemical
(	O
Kytril	Chemical
;	O
SmithKline	O
Beecham	O
Pharmaceuticals,	O
Philadelphia,	O
PA)	O
when	O
administered	O
as	O
a	O
single	O
intravenous	O
(IV)	O
dose	O
for	O
prophylaxis	O
of	O
cisplatin	Chemical
-induced	O
nausea	Disease
and	O
vomiting	Disease
.	O
PATIENTS	O
AND	O
METHODS:	O
One	O
hundred	O
eighty-four	O
chemotherapy-naive	O
patients	O
receiving	O
high-dose	O
cisplatin	Chemical
(81	O
to	O
120	O
mg/m2)	O
were	O
randomized	O
to	O
receive	O
one	O
of	O
four	O
granisetron	Chemical
doses	O
(5,	O
10,	O
20,	O
or	O
40	O
micrograms/kg)	O
administered	O
before	O
chemotherapy.	O
Patients	O
were	O
observed	O
on	O
an	O
inpatient	O
basis	O
for	O
18	O
to	O
24	O
hours,	O
and	O
vital	O
signs,	O
nausea	Disease
,	O
vomiting	Disease
,	O
retching,	O
and	O
appetite	O
were	O
assessed.	O
Safety	O
analyses	O
included	O
incidence	O
of	O
adverse	O
experiences	O
and	O
laboratory	O
parameter	O
changes.	O
RESULTS:	O
After	O
granisetron	Chemical
doses	O
of	O
5,	O
10,	O
20,	O
and	O
40	O
micrograms/kg,	O
a	O
major	O
response	O
(<	O
or	O
=	O
two	O
vomiting	Disease
or	O
retching	O
episodes,	O
and	O
no	O
antiemetic	O
rescue)	O
was	O
recorded	O
in	O
23%,	O
57%,	O
58%,	O
and	O
60%	O
of	O
patients,	O
respectively,	O
and	O
a	O
complete	O
response	O
(no	O
vomiting	Disease
or	O
retching,	O
and	O
no	O
antiemetic	O
rescue)	O
in	O
18%,	O
41%,	O
40%,	O
and	O
47%	O
of	O
patients,	O
respectively.	O
There	O
was	O
a	O
statistically	O
longer	O
time	O
to	O
first	O
episode	O
of	O
nausea	Disease
(P	O
=	O
.0015)	O
and	O
vomiting	Disease
(P	O
=	O
.0001),	O
and	O
fewer	O
patients	O
were	O
administered	O
additional	O
antiemetic	O
medication	O
in	O
the	O
10-micrograms/kg	O
dosing	O
groups	O
than	O
in	O
the	O
5-micrograms/kg	O
dosing	O
group.	O
As	O
granisetron	Chemical
dose	O
increased,	O
appetite	O
return	O
increased	O
(P	O
=	O
.040).	O
Headache	Disease
was	O
the	O
most	O
frequently	O
reported	O
adverse	O
event	O
(20%).	O
CONCLUSION:	O
A	O
single	O
10-,	O
20-,	O
or	O
40-micrograms/kg	O
dose	O
of	O
granisetron	Chemical
was	O
effective	O
in	O
controlling	O
vomiting	Disease
in	O
57%	O
to	O
60%	O
of	O
patients	O
who	O
received	O
cisplatin	Chemical
at	O
doses	O
greater	O
than	O
81	O
mg/m2	O
and	O
totally	O
prevented	O
vomiting	Disease
in	O
40%	O
to	O
47%	O
of	O
patients.	O
There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
efficacy	O
between	O
the	O
10-micrograms/kg	O
dose	O
and	O
the	O
20-	O
and	O
40-micrograms/kg	O
doses.	O
Granisetron	Chemical

Adverse	O
interaction	O
between	O
clonidine	Chemical
and	O
verapamil	Chemical
.	O
OBJECTIVE:	O
To	O
report	O
two	O
cases	O
of	O
a	O
possible	O
adverse	O
interaction	O
between	O
clonidine	Chemical
and	O
verapamil	Chemical
resulting	O
in	O
atrioventricular	Disease
(AV)	Disease
block	Disease
in	O
both	O
patients	O
and	O
severe	O
hypotension	Disease
in	O
one	O
patient.	O
CASE	O
SUMMARIES:	O
A	O
54-year-old	O
woman	O
with	O
hyperaldosteronism	Disease
was	O
treated	O
with	O
verapamil	Chemical
480	O
mg/d	O
and	O
spironolactone	Chemical
100	O
mg/d.	O
After	O
the	O
addition	O
of	O
a	O
minimal	O
dose	O
of	O
clonidine	Chemical
(0.15	O
mg	O
bid),	O
she	O
developed	O
complete	O
AV	Disease
block	Disease
and	O
severe	O
hypotension	Disease
,	O
which	O
resolved	O
upon	O
cessation	O
of	O
all	O
medications.	O
A	O
65-year-old	O
woman	O
was	O
treated	O
with	O
extended-release	O
verapamil	Chemical
240	O
mg/d.	O
After	O
the	O
addition	O
of	O
clonidine	Chemical
0.15	O
mg	O
bid	O
she	O
developed	O
complete	O
AV	Disease
block	Disease
,	O
which	O
resolved	O
after	O
all	O
therapy	O
was	O
stopped.	O
DISCUSSION:	O
An	O
adverse	O
interaction	O
between	O
clonidine	Chemical
and	O
verapamil	Chemical
has	O
not	O
been	O
reported	O
previously.	O
We	O
describe	O
two	O
such	O
cases	O
and	O
discuss	O
the	O
various	O
mechanisms	O
that	O
might	O
cause	O
such	O
an	O
interaction.	O
Clinicians	O
should	O
be	O
acquainted	O
with	O
this	O
possibly	O
fatal	O
interaction	O
between	O
two	O
commonly	O
used	O
antihypertensive	O
drugs.	O
CONCLUSIONS:	O
Caution	O
is	O
recommended	O
in	O
combining	O
clonidine	Chemical
and	O
verapamil	Chemical

Pharmacological	O
studies	O
on	O
a	O
new	O
dihydrothienopyridine	Chemical
calcium	Chemical
antagonist,	O
S-312-d	Chemical
.	O
5th	O
communication:	O
anticonvulsant	O
effects	O
in	O
mice.	O
S-312	Chemical
,	O
S-312-d	Chemical
,	O
but	O
not	O
S-312-l	Chemical
,	O
L-type	O
calcium	Chemical
channel	O
antagonists,	O
showed	O
anticonvulsant	O
effects	O
on	O
the	O
audiogenic	Disease
tonic	Disease
convulsions	Disease
in	O
DBA/2	O
mice;	O
and	O
their	O
ED50	O
values	O
were	O
18.4	O
(12.8-27.1)	O
mg/kg,	O
p.o.	O
and	O
15.0	O
(10.2-23.7)	O
mg/kg,	O
p.o.,	O
respectively,	O
while	O
that	O
of	O
flunarizine	Chemical
was	O
34.0	O
(26.0-44.8)	O
mg/kg,	O
p.o.	O
Although	O
moderate	O
anticonvulsant	O
effects	O
of	O
S-312-d	Chemical
in	O
higher	O
doses	O
were	O
observed	O
against	O
the	O
clonic	O
convulsions	Disease
induced	O
by	O
pentylenetetrazole	Chemical
(85	O
mg/kg,	O
s.c.)	O
or	O
bemegride	Chemical
(40	O
mg/kg,	O
s.c.),	O
no	O
effects	O
were	O
observed	O
in	O
convulsions	Disease
induced	O
by	O
N-methyl-D-aspartate	Chemical
,	O
picrotoxin	Chemical
,	O
or	O
electroshock	O
in	O
Slc:ddY	O
mice.	O
S-312-d	Chemical
may	O
be	O
useful	O
in	O
the	O
therapy	O
of	O
certain	O
types	O
of	O
human	O
epilepsy	Disease

Transmural	O
myocardial	Disease
infarction	Disease
with	O
sumatriptan	Chemical
.	O
For	O
sumatriptan	Chemical
,	O
tightness	O
in	O
the	O
chest	O
caused	O
by	O
an	O
unknown	O
mechanism	O
has	O
been	O
reported	O
in	O
3-5%	O
of	O
users.	O
We	O
describe	O
a	O
47-year-old	O
woman	O
with	O
an	O
acute	O
myocardial	Disease
infarction	Disease
after	O
administration	O
of	O
sumatriptan	Chemical
6	O
mg	O
subcutaneously	O
for	O
cluster	Disease
headache	Disease
.	O
The	O
patient	O
had	O
no	O
history	O
of	O
underlying	O
ischaemic	Disease
heart	Disease
disease	Disease
or	O
Prinzmetal's	Disease
angina	Disease

Flumazenil	Chemical
induces	O
seizures	Disease
and	O
death	O
in	O
mixed	O
cocaine	Chemical
-	O
diazepam	Chemical
intoxications.	O
STUDY	O
HYPOTHESIS:	O
Administration	O
of	O
the	O
benzodiazepine	Chemical
antagonist	O
flumazenil	Chemical
may	O
unmask	O
seizures	Disease
in	O
mixed	O
cocaine	Chemical
-	O
benzodiazepine	Chemical
intoxication.	O
DESIGN:	O
Male	O
Sprague-Dawley	O
rats	O
received	O
100	O
mg/kg	O
cocaine	Chemical
IP	O
alone,	O
5	O
mg/kg	O
diazepam	Chemical
alone,	O
or	O
a	O
combination	O
of	O
diazepam	Chemical
and	O
cocaine	Chemical
.	O
Three	O
minutes	O
later,	O
groups	O
were	O
challenged	O
with	O
vehicle	O
or	O
flumazenil	Chemical
5	O
or	O
10	O
mg/kg	O
IP.	O
Animal	O
behavior,	O
seizures	Disease
(time	O
to	O
and	O
incidence),	O
death	O
(time	O
to	O
and	O
incidence),	O
and	O
cortical	O
EEG	O
tracings	O
were	O
recorded.	O
INTERVENTIONS:	O
Administration	O
of	O
flumazenil	Chemical
to	O
animals	O
after	O
they	O
had	O
received	O
a	O
combination	O
dose	O
of	O
cocaine	Chemical
and	O
diazepam	Chemical
.	O
RESULTS:	O
In	O
group	O
1,	O
animals	O
received	O
cocaine	Chemical
followed	O
by	O
vehicle.	O
This	O
resulted	O
in	O
100%	O
developing	O
seizures	Disease
and	O
death.	O
Group	O
2	O
received	O
diazepam	Chemical
alone	O
followed	O
by	O
vehicle.	O
Animals	O
became	O
somnolent	O
and	O
none	O
died.	O
Group	O
3	O
received	O
diazepam	Chemical
followed	O
by	O
5	O
mg/kg	O
flumazenil	Chemical
.	O
Animals	O
became	O
somnolent	O
after	O
diazepam	Chemical
and	O
then	O
active	O
after	O
flumazenil	Chemical
administration.	O
In	O
group	O
4,	O
a	O
combination	O
of	O
cocaine	Chemical
and	O
diazepam	Chemical
was	O
administered	O
simultaneously.	O
This	O
resulted	O
in	O
no	O
overt	O
or	O
EEG-detectable	O
seizures	Disease
and	O
a	O
50%	O
incidence	O
of	O
death.	O
Group	O
5	O
received	O
a	O
similar	O
combination	O
of	O
cocaine	Chemical
and	O
diazepam	Chemical
,	O
followed	O
later	O
by	O
5	O
mg/kg	O
flumazenil	Chemical
.	O
This	O
resulted	O
in	O
an	O
increased	O
incidence	O
of	O
seizures	Disease
,	O
90%	O
(P	O
<	O
.01),	O
and	O
death,	O
100%	O
(P	O
<	O
or	O
=	O
.01),	O
compared	O
with	O
group	O
4.	O
Group	O
6	O
received	O
cocaine	Chemical
and	O
diazepam	Chemical
followed	O
by	O
10	O
mg/kg	O
flumazenil	Chemical
.	O
This	O
also	O
resulted	O
in	O
an	O
increased	O
incidence	O
of	O
seizures	Disease
,	O
90%	O
(P	O
<	O
or	O
=	O
.01),	O
and	O
death,	O
90%	O
(P	O
<	O
or	O
=	O
.05),	O
compared	O
with	O
group	O
4.	O
CONCLUSION:	O
Flumazenil	Chemical
can	O
unmask	O
seizures	Disease
and	O
increase	O
the	O
incidence	O
of	O
death	O
in	O
a	O
model	O
of	O
combined	O
cocaine	Chemical
-	O
diazepam	Chemical

Mechanisms	O
for	O
protective	O
effects	O
of	O
free	O
radical	O
scavengers	O
on	O
gentamicin	Chemical
-mediated	O
nephropathy	Disease
in	O
rats.	O
Studies	O
were	O
performed	O
to	O
examine	O
the	O
mechanisms	O
for	O
the	O
protective	O
effects	O
of	O
free	O
radical	O
scavengers	O
on	O
gentamicin	Chemical
(	O
GM	Chemical
)-mediated	O
nephropathy	Disease
.	O
Administration	O
of	O
GM	Chemical
at	O
40	O
mg/kg	O
sc	O
for	O
13	O
days	O
to	O
rats	O
induced	O
a	O
significant	O
reduction	O
in	O
renal	O
blood	O
flow	O
(RBF)	O
and	O
inulin	O
clearance	O
(CIn)	O
as	O
well	O
as	O
marked	O
tubular	Disease
damage	Disease
.	O
A	O
significant	O
reduction	O
in	O
urinary	O
guanosine	Chemical
3',5'-cyclic	Chemical
monophosphate	Chemical
(	O
cGMP	Chemical
)	O
excretion	O
and	O
a	O
significant	O
increase	O
in	O
renal	O
cortical	O
renin	O
and	O
endothelin-1	O
contents	O
were	O
also	O
observed	O
in	O
GM	Chemical
-mediated	O
nephropathy	Disease
.	O
Superoxide	Chemical
dismutase	O
(SOD)	O
or	O
dimethylthiourea	Chemical
(	O
DMTU	Chemical
)	O
significantly	O
lessened	O
the	O
GM	Chemical
-induced	O
decrement	O
in	O
CIn.	O
The	O
SOD-induced	O
increase	O
in	O
glomerular	O
filtration	O
rate	O
was	O
associated	O
with	O
a	O
marked	O
improvement	O
in	O
RBF,	O
an	O
increase	O
in	O
urinary	O
cGMP	Chemical
excretion,	O
and	O
a	O
decrease	O
in	O
renal	O
renin	O
and	O
endothelin-1	O
content.	O
SOD	O
did	O
not	O
attenuate	O
the	O
tubular	Disease
damage	Disease
.	O
In	O
contrast,	O
DMTU	Chemical
significantly	O
reduced	O
the	O
tubular	Disease
damage	Disease
and	O
lipid	O
peroxidation,	O
but	O
it	O
did	O
not	O
affect	O
renal	O
hemodynamics	O
and	O
vasoactive	O
substances.	O
Neither	O
SOD	O
nor	O
DMTU	Chemical
affected	O
the	O
renal	O
cortical	O
GM	Chemical
content	O
in	O
GM	Chemical
-treated	O
rats.	O
These	O
results	O
suggest	O
that	O
1)	O
both	O
SOD	O
and	O
DMTU	Chemical
have	O
protective	O
effects	O
on	O
GM	Chemical
-mediated	O
nephropathy	Disease
,	O
2)	O
the	O
mechanisms	O
for	O
the	O
protective	O
effects	O
differ	O
for	O
SOD	O
and	O
DMTU	Chemical
,	O
and	O
3)	O
superoxide	Chemical
anions	O
play	O
a	O
critical	O
role	O
in	O
GM	Chemical

Assessment	O
of	O
cardiomyocyte	O
DNA	O
synthesis	O
during	O
hypertrophy	Disease
in	O
adult	O
mice.	O
The	O
ability	O
of	O
cardiomyocytes	O
to	O
synthesize	O
DNA	O
in	O
response	O
to	O
experimentally	O
induced	O
cardiac	Disease
hypertrophy	Disease
was	O
assessed	O
in	O
adult	O
mice.	O
Isoproterenol	Chemical
delivered	O
by	O
osmotic	O
minipump	O
implantation	O
in	O
adult	O
C3Heb/FeJ	O
mice	O
resulted	O
in	O
a	O
46%	O
increase	O
in	O
heart	O
weight	O
and	O
a	O
19.3%	O
increase	O
in	O
cardiomyocyte	O
area.	O
No	O
DNA	O
synthesis,	O
as	O
assessed	O
by	O
autoradiographic	O
analysis	O
of	O
isolated	O
cardiomyocytes,	O
was	O
observed	O
in	O
control	O
or	O
hypertrophic	Disease
hearts	Disease
.	O
A	O
survey	O
of	O
15	O
independent	O
inbred	O
strains	O
of	O
mice	O
revealed	O
that	O
ventricular	O
cardiomyocyte	O
nuclear	O
number	O
ranged	O
from	O
3	O
to	O
13%	O
mononucleate,	O
suggesting	O
that	O
cardiomyocyte	O
terminal	O
differentiation	O
is	O
influenced	O
directly	O
or	O
indirectly	O
by	O
genetic	O
background.	O
To	O
determine	O
whether	O
the	O
capacity	O
for	O
reactive	O
DNA	O
synthesis	O
was	O
also	O
subject	O
to	O
genetic	O
regulation,	O
cardiac	Disease
hypertrophy	Disease
was	O
induced	O
in	O
the	O
strains	O
of	O
mice	O
comprising	O
the	O
extremes	O
of	O
the	O
nuclear	O
number	O
survey.	O
These	O
data	O
indicate	O
that	O
adult	O
mouse	O
atrial	O
and	O
ventricular	O
cardiomyocytes	O
do	O
not	O
synthesize	O
DNA	O
in	O
response	O
to	O
isoproterenol	Chemical
-induced	O
cardiac	Disease
hypertrophy	Disease

Central	O
cardiovascular	O
effects	O
of	O
AVP	Chemical
and	O
ANP	O
in	O
normotensive	O
and	O
spontaneously	O
hypertensive	Disease
rats.	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
compare	O
influence	O
of	O
central	O
arginine	Chemical
vasopressin	Chemical
(	O
AVP	Chemical
)	O
and	O
of	O
atrial	O
natriuretic	O
peptide	O
(ANP)	O
on	O
control	O
of	O
arterial	O
blood	O
pressure	O
(MAP)	O
and	O
heart	O
rate	O
(HR)	O
in	O
normotensive	O
(WKY)	O
and	O
spontaneously	O
hypertensive	Disease
(SHR)	O
rats.	O
Three	O
series	O
of	O
experiments	O
were	O
performed	O
on	O
30	O
WKY	O
and	O
30	O
SHR,	O
chronically	O
instrumented	O
with	O
guide	O
tubes	O
in	O
the	O
lateral	O
ventricle	O
(LV)	O
and	O
arterial	O
and	O
venous	O
catheters.	O
MAP	O
and	O
HR	O
were	O
monitored	O
before	O
and	O
after	O
i.v.	O
injections	O
of	O
either	O
vehicle	O
or	O
1,	O
10	O
and	O
50	O
ng	O
of	O
AVP	Chemical
and	O
25,	O
125	O
and	O
500	O
ng	O
of	O
ANP.	O
Sensitivity	O
of	O
cardiac	O
component	O
of	O
baroreflex	O
(CCB),	O
expressed	O
as	O
a	O
slope	O
of	O
the	O
regression	O
line	O
was	O
determined	O
from	O
relationships	O
between	O
systolic	O
arterial	O
pressure	O
(SAP)	O
and	O
HR	O
period	O
(HRp)	O
during	O
phenylephrine	Chemical
(	O
Phe	Chemical
)-induced	O
hypertension	Disease
and	O
sodium	Chemical
nitroprusside	Chemical
(	O
SN	Chemical
)-induced	O
hypotension	Disease
.	O
CCB	O
was	O
measured	O
before	O
and	O
after	O
administration	O
of	O
either	O
vehicle,	O
AVP	Chemical
,	O
ANP,	O
or	O
both	O
peptides	O
together.	O
Increases	O
of	O
MAP	O
occurred	O
after	O
LV	O
administration	O
of	O
1,	O
10	O
and	O
50	O
ng	O
of	O
AVP	Chemical
in	O
WKY	O
and	O
of	O
10	O
and	O
50	O
ng	O
in	O
SHR.	O
ANP	O
did	O
not	O
cause	O
significant	O
changes	O
in	O
MAP	O
in	O
both	O
strains	O
as	O
compared	O
to	O
vehicle,	O
but	O
it	O
abolished	O
AVP	Chemical
-induced	O
MAP	O
increase	O
in	O
WKY	O
and	O
SHR.	O
CCB	O
was	O
reduced	O
in	O
WKY	O
and	O
SHR	O
after	O
LV	O
administration	O
of	O
AVP	Chemical
during	O
SN	Chemical
-induced	O
hypotension	Disease
.	O
In	O
SHR	O
but	O
not	O
in	O
WKY	O
administration	O
of	O
ANP,	O
AVP	Chemical
and	O
ANP	O
+	O
AVP	Chemical
decreased	O
CCB	O
during	O
Phe	Chemical
-induced	O
MAP	O
elevation.	O
The	O
results	O
indicate	O
that	O
centrally	O
applied	O
AVP	Chemical

Cutaneous	O
exposure	O
to	O
warfarin	Chemical
-like	O
anticoagulant	O
causing	O
an	O
intracerebral	Disease
hemorrhage	Disease
:	O
a	O
case	O
report.	O
A	O
case	O
of	O
intercerebral	O
hematoma	Disease
due	O
to	O
warfarin	Chemical
-induced	O
coagulopathy	Disease
is	O
presented.	O
The	O
39-year-old	O
woman	O
had	O
spread	O
a	O
warfarin	Chemical
-type	O
rat	O
poison	O
around	O
her	O
house	O
weekly	O
using	O
her	O
bare	O
hands,	O
with	O
no	O
washing	O
post	O
application.	O
Percutaneous	O
absorption	O
of	O
warfarin	Chemical
causing	O
coagulopathy	Disease
,	O
reported	O
three	O
times	O
in	O
the	O
past,	O
is	O
a	O
significant	O
risk	O
if	O
protective	O
measures,	O
such	O
as	O
gloves,	O
are	O
not	O
used.	O
An	O
adverse	O
drug	O
interaction	O
with	O
piroxicam	Chemical
,	O
which	O
she	O
took	O
occasionally,	O
may	O
have	O
exacerbated	O
the	O
coagulopathy	Disease

Pediatric	O
heart	O
transplantation	O
without	O
chronic	O
maintenance	O
steroids	Chemical
.	O
From	O
1986	O
to	O
February	O
1993,	O
40	O
children	O
aged	O
2	O
months	O
to	O
18	O
years	O
(average	O
age	O
10.4	O
+/-	O
5.8	O
years)	O
underwent	O
heart	O
transplantation.	O
Indications	O
for	O
transplantation	O
were	O
idiopathic	Disease
cardiomyopathy	Disease
(52%),	O
congenital	Disease
heart	Disease
disease	Disease
(35%)	O
with	O
and	O
without	O
prior	O
repair	O
(71%	O
and	O
29%,	O
respectively),	O
hypertrophic	Disease
cardiomyopathy	Disease
(5%),	O
valvular	Disease
heart	Disease
disease	Disease
(3%),	O
and	O
doxorubicin	Chemical
	O
cardiomyopathy	Disease
(5%).	O
Patients	O
were	O
managed	O
with	O
cyclosporine	Chemical
and	O
azathioprine	Chemical
.	O
No	O
prophylaxis	O
with	O
antilymphocyte	O
globulin	O
was	O
used.	O
Steroids	Chemical
were	O
given	O
to	O
39%	O
of	O
patients	O
for	O
refractory	O
rejection,	O
but	O
weaning	O
was	O
always	O
attempted	O
and	O
generally	O
successful	O
(64%).	O
Five	O
patients	O
(14%)	O
received	O
maintenance	O
steroids	Chemical
.	O
Four	O
patients	O
died	O
in	O
the	O
perioperative	O
period	O
and	O
one	O
died	O
4	O
months	O
later.	O
There	O
have	O
been	O
no	O
deaths	O
related	O
to	O
rejection	O
or	O
infection	Disease
.	O
Average	O
follow-up	O
was	O
36	O
+/-	O
19	O
months	O
(range	O
1	O
to	O
65	O
months).	O
Cumulative	O
survival	O
is	O
88%	O
at	O
5	O
years.	O
In	O
patients	O
less	O
than	O
7	O
years	O
of	O
age,	O
rejection	O
was	O
monitored	O
noninvasively.	O
In	O
the	O
first	O
postoperative	O
month,	O
89%	O
of	O
patients	O
were	O
treated	O
for	O
rejection.	O
Freedom	O
from	O
serious	O
infections	Disease
was	O
83%	O
at	O
1	O
month	O
and	O
65%	O
at	O
1	O
year.	O
Cytomegalovirus	Disease
infections	Disease
were	O
treated	O
successfully	O
with	O
ganciclovir	Chemical
in	O
11	O
patients.	O
No	O
impairment	O
of	O
growth	O
was	O
observed	O
in	O
children	O
who	O
underwent	O
transplantation	O
compared	O
with	O
a	O
control	O
population.	O
Twenty-one	O
patients	O
(60%)	O
have	O
undergone	O
annual	O
catheterizations	O
and	O
no	O
sign	O
of	O
graft	O
atherosclerosis	Disease
has	O
been	O
observed.	O
Seizures	Disease
occurred	O
in	O
five	O
patients	O
(14%)	O
and	O
hypertension	Disease
was	O
treated	O
in	O
10	O
patients	O
(28%).	O
No	O
patient	O
was	O
disabled	O
and	O
no	O
lymphoproliferative	Disease
disorder	Disease

Delirium	Disease
during	O
fluoxetine	Chemical
treatment.	O
A	O
case	O
report.	O
The	O
correlation	O
between	O
high	O
serum	O
tricyclic	O
antidepressant	O
concentrations	O
and	O
central	O
nervous	O
system	O
side	O
effects	O
has	O
been	O
well	O
established.	O
Only	O
a	O
few	O
reports	O
exist,	O
however,	O
on	O
the	O
relationship	O
between	O
the	O
serum	O
concentrations	O
of	O
selective	O
serotonin	Chemical
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
their	O
toxic	O
effects.	O
In	O
some	O
cases,	O
a	O
high	O
serum	O
concentration	O
of	O
citalopram	Chemical
(>	O
600	O
nmol/L)	O
in	O
elderly	O
patients	O
has	O
been	O
associated	O
with	O
increased	O
somnolence	Disease
and	O
movement	Disease
difficulties	Disease
.	O
Widespread	O
cognitive	Disease
disorders	Disease
,	O
such	O
as	O
delirium	Disease
,	O
have	O
not	O
been	O
previously	O
linked	O
with	O
high	O
blood	O
levels	O
of	O
SSRIs.	O
In	O
this	O
report,	O
we	O
describe	O
a	O
patient	O
with	O
acute	O
hyperkinetic	Disease
	O
delirium	Disease
connected	O
with	O
a	O
high	O
serum	O
total	O
fluoxetine	Chemical
(	O
fluoxetine	Chemical
plus	O
desmethylfluoxetine	Chemical

Pulmonary	Disease
edema	Disease
and	O
shock	Disease
after	O
high-dose	O
aracytine-C	Chemical
for	O
lymphoma	Disease
;	O
possible	O
role	O
of	O
TNF-alpha	O
and	O
PAF.	O
Four	O
out	O
of	O
23	O
consecutive	O
patients	O
treated	O
with	O
high-dose	O
Ara-C	Chemical
for	O
lymphomas	Disease
in	O
our	O
institution	O
developed	O
a	O
strikingly	O
similar	O
syndrome	O
during	O
the	O
perfusion.	O
It	O
was	O
characterized	O
by	O
the	O
onset	O
of	O
fever	Disease
,	O
diarrhea	Disease
,	O
shock	Disease
,	O
pulmonary	Disease
edema	Disease
,	O
acute	Disease
renal	Disease
failure	Disease
,	O
metabolic	Disease
acidosis	Disease
,	O
weight	Disease
gain	Disease
and	O
leukocytosis	Disease
.	O
Thorough	O
bacteriological	O
screening	O
failed	O
to	O
provide	O
evidence	O
of	O
infection	Disease
.	O
Sequential	O
biological	O
assays	O
of	O
IL-1,	O
IL-2,	O
TNF	O
and	O
PAF	O
were	O
performed	O
during	O
Ara-C	Chemical
infusion	O
to	O
ten	O
patients,	O
including	O
the	O
four	O
who	O
developed	O
the	O
syndrome.	O
TNF	O
and	O
PAF	O
activity	O
was	O
found	O
in	O
the	O
serum	O
of	O
respectively	O
two	O
and	O
four	O
of	O
the	O
cases,	O
but	O
not	O
in	O
the	O
six	O
controls.	O
As	O
TNF	O
and	O
PAF	O
are	O
thought	O
to	O
be	O
involved	O
in	O
the	O
development	O
of	O
septic	O
shock	Disease
and	O
adult	Disease
respiratory	Disease
distress	Disease
syndrome	Disease
,	O
we	O
hypothesize	O
that	O
high-dose	O
Ara-C	Chemical

Protective	O
effect	O
of	O
clentiazem	Chemical
against	O
epinephrine	Chemical
-induced	O
cardiac	Disease
injury	Disease
in	O
rats.	O
We	O
investigated	O
the	O
effects	O
of	O
clentiazem	Chemical
,	O
a	O
1,5-benzothiazepine	Chemical
	O
calcium	Chemical
antagonist,	O
on	O
epinephrine	Chemical
-induced	O
cardiomyopathy	Disease
in	O
rats.	O
With	O
2-week	O
chronic	O
epinephrine	Chemical
infusion,	O
16	O
of	O
30	O
rats	O
died	O
within	O
4	O
days,	O
and	O
severe	O
ischemic	Disease
lesions	Disease
and	O
fibrosis	Disease
of	O
the	O
left	O
ventricles	O
were	O
observed.	O
In	O
epinephrine	Chemical
-treated	O
rats,	O
left	O
atrial	O
and	O
left	O
ventricular	O
papillary	O
muscle	O
contractile	O
responses	O
to	O
isoproterenol	Chemical
were	O
reduced,	O
but	O
responses	O
to	O
calcium	Chemical
were	O
normal	O
or	O
enhanced	O
compared	O
to	O
controls.	O
Left	O
ventricular	O
alpha	O
and	O
beta	O
adrenoceptor	O
densities	O
were	O
also	O
reduced	O
compared	O
to	O
controls.	O
Treatment	O
with	O
clentiazem	Chemical
prevented	O
epinephrine	Chemical
-induced	O
death	O
(P	O
<	O
.05),	O
and	O
attenuated	O
the	O
ventricular	O
ischemic	Disease
lesions	Disease
and	O
fibrosis	Disease
,	O
in	O
a	O
dose-dependent	O
manner.	O
Left	O
atrial	O
and	O
left	O
ventricular	O
papillary	O
muscle	O
contractile	O
responses	O
to	O
isoproterenol	Chemical
were	O
reduced	O
compared	O
to	O
controls	O
in	O
groups	O
treated	O
with	O
clentiazem	Chemical
alone,	O
but	O
combined	O
with	O
epinephrine	Chemical
,	O
clentiazem	Chemical
restored	O
left	O
atrial	O
responses	O
and	O
enhanced	O
left	O
ventricular	O
papillary	O
responses	O
to	O
isoproterenol	Chemical
.	O
On	O
the	O
other	O
hand	O
clentiazem	Chemical
did	O
not	O
prevent	O
epinephrine	Chemical
-induced	O
down-regulation	O
of	O
alpha	O
and	O
beta	O
adrenoceptors.	O
Interestingly,	O
clentiazem	Chemical
,	O
infused	O
alone,	O
resulted	O
in	O
decreased	O
adrenergic	O
receptor	O
densities	O
in	O
the	O
left	O
ventricle.	O
Clentiazem	Chemical
also	O
did	O
not	O
prevent	O
the	O
enhanced	O
responses	O
to	O
calcium	Chemical
seen	O
in	O
the	O
epinephrine	Chemical
-treated	O
animals,	O
although	O
the	O
high	O
dose	O
of	O
clentiazem	Chemical
partially	O
attenuated	O
the	O
maximal	O
response	O
to	O
calcium	Chemical
compared	O
to	O
epinephrine	Chemical
-treated	O
animals.	O
In	O
conclusion,	O
clentiazem	Chemical
attenuated	O
epinephrine	Chemical
-induced	O
cardiac	Disease
injury	Disease

Cocaine	Chemical
induced	O
myocardial	Disease
ischemia	Disease
.	O
We	O
report	O
a	O
case	O
of	O
myocardial	Disease
ischemia	Disease
induced	O
by	O
cocaine	Chemical
.	O
The	O
ischemia	Disease
probably	O
induced	O
by	O
coronary	Disease
artery	Disease
spasm	Disease
was	O
reversed	O
by	O
nitroglycerin	Chemical
and	O
calcium	Chemical

Doxorubicin	Chemical
-induced	O
cardiotoxicity	Disease
monitored	O
by	O
ECG	O
in	O
freely	O
moving	O
mice.	O
A	O
new	O
model	O
to	O
test	O
potential	O
protectors.	O
In	O
laboratory	O
animals,	O
histology	O
is	O
most	O
commonly	O
used	O
to	O
study	O
doxorubicin	Chemical
-induced	O
cardiotoxicity	Disease
.	O
However,	O
for	O
monitoring	O
during	O
treatment,	O
large	O
numbers	O
of	O
animals	O
are	O
needed.	O
Recently	O
we	O
developed	O
a	O
new	O
method	O
to	O
measure	O
ECG	O
values	O
in	O
freely	O
moving	O
mice	O
by	O
telemetry.	O
With	O
this	O
model	O
we	O
investigated	O
the	O
effect	O
of	O
chronic	O
doxorubicin	Chemical
administration	O
on	O
the	O
ECG	O
of	O
freely	O
moving	O
BALB/c	O
mice	O
and	O
the	O
efficacy	O
of	O
ICRF-187	Chemical
as	O
a	O
protective	O
agent.	O
The	O
ST	O
interval	O
significantly	O
widened	O
from	O
15.0	O
+/-	O
1.5	O
to	O
56.8	O
+/-	O
11.8	O
ms	O
in	O
week	O
10	O
(7	O
weekly	O
doses	O
of	O
4	O
mg/kg	O
doxorubicin	Chemical
given	O
i.v.	O
plus	O
3	O
weeks	O
of	O
observation).	O
The	O
ECG	O
of	O
the	O
control	O
animals	O
did	O
not	O
change	O
during	O
the	O
entire	O
study.	O
After	O
sacrifice	O
the	O
hearts	O
of	O
doxorubicin	Chemical
-treated	O
animals	O
were	O
enlarged	O
and	O
the	O
atria	O
were	O
hypertrophic	Disease
.	O
As	O
this	O
schedule	O
exerted	O
more	O
toxicity	Disease
than	O
needed	O
to	O
investigate	O
protective	O
agents,	O
the	O
protection	O
of	O
ICRF-187	Chemical
was	O
determined	O
using	O
a	O
dose	O
schedule	O
with	O
lower	O
general	O
toxicity	Disease
(6	O
weekly	O
doses	O
of	O
4	O
mg/kg	O
doxorubicin	Chemical
given	O
i.v.	O
plus	O
2	O
weeks	O
of	O
observation).	O
On	O
this	O
schedule,	O
the	O
animals'	O
hearts	O
appeared	O
normal	O
after	O
sacrifice	O
and	O
ICRF-187	Chemical
(50	O
mg/kg	O
given	O
i.p.	O
1	O
h	O
before	O
doxorubicin	Chemical
)	O
provided	O
almost	O
full	O
protection.	O
These	O
data	O
were	O
confirmed	O
by	O
histology.	O
The	O
results	O
indicate	O
that	O
this	O
new	O
model	O
is	O
very	O
sensitive	O
and	O
enables	O
monitoring	O
of	O
the	O
development	O
of	O
cardiotoxicity	Disease
with	O
time.	O
These	O
findings	O
result	O
in	O
a	O
model	O
that	O
allows	O
the	O
testing	O
of	O
protectors	O
against	O
doxorubicin	Chemical
-induced	O
cardiotoxicity	Disease
as	O
demonstrated	O
by	O
the	O
protection	O
provided	O
by	O
ICRF-187	Chemical

Epinephrine	Chemical
dysrhythmogenicity	O
is	O
not	O
enhanced	O
by	O
subtoxic	O
bupivacaine	Chemical
in	O
dogs.	O
Since	O
bupivacaine	Chemical
and	O
epinephrine	Chemical
may	O
both	O
precipitate	O
dysrhythmias	Disease
,	O
circulating	O
bupivacaine	Chemical
during	O
regional	O
anesthesia	O
could	O
potentiate	O
dysrhythmogenic	O
effects	O
of	O
epinephrine	Chemical
.	O
We	O
therefore	O
examined	O
whether	O
bupivacaine	Chemical
alters	O
the	O
dysrhythmogenicity	O
of	O
subsequent	O
administration	O
of	O
epinephrine	Chemical
in	O
conscious,	O
healthy	O
dogs	O
and	O
in	O
anesthetized	O
dogs	O
with	O
myocardial	Disease
infarction	Disease
.	O
Forty-one	O
conscious	O
dogs	O
received	O
10	O
micrograms.kg-1.min-1	O
epinephrine	Chemical
.	O
Seventeen	O
animals	O
responded	O
with	O
ventricular	Disease
tachycardia	Disease
(	O
VT	Disease
)	O
within	O
3	O
min.	O
After	O
3	O
h,	O
these	O
responders	O
randomly	O
received	O
1	O
or	O
2	O
mg/kg	O
bupivacaine	Chemical
or	O
saline	O
over	O
5	O
min,	O
followed	O
by	O
10	O
micrograms.kg-1.min-1	O
epinephrine	Chemical
.	O
In	O
the	O
bupivacaine	Chemical
groups,	O
epinephrine	Chemical
caused	O
fewer	O
prodysrhythmic	O
effects	O
than	O
without	O
bupivacaine	Chemical
.	O
VT	Disease
appeared	O
in	O
fewer	O
dogs	O
and	O
at	O
a	O
later	O
time,	O
and	O
there	O
were	O
more	O
sinoatrial	O
beats	O
and	O
less	O
ectopies.	O
Epinephrine	Chemical
shortened	O
QT	O
less	O
after	O
bupivacaine	Chemical
than	O
in	O
control	O
animals.	O
One	O
day	O
after	O
experimental	O
myocardial	Disease
infarction	Disease
,	O
six	O
additional	O
halothane	Chemical
-anesthetized	O
dogs	O
received	O
4	O
micrograms.kg-1.min-1	O
epinephrine	Chemical
until	O
VT	Disease
appeared.	O
After	O
45	O
min,	O
1	O
mg/kg	O
bupivacaine	Chemical
was	O
injected	O
over	O
5	O
min,	O
again	O
followed	O
by	O
4	O
micrograms.kg-1.min-1	O
epinephrine	Chemical
.	O
In	O
these	O
dogs,	O
the	O
prodysrhythmic	O
response	O
to	O
epinephrine	Chemical
was	O
also	O
mitigated	O
by	O
preceding	O
bupivacaine	Chemical
.	O
Bupivacaine	Chemical
antagonizes	O
epinephrine	Chemical
dysrhythmogenicity	O
in	O
conscious	O
dogs	O
susceptible	O
to	O
VT	Disease
and	O
in	O
anesthetized	O
dogs	O
with	O
spontaneous	O
postinfarct	O
dysrhythmias	Disease
.	O
There	O
is	O
no	O
evidence	O
that	O
systemic	O
subtoxic	O
bupivacaine	Chemical
administration	O
enhances	O
the	O
dysrhythmogenicity	O
of	O
subsequent	O
epinephrine	Chemical

Milk-alkali	Disease
syndrome	Disease
induced	O
by	O
1,25(OH)2D	Chemical
in	O
a	O
patient	O
with	O
hypoparathyroidism	Disease
.	O
Milk-alkali	Disease
syndrome	Disease
was	O
first	O
described	O
70	O
years	O
ago	O
in	O
the	O
context	O
of	O
the	O
treatment	O
of	O
peptic	Disease
ulcer	Disease
disease	Disease
with	O
large	O
amounts	O
of	O
calcium	Chemical
and	O
alkali	Chemical
.	O
Although	O
with	O
current	O
ulcer	Disease
therapy	O
(H-2	O
blockers,	O
omeprazole	Chemical
,	O
and	O
sucralfate	Chemical
),	O
the	O
frequency	O
of	O
milk-alkali	Disease
syndrome	Disease
has	O
decreased	O
significantly,	O
the	O
classic	O
triad	O
of	O
hypercalcemia	Disease
,	O
alkalosis	Disease
,	O
and	O
renal	Disease
impairment	Disease
remains	O
the	O
hallmark	O
of	O
the	O
syndrome.	O
Milk-alkali	Disease
syndrome	Disease
can	O
present	O
serious	O
and	O
occasionally	O
life-threatening	O
illness	O
unless	O
diagnosed	O
and	O
treated	O
appropriately.	O
This	O
article	O
presents	O
a	O
patient	O
with	O
hypoparathyroidism	Disease
who	O
was	O
treated	O
with	O
calcium	Chemical
carbonate	Chemical
and	O
calcitriol	Chemical
resulting	O
in	O
two	O
admissions	O
to	O
the	O
hospital	O
for	O
milk-alkali	Disease
syndrome	Disease
.	O
The	O
patient	O
was	O
successfully	O
treated	O
with	O
intravenous	O
pamidronate	Chemical
on	O
his	O
first	O
admission	O
and	O
with	O
hydrocortisone	Chemical
on	O
the	O
second.	O
This	O
illustrates	O
intravenous	O
pamidronate	Chemical
as	O
a	O
valuable	O
therapeutic	O
tool	O
when	O
milk-alkali	Disease
syndrome	Disease
presents	O
as	O
hypercalcemic	Disease
emergency	Disease

Encephalopathy	Disease
during	O
amitriptyline	Chemical
therapy:	O
are	O
neuroleptic	Disease
malignant	Disease
syndrome	Disease
and	O
serotonin	Disease
syndrome	Disease
spectrum	O
disorders?	O
This	O
report	O
describes	O
a	O
case	O
of	O
encephalopathy	Disease
developed	O
in	O
the	O
course	O
of	O
amitriptyline	Chemical
therapy,	O
during	O
a	O
remission	O
of	O
unipolar	Disease
depression	Disease
.	O
This	O
patient	O
could	O
have	O
been	O
diagnosed	O
as	O
having	O
either	O
neuroleptic	Disease
malignant	Disease
syndrome	Disease
(	O
NMS	Disease
)	O
or	O
serotonin	Disease
syndrome	Disease
(	O
SS	Disease
).	O
The	O
major	O
determinant	O
of	O
the	O
symptoms	O
may	O
have	O
been	O
dopamine	Chemical
/	O
serotonin	Chemical
imbalance	O
in	O
the	O
central	O
nervous	O
system.	O
The	O
NMS	Disease
-like	O
encephalopathy	Disease
that	O
develops	O
in	O
association	O
with	O
the	O
use	O
of	O
antidepressants	O
indicates	O
that	O
NMS	Disease
and	O
SS	Disease

Genetic	O
separation	O
of	O
tumor	Disease
growth	O
and	O
hemorrhagic	Disease
phenotypes	O
in	O
an	O
estrogen	Chemical
-induced	O
tumor	Disease
.	O
Chronic	O
administration	O
of	O
estrogen	Chemical
to	O
the	O
Fischer	O
344	O
(F344)	O
rat	O
induces	O
growth	O
of	O
large,	O
hemorrhagic	Disease
	O
pituitary	Disease
tumors	Disease
.	O
Ten	O
weeks	O
of	O
diethylstilbestrol	Chemical
(	O
DES	Chemical
)	O
treatment	O
caused	O
female	O
F344	O
rat	O
pituitaries	O
to	O
grow	O
to	O
an	O
average	O
of	O
109.2	O
+/-	O
6.3	O
mg	O
(mean	O
+/-	O
SE)	O
versus	O
11.3	O
+/-	O
1.4	O
mg	O
for	O
untreated	O
rats,	O
and	O
to	O
become	O
highly	O
hemorrhagic	Disease
.	O
The	O
same	O
DES	Chemical
treatment	O
produced	O
no	O
significant	O
growth	O
(8.9	O
+/-	O
0.5	O
mg	O
for	O
treated	O
females	O
versus	O
8.7	O
+/-	O
1.1	O
for	O
untreated	O
females)	O
or	O
morphological	O
changes	O
in	O
Brown	O
Norway	O
(BN)	O
rat	O
pituitaries.	O
An	O
F1	O
hybrid	O
of	O
F344	O
and	O
BN	O
exhibited	O
significant	O
pituitary	O
growth	O
after	O
10	O
weeks	O
of	O
DES	Chemical
treatment	O
with	O
an	O
average	O
mass	O
of	O
26.3	O
+/-	O
0.7	O
mg	O
compared	O
with	O
8.6	O
+/-	O
0.9	O
mg	O
for	O
untreated	O
rats.	O
Surprisingly,	O
the	O
F1	O
hybrid	O
tumors	Disease
were	O
not	O
hemorrhagic	Disease
and	O
had	O
hemoglobin	O
content	O
and	O
outward	O
appearance	O
identical	O
to	O
that	O
of	O
BN.	O
Expression	O
of	O
both	O
growth	O
and	O
morphological	O
changes	O
is	O
due	O
to	O
multiple	O
genes.	O
However,	O
while	O
DES	Chemical
-induced	O
pituitary	O
growth	O
exhibited	O
quantitative,	O
additive	O
inheritance,	O
the	O
hemorrhagic	Disease
phenotype	O
exhibited	O
recessive,	O
epistatic	O
inheritance.	O
Only	O
5	O
of	O
the	O
160	O
F2	O
pituitaries	O
exhibited	O
the	O
hemorrhagic	Disease
phenotype;	O
36	O
of	O
the	O
160	O
F2	O
pituitaries	O
were	O
in	O
the	O
F344	O
range	O
of	O
mass,	O
but	O
31	O
of	O
these	O
were	O
not	O
hemorrhagic	Disease
,	O
indicating	O
that	O
the	O
hemorrhagic	Disease
phenotype	O
is	O
not	O
merely	O
a	O
consequence	O
of	O
extensive	O
growth.	O
The	O
hemorrhagic	Disease

Increased	O
expression	O
of	O
neuronal	O
nitric	Chemical
oxide	Chemical
synthase	O
in	O
bladder	O
afferent	O
pathways	O
following	O
chronic	O
bladder	Disease
irritation	Disease
.	O
Immunocytochemical	O
techniques	O
were	O
used	O
to	O
examine	O
alterations	O
in	O
the	O
expression	O
of	O
neuronal	O
nitric	Chemical
oxide	Chemical
synthase	O
(NOS)	O
in	O
bladder	O
pathways	O
following	O
acute	O
and	O
chronic	O
irritation	Disease
of	Disease
the	Disease
urinary	Disease
tract	Disease
of	O
the	O
rat.	O
Chemical	O
cystitis	Disease
was	O
induced	O
by	O
cyclophosphamide	Chemical
(	O
CYP	Chemical
)	O
which	O
is	O
metabolized	O
to	O
acrolein	Chemical
,	O
an	O
irritant	O
eliminated	O
in	O
the	O
urine.	O
Injection	O
of	O
CYP	Chemical
(n	O
=	O
10,	O
75	O
mg/kg,	O
i.p.)	O
2	O
hours	O
prior	O
to	O
perfusion	O
(acute	O
treatment)	O
of	O
the	O
animals	O
increased	O
Fos-immunoreactivity	O
(IR)	O
in	O
neurons	O
in	O
the	O
dorsal	O
commissure,	O
dorsal	O
horn,	O
and	O
autonomic	O
regions	O
of	O
spinal	O
segments	O
(L1-L2	O
and	O
L6-S1)	O
which	O
receive	O
afferent	O
inputs	O
from	O
the	O
bladder,	O
urethra,	O
and	O
ureter.	O
Fos-IR	O
in	O
the	O
spinal	O
cord	O
was	O
not	O
changed	O
in	O
rats	O
receiving	O
chronic	O
CYP	Chemical
treatment	O
(n	O
=	O
15,	O
75	O
mg/kg,	O
i.p.,	O
every	O
3rd	O
day	O
for	O
2	O
weeks).	O
In	O
control	O
animals	O
and	O
in	O
animals	O
treated	O
acutely	O
with	O
CYP	Chemical
,	O
only	O
small	O
numbers	O
of	O
NOS-IR	O
cells	O
(0.5-0.7	O
cell	O
profiles/sections)	O
were	O
detected	O
in	O
the	O
L6-S1	O
dorsal	O
root	O
ganglia	O
(DRG).	O
Chronic	O
CYP	Chemical
administration	O
significantly	O
(P	O
<	O
or	O
=	O
.002)	O
increased	O
bladder	O
weight	O
by	O
60%	O
and	O
increased	O
(7-	O
to	O
11-fold)	O
the	O
numbers	O
of	O
NOS-immunoreactive	O
(IR)	O
afferent	O
neurons	O
in	O
the	O
L6-S1	O
DRG.	O
A	O
small	O
increase	O
(1.5-fold)	O
also	O
occurred	O
in	O
the	O
L1	O
DRG,	O
but	O
no	O
change	O
was	O
detected	O
in	O
the	O
L2	O
and	O
L5	O
DRG.	O
Bladder	O
afferent	O
cells	O
in	O
the	O
L6-S1	O
DRG	O
labeled	O
by	O
Fluorogold	O
(40	O
microliters)	O
injected	O
into	O
the	O
bladder	O
wall	O
did	O
not	O
exhibit	O
NOS-IR	O
in	O
control	O
animals;	O
however,	O
following	O
chronic	O
CYP	Chemical

Effects	O
of	O
a	O
new	O
calcium	Chemical
antagonist,	O
CD-832	Chemical
,	O
on	O
isoproterenol	Chemical
-induced	O
myocardial	Disease
ischemia	Disease
in	O
dogs	O
with	O
partial	O
coronary	Disease
stenosis	Disease
.	O
Effects	O
of	O
CD-832	Chemical
on	O
isoproterenol	Chemical
(	O
ISO	Chemical
)-induced	O
myocardial	Disease
ischemia	Disease
were	O
studied	O
in	O
dogs	O
with	O
partial	O
coronary	Disease
stenosis	Disease
of	O
the	O
left	O
circumflex	O
coronary	O
artery	O
and	O
findings	O
were	O
compared	O
with	O
those	O
for	O
nifedipine	Chemical
or	O
diltiazem	Chemical
.	O
In	O
the	O
presence	O
of	O
coronary	Disease
artery	Disease
stenosis	Disease
,	O
3-min	O
periods	O
of	O
intracoronary	O
ISO	Chemical
infusion	O
(10	O
ng/kg/min)	O
increased	O
heart	O
rate	O
and	O
maximal	O
rate	O
of	O
left	O
ventricular	O
pressure	O
rise,	O
which	O
resulted	O
in	O
a	O
decrease	O
in	O
percentage	O
segmental	O
shortening	O
and	O
ST-segment	O
elevation	O
of	O
the	O
epicardial	O
electrocardiogram.	O
After	O
the	O
control	O
ISO	Chemical
infusion	O
with	O
stenosis	Disease
was	O
performed,	O
equihypotensive	O
doses	O
of	O
CD-832	Chemical
(3	O
and	O
10	O
micrograms/kg/min,	O
n	O
=	O
7),	O
nifedipine	Chemical
(1	O
and	O
3	O
micrograms/kg/min,	O
n	O
=	O
9)	O
or	O
diltiazem	Chemical
(10	O
and	O
30	O
micrograms/kg/min,	O
n	O
=	O
7)	O
were	O
infused	O
5	O
min	O
before	O
and	O
during	O
the	O
second	O
and	O
third	O
ISO	Chemical
infusion.	O
Both	O
CD-832	Chemical
and	O
diltiazem	Chemical
,	O
but	O
not	O
nifedipine	Chemical
,	O
significantly	O
reduced	O
the	O
increase	O
in	O
heart	O
rate	O
induced	O
by	O
ISO	Chemical
infusion.	O
In	O
contrast	O
to	O
nifedipine	Chemical
,	O
CD-832	Chemical
(10	O
micrograms/kg/min)	O
prevented	O
the	O
decrease	O
in	O
percentage	O
segmental	O
shortening	O
from	O
32	O
+/-	O
12%	O
to	O
115	O
+/-	O
26%	O
of	O
the	O
control	O
value	O
(P	O
<	O
.01)	O
and	O
ST-segment	O
elevation	O
from	O
5.6	O
+/-	O
1.0	O
mV	O
to	O
1.6	O
+/-	O
1.3	O
mV	O
(P	O
<	O
.01)	O
at	O
3	O
min	O
after	O
ISO	Chemical
infusion	O
with	O
stenosis	Disease
.	O
Diltiazem	Chemical
(30	O
micrograms/kg/min)	O
also	O
prevented	O
the	O
decrease	O
in	O
percentage	O
segmental	O
shortening	O
from	O
34	O
+/-	O
14%	O
to	O
63	O
+/-	O
18%	O
of	O
the	O
control	O
value	O
(P	O
<	O
.05)	O
and	O
ST-segment	O
elevation	O
from	O
4.7	O
+/-	O
0.7	O
mV	O
to	O
2.1	O
+/-	O
0.7	O
mV	O
(P	O
<	O
.01)	O
at	O
3	O
min	O
after	O
ISO	Chemical
infusion	O
with	O
stenosis	Disease
.	O
These	O
data	O
show	O
that	O
CD-832	Chemical
improves	O
myocardial	Disease
ischemia	Disease
during	O
ISO	Chemical
infusion	O
with	O
stenosis	Disease
and	O
suggest	O
that	O
the	O
negative	O
chronotropic	O
property	O
of	O
CD-832	Chemical
plays	O
a	O
major	O
role	O
in	O
the	O
beneficial	O
effects	O
of	O
CD-832	Chemical

The	O
effect	O
of	O
recombinant	O
human	O
insulin-like	O
growth	O
factor-I	O
on	O
chronic	O
puromycin	Chemical
aminonucleoside	Chemical
	O
nephropathy	Disease
in	O
rats.	O
We	O
recently	O
demonstrated	O
that	O
recombinant	O
hGH	O
exacerbates	O
renal	O
functional	O
and	O
structural	O
injury	O
in	O
chronic	O
puromycin	Chemical
aminonucleoside	Chemical
(	O
PAN	Chemical
)	O
nephropathy	Disease
,	O
an	O
experimental	O
model	O
of	O
glomerular	Disease
disease	Disease
.	O
Therefore,	O
we	O
examined	O
whether	O
recombinant	O
human	O
(rh)	O
IGF-I	O
is	O
a	O
safer	O
alternative	O
for	O
the	O
treatment	O
of	O
growth	Disease
failure	Disease
in	O
rats	O
with	O
chronic	O
PAN	Chemical
	O
nephropathy	Disease
.	O
The	O
glomerulopathy	Disease
was	O
induced	O
by	O
seven	O
serial	O
injections	O
of	O
PAN	Chemical
over	O
12	O
wk.	O
Experimental	O
animals	O
(n	O
=	O
6)	O
received	O
rhIGF-I,	O
400	O
micrograms/d,	O
whereas	O
control	O
rats	O
(n	O
=	O
6)	O
received	O
the	O
vehicle.	O
rhIGF-I	O
improved	O
weight	O
gain	O
by	O
14%	O
(p	O
<	O
0.05),	O
without	O
altering	O
hematocrit	O
or	O
blood	O
pressure	O
in	O
rats	O
with	O
renal	Disease
disease	Disease
.	O
Urinary	O
protein	O
excretion	O
was	O
unaltered	O
by	O
rhIGF-I	O
treatment	O
in	O
rats	O
with	O
chronic	O
PAN	Chemical
	O
nephropathy	Disease
.	O
After	O
12	O
wk,	O
the	O
inulin	O
clearance	O
was	O
higher	O
in	O
rhIGF-I-treated	O
rats,	O
0.48	O
+/-	O
0.08	O
versus	O
0.24	O
+/-	O
0.06	O
mL/min/100	O
g	O
of	O
body	O
weight	O
in	O
untreated	O
PAN	Chemical
	O
nephropathy	Disease
animals,	O
p	O
<	O
0.05.	O
The	O
improvement	O
in	O
GFR	O
was	O
not	O
associated	O
with	O
enhanced	O
glomerular	Disease
hypertrophy	Disease
or	O
increased	O
segmental	O
glomerulosclerosis	Disease
,	O
tubulointerstitial	Disease
injury	Disease
,	O
or	O
renal	O
cortical	O
malondialdehyde	Chemical
content.	O
In	O
rats	O
with	O
PAN	Chemical
	O
nephropathy	Disease
,	O
administration	O
of	O
rhIGF-I	O
increased	O
IGF-I	O
and	O
GH	O
receptor	O
gene	O
expression,	O
without	O
altering	O
the	O
steady	O
state	O
level	O
of	O
IGF-I	O
receptor	O
mRNA.	O
In	O
normal	O
rats	O
with	O
intact	O
kidneys,	O
rhIGF-I	O
administration	O
(n	O
=	O
4)	O
did	O
not	O
alter	O
weight	O
gain,	O
blood	O
pressure,	O
proteinuria	Disease
,	O
GFR,	O
glomerular	O
planar	O
area,	O
renal	O
cortical	O
malondialdehyde	Chemical
content,	O
or	O
glomerular	O
or	O
tubulointerstitial	Disease
damage	Disease
,	O
compared	O
with	O
untreated	O
animals	O
(n	O
=	O
4).	O
rhIGF-I	O
treatment	O
reduced	O
the	O
steady	O
state	O
renal	O
IGF-I	O
mRNA	O
level	O
but	O
did	O
not	O
modify	O
gene	O
expression	O
of	O
the	O
IGF-I	O
or	O
GH	O
receptors.	O
We	O
conclude	O
that:	O
1)	O
administration	O
of	O
rhIGF-I	O
improves	O
growth	O
and	O
GFR	O
in	O
rats	O
with	O
chronic	O
PAN	Chemical
	O
nephropathy	Disease

Nefiracetam	Chemical
(	O
DM-9384	Chemical
)	O
reverses	O
apomorphine	Chemical
-induced	O
amnesia	Disease
of	O
a	O
passive	O
avoidance	O
response:	O
delayed	O
emergence	O
of	O
the	O
memory	O
retention	O
effects.	O
Nefiracetam	Chemical
is	O
a	O
novel	O
pyrrolidone	Chemical
derivative	O
which	O
attenuates	O
scopolamine	Chemical
-induced	O
learning	Disease
and	Disease
post-training	Disease
consolidation	Disease
deficits	Disease
.	O
Given	O
that	O
apomorphine	Chemical
inhibits	O
passive	O
avoidance	O
retention	O
when	O
given	O
during	O
training	O
or	O
in	O
a	O
defined	O
10-12h	O
post-training	O
period,	O
we	O
evaluated	O
the	O
ability	O
of	O
nefiracetam	Chemical
to	O
attenuate	O
amnesia	Disease
induced	O
by	O
dopaminergic	O
agonism.	O
A	O
step-down	O
passive	O
avoidance	O
paradigm	O
was	O
employed	O
and	O
nefiracetam	Chemical
(3	O
mg/kg)	O
and	O
apomorphine	Chemical
(0.5	O
mg/kg)	O
were	O
given	O
alone	O
or	O
in	O
combination	O
during	O
training	O
and	O
at	O
the	O
10-12h	O
post-training	O
period	O
of	O
consolidation.	O
Co-administration	O
of	O
nefiracetam	Chemical
and	O
apomorphine	Chemical
during	O
training	O
or	O
10h	O
thereafter	O
produced	O
no	O
significant	O
anti-amnesic	O
effect.	O
However,	O
administration	O
of	O
nefiracetam	Chemical
during	O
training	O
completely	O
reversed	O
the	O
amnesia	Disease
induced	O
by	O
apomorphine	Chemical
at	O
the	O
10h	O
post-training	O
time	O
and	O
the	O
converse	O
was	O
also	O
true.	O
These	O
effects	O
were	O
not	O
mediated	O
by	O
a	O
dopaminergic	O
mechanism	O
as	O
nefiracetam	Chemical
,	O
at	O
millimolar	O
concentrations,	O
failed	O
to	O
displace	O
either	O
[3H]	O
SCH	Chemical
23390	Chemical
or	O
[3H]	O
spiperone	Chemical
binding	O
from	O
D1	O
or	O
D2	O
dopamine	Chemical
receptor	O
subtypes,	O
respectively.	O
It	O
is	O
suggested	O
that	O
nefiracetam	Chemical

Human	O
corticotropin	Chemical
-releasing	O
hormone	O
and	O
thyrotropin	Chemical
-releasing	O
hormone	O
modulate	O
the	O
hypercapnic	Disease
ventilatory	O
response	O
in	O
humans.	O
Human	O
corticotropin	Chemical
-releasing	O
hormone	O
(hCRH)	O
and	O
thyrotropin	Chemical
-releasing	O
hormone	O
(TRH)	O
are	O
known	O
to	O
stimulate	O
ventilation	O
after	O
i.v.	O
administration	O
in	O
humans.	O
In	O
a	O
placebo-controlled,	O
single-blind	O
study	O
we	O
aimed	O
to	O
clarify	O
if	O
both	O
peptides	O
act	O
by	O
altering	O
central	O
chemosensitivity.	O
Two	O
subsequent	O
CO2	Chemical
-rebreathing	O
tests	O
were	O
performed	O
in	O
healthy	O
young	O
volunteers.	O
During	O
the	O
first	O
test	O
0.9%	O
NaCl	Chemical
was	O
given	O
i.v.;	O
during	O
the	O
second	O
test	O
200	O
micrograms	O
of	O
hCRH	O
(n	O
=	O
12)	O
or	O
400	O
micrograms	O
of	O
TRH	O
(n	O
=	O
6)	O
was	O
administered	O
i.v.	O
Nine	O
subjects	O
received	O
0.9%	O
NaCl	Chemical
i.v.	O
during	O
both	O
rebreathing	O
manoeuvres.	O
The	O
CO2	Chemical
-response	O
curves	O
for	O
the	O
two	O
tests	O
were	O
compared	O
within	O
the	O
same	O
subject.	O
In	O
the	O
hCRH	O
group	O
a	O
marked	O
parallel	O
shift	O
of	O
the	O
CO2	Chemical
-response	O
curve	O
to	O
the	O
left	O
was	O
observed	O
after	O
hCRH	O
(P	O
<	O
0.01).	O
The	O
same	O
effect	O
occurred	O
following	O
TRH	O
but	O
was	O
less	O
striking	O
(P	O
=	O
0.05).	O
hCRH	O
and	O
TRH	O
caused	O
a	O
reduction	O
in	O
the	O
CO2	Chemical
threshold.	O
The	O
CO2	Chemical
-response	O
curves	O
in	O
the	O
control	O
group	O
were	O
nearly	O
identical.	O
The	O
results	O
indicate	O
an	O
additive	O
effect	O
of	O
both	O
releasing	O
hormones	O
on	O
the	O
hypercapnic	Disease

Lamivudine	Chemical
is	O
effective	O
in	O
suppressing	O
hepatitis	Disease
B	Disease
virus	O
DNA	O
in	O
Chinese	O
hepatitis	Chemical
B	Chemical
surface	Chemical
antigen	Chemical
carriers:	O
a	O
placebo-controlled	O
trial.	O
Lamivudine	Chemical
is	O
a	O
novel	O
2',3'-dideoxy	Chemical
cytosine	Chemical
analogue	O
that	O
has	O
potent	O
inhibitory	O
effects	O
on	O
hepatitis	Disease
B	Disease
virus	O
replication	O
in	O
vitro	O
and	O
in	O
vivo.	O
We	O
performed	O
a	O
single-blind,	O
placebo-controlled	O
study	O
to	O
assess	O
its	O
effectiveness	O
and	O
safety	O
in	O
Chinese	O
hepatitis	Chemical
B	Chemical
surface	Chemical
antigen	Chemical
(	O
HBsAg	Chemical
)	O
carriers.	O
Forty-two	O
Chinese	O
HBsAg	Chemical
carriers	O
were	O
randomized	O
to	O
receive	O
placebo	O
(6	O
patients)	O
or	O
lamivudine	Chemical
orally	O
in	O
dosages	O
of	O
25	O
mg,	O
100	O
mg,	O
or	O
300	O
mg	O
daily	O
(12	O
patients	O
for	O
each	O
dosage).	O
The	O
drug	O
was	O
given	O
for	O
4	O
weeks.	O
The	O
patients	O
were	O
closely	O
monitored	O
clinically,	O
biochemically,	O
and	O
serologically	O
up	O
to	O
4	O
weeks	O
after	O
drug	O
treatment.	O
All	O
36	O
patients	O
receiving	O
lamivudine	Chemical
had	O
a	O
decrease	O
in	O
hepatitis	Disease
B	Disease
virus	O
(HBV)	O
DNA	O
values	O
of	O
>90%	O
(P	O
<	O
.001	O
compared	O
with	O
placebo).	O
Although	O
25	O
mg	O
of	O
lamivudine	Chemical
was	O
slightly	O
less	O
effective	O
than	O
100	O
mg	O
(P	O
=	O
.011)	O
and	O
300	O
mg	O
(P	O
=	O
.005),	O
it	O
still	O
induced	O
94%	O
suppression	O
of	O
HBV	O
DNA	O
after	O
the	O
fourth	O
week	O
of	O
therapy.	O
HBV	O
DNA	O
values	O
returned	O
to	O
pretreatment	O
levels	O
within	O
4	O
weeks	O
of	O
cessation	O
of	O
therapy.	O
There	O
was	O
no	O
change	O
in	O
the	O
hepatitis	Disease
B	Disease
e	O
antigen	O
status	O
or	O
in	O
aminotransferase	O
levels.	O
No	O
serious	O
adverse	O
events	O
were	O
observed.	O
In	O
conclusion,	O
a	O
4-week	O
course	O
of	O
lamivudine	Chemical
was	O
safe	O
and	O
effective	O
in	O
suppression	O
of	O
HBV	O
DNA	O
in	O
Chinese	O
HBsAg	Chemical
carriers.	O
The	O
suppression	O
was	O
>90%	O
but	O
reversible.	O
Studies	O
with	O
long-term	O
lamivudine	Chemical

Population-based	O
study	O
of	O
risk	O
of	O
venous	Disease
thromboembolism	Disease
associated	O
with	O
various	O
oral	Chemical
contraceptives	Chemical
.	O
BACKGROUND:	O
Four	O
studies	O
published	O
since	O
December,	O
1995,	O
reported	O
that	O
the	O
incidence	O
of	O
venous	Disease
thromboembolism	Disease
(	O
VTE	Disease
)	O
was	O
higher	O
in	O
women	O
who	O
used	O
oral	Chemical
contraceptives	Chemical
(	O
OCs	Chemical
)	O
containing	O
the	O
third-generation	O
progestagens	Chemical
	O
gestodene	Chemical
or	O
desogestrel	Chemical
than	O
in	O
users	O
of	O
OCs	Chemical
containing	O
second-generation	O
progestagens	Chemical
.	O
However,	O
confounding	O
and	O
bias	O
in	O
the	O
design	O
of	O
these	O
studies	O
may	O
have	O
affected	O
the	O
findings.	O
The	O
aim	O
of	O
our	O
study	O
was	O
to	O
re-examine	O
the	O
association	O
between	O
risk	O
of	O
VTE	Disease
and	O
OC	Chemical
use	O
with	O
a	O
different	O
study	O
design	O
and	O
analysis	O
to	O
avoid	O
some	O
of	O
the	O
bias	O
and	O
confounding	O
of	O
the	O
earlier	O
studies.	O
METHODS:	O
We	O
used	O
computer	O
records	O
of	O
patients	O
from	O
143	O
general	O
practices	O
in	O
the	O
UK.	O
The	O
study	O
was	O
based	O
on	O
the	O
medical	O
records	O
of	O
about	O
540,000	O
women	O
born	O
between	O
1941	O
and	O
1981.	O
All	O
women	O
who	O
had	O
a	O
recorded	O
diagnosis	O
of	O
deep-vein	Disease
thrombosis	Disease
,	O
venous	Disease
thrombosis	Disease
not	O
otherwise	O
specified,	O
or	O
pulmonary	O
embolus	O
during	O
the	O
study	O
period,	O
and	O
who	O
had	O
been	O
treated	O
with	O
an	O
anticoagulant	O
were	O
identified	O
as	O
potential	O
cases	O
of	O
VTE	Disease
.	O
We	O
did	O
a	O
cohort	O
analysis	O
to	O
estimate	O
and	O
compare	O
incidence	O
of	O
VTE	Disease
in	O
users	O
of	O
the	O
main	O
OC	Chemical
preparations,	O
and	O
a	O
nested	O
case-control	O
study	O
to	O
calculate	O
the	O
odds	O
ratios	O
of	O
VTE	Disease
associated	O
with	O
use	O
of	O
different	O
types	O
of	O
OC	Chemical
,	O
after	O
adjustment	O
for	O
potential	O
confounding	O
factors.	O
In	O
the	O
case-control	O
study,	O
we	O
matched	O
cases	O
to	O
controls	O
by	O
exact	O
year	O
of	O
birth,	O
practice,	O
and	O
current	O
use	O
of	O
OCs	Chemical
.	O
We	O
used	O
a	O
multiple	O
logistic	O
regression	O
model	O
that	O
included	O
body-mass	O
index,	O
number	O
of	O
cycles,	O
change	O
in	O
type	O
of	O
OC	Chemical
prescribed	O
within	O
3	O
months	O
of	O
the	O
event,	O
previous	O
pregnancy,	O
and	O
concurrent	O
disease.	O
FINDINGS:	O
85	O
women	O
met	O
the	O
inclusion	O
criteria	O
for	O
VTE	Disease
,	O
two	O
of	O
whom	O
were	O
users	O
of	O
progestagen	Chemical
-only	O
OCs	Chemical
.	O
Of	O
the	O
83	O
cases	O
of	O
VTE	Disease
associated	O
with	O
use	O
of	O
combined	O
OCs	Chemical
,	O
43	O
were	O
recorded	O
as	O
deep-vein	Disease
thrombosis	Disease
,	O
35	O
as	O
pulmonary	O
thrombosis	Disease
,	O
and	O
five	O
as	O
venous	Disease
thrombosis	Disease
not	O
otherwise	O
specified.	O
The	O
crude	O
rate	O
of	O
VTE	Disease
per	O
10,000	O
woman-years	O
was	O
4.10	O
in	O
current	O
users	O
of	O
any	O
OC	Chemical
,	O
3.10	O
in	O
users	O
of	O
second-generation	O
OCs	Chemical
,	O
and	O
4.96	O
in	O
users	O
of	O
third-generation	O
preparations.	O
After	O
adjustment	O
for	O
age,	O
the	O
rate	O
ratio	O
of	O
VTE	Disease
in	O
users	O
of	O
third-generation	O
relative	O
to	O
second-generation	O
OCs	Chemical
was	O
1.68	O
(95%	O
CI	O
1.04-2.75).	O
Logistic	O
regression	O
showed	O
no	O
significant	O
difference	O
in	O
the	O
risk	O
of	O
VTE	Disease
between	O
users	O
of	O
third-generation	O
and	O
second-generation	O
OCs	Chemical
.	O
Among	O
users	O
of	O
third-generation	O
progestagens	Chemical
,	O
the	O
risk	O
of	O
VTE	Disease
was	O
higher	O
in	O
users	O
of	O
desogestrel	Chemical
with	O
20	O
g	O
ethinyloestradiol	Chemical
than	O
in	O
users	O
of	O
gestodene	Chemical
or	O
desogestrel	Chemical
with	O
30	O
g	O
ethinyloestradiol	Chemical
.	O
With	O
all	O
second-generation	O
OCs	Chemical
as	O
the	O
reference,	O
the	O
odds	O
ratios	O
for	O
VTE	Disease
were	O
3.49	O
(1.21-10.12)	O
for	O
desogestrel	Chemical
plus	O
20	O
g	O
ethinyloestradiol	Chemical
and	O
1.18	O
(0.66-2.17)	O
for	O
the	O
other	O
third-generation	O
progestagens	Chemical
.	O
INTERPRETATION:	O
The	O
previously	O
reported	O
increase	O
in	O
odds	O
ratio	O
associated	O
with	O
third-generation	O
OCs	Chemical
when	O
compared	O
with	O
second-generation	O
products	O
is	O
likely	O
to	O
have	O
been	O
the	O
result	O
of	O
residual	O
confounding	O
by	O
age.	O
The	O
increased	O
odds	O
ratio	O
associated	O
with	O
products	O
containing	O
20	O
micrograms	O
ethinyloestradiol	Chemical
and	O
desogestrel	Chemical

MK-801	Chemical
augments	O
pilocarpine	Chemical
-induced	O
electrographic	O
seizure	Disease
but	O
protects	O
against	O
brain	Disease
damage	Disease
in	O
rats.	O
1.	O
The	O
authors	O
examined	O
the	O
anticonvulsant	O
effects	O
of	O
MK-801	Chemical
on	O
the	O
pilocarpine	Chemical
-induced	O
seizure	Disease
model.	O
Intraperitoneal	O
injection	O
of	O
pilocarpine	Chemical
(400	O
mg/kg)	O
induced	O
tonic	Disease
and	Disease
clonic	Disease
seizure	Disease
.	O
Scopolamine	Chemical
(10	O
mg/kg)	O
and	O
pentobarbital	Chemical
(5	O
mg/kg)	O
prevented	O
development	O
of	O
pilocarpine	Chemical
-induced	O
behavioral	O
seizure	Disease
but	O
MK-801	Chemical
(0.5	O
mg/kg)	O
did	O
not.	O
2.	O
An	O
electrical	O
seizure	Disease
measured	O
with	O
hippocampal	O
EEG	O
appeared	O
in	O
the	O
pilocarpine	Chemical
-treated	O
group.	O
Scopolamine	Chemical
and	O
pentobarbital	Chemical
blocked	O
the	O
pilocarpine	Chemical
-induced	O
electrographic	O
seizure	Disease
,	O
MK-801	Chemical
treatment	O
augmented	O
the	O
electrographic	O
seizure	Disease
induced	O
by	O
pilocarpine	Chemical
.	O
3.	O
Brain	Disease
damage	Disease
was	O
assessed	O
by	O
examining	O
the	O
hippocampus	O
microscopically.	O
Pilocarpine	Chemical
produced	O
neuronal	Disease
death	Disease
in	O
the	O
hippocampus,	O
which	O
showed	O
pyknotic	O
changes.	O
Pentobarbital	Chemical
,	O
scopolamine	Chemical
and	O
MK-801	Chemical
protected	O
the	O
brain	Disease
damage	Disease
by	O
pilocarpine	Chemical
,	O
though	O
in	O
the	O
MK-801	Chemical
-treated	O
group,	O
the	O
pyramidal	O
cells	O
of	O
hippocampus	O
appeared	O
darker	O
than	O
normal.	O
In	O
all	O
treatments,	O
granule	O
cells	O
of	O
the	O
dentate	O
gyrus	O
were	O
not	O
affected.	O
4.	O
These	O
results	O
indicate	O
that	O
status	Disease
epilepticus	Disease
induced	O
by	O
pilocarpine	Chemical
is	O
initiated	O
by	O
cholinergic	O
overstimulation	O
and	O
propagated	O
by	O
glutamatergic	O
transmission,	O
the	O
elevation	O
of	O
which	O
may	O
cause	O
brain	Disease
damage	Disease
through	O
an	O
excitatory	O
NMDA	Chemical

Paclitaxel	Chemical
,	O
5-fluorouracil	Chemical
,	O
and	O
folinic	Chemical
acid	Chemical
in	O
metastatic	O
breast	Disease
cancer	Disease
:	O
BRE-26,	O
a	O
phase	O
II	O
trial.	O
5-Fluorouracil	Chemical
plus	O
folinic	Chemical
acid	Chemical
and	O
paclitaxel	Chemical
(	O
Taxol	Chemical
;	O
Bristol-Myers	O
Squibb	O
Company,	O
Princeton,	O
NJ)	O
are	O
effective	O
salvage	O
therapies	O
for	O
metastatic	O
breast	Disease
cancer	Disease
patients.	O
Paclitaxel	Chemical
and	O
5-fluorouracil	Chemical
have	O
additive	O
cytotoxicity	Disease
in	O
MCF-7	O
cell	O
lines.	O
We	O
performed	O
a	O
phase	O
II	O
trial	O
of	O
paclitaxel	Chemical
175	O
mg/m2	O
over	O
3	O
hours	O
on	O
day	O
I	O
followed	O
by	O
folinic	Chemical
acid	Chemical
300	O
mg	O
over	O
1	O
hour	O
before	O
5-fluorouracil	Chemical
350	O
mg/m2	O
on	O
days	O
1	O
to	O
3	O
every	O
28	O
days	O
(TFL)	O
in	O
women	O
with	O
metastatic	O
breast	Disease
cancer	Disease
.	O
Analysis	O
is	O
reported	O
on	O
37	O
patients	O
with	O
a	O
minimum	O
of	O
6	O
months	O
follow-up	O
who	O
received	O
a	O
total	O
of	O
192	O
cycles	O
of	O
TFL:	O
nine	O
cycles	O
(5%)	O
were	O
associated	O
with	O
grade	O
3/4	O
neutropenia	Disease
requiring	O
hospitalization;	O
seven	O
(4%)	O
cycles	O
in	O
two	O
patients	O
required	O
granulocyte	Chemical
colony-stimulating	Chemical
factor	Chemical
due	O
to	O
neutropenia	Disease
;	O
no	O
patient	O
required	O
platelet	O
transfusions.	O
Grade	O
3/4	O
nonhematologic	O
toxicities	Disease
were	O
uncommon.	O
Among	O
the	O
34	O
patients	O
evaluable	O
for	O
response,	O
there	O
were	O
three	O
complete	O
responses	O
(9%)	O
and	O
18	O
partial	O
responses	O
(53%)	O
for	O
an	O
overall	O
response	O
rate	O
of	O
62%.	O
Of	O
the	O
19	O
evaluable	O
patients	O
with	O
prior	O
doxorubicin	Chemical
exposure,	O
11	O
(58%)	O
responded	O
compared	O
with	O
nine	O
of	O
15	O
(60%)	O
without	O
prior	O
doxorubicin	Chemical
.	O
Plasma	O
paclitaxel	Chemical
concentrations	O
were	O
measured	O
at	O
the	O
completion	O
of	O
paclitaxel	Chemical
infusion	O
and	O
at	O
24	O
hours	O
in	O
19	O
patients.	O
TFL	O
is	O
an	O
active,	O
well-tolerated	O
regimen	O
in	O
metastatic	O
breast	Disease
cancer	Disease

Efficacy	O
and	O
proarrhythmia	Disease
with	O
the	O
use	O
of	O
d,l-sotalol	Chemical
for	O
sustained	O
ventricular	Disease
tachyarrhythmias	Disease
.	O
This	O
study	O
prospectively	O
evaluated	O
the	O
clinical	O
efficacy,	O
the	O
incidence	O
of	O
torsades	Disease
de	Disease
pointes	Disease
,	O
and	O
the	O
presumable	O
risk	O
factors	O
for	O
torsades	Disease
de	Disease
pointes	Disease
in	O
patients	O
treated	O
with	O
d,l-sotalol	Chemical
for	O
sustained	O
ventricular	Disease
tachyarrhythmias	Disease
.	O
Eighty-one	O
consecutive	O
patients	O
(54	O
with	O
coronary	Disease
artery	Disease
disease	Disease
,	O
and	O
20	O
with	O
dilated	Disease
cardiomyopathy	Disease
)	O
with	O
inducible	O
sustained	O
ventricular	Disease
tachycardia	Disease
or	O
ventricular	Disease
fibrillation	Disease
received	O
oral	O
d,l-sotalol	Chemical
to	O
prevent	O
induction	O
of	O
the	O
ventricular	Disease
tachyarrhythmia	Disease
.	O
During	O
oral	O
loading	O
with	O
d,l-sotalol	Chemical
,	O
continuous	O
electrocardiographic	O
(ECG)	O
monitoring	O
was	O
performed.	O
Those	O
patients	O
in	O
whom	O
d,l-sotalol	Chemical
prevented	O
induction	O
of	O
ventricular	Disease
tachycardia	Disease
or	O
ventricular	Disease
fibrillation	Disease
were	O
discharged	O
with	O
the	O
drug	O
and	O
followed	O
up	O
on	O
an	O
outpatient	O
basis	O
for	O
21	O
+/-	O
18	O
months.	O
Induction	O
of	O
the	O
ventricular	Disease
tachyarrhythmia	Disease
was	O
prevented	O
by	O
oral	O
d,l-sotalol	Chemical
in	O
35	O
(43%)	O
patients;	O
the	O
ventricular	Disease
tachyarrhythmia	Disease
remained	O
inducible	O
in	O
40	O
(49%)	O
patients;	O
and	O
two	O
(2.5%)	O
patients	O
did	O
not	O
tolerate	O
even	O
40	O
mg	O
of	O
d,l-sotalol	Chemical
once	O
daily.	O
Four	O
(5%)	O
patients	O
had	O
from	O
torsades	Disease
de	Disease
pointes	Disease
during	O
the	O
initial	O
oral	O
treatment	O
with	O
d,l-sotalol	Chemical
.	O
Neither	O
ECG	O
[sinus-cycle	O
length	O
(SCL),	O
QT	O
or	O
QTc	O
interval,	O
or	O
U	O
wave]	O
nor	O
clinical	O
parameters	O
identified	O
patients	O
at	O
risk	O
for	O
torsades	Disease
de	Disease
pointes	Disease
.	O
However,	O
the	O
oral	O
dose	O
of	O
d,l-sotalol	Chemical
was	O
significantly	O
lower	O
in	O
patients	O
with	O
torsades	Disease
de	Disease
pointes	Disease
(200	O
+/-	O
46	O
vs.	O
328	O
+/-	O
53	O
mg/day;	O
p	O
=	O
0.0017).	O
Risk	O
factors	O
associated	O
with	O
the	O
development	O
of	O
torsades	Disease
de	Disease
pointes	Disease
were	O
the	O
appearance	O
of	O
an	O
U	O
wave	O
(p	O
=	O
0.049),	O
female	O
gender	O
(p	O
=	O
0.015),	O
and	O
significant	O
dose-corrected	O
changes	O
of	O
SCL,	O
QT	O
interval,	O
and	O
QTc	O
interval	O
(p	O
<	O
0.05).	O
During	O
follow-up,	O
seven	O
(20%)	O
patients	O
had	O
a	O
nonfatal	O
ventricular	Disease
tachycardia	Disease
recurrence,	O
and	O
two	O
(6%)	O
patients	O
died	O
suddenly.	O
One	O
female	O
patient	O
with	O
stable	O
cardiac	Disease
disease	Disease
had	O
recurrent	O
torsades	Disease
de	Disease
pointes	Disease
after	O
2	O
years	O
of	O
successful	O
treatment	O
with	O
d,l-sotalol	Chemical
.	O
Torsades	Disease
de	Disease
pointes	Disease
occurred	O
early	O
during	O
treatment	O
even	O
with	O
low	O
doses	O
of	O
oral	O
d,l-sotalol	Chemical
.	O
Pronounced	O
changes	O
in	O
the	O
surface	O
ECG	O
(cycle	O
length,	O
QT,	O
and	O
QTc)	O
in	O
relation	O
to	O
the	O
dose	O
of	O
oral	O
d,l-sotalol	Chemical
might	O
identify	O
a	O
subgroup	O
of	O
patients	O
with	O
an	O
increased	O
risk	O
for	O
torsades	Disease
de	Disease
pointes	Disease
.	O
Other	O
ECG	O
parameters	O
before	O
the	O
application	O
of	O
d,l-sotalol	Chemical
did	O
not	O
identify	O
patients	O
at	O
increased	O
risk	O
for	O
torsades	Disease
de	Disease
pointes	Disease
.	O
Recurrence	O
rates	O
of	O
ventricular	Disease
tachyarrhythmias	Disease
are	O
high	O
despite	O
complete	O
suppression	O
of	O
the	O
arrhythmia	Disease
during	O
programmed	O
stimulation.	O
Therefore	O
programmed	O
electrical	O
stimulation	O
in	O
the	O
case	O
of	O
d,l-sotalol	Chemical

Chronic	O
hyperprolactinemia	Disease
and	O
changes	O
in	O
dopamine	Chemical
neurons.	O
The	O
tuberoinfundibular	O
dopaminergic	O
(TIDA)	O
system	O
is	O
known	O
to	O
inhibit	O
prolactin	O
(PRL)	O
secretion.	O
In	O
young	O
animals	O
this	O
system	O
responds	O
to	O
acute	O
elevations	O
in	O
serum	O
PRL	O
by	O
increasing	O
its	O
activity.	O
However,	O
this	O
responsiveness	O
is	O
lost	O
in	O
aging	O
rats	O
with	O
chronically	O
high	O
serum	O
PRL	O
levels.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
induce	O
hyperprolactinemia	Disease
in	O
rats	O
for	O
extended	O
periods	O
of	O
time	O
and	O
examine	O
its	O
effects	O
on	O
dopaminergic	O
systems	O
in	O
the	O
brain.	O
Hyperprolactinemia	Disease
was	O
induced	O
by	O
treatment	O
with	O
haloperidol	Chemical
,	O
a	O
dopamine	Chemical
receptor	O
antagonist,	O
and	O
Palkovits'	O
microdissection	O
technique	O
in	O
combination	O
with	O
high-performance	O
liquid	O
chromatography	O
was	O
used	O
to	O
measure	O
neurotransmitter	O
concentrations	O
in	O
several	O
areas	O
of	O
the	O
brain.	O
After	O
6	O
months	O
of	O
hyperprolactinemia	Disease
,	O
dopamine	Chemical
(	O
DA	Chemical
)	O
concentrations	O
in	O
the	O
median	O
eminence	O
(ME)	O
increased	O
by	O
84%	O
over	O
the	O
control	O
group.	O
Nine	O
months	O
of	O
hyperprolactinemia	Disease
produced	O
a	O
50%	O
increase	O
in	O
DA	Chemical
concentrations	O
in	O
the	O
ME	O
over	O
the	O
control	O
group.	O
However,	O
DA	Chemical
response	O
was	O
lost	O
if	O
a	O
9-month	O
long	O
haloperidol	Chemical
-induced	O
hyperprolactinemia	Disease
was	O
followed	O
by	O
a	O
1	O
1/2	O
month-long	O
extremely	O
high	O
increase	O
in	O
serum	O
PRL	O
levels	O
produced	O
by	O
implantation	O
of	O
MMQ	O
cells	O
under	O
the	O
kidney	O
capsule.	O
There	O
was	O
no	O
change	O
in	O
the	O
levels	O
of	O
DA	Chemical
,	O
norepinephrine	Chemical
(	O
NE	Chemical
),	O
serotonin	Chemical
(	O
5-HT	Chemical
),	O
or	O
their	O
metabolites	O
in	O
the	O
arcuate	O
nucleus	O
(AN),	O
medial	O
preoptic	O
area	O
(MPA),	O
caudate	O
putamen	O
(CP),	O
substantia	O
nigra	O
(SN),	O
and	O
zona	O
incerta	O
(ZI),	O
except	O
for	O
a	O
decrease	O
in	O
5-hydroxyindoleacetic	Chemical
acid	Chemical
(	O
5-HIAA	Chemical
)	O
in	O
the	O
AN	O
after	O
6-months	O
of	O
hyperprolactinemia	Disease
and	O
an	O
increase	O
in	O
DA	Chemical
concentrations	O
in	O
the	O
AN	O
after	O
9-months	O
of	O
hyperprolactinemia	Disease
.	O
These	O
results	O
demonstrate	O
that	O
hyperprolactinemia	Disease
specifically	O
affects	O
TIDA	O
neurons	O
and	O
these	O
effects	O
vary,	O
depending	O
on	O
the	O
duration	O
and	O
intensity	O
of	O
hyperprolactinemia	Disease
.	O
The	O
age-related	O
decrease	O
in	O
hypothalamic	O
dopamine	Chemical

Treatment-related	O
disseminated	O
necrotizing	O
leukoencephalopathy	Disease
with	O
characteristic	O
contrast	O
enhancement	O
of	O
the	O
white	O
matter.	O
This	O
report	O
describes	O
unique	O
contrast	O
enhancement	O
of	O
the	O
white	O
matter	O
on	O
T1-weighted	O
magnetic	O
resonance	O
images	O
of	O
two	O
patients	O
with	O
disseminated	O
necrotizing	O
leukoencephalopathy	Disease
,	O
which	O
developed	O
from	O
acute	Disease
lymphoblastic	Disease
leukemia	Disease
treated	O
with	O
high-dose	O
methotrexate	Chemical
.	O
In	O
both	O
patients,	O
the	O
enhancement	O
was	O
more	O
pronounced	O
near	O
the	O
base	O
of	O
the	O
brain	O
than	O
at	O
the	O
vertex.	O
Necropsy	O
of	O
the	O
first	O
case	O
revealed	O
loss	Disease
of	Disease
myelination	Disease
and	O
necrosis	Disease
of	O
the	O
white	O
matter.	O
Possible	O
mechanisms	O
causing	O
such	O
a	O
leukoencephalopathy	Disease

Thrombotic	Disease
complications	O
in	O
acute	Disease
promyelocytic	Disease
leukemia	Disease
during	O
all-trans-retinoic	Chemical
acid	Chemical
therapy.	O
A	O
case	O
of	O
acute	Disease
renal	Disease
failure	Disease
,	O
due	O
to	O
occlusion	Disease
of	Disease
renal	Disease
vessels	Disease
in	O
a	O
patient	O
with	O
acute	Disease
promyelocytic	Disease
leukemia	Disease
(	O
APL	Disease
)	O
treated	O
with	O
all-trans-retinoic	Chemical
acid	Chemical
(	O
ATRA	Chemical
)	O
and	O
tranexamic	Chemical
acid	Chemical
has	O
been	O
described	O
recently.	O
We	O
report	O
a	O
case	O
of	O
acute	Disease
renal	Disease
failure	Disease
in	O
an	O
APL	Disease
patient	O
treated	O
with	O
ATRA	Chemical
alone.	O
This	O
case	O
further	O
supports	O
the	O
concern	O
about	O
thromboembolic	Disease
complications	O
associated	O
with	O
ATRA	Chemical
therapy	O
in	O
APL	Disease
patients.	O
The	O
patients,	O
a	O
43-year-old	O
man,	O
presented	O
all	O
the	O
signs	O
and	O
symptoms	O
of	O
APL	Disease
and	O
was	O
included	O
in	O
a	O
treatment	O
protocol	O
with	O
ATRA	Chemical
.	O
After	O
10	O
days	O
of	O
treatment,	O
he	O
developed	O
acute	Disease
renal	Disease
failure	Disease
that	O
was	O
completely	O
reversible	O
after	O
complete	O
remission	O
of	O
APL	Disease
was	O
achieved	O
and	O
therapy	O
discontinued.	O
We	O
conclude	O
that	O
ATRA	Chemical
is	O
a	O
valid	O
therapeutic	O
choice	O
for	O
patients	O
with	O
APL	Disease
,	O
although	O
the	O
procoagulant	O
tendency	O
is	O
not	O
completely	O
corrected.	O
Thrombotic	Disease
events,	O
however,	O
could	O
be	O
avoided	O
by	O
using	O
low-dose	O
heparin	Chemical

Pupillary	O
changes	O
associated	O
with	O
the	O
development	O
of	O
stimulant-induced	O
mania	Disease
:	O
a	O
case	O
report.	O
A	O
30-year-old	O
cocaine	Chemical
-dependent	O
man	O
who	O
was	O
a	O
subject	O
in	O
a	O
study	O
evaluating	O
the	O
anticraving	O
efficacy	O
of	O
the	O
stimulant	O
medication	O
diethylpropion	Chemical
(	O
DEP	Chemical
)	O
became	O
manic	Disease
during	O
his	O
second	O
week	O
on	O
the	O
study	O
drug.	O
Pupillometric	O
changes	O
while	O
on	O
DEP	Chemical
,	O
especially	O
changes	O
in	O
the	O
total	O
power	O
of	O
pupillary	Disease
oscillation	Disease
,	O
were	O
dramatically	O
different	O
than	O
those	O
observed	O
in	O
the	O
eight	O
other	O
study	O
subjects	O
who	O
did	O
not	O
become	O
manic	Disease
.	O
The	O
large	O
changes	O
in	O
total	O
power	O
of	O
pupillary	Disease
oscillation	Disease
occurred	O
a	O
few	O
days	O
before	O
the	O
patient	O
became	O
fully	O
manic	Disease
.	O
Such	O
medication-associated	O
changes	O
in	O
the	O
total	O
power	O
of	O
pupillary	Disease
oscillation	Disease
might	O
be	O
of	O
utility	O
in	O
identifying	O
persons	O
at	O
risk	O
for	O
manic	Disease

The	O
negative	O
mucosal	O
potential:	O
separating	O
central	O
and	O
peripheral	O
effects	O
of	O
NSAIDs	O
in	O
man.	O
OBJECTIVE:	O
We	O
wanted	O
to	O
test	O
whether	O
assessment	O
of	O
both	O
a	O
central	O
pain	Disease
-related	O
signal	O
(chemo-somatosensory	O
evoked	O
potential,	O
CSSEP)	O
and	O
a	O
concomitantly	O
recorded	O
peripheral	O
signal	O
(negative	O
mucosal	O
potential,	O
NMP)	O
allows	O
for	O
separation	O
of	O
central	O
and	O
peripheral	O
effects	O
of	O
NSAIDs.	O
For	O
this	O
purpose,	O
experimental	O
conditions	O
were	O
created	O
in	O
which	O
NSAIDs	O
had	O
previously	O
been	O
observed	O
to	O
produce	O
effects	O
on	O
phasic	O
and	O
tonic	O
pain	Disease
by	O
either	O
central	O
or	O
peripheral	O
mechanisms.	O
METHODS:	O
According	O
to	O
a	O
double-blind,	O
randomised,	O
controlled,	O
threefold	O
cross-over	O
design,	O
18	O
healthy	O
subjects	O
(11	O
males,	O
7	O
females;	O
mean	O
age	O
26	O
years)	O
received	O
either	O
placebo,	O
400	O
mg	O
ibuprofen	Chemical
,	O
or	O
800	O
mg	O
ibuprofen	Chemical
.	O
Phasic	O
pain	Disease
was	O
applied	O
by	O
means	O
of	O
short	O
pulses	O
of	O
CO2	Chemical
to	O
the	O
nasal	O
mucosa	O
(stimulus	O
duration	O
500	O
ms,	O
interval	O
approximately	O
60	O
s),	O
and	O
tonic	O
pain	Disease
was	O
induced	O
in	O
the	O
nasal	O
cavity	O
by	O
means	O
of	O
dry	O
air	O
of	O
controlled	O
temperature,	O
humidity	O
and	O
flow	O
rate	O
(22	O
degrees	O
C,	O
0%	O
relative	O
humidity,	O
145	O
ml.s-1).	O
Both	O
CSSEPs	O
as	O
central	O
and	O
NMPs	O
as	O
peripheral	O
correlates	O
of	O
pain	Disease
were	O
obtained	O
in	O
response	O
to	O
the	O
CO2	Chemical
stimuli.	O
Additionally,	O
the	O
subjects	O
rated	O
the	O
intensity	O
of	O
both	O
phasic	O
and	O
tonic	O
pain	Disease
by	O
means	O
of	O
visual	O
analogue	O
scales.	O
RESULTS:	O
As	O
described	O
earlier,	O
administration	O
of	O
ibuprofen	Chemical
was	O
followed	O
by	O
a	O
decrease	O
in	O
tonic	O
pain	Disease
but-relative	O
to	O
placebo-an	O
increase	O
in	O
correlates	O
of	O
phasic	O
pain	Disease
,	O
indicating	O
a	O
specific	O
effect	O
of	O
ibuprofen	Chemical
on	O
the	O
interaction	O
between	O
the	O
pain	Disease
stimuli	O
under	O
these	O
special	O
experimental	O
conditions.	O
Based	O
on	O
the	O
similar	O
behaviour	O
of	O
CSSEP	O
and	O
NMP,	O
it	O
was	O
concluded	O
that	O
the	O
pharmacological	O
process	O
underlying	O
this	O
phenomenon	O
was	O
localised	O
in	O
the	O
periphery.	O
By	O
means	O
of	O
the	O
simultaneous	O
recording	O
of	O
interrelated	O
peripheral	O
and	O
central	O
electrophysiologic	O
correlates	O
of	O
nociception,	O
it	O
was	O
possible	O
to	O
separate	O
central	O
and	O
peripheral	O
effects	O
of	O
an	O
NSAID.	O
The	O
major	O
advantage	O
of	O
this	O
pain	Disease
model	O
is	O
the	O
possibility	O
of	O
obtaining	O
peripheral	O
pain	Disease

Acute	O
severe	O
depression	Disease
following	O
peri-operative	O
ondansetron	Chemical
.	O
A	O
41-year-old	O
woman	O
with	O
a	O
strong	O
history	O
of	O
postoperative	Disease
nausea	Disease
and	Disease
vomiting	Disease
presented	O
for	O
abdominal	O
hysterectomy	O
3	O
months	O
after	O
a	O
previous	O
anaesthetic	O
where	O
ondansetron	Chemical
prophylaxis	O
had	O
been	O
used.	O
She	O
had	O
developed	O
a	O
severe	O
acute	O
major	Disease
depression	Disease
disorder	Disease
almost	O
immediately	O
thereafter,	O
possibly	O
related	O
to	O
the	O
use	O
of	O
a	O
serotonin	Chemical
antagonist.	O
Nine	O
years	O
before	O
she	O
had	O
experienced	O
a	O
self-limited	O
puerperal	O
depressive	Disease
episode	Disease
.	O
Anaesthesia	O
with	O
a	O
propofol	Chemical
infusion	O
and	O
avoidance	O
of	O
serotonin	Chemical
antagonists	O
provided	O
a	O
nausea	Disease
-free	O
postoperative	O
course	O
without	O
exacerbation	O
of	O
the	O
depression	Disease
disorder	Disease

Hypertensive	Disease
response	O
during	O
dobutamine	Chemical
stress	O
echocardiography.	O
Among	O
3,129	O
dobutamine	Chemical
stress	O
echocardiographic	O
studies,	O
a	O
hypertensive	Disease
response,	O
defined	O
as	O
systolic	O
blood	O
pressure	O
(BP)	O
>	O
or	O
=	O
220	O
mm	O
Hg	O
and/or	O
diastolic	O
BP	O
>	O
or	O
=	O
110	O
mm	O
Hg,	O
occurred	O
in	O
30	O
patients	O
(1%).	O
Patients	O
with	O
this	O
response	O
more	O
often	O
had	O
a	O
history	O
of	O
hypertension	Disease
and	O
had	O
higher	O
resting	O
systolic	O
and	O
diastolic	O
BP	O
before	O
dobutamine	Chemical

Continuously	O
nebulized	O
albuterol	Chemical
in	O
severe	O
exacerbations	O
of	O
asthma	Disease
in	O
adults:	O
a	O
case-controlled	O
study.	O
A	O
retrospective,	O
case-controlled	O
analysis	O
comparing	O
patients	O
admitted	O
to	O
a	O
medical	O
intensive	O
care	O
unit	O
with	O
severe	O
exacerbations	O
of	O
asthma	Disease
who	O
received	O
continuously	O
nebulized	O
albuterol	Chemical
(CNA)	O
versus	O
intermittent	O
albuterol	Chemical
(INA)	O
treatments	O
is	O
reported.	O
Forty	O
matched	O
pairs	O
of	O
patients	O
with	O
asthma	Disease
are	O
compared.	O
CNA	O
was	O
administered	O
for	O
a	O
mean	O
of	O
11	O
+/-	O
10	O
hr.	O
The	O
incidence	O
of	O
cardiac	Disease
dysrhythmias	Disease
was	O
similar	O
between	O
groups.	O
Symptomatic	O
hypokalemia	Disease

Hyperosmolar	Disease
nonketotic	Disease
coma	Disease
precipitated	O
by	O
lithium	Chemical
-induced	O
nephrogenic	Disease
diabetes	Disease
insipidus	Disease
.	O
A	O
45-year-old	O
man,	O
with	O
a	O
10-year	O
history	O
of	O
manic	Disease
depression	Disease
treated	O
with	O
lithium	Chemical
,	O
was	O
admitted	O
with	O
hyperosmolar,	Disease
nonketotic	Disease
coma	Disease
.	O
He	O
gave	O
a	O
five-year	O
history	O
of	O
polyuria	Disease
and	O
polydipsia	Disease
,	O
during	O
which	O
time	O
urinalysis	O
had	O
been	O
negative	O
for	O
glucose	Chemical
.	O
After	O
recovery	O
from	O
hyperglycaemia	Disease
,	O
he	O
remained	O
polyuric	Disease
despite	O
normal	O
blood	O
glucose	Chemical
concentrations;	O
water	O
deprivation	O
testing	O
indicated	O
nephrogenic	Disease
diabetes	Disease
insipidus	Disease
,	O
likely	O
to	O
be	O
lithium	Chemical
-induced.	O
We	O
hypothesize	O
that	O
when	O
this	O
man	O
developed	O
type	Disease
2	Disease
diabetes	Disease
,	O
chronic	O
polyuria	Disease
due	O
to	O
nephrogenic	Disease
diabetes	Disease
insipidus	Disease
was	O
sufficient	O
to	O
precipitate	O
hyperosmolar	O
dehydration	Disease

Effects	O
of	O
the	O
intracoronary	O
infusion	O
of	O
cocaine	Chemical
on	O
left	O
ventricular	O
systolic	O
and	O
diastolic	O
function	O
in	O
humans.	O
BACKGROUND:	O
In	O
dogs,	O
a	O
large	O
amount	O
of	O
intravenous	O
cocaine	Chemical
causes	O
a	O
profound	O
deterioration	Disease
of	Disease
left	Disease
ventricular	Disease
(LV)	Disease
systolic	Disease
function	Disease
and	O
an	O
increase	O
in	O
LV	O
end-diastolic	O
pressure.	O
This	O
study	O
was	O
done	O
to	O
assess	O
the	O
influence	O
of	O
a	O
high	O
intracoronary	O
cocaine	Chemical
concentration	O
on	O
LV	O
systolic	O
and	O
diastolic	O
function	O
in	O
humans.	O
METHODS	O
AND	O
RESULTS:	O
In	O
20	O
patients	O
(14	O
men	O
and	O
6	O
women	O
aged	O
39	O
to	O
72	O
years)	O
referred	O
for	O
cardiac	O
catheterization	O
for	O
the	O
evaluation	O
of	O
chest	Disease
pain	Disease
,	O
we	O
measured	O
heart	O
rate,	O
systemic	O
arterial	O
pressure,	O
LV	O
pressure	O
and	O
its	O
first	O
derivative	O
(dP/dt),	O
and	O
LV	O
volumes	O
and	O
ejection	O
fraction	O
before	O
and	O
during	O
the	O
final	O
2	O
to	O
3	O
minutes	O
of	O
a	O
15-minute	O
intracoronary	O
infusion	O
of	O
saline	O
(n=10,	O
control	O
subjects)	O
or	O
cocaine	Chemical
hydrochloride	Chemical
1	O
mg/min	O
(n=10).	O
No	O
variable	O
changed	O
with	O
saline.	O
With	O
cocaine	Chemical
,	O
the	O
drug	O
concentration	O
in	O
blood	O
obtained	O
from	O
the	O
coronary	O
sinus	O
was	O
3.0+/-0.4	O
(mean+/-SD)	O
mg/L,	O
similar	O
in	O
magnitude	O
to	O
the	O
blood	O
cocaine	Chemical
concentration	O
reported	O
in	O
abusers	O
dying	O
of	O
cocaine	Chemical
intoxication.	O
Cocaine	Chemical
induced	O
no	O
significant	O
change	O
in	O
heart	O
rate,	O
LV	O
dP/dt	O
(positive	O
or	O
negative),	O
or	O
LV	O
end-diastolic	O
volume,	O
but	O
it	O
caused	O
an	O
increase	O
in	O
systolic	O
and	O
mean	O
arterial	O
pressures,	O
LV	O
end-diastolic	O
pressure,	O
and	O
LV	O
end-systolic	O
volume,	O
as	O
well	O
as	O
a	O
decrease	O
in	O
LV	O
ejection	O
fraction.	O
CONCLUSIONS:	O
In	O
humans,	O
the	O
intracoronary	O
infusion	O
of	O
cocaine	Chemical
sufficient	O
in	O
amount	O
to	O
achieve	O
a	O
high	O
drug	O
concentration	O
in	O
coronary	O
sinus	O
blood	O
causes	O
a	O
deterioration	Disease
of	Disease
LV	Disease
systolic	Disease
and	Disease
diastolic	Disease
performance	Disease

Heparin	Chemical
-induced	O
thrombocytopenia	Disease
,	O
paradoxical	O
thromboembolism	Disease
,	O
and	O
other	O
side	O
effects	O
of	O
heparin	Chemical
therapy.	O
Although	O
several	O
new	O
anticoagulant	O
drugs	O
are	O
in	O
development,	O
heparin	Chemical
remains	O
the	O
drug	O
of	O
choice	O
for	O
most	O
anticoagulation	O
needs.	O
The	O
clinical	O
effects	O
of	O
heparin	Chemical
are	O
meritorious,	O
but	O
side	O
effects	O
do	O
exist.	O
Important	O
untoward	O
effects	O
of	O
heparin	Chemical
therapy	O
including	O
heparin	Chemical
-induced	O
thrombocytopenia	Disease
,	O
heparin	Chemical
-associated	O
osteoporosis	Disease
,	O
eosinophilia	Disease
,	O
skin	Disease
reactions	Disease
,	O
allergic	Disease
reactions	Disease
other	O
than	O
thrombocytopenia	Disease
and	O
alopecia	Disease

Nonopaque	O
crystal	O
deposition	O
causing	O
ureteric	Disease
obstruction	Disease
in	O
patients	O
with	O
HIV	O
undergoing	O
indinavir	Chemical
therapy.	O
OBJECTIVE:	O
We	O
describe	O
the	O
unique	O
CT	O
features	O
of	O
ureteric	Disease
calculi	Disease
in	O
six	O
HIV-infected	Disease
patients	O
receiving	O
indinavir	Chemical
,	O
the	O
most	O
commonly	O
used	O
HIV	O
protease	O
inhibitor,	O
which	O
is	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
urolithiasis	Disease
.	O
CONCLUSION:	O
Ureteric	Disease
obstruction	Disease
caused	O
by	O
precipitated	O
indinavir	Chemical
crystals	O
may	O
be	O
difficult	O
to	O
diagnose	O
with	O
unenhanced	O
CT.	O
The	O
calculi	O
are	O
not	O
opaque,	O
and	O
secondary	O
signs	O
of	O
obstruction	O
may	O
be	O
absent	O
or	O
minimal	O
and	O
should	O
be	O
sought	O
carefully.	O
Images	O
may	O
need	O
to	O
be	O
obtained	O
using	O
i.v.	O
contrast	O
material	O
to	O
enable	O
diagnosis	O
of	O
ureteric	Disease
stones	Disease
or	Disease
obstruction	Disease
in	O
patients	O
with	O
HIV	Disease
infection	Disease
who	O
receive	O
indinavir	Chemical

Ischemic	Disease
colitis	Disease
and	O
sumatriptan	Chemical
use.	O
Sumatriptan	Chemical
succinate	Chemical
,	O
a	O
serotonin	Chemical
-1	O
(	O
5-hydroxytryptamine	Chemical
-1)	O
receptor	O
agonist,	O
is	O
an	O
antimigraine	O
drug	O
that	O
is	O
reported	O
to	O
act	O
by	O
selectively	O
constricting	O
intracranial	O
arteries.	O
Recently,	O
vasopressor	O
responses	O
that	O
are	O
distinct	O
from	O
the	O
cranial	O
circulation	O
have	O
been	O
demonstrated	O
to	O
occur	O
in	O
the	O
systemic,	O
pulmonary,	O
and	O
coronary	O
circulations.	O
Cases	O
have	O
been	O
published	O
of	O
coronary	Disease
vasospasm	Disease
,	O
myocardial	Disease
ischemia	Disease
,	O
and	O
myocardial	Disease
infarction	Disease
occurring	O
after	O
sumatriptan	Chemical
use.	O
We	O
report	O
on	O
the	O
development	O
of	O
8	O
serious	O
cases	O
of	O
ischemic	Disease
colitis	Disease
in	O
patients	O
with	O
migraine	Disease
treated	O
with	O
sumatriptan	Chemical

Pallidotomy	O
with	O
the	O
gamma	O
knife:	O
a	O
positive	O
experience.	O
51	O
patients	O
with	O
medically	O
refractory	O
Parkinson's	Disease
disease	Disease
underwent	O
stereotactic	O
posteromedial	O
pallidotomy	O
between	O
August	O
1993	O
and	O
February	O
1997	O
for	O
treatment	O
of	O
bradykinesia	Disease
,	O
rigidity	Disease
,	O
and	O
L-DOPA	Chemical
-induced	O
dyskinesias	Disease
.	O
In	O
29	O
patients,	O
the	O
pallidotomies	O
were	O
performed	O
with	O
the	O
Leksell	O
Gamma	O
Knife	O
and	O
in	O
22	O
they	O
were	O
performed	O
with	O
the	O
standard	O
radiofrequency	O
(RF)	O
method.	O
Clinical	O
assessment	O
as	O
well	O
as	O
blinded	O
ratings	O
of	O
Unified	O
Parkinson's	Disease
Disease	Disease
Rating	O
Scale	O
(UPDRS)	O
scores	O
were	O
carried	O
out	O
pre-	O
and	O
postoperatively.	O
Mean	O
follow-up	O
time	O
is	O
20.6	O
months	O
(range	O
6-48)	O
and	O
all	O
except	O
4	O
patients	O
have	O
been	O
followed	O
more	O
than	O
one	O
year.	O
85	O
percent	O
of	O
patients	O
with	O
dyskinesias	Disease
were	O
relieved	O
of	O
symptoms,	O
regardless	O
of	O
whether	O
the	O
pallidotomies	O
were	O
performed	O
with	O
the	O
Gamma	O
Knife	O
or	O
radiofrequency	O
methods.	O
About	O
2/3	O
of	O
the	O
patients	O
in	O
both	O
Gamma	O
Knife	O
and	O
radiofrequency	O
groups	O
showed	O
improvements	O
in	O
bradykinesia	Disease
and	O
rigidity	Disease
,	O
although	O
when	O
considered	O
as	O
a	O
group	O
neither	O
the	O
Gamma	O
Knife	O
nor	O
the	O
radiofrequency	O
group	O
showed	O
statistically	O
significant	O
improvements	O
in	O
UPDRS	O
scores.	O
One	O
patient	O
in	O
the	O
Gamma	O
Knife	O
group	O
(3.4%)	O
developed	O
a	O
homonymous	Disease
hemianopsia	Disease
9	O
months	O
following	O
treatment	O
and	O
5	O
patients	O
(27.7%)	O
in	O
the	O
radiofrequency	O
group	O
became	O
transiently	O
confused	O
postoperatively.	O
No	O
other	O
complications	O
were	O
seen.	O
Gamma	O
Knife	O
pallidotomy	O
is	O
as	O
effective	O
as	O
radiofrequency	O
pallidotomy	O
in	O
controlling	O
certain	O
of	O
the	O
symptoms	O
of	O
Parkinson's	Disease
disease	Disease
.	O
It	O
may	O
be	O
the	O
only	O
practical	O
technique	O
available	O
in	O
certain	O
patients,	O
such	O
as	O
those	O
who	O
take	O
anticoagulants,	O
have	O
bleeding	Disease

Neuroleptic	Disease
malignant	Disease
syndrome	Disease
and	O
methylphenidate	Chemical
.	O
A	O
1-year-old	O
female	O
presented	O
with	O
neuroleptic	Disease
malignant	Disease
syndrome	Disease
probably	O
caused	O
by	O
methylphenidate	Chemical
.	O
She	O
had	O
defects	O
in	O
the	O
supratentorial	O
brain	O
including	O
the	O
basal	O
ganglia	O
and	O
the	O
striatum	O
(	O
multicystic	Disease
encephalomalacia	Disease
)	O
due	O
to	O
severe	O
perinatal	O
hypoxic-ischemic	Disease
encephalopathy	Disease
,	O
which	O
was	O
considered	O
to	O
be	O
a	O
possible	O
predisposing	O
factor	O
causing	O
neuroleptic	Disease
malignant	Disease
syndrome	Disease
.	O
A	O
dopaminergic	O
blockade	O
mechanism	O
generally	O
is	O
accepted	O
as	O
the	O
pathogenesis	O
of	O
this	O
syndrome.	O
However,	O
methylphenidate	Chemical
is	O
a	O
dopamine	Chemical
agonist	O
via	O
the	O
inhibition	O
of	O
uptake	O
of	O
dopamine	Chemical
,	O
and	O
therefore	O
dopaminergic	O
systems	O
in	O
the	O
brainstem	O
(mainly	O
the	O
midbrain)	O
and	O
the	O
spinal	O
cord	O
were	O
unlikely	O
to	O
participate	O
in	O
the	O
onset	O
of	O
this	O
syndrome.	O
A	O
relative	O
gamma-aminobutyric	Chemical
acid	Chemical
-ergic	O
deficiency	O
might	O
occur	O
because	O
diazepam	Chemical
,	O
a	O
gamma-aminobutyric	Chemical
acid	Chemical
-mimetic	O
agent,	O
was	O
strikingly	O
effective.	O
This	O
is	O
the	O
first	O
reported	O
patient	O
with	O
neuroleptic	Disease
malignant	Disease
syndrome	Disease
probably	O
caused	O
by	O
methylphenidate	Chemical

Differential	O
effects	O
of	O
17alpha-ethinylestradiol	Chemical
on	O
the	O
neutral	O
and	O
acidic	O
pathways	O
of	O
bile	Chemical
salt	Chemical
synthesis	O
in	O
the	O
rat.	O
Effects	O
of	O
17alpha-ethinylestradiol	Chemical
(	O
EE	Chemical
)	O
on	O
the	O
neutral	O
and	O
acidic	O
biosynthetic	O
pathways	O
of	O
bile	Chemical
salt	Chemical
(	O
BS	Chemical
)	O
synthesis	O
were	O
evaluated	O
in	O
rats	O
with	O
an	O
intact	O
enterohepatic	O
circulation	O
and	O
in	O
rats	O
with	O
long-term	O
bile	O
diversion	O
to	O
induce	O
BS	Chemical
synthesis.	O
For	O
this	O
purpose,	O
bile	Chemical
salt	Chemical
pool	O
composition,	O
synthesis	O
of	O
individual	O
BS	Chemical
in	O
vivo,	O
hepatic	O
activities,	O
and	O
expression	O
levels	O
of	O
cholesterol	Chemical
7alpha-hydroxylase	O
(CYP7A),	O
and	O
sterol	Chemical
27-hydroxylase	O
(CYP27),	O
as	O
well	O
as	O
of	O
other	O
enzymes	O
involved	O
in	O
BS	Chemical
synthesis,	O
were	O
analyzed	O
in	O
rats	O
treated	O
with	O
EE	Chemical
(5	O
mg/kg,	O
3	O
days)	O
or	O
its	O
vehicle.	O
BS	Chemical
pool	O
size	O
was	O
decreased	O
by	O
27%	O
but	O
total	O
BS	Chemical
synthesis	O
was	O
not	O
affected	O
by	O
EE	Chemical
in	O
intact	O
rats.	O
Synthesis	O
of	O
cholate	Chemical
was	O
reduced	O
by	O
68%	O
in	O
EE	Chemical
-treated	O
rats,	O
while	O
that	O
of	O
chenodeoxycholate	Chemical
was	O
increased	O
by	O
60%.	O
The	O
recently	O
identified	O
Delta22-isomer	O
of	O
beta-muricholate	O
contributed	O
for	O
5.4%	O
and	O
18.3	O
%	O
(P	O
<	O
0.01)	O
to	O
the	O
pool	O
in	O
control	O
and	O
EE	Chemical
-treated	O
rats,	O
respectively,	O
but	O
could	O
not	O
be	O
detected	O
in	O
bile	O
after	O
exhaustion	O
of	O
the	O
pool.	O
A	O
clear	O
reduction	O
of	O
BS	Chemical
synthesis	O
was	O
found	O
in	O
bile-diverted	O
rats	O
treated	O
with	O
EE	Chemical
,	O
yet	O
biliary	O
BS	Chemical
composition	O
was	O
only	O
minimally	O
affected.	O
Activity	O
of	O
CYP7A	O
was	O
decreased	O
by	O
EE	Chemical
in	O
both	O
intact	O
and	O
bile-diverted	O
rats,	O
whereas	O
the	O
activity	O
of	O
the	O
CYP27	O
was	O
not	O
affected.	O
Hepatic	O
mRNA	O
levels	O
of	O
CYP7A	O
were	O
significantly	O
reduced	O
by	O
EE	Chemical
in	O
bile-diverted	O
rats	O
only;	O
CYP27	O
mRNA	O
levels	O
were	O
not	O
affected	O
by	O
EE	Chemical
.	O
In	O
addition,	O
mRNA	O
levels	O
of	O
sterol	Chemical
12alpha-hydroxylase	O
and	O
lithocholate	O
6beta-hydroxylase	O
were	O
increased	O
by	O
bile	O
diversion	O
and	O
suppressed	O
by	O
EE	Chemical
.	O
This	O
study	O
shows	O
that	O
17alpha-ethinylestradiol	Chemical
(	O
EE	Chemical
)-induced	O
intrahepatic	Disease
cholestasis	Disease
in	O
rats	O
is	O
associated	O
with	O
selective	O
inhibition	O
of	O
the	O
neutral	O
pathway	O
of	O
bile	Chemical
salt	Chemical
(	O
BS	Chemical
)	O
synthesis.	O
Simultaneous	O
impairment	O
of	O
other	O
enzymes	O
in	O
the	O
BS	Chemical
biosynthetic	O
pathways	O
may	O
contribute	O
to	O
overall	O
effects	O
of	O
EE	Chemical
on	O
BS	Chemical

Glibenclamide	Chemical
-sensitive	O
hypotension	Disease
produced	O
by	O
helodermin	Chemical
assessed	O
in	O
the	O
rat.	O
The	O
effects	O
of	O
helodermin	Chemical
,	O
a	O
basic	O
35-	O
amino	Chemical
acid	Chemical
peptide	O
isolated	O
from	O
the	O
venom	O
of	O
a	O
lizard	O
salivary	O
gland,	O
on	O
arterial	O
blood	O
pressure	O
and	O
heart	O
rate	O
were	O
examined	O
in	O
the	O
rat,	O
focusing	O
on	O
the	O
possibility	O
that	O
activation	O
of	O
ATP	Chemical
sensitive	O
K	Chemical
+	O
(	O
K	Chemical
(	O
ATP	Chemical
))	O
channels	O
is	O
involved	O
in	O
the	O
responses.	O
The	O
results	O
were	O
also	O
compared	O
with	O
those	O
of	O
vasoactive	O
intestinal	O
polypeptide	O
(VIP).	O
Helodermin	Chemical
produced	O
hypotension	Disease
in	O
a	O
dose-dependent	O
manner	O
with	O
approximately	O
similar	O
potency	O
and	O
duration	O
to	O
VIP.	O
Hypotension	Disease
induced	O
by	O
both	O
peptides	O
was	O
significantly	O
attenuated	O
by	O
glibenclamide	Chemical
,	O
which	O
abolished	O
a	O
levcromakalim	Chemical
-produced	O
decrease	O
in	O
arterial	O
blood	O
pressure.	O
Oxyhemoglobin	O
did	O
not	O
affect	O
helodermin	Chemical
-induced	O
hypotension	Disease
,	O
whereas	O
it	O
shortened	O
the	O
duration	O
of	O
acetylcholine	Chemical
(	O
ACh	Chemical
)-produced	O
hypotension	Disease
.	O
These	O
findings	O
suggest	O
that	O
helodermin	Chemical
-produced	O
hypotension	Disease
is	O
partly	O
attributable	O
to	O
the	O
activation	O
of	O
glibenclamide	Chemical
-sensitive	O
K	Chemical
+	O
channels	O
(	O
K	Chemical
(	O
ATP	Chemical
)	O
channels),	O
which	O
presumably	O
exist	O
on	O
arterial	O
smooth	O
muscle	O
cells.	O
EDRF	O
(endothelium-derived	O
relaxing	O
factor)/	O
nitric	Chemical
oxide	Chemical
does	O
not	O
seem	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
peptide-produced	O
hypotension	Disease

Long-term	O
efficacy	O
and	O
adverse	O
event	O
of	O
nifedipine	Chemical
sustained-release	O
tablets	O
for	O
cyclosporin	Chemical
A	Chemical
-induced	O
hypertension	Disease
in	O
patients	O
with	O
psoriasis	Disease
.	O
Thirteen	O
psoriatic	Disease
patients	O
with	O
hypertension	Disease
during	O
the	O
course	O
of	O
cyclosporin	Chemical
A	Chemical
therapy	O
were	O
treated	O
for	O
25	O
months	O
with	O
a	O
calcium	Chemical
channel	O
blocker,	O
sustained-release	O
nifedipine	Chemical
,	O
to	O
study	O
the	O
clinical	O
antihypertensive	O
effects	O
and	O
adverse	O
events	O
during	O
treatment	O
with	O
both	O
drugs.	O
Seven	O
of	O
the	O
13	O
patients	O
had	O
exhibited	O
a	O
subclinical	O
hypertensive	Disease
state	O
before	O
cyclosporin	Chemical
A	Chemical
therapy.	O
Both	O
systolic	O
and	O
diastolic	O
blood	O
pressures	O
of	O
these	O
13	O
patients	O
were	O
decreased	O
significantly	O
after	O
4	O
weeks	O
of	O
nifedipine	Chemical
therapy,	O
and	O
blood	O
pressure	O
was	O
maintained	O
within	O
the	O
normal	O
range	O
thereafter	O
for	O
25	O
months.	O
The	O
adverse	O
events	O
during	O
combined	O
therapy	O
with	O
cyclosporin	Chemical
A	Chemical
and	O
nifedipine	Chemical
included	O
an	O
increase	O
in	O
blood	Chemical
urea	Chemical
nitrogen	Chemical
levels	O
in	O
9	O
of	O
the	O
13	O
patients	O
and	O
development	O
of	O
gingival	Disease
hyperplasia	Disease
in	O
2	O
of	O
the	O
13	O
patients.	O
Our	O
findings	O
indicate	O
that	O
sustained-release	O
nifedipine	Chemical
is	O
useful	O
for	O
hypertensive	Disease
	O
psoriatic	Disease
patients	O
under	O
long-term	O
treatment	O
with	O
cyclosporin	Chemical
A	Chemical
,	O
but	O
that	O
these	O
patients	O
should	O
be	O
monitored	O
for	O
gingival	Disease
hyperplasia	Disease

Torsade	Disease
de	Disease
pointes	Disease
	O
ventricular	Disease
tachycardia	Disease
during	O
low	O
dose	O
intermittent	O
dobutamine	Chemical
treatment	O
in	O
a	O
patient	O
with	O
dilated	Disease
cardiomyopathy	Disease
and	O
congestive	Disease
heart	Disease
failure	Disease
.	O
The	O
authors	O
describe	O
the	O
case	O
of	O
a	O
56-year-old	O
woman	O
with	O
chronic,	O
severe	O
heart	Disease
failure	Disease
secondary	O
to	O
dilated	Disease
cardiomyopathy	Disease
and	O
absence	O
of	O
significant	O
ventricular	Disease
arrhythmias	Disease
who	O
developed	O
QT	Disease
prolongation	Disease
and	O
torsade	Disease
de	Disease
pointes	Disease
	O
ventricular	Disease
tachycardia	Disease
during	O
one	O
cycle	O
of	O
intermittent	O
low	O
dose	O
(2.5	O
mcg/kg	O
per	O
min)	O
dobutamine	Chemical
.	O
This	O
report	O
of	O
torsade	Disease
de	Disease
pointes	Disease
	O
ventricular	Disease
tachycardia	Disease
during	O
intermittent	O
dobutamine	Chemical
supports	O
the	O
hypothesis	O
that	O
unpredictable	O
fatal	O
arrhythmias	Disease
may	O
occur	O
even	O
with	O
low	O
doses	O
and	O
in	O
patients	O
with	O
no	O
history	O
of	O
significant	O
rhythm	O
disturbances.	O
The	O
mechanisms	O
of	O
proarrhythmic	O
effects	O
of	O
Dubutamine	Chemical

Positive	O
skin	O
tests	O
in	O
late	O
reactions	O
to	O
radiographic	O
contrast	Chemical
media	Chemical
.	O
In	O
the	O
last	O
few	O
years	O
delayed	O
reactions	O
several	O
hours	O
after	O
the	O
injection	O
of	O
radiographic	O
and	O
contrast	Chemical
materials	Chemical
(	O
PRC	Chemical
)	O
have	O
been	O
described	O
with	O
increasing	O
frequency.	O
The	O
authors	O
report	O
two	O
observations	O
on	O
patients	O
with	O
delayed	O
reactions	O
in	O
whom	O
intradermoreactions	O
(IDR)	O
and	O
patch	O
tests	O
to	O
a	O
series	O
of	O
ionic	O
and	O
non	O
ionic	O
PRC	Chemical
were	O
studied.	O
After	O
angiography	O
by	O
the	O
venous	O
route	O
in	O
patient	O
n	O
degree	O
1	O
a	O
biphasic	O
reaction	O
with	O
an	O
immediate	O
reaction	O
(	O
dyspnea	Disease
,	O
loss	Disease
of	Disease
consciousness	Disease
)	O
and	O
delayed	O
macro-papular	Disease
rash	Disease
appeared,	O
whilst	O
patient	O
n	O
degree	O
2	O
developed	O
a	O
generalised	O
sensation	O
of	O
heat,	O
persistent	O
pain	Disease
at	O
the	O
site	O
of	O
injection	O
immediately	O
and	O
a	O
generalised	O
macro-papular	O
reaction	O
after	O
24	O
hours.	O
The	O
skin	O
tests	O
revealed	O
positive	O
delayed	O
reactions	O
of	O
24	O
hours	O
and	O
48	O
hours	O
by	O
IDR	O
and	O
patch	O
tests	O
to	O
only	O
some	O
PRC	Chemical
with	O
common	O
chains	O
in	O
their	O
structures.	O
The	O
positive	O
skin	O
tests	O
are	O
in	O
favour	O
of	O
immunological	O
reactions	O
and	O
may	O
help	O
in	O
diagnosis	O
of	O
allergy	Disease

Risk	O
of	O
transient	O
hyperammonemic	Disease
encephalopathy	Disease
in	O
cancer	Disease
patients	O
who	O
received	O
continuous	O
infusion	O
of	O
5-fluorouracil	Chemical
with	O
the	O
complication	O
of	O
dehydration	Disease
and	O
infection	Disease
.	O
From	O
1986	O
to	O
1998,	O
29	O
cancer	Disease
patients	O
who	O
had	O
32	O
episodes	O
of	O
transient	O
hyperammonemic	Disease
encephalopathy	Disease
related	O
to	O
continuous	O
infusion	O
of	O
5-fluorouracil	Chemical
(	O
5-FU	Chemical
)	O
were	O
identified.	O
None	O
of	O
the	O
patients	O
had	O
decompensated	O
liver	Disease
disease	Disease
.	O
Onset	O
of	O
hyperammonemic	Disease
encephalopathy	Disease
varied	O
from	O
0.5	O
to	O
5	O
days	O
(mean:	O
2.6	O
+/-	O
1.3	O
days)	O
after	O
the	O
initiation	O
of	O
chemotherapy.	O
Plasma	O
ammonium	Chemical
level	O
ranged	O
from	O
248	O
to	O
2387	O
microg%	O
(mean:	O
626	O
+/-	O
431	O
microg%).	O
Among	O
the	O
32	O
episodes,	O
26	O
(81%)	O
had	O
various	O
degrees	O
of	O
azotemia	Disease
,	O
18	O
(56%)	O
occurred	O
during	O
bacterial	Disease
infections	Disease
and	O
14	O
(44%)	O
without	O
infection	Disease
occurred	O
during	O
periods	O
of	O
dehydration	Disease
.	O
Higher	O
plasma	O
ammonium	Chemical
levels	O
and	O
more	O
rapid	O
onset	O
of	O
hyperammonemia	Disease
were	O
seen	O
in	O
18	O
patients	O
with	O
bacterial	Disease
infections	Disease
(p=0.003	O
and	O
0.0006,	O
respectively)	O
and	O
in	O
nine	O
patients	O
receiving	O
high	O
daily	O
doses	O
(2600	O
or	O
1800	O
mg/m2)	O
of	O
5-FU	Chemical
(p=0.0001	O
and	O
<	O
0.0001,	O
respectively).	O
In	O
25	O
out	O
of	O
32	O
episodes	O
(78%),	O
plasma	O
ammonium	Chemical
levels	O
and	O
mental	O
status	O
returned	O
to	O
normal	O
within	O
2	O
days	O
after	O
adequate	O
management.	O
In	O
conclusion,	O
hyperammonemic	Disease
encephalopathy	Disease
can	O
occur	O
in	O
patients	O
receiving	O
continuous	O
infusion	O
of	O
5-FU	Chemical
.	O
Azotemia	Disease
,	O
body	O
fluid	O
insufficiency	O
and	O
bacterial	Disease
infections	Disease
were	O
frequently	O
found	O
in	O
these	O
patients.	O
It	O
is	O
therefore	O
important	O
to	O
recognize	O
this	O
condition	O
in	O
patients	O
receiving	O
continuous	O
infusion	O
of	O
5-FU	Chemical

The	O
effects	O
of	O
quinine	Chemical
and	O
4-aminopyridine	Chemical
on	O
conditioned	O
place	O
preference	O
and	O
changes	O
in	O
motor	O
activity	O
induced	O
by	O
morphine	Chemical
in	O
rats.	O
1.	O
The	O
effects	O
of	O
two	O
unselective	O
potassium	Chemical
(	O
K	Chemical
(+)-)	O
channel	O
blockers,	O
quinine	Chemical
(12.5,	O
25	O
and	O
50	O
mg/kg)	O
and	O
4-aminopyridine	Chemical
(1	O
and	O
2	O
mg/kg),	O
on	O
conditioned	O
place	O
preference	O
and	O
biphasic	O
changes	O
in	O
motor	O
activity	O
induced	O
by	O
morphine	Chemical
(10	O
mg/kg)	O
were	O
tested	O
in	O
Wistar	O
rats.	O
Quinine	Chemical
is	O
known	O
to	O
block	O
voltage-,	O
calcium	Chemical
-	O
and	O
ATP	Chemical
-sensitive	O
K	Chemical
(+)-channels	O
while	O
4-aminopyridine	Chemical
is	O
known	O
to	O
block	O
voltage-sensitive	O
K	Chemical
(+)-channels.	O
2.	O
In	O
the	O
counterbalanced	O
method,	O
quinine	Chemical
attenuated	O
morphine	Chemical
-induced	O
place	O
preference,	O
whereas	O
4-aminopyridine	Chemical
was	O
ineffective.	O
In	O
the	O
motor	O
activity	O
test	O
measured	O
with	O
an	O
Animex-activity	O
meter	O
neither	O
of	O
the	O
K	Chemical
(+)-channel	O
blockers	O
affected	O
morphine	Chemical
-induced	O
hypoactivity	Disease
,	O
but	O
both	O
K	Chemical
(+)-channel	O
blockers	O
prevented	O
morphine	Chemical
-induced	O
secondary	O
hyperactivity	Disease
.	O
3.	O
These	O
results	O
suggest	O
the	O
involvement	O
of	O
quinine	Chemical
-sensitive	O
but	O
not	O
4-aminopyridine	Chemical
-sensitive	O
K	Chemical
(+)-channels	O
in	O
morphine	Chemical
reward.	O
It	O
is	O
also	O
suggested	O
that	O
the	O
blockade	O
of	O
K	Chemical
(+)-channels	O
sensitive	O
to	O
these	O
blockers	O
is	O
not	O
sufficient	O
to	O
prevent	O
morphine	Chemical
-induced	O
hypoactivity	Disease
whereas	O
morphine	Chemical
-induced	O
hyperactivity	Disease
seems	O
to	O
be	O
connected	O
to	O
both	O
quinine	Chemical
-	O
and	O
4-aminopyridine	Chemical
-sensitive	O
K	Chemical

Nociceptin	Chemical
/	O
orphanin	Chemical
FQ	Chemical
and	O
nocistatin	Chemical
on	O
learning	Disease
and	Disease
memory	Disease
impairment	Disease
induced	O
by	O
scopolamine	Chemical
in	O
mice.	O
1.	O
Nociceptin	Chemical
,	O
also	O
known	O
as	O
orphanin	Chemical
FQ	Chemical
,	O
is	O
an	O
endogenous	O
ligand	O
for	O
the	O
orphan	O
opioid	O
receptor-like	O
receptor	O
1	O
(ORL1)	O
and	O
involves	O
in	O
various	O
functions	O
in	O
the	O
central	O
nervous	O
system	O
(CNS).	O
On	O
the	O
other	O
hand,	O
nocistatin	Chemical
is	O
recently	O
isolated	O
from	O
the	O
same	O
precursor	O
as	O
nociceptin	Chemical
and	O
blocks	O
nociceptin	Chemical
-induced	O
allodynia	Disease
and	O
hyperalgesia	Disease
.	O
2.	O
Although	O
ORL1	O
receptors	O
which	O
display	O
a	O
high	O
degree	O
of	O
sequence	O
homology	O
with	O
classical	O
opioid	O
receptors	O
are	O
abundant	O
in	O
the	O
hippocampus,	O
little	O
is	O
known	O
regarding	O
their	O
role	O
in	O
learning	O
and	O
memory.	O
3.	O
The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
whether	O
nociceptin	Chemical
/	O
orphanin	Chemical
FQ	Chemical
and	O
nocistatin	Chemical
could	O
modulate	O
impairment	Disease
of	Disease
learning	Disease
and	Disease
memory	Disease
induced	O
by	O
scopolamine	Chemical
,	O
a	O
muscarinic	O
cholinergic	O
receptor	O
antagonist,	O
using	O
spontaneous	O
alternation	O
of	O
Y-maze	O
and	O
step-down	O
type	O
passive	O
avoidance	O
tasks	O
in	O
mice.	O
4.	O
While	O
nocistatin	Chemical
(0.5-5.0	O
nmol	O
mouse-1,	O
i.c.v.)	O
administered	O
30	O
min	O
before	O
spontaneous	O
alternation	O
performance	O
or	O
the	O
training	O
session	O
of	O
the	O
passive	O
avoidance	O
task,	O
had	O
no	O
effect	O
on	O
spontaneous	O
alternation	O
or	O
passive	O
avoidance	O
behaviours,	O
a	O
lower	O
per	O
cent	O
alternation	O
and	O
shorter	O
median	O
step-down	O
latency	O
in	O
the	O
retention	O
test	O
were	O
obtained	O
in	O
nociceptin	Chemical
(1.5	O
and/or	O
5.0	O
nmol	O
mouse-1,	O
i.c.v.)-treated	O
normal	O
mice.	O
5.	O
Administration	O
of	O
nocistatin	Chemical
(1.5	O
and/or	O
5.0	O
nmol	O
mouse-1,	O
i.c.v.)	O
30	O
min	O
before	O
spontaneous	O
alternation	O
performance	O
or	O
the	O
training	O
session	O
of	O
the	O
passive	O
avoidance	O
task,	O
attenuated	O
the	O
scopolamine	Chemical
-induced	O
impairment	O
of	O
spontaneous	O
alternation	O
and	O
passive	O
avoidance	O
behaviours.	O
6.	O
These	O
results	O
indicated	O
that	O
nocistatin	Chemical
,	O
a	O
new	O
biologically	O
active	O
peptide,	O
ameliorates	O
impairments	O
of	O
spontaneous	O
alternation	O
and	O
passive	O
avoidance	O
induced	O
by	O
scopolamine	Chemical

Meloxicam	Chemical
-induced	O
liver	Disease
toxicity	Disease
.	O
We	O
report	O
the	O
case	O
of	O
a	O
female	O
patient	O
with	O
rheumatoid	Disease
arthritis	Disease
who	O
developed	O
acute	O
cytolytic	O
hepatitis	Disease
due	O
to	O
meloxicam	Chemical
.	O
Recently	O
introduced	O
in	O
Belgium,	O
meloxicam	Chemical
is	O
the	O
first	O
nonsteroidal	O
antiinflammatory	O
drug	O
with	O
selective	O
action	O
on	O
the	O
inducible	O
form	O
of	O
cyclooxygenase	O
2.	O
The	O
acute	O
cytolytic	O
hepatitis	Disease
occurred	O
rapidly	O
after	O
meloxicam	Chemical
administration	O
and	O
was	O
associated	O
with	O
the	O
development	O
of	O
antinuclear	O
antibodies	O
suggesting	O
a	O
hypersensitivity	Disease
mechanism.	O
This	O
first	O
case	O
of	O
meloxicam	Chemical
related	O
liver	Disease
toxicity	Disease
demonstrates	O
the	O
potential	O
of	O
this	O
drug	O
to	O
induce	O
hepatic	Disease
damage	Disease

Induction	O
of	O
apoptosis	O
by	O
remoxipride	Chemical
metabolites	O
in	O
HL60	O
and	O
CD34+/CD19-	O
human	O
bone	O
marrow	O
progenitor	O
cells:	O
potential	O
relevance	O
to	O
remoxipride	Chemical
-induced	O
aplastic	Disease
anemia	Disease
.	O
The	O
antipsychotic	O
agent,	O
remoxipride	Chemical
[	O
(S)-(-)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz	Chemical
amide	Chemical
]	O
has	O
been	O
associated	O
with	O
acquired	O
aplastic	Disease
anemia	Disease
.	O
We	O
have	O
examined	O
the	O
ability	O
of	O
remoxipride	Chemical
,	O
three	O
pyrrolidine	Chemical
ring	O
metabolites	O
and	O
five	O
aromatic	O
ring	O
metabolites	O
of	O
the	O
parent	O
compound	O
to	O
induce	O
apoptosis	O
in	O
HL60	O
cells	O
and	O
human	O
bone	O
marrow	O
progenitor	O
(HBMP)	O
cells.	O
Cells	O
were	O
treated	O
for	O
0-24	O
h	O
with	O
each	O
compound	O
(0-200	O
microM).	O
Apoptosis	O
was	O
assessed	O
by	O
fluorescence	O
microscopy	O
in	O
Hoechst	Chemical
33342	Chemical
-	O
and	O
propidium	Chemical
iodide	Chemical
stained	O
cell	O
samples.	O
Results	O
were	O
confirmed	O
by	O
determination	O
of	O
internucleosomal	O
DNA	O
fragmentation	O
using	O
gel	O
electrophoresis	O
for	O
HL60	O
cell	O
samples	O
and	O
terminal	O
deoxynucleotidyl	O
transferase	O
assay	O
in	O
HBMP	O
cells.	O
The	O
catechol	Chemical
and	O
hydroquinone	Chemical
metabolites,	O
NCQ436	Chemical
and	O
NCQ344	Chemical
,	O
induced	O
apoptosis	O
in	O
HL60	O
and	O
HBMP	O
cells	O
in	O
a	O
time-	O
and	O
concentration	O
dependent	O
manner,	O
while	O
the	O
phenols	Chemical
,	O
NCR181,	O
FLA873,	O
and	O
FLA797	Chemical
,	O
and	O
the	O
derivatives	O
formed	O
by	O
oxidation	O
of	O
the	O
pyrrolidine	Chemical
ring,	O
FLA838,	O
NCM001,	O
and	O
NCL118,	O
had	O
no	O
effect.	O
No	O
necrosis	Disease
was	O
observed	O
in	O
cells	O
treated	O
with	O
NCQ436	Chemical
but	O
NCQ344	Chemical
had	O
a	O
biphasic	O
effect	O
in	O
both	O
cell	O
types,	O
inducing	O
apoptosis	O
at	O
lower	O
concentrations	O
and	O
necrosis	Disease
at	O
higher	O
concentrations.	O
These	O
data	O
show	O
that	O
the	O
catechol	Chemical
and	O
hydroquinone	Chemical
metabolites	O
of	O
remoxipride	Chemical
have	O
direct	O
toxic	O
effects	O
in	O
HL60	O
and	O
HBMP	O
cells,	O
leading	O
to	O
apoptosis,	O
while	O
the	O
phenol	Chemical
metabolites	O
were	O
inactive.	O
Similarly,	O
benzene	Chemical
-derived	O
catechol	Chemical
and	O
hydroquinone	Chemical
,	O
but	O
not	O
phenol	Chemical
,	O
induce	O
apoptosis	O
in	O
HBMP	O
cells	O
[Moran	O
et	O
al.,	O
Mol.	O
Pharmacol.,	O
50	O
(1996)	O
610-615].	O
We	O
propose	O
that	O
remoxipride	Chemical
and	O
benzene	Chemical
may	O
induce	O
aplastic	Disease
anemia	Disease
via	O
production	O
of	O
similar	O
reactive	O
metabolites	O
and	O
that	O
the	O
ability	O
of	O
NCQ436	Chemical
and	O
NCQ344	Chemical
to	O
induce	O
apoptosis	O
in	O
HBMP	O
cells	O
may	O
contribute	O
to	O
the	O
mechanism	O
underlying	O
acquired	O
aplastic	Disease
anemia	Disease
that	O
has	O
been	O
associated	O
with	O
remoxipride	Chemical

Synthesis	O
and	O
preliminary	O
pharmacological	O
investigations	O
of	O
1-(1,2-dihydro-2-acenaphthylenyl)piperazine	Chemical
derivatives	O
as	O
potential	O
atypical	O
antipsychotic	O
agents	O
in	O
mice.	O
In	O
research	O
towards	O
the	O
development	O
of	O
new	O
atypical	O
antipsychotic	O
agents,	O
one	O
strategy	O
is	O
that	O
the	O
dopaminergic	O
system	O
can	O
be	O
modulated	O
through	O
manipulation	O
of	O
the	O
serotonergic	O
system.	O
The	O
synthesis	O
and	O
preliminary	O
pharmacological	O
evaluation	O
of	O
a	O
series	O
of	O
potential	O
atypical	O
antipsychotic	O
agents	O
based	O
on	O
the	O
structure	O
of	O
1-(1,2-dihydro-2-acenaphthylenyl)piperazine	Chemical
(7)	O
is	O
described.	O
Compound	O
7e,	O
5-{2-[4-(1,2-dihydro-2-acenaphthylenyl)piperazinyl]ethyl}-2,3-dihy	Chemical
dro-1H-	Chemical
indol-2-one	Chemical
,	O
from	O
this	O
series	O
showed	O
significant	O
affinities	O
at	O
the	O
5-HT1A	O
and	O
5-HT2A	O
receptors	O
and	O
moderate	O
affinity	O
at	O
the	O
D2	O
receptor.	O
7e	O
exhibits	O
a	O
high	O
reversal	O
of	O
catalepsy	Disease
induced	O
by	O
haloperidol	Chemical

Sub-chronic	O
inhibition	O
of	O
nitric-oxide	Chemical
synthesis	O
modifies	O
haloperidol	Chemical
-induced	O
catalepsy	Disease
and	O
the	O
number	O
of	O
NADPH	Chemical
-diaphorase	O
neurons	O
in	O
mice.	O
RATIONALE:	O
NG-nitro-L-arginine	Chemical
(	O
L-NOARG	Chemical
),	O
an	O
inhibitor	O
of	O
nitric-oxide	Chemical
synthase	O
(NOS),	O
induces	O
catalepsy	Disease
in	O
mice.	O
This	O
effect	O
undergoes	O
rapid	O
tolerance,	O
showing	O
a	O
significant	O
decrease	O
after	O
2	O
days	O
of	O
sub-chronic	O
L-NOARG	Chemical
treatment.	O
Nitric	Chemical
oxide	Chemical
(	O
NO	Chemical
)	O
has	O
been	O
shown	O
to	O
influence	O
dopaminergic	O
neurotransmission	O
in	O
the	O
striatum.	O
Neuroleptic	O
drugs	O
such	O
as	O
haloperidol	Chemical
,	O
which	O
block	O
dopamine	Chemical
receptors,	O
also	O
cause	O
catalepsy	Disease
in	O
rodents.	O
OBJECTIVES:	O
To	O
investigate	O
the	O
effects	O
of	O
subchronic	O
L-NOARG	Chemical
treatment	O
in	O
haloperidol	Chemical
-induced	O
catalepsy	Disease
and	O
the	O
number	O
of	O
NOS	O
neurons	O
in	O
areas	O
related	O
to	O
motor	O
control.	O
METHODS:	O
Male	O
albino	O
Swiss	O
mice	O
were	O
treated	O
sub-chronically	O
(twice	O
a	O
day	O
for	O
4	O
days)	O
with	O
L-NOARG	Chemical
(40	O
mg/kg	O
i.p.)	O
or	O
haloperidol	Chemical
(1	O
mg/kg	O
i.p.).	O
Catalepsy	Disease
was	O
evaluated	O
at	O
the	O
beginning	O
and	O
the	O
end	O
of	O
the	O
treatments.	O
Reduced	O
nicotinamide	Chemical
adenine	Chemical
dinucleotide	Chemical
phosphate	Chemical
-diaphorase	O
(	O
NADPH	Chemical
-d)	O
histochemistry	O
was	O
also	O
employed	O
to	O
visualize	O
NOS	O
as	O
an	O
index	O
of	O
enzyme	O
expression	O
in	O
mice	O
brain	O
regions	O
related	O
to	O
motor	O
control.	O
RESULTS:	O
L-NOARG	Chemical
sub-chronic	O
administration	O
produced	O
tolerance	O
of	O
L-NOARG	Chemical
and	O
of	O
haloperidol	Chemical
-induced	O
catalepsy	Disease
.	O
It	O
also	O
induced	O
an	O
increase	O
in	O
the	O
number	O
of	O
NADPH	Chemical
-d-positive	O
cells	O
in	O
the	O
dorsal	O
part	O
of	O
the	O
caudate	O
and	O
accumbens	O
nuclei	O
compared	O
with	O
haloperidol	Chemical
and	O
in	O
the	O
pedunculopontine	O
tegmental	O
nucleus	O
compared	O
with	O
saline.	O
In	O
contrast,	O
there	O
was	O
a	O
decrease	O
in	O
NADPH	Chemical
-d	O
neuron	O
number	O
in	O
the	O
substantia	O
nigra,	O
pars	O
compacta	O
in	O
both	O
haloperidol	Chemical
-treated	O
and	O
L-NOARG	Chemical
-treated	O
animals.	O
CONCLUSIONS:	O
The	O
results	O
give	O
further	O
support	O
to	O
the	O
hypothesis	O
that	O
NO	Chemical

Prolonged	O
left	Disease
ventricular	Disease
dysfunction	Disease
occurs	O
in	O
patients	O
with	O
coronary	Disease
artery	Disease
disease	Disease
after	O
both	O
dobutamine	Chemical
and	O
exercise	O
induced	O
myocardial	Disease
ischaemia	Disease
.	O
OBJECTIVE:	O
To	O
determine	O
whether	O
pharmacological	O
stress	O
leads	O
to	O
prolonged	O
but	O
reversible	O
left	Disease
ventricular	Disease
dysfunction	Disease
in	O
patients	O
with	O
coronary	Disease
artery	Disease
disease	Disease
,	O
similar	O
to	O
that	O
seen	O
after	O
exercise.	O
DESIGN:	O
A	O
randomised	O
crossover	O
study	O
of	O
recovery	O
time	O
of	O
systolic	O
and	O
diastolic	O
left	O
ventricular	O
function	O
after	O
exercise	O
and	O
dobutamine	Chemical
induced	O
ischaemia	Disease
.	O
SUBJECTS:	O
10	O
patients	O
with	O
stable	Disease
angina	Disease
,	O
angiographically	O
proven	O
coronary	Disease
artery	Disease
disease	Disease
,	O
and	O
normal	O
left	O
ventricular	O
function.	O
INTERVENTIONS:	O
Treadmill	O
exercise	O
and	O
dobutamine	Chemical
stress	O
were	O
performed	O
on	O
different	O
days.	O
Quantitative	O
assessment	O
of	O
systolic	O
and	O
diastolic	O
left	O
ventricular	O
function	O
was	O
performed	O
using	O
transthoracic	O
echocardiography	O
at	O
baseline	O
and	O
at	O
regular	O
intervals	O
after	O
each	O
test.	O
RESULTS:	O
Both	O
forms	O
of	O
stress	O
led	O
to	O
prolonged	O
but	O
reversible	O
systolic	O
and	O
diastolic	O
dysfunction.	O
There	O
was	O
no	O
difference	O
in	O
the	O
maximum	O
double	O
product	O
(p	O
=	O
0.53)	O
or	O
ST	O
depression	Disease
(p	O
=	O
0.63)	O
with	O
either	O
form	O
of	O
stress.	O
After	O
exercise,	O
ejection	O
fraction	O
was	O
reduced	O
at	O
15	O
and	O
30	O
minutes	O
compared	O
with	O
baseline	O
(mean	O
(SEM),	O
-5.6	O
(1.5)%,	O
p	O
<	O
0.05;	O
and	O
-6.1	O
(2.2)%,	O
p	O
<	O
0.	O
01),	O
and	O
at	O
30	O
and	O
45	O
minutes	O
after	O
dobutamine	Chemical
(-10.8	O
(1.8)%	O
and	O
-5.	O
5	O
(1.8)%,	O
both	O
p	O
<	O
0.01).	O
Regional	O
analysis	O
showed	O
a	O
reduction	O
in	O
the	O
worst	O
affected	O
segment	O
15	O
and	O
30	O
minutes	O
after	O
exercise	O
(-27.9	O
(7.2)%	O
and	O
-28.6	O
(5.7)%,	O
both	O
p	O
<	O
0.01),	O
and	O
at	O
30	O
minutes	O
after	O
dobutamine	Chemical
(-32	O
(5.3)%,	O
p	O
<	O
0.01).	O
The	O
isovolumic	O
relaxation	O
period	O
was	O
prolonged	O
45	O
minutes	O
after	O
each	O
form	O
of	O
stress	O
(p	O
<	O
0.05).	O
CONCLUSIONS:	O
In	O
patients	O
with	O
coronary	Disease
artery	Disease
disease	Disease
,	O
dobutamine	Chemical
induced	O
ischaemia	Disease
results	O
in	O
prolonged	O
reversible	O
left	Disease
ventricular	Disease
dysfunction	Disease
,	O
presumed	O
to	O
be	O
myocardial	Disease
stunning	Disease
,	O
similar	O
to	O
that	O
seen	O
after	O
exercise.	O
Dobutamine	Chemical
induced	O
ischaemia	Disease
could	O
therefore	O
be	O
used	O
to	O
study	O
the	O
pathophysiology	O
of	O
this	O
phenomenon	O
further	O
in	O
patients	O
with	O
coronary	Disease
artery	Disease
disease	Disease

Anorexigens	O
and	O
pulmonary	Disease
hypertension	Disease
in	O
the	O
United	O
States:	O
results	O
from	O
the	O
surveillance	O
of	O
North	O
American	O
pulmonary	Disease
hypertension	Disease
.	O
BACKGROUND:	O
The	O
use	O
of	O
appetite	O
suppressants	O
in	O
Europe	O
has	O
been	O
associated	O
with	O
the	O
development	O
of	O
primary	Disease
pulmonary	Disease
hypertension	Disease
(	O
PPH	Disease
).	O
Recently,	O
fenfluramine	Chemical
appetite	O
suppressants	O
became	O
widely	O
used	O
in	O
the	O
United	O
States	O
but	O
were	O
withdrawn	O
in	O
September	O
1997	O
because	O
of	O
concerns	O
over	O
adverse	O
effects.	O
MATERIALS	O
AND	O
METHODS:	O
We	O
conducted	O
a	O
prospective	O
surveillance	O
study	O
on	O
patients	O
diagnosed	O
with	O
pulmonary	Disease
hypertension	Disease
at	O
12	O
large	O
referral	O
centers	O
in	O
North	O
America.	O
Data	O
collected	O
on	O
patients	O
seen	O
from	O
September	O
1,	O
1996,	O
to	O
December	O
31,	O
1997,	O
included	O
the	O
cause	O
of	O
the	O
pulmonary	Disease
hypertension	Disease
and	O
its	O
severity.	O
Patients	O
with	O
no	O
identifiable	O
cause	O
of	O
pulmonary	Disease
hypertension	Disease
were	O
classed	O
as	O
PPH	Disease
.	O
A	O
history	O
of	O
drug	O
exposure	O
also	O
was	O
taken	O
with	O
special	O
attention	O
on	O
the	O
use	O
of	O
antidepressants,	O
anorexigens,	O
and	O
amphetamines	Chemical
.	O
RESULTS:	O
Five	O
hundred	O
seventy-nine	O
patients	O
were	O
studied,	O
205	O
with	O
PPH	Disease
and	O
374	O
with	O
pulmonary	Disease
hypertension	Disease
from	O
other	O
causes	O
(secondary	O
pulmonary	Disease
hypertension	Disease
[SPH]).	O
The	O
use	O
of	O
anorexigens	O
was	O
common	O
in	O
both	O
groups.	O
However,	O
of	O
the	O
medications	O
surveyed,	O
only	O
the	O
fenfluramines	Chemical
had	O
a	O
significant	O
preferential	O
association	O
with	O
PPH	Disease
as	O
compared	O
with	O
SPH	O
(adjusted	O
odds	O
ratio	O
for	O
use	O
>	O
6	O
months,	O
7.5;	O
95%	O
confidence	O
interval,	O
1.7	O
to	O
32.4).	O
The	O
association	O
was	O
stronger	O
with	O
longer	O
duration	O
of	O
use	O
when	O
compared	O
to	O
shorter	O
duration	O
of	O
use	O
and	O
was	O
more	O
pronounced	O
in	O
recent	O
users	O
than	O
in	O
remote	O
users.	O
An	O
unexpectedly	O
high	O
(11.4%)	O
number	O
of	O
patients	O
with	O
SPH	O
had	O
used	O
anorexigens.	O
CONCLUSION:	O
The	O
magnitude	O
of	O
the	O
association	O
with	O
PPH	Disease
,	O
the	O
increase	O
of	O
association	O
with	O
increasing	O
duration	O
of	O
use,	O
and	O
the	O
specificity	O
for	O
fenfluramines	Chemical
are	O
consistent	O
with	O
previous	O
studies	O
indicating	O
that	O
fenfluramines	Chemical
are	O
causally	O
related	O
to	O
PPH	Disease
.	O
The	O
high	O
prevalence	O
of	O
anorexigen	O
use	O
in	O
patients	O
with	O
SPH	O
also	O
raises	O
the	O
possibility	O
that	O
these	O
drugs	O
precipitate	O
pulmonary	Disease
hypertension	Disease

Clinical	O
aspects	O
of	O
heparin	Chemical
-induced	O
thrombocytopenia	Disease
and	O
thrombosis	Disease
and	O
other	O
side	O
effects	O
of	O
heparin	Chemical
therapy.	O
Heparin	Chemical
,	O
first	O
used	O
to	O
prevent	O
the	O
clotting	O
of	O
blood	O
in	O
vitro,	O
has	O
been	O
clinically	O
used	O
to	O
treat	O
thrombosis	Disease
for	O
more	O
than	O
50	O
years.	O
Although	O
several	O
new	O
anticoagulant	O
drugs	O
are	O
in	O
development,	O
heparin	Chemical
remains	O
the	O
anticoagulant	O
of	O
choice	O
to	O
treat	O
acute	O
thrombotic	Disease
episodes.	O
The	O
clinical	O
effects	O
of	O
heparin	Chemical
are	O
meritorious,	O
but	O
side	O
effects	O
do	O
exist.	O
Bleeding	Disease
is	O
the	O
primary	O
untoward	O
effect	O
of	O
heparin	Chemical
.	O
Major	O
bleeding	Disease
is	O
of	O
primary	O
concern	O
in	O
patients	O
receiving	O
heparin	Chemical
therapy.	O
However,	O
additional	O
important	O
untoward	O
effects	O
of	O
heparin	Chemical
therapy	O
include	O
heparin	Chemical
-induced	O
thrombocytopenia	Disease
,	O
heparin	Chemical
-associated	O
osteoporosis	Disease
,	O
eosinophilia	Disease
,	O
skin	Disease
reactions	Disease
,	O
allergic	Disease
reactions	Disease
other	O
than	O
thrombocytopenia	Disease
,	O
alopecia	Disease
,	O
transaminasemia,	O
hyperkalemia	Disease
,	O
hypoaldosteronism	Disease
,	O
and	O
priapism	Disease
.	O
These	O
side	O
effects	O
are	O
relatively	O
rare	O
in	O
a	O
given	O
individual,	O
but	O
given	O
the	O
extremely	O
widespread	O
use	O
of	O
heparin	Chemical
,	O
some	O
are	O
quite	O
common,	O
particularly	O
HITT	Disease
and	O
osteoporosis	Disease
.	O
Although	O
reasonable	O
incidences	O
of	O
many	O
of	O
these	O
side	O
effects	O
can	O
be	O
"softly"	O
deduced	O
from	O
current	O
reports	O
dealing	O
with	O
unfractionated	O
heparin	Chemical
,	O
at	O
present	O
the	O
incidences	O
of	O
these	O
side	O
effects	O
with	O
newer	O
low	O
molecular	O
weight	O
heparins	Chemical

A	O
case	O
of	O
bilateral	O
optic	Disease
neuropathy	Disease
in	O
a	O
patient	O
on	O
tacrolimus	Chemical
(	O
FK506	Chemical
)	O
therapy	O
after	O
liver	O
transplantation.	O
PURPOSE:	O
To	O
report	O
a	O
case	O
of	O
bilateral	O
optic	Disease
neuropathy	Disease
in	O
a	O
patient	O
receiving	O
tacrolimus	Chemical
(	O
FK	Chemical
506	Chemical
,	O
Prograf;	O
Fujisawa	O
USA,	O
Inc,	O
Deerfield,	O
Illinois)	O
for	O
immunosuppression	O
after	O
orthotropic	O
liver	O
transplantation.	O
METHOD:	O
Case	O
report.	O
In	O
a	O
58-year-old	O
man	O
receiving	O
tacrolimus	Chemical
after	O
orthotropic	O
liver	O
transplantation,	O
serial	O
neuro-ophthalmologic	O
examinations	O
and	O
laboratory	O
studies	O
were	O
performed.	O
RESULTS:	O
The	O
patient	O
had	O
episodic	O
deterioration	O
of	O
vision	O
in	O
both	O
eyes,	O
with	O
clinical	O
features	O
resembling	O
ischemic	Disease
optic	Disease
neuropathies	Disease
.	O
Deterioration	Disease
of	Disease
vision	Disease
occurred	O
despite	O
discontinuation	O
of	O
the	O
tacrolimus	Chemical
.	O
CONCLUSION:	O
Tacrolimus	Chemical
and	O
other	O
immunosuppressive	O
agents	O
may	O
be	O
associated	O
with	O
optic	Disease
nerve	Disease
toxicity	Disease

Hypercalcemia	Disease
,	O
arrhythmia	Disease
,	O
and	O
mood	O
stabilizers.	O
Recent	O
findings	O
in	O
a	O
bipolar	Disease
patient	O
receiving	O
maintenance	O
lithium	Chemical
therapy	O
who	O
developed	O
hypercalcemia	Disease
and	O
severe	O
bradyarrhythmia	Disease
prompted	O
the	O
authors	O
to	O
conduct	O
a	O
retrospective	O
study	O
of	O
bipolar	Disease
patients	O
with	O
lithium	Chemical
-associated	O
hypercalcemia	Disease
.	O
A	O
printout	O
of	O
all	O
cases	O
of	O
hypercalcemia	Disease
that	O
presented	O
during	O
a	O
1-year	O
period	O
was	O
generated.	O
After	O
eliminating	O
spurious	O
hypercalcemias	Disease
or	O
those	O
associated	O
with	O
intravenous	O
fluids,	O
the	O
authors	O
identified	O
18	O
non-	O
lithium	Chemical
-treated	O
patients	O
with	O
hypercalcemias	Disease
related	O
to	O
malignancies	Disease
and	O
other	O
medical	O
conditions	O
(group	O
A)	O
and	O
12	O
patients	O
with	O
lithium	Chemical
-associated	O
hypercalcemia	Disease
(group	O
B).	O
Patients	O
in	O
group	O
B	O
were	O
not	O
comparable	O
to	O
those	O
in	O
group	O
A,	O
as	O
the	O
latter	O
were	O
medically	O
compromised	O
and	O
were	O
receiving	O
multiple	O
pharmacotherapies.	O
Thus,	O
two	O
control	O
groups	O
were	O
generated:	O
group	O
C1,	O
which	O
included	O
age-	O
and	O
sex-comparable	O
lithium	Chemical
-treated	O
bipolar	Disease
normocalcemic	O
patients,	O
and	O
group	O
C2,	O
which	O
included	O
bipolar	Disease
normocalcemic	O
patients	O
treated	O
with	O
anticonvulsant	O
mood	O
stabilizers.	O
The	O
electrocardiographic	O
(ECG)	O
findings	O
for	O
patients	O
in	O
group	O
B	O
were	O
compared	O
with	O
those	O
of	O
patients	O
in	O
groups	O
C1	O
and	O
C2.	O
It	O
was	O
found	O
that	O
these	O
groups	O
did	O
not	O
differ	O
in	O
their	O
overall	O
frequency	O
of	O
ECG	O
abnormalities;	O
however,	O
there	O
were	O
significant	O
differences	O
in	O
the	O
frequency	O
of	O
conduction	O
defects.	O
Patients	O
with	O
hypercalcemia	Disease
resulting	O
from	O
medical	O
diseases	O
and	O
bipolar	Disease
patients	O
with	O
lithium	Chemical
-associated	O
hypercalcemia	Disease

Attenuation	O
of	O
nephrotoxicity	Disease
by	O
a	O
novel	O
lipid	O
nanosphere	O
(NS-718)	O
incorporating	O
amphotericin	Chemical
B	Chemical
.	O
NS-718,	O
a	O
lipid	O
nanosphere	O
incorporating	O
amphotericin	Chemical
B	Chemical
,	O
is	O
effective	O
against	O
pathogenic	O
fungi	O
and	O
has	O
low	O
toxicity	Disease
.	O
We	O
compared	O
the	O
toxicity	Disease
of	O
NS-718	O
with	O
that	O
of	O
Fungizone	Chemical
(	O
amphotericin	Chemical
B-sodium	Chemical
deoxycholate	Chemical
;	O
D-AmB	Chemical
)	O
in	O
vitro	O
using	O
renal	O
cell	O
cultures	O
and	O
in	O
vivo	O
by	O
biochemical	O
analysis,	O
histopathological	O
study	O
of	O
the	O
kidney	O
and	O
pharmacokinetic	O
study	O
of	O
amphotericin	Chemical
B	Chemical
following	O
intravenous	O
infusion	O
of	O
the	O
formulation	O
in	O
rats.	O
Incubation	O
with	O
NS-718	O
resulted	O
in	O
significantly	O
less	O
damage	O
of	O
cultured	O
human	O
renal	O
proximal	O
tubular	O
epithelial	O
cells	O
compared	O
with	O
D-AmB	Chemical
.	O
Serum	O
blood	O
urea	Chemical
and	O
creatinine	Chemical
concentrations	O
increased	O
significantly	O
in	O
rats	O
given	O
an	O
iv	O
infusion	O
of	O
D-AmB	Chemical
3	O
mg/kg	O
but	O
not	O
in	O
those	O
given	O
the	O
same	O
dose	O
of	O
NS-718.	O
Histopathological	O
examination	O
of	O
the	O
kidney	O
showed	O
tubular	Disease
necrosis	Disease
in	O
D-AmB	Chemical
-treated	O
rats	O
but	O
no	O
change	O
in	O
NS-718-treated	O
rats.	O
Amphotericin	Chemical
B	Chemical
concentrations	O
in	O
the	O
kidney	O
in	O
NS-718-treated	O
rats	O
were	O
higher	O
than	O
those	O
in	O
D-AmB	Chemical
-treated	O
rats.	O
Our	O
in	O
vitro	O
and	O
in	O
vivo	O
results	O
suggest	O
that	O
incorporation	O
of	O
amphotericin	Chemical
B	Chemical
into	O
lipid	O
nanospheres	O
of	O
NS-718	O
attenuates	O
the	O
nephrotoxicity	Disease
of	O
amphotericin	Chemical
B	Chemical

Patterns	O
of	O
sulfadiazine	Chemical
	O
acute	Disease
nephrotoxicity	Disease
.	O
Sulfadiazine	Chemical
	O
acute	Disease
nephrotoxicity	Disease
is	O
reviving	O
specially	O
because	O
of	O
its	O
use	O
in	O
toxoplasmosis	Disease
in	O
HIV-positive	O
patients.	O
We	O
report	O
4	O
cases,	O
one	O
of	O
them	O
in	O
a	O
previously	O
healthy	O
person.	O
Under	O
treatment	O
with	O
sulfadiazine	Chemical
they	O
developed	O
oliguria	Disease
,	O
abdominal	Disease
pain	Disease
,	O
renal	Disease
failure	Disease
and	O
showed	O
multiple	O
radiolucent	O
renal	Disease
calculi	Disease
in	O
echography.	O
All	O
patients	O
recovered	O
their	O
previous	O
normal	O
renal	O
function	O
after	O
adequate	O
hydration	O
and	O
alcalinization.	O
A	O
nephrostomy	O
tube	O
had	O
to	O
be	O
placed	O
in	O
one	O
of	O
the	O
patients	O
for	O
ureteral	Disease
lithiasis	Disease
in	O
a	O
single	O
functional	O
kidney.	O
None	O
of	O
them	O
needed	O
dialysis	O
or	O
a	O
renal	O
biopsy	O
because	O
of	O
a	O
typical	O
benign	O
course.	O
Treatment	O
with	O
sulfadiazine	Chemical

Downbeat	Disease
nystagmus	Disease
associated	O
with	O
intravenous	O
patient-controlled	O
administration	O
of	O
morphine	Chemical
.	O
IMPLICATIONS:	O
This	O
case	O
documents	O
a	O
patient	O
who	O
developed	O
dizziness	Disease
with	O
downbeating	Disease
nystagmus	Disease
while	O
receiving	O
a	O
relatively	O
large	O
dose	O
of	O
IV	O
patient-controlled	O
analgesia	O
morphine	Chemical
.	O
Although	O
there	O
have	O
been	O
case	O
reports	O
of	O
epidural	O
morphine	Chemical
with	O
these	O
symptoms	O
and	O
signs,	O
this	O
has	O
not	O
been	O
previously	O
documented	O
with	O
IV	O
or	O
patient-controlled	O
analgesia	O
morphine	Chemical

Hemodynamic	O
and	O
antiadrenergic	O
effects	O
of	O
dronedarone	Chemical
and	O
amiodarone	Chemical
in	O
animals	O
with	O
a	O
healed	O
myocardial	Disease
infarction	Disease
.	O
The	O
hemodynamic	O
and	O
antiadrenergic	O
effects	O
of	O
dronedarone	Chemical
,	O
a	O
noniodinated	O
compound	O
structurally	O
related	O
to	O
amiodarone	Chemical
,	O
were	O
compared	O
with	O
those	O
of	O
amiodarone	Chemical
after	O
prolonged	O
oral	O
administration,	O
both	O
at	O
rest	O
and	O
during	O
sympathetic	O
stimulation	O
in	O
conscious	O
dogs	O
with	O
a	O
healed	O
myocardial	Disease
infarction	Disease
.	O
All	O
dogs	O
(n	O
=	O
6)	O
randomly	O
received	O
orally	O
dronedarone	Chemical
(10	O
and	O
30	O
mg/kg),	O
amiodarone	Chemical
(10	O
and	O
30	O
mg/kg),	O
and	O
placebo	O
twice	O
daily	O
for	O
7	O
days,	O
with	O
a	O
3-week	O
washout	O
between	O
consecutive	O
treatments.	O
Heart	O
rate	O
(HR),	O
mean	O
arterial	O
pressure	O
(MBP),	O
positive	O
rate	O
of	O
increase	O
of	O
left	O
ventricular	O
pressure	O
(+LVdP/dt),	O
echocardiographically	O
assessed	O
left	O
ventricular	O
ejection	O
fraction	O
(LVEF),	O
and	O
fractional	O
shortening	O
(FS),	O
as	O
well	O
as	O
chronotropic	O
response	O
to	O
isoproterenol	Chemical
and	O
exercise-induced	O
sympathetic	O
stimulation	O
were	O
evaluated	O
under	O
baseline	O
and	O
posttreatment	O
conditions.	O
Resting	O
values	O
of	O
LVEF,	O
FS,	O
+LVdP/dt,	O
and	O
MBP	O
remained	O
unchanged	O
whatever	O
the	O
drug	O
and	O
the	O
dosing	O
regimen,	O
whereas	O
resting	O
HR	O
was	O
significantly	O
and	O
dose-dependently	O
lowered	O
after	O
dronedarone	Chemical
and	O
to	O
a	O
lesser	O
extent	O
after	O
amiodarone	Chemical
.	O
Both	O
dronedarone	Chemical
and	O
amiodarone	Chemical
significantly	O
reduced	O
the	O
exercise-induced	O
tachycardia	Disease
and,	O
at	O
the	O
highest	O
dose,	O
decreased	O
the	O
isoproterenol	Chemical
-induced	O
tachycardia	Disease
.	O
Thus,	O
dronedarone	Chemical
and	O
amiodarone	Chemical
displayed	O
a	O
similar	O
level	O
of	O
antiadrenergic	O
effect	O
and	O
did	O
not	O
impair	O
the	O
resting	O
left	O
ventricular	O
function.	O
Consequently,	O
dronedarone	Chemical
might	O
be	O
particularly	O
suitable	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
various	O
clinical	O
arrhythmias	Disease

Phase	O
2	O
trial	O
of	O
liposomal	O
doxorubicin	Chemical
(40	O
mg/m(2))	O
in	O
platinum	Chemical
/	O
paclitaxel	Chemical
-refractory	O
ovarian	Disease
and	Disease
fallopian	Disease
tube	Disease
cancers	Disease
and	O
primary	O
carcinoma	Disease
of	Disease
the	Disease
peritoneum	Disease
.	O
BACKGROUND:	O
Several	O
studies	O
have	O
demonstrated	O
liposomal	O
doxorubicin	Chemical
(	O
Doxil	Chemical
)	O
to	O
be	O
an	O
active	O
antineoplastic	O
agent	O
in	O
platinum	Chemical
-resistant	O
ovarian	Disease
cancer	Disease
,	O
with	O
dose	O
limiting	O
toxicity	Disease
of	O
the	O
standard	O
dosing	O
regimen	O
(50	O
mg/m(2)	O
q	O
4	O
weeks)	O
being	O
severe	O
erythrodysesthesia	Disease
("	O
hand-foot	Disease
syndrome	Disease
")	O
and	O
stomatitis	Disease
.	O
We	O
wished	O
to	O
develop	O
a	O
more	O
tolerable	O
liposomal	O
doxorubicin	Chemical
treatment	O
regimen	O
and	O
document	O
its	O
level	O
of	O
activity	O
in	O
a	O
well-defined	O
patient	O
population	O
with	O
platinum	Chemical
/	O
paclitaxel	Chemical
-refractory	O
disease.	O
METHODS	O
AND	O
MATERIALS:	O
Patients	O
with	O
ovarian	Disease
or	Disease
fallopian	Disease
tube	Disease
cancers	Disease
or	O
primary	O
peritoneal	Disease
carcinoma	Disease
with	O
platinum	Chemical
/	O
paclitaxel	Chemical
-refractory	O
disease	O
(stable	O
or	O
progressive	O
disease	O
following	O
treatment	O
with	O
these	O
agents	O
or	O
previous	O
objective	O
response	O
<3	O
months	O
in	O
duration)	O
were	O
treated	O
with	O
liposomal	O
doxorubicin	Chemical
at	O
a	O
dose	O
of	O
40	O
mg/m(2)	O
q	O
4	O
weeks.	O
RESULTS:	O
A	O
total	O
of	O
49	O
patients	O
(median	O
age:	O
60;	O
range	O
41-81)	O
entered	O
this	O
phase	O
2	O
trial.	O
The	O
median	O
number	O
of	O
prior	O
regimens	O
was	O
2	O
(range:	O
1-6).	O
Six	O
(12%)	O
and	O
4	O
(8%)	O
patients	O
experienced	O
grade	O
2	O
hand-foot	Disease
syndrome	Disease
and	O
stomatitis	Disease
,	O
respectively	O
(no	O
episodes	O
of	O
grade	O
3).	O
One	O
patient	O
developed	O
grade	O
3	O
diarrhea	Disease
requiring	O
hospitalization	O
for	O
hydration.	O
Six	O
(12%)	O
individuals	O
required	O
dose	O
reductions.	O
The	O
median	O
number	O
of	O
courses	O
of	O
liposomal	O
doxorubicin	Chemical
administered	O
on	O
this	O
protocol	O
was	O
2	O
(range:	O
1-12).	O
Four	O
of	O
44	O
patients	O
(9%)	O
evaluable	O
for	O
response	O
exhibited	O
objective	O
and	O
subjective	O
evidence	O
of	O
an	O
antineoplastic	O
effect	O
of	O
therapy.	O
CONCLUSION:	O
This	O
modified	O
liposomal	O
doxorubicin	Chemical
regimen	O
results	O
in	O
less	O
toxicity	Disease
(	O
stomatitis	Disease
,	O
hand-foot	Disease
syndrome	Disease
)	O
than	O
the	O
standard	O
FDA-approved	O
dose	O
schedule.	O
Definite,	O
although	O
limited,	O
antineoplastic	O
activity	O
is	O
observed	O
in	O
patients	O
with	O
well-defined	O
platinum	Chemical
-	O
and	O
paclitaxel	Chemical
-refractory	O
ovarian	Disease
cancer	Disease

Efficacy	O
of	O
olanzapine	Chemical
in	O
acute	O
bipolar	Disease
mania	Disease
:	O
a	O
double-blind,	O
placebo-controlled	O
study.	O
The	O
Olanzipine	Chemical
HGGW	O
Study	O
Group.	O
BACKGROUND:	O
We	O
compared	O
the	O
efficacy	O
and	O
safety	O
of	O
olanzapine	Chemical
vs	O
placebo	O
for	O
the	O
treatment	O
of	O
acute	O
bipolar	Disease
mania	Disease
.	O
METHODS:	O
Four-week,	O
randomized,	O
double-blind,	O
parallel	O
study.	O
A	O
total	O
of	O
115	O
patients	O
with	O
a	O
DSM-IV	O
diagnosis	O
of	O
bipolar	Disease
disorder	Disease
,	O
manic	Disease
or	O
mixed,	O
were	O
randomized	O
to	O
olanzapine	Chemical
,	O
5	O
to	O
20	O
mg/d	O
(n	O
=	O
55),	O
or	O
placebo	O
(n	O
=	O
60).	O
The	O
primary	O
efficacy	O
measure	O
was	O
the	O
Young-	O
Mania	Disease
Rating	O
Scale	O
(Y-MRS)	O
total	O
score.	O
Response	O
and	O
euthymia	O
were	O
defined,	O
a	O
priori,	O
as	O
at	O
least	O
a	O
50%	O
improvement	O
from	O
baseline	O
to	O
end	O
point	O
and	O
as	O
a	O
score	O
of	O
no	O
less	O
than	O
12	O
at	O
end	O
point	O
in	O
the	O
Y-MRS	O
total	O
score,	O
respectively.	O
Safety	O
was	O
assessed	O
using	O
adverse	O
events,	O
Extrapyramidal	Disease
Symptom	Disease
(	O
EPS	Disease
)	O
rating	O
scales,	O
laboratory	O
values,	O
electrocardiograms,	O
vital	O
signs,	O
and	O
weight	O
change.	O
RESULTS:	O
Olanzapine	Chemical
-treated	O
patients	O
demonstrated	O
a	O
statistically	O
significant	O
greater	O
mean	O
(+/-	O
SD)	O
improvement	O
in	O
Y-MRS	O
total	O
score	O
than	O
placebo-treated	O
patients	O
(-14.8	O
+/-	O
12.5	O
and	O
-8.1	O
+/-	O
12.7,	O
respectively;	O
P<.001),	O
which	O
was	O
evident	O
at	O
the	O
first	O
postbaseline	O
observation	O
1	O
week	O
after	O
randomization	O
and	O
was	O
maintained	O
throughout	O
the	O
study	O
(last	O
observation	O
carried	O
forward).	O
Olanzapine	Chemical
-treated	O
patients	O
demonstrated	O
a	O
higher	O
rate	O
of	O
response	O
(65%	O
vs	O
43%,	O
respectively;	O
P	O
=.02)	O
and	O
euthymia	O
(61%	O
vs	O
36%,	O
respectively;	O
P	O
=.	O
01)	O
than	O
placebo-treated	O
patients.	O
There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
EPSs	Disease
between	O
groups.	O
However,	O
olanzapine	Chemical
-treated	O
patients	O
had	O
a	O
statistically	O
significant	O
greater	O
mean	O
(+/-	O
SD)	O
weight	Disease
gain	Disease
than	O
placebo-treated	O
patients	O
(2.1	O
+/-	O
2.8	O
vs	O
0.45	O
+/-	O
2.3	O
kg,	O
respectively)	O
and	O
also	O
experienced	O
more	O
treatment-emergent	O
somnolence	Disease
(21	O
patients	O
[38.2%]	O
vs	O
5	O
[8.3%	O
],	O
respectively).	O
CONCLUSION:	O
Olanzapine	Chemical
demonstrated	O
greater	O
efficacy	O
than	O
placebo	O
in	O
the	O
treatment	O
of	O
acute	O
bipolar	Disease
mania	Disease

The	O
effect	O
of	O
pupil	Disease
dilation	Disease
with	O
tropicamide	Chemical
on	O
vision	O
and	O
driving	O
simulator	O
performance.	O
PURPOSE:	O
To	O
assess	O
the	O
effect	O
of	O
pupil	Disease
dilation	Disease
on	O
vision	O
and	O
driving	O
ability.	O
METHODS:	O
A	O
series	O
of	O
tests	O
on	O
various	O
parameters	O
of	O
visual	O
function	O
and	O
driving	O
simulator	O
performance	O
were	O
performed	O
on	O
12	O
healthy	O
drivers,	O
before	O
and	O
after	O
pupil	Disease
dilation	Disease
using	O
guttae	O
tropicamide	Chemical
1%.	O
A	O
driving	O
simulator	O
(Transport	O
Research	O
Laboratory)	O
was	O
used	O
to	O
measure	O
reaction	O
time	O
(RT),	O
speed	O
maintenance	O
and	O
steering	O
accuracy.	O
Tests	O
of	O
basic	O
visual	O
function	O
included	O
high-	O
and	O
low-contrast	O
visual	O
acuity	O
(HCVA	O
and	O
LCVA),	O
Pelli-Robson	O
contrast	O
threshold	O
(CT)	O
and	O
Goldmann	O
perimetry	O
(FIELDS).	O
Useful	O
Field	O
of	O
View	O
(UFOV--a	O
test	O
of	O
visual	O
attention)	O
was	O
also	O
undertaken.	O
The	O
mean	O
differences	O
in	O
the	O
pre-	O
and	O
post-dilatation	O
measurements	O
were	O
tested	O
for	O
statistical	O
significance	O
at	O
the	O
95%	O
level	O
using	O
one-tail	O
paired	O
t-tests.	O
RESULTS:	O
Pupillary	Disease
dilation	Disease
resulted	O
in	O
a	O
statistically	O
significant	O
deterioration	O
in	O
CT	O
and	O
HCVA	O
only.	O
Five	O
of	O
12	O
drivers	O
also	O
exhibited	O
deterioration	O
in	O
LCVA,	O
CT	O
and	O
RT.	O
Little	O
evidence	O
emerged	O
for	O
deterioration	O
in	O
FIELDS	O
and	O
UFOV.	O
Also,	O
7	O
of	O
12	O
drivers	O
appeared	O
to	O
adjust	O
their	O
driving	O
behaviour	O
by	O
reducing	O
their	O
speed	O
on	O
the	O
driving	O
simulator,	O
leading	O
to	O
improved	O
steering	O
accuracy.	O
CONCLUSIONS:	O
Pupillary	Disease
dilation	Disease

A	O
case	O
of	O
isotretinoin	Disease
embryopathy	Disease
with	O
bilateral	O
anotia	Disease
and	O
Taussig-Bing	Disease
malformation	Disease
.	O
We	O
report	O
a	O
newborn	O
infant	O
with	O
multiple	O
congenital	O
anomalies	O
(	O
anotia	Disease
and	O
Taussig-Bing	Disease
malformation	Disease
)	O
due	O
to	O
exposure	O
to	O
isotretinoin	Chemical
within	O
the	O
first	O
trimester.	O
In	O
this	O
paper	O
we	O
aim	O
to	O
draw	O
to	O
the	O
fact	O
that	O
caution	O
is	O
needed	O
when	O
prescribing	O
vitamin	Chemical
A	Chemical

Effect	O
of	O
methoxamine	Chemical
on	O
maximum	O
urethral	O
pressure	O
in	O
women	O
with	O
genuine	O
stress	Disease
incontinence	Disease
:	O
a	O
placebo-controlled,	O
double-blind	O
crossover	O
study.	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
the	O
potential	O
role	O
for	O
a	O
selective	O
alpha1-adrenoceptor	O
agonist	O
in	O
the	O
treatment	O
of	O
urinary	Disease
stress	Disease
incontinence	Disease
.	O
A	O
randomised,	O
double-blind,	O
placebo-controlled,	O
crossover	O
study	O
design	O
was	O
employed.	O
Half	O
log	O
incremental	O
doses	O
of	O
intravenous	O
methoxamine	Chemical
or	O
placebo	O
(saline)	O
were	O
administered	O
to	O
a	O
group	O
of	O
women	O
with	O
genuine	O
stress	Disease
incontinence	Disease
while	O
measuring	O
maximum	O
urethral	O
pressure	O
(MUP),	O
blood	O
pressure,	O
heart	O
rate,	O
and	O
symptomatic	O
side	O
effects.	O
Methoxamine	Chemical
evoked	O
non-significant	O
increases	O
in	O
MUP	O
and	O
diastolic	O
blood	O
pressure	O
but	O
caused	O
a	Disease
significant	Disease
rise	Disease
in	Disease
systolic	Disease
blood	Disease
pressure	Disease
and	O
significant	O
fall	O
in	O
heart	O
rate	O
at	O
maximum	O
dosage.	O
Systemic	O
side	O
effects	O
including	O
piloerection,	O
headache	Disease
,	O
and	O
cold	O
extremities	O
were	O
experienced	O
in	O
all	O
subjects.	O
The	O
results	O
indicate	O
that	O
the	O
clinical	O
usefulness	O
of	O
direct,	O
peripherally	O
acting	O
sub-type-selective	O
alpha1-adrenoceptor	O
agonists	O
in	O
the	O
medical	O
treatment	O
of	O
stress	Disease
incontinence	Disease

Toleration	O
of	O
high	O
doses	O
of	O
angiotensin-converting	Chemical
enzyme	Chemical
inhibitors	Chemical
in	O
patients	O
with	O
chronic	O
heart	Disease
failure	Disease
:	O
results	O
from	O
the	O
ATLAS	O
trial.	O
The	O
Assessment	O
of	O
Treatment	O
with	O
Lisinopril	Chemical
and	O
Survival.	O
BACKGROUND:	O
Treatment	O
with	O
angiotensin-converting	Chemical
enzyme	Chemical
(ACE)	Chemical
inhibitors	Chemical
reduces	O
mortality	O
and	O
morbidity	O
in	O
patients	O
with	O
chronic	O
heart	Disease
failure	Disease
(	O
CHF	Disease
),	O
but	O
most	O
affected	O
patients	O
are	O
not	O
receiving	O
these	O
agents	O
or	O
are	O
being	O
treated	O
with	O
doses	O
lower	O
than	O
those	O
found	O
to	O
be	O
efficacious	O
in	O
trials,	O
primarily	O
because	O
of	O
concerns	O
about	O
the	O
safety	O
and	O
tolerability	O
of	O
these	O
agents,	O
especially	O
at	O
the	O
recommended	O
doses.	O
The	O
present	O
study	O
examines	O
the	O
safety	O
and	O
tolerability	O
of	O
high-	O
compared	O
with	O
low-dose	O
lisinopril	Chemical
in	O
CHF	Disease
.	O
METHODS:	O
The	O
Assessment	O
of	O
Lisinopril	Chemical
and	O
Survival	O
study	O
was	O
a	O
multicenter,	O
randomized,	O
double-blind	O
trial	O
in	O
which	O
patients	O
with	O
or	O
without	O
previous	O
ACE	Chemical
inhibitor	Chemical
treatment	O
were	O
stabilized	O
receiving	O
medium-dose	O
lisinopril	Chemical
(12.5	O
or	O
15.0	O
mg	O
once	O
daily	O
[OD])	O
for	O
2	O
to	O
4	O
weeks	O
and	O
then	O
randomized	O
to	O
high-	O
(35.0	O
or	O
32.5	O
mg	O
OD)	O
or	O
low-dose	O
(5.0	O
or	O
2.5	O
mg	O
OD)	O
groups.	O
Patients	O
with	O
New	O
York	O
Heart	O
Association	O
classes	O
II	O
to	O
IV	O
CHF	Disease
and	O
left	O
ventricular	O
ejection	O
fractions	O
of	O
no	O
greater	O
than	O
0.30	O
(n	O
=	O
3164)	O
were	O
randomized	O
and	O
followed	O
up	O
for	O
a	O
median	O
of	O
46	O
months.	O
We	O
examined	O
the	O
occurrence	O
of	O
adverse	O
events	O
and	O
the	O
need	O
for	O
discontinuation	O
and	O
dose	O
reduction	O
during	O
treatment,	O
with	O
a	O
focus	O
on	O
hypotension	Disease
and	O
renal	Disease
dysfunction	Disease
.	O
RESULTS:	O
Of	O
405	O
patients	O
not	O
previously	O
receiving	O
an	O
ACE	Chemical
inhibitor	Chemical
,	O
doses	O
in	O
only	O
4.2%	O
could	O
not	O
be	O
titrated	O
to	O
the	O
medium	O
doses	O
required	O
for	O
randomization	O
because	O
of	O
symptoms	O
possibly	O
related	O
to	O
hypotension	Disease
(2.0%)	O
or	O
because	O
of	O
renal	Disease
dysfunction	Disease
or	O
hyperkalemia	Disease
(2.3%).	O
Doses	O
in	O
more	O
than	O
90%	O
of	O
randomized	O
patients	O
in	O
the	O
high-	O
and	O
low-dose	O
groups	O
were	O
titrated	O
to	O
their	O
assigned	O
target,	O
and	O
the	O
mean	O
doses	O
of	O
blinded	O
medication	O
in	O
both	O
groups	O
remained	O
similar	O
throughout	O
the	O
study.	O
Withdrawals	O
occurred	O
in	O
27.1%	O
of	O
the	O
high-	O
and	O
30.7%	O
of	O
the	O
low-dose	O
groups.	O
Subgroups	O
presumed	O
to	O
be	O
at	O
higher	O
risk	O
for	O
ACE	Chemical
inhibitor	Chemical
intolerance	O
(blood	O
pressure,	O
<120	O
mm	O
Hg;	O
creatinine	Chemical
,	O
>	O
or	O
=132.6	O
micromol/L	O
[>	O
or	O
=1.5	O
mg/dL];	O
age,	O
>	O
or	O
=70	O
years;	O
and	O
patients	O
with	O
diabetes	Disease
)	O
generally	O
tolerated	O
the	O
high-dose	O
strategy.	O
CONCLUSIONS:	O
These	O
findings	O
demonstrate	O
that	O
ACE	Chemical
inhibitor	Chemical
therapy	O
in	O
most	O
patients	O
with	O
CHF	Disease

Cocaine	Chemical
,	O
ethanol	Chemical
,	O
and	O
cocaethylene	Chemical
	O
cardiotoxity	Disease
in	O
an	O
animal	O
model	O
of	O
cocaine	Disease
and	Disease
ethanol	Disease
abuse	Disease
.	O
OBJECTIVES:	O
Simultaneous	O
abuse	Disease
of	Disease
cocaine	Disease
and	Disease
ethanol	Disease
affects	O
12	O
million	O
Americans	O
annually.	O
In	O
combination,	O
these	O
substances	O
are	O
substantially	O
more	O
toxic	O
than	O
either	O
drug	O
alone.	O
Their	O
combined	O
cardiac	Disease
toxicity	Disease
may	O
be	O
due	O
to	O
independent	O
effects	O
of	O
each	O
drug;	O
however,	O
they	O
may	O
also	O
be	O
due	O
to	O
cocaethylene	Chemical
(	O
CE	Chemical
),	O
a	O
cocaine	Chemical
metabolite	O
formed	O
only	O
in	O
the	O
presence	O
of	O
ethanol	Chemical
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
delineate	O
the	O
role	O
of	O
CE	Chemical
in	O
the	O
combined	O
cardiotoxicity	Disease
of	O
cocaine	Chemical
and	O
ethanol	Chemical
in	O
a	O
model	O
simulating	O
their	O
abuse.	O
METHODS:	O
Twenty-three	O
dogs	O
were	O
randomized	O
to	O
receive	O
either	O
1)	O
three	O
intravenous	O
(IV)	O
boluses	O
of	O
cocaine	Chemical
7.5	O
mg/kg	O
with	O
ethanol	Chemical
(1	O
g/kg)	O
as	O
an	O
IV	O
infusion	O
(C+E,	O
n	O
=	O
8),	O
2)	O
three	O
cocaine	Chemical
boluses	O
only	O
(C,	O
n	O
=	O
6),	O
3)	O
ethanol	Chemical
infusion	O
only	O
(E,	O
n	O
=	O
5),	O
or	O
4)	O
placebo	O
boluses	O
and	O
infusion	O
(n	O
=	O
4).	O
Hemodynamic	O
measurements,	O
electrocardiograms,	O
and	O
serum	O
drug	O
concentrations	O
were	O
obtained	O
at	O
baseline,	O
and	O
then	O
at	O
fixed	O
time	O
intervals	O
after	O
each	O
drug	O
was	O
administered.	O
RESULTS:	O
Two	O
of	O
eight	O
dogs	O
in	O
the	O
C+E	O
group	O
experienced	O
cardiovascular	Disease
collapse	Disease
.	O
The	O
most	O
dramatic	O
hemodynamic	O
changes	O
occurred	O
after	O
each	O
cocaine	Chemical
bolus	O
in	O
the	O
C+E	O
and	O
C	O
only	O
groups;	O
however,	O
persistent	O
hemodynamic	O
changes	O
occurred	O
in	O
the	O
C+E	O
group.	O
Peak	O
CE	Chemical
levels	O
were	O
associated	O
with	O
a	O
45%	O
(SD	O
+/-	O
22%,	O
95%	O
CI	O
=	O
22%	O
to	O
69%)	O
decrease	Disease
in	Disease
cardiac	Disease
output	Disease
(p	O
<	O
0.05),	O
a	O
56%	O
(SD	O
+/-	O
23%,	O
95%	O
CI	O
=	O
32%	O
to	O
80%)	O
decrease	O
in	O
dP/dt(max)	O
(p	O
<.006),	O
and	O
a	O
23%	O
(SD	O
+/-	O
15%,	O
95%	O
CI	O
=	O
7%	O
to	O
49%)	O
decrease	O
in	O
SVO(2)	O
(p	O
<	O
0.025).	O
Ventricular	Disease
arrhythmias	Disease
were	O
primarily	O
observed	O
in	O
the	O
C+E	O
group,	O
in	O
which	O
four	O
of	O
eight	O
dogs	O
experienced	O
ventricular	Disease
tachycardia	Disease
.	O
CONCLUSIONS:	O
Cocaine	Chemical
and	O
ethanol	Chemical
in	O
combination	O
were	O
more	O
toxic	O
than	O
either	O
substance	O
alone.	O
Co-administration	O
resulted	O
in	O
prolonged	O
cardiac	Disease
toxicity	Disease
and	O
was	O
dysrhythmogenic.	O
Peak	O
serum	O
cocaethylene	Chemical
concentrations	O
were	O
associated	O
with	O
prolonged	O
myocardial	Disease
depression	Disease

Worsening	O
of	O
Parkinsonism	Disease
after	O
the	O
use	O
of	O
veralipride	Chemical
for	O
treatment	O
of	O
menopause:	O
case	O
report.	O
We	O
describe	O
a	O
female	O
patient	O
with	O
stable	O
Parkinson's	Disease
disease	Disease
who	O
has	O
shown	O
a	O
marked	O
worsening	O
of	O
her	O
motor	O
functions	O
following	O
therapy	O
of	O
menopause	O
related	O
symptoms	O
with	O
veralipride	Chemical
,	O
as	O
well	O
as	O
the	O
improvement	O
of	O
her	O
symptoms	O
back	O
to	O
baseline	O
after	O
discontinuation	O
of	O
the	O
drug.	O
We	O
emphasize	O
the	O
anti-dopaminergic	O
effect	O
of	O
veralipride	Chemical

Viracept	Chemical
and	O
irregular	Disease
heartbeat	Disease
warning.	O
A	O
group	O
of	O
doctors	O
in	O
Boston	O
warn	O
that	O
the	O
protease	O
inhibitor	O
Viracept	Chemical
may	O
cause	O
an	O
irregular	Disease
heart	Disease
beat	Disease
,	O
known	O
as	O
bradycardia	Disease
,	O
in	O
people	O
with	O
HIV.	O
Bradycardia	Disease
occurred	O
in	O
a	O
45-year-old	O
male	O
patient	O
who	O
was	O
Viracept	Chemical

Frequency	O
of	O
appearance	O
of	O
myeloperoxidase-antineutrophil	O
cytoplasmic	O
antibody	O
(MPO-ANCA)	O
in	O
Graves'	Disease
disease	Disease
patients	O
treated	O
with	O
propylthiouracil	Chemical
and	O
the	O
relationship	O
between	O
MPO-ANCA	O
and	O
clinical	O
manifestations.	O
OBJECTIVE:	O
Myeloperoxidase	O
antineutrophil	O
cytoplasmic	O
antibody	O
(MPO-ANCA)-positive	O
vasculitis	Disease
has	O
been	O
reported	O
in	O
patients	O
with	O
Graves'	Disease
disease	Disease
who	O
were	O
treated	O
with	O
propylthiouracil	Chemical
(	O
PTU	Chemical
).	O
The	O
appearance	O
of	O
MPO-ANCA	O
in	O
these	O
cases	O
was	O
suspected	O
of	O
being	O
related	O
to	O
PTU	Chemical
because	O
the	O
titres	O
of	O
MPO-ANCA	O
decreased	O
when	O
PTU	Chemical
was	O
stopped.	O
Nevertheless,	O
there	O
have	O
been	O
no	O
studies	O
on	O
the	O
temporal	O
relationship	O
between	O
the	O
appearance	O
of	O
MPO-ANCA	O
and	O
vasculitis	Disease
during	O
PTU	Chemical
therapy,	O
or	O
on	O
the	O
incidence	O
of	O
MPO-ANCA	O
in	O
untreated	O
Graves'	Disease
disease	Disease
patients.	O
Therefore,	O
we	O
sought	O
to	O
address	O
these	O
parameters	O
in	O
patients	O
with	O
Graves'	Disease
disease	Disease
.	O
PATIENTS:	O
We	O
investigated	O
102	O
untreated	O
patients	O
with	O
hyperthyroidism	Disease
due	O
to	O
Graves'	Disease
disease	Disease
for	O
the	O
presence	O
of	O
MPO-ANCA,	O
and	O
for	O
the	O
development	O
vasculitis	Disease
after	O
starting	O
PTU	Chemical
therapy.	O
Twenty-nine	O
of	O
them	O
were	O
later	O
excluded	O
because	O
of	O
adverse	O
effects	O
of	O
PTU	Chemical
or	O
because	O
the	O
observation	O
period	O
was	O
less	O
than	O
3	O
months.	O
The	O
remaining	O
73	O
patients	O
(55	O
women	O
and	O
18	O
men),	O
all	O
of	O
whom	O
were	O
examined	O
for	O
more	O
than	O
3	O
months,	O
were	O
adopted	O
as	O
the	O
subjects	O
of	O
the	O
investigation.	O
The	O
median	O
observation	O
period	O
was	O
23.6	O
months	O
(range:	O
3-37	O
months).	O
MEASUREMENTS:	O
MPO-ANCA	O
was	O
measured	O
at	O
intervals	O
of	O
2-6	O
months.	O
RESULTS:	O
Before	O
treatment,	O
the	O
MPO-ANCA	O
titres	O
of	O
all	O
102	O
untreated	O
Graves'	Disease
disease	Disease
patients	O
were	O
within	O
the	O
reference	O
range	O
(below	O
10	O
U/ml).	O
Three	O
(4.1%)	O
of	O
the	O
73	O
patients	O
were	O
positive	O
for	O
MPO-ANCA	O
at	O
13,	O
16	O
and	O
17	O
months,	O
respectively,	O
after	O
the	O
start	O
of	O
PTU	Chemical
therapy.	O
In	O
two	O
of	O
them,	O
the	O
MPO-ANCA	O
titres	O
transiently	O
increased	O
to	O
12.8	O
and	O
15.0	O
U/ml,	O
respectively,	O
despite	O
continued	O
PTU	Chemical
therapy,	O
but	O
no	O
vasculitic	Disease
disorders	Disease
developed.	O
In	O
the	O
third	O
patient,	O
the	O
MPO-ANCA	O
titre	O
increased	O
to	O
204	O
U/ml	O
and	O
she	O
developed	O
a	O
higher	O
fever	Disease
,	O
oral	Disease
ulcers	Disease
and	O
polyarthralgia	Disease
,	O
but	O
the	O
symptoms	O
resolved	O
2	O
weeks	O
after	O
stopping	O
PTU	Chemical
therapy,	O
and	O
the	O
MPO-ANCA	O
titre	O
decreased	O
to	O
20.7	O
U/ml	O
by	O
4	O
months	O
after	O
discontinuing	O
PTU	Chemical
.	O
CONCLUSIONS:	O
PTU	Chemical
therapy	O
may	O
be	O
related	O
to	O
the	O
appearance	O
of	O
MPO-ANCA,	O
but	O
MPO-ANCA	O
does	O
not	O
appear	O
to	O
be	O
closely	O
related	O
to	O
vasculitis	Disease

Prevalence	O
of	O
heart	Disease
disease	Disease
in	O
asymptomatic	O
chronic	O
cocaine	Chemical
users.	O
To	O
determine	O
the	O
prevalence	O
of	O
heart	Disease
disease	Disease
in	O
outpatient	O
young	O
asymptomatic	O
chronic	O
cocaine	Chemical
users,	O
35	O
cocaine	Chemical
users	O
and	O
32	O
age-matched	O
controls	O
underwent	O
resting	O
and	O
exercise	O
electrocardiography	O
(ECG)	O
and	O
Doppler	O
echocardiography.	O
Findings	O
consistent	O
with	O
coronary	Disease
artery	Disease
disease	Disease
were	O
detected	O
in	O
12	O
(34%)	O
patients	O
and	O
3	O
(9%)	O
controls	O
(p	O
=	O
0.01).	O
Decreased	O
left	O
ventricular	O
systolic	O
function	O
was	O
demonstrated	O
in	O
5	O
(14%)	O
patients,	O
but	O
in	O
none	O
of	O
the	O
controls	O
(p	O
=	O
0.055).	O
Finally,	O
resting	O
and	O
peak	O
exercise	O
abnormal	Disease
left	Disease
ventricular	Disease
filling	Disease
was	O
detected	O
in	O
38	O
and	O
35%	O
of	O
patients	O
as	O
compared	O
to	O
19	O
and	O
9%	O
of	O
controls,	O
respectively	O
(p	O
=	O
0.11	O
and	O
0.02,	O
respectively).	O
We	O
conclude	O
that	O
coronary	Disease
artery	Disease
or	Disease
myocardial	Disease
disease	Disease
is	O
common	O
(38%)	O
in	O
young	O
asymptomatic	O
chronic	O
cocaine	Chemical

Cardioprotective	O
effects	O
of	O
Picrorrhiza	O
kurroa	O
against	O
isoproterenol	Chemical
-induced	O
myocardial	O
stress	O
in	O
rats.	O
The	O
cardioprotective	O
effect	O
of	O
the	O
ethanol	Chemical
extract	O
of	O
Picrorrhiza	O
kurroa	O
rhizomes	O
and	O
roots	O
(PK)	O
on	O
isoproterenol	Chemical
-induced	O
myocardial	Disease
infarction	Disease
in	O
rats	O
with	O
respect	O
to	O
lipid	O
metabolism	O
in	O
serum	O
and	O
heart	O
tissue	O
has	O
been	O
investigated.	O
Oral	O
pre-treatment	O
with	O
PK	O
(80	O
mg	O
kg(-1)	O
day(-1)	O
for	O
15	O
days)	O
significantly	O
prevented	O
the	O
isoproterenol	Chemical
-induced	O
myocardial	Disease
infarction	Disease

Phase	O
2	O
early	O
afterdepolarization	O
as	O
a	O
trigger	O
of	O
polymorphic	O
ventricular	Disease
tachycardia	Disease
in	O
acquired	O
long-QT	Disease
syndrome	Disease
:	O
direct	O
evidence	O
from	O
intracellular	O
recordings	O
in	O
the	O
intact	O
left	O
ventricular	O
wall.	O
BACKGROUND:	O
This	O
study	O
examined	O
the	O
role	O
of	O
phase	O
2	O
early	O
afterdepolarization	O
(EAD)	O
in	O
producing	O
a	O
trigger	O
to	O
initiate	O
torsade	Disease
de	Disease
pointes	Disease
(	O
TdP	Disease
)	O
with	O
QT	Disease
prolongation	Disease
induced	O
by	O
dl-	O
sotalol	Chemical
and	O
azimilide	Chemical
.	O
The	O
contribution	O
of	O
transmural	O
dispersion	O
of	O
repolarization	O
(TDR)	O
to	O
transmural	O
propagation	O
of	O
EAD	O
and	O
the	O
maintenance	O
of	O
TdP	Disease
was	O
also	O
evaluated.	O
METHODS	O
AND	O
RESULTS:	O
Transmembrane	O
action	O
potentials	O
from	O
epicardium,	O
midmyocardium,	O
and	O
endocardium	O
were	O
recorded	O
simultaneously,	O
together	O
with	O
a	O
transmural	O
ECG,	O
in	O
arterially	O
perfused	O
canine	O
and	O
rabbit	O
left	O
ventricular	O
preparations.	O
dl-	O
Sotalol	Chemical
preferentially	O
prolonged	O
action	O
potential	O
duration	O
(APD)	O
in	O
M	O
cells	O
dose-dependently	O
(1	O
to	O
100	O
micromol/L),	O
leading	O
to	O
QT	Disease
prolongation	Disease
and	O
an	O
increase	O
in	O
TDR.	O
Azimilide	Chemical
,	O
however,	O
significantly	O
prolonged	O
APD	O
and	O
QT	O
interval	O
at	O
concentrations	O
from	O
0.1	O
to	O
10	O
micromol/L	O
but	O
shortened	O
them	O
at	O
30	O
micromol/L.	O
Unlike	O
dl-	O
sotalol	Chemical
,	O
azimilide	Chemical
(>3	O
micromol/L)	O
increased	O
epicardial	O
APD	O
markedly,	O
causing	O
a	O
diminished	O
TDR.	O
Although	O
both	O
dl-	O
sotalol	Chemical
and	O
azimilide	Chemical
rarely	O
induced	O
EADs	O
in	O
canine	O
left	O
ventricles,	O
they	O
produced	O
frequent	O
EADs	O
in	O
rabbits,	O
in	O
which	O
more	O
pronounced	O
QT	Disease
prolongation	Disease
was	O
seen.	O
An	O
increase	O
in	O
TDR	O
by	O
dl-	O
sotalol	Chemical
facilitated	O
transmural	O
propagation	O
of	O
EADs	O
that	O
initiated	O
multiple	O
episodes	O
of	O
spontaneous	O
TdP	Disease
in	O
3	O
of	O
6	O
rabbit	O
left	O
ventricles.	O
Of	O
note,	O
although	O
azimilide	Chemical
(3	O
to	O
10	O
micromol/L)	O
increased	O
APD	O
more	O
than	O
dl-	O
sotalol	Chemical
,	O
its	O
EADs	O
often	O
failed	O
to	O
propagate	O
transmurally,	O
probably	O
because	O
of	O
a	O
diminished	O
TDR.	O
CONCLUSIONS:	O
This	O
study	O
provides	O
the	O
first	O
direct	O
evidence	O
from	O
intracellular	O
action	O
potential	O
recordings	O
that	O
phase	O
2	O
EAD	O
can	O
be	O
generated	O
from	O
intact	O
ventricular	O
wall	O
and	O
produce	O
a	O
trigger	O
to	O
initiate	O
the	O
onset	O
of	O
TdP	Disease
under	O
QT	Disease
prolongation	Disease

Prenatal	O
cocaine	Chemical
exposure	O
and	O
cranial	O
sonographic	O
findings	O
in	O
preterm	Disease
infants	Disease
.	O
PURPOSE:	O
Prenatal	O
cocaine	Chemical
exposure	O
has	O
been	O
linked	O
with	O
subependymal	O
hemorrhage	Disease
and	O
the	O
formation	O
of	O
cysts	Disease
that	O
are	O
detectable	O
on	O
cranial	O
sonography	O
in	O
neonates	O
born	O
at	O
term.	O
We	O
sought	O
to	O
determine	O
if	O
prenatal	O
cocaine	Chemical
exposure	O
increases	O
the	O
incidence	O
of	O
subependymal	Disease
cysts	Disease
in	O
preterm	Disease
infants	Disease
.	O
METHODS:	O
We	O
retrospectively	O
reviewed	O
the	O
medical	O
records	O
and	O
cranial	O
sonograms	O
obtained	O
during	O
a	O
1-year	O
period	O
on	O
122	O
premature	Disease
(<	Disease
36	Disease
weeks	Disease
of	Disease
gestation)	Disease
infants	Disease
.	O
Infants	O
were	O
categorized	O
into	O
1	O
of	O
2	O
groups:	O
those	O
exposed	O
to	O
cocaine	Chemical
and	O
those	O
not	O
exposed	O
to	O
cocaine	Chemical
.	O
Infants	O
were	O
assigned	O
to	O
the	O
cocaine	Chemical
-exposed	O
group	O
if	O
there	O
was	O
a	O
maternal	O
history	O
of	O
cocaine	Disease
abuse	Disease
during	O
pregnancy	O
or	O
if	O
maternal	O
or	O
neonatal	O
urine	O
toxicology	O
results	O
were	O
positive	O
at	O
the	O
time	O
of	O
delivery.	O
RESULTS:	O
Five	O
of	O
the	O
122	O
infants	O
were	O
excluded	O
from	O
the	O
study	O
because	O
of	O
insufficient	O
medical	O
and	O
drug	O
histories.	O
The	O
incidence	O
of	O
subependymal	Disease
cysts	Disease
in	O
the	O
117	O
remaining	O
infants	O
was	O
14%	O
(16	O
of	O
117).	O
The	O
incidence	O
of	O
subependymal	Disease
cysts	Disease
in	O
infants	O
exposed	O
to	O
cocaine	Chemical
prenatally	O
was	O
44%	O
(8	O
of	O
18)	O
compared	O
with	O
8%	O
(8	O
of	O
99)	O
in	O
the	O
unexposed	O
group	O
(p	O
<	O
0.01).	O
CONCLUSIONS:	O
We	O
found	O
an	O
increased	O
incidence	O
of	O
subependymal	Disease
cyst	Disease
formation	O
in	O
preterm	Disease
infants	Disease
who	O
were	O
exposed	O
to	O
cocaine	Chemical

Thalidomide	Chemical
	O
neuropathy	Disease
in	O
patients	O
treated	O
for	O
metastatic	O
prostate	Disease
cancer	Disease
.	O
We	O
prospectively	O
evaluated	O
thalidomide	Chemical
-induced	O
neuropathy	Disease
using	O
electrodiagnostic	O
studies.	O
Sixty-seven	O
men	O
with	O
metastatic	O
androgen	Chemical
-independent	O
prostate	Disease
cancer	Disease
in	O
an	O
open-label	O
trial	O
of	O
oral	O
thalidomide	Chemical
underwent	O
neurologic	O
examinations	O
and	O
nerve	O
conduction	O
studies	O
(NCS)	O
prior	O
to	O
and	O
at	O
3-month	O
intervals	O
during	O
treatment.	O
NCS	O
included	O
recording	O
of	O
sensory	O
nerve	O
action	O
potentials	O
(SNAPs)	O
from	O
median,	O
radial,	O
ulnar,	O
and	O
sural	O
nerves.	O
SNAP	O
amplitudes	O
for	O
each	O
nerve	O
were	O
expressed	O
as	O
the	O
percentage	O
of	O
its	O
baseline,	O
and	O
the	O
mean	O
of	O
the	O
four	O
was	O
termed	O
the	O
SNAP	O
index.	O
A	O
40%	O
decline	O
in	O
the	O
SNAP	O
index	O
was	O
considered	O
clinically	O
significant.	O
Thalidomide	Chemical
was	O
discontinued	O
in	O
55	O
patients	O
for	O
lack	O
of	O
therapeutic	O
response.	O
Of	O
67	O
patients	O
initially	O
enrolled,	O
24	O
remained	O
on	O
thalidomide	Chemical
for	O
3	O
months,	O
8	O
remained	O
at	O
6	O
months,	O
and	O
3	O
remained	O
at	O
9	O
months.	O
Six	O
patients	O
developed	O
neuropathy	Disease
.	O
Clinical	O
symptoms	O
and	O
a	O
decline	O
in	O
the	O
SNAP	O
index	O
occurred	O
concurrently.	O
Older	O
age	O
and	O
cumulative	O
dose	O
were	O
possible	O
contributing	O
factors.	O
Neuropathy	Disease
may	O
thus	O
be	O
a	O
common	O
complication	O
of	O
thalidomide	Chemical
in	O
older	O
patients.	O
The	O
SNAP	O
index	O
can	O
be	O
used	O
to	O
monitor	O
peripheral	Disease
neuropathy	Disease

Overexpression	O
of	O
copper	Chemical
/	O
zinc	Chemical
-	O
superoxide	Chemical
dismutase	O
protects	O
from	O
kanamycin	Chemical
-induced	O
hearing	Disease
loss	Disease
.	O
The	O
participation	O
of	O
reactive	O
oxygen	Chemical
species	O
in	O
aminoglycoside	Chemical
-induced	O
ototoxicity	Disease
has	O
been	O
deduced	O
from	O
observations	O
that	O
aminoglycoside	Chemical
-	O
iron	Chemical
complexes	O
catalyze	O
the	O
formation	O
of	O
superoxide	Chemical
radicals	O
in	O
vitro	O
and	O
that	O
antioxidants	O
attenuate	O
ototoxicity	Disease
in	O
vivo.	O
We	O
therefore	O
hypothesized	O
that	O
overexpression	O
of	O
Cu	Chemical
/	O
Zn	Chemical
-	O
superoxide	Chemical
dismutase	O
(h-SOD1)	O
should	O
protect	O
transgenic	O
mice	O
from	O
ototoxicity	Disease
.	O
Immunocytochemistry	O
confirmed	O
expression	O
of	O
h-SOD1	O
in	O
inner	O
ear	O
tissues	O
of	O
transgenic	O
C57BL/6-TgN[SOD1]3Cje	O
mice.	O
Transgenic	O
and	O
nontransgenic	O
littermates	O
received	O
kanamycin	Chemical
(400	O
mg/kg	O
body	O
weight/day)	O
for	O
10	O
days	O
beginning	O
on	O
day	O
10	O
after	O
birth.	O
Auditory	O
thresholds	O
were	O
tested	O
by	O
evoked	O
auditory	O
brain	O
stem	O
responses	O
at	O
1	O
month	O
after	O
birth.	O
In	O
nontransgenic	O
animals,	O
the	O
threshold	O
in	O
the	O
kanamycin	Chemical
-treated	O
group	O
was	O
45-50	O
dB	O
higher	O
than	O
in	O
saline-injected	O
controls.	O
In	O
the	O
transgenic	O
group,	O
kanamycin	Chemical
increased	O
the	O
threshold	O
by	O
only	O
15	O
dB	O
over	O
the	O
respective	O
controls.	O
The	O
effects	O
were	O
similar	O
at	O
12	O
and	O
24	O
kHz.	O
The	O
protection	O
by	O
overexpression	O
of	O
superoxide	Chemical
dismutase	O
supports	O
the	O
hypothesis	O
that	O
oxidant	O
stress	O
plays	O
a	O
significant	O
role	O
in	O
aminoglycoside	Chemical
-induced	O
ototoxicity	Disease

Prednisone	Chemical
induces	O
anxiety	Disease
and	O
glial	O
cerebral	O
changes	O
in	O
rats.	O
OBJECTIVE:	O
To	O
assess	O
whether	O
prednisone	Chemical
(	O
PDN	Chemical
)	O
produces	O
anxiety	Disease
and/or	O
cerebral	O
glial	O
changes	O
in	O
rats.	O
METHODS:	O
Male	O
Wistar	O
rats	O
were	O
studied	O
and	O
3	O
groups	O
were	O
formed	O
(8	O
rats	O
per	O
group).	O
The	O
moderate-dose	O
group	O
received	O
5	O
mg/kg/day	O
PDN	Chemical
released	O
from	O
a	O
subcutaneous	O
implant.	O
In	O
the	O
high-dose	O
group,	O
implants	O
containing	O
PDN	Chemical
equivalent	O
to	O
60	O
mg/kg/day	O
were	O
applied.	O
In	O
the	O
control	O
group	O
implants	O
contained	O
no	O
PDN	Chemical
.	O
Anxiety	Disease
was	O
assessed	O
using	O
an	O
open	O
field	O
and	O
elevated	O
plus-maze	O
devices.	O
The	O
number	O
of	O
cells	O
and	O
cytoplasmic	O
transformation	O
of	O
astrocytes	O
and	O
microglia	O
cells	O
were	O
assessed	O
by	O
immunohistochemical	O
analyses.	O
RESULTS:	O
Anxiety	Disease
was	O
documented	O
in	O
both	O
groups	O
of	O
PDN	Chemical
treated	O
rats	O
compared	O
with	O
controls.	O
The	O
magnitude	O
of	O
transformation	O
of	O
the	O
microglia	O
assessed	O
by	O
the	O
number	O
of	O
intersections	O
was	O
significantly	O
higher	O
in	O
the	O
PDN	Chemical
groups	O
than	O
in	O
controls	O
in	O
the	O
prefrontal	O
cortex	O
(moderate-dose,	O
24.1;	O
high-dose,	O
23.6;	O
controls	O
18.7;	O
p	O
<	O
0.01)	O
and	O
striatum	O
(moderate-dose	O
25.6;	O
high-dose	O
26.3;	O
controls	O
18.9;	O
p	O
<	O
0.01),	O
but	O
not	O
in	O
hippocampus.	O
The	O
number	O
of	O
stained	O
microglia	O
cells	O
was	O
significantly	O
higher	O
in	O
the	O
PDN	Chemical
treated	O
groups	O
in	O
the	O
prefrontal	O
cortex	O
than	O
in	O
controls	O
(moderate-dose,	O
29.1;	O
high-dose,	O
28.4;	O
control,	O
17.7	O
cells	O
per	O
field;	O
p	O
<	O
0.01).	O
Stained	O
microglia	O
cells	O
were	O
significantly	O
more	O
numerous	O
striatum	O
and	O
hippocampus	O
in	O
the	O
high-dose	O
group	O
compared	O
to	O
controls.	O
CONCLUSION:	O
Subacute	O
exposure	O
to	O
PDN	Chemical
induced	O
anxiety	Disease
and	O
reactivity	O
of	O
microglia.	O
The	O
relevance	O
of	O
these	O
features	O
for	O
patients	O
using	O
PDN	Chemical

Phase	O
II	O
study	O
of	O
carboplatin	Chemical
and	O
liposomal	O
doxorubicin	Chemical
in	O
patients	O
with	O
recurrent	O
squamous	Disease
cell	Disease
carcinoma	Disease
of	Disease
the	Disease
cervix	Disease
.	O
BACKGROUND:	O
The	O
activity	O
of	O
the	O
combination	O
of	O
carboplatin	Chemical
and	O
liposomal	O
doxorubicin	Chemical
was	O
tested	O
in	O
a	O
Phase	O
II	O
study	O
of	O
patients	O
with	O
recurrent	O
cervical	Disease
carcinoma	Disease
.	O
METHODS:	O
The	O
combination	O
of	O
carboplatin	Chemical
(area	O
under	O
the	O
concentration	O
curve	O
[AUC],	O
5)	O
and	O
liposomal	O
doxorubicin	Chemical
(	O
Doxil	Chemical
;	O
starting	O
dose,	O
40	O
mg/m(2))	O
was	O
administered	O
intravenously	O
every	O
28	O
days	O
to	O
37	O
patients	O
with	O
recurrent	O
squamous	Disease
cell	Disease
cervical	Disease
carcinoma	Disease
to	O
determine	O
antitumor	O
activity	O
and	O
toxicity	Disease
profile.	O
RESULTS:	O
Twenty-nine	O
patients	O
were	O
assessable	O
for	O
response,	O
and	O
35	O
patients	O
were	O
assessable	O
for	O
toxicity	Disease
.	O
The	O
overall	O
response	O
rate	O
was	O
38%,	O
the	O
median	O
time	O
to	O
response	O
was	O
10	O
weeks,	O
the	O
median	O
duration	O
of	O
response	O
was	O
26	O
weeks,	O
and	O
the	O
median	O
survival	O
was	O
37	O
weeks.	O
The	O
main	O
toxic	O
effect	O
was	O
myelosuppression	Disease
,	O
with	O
Grade	O
3	O
and	O
4	O
neutropenia	Disease
in	O
16	O
patients,	O
anemia	Disease
in	O
12	O
patients,	O
thrombocytopenia	Disease
in	O
11	O
patients,	O
and	O
neutropenic	Disease
fever	Disease
in	O
3	O
patients.	O
Four	O
patients	O
had	O
five	O
infusion-related	O
reactions	O
during	O
the	O
infusion	O
of	O
liposomal	O
doxorubicin	Chemical
,	O
leading	O
to	O
treatment	O
discontinuation	O
in	O
three	O
patients.	O
Grade	O
>	O
or	O
=	O
2	O
nonhematologic	O
toxicity	Disease
included	O
nausea	Disease
in	O
17	O
patients,	O
emesis	Disease
in	O
14	O
patients,	O
fatigue	Disease
in	O
9	O
patients,	O
mucositis	Disease
and/or	O
stomatitis	Disease
in	O
8	O
patients,	O
constipation	Disease
in	O
6	O
patients,	O
weight	Disease
loss	Disease
in	O
5	O
patients,	O
hand-foot	Disease
syndrome	Disease
in	O
2	O
patients,	O
and	O
skin	Disease
reactions	Disease
in	O
3	O
patients.	O
CONCLUSIONS:	O
The	O
combination	O
of	O
carboplatin	Chemical
and	O
liposomal	O
doxorubicin	Chemical
has	O
modest	O
activity	O
in	O
patients	O
with	O
recurrent	O
cervical	Disease
carcinoma	Disease

Antimicrobial-induced	O
mania	Disease
(	O
antibiomania	Disease
):	O
a	O
review	O
of	O
spontaneous	O
reports.	O
The	O
authors	O
reviewed	O
reported	O
cases	O
of	O
antibiotic-induced	O
manic	Disease
episodes	O
by	O
means	O
of	O
a	O
MEDLINE	O
and	O
PsychLit	O
search	O
for	O
reports	O
of	O
antibiotic-induced	O
mania	Disease
.	O
Unpublished	O
reports	O
were	O
requested	O
from	O
the	O
World	O
Health	O
Organization	O
(WHO)	O
and	O
the	O
Food	O
and	O
Drug	O
Administration	O
(FDA).	O
Twenty-one	O
reports	O
of	O
antimicrobial-induced	O
mania	Disease
were	O
found	O
in	O
the	O
literature.	O
There	O
were	O
6	O
cases	O
implicating	O
clarithromycin	Chemical
,	O
13	O
implicating	O
isoniazid	Chemical
,	O
and	O
1	O
case	O
each	O
implicating	O
erythromycin	Chemical
and	O
amoxicillin	Chemical
.	O
The	O
WHO	O
reported	O
82	O
cases.	O
Of	O
these,	O
clarithromycin	Chemical
was	O
implicated	O
in	O
23	O
(27.6%)	O
cases,	O
ciprofloxacin	Chemical
in	O
12	O
(14.4%)	O
cases,	O
and	O
ofloxacin	Chemical
in	O
10	O
(12%)	O
cases.	O
Cotrimoxazole	Chemical
,	O
metronidazole	Chemical
,	O
and	O
erythromycin	Chemical
were	O
involved	O
in	O
15	O
reported	O
manic	Disease
episodes.	O
Cases	O
reported	O
by	O
the	O
FDA	O
showed	O
clarithromycin	Chemical
and	O
ciprofloxacin	Chemical
to	O
be	O
the	O
most	O
frequently	O
associated	O
with	O
the	O
development	O
of	O
mania	Disease
.	O
Statistical	O
analysis	O
of	O
the	O
data	O
would	O
not	O
have	O
demonstrated	O
a	O
significant	O
statistical	O
correlative	O
risk	O
and	O
was	O
therefore	O
not	O
undertaken.	O
Patients	O
have	O
an	O
increased	O
risk	O
of	O
developing	O
mania	Disease
while	O
being	O
treated	O
with	O
antimicrobials.	O
Although	O
this	O
is	O
not	O
a	O
statistically	O
significant	O
risk,	O
physicians	O
must	O
be	O
aware	O
of	O
the	O
effect	O
and	O
reversibility.	O
Further	O
research	O
clearly	O
is	O
required	O
to	O
determine	O
the	O
incidence	O
of	O
antimicrobial-induced	O
mania	Disease
,	O
the	O
relative	O
risk	O
factors	O
of	O
developing	O
an	O
antimicrobial-induced	O
manic	Disease
episode	O
among	O
various	O
demographic	O
populations,	O
and	O
the	O
incidence	O
of	O
patients	O
who	O
continue	O
to	O
have	O
persistent	O
affective	O
disorders	O
once	O
the	O
initial	O
episode,	O
which	O
occurs	O
while	O
the	O
patient	O
is	O
taking	O
antibiotics,	O
subsides.	O
The	O
authors	O
elected	O
to	O
name	O
this	O
syndrome	O
"	O
antibiomania	Disease

Levodopa	Chemical
-induced	O
ocular	Disease
dyskinesias	Disease
in	O
Parkinson's	Disease
disease	Disease
.	O
Levodopa	Chemical
-induced	O
ocular	Disease
dyskinesias	Disease
are	O
very	O
uncommon.	O
Usually	O
they	O
occur	O
simultaneously	O
with	O
limb	O
peak-dose	O
choreatic	Disease
dyskinesias	Disease
.	O
We	O
report	O
on	O
a	O
patient	O
with	O
leftward	O
and	O
upward	O
deviations	O
of	O
gaze	O
during	O
the	O
peak	O
effect	O
of	O
levodopa	Chemical
,	O
and	O
hypothesize	O
that	O
a	O
severe	O
dopaminergic	O
denervation	O
in	O
the	O
caudate	O
nucleus	O
is	O
needed	O
for	O
the	O
appearance	O
of	O
these	O
levodopa	Chemical
-induce	O
ocular	Disease
dyskinesias	Disease

A	O
comparison	O
of	O
glyceryl	Chemical
trinitrate	Chemical
with	O
diclofenac	Chemical
for	O
the	O
treatment	O
of	O
primary	O
dysmenorrhea	Disease
:	O
an	O
open,	O
randomized,	O
cross-over	O
trial.	O
Primary	O
dysmenorrhea	Disease
is	O
a	O
syndrome	O
characterized	O
by	O
painful	O
uterine	O
contractility	O
caused	O
by	O
a	O
hypersecretion	O
of	O
endometrial	O
prostaglandins	Chemical
;	O
non-steroidal	O
anti-inflammatory	O
drugs	O
are	O
the	O
first	O
choice	O
for	O
its	O
treatment.	O
However,	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
have	O
demonstrated	O
that	O
myometrial	O
cells	O
are	O
also	O
targets	O
of	O
the	O
relaxant	O
effects	O
of	O
nitric	Chemical
oxide	Chemical
(	O
NO	Chemical
).	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
efficacy	O
of	O
glyceryl	Chemical
trinitrate	Chemical
(	O
GTN	Chemical
),	O
an	O
NO	Chemical
donor,	O
in	O
the	O
resolution	O
of	O
primary	O
dysmenorrhea	Disease
in	O
comparison	O
with	O
diclofenac	Chemical
(	O
DCF	Chemical
).	O
A	O
total	O
of	O
24	O
patients	O
with	O
the	O
diagnosis	O
of	O
severe	O
primary	O
dysmenorrhea	Disease
were	O
studied	O
during	O
two	O
consecutive	O
menstrual	O
cycles.	O
In	O
an	O
open,	O
cross-over,	O
controlled	O
design,	O
patients	O
were	O
randomized	O
to	O
receive	O
either	O
DCF	Chemical
per	O
os	O
or	O
GTN	Chemical
patches	O
the	O
first	O
days	O
of	O
menses,	O
when	O
menstrual	O
cramps	O
became	O
unendurable.	O
In	O
the	O
subsequent	O
cycle	O
the	O
other	O
treatment	O
was	O
used.	O
Patients	O
received	O
up	O
to	O
3	O
doses/day	O
of	O
50	O
mg	O
DCF	Chemical
or	O
2.5	O
mg/24	O
h	O
transdermal	O
GTN	Chemical
for	O
the	O
first	O
3	O
days	O
of	O
the	O
cycle,	O
according	O
to	O
their	O
needs.	O
The	O
participants	O
recorded	O
menstrual	O
symptoms	O
and	O
possible	O
side-effects	O
at	O
different	O
times	O
(0,	O
30,	O
60,	O
120	O
minutes)	O
after	O
the	O
first	O
dose	O
of	O
medication	O
on	O
the	O
first	O
day	O
of	O
the	O
cycle,	O
with	O
both	O
drugs.	O
The	O
difference	O
in	O
pain	Disease
intensity	O
score	O
(DPI)	O
was	O
the	O
main	O
outcome	O
variable.	O
Both	O
treatments	O
significantly	O
reduced	O
DPI	O
by	O
the	O
30th	O
minute	O
(	O
GTN	Chemical
,	O
-12.8	O
+/-	O
17.9;	O
DCF	Chemical
,	O
-18.9	O
+/-	O
16.6).	O
However,	O
DCF	Chemical
continued	O
to	O
be	O
effective	O
in	O
reducing	O
pelvic	Disease
pain	Disease
for	O
two	O
hours,	O
whereas	O
GTN	Chemical
scores	O
remained	O
more	O
or	O
less	O
stable	O
after	O
30	O
min	O
and	O
significantly	O
higher	O
than	O
those	O
for	O
DFC	O
(after	O
one	O
hour:	O
GTN	Chemical
,	O
-12.8	O
+/-	O
17.9;	O
DFC,	O
-18.9	O
+/-	O
16.6	O
and	O
after	O
two	O
hours:	O
GTN	Chemical
,	O
-23.7	O
+/-	O
20.5;	O
DFC,	O
-59.7	O
+/-	O
17.9,	O
p	O
=	O
0.0001).	O
Low	Disease
back	Disease
pain	Disease
was	O
also	O
relieved	O
by	O
both	O
drugs.	O
Headache	Disease
was	O
significantly	O
increased	O
by	O
GTN	Chemical
but	O
not	O
by	O
DCF	Chemical
.	O
Eight	O
patients	O
stopped	O
using	O
GTN	Chemical
because	O
headache	Disease
--attributed	O
to	O
its	O
use--became	O
intolerable.	O
These	O
findings	O
indicate	O
that	O
GTN	Chemical
has	O
a	O
reduced	O
efficacy	O
and	O
tolerability	O
by	O
comparison	O
with	O
DCF	Chemical
in	O
the	O
treatment	O
of	O
primary	O
dysmenorrhea	Disease

Temocapril	Chemical
,	O
a	O
long-acting	O
non-SH	O
group	O
angiotensin	Chemical
converting	O
enzyme	O
inhibitor,	O
modulates	O
glomerular	Disease
injury	Disease
in	O
chronic	O
puromycin	Chemical
aminonucleoside	Chemical
	O
nephrosis	Disease
.	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
whether	O
chronic	O
administration	O
of	O
temocapril	Chemical
,	O
a	O
long-acting	O
non-SH	O
group	O
angiotensin	Chemical
converting	O
enzyme	O
(ACE)	O
inhibitor,	O
reduced	O
proteinuria	Disease
,	O
inhibited	O
glomerular	O
hypertrophy	Disease
and	O
prevented	O
glomerulosclerosis	Disease
in	O
chronic	O
puromycin	Chemical
aminonucleoside	Chemical
(	O
PAN	Chemical
)	O
-	O
induced	O
nephrotic	Disease
rats.	O
Nephrosis	Disease
was	O
induced	O
by	O
injection	O
of	O
PAN	Chemical
(15mg/100g	O
body	O
weight)	O
in	O
male	O
Sprague-Dawley	O
(SD)	O
rats.	O
Four	O
groups	O
were	O
used,	O
i)	O
the	O
PAN	Chemical
group	O
(14),	O
ii)	O
PAN	Chemical
/	O
temocapril	Chemical
(13),	O
iii)	O
temocapril	Chemical
(14)	O
and	O
iv)	O
untreated	O
controls	O
(15).	O
Temocapril	Chemical
(8	O
mg/kg/day)	O
was	O
administered	O
to	O
the	O
rats	O
which	O
were	O
killed	O
at	O
weeks	O
4,	O
14	O
or	O
20.	O
At	O
each	O
time	O
point,	O
systolic	O
blood	O
pressure	O
(BP),	O
urinary	O
protein	O
excretion	O
and	O
renal	O
histopathological	O
findings	O
were	O
evaluated,	O
and	O
morphometric	O
image	O
analysis	O
was	O
done.	O
Systolic	O
BP	O
in	O
the	O
PAN	Chemical
group	O
was	O
significantly	O
high	O
at	O
4,	O
14	O
and	O
20	O
weeks,	O
but	O
was	O
normal	O
in	O
the	O
PAN	Chemical
/	O
temocapril	Chemical
group.	O
Urinary	O
protein	O
excretion	O
in	O
the	O
PAN	Chemical
group	O
increased	O
significantly,	O
peaking	O
at	O
8	O
days,	O
then	O
decreased	O
at	O
4	O
weeks,	O
but	O
rose	O
again	O
significantly	O
at	O
14	O
and	O
20	O
weeks.	O
Temocapril	Chemical
did	O
not	O
attenuate	O
proteinuria	Disease
at	O
8	O
days,	O
but	O
it	O
did	O
markedly	O
lower	O
it	O
from	O
weeks	O
4	O
to	O
20.	O
The	O
glomerulosclerosis	Disease
index	O
(GSI)	O
was	O
6.21	O
%	O
at	O
4	O
weeks	O
and	O
respectively	O
25.35	O
%	O
and	O
30.49	O
%	O
at	O
14	O
and	O
20	O
weeks	O
in	O
the	O
PAN	Chemical
group.	O
There	O
was	O
a	O
significant	O
correlation	O
between	O
urinary	O
protein	O
excretion	O
and	O
GSI	O
(r	O
=	O
0.808,	O
p	O
<	O
0.0001).	O
The	O
ratio	O
of	O
glomerular	O
tuft	O
area	O
to	O
the	O
area	O
of	O
Bowman's	O
capsules	O
(GT/BC)	O
in	O
the	O
PAN	Chemical
group	O
was	O
significantly	O
increased,	O
but	O
it	O
was	O
significantly	O
lower	O
in	O
the	O
PAN	Chemical
/	O
temocapril	Chemical
group.	O
It	O
appears	O
that	O
temocapril	Chemical
was	O
effective	O
in	O
retarding	O
renal	O
progression	O
and	O
protected	O
renal	O
function	O
in	O
PAN	Chemical
	O
neprotic	Disease

Pulmonary	Disease
hypertension	Disease
after	O
ibuprofen	Chemical
prophylaxis	O
in	O
very	O
preterm	O
infants.	O
We	O
report	O
three	O
cases	O
of	O
severe	O
hypoxaemia	Disease
after	O
ibuprofen	Chemical
administration	O
during	O
a	O
randomised	O
controlled	O
trial	O
of	O
prophylactic	O
treatment	O
of	O
patent	Disease
ductus	Disease
arteriosus	Disease
with	O
ibuprofen	Chemical
in	O
premature	O
infants	O
born	O
at	O
less	O
than	O
28	O
weeks	O
of	O
gestation.	O
Echocardiography	O
showed	O
severely	O
decreased	O
pulmonary	O
blood	O
flow.	O
Hypoxaemia	Disease
resolved	O
quickly	O
on	O
inhaled	O
nitric	Chemical
oxide	Chemical
therapy.	O
We	O
suggest	O
that	O
investigators	O
involved	O
in	O
similar	O
trials	O
pay	O
close	O
attention	O
to	O
pulmonary	O
pressure	O
if	O
hypoxaemia	Disease
occurs	O
after	O
prophylactic	O
administration	O
of	O
ibuprofen	Chemical

Hyponatremia	Disease
and	O
syndrome	Disease
of	Disease
inappropriate	Disease
anti-diuretic	Disease
hormone	Disease
reported	O
with	O
the	O
use	O
of	O
Vincristine	Chemical
:	O
an	O
over-representation	O
of	O
Asians?	O
PURPOSE:	O
This	O
retrospective	O
study	O
used	O
a	O
pharmaceutical	O
company's	O
global	O
safety	O
database	O
to	O
determine	O
the	O
reporting	O
rate	O
of	O
hyponatremia	Disease
and/or	O
syndrome	Disease
of	Disease
inappropriate	Disease
secretion	Disease
of	Disease
anti-diuretic	Disease
hormone	Disease
(	O
SIADH	Disease
)	O
among	O
vincristine	Chemical
-treated	O
patients	O
and	O
to	O
explore	O
the	O
possibility	O
of	O
at-risk	O
population	O
subgroups.	O
METHOD:	O
We	O
searched	O
the	O
Eli	O
Lilly	O
and	O
Company's	O
computerized	O
adverse	O
event	O
database	O
for	O
all	O
reported	O
cases	O
of	O
hyponatremia	Disease
and/or	O
SIADH	Disease
as	O
of	O
1	O
November	O
1999	O
that	O
had	O
been	O
reported	O
during	O
the	O
use	O
of	O
vincristine	Chemical
.	O
RESULTS:	O
A	O
total	O
of	O
76	O
cases	O
of	O
hyponatremia	Disease
and/or	O
SIADH	Disease
associated	O
with	O
vincristine	Chemical
use	O
were	O
identified.	O
The	O
overall	O
reporting	O
rate	O
was	O
estimated	O
to	O
be	O
1.3/100,000	O
treated	O
patients.	O
The	O
average	O
age	O
of	O
patients	O
was	O
35.6	O
+/-	O
28.3	O
years,	O
and	O
62%	O
were	O
males.	O
Approximately	O
75%	O
of	O
the	O
patients	O
were	O
receiving	O
treatment	O
for	O
leukemia	Disease
or	O
lymphoma	Disease
.	O
Among	O
the	O
39	O
reports	O
that	O
included	O
information	O
on	O
race,	O
the	O
racial	O
distribution	O
was:	O
1	O
Black,	O
3	O
Caucasian,	O
and	O
35	O
Asian.	O
CONCLUSION:	O
Our	O
data	O
suggest	O
that	O
Asian	O
patients	O
may	O
be	O
at	O
increased	O
risk	O
of	O
hyponatremia	Disease
and/or	O
SIADH	Disease
associated	O
with	O
vincristine	Chemical
use.	O
Although	O
the	O
overall	O
reported	O
rate	O
of	O
SIADH	Disease
associated	O
with	O
vincristine	Chemical

Delayed	O
toxicity	Disease
of	O
cyclophosphamide	Chemical
on	O
the	O
bladder	O
of	O
DBA/2	O
and	O
C57BL/6	O
female	O
mouse.	O
The	O
present	O
study	O
describes	O
the	O
delayed	O
development	O
of	O
a	O
severe	O
bladder	O
pathology	O
in	O
a	O
susceptible	O
strain	O
of	O
mice	O
(DBA/2)	O
but	O
not	O
in	O
a	O
resistant	O
strain	O
(C57BL/6)	O
when	O
both	O
were	O
treated	O
with	O
a	O
single	O
300	O
mg/kg	O
dose	O
of	O
cyclophosphamide	Chemical
(	O
CY	Chemical
).	O
Inbred	O
DBA/2	O
and	O
C57BL/6	O
female	O
mice	O
were	O
injected	O
with	O
CY	Chemical
,	O
and	O
the	O
effect	O
of	O
the	O
drug	O
on	O
the	O
bladder	O
was	O
assessed	O
during	O
100	O
days	O
by	O
light	O
microscopy	O
using	O
different	O
staining	O
procedures,	O
and	O
after	O
30	O
days	O
by	O
conventional	O
electron	O
microscopy.	O
Early	O
CY	Chemical
	O
toxicity	Disease
caused	O
a	O
typical	O
haemorrhagic	Disease
	O
cystitis	Disease
in	O
both	O
strains	O
that	O
was	O
completely	O
repaired	O
in	O
about	O
7-10	O
days.	O
After	O
30	O
days	O
of	O
CY	Chemical
injection	O
ulcerous	O
and	O
non-ulcerous	O
forms	O
of	O
chronic	O
cystitis	Disease
appeared	O
in	O
86%	O
of	O
DBA/2	O
mice	O
but	O
only	O
in	O
4%	O
of	O
C57BL/6	O
mice.	O
Delayed	O
cystitis	Disease
was	O
characterized	O
by	O
infiltration	O
and	O
transepithelial	O
passage	O
into	O
the	O
lumen	O
of	O
inflammatory	O
cells	O
and	O
by	O
frequent	O
exfoliation	O
of	O
the	O
urothelium.	O
Mast	O
cells	O
appeared	O
in	O
the	O
connective	O
and	O
muscular	O
layers	O
of	O
the	O
bladder	O
at	O
a	O
much	O
higher	O
number	O
in	O
DBA/2	O
mice	O
than	O
in	O
C57BL/6	O
mice	O
or	O
untreated	O
controls.	O
Electron	O
microscopy	O
disclosed	O
the	O
absence	O
of	O
the	O
typical	O
discoidal	O
vesicles	O
normally	O
present	O
in	O
the	O
cytoplasm	O
of	O
surface	O
cells.	O
Instead,	O
numerous	O
abnormal	O
vesicles	O
containing	O
one	O
or	O
several	O
dark	O
granules	O
were	O
observed	O
in	O
the	O
cytoplasm	O
of	O
cells	O
from	O
all	O
the	O
epithelial	O
layers.	O
Delayed	O
cystitis	Disease
still	O
persisted	O
in	O
DBA/2	O
mice	O
100	O
days	O
after	O
treatment.	O
These	O
results	O
indicate	O
that	O
delayed	O
toxicity	Disease
of	O
CY	Chemical
in	O
female	O
DBA/2	O
mice	O
causes	O
a	O
bladder	O
pathology	O
that	O
is	O
not	O
observed	O
in	O
C57BL/6	O
mice.	O
This	O
pathology	O
resembles	O
interstitial	Disease
cystitis	Disease

High-dose	O
5-fluorouracil	Chemical
/	O
folinic	Chemical
acid	Chemical
in	O
combination	O
with	O
three-weekly	O
mitomycin	Chemical
C	Chemical
in	O
the	O
treatment	O
of	O
advanced	O
gastric	Disease
cancer	Disease
.	O
A	O
phase	O
II	O
study.	O
BACKGROUND:	O
The	O
24-hour	O
continuous	O
infusion	O
of	O
5-fluorouracil	Chemical
(	O
5-FU	Chemical
)	O
and	O
folinic	Chemical
acid	Chemical
(	O
FA	Chemical
)	O
as	O
part	O
of	O
several	O
new	O
multidrug	O
chemotherapy	O
regimens	O
in	O
advanced	O
gastric	Disease
cancer	Disease
(	O
AGC	Disease
)	O
has	O
shown	O
to	O
be	O
effective,	O
with	O
low	O
toxicity	Disease
.	O
In	O
a	O
previous	O
phase	O
II	O
study	O
with	O
3-weekly	O
bolus	O
5-FU	Chemical
,	O
FA	Chemical
and	O
mitomycin	Chemical
C	Chemical
(	O
MMC	Chemical
)	O
we	O
found	O
a	O
low	O
toxicity	Disease
rate	O
and	O
response	O
rates	O
comparable	O
to	O
those	O
of	O
regimens	O
such	O
as	O
ELF,	O
FAM	O
or	O
FAMTX,	O
and	O
a	O
promising	O
median	O
overall	O
survival.	O
In	O
order	O
to	O
improve	O
this	O
MMC	Chemical
-dependent	O
schedule	O
we	O
initiated	O
a	O
phase	O
II	O
study	O
with	O
high-dose	O
5-FU	Chemical
/	O
FA	Chemical
and	O
3-weekly	O
bolus	O
MMC	Chemical
.	O
PATIENTS	O
AND	O
METHODS:	O
From	O
February,	O
1998	O
to	O
September,	O
2000	O
we	O
recruited	O
33	O
patients	O
with	O
AGC	Disease
to	O
receive	O
weekly	O
24-hour	O
5-FU	Chemical
2,600	O
mg/m(2)	O
preceded	O
by	O
2-hour	O
FA	Chemical
500	O
mg/m(2)	O
for	O
6	O
weeks,	O
followed	O
by	O
a	O
2-week	O
rest	O
period.	O
Bolus	O
MMC	Chemical
10	O
mg/m(2)	O
was	O
added	O
in	O
3-weekly	O
intervals.	O
Treatment	O
given	O
on	O
an	O
outpatient	O
basis,	O
using	O
portable	O
pump	O
systems,	O
was	O
repeated	O
on	O
day	O
57.	O
Patients'	O
characteristics	O
were:	O
male/female	O
ratio	O
20/13;	O
median	O
age	O
57	O
(27-75)	O
years;	O
median	O
WHO	O
status	O
1	O
(0-2).	O
18	O
patients	O
had	O
a	O
primary	O
AGC	Disease
,	O
and	O
15	O
showed	O
a	O
relapsed	O
AGC	Disease
.	O
Median	O
follow-up	O
was	O
11.8	O
months	O
(range	O
of	O
those	O
surviving:	O
2.7-11.8	O
months).	O
RESULTS:	O
32	O
patients	O
were	O
evaluable	O
for	O
response	O
-	O
complete	O
remission	O
9.1%	O
(n	O
=	O
3),	O
partial	O
remission	O
45.5%	O
(n	O
=	O
15),	O
no	O
change	O
27.3%	O
(n	O
=	O
9),	O
progressive	O
disease	O
15.1%	O
(n	O
=	O
5).	O
Median	O
overall	O
survival	O
time	O
was	O
10.2	O
months	O
[95%	O
confidence	O
interval	O
(CI):	O
8.7-11.6],	O
and	O
median	O
progression-free	O
survival	O
time	O
was	O
7.6	O
months	O
(95%	O
CI:	O
4.4-10.9).	O
The	O
worst	O
toxicities	Disease
(%)	O
observed	O
were	O
(CTC-NCI	O
1/2/3):	O
leukopenia	Disease
45.5/18.2/6.1,	O
thrombocytopenia	Disease
33.3/9.1/6.1,	O
vomitus	Disease
24.2/9.1/0,	O
diarrhea	Disease
36.4/6.1/3.0,	O
stomatitis	Disease
18.2/9.1/0,	O
hand-foot	Disease
syndrome	Disease
12.1/0/0.	O
Two	O
patients	O
developed	O
hemolytic-uremic	Disease
syndrome	Disease
(	O
HUS	Disease
).	O
CONCLUSIONS:	O
High-dose	O
5-FU	Chemical
/	O
FA	Chemical
/	O
MMC	Chemical
is	O
an	O
effective	O
and	O
well-tolerated	O
outpatient	O
regimen	O
for	O
AGC	Disease
(objective	O
response	O
rate	O
54.6%).	O
It	O
may	O
serve	O
as	O
an	O
alternative	O
to	O
cisplatin	Chemical
-containing	O
regimens;	O
however,	O
it	O
has	O
to	O
be	O
considered	O
that	O
possibly	O
HUS	Disease

Persistent	O
sterile	O
leukocyturia	Disease
is	O
associated	O
with	O
impaired	Disease
renal	Disease
function	Disease
in	O
human	Disease
immunodeficiency	Disease
virus	Disease
type	Disease
1-infected	Disease
children	O
treated	O
with	O
indinavir	Chemical
.	O
BACKGROUND:	O
Prolonged	O
administration	O
of	O
indinavir	Chemical
is	O
associated	O
with	O
the	O
occurrence	O
of	O
a	O
variety	O
of	O
renal	O
complications	O
in	O
adults.	O
These	O
well-documented	O
side	O
effects	O
have	O
restricted	O
the	O
use	O
of	O
this	O
potent	O
protease	O
inhibitor	O
in	O
children.	O
DESIGN:	O
A	O
prospective	O
study	O
to	O
monitor	O
indinavir	Chemical
-related	O
nephrotoxicity	Disease
in	O
a	O
cohort	O
of	O
30	O
human	Disease
immunodeficiency	Disease
virus	Disease
type	Disease
1-infected	Disease
children	O
treated	O
with	O
indinavir	Chemical
.	O
METHODS:	O
Urinary	O
pH,	O
albumin,	O
creatinine	Chemical
,	O
the	O
presence	O
of	O
erythrocytes,	O
leukocytes,	O
bacteria	O
and	O
crystals,	O
and	O
culture	O
were	O
analyzed	O
every	O
3	O
months	O
for	O
96	O
weeks.	O
Serum	O
creatinine	Chemical
levels	O
were	O
routinely	O
determined	O
at	O
the	O
same	O
time	O
points.	O
Steady-state	O
pharmacokinetics	O
of	O
indinavir	Chemical
were	O
done	O
at	O
week	O
4	O
after	O
the	O
initiation	O
of	O
indinavir	Chemical
.	O
RESULTS:	O
The	O
cumulative	O
incidence	O
of	O
persistent	O
sterile	O
leukocyturia	Disease
(>	O
or	O
=75	O
cells/	O
micro	O
L	O
in	O
at	O
least	O
2	O
consecutive	O
visits)	O
after	O
96	O
weeks	O
was	O
53%.	O
Persistent	O
sterile	O
leukocyturia	Disease
was	O
frequently	O
associated	O
with	O
a	O
mild	O
increase	O
in	O
the	O
urine	O
albumin/	O
creatinine	Chemical
ratio	O
and	O
by	O
microscopic	O
hematuria	Disease
.	O
The	O
cumulative	O
incidence	O
of	O
serum	O
creatinine	Chemical
levels	O
>50%	O
above	O
normal	O
was	O
33%	O
after	O
96	O
weeks.	O
Children	O
with	O
persistent	O
sterile	O
leukocyturia	Disease
more	O
frequently	O
had	O
serum	O
creatinine	Chemical
levels	O
of	O
50%	O
above	O
normal	O
than	O
those	O
children	O
without	O
persistent	O
sterile	O
leukocyturia	Disease
.	O
In	O
children	O
younger	O
than	O
5.6	O
years,	O
persistent	O
sterile	O
leukocyturia	Disease
was	O
significantly	O
more	O
frequent	O
than	O
in	O
older	O
children.	O
A	O
higher	O
cumulative	O
incidence	O
of	O
persistent	O
leukocyturia	Disease
was	O
found	O
in	O
children	O
with	O
an	O
area	O
under	O
the	O
curve	O
>19	O
mg/L	O
x	O
h	O
or	O
a	O
peak	O
serum	O
level	O
of	O
indinavir	Chemical
>12	O
mg/L.	O
In	O
4	O
children,	O
indinavir	Chemical
was	O
discontinued	O
because	O
of	O
nephrotoxicity	Disease
.	O
Subsequently,	O
the	O
serum	O
creatinine	Chemical
levels	O
decreased,	O
the	O
urine	O
albumin/	O
creatinine	Chemical
ratios	O
returned	O
to	O
zero,	O
and	O
the	O
leukocyturia	Disease
disappeared	O
within	O
3	O
months.	O
CONCLUSIONS:	O
Children	O
treated	O
with	O
indinavir	Chemical
have	O
a	O
high	O
cumulative	O
incidence	O
of	O
persistent	O
sterile	O
leukocyturia	Disease
.	O
Children	O
with	O
persistent	O
sterile	O
leukocyturia	Disease
more	O
frequently	O
had	O
an	O
increase	O
in	O
serum	O
creatinine	Chemical
levels	O
of	O
>50%	O
above	O
normal.	O
Younger	O
children	O
have	O
an	O
additional	O
risk	O
for	O
renal	O
complications.	O
The	O
impairment	Disease
of	Disease
the	Disease
renal	Disease
function	Disease
in	O
these	O
children	O
occurred	O
in	O
the	O
absence	O
of	O
clinical	O
symptoms	O
of	O
nephrolithiasis	Disease
.	O
Indinavir	Chemical
-associated	O
nephrotoxicity	Disease
must	O
be	O
monitored	O
closely,	O
especially	O
in	O
children	O
with	O
risk	O
factors	O
such	O
as	O
persistent	O
sterile	O
leukocyturia	Disease
,	O
age	O
<5.6	O
years,	O
an	O
area	O
under	O
the	O
curve	O
of	O
indinavir	Chemical

Utility	O
of	O
troponin	O
I	O
in	O
patients	O
with	O
cocaine	Chemical
-associated	O
chest	Disease
pain	Disease
.	O
Baseline	O
electrocardiogram	O
abnormalities	O
and	O
market	O
elevations	O
not	O
associated	O
with	O
myocardial	Disease
necrosis	Disease
make	O
accurate	O
diagnosis	O
of	O
myocardial	Disease
infarction	Disease
(	O
MI	Disease
)	O
difficult	O
in	O
patients	O
with	O
cocaine	Chemical
-associated	O
chest	Disease
pain	Disease
.	O
Troponin	O
sampling	O
may	O
offer	O
greater	O
diagnostic	O
utility	O
in	O
these	O
patients.	O
OBJECTIVE:	O
To	O
assess	O
outcomes	O
based	O
on	O
troponin	O
positivity	O
in	O
patients	O
with	O
cocaine	Chemical
	O
chest	Disease
pain	Disease
admitted	O
for	O
exclusion	O
of	O
MI	Disease
.	O
METHODS:	O
Outcomes	O
were	O
examined	O
in	O
patients	O
admitted	O
for	O
possible	O
MI	Disease
after	O
cocaine	Chemical
use.	O
All	O
patients	O
underwent	O
a	O
rapid	O
rule-in	O
protocol	O
that	O
included	O
serial	O
sampling	O
of	O
creatine	Chemical
kinase	O
(CK),	O
CK-MB,	O
and	O
cardiac	O
troponin	O
I	O
(cTnI)	O
over	O
eight	O
hours.	O
Outcomes	O
included	O
CK-MB	O
MI	Disease
(CK-MB	O
>or=	O
8	O
ng/mL	O
with	O
a	O
relative	O
index	O
[(CK-MB	O
x	O
100)/total	O
CK]	O
>or=	O
4,	O
cardiac	Disease
death	Disease
,	O
and	O
significant	O
coronary	Disease
disease	Disease
(>or=50%).	O
RESULTS:	O
Of	O
the	O
246	O
admitted	O
patients,	O
34	O
(14%)	O
met	O
CK-MB	O
criteria	O
for	O
MI	Disease
and	O
38	O
(16%)	O
had	O
cTnI	O
elevations.	O
Angiography	O
was	O
performed	O
in	O
29	O
of	O
38	O
patients	O
who	O
were	O
cTnI-positive,	O
with	O
significant	O
disease	O
present	O
in	O
25	O
(86%).	O
Three	O
of	O
the	O
four	O
patients	O
without	O
significant	O
disease	O
who	O
had	O
cTnI	O
elevations	O
met	O
CK-MB	O
criteria	O
for	O
MI	Disease
,	O
and	O
the	O
other	O
had	O
a	O
peak	O
CK-MB	O
level	O
of	O
13	O
ng/mL.	O
Sensitivities,	O
specificities,	O
and	O
positive	O
and	O
negative	O
likelihood	O
ratios	O
for	O
predicting	O
cardiac	Disease
death	Disease
or	O
significant	O
disease	O
were	O
high	O
for	O
both	O
CK-MB	O
MI	Disease
and	O
cTnI	O
and	O
were	O
not	O
significantly	O
different.	O
CONCLUSIONS:	O
Most	O
patients	O
with	O
cTnI	O
elevations	O
meet	O
CK-MB	O
criteria	O
for	O
MI	Disease
,	O
as	O
well	O
as	O
have	O
a	O
high	O
incidence	O
of	O
underlying	O
significant	O
disease.	O
Troponin	O
appears	O
to	O
have	O
an	O
equivalent	O
diagnostic	O
accuracy	O
compared	O
with	O
CK-MB	O
for	O
diagnosing	O
necrosis	Disease
in	O
patients	O
with	O
cocaine	Chemical
-associated	O
chest	Disease
pain	Disease
and	O
suspected	O
MI	Disease

Acute	O
interstitial	Disease
nephritis	Disease
due	O
to	O
nicergoline	Chemical
(	O
Sermion	Chemical
).	O
We	O
report	O
a	O
case	O
of	O
acute	O
interstitial	Disease
nephritis	Disease
(	O
AIN	Disease
)	O
due	O
to	O
nicergoline	Chemical
(	O
Sermion	Chemical
).	O
A	O
50-year-old	O
patient	O
admitted	O
to	O
our	O
hospital	O
for	O
fever	Disease
and	O
acute	Disease
renal	Disease
failure	Disease
.	O
Before	O
admission,	O
he	O
had	O
been	O
taking	O
nicergoline	Chemical
and	O
bendazac	Chemical
lysine	Chemical
due	O
to	O
retinal	Disease
vein	Disease
occlusion	Disease
at	O
ophthalmologic	O
department.	O
Thereafter,	O
he	O
experienced	O
intermittent	O
fever	Disease
and	O
skin	Disease
rash	Disease
.	O
On	O
admission,	O
clinical	O
symptoms	O
(i.e.	O
arthralgia	Disease
and	O
fever	Disease
)	O
and	O
laboratory	O
findings	O
(i.e.	O
eosinophilia	Disease
and	O
renal	Disease
failure	Disease
)	O
suggested	O
AIN	Disease
,	O
and	O
which	O
was	O
confirmed	O
by	O
pathologic	O
findings	O
on	O
renal	O
biopsy.	O
A	O
lymphocyte	O
transformation	O
test	O
demonstrated	O
a	O
positive	O
result	O
against	O
nicergoline	Chemical
.	O
Treatment	O
was	O
consisted	O
of	O
withdrawal	O
of	O
nicergoline	Chemical
and	O
intravenous	O
methylprednisolone	Chemical
,	O
and	O
his	O
renal	O
function	O
was	O
completely	O
recovered.	O
To	O
our	O
knowledge,	O
this	O
is	O
the	O
first	O
report	O
of	O
nicergoline	Chemical
-associated	O
AIN	Disease

Neuroleptic	Disease
malignant	Disease
syndrome	Disease
complicated	O
by	O
massive	O
intestinal	O
bleeding	Disease
in	O
a	O
patient	O
with	O
chronic	Disease
renal	Disease
failure	Disease
.	O
A	O
patient	O
with	O
chronic	Disease
renal	Disease
failure	Disease
(	O
CRF	Disease
)	O
developed	O
neuroleptic	Disease
malignant	Disease
syndrome	Disease
(	O
NMS	Disease
)	O
after	O
administration	O
of	O
risperidone	Chemical
and	O
levomepromazine	Chemical
.	O
In	O
addition	O
to	O
the	O
typical	O
symptoms	O
of	O
NMS	Disease
,	O
massive	O
intestinal	O
bleeding	Disease
was	O
observed	O
during	O
the	O
episode.	O
This	O
report	O
suggests	O
that	O
NMS	Disease
in	O
a	O
patient	O
with	O
CRF	Disease
may	O
be	O
complicated	O
by	O
intestinal	O
bleeding	Disease

Blood	O
brain	O
barrier	O
in	O
right-	O
and	O
left-pawed	O
female	O
rats	O
assessed	O
by	O
a	O
new	O
staining	O
method.	O
The	O
asymmetrical	O
breakdown	O
of	O
the	O
blood-brain	O
barrier	O
(BBB)	O
was	O
studied	O
in	O
female	O
rats.	O
Paw	O
preference	O
was	O
assessed	O
by	O
a	O
food	O
reaching	O
test.	O
Adrenaline	Chemical
-induced	O
hypertension	Disease
was	O
used	O
to	O
destroy	O
the	O
BBB,	O
which	O
was	O
evaluated	O
using	O
triphenyltetrazolium	Chemical
(	O
TTC	Chemical
)	O
staining	O
of	O
the	O
brain	O
slices	O
just	O
after	O
giving	O
adrenaline	Chemical
for	O
30	O
s.	O
In	O
normal	O
rats,	O
the	O
whole	O
brain	O
sections	O
exhibited	O
complete	O
staining	O
with	O
TTC	Chemical
.	O
After	O
adrenaline	Chemical
infusion	O
for	O
30	O
s,	O
there	O
were	O
large	O
unstained	O
areas	O
in	O
the	O
left	O
brain	O
in	O
right-pawed	O
animals,	O
and	O
vice	O
versa	O
in	O
left-pawed	O
animals.	O
Similar	O
results	O
were	O
obtained	O
in	O
seizure	Disease

Carvedilol	Chemical
protects	O
against	O
doxorubicin	Chemical
-induced	O
mitochondrial	O
cardiomyopathy	Disease
.	O
Several	O
cytopathic	O
mechanisms	O
have	O
been	O
suggested	O
to	O
mediate	O
the	O
dose-limiting	O
cumulative	O
and	O
irreversible	O
cardiomyopathy	Disease
caused	O
by	O
doxorubicin	Chemical
.	O
Recent	O
evidence	O
indicates	O
that	O
oxidative	O
stress	O
and	O
mitochondrial	Disease
dysfunction	Disease
are	O
key	O
factors	O
in	O
the	O
pathogenic	O
process.	O
The	O
objective	O
of	O
this	O
investigation	O
was	O
to	O
test	O
the	O
hypothesis	O
that	O
carvedilol	Chemical
,	O
a	O
nonselective	O
beta-adrenergic	O
receptor	O
antagonist	O
with	O
potent	O
antioxidant	O
properties,	O
protects	O
against	O
the	O
cardiac	O
and	O
hepatic	O
mitochondrial	O
bioenergetic	O
dysfunction	O
associated	O
with	O
subchronic	O
doxorubicin	Chemical
	O
toxicity	Disease
.	O
Heart	O
and	O
liver	O
mitochondria	O
were	O
isolated	O
from	O
rats	O
treated	O
for	O
7	O
weeks	O
with	O
doxorubicin	Chemical
(2	O
mg/kg	O
sc/week),	O
carvedilol	Chemical
(1	O
mg/kg	O
ip/week),	O
or	O
the	O
combination	O
of	O
the	O
two	O
drugs.	O
Heart	O
mitochondria	O
isolated	O
from	O
doxorubicin	Chemical
-treated	O
rats	O
exhibited	O
depressed	O
rates	O
for	O
state	O
3	O
respiration	O
(336	O
+/-	O
26	O
versus	O
425	O
+/-	O
53	O
natom	O
O/min/mg	O
protein)	O
and	O
a	O
lower	O
respiratory	O
control	O
ratio	O
(RCR)	O
(4.3	O
+/-	O
0.6	O
versus	O
5.8	O
+/-	O
0.4)	O
compared	O
with	O
cardiac	O
mitochondria	O
isolated	O
from	O
saline-treated	O
rats.	O
Mitochondrial	O
calcium	Chemical
-loading	O
capacity	O
and	O
the	O
activity	O
of	O
NADH-dehydrogenase	O
were	O
also	O
suppressed	O
in	O
cardiac	O
mitochondria	O
from	O
doxorubicin	Chemical
-treated	O
rats.	O
Doxorubicin	Chemical
treatment	O
also	O
caused	O
a	O
decrease	O
in	O
RCR	O
for	O
liver	O
mitochondria	O
(3.9	O
+/-	O
0.9	O
versus	O
5.6	O
+/-	O
0.7	O
for	O
control	O
rats)	O
and	O
inhibition	O
of	O
hepatic	O
cytochrome	O
oxidase	O
activity.	O
Coadministration	O
of	O
carvedilol	Chemical
decreased	O
the	O
extent	O
of	O
cellular	O
vacuolization	O
in	O
cardiac	O
myocytes	O
and	O
prevented	O
the	O
inhibitory	O
effect	O
of	O
doxorubicin	Chemical
on	O
mitochondrial	O
respiration	O
in	O
both	O
heart	O
and	O
liver.	O
Carvedilol	Chemical
also	O
prevented	O
the	O
decrease	O
in	O
mitochondrial	O
Ca	Chemical
(2+)	O
loading	O
capacity	O
and	O
the	O
inhibition	O
of	O
the	O
respiratory	O
complexes	O
of	O
heart	O
mitochondria	O
caused	O
by	O
doxorubicin	Chemical
.	O
Carvedilol	Chemical
by	O
itself	O
did	O
not	O
affect	O
any	O
of	O
the	O
parameters	O
measured	O
for	O
heart	O
or	O
liver	O
mitochondria.	O
It	O
is	O
concluded	O
that	O
this	O
protection	O
by	O
carvedilol	Chemical
against	O
both	O
the	O
structural	O
and	O
functional	O
cardiac	O
tissue	O
damage	O
may	O
afford	O
significant	O
clinical	O
advantage	O
in	O
minimizing	O
the	O
dose-limiting	O
mitochondrial	Disease
dysfunction	Disease
and	O
cardiomyopathy	Disease
that	O
accompanies	O
long-term	O
doxorubicin	Chemical
therapy	O
in	O
cancer	Disease

Cocaine	Chemical
-induced	O
hyperactivity	Disease
is	O
more	O
influenced	O
by	O
adenosine	Chemical
receptor	O
agonists	O
than	O
amphetamine	Chemical
-induced	O
hyperactivity	Disease
.	O
The	O
influence	O
of	O
adenosine	Chemical
receptor	O
agonists	O
and	O
antagonists	O
on	O
cocaine	Chemical
-and	O
amphetamine	Chemical
-induced	O
hyperactivity	Disease
was	O
examined	O
in	O
mice.	O
All	O
adenosine	Chemical
receptor	O
agonists	O
significantly	O
decreased	Disease
the	Disease
locomotor	Disease
activity	Disease
in	O
mice,	O
and	O
the	O
effects	O
were	O
dose-dependent.	O
It	O
seems	O
that	O
adenosine	Chemical
A1	O
and	O
A2	O
receptors	O
might	O
be	O
involved	O
in	O
this	O
reaction.	O
Moreover,	O
all	O
adenosine	Chemical
receptor	O
agonists:	O
2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamidoadenosine	Chemical
(	O
CGS	Chemical
21680	Chemical
),	O
A2A	O
receptor	O
agonist,	O
N6-cyclopentyladenosine	Chemical
(	O
CPA	Chemical
),	O
A1	O
receptor	O
agonist,	O
and	O
5'-N-ethylcarboxamidoadenosine	Chemical
(	O
NECA	Chemical
),	O
A2/A1	O
receptor	O
agonist	O
significantly	O
and	O
dose-dependently	O
decreased	O
cocaine	Chemical
-induced	O
locomotor	O
activity.	O
CPA	Chemical
reduced	O
cocaine	Chemical
action	O
at	O
the	O
doses	O
which,	O
given	O
alone,	O
did	O
not	O
influence	O
motility,	O
while	O
CGS	Chemical
21680	Chemical
and	O
NECA	Chemical
decreased	O
the	O
action	O
of	O
cocaine	Chemical
at	O
the	O
doses	O
which,	O
given	O
alone,	O
decreased	O
locomotor	O
activity	O
in	O
animals.	O
These	O
results	O
suggest	O
the	O
involvement	O
of	O
both	O
adenosine	Chemical
receptors	O
in	O
the	O
action	O
of	O
cocaine	Chemical
although	O
agonists	O
of	O
A1	O
receptors	O
seem	O
to	O
have	O
stronger	O
influence	O
on	O
it.	O
The	O
selective	O
blockade	O
of	O
A2	O
adenosine	Chemical
receptor	O
by	O
DMPX	Chemical
(	O
3,7-dimethyl-1-propargylxanthine	Chemical
)	O
significantly	O
enhanced	O
cocaine	Chemical
-induced	O
locomotor	O
activity	O
of	O
animals.	O
Caffeine	Chemical
had	O
similar	O
action	O
but	O
the	O
effect	O
was	O
not	O
significant.	O
CPT	Chemical
(	O
8-cyclopentyltheophylline	Chemical
)--A1	O
receptor	O
antagonist,	O
did	O
not	O
show	O
any	O
influence	O
in	O
this	O
test.	O
Similarly,	O
all	O
adenosine	Chemical
receptor	O
agonists	O
decreased	O
amphetamine	Chemical
-induced	O
hyperactivity	Disease
,	O
but	O
at	O
the	O
higher	O
doses	O
than	O
those	O
which	O
were	O
active	O
in	O
cocaine	Chemical
-induced	O
hyperactivity	Disease
.	O
The	O
selective	O
blockade	O
of	O
A2	O
adenosine	Chemical
receptors	O
(	O
DMPX	Chemical
)	O
and	O
non-selective	O
blockade	O
of	O
adenosine	Chemical
receptors	O
(	O
caffeine	Chemical
)	O
significantly	O
increased	O
the	O
action	O
of	O
amphetamine	Chemical
in	O
the	O
locomotor	O
activity	O
test.	O
Our	O
results	O
have	O
shown	O
that	O
all	O
adenosine	Chemical
receptor	O
agonists	O
(A1	O
and	O
A2)	O
reduce	O
cocaine	Chemical
-	O
and	O
amphetamine	Chemical
-induced	O
locomotor	O
activity	O
and	O
indicate	O
that	O
cocaine	Chemical
-induced	O
hyperactivity	Disease
is	O
more	O
influenced	O
by	O
adenosine	Chemical
receptor	O
agonists	O
(particularly	O
A1	O
receptors)	O
than	O
amphetamine	Chemical
-induced	O
hyperactivity	Disease

Amiodarone	Chemical
and	O
the	O
risk	O
of	O
bradyarrhythmia	Disease
requiring	O
permanent	O
pacemaker	O
in	O
elderly	O
patients	O
with	O
atrial	Disease
fibrillation	Disease
and	O
prior	O
myocardial	Disease
infarction	Disease
.	O
OBJECTIVES:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
use	O
of	O
amiodarone	Chemical
in	O
patients	O
with	O
atrial	Disease
fibrillation	Disease
(	O
AF	Disease
)	O
increases	O
the	O
risk	O
of	O
bradyarrhythmia	Disease
requiring	O
a	O
permanent	O
pacemaker.	O
BACKGROUND:	O
Reports	O
of	O
severe	O
bradyarrhythmia	Disease
during	O
amiodarone	Chemical
therapy	O
are	O
infrequent	O
and	O
limited	O
to	O
studies	O
assessing	O
the	O
therapy's	O
use	O
in	O
the	O
management	O
of	O
patients	O
with	O
ventricular	Disease
arrhythmias	Disease
.	O
METHODS:	O
A	O
study	O
cohort	O
of	O
8,770	O
patients	O
age	O
>	O
or	O
=65	O
years	O
with	O
a	O
new	O
diagnosis	O
of	O
AF	Disease
was	O
identified	O
from	O
a	O
provincewide	O
database	O
of	O
Quebec	O
residents	O
with	O
a	O
myocardial	Disease
infarction	Disease
(	O
MI	Disease
)	O
between	O
1991	O
and	O
1999.	O
Using	O
a	O
nested	O
case-control	O
design,	O
477	O
cases	O
of	O
bradyarrhythmia	Disease
requiring	O
a	O
permanent	O
pacemaker	O
were	O
matched	O
(1:4)	O
to	O
1,908	O
controls.	O
Multivariable	O
logistic	O
regression	O
was	O
used	O
to	O
estimate	O
the	O
odds	O
ratio	O
(OR)	O
of	O
pacemaker	O
insertion	O
associated	O
with	O
amiodarone	Chemical
use,	O
controlling	O
for	O
baseline	O
risk	O
factors	O
and	O
exposure	O
to	O
sotalol	Chemical
,	O
Class	O
I	O
antiarrhythmic	O
agents,	O
beta-blockers,	O
calcium	Chemical
channel	O
blockers,	O
and	O
digoxin	Chemical
.	O
RESULTS:	O
amiodarone	Chemical
use	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
pacemaker	O
insertion	O
(OR:	O
2.14,	O
95%	O
confidence	O
interval	O
[CI]:	O
1.30	O
to	O
3.54).	O
This	O
effect	O
was	O
modified	O
by	O
gender,	O
with	O
a	O
greater	O
risk	O
in	O
women	O
versus	O
men	O
(OR:	O
3.86,	O
95%	O
CI:	O
1.70	O
to	O
8.75	O
vs.	O
OR:	O
1.52,	O
95%	O
CI:	O
0.80	O
to	O
2.89).	O
Digoxin	Chemical
was	O
the	O
only	O
other	O
medication	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
pacemaker	O
insertion	O
(OR:	O
1.78,	O
95%	O
CI:	O
1.37	O
to	O
2.31).	O
CONCLUSIONS:	O
This	O
study	O
suggests	O
that	O
the	O
use	O
of	O
amiodarone	Chemical
in	O
elderly	O
patients	O
with	O
AF	Disease
and	O
a	O
previous	O
MI	Disease
increases	O
the	O
risk	O
of	O
bradyarrhythmia	Disease
requiring	O
a	O
permanent	O
pacemaker.	O
The	O
finding	O
of	O
an	O
augmented	O
risk	O
of	O
pacemaker	O
insertion	O
in	O
elderly	O
women	O
receiving	O
amiodarone	Chemical

Indomethacin	Chemical
-induced	O
morphologic	O
changes	O
in	O
the	O
rat	O
urinary	O
bladder	O
epithelium.	O
OBJECTIVES:	O
To	O
evaluate	O
the	O
morphologic	O
changes	O
in	O
rat	O
urothelium	O
induced	O
by	O
indomethacin	Chemical
.	O
Nonsteroidal	O
anti-inflammatory	O
drug-induced	O
cystitis	Disease
is	O
a	O
poorly	O
recognized	O
and	O
under-reported	O
condition.	O
In	O
addition	O
to	O
tiaprofenic	Chemical
acid	Chemical
,	O
indomethacin	Chemical
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
this	O
condition.	O
METHODS:	O
Three	O
groups	O
were	O
established:	O
a	O
control	O
group	O
(n	O
=	O
10),	O
a	O
high-dose	O
group	O
(n	O
=	O
10),	O
treated	O
with	O
one	O
intraperitoneal	O
injection	O
of	O
indomethacin	Chemical
20	O
mg/kg,	O
and	O
a	O
therapeutic	O
dose	O
group	O
(n	O
=	O
10)	O
in	O
which	O
oral	O
indomethacin	Chemical
was	O
administered	O
3.25	O
mg/kg	O
body	O
weight	O
daily	O
for	O
3	O
weeks.	O
The	O
animals	O
were	O
then	O
killed	O
and	O
the	O
bladders	O
removed	O
for	O
light	O
and	O
electron	O
microscopic	O
studies.	O
RESULTS:	O
The	O
light	O
microscopic	O
findings	O
showed	O
some	O
focal	O
epithelial	O
degeneration	O
that	O
was	O
more	O
prominent	O
in	O
the	O
high-dose	O
group.	O
When	O
compared	O
with	O
the	O
control	O
group,	O
both	O
indomethacin	Chemical
groups	O
revealed	O
statistically	O
increased	O
numbers	O
of	O
mast	O
cells	O
in	O
the	O
mucosa	O
(P	O
<0.0001)	O
and	O
penetration	O
of	O
lanthanum	Chemical
nitrate	Chemical
through	O
intercellular	O
areas	O
of	O
the	O
epithelium.	O
Furthermore,	O
the	O
difference	O
in	O
mast	O
cell	O
counts	O
between	O
the	O
high	O
and	O
therapeutic	O
dose	O
groups	O
was	O
also	O
statistically	O
significant	O
(P	O
<0.0001).	O
CONCLUSIONS:	O
Indomethacin	Chemical
resulted	O
in	O
histopathologic	O
findings	O
typical	O
of	O
interstitial	Disease
cystitis	Disease
,	O
such	O
as	O
leaky	O
bladder	O
epithelium	O
and	O
mucosal	O
mastocytosis	Disease
.	O
The	O
true	O
incidence	O
of	O
nonsteroidal	O
anti-inflammatory	O
drug-induced	O
cystitis	Disease

An	O
open-label	O
phase	O
II	O
study	O
of	O
low-dose	O
thalidomide	Chemical
in	O
androgen	Chemical
-independent	O
prostate	Disease
cancer	Disease
.	O
The	O
antiangiogenic	O
effects	O
of	O
thalidomide	Chemical
have	O
been	O
assessed	O
in	O
clinical	O
trials	O
in	O
patients	O
with	O
various	O
solid	O
and	O
haematological	Disease
malignancies	Disease
.	O
Thalidomide	Chemical
blocks	O
the	O
activity	O
of	O
angiogenic	O
agents	O
including	O
bFGF,	O
VEGF	O
and	O
IL-6.	O
We	O
undertook	O
an	O
open-label	O
study	O
using	O
thalidomide	Chemical
100	O
mg	O
once	O
daily	O
for	O
up	O
to	O
6	O
months	O
in	O
20	O
men	O
with	O
androgen	Chemical
-independent	O
prostate	Disease
cancer	Disease
.	O
The	O
mean	O
time	O
of	O
study	O
was	O
109	O
days	O
(median	O
107,	O
range	O
4-184	O
days).	O
Patients	O
underwent	O
regular	O
measurement	O
of	O
prostate-specific	O
antigen	O
(PSA),	O
urea	Chemical
and	O
electrolytes,	O
serum	O
bFGF	O
and	O
VEGF.	O
Three	O
men	O
(15%)	O
showed	O
a	O
decline	O
in	O
serum	O
PSA	O
of	O
at	O
least	O
50%,	O
sustained	O
throughout	O
treatment.	O
Of	O
16	O
men	O
treated	O
for	O
at	O
least	O
2	O
months,	O
six	O
(37.5%)	O
showed	O
a	O
fall	O
in	O
absolute	O
PSA	O
by	O
a	O
median	O
of	O
48%.	O
Increasing	O
levels	O
of	O
serum	O
bFGF	O
and	O
VEGF	O
were	O
associated	O
with	O
progressive	O
disease;	O
five	O
of	O
six	O
men	O
who	O
demonstrated	O
a	O
fall	O
in	O
PSA	O
also	O
showed	O
a	O
decline	O
in	O
bFGF	O
and	O
VEGF	O
levels,	O
and	O
three	O
of	O
four	O
men	O
with	O
a	O
rising	O
PSA	O
showed	O
an	O
increase	O
in	O
both	O
growth	O
factors.	O
Adverse	O
effects	O
included	O
constipation	Disease
,	O
morning	O
drowsiness	Disease
,	O
dizziness	Disease
and	O
rash	Disease
,	O
and	O
resulted	O
in	O
withdrawal	O
from	O
the	O
study	O
by	O
three	O
men.	O
Evidence	O
of	O
peripheral	Disease
sensory	Disease
neuropathy	Disease
was	O
found	O
in	O
nine	O
of	O
13	O
men	O
before	O
treatment.	O
In	O
the	O
seven	O
men	O
who	O
completed	O
six	O
months	O
on	O
thalidomide	Chemical
,	O
subclinical	O
evidence	O
of	O
peripheral	Disease
neuropathy	Disease
was	O
found	O
in	O
four	O
before	O
treatment,	O
but	O
in	O
all	O
seven	O
at	O
repeat	O
testing.	O
The	O
findings	O
indicate	O
that	O
thalidomide	Chemical
may	O
be	O
an	O
option	O
for	O
patients	O
who	O
have	O
failed	O
other	O
forms	O
of	O
therapy,	O
provided	O
close	O
follow-up	O
is	O
maintained	O
for	O
development	O
of	O
peripheral	Disease
neuropathy	Disease

Central	Disease
nervous	Disease
system	Disease
toxicity	Disease
following	O
the	O
administration	O
of	O
levobupivacaine	Chemical
for	O
lumbar	O
plexus	O
block:	O
A	O
report	O
of	O
two	O
cases.	O
BACKGROUND	O
AND	O
OBJECTIVES:	O
Central	Disease
nervous	Disease
system	Disease
and	Disease
cardiac	Disease
toxicity	Disease
following	O
the	O
administration	O
of	O
local	O
anesthetics	O
is	O
a	O
recognized	O
complication	O
of	O
regional	O
anesthesia.	O
Levobupivacaine	Chemical
,	O
the	O
pure	O
S(-)	O
enantiomer	O
of	O
bupivacaine	Chemical
,	O
was	O
developed	O
to	O
improve	O
the	O
cardiac	O
safety	O
profile	O
of	O
bupivacaine	Chemical
.	O
We	O
describe	O
2	O
cases	O
of	O
grand	Disease
mal	Disease
seizures	Disease
following	O
accidental	O
intravascular	O
injection	O
of	O
levobupivacaine	Chemical
.	O
CASE	O
REPORT:	O
Two	O
patients	O
presenting	O
for	O
elective	O
orthopedic	O
surgery	O
of	O
the	O
lower	O
limb	O
underwent	O
blockade	O
of	O
the	O
lumbar	O
plexus	O
via	O
the	O
posterior	O
approach.	O
Immediately	O
after	O
the	O
administration	O
of	O
levobupivacaine	Chemical
0.5%	O
with	O
epinephrine	Chemical
2.5	O
microgram/mL,	O
the	O
patients	O
developed	O
grand	Disease
mal	Disease
seizures	Disease
,	O
despite	O
negative	O
aspiration	O
for	O
blood	O
and	O
no	O
clinical	O
signs	O
of	O
intravenous	O
epinephrine	Chemical
administration.	O
The	O
seizures	Disease
were	O
successfully	O
treated	O
with	O
sodium	Chemical
thiopental	Chemical
in	O
addition	O
to	O
succinylcholine	Chemical
in	O
1	O
patient.	O
Neither	O
patient	O
developed	O
signs	O
of	O
cardiovascular	Disease
toxicity	Disease
.	O
Both	O
patients	O
were	O
treated	O
preoperatively	O
with	O
beta-adrenergic	O
antagonist	O
medications,	O
which	O
may	O
have	O
masked	O
the	O
cardiovascular	O
signs	O
of	O
the	O
unintentional	O
intravascular	O
administration	O
of	O
levobupivacaine	Chemical
with	O
epinephrine	Chemical
.	O
CONCLUSIONS:	O
Although	O
levobupivacaine	Chemical
may	O
have	O
a	O
safer	O
cardiac	Disease
toxicity	Disease
profile	O
than	O
racemic	O
bupivacaine	Chemical
,	O
if	O
adequate	O
amounts	O
of	O
levobupivacaine	Chemical
reach	O
the	O
circulation,	O
it	O
will	O
result	O
in	O
convulsions	Disease
.	O
Plasma	O
concentrations	O
sufficient	O
to	O
result	O
in	O
central	Disease
nervous	Disease
system	Disease
toxicity	Disease
did	O
not	O
produce	O
manifestations	O
of	O
cardiac	Disease
toxicity	Disease

Anaesthetic	O
complications	O
associated	O
with	O
myotonia	Disease
congenita	Disease
:	O
case	O
study	O
and	O
comparison	O
with	O
other	O
myotonic	Disease
disorders	Disease
.	O
Myotonia	Disease
congenita	Disease
(	O
MC	Disease
)	O
is	O
caused	O
by	O
a	O
defect	O
in	O
the	O
skeletal	O
muscle	O
chloride	Chemical
channel	O
function,	O
which	O
may	O
cause	O
sustained	Disease
membrane	Disease
depolarisation	Disease
.	O
We	O
describe	O
a	O
previously	O
healthy	O
32-year-old	O
woman	O
who	O
developed	O
a	O
life-threatening	O
muscle	Disease
spasm	Disease
and	O
secondary	O
ventilation	O
difficulties	O
following	O
a	O
preoperative	O
injection	O
of	O
suxamethonium	Chemical
.	O
The	O
muscle	Disease
spasms	Disease
disappeared	O
spontaneously	O
and	O
the	O
surgery	O
proceeded	O
without	O
further	O
problems.	O
When	O
subsequently	O
questioned,	O
she	O
reported	O
minor	O
symptoms	O
suggesting	O
a	O
myotonic	Disease
condition	Disease
.	O
Myotonia	Disease
was	O
found	O
on	O
clinical	O
examination	O
and	O
EMG.	O
The	O
diagnosis	O
MC	Disease
was	O
confirmed	O
genetically.	O
Neither	O
the	O
patient	O
nor	O
the	O
anaesthetist	O
were	O
aware	O
of	O
the	O
diagnosis	O
before	O
this	O
potentially	O
lethal	O
complication	O
occurred.	O
We	O
give	O
a	O
brief	O
overview	O
of	O
ion	Disease
channel	Disease
disorders	Disease
including	O
malignant	Disease
hyperthermia	Disease

Respiratory	O
pattern	O
in	O
a	O
rat	O
model	O
of	O
epilepsy	Disease
.	O
PURPOSE:	O
Apnea	Disease
is	O
known	O
to	O
occur	O
during	O
seizures	Disease
,	O
but	O
systematic	O
studies	O
of	O
ictal	O
respiratory	O
changes	O
in	O
adults	O
are	O
few.	O
Data	O
regarding	O
respiratory	O
pattern	O
defects	O
during	O
interictal	O
periods	O
also	O
are	O
scarce.	O
Here	O
we	O
sought	O
to	O
generate	O
information	O
with	O
regard	O
to	O
the	O
interictal	O
period	O
in	O
animals	O
with	O
pilocarpine	Chemical
-induced	O
epilepsy	Disease
.	O
METHODS:	O
Twelve	O
rats	O
(six	O
chronically	O
epileptic	Disease
animals	O
and	O
six	O
controls)	O
were	O
anesthetized,	O
given	O
tracheotomies,	O
and	O
subjected	O
to	O
hyperventilation	Disease
or	O
hypoventilation	O
conditions.	O
Breathing	O
movements	O
caused	O
changes	O
in	O
thoracic	O
volume	O
and	O
forced	O
air	O
to	O
flow	O
tidally	O
through	O
a	O
pneumotachograph.	O
This	O
flow	O
was	O
measured	O
by	O
using	O
a	O
differential	O
pressure	O
transducer,	O
passed	O
through	O
a	O
polygraph,	O
and	O
from	O
this	O
to	O
a	O
computer	O
with	O
custom	O
software	O
that	O
derived	O
ventilation	O
(VE),	O
tidal	O
volume	O
(VT),	O
inspiratory	O
time	O
(TI),	O
expiratory	O
time	O
(TE),	O
breathing	O
frequency	O
(f),	O
and	O
mean	O
inspiratory	O
flow	O
(VT/TI)	O
on	O
a	O
breath-by-breath	O
basis.	O
RESULTS:	O
The	O
hyperventilation	Disease
maneuver	O
caused	O
a	O
decrease	O
in	O
spontaneous	O
ventilation	O
in	O
pilocarpine	Chemical
-treated	O
and	O
control	O
rats.	O
Although	O
VE	O
had	O
a	O
similar	O
decrease	O
in	O
both	O
groups,	O
in	O
the	O
epileptic	Disease
group,	O
the	O
decrease	O
in	O
VE	O
was	O
due	O
to	O
a	O
significant	O
(p	O
<	O
0.05)	O
increase	O
in	O
TE	O
peak	O
in	O
relation	O
to	O
that	O
of	O
the	O
control	O
animals.	O
The	O
hypoventilation	O
maneuver	O
led	O
to	O
an	O
increase	O
in	O
the	O
arterial	O
Paco2,	O
followed	O
by	O
an	O
increase	O
in	O
VE.	O
In	O
the	O
epileptic	Disease
group,	O
the	O
increase	O
in	O
VE	O
was	O
mediated	O
by	O
a	O
significant	O
(p	O
<	O
0.05)	O
decrease	O
in	O
TE	O
peak	O
compared	O
with	O
the	O
control	O
group.	O
Systemic	O
application	O
of	O
KCN,	O
to	O
evaluate	O
the	O
effects	O
of	O
peripheral	O
chemoreception	O
activation	O
on	O
ventilation,	O
led	O
to	O
a	O
similar	O
increase	O
in	O
VE	O
for	O
both	O
groups.	O
CONCLUSIONS:	O
The	O
data	O
indicate	O
that	O
pilocarpine	Chemical
-treated	O
animals	O
have	O
an	O
altered	O
ability	O
to	O
react	O
to	O
(or	O
compensate	O
for)	O
blood	O
gas	O
changes	O
with	O
changes	O
in	O
ventilation	O
and	O
suggest	O
that	O
it	O
is	O
centrally	O
determined.	O
We	O
speculate	O
on	O
the	O
possible	O
relation	O
of	O
the	O
current	O
findings	O
on	O
treating	O
different	O
epilepsy	Disease

Increased	O
serum	O
soluble	O
Fas	O
in	O
patients	O
with	O
acute	Disease
liver	Disease
failure	Disease
due	O
to	O
paracetamol	Chemical
	O
overdose	Disease
.	O
BACKGROUND/AIMS:	O
Experimental	O
studies	O
have	O
suggested	O
that	O
apoptosis	O
via	O
the	O
Fas/Fas	O
Ligand	O
signaling	O
system	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
acute	Disease
liver	Disease
failure	Disease
.	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
soluble	O
form	O
of	O
Fas	O
in	O
patients	O
with	O
acute	Disease
liver	Disease
failure	Disease
.	O
METHODOLOGY:	O
Serum	O
levels	O
of	O
sFas	O
(soluble	O
Fas)	O
were	O
measured	O
by	O
ELISA	O
in	O
24	O
patients	O
with	O
acute	Disease
liver	Disease
failure	Disease
and	O
10	O
normal	O
control	O
subjects.	O
Serum	O
levels	O
of	O
tumor	Disease
	O
necrosis	Disease
factor-alpha	O
and	O
interferon-gamma	O
were	O
also	O
determined	O
by	O
ELISA.	O
RESULTS:	O
Serum	O
sFas	O
was	O
significantly	O
increased	O
in	O
patients	O
with	O
acute	Disease
liver	Disease
failure	Disease
(median,	O
26.8	O
U/mL;	O
range,	O
6.9-52.7	O
U/mL)	O
compared	O
to	O
the	O
normal	O
controls	O
(median,	O
8.6	O
U/mL;	O
range,	O
6.5-12.0	O
U/mL,	O
P	O
<	O
0.0001).	O
Levels	O
were	O
significantly	O
greater	O
in	O
patients	O
with	O
acute	Disease
liver	Disease
failure	Disease
due	O
to	O
paracetamol	Chemical
	O
overdose	Disease
(median,	O
28.7	O
U/mL;	O
range,	O
12.8-52.7	O
U/mL,	O
n	O
=	O
17)	O
than	O
those	O
due	O
to	O
non-A	O
to	O
E	O
hepatitis	Disease
(median,	O
12.5	O
U/mL;	O
range,	O
6.9-46.0	O
U/mL,	O
n	O
=	O
7,	O
P	O
<	O
0.01).	O
There	O
was	O
no	O
relationship	O
of	O
sFas	O
to	O
eventual	O
outcome	O
in	O
the	O
patients.	O
A	O
significant	O
correlation	O
was	O
observed	O
between	O
serum	O
sFas	O
levels	O
and	O
aspartate	Chemical
aminotransferase	O
(r	O
=	O
0.613,	O
P	O
<	O
0.01).	O
CONCLUSIONS:	O
The	O
increased	O
concentration	O
of	O
sFas	O
in	O
serum	O
of	O
patients	O
with	O
acute	Disease
liver	Disease
failure	Disease
may	O
reflect	O
activation	O
of	O
Fas-mediated	O
apoptosis	O
in	O
the	O
liver	O
and	O
this	O
together	O
with	O
increased	O
tumor	Disease
	O
necrosis	Disease

Bilateral	O
subthalamic	O
nucleus	O
stimulation	O
for	O
Parkinson's	Disease
disease	Disease
.	O
High	O
frequency	O
stimulation	O
of	O
the	O
subthalamic	O
nucleus	O
(STN)	O
is	O
known	O
to	O
ameliorate	O
the	O
signs	O
and	O
symptoms	O
of	O
advanced	O
Parkinson's	Disease
disease	Disease
.	O
AIM:	O
We	O
studied	O
the	O
effect	O
of	O
high	O
frequency	O
STN	O
stimulation	O
in	O
23	O
patients.	O
METHOD:	O
Twenty-three	O
patients	O
suffering	O
from	O
severe	O
Parkinson's	Disease
disease	Disease
(Stages	O
III-V	O
on	O
Hoehn	O
and	O
Yahr	O
scale)	O
and,	O
particularly	O
bradykinesia	Disease
,	O
rigidity	Disease
,	O
and	O
levodopa	Chemical
-induced	O
dyskinesias	Disease
underwent	O
bilateral	O
implantation	O
of	O
electrodes	O
in	O
the	O
STN.	O
Preoperative	O
and	O
postoperative	O
assessments	O
of	O
these	O
patients	O
at	O
1,	O
3,	O
6	O
and	O
12	O
months	O
follow-up,	O
in	O
"on"	O
and	O
"off"	O
drug	O
conditions,	O
was	O
carried	O
out	O
using	O
Unified	O
Parkinson's	Disease
Disease	Disease
Rating	O
Scale,	O
Hoehn	O
and	O
Yahr	O
staging,	O
England	O
activities	O
of	O
daily	O
living	O
score	O
and	O
video	O
recordings.	O
RESULTS:	O
After	O
one	O
year	O
of	O
electrical	O
stimulation	O
of	O
the	O
STN,	O
the	O
patients'	O
scores	O
for	O
activities	O
of	O
daily	O
living	O
and	O
motor	O
examination	O
scores	O
(Unified	O
Parkinson's	Disease
Disease	Disease
Rating	O
Scale	O
parts	O
II	O
and	O
III)	O
off	O
medication	O
improved	O
by	O
62%	O
and	O
61%	O
respectively	O
(p<0.0005).	O
The	O
subscores	O
for	O
the	O
akinesia	Disease
,	O
rigidity	Disease
,	O
tremor	Disease
and	O
gait	O
also	O
improved.	O
(p<0.0005).	O
The	O
average	O
levodopa	Chemical
dose	O
decreased	O
from	O
813	O
mg	O
to	O
359	O
mg.	O
The	O
cognitive	O
functions	O
remained	O
unchanged.	O
Two	O
patients	O
developed	O
device-related	O
complications	O
and	O
two	O
patients	O
experienced	O
abnormal	O
weight	O
gain.	O
CONCLUSION:	O
Bilateral	O
subthalamic	O
nucleus	O
stimulation	O
is	O
an	O
effective	O
treatment	O
for	O
advanced	O
Parkinson's	Disease
disease	Disease
.	O
It	O
reduces	O
the	O
severity	O
of	O
"off"	O
phase	O
symptoms,	O
improves	O
the	O
axial	O
symptoms	O
and	O
reduces	O
levodopa	Chemical
requirements.	O
The	O
reduction	O
in	O
the	O
levodopa	Chemical
dose	O
is	O
useful	O
in	O
controlling	O
drug-induced	Disease
dyskinesias	Disease

Ocular	O
motility	O
changes	O
after	O
subtenon	O
carboplatin	Chemical
chemotherapy	O
for	O
retinoblastoma	Disease
.	O
BACKGROUND:	O
Focal	O
subtenon	O
carboplatin	Chemical
injections	O
have	O
recently	O
been	O
used	O
as	O
a	O
presumably	O
toxicity	Disease
-free	O
adjunct	O
to	O
systemic	O
chemotherapy	O
for	O
intraocular	O
retinoblastoma	Disease
.	O
OBJECTIVE:	O
To	O
report	O
our	O
clinical	O
experience	O
with	O
abnormal	Disease
ocular	Disease
motility	Disease
in	O
patients	O
treated	O
with	O
subtenon	O
carboplatin	Chemical
chemotherapy.	O
METHODS:	O
We	O
noted	O
abnormal	Disease
ocular	Disease
motility	Disease
in	O
10	O
consecutive	O
patients	O
with	O
retinoblastoma	Disease
who	O
had	O
received	O
subtenon	O
carboplatin	Chemical
.	O
During	O
ocular	O
manipulation	O
under	O
general	O
anesthesia,	O
we	O
assessed	O
their	O
eyes	O
by	O
forced	O
duction	O
testing,	O
comparing	O
ocular	O
motility	O
after	O
tumor	Disease
control	O
with	O
ocular	O
motility	O
at	O
diagnosis.	O
Eyes	O
subsequently	O
enucleated	O
because	O
of	O
treatment	O
failure	O
(n	O
=	O
4)	O
were	O
examined	O
histologically.	O
RESULTS:	O
Limitation	O
of	O
ocular	O
motility	O
was	O
detected	O
in	O
all	O
12	O
eyes	O
of	O
10	O
patients	O
treated	O
for	O
intraocular	O
retinoblastoma	Disease
with	O
1	O
to	O
6	O
injections	O
of	O
subtenon	O
carboplatin	Chemical
as	O
part	O
of	O
multimodality	O
therapy.	O
Histopathological	O
examination	O
revealed	O
many	O
lipophages	O
in	O
the	O
periorbital	O
fat	O
surrounding	O
the	O
optic	O
nerve	O
in	O
1	O
eye,	O
indicative	O
of	O
phagocytosis	O
of	O
previously	O
existing	O
fat	O
cells	O
and	O
suggesting	O
prior	O
fat	O
necrosis	Disease
.	O
The	O
enucleations	O
were	O
technically	O
difficult	O
and	O
hazardous	O
for	O
globe	O
rupture	Disease
because	O
of	O
extensive	O
orbital	O
soft	O
tissue	O
adhesions.	O
CONCLUSIONS:	O
Subtenon	O
carboplatin	Chemical
chemotherapy	O
is	O
associated	O
with	O
significant	O
fibrosis	Disease
of	O
orbital	O
soft	O
tissues,	O
leading	O
to	O
mechanical	O
restriction	O
of	O
eye	O
movements	O
and	O
making	O
subsequent	O
enucleation	O
difficult.	O
Subtenon	O
carboplatin	Chemical
is	O
not	O
free	O
of	O
toxicity	Disease

Ethambutol	Chemical
and	O
optic	Disease
neuropathy	Disease
.	O
PURPOSE:	O
To	O
demonstrate	O
the	O
association	O
between	O
ethambutol	Chemical
and	O
optic	Disease
neuropathy	Disease
.	O
METHOD:	O
Thirteen	O
patients	O
who	O
developed	O
optic	Disease
neuropathy	Disease
after	O
being	O
treated	O
with	O
ethambutol	Chemical
for	O
tuberculosis	Disease
of	Disease
the	Disease
lung	Disease
or	Disease
lymph	Disease
node	Disease
at	O
Siriraj	O
Hospital	O
between	O
1997	O
and	O
2001	O
were	O
retrospectively	O
reviewed.	O
The	O
clinical	O
characteristics	O
and	O
initial	O
and	O
final	O
visual	O
acuity	O
were	O
analyzed	O
to	O
determine	O
visual	O
outcome.	O
RESULTS:	O
All	O
patients	O
had	O
optic	Disease
neuropathy	Disease
between	O
1	O
to	O
6	O
months	O
(mean	O
=	O
2.9	O
months)	O
after	O
starting	O
ethambutol	Chemical
therapy	O
at	O
a	O
dosage	O
ranging	O
from	O
13	O
to	O
20	O
mg/kg/day	O
(mean	O
=	O
17	O
mg/kg/day).	O
Seven	O
(54%)	O
of	O
the	O
13	O
patients	O
experienced	O
visual	O
recovery	O
after	O
stopping	O
the	O
drug.	O
Of	O
6	O
patients	O
with	O
irreversible	O
visual	Disease
impairment	Disease
,	O
4	O
patients	O
had	O
diabetes	Disease
mellitus	Disease
,	O
glaucoma	Disease
and	O
a	O
history	O
of	O
heavy	O
smoking.	O
CONCLUSION:	O
Early	O
recognition	O
of	O
optic	Disease
neuropathy	Disease
should	O
be	O
considered	O
in	O
patients	O
with	O
ethambutol	Chemical
therapy.	O
A	O
low	O
dose	O
and	O
prompt	O
discontinuation	O
of	O
the	O
drug	O
is	O
recommended	O
particularly	O
in	O
individuals	O
with	O
diabetes	Disease
mellitus	Disease
,	O
glaucoma	Disease

Treatment	O
of	O
compensatory	O
gustatory	Disease
hyperhidrosis	Disease
with	O
topical	O
glycopyrrolate	Chemical
.	O
Gustatory	Disease
hyperhidrosis	Disease
is	O
facial	O
sweating	Disease
usually	O
associated	O
with	O
the	O
eating	O
of	O
hot	O
spicy	O
food	O
or	O
even	O
smelling	O
this	O
food.	O
Current	O
options	O
of	O
treatment	O
include	O
oral	O
anticholinergic	O
drugs,	O
the	O
topical	O
application	O
of	O
anticholinergics	O
or	O
aluminum	Chemical
chloride	Chemical
,	O
and	O
the	O
injection	O
of	O
botulinum	O
toxin.	O
Thirteen	O
patients	O
have	O
been	O
treated	O
to	O
date	O
with	O
1.5%	O
or	O
2%	O
topical	O
glycopyrrolate	Chemical
.	O
All	O
patients	O
had	O
gustatory	Disease
hyperhidrosis	Disease
,	O
which	O
interfered	O
with	O
their	O
social	O
activities,	O
after	O
transthroacic	O
endoscopic	O
sympathectomy,	O
and	O
which	O
was	O
associated	O
with	O
compensatory	O
focal	O
hyperhidrosis	Disease
.	O
After	O
applying	O
topical	O
glycopyrrolate	Chemical
,	O
the	O
subjective	O
effect	O
was	O
excellent	O
(no	O
sweating	Disease
after	O
eating	O
hot	O
spicy	O
food)	O
in	O
10	O
patients	O
(77%),	O
and	O
fair	O
(clearly	O
reduced	O
sweating	Disease
)	O
in	O
3	O
patients	O
(23%).	O
All	O
had	O
reported	O
incidents	O
of	O
being	O
very	O
embarrassed	O
whilst	O
eating	O
hot	O
spicy	O
foods.	O
Adverse	O
effects	O
included	O
a	O
mildly	O
dry	Disease
mouth	Disease
and	O
a	O
sore	Disease
throat	Disease
in	O
2	O
patients	O
(2%	O
glycopyrrolate	Chemical
),	O
a	O
light	O
headache	Disease
in	O
1	O
patient	O
(1.5%	O
glycopyrrolate	Chemical
).	O
The	O
topical	O
application	O
of	O
a	O
glycopyrrolate	Chemical
pad	O
appeared	O
to	O
be	O
safe,	O
efficacious,	O
well	O
tolerated,	O
and	O
a	O
convenient	O
method	O
of	O
treatment	O
for	O
moderate	O
to	O
severe	O
symptoms	O
of	O
gustatory	Disease
hyperhidrosis	Disease

Pharmacological	O
characteristics	O
and	O
side	O
effects	O
of	O
a	O
new	O
galenic	O
formulation	O
of	O
propofol	Chemical
without	O
soyabean	O
oil.	O
We	O
compared	O
the	O
pharmacokinetics,	O
pharmacodynamics	O
and	O
safety	O
profile	O
of	O
a	O
new	O
galenic	O
formulation	O
of	O
propofol	Chemical
(AM149	O
1%),	O
which	O
does	O
not	O
contain	O
soyabean	O
oil,	O
with	O
a	O
standard	O
formulation	O
of	O
propofol	Chemical
(	O
Disoprivan	Chemical
1%).	O
In	O
a	O
randomised,	O
double-blind,	O
cross-over	O
study,	O
30	O
healthy	O
volunteers	O
received	O
a	O
single	O
intravenous	O
bolus	O
injection	O
of	O
2.5	O
mg.kg-1	O
propofol	Chemical
.	O
Plasma	O
propofol	Chemical
levels	O
were	O
measured	O
for	O
48	O
h	O
following	O
drug	O
administration	O
and	O
evaluated	O
according	O
to	O
a	O
three-compartment	O
model.	O
The	O
pharmacodynamic	O
parameters	O
assessed	O
included	O
induction	O
and	O
emergence	O
times,	O
respiratory	O
and	O
cardiovascular	O
effects,	O
and	O
pain	Disease
on	O
injection.	O
Patients	O
were	O
monitored	O
for	O
side	O
effects	O
over	O
48	O
h.	O
Owing	O
to	O
a	O
high	O
incidence	O
of	O
thrombophlebitis	Disease
,	O
the	O
study	O
was	O
terminated	O
prematurely	O
and	O
only	O
the	O
data	O
of	O
the	O
two	O
parallel	O
treatment	O
groups	O
(15	O
patients	O
in	O
each	O
group)	O
were	O
analysed.	O
Plasma	O
concentrations	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
formulations.	O
Anaesthesia	O
induction	O
and	O
emergence	O
times,	O
respiratory	O
and	O
cardiovascular	O
variables	O
showed	O
no	O
significant	O
differences	O
between	O
the	O
two	O
treatment	O
groups.	O
Pain	Disease
on	O
injection	O
(80	O
vs.	O
20%,	O
p	O
<	O
0.01)	O
and	O
thrombophlebitis	Disease
(93.3	O
vs.	O
6.6%,	O
p	O
<	O
0.001)	O
occurred	O
more	O
frequently	O
with	O
AM149	O
than	O
with	O
Disoprivan	Chemical
.	O
Although	O
both	O
formulations	O
had	O
similar	O
pharmacokinetic	O
and	O
pharmacodynamic	O
profiles	O
the	O
new	O
formulation	O
is	O
not	O
suitable	O
for	O
clinical	O
use	O
due	O
to	O
the	O
high	O
incidence	O
of	O
thrombophlebitis	Disease

Vinorelbine	Chemical
-related	O
cardiac	O
events:	O
a	O
meta-analysis	O
of	O
randomized	O
clinical	O
trials.	O
Several	O
cases	O
of	O
cardiac	O
adverse	O
reactions	O
related	O
to	O
vinorelbine	Chemical
(	O
VNR	Chemical
)	O
have	O
been	O
reported	O
in	O
the	O
literature.	O
In	O
order	O
to	O
quantify	O
the	O
incidence	O
of	O
these	O
cardiac	O
events,	O
we	O
performed	O
a	O
meta-analysis	O
of	O
clinical	O
trials	O
comparing	O
VNR	Chemical
with	O
other	O
chemotherapeutic	O
agents	O
in	O
the	O
treatment	O
of	O
various	O
malignancies	Disease
.	O
Randomized	O
clinical	O
trials	O
comparing	O
VNR	Chemical
with	O
other	O
drugs	O
in	O
the	O
treatment	O
of	O
cancer	Disease
were	O
searched	O
in	O
Medline,	O
Embase,	O
Evidence-based	O
Medicine	O
Reviews	O
databases	O
and	O
the	O
Cochrane	O
library	O
from	O
1987	O
to	O
2002.	O
Outcomes	O
of	O
interest	O
were	O
severe	O
cardiac	O
events,	O
toxic	O
deaths	O
and	O
cardiac	O
event-related	O
deaths	O
reported	O
in	O
each	O
publication.	O
We	O
found	O
19	O
trials,	O
involving	O
2441	O
patients	O
treated	O
by	O
VNR	Chemical
and	O
2050	O
control	O
patients.	O
The	O
incidence	O
of	O
cardiac	O
events	O
with	O
VNR	Chemical
was	O
1.19%	O
[95%	O
confidence	O
interval	O
(CI)	O
(0.75;	O
1.67)].	O
There	O
was	O
no	O
difference	O
in	O
the	O
risk	O
of	O
cardiac	O
events	O
between	O
VNR	Chemical
and	O
other	O
drugs	O
[odds	O
ratio:	O
0.92,	O
95%	O
CI	O
(0.54;	O
1.55)].	O
The	O
risk	O
of	O
VNR	Chemical
cardiac	O
events	O
was	O
similar	O
to	O
vindesine	Chemical
(	O
VDS	Chemical
)	O
and	O
other	O
cardiotoxic	Disease
drugs	O
[	O
fluorouracil	Chemical
,	O
anthracyclines	Chemical
,	O
gemcitabine	Chemical
(	O
GEM	Chemical
)	O
em	O
leader	O
].	O
Even	O
if	O
it	O
did	O
not	O
reach	O
statistical	O
significance	O
because	O
of	O
a	O
few	O
number	O
of	O
cases,	O
the	O
risk	O
was	O
lower	O
in	O
trials	O
excluding	O
patients	O
with	O
cardiac	O
history,	O
and	O
seemed	O
to	O
be	O
higher	O
in	O
trials	O
including	O
patients	O
with	O
pre-existing	O
cardiac	Disease
diseases	Disease
.	O
Vinorelbine	Chemical
-related	O
cardiac	O
events	O
concern	O
about	O
1%	O
of	O
treated	O
patients	O
in	O
clinical	O
trials.	O
However,	O
the	O
risk	O
associated	O
with	O
VNR	Chemical

MRI	O
findings	O
of	O
hypoxic	O
cortical	O
laminar	O
necrosis	Disease
in	O
a	O
child	O
with	O
hemolytic	Disease
anemia	Disease
crisis.	O
We	O
present	O
magnetic	O
resonance	O
imaging	O
findings	O
of	O
a	O
5-year-old	O
girl	O
who	O
had	O
a	O
rapidly	O
installing	O
hemolytic	Disease
anemia	Disease
crisis	O
induced	O
by	O
trimethoprim-sulfomethoxazole	Chemical
,	O
resulting	O
in	O
cerebral	Disease
anoxia	Disease
leading	O
to	O
permanent	O
damage.	O
Magnetic	O
Resonance	O
imaging	O
revealed	O
cortical	O
laminar	O
necrosis	Disease
in	O
arterial	O
border	O
zones	O
in	O
both	O
cerebral	O
hemispheres,	O
ischemic	O
changes	O
in	O
subcortical	O
white	O
matter	O
of	O
left	O
cerebral	O
hemisphere,	O
and	O
in	O
the	O
left	O
putamen.	O
Although	O
cortical	O
laminar	O
necrosis	Disease

The	O
natural	O
history	O
of	O
Vigabatrin	Chemical
associated	O
visual	Disease
field	Disease
defects	Disease
in	O
patients	O
electing	O
to	O
continue	O
their	O
medication.	O
PURPOSE:	O
To	O
determine	O
the	O
natural	O
history	O
of	O
visual	Disease
field	Disease
defects	Disease
in	O
a	O
group	O
of	O
patients	O
known	O
to	O
have	O
Vigabatrin	Chemical
-associated	O
changes	O
who	O
elected	O
to	O
continue	O
the	O
medication	O
because	O
of	O
good	O
seizure	Disease
control.	O
METHODS:	O
All	O
patients	O
taking	O
Vigabatrin	Chemical
alone	O
or	O
in	O
combination	O
with	O
other	O
antiepileptic	O
drugs	O
for	O
at	O
least	O
5	O
years	O
(range	O
5-12	O
years)	O
were	O
entered	O
into	O
a	O
visual	O
surveillance	O
programme.	O
Patients	O
were	O
followed	O
up	O
at	O
6-monthly	O
intervals	O
for	O
not	O
less	O
than	O
18	O
months	O
(range	O
18-43	O
months).	O
In	O
all,	O
16	O
patients	O
with	O
unequivocal	O
defects	O
continued	O
the	O
medication.	O
Following	O
already	O
published	O
methodology	O
(Eye	O
2002;	O
16;567-571)	O
monocular	O
mean	O
radial	O
degrees	O
(MRDs)	O
to	O
the	O
I/4e	O
isopter	O
on	O
Goldmann	O
perimetry	O
was	O
calculated	O
for	O
the	O
right	O
eye	O
at	O
the	O
time	O
of	O
discovery	O
of	O
a	O
visual	Disease
field	Disease
defect	Disease
and	O
again	O
after	O
not	O
less	O
than	O
18	O
months	O
follow-up.	O
RESULTS:	O
Mean	O
right	O
eye	O
MRD	O
at	O
presentation	O
was	O
36.98	O
degrees	O
(range	O
22.25-51.0),	O
compared	O
to	O
38.40	O
degrees	O
(range	O
22.5-49.75)	O
after	O
follow-up;	O
P=0.338	O
unpaired	O
t-test.	O
Only	O
one	O
patient	O
demonstrated	O
a	O
deterioration	Disease
in	Disease
visual	Disease
field	Disease
during	O
the	O
study	O
period	O
and	O
discontinued	O
treatment.	O
CONCLUSION:	O
Established	O
visual	Disease
field	Disease
defects	Disease
presumed	O
to	O
be	O
due	O
to	O
Vigabatrin	Chemical
therapy	O
did	O
not	O
usually	O
progress	O
in	O
spite	O
of	O
continuing	O
use	O
of	O
the	O
medication.	O
These	O
data	O
give	O
support	O
to	O
the	O
hypothesis	O
that	O
the	O
pathogenesis	O
of	O
Vigabatrin	Chemical
-associated	O
visual	Disease
field	Disease
defects	Disease
may	O
be	O
an	O
idiosyncratic	O
adverse	O
drug	O
reaction	O
rather	O
than	O
dose-dependent	O
toxicity	Disease

Induction	O
of	O
rosaceiform	O
dermatitis	Disease
during	O
treatment	O
of	O
facial	Disease
inflammatory	Disease
dermatoses	Disease
with	O
tacrolimus	Chemical
ointment.	O
BACKGROUND:	O
Tacrolimus	Chemical
ointment	O
is	O
increasingly	O
used	O
for	O
anti-inflammatory	O
treatment	O
of	O
sensitive	O
areas	O
such	O
as	O
the	O
face,	O
and	O
recent	O
observations	O
indicate	O
that	O
the	O
treatment	O
is	O
effective	O
in	O
steroid	Chemical
-aggravated	O
rosacea	Disease
and	O
perioral	Disease
dermatitis	Disease
.	O
We	O
report	O
on	O
rosaceiform	O
dermatitis	Disease
as	O
a	O
complication	O
of	O
treatment	O
with	O
tacrolimus	Chemical
ointment.	O
OBSERVATIONS:	O
Six	O
adult	O
patients	O
with	O
inflammatory	Disease
facial	Disease
dermatoses	Disease
were	O
treated	O
with	O
tacrolimus	Chemical
ointment	O
because	O
of	O
the	O
ineffectiveness	O
of	O
standard	O
treatments.	O
Within	O
2	O
to	O
3	O
weeks	O
of	O
initially	O
effective	O
and	O
well-tolerated	O
treatment,	O
3	O
patients	O
with	O
a	O
history	O
of	O
rosacea	Disease
and	O
1	O
with	O
a	O
history	O
of	O
acne	Disease
experienced	O
sudden	O
worsening	O
with	O
pustular	O
rosaceiform	O
lesions.	O
Biopsy	O
revealed	O
an	O
abundance	O
of	O
Demodex	O
mites	O
in	O
2	O
of	O
these	O
patients.	O
In	O
1	O
patient	O
with	O
eyelid	O
eczema	Disease
,	O
rosaceiform	O
periocular	Disease
dermatitis	Disease
gradually	O
appeared	O
after	O
3	O
weeks	O
of	O
treatment.	O
In	O
1	O
patient	O
with	O
atopic	Disease
dermatitis	Disease
,	O
telangiectatic	O
and	O
papular	Disease
rosacea	Disease
insidiously	O
appeared	O
after	O
5	O
months	O
of	O
treatment.	O
CONCLUSIONS:	O
Our	O
observations	O
suggest	O
that	O
the	O
spectrum	O
of	O
rosaceiform	O
dermatitis	Disease
as	O
a	O
complication	O
of	O
treatment	O
with	O
tacrolimus	Chemical
ointment	O
is	O
heterogeneous.	O
A	O
variety	O
of	O
factors,	O
such	O
as	O
vasoactive	O
properties	O
of	O
tacrolimus	Chemical

Structural	O
abnormalities	O
in	O
the	O
brains	O
of	O
human	O
subjects	O
who	O
use	O
methamphetamine	Chemical
.	O
We	O
visualize,	O
for	O
the	O
first	O
time,	O
the	O
profile	O
of	O
structural	Disease
deficits	Disease
in	Disease
the	Disease
human	Disease
brain	Disease
associated	O
with	O
chronic	O
methamphetamine	Chemical
(	O
MA	Chemical
)	O
abuse.	O
Studies	O
of	O
human	O
subjects	O
who	O
have	O
used	O
MA	Chemical
chronically	O
have	O
revealed	O
deficits	O
in	O
dopaminergic	O
and	O
serotonergic	O
systems	O
and	O
cerebral	O
metabolic	Disease
abnormalities	Disease
.	O
Using	O
magnetic	O
resonance	O
imaging	O
(MRI)	O
and	O
new	O
computational	O
brain-mapping	O
techniques,	O
we	O
determined	O
the	O
pattern	O
of	O
structural	O
brain	O
alterations	O
associated	O
with	O
chronic	O
MA	Chemical
abuse	O
in	O
human	O
subjects	O
and	O
related	O
these	O
deficits	O
to	O
cognitive	Disease
impairment	Disease
.	O
We	O
used	O
high-resolution	O
MRI	O
and	O
surface-based	O
computational	O
image	O
analyses	O
to	O
map	O
regional	O
abnormalities	Disease
in	Disease
the	Disease
cortex,	Disease
hippocampus,	Disease
white	Disease
matter,	Disease
and	Disease
ventricles	Disease
in	O
22	O
human	O
subjects	O
who	O
used	O
MA	Chemical
and	O
21	O
age-matched,	O
healthy	O
controls.	O
Cortical	O
maps	O
revealed	O
severe	O
gray-matter	O
deficits	O
in	O
the	O
cingulate,	O
limbic,	O
and	O
paralimbic	O
cortices	O
of	O
MA	Chemical
abusers	O
(averaging	O
11.3%	O
below	O
control;	O
p	O
<	O
0.05).	O
On	O
average,	O
MA	Chemical
abusers	O
had	O
7.8%	O
smaller	O
hippocampal	O
volumes	O
than	O
control	O
subjects	O
(p	O
<	O
0.01;	O
left,	O
p	O
=	O
0.01;	O
right,	O
p	O
<	O
0.05)	O
and	O
significant	O
white-matter	O
hypertrophy	Disease
(7.0%;	O
p	O
<	O
0.01).	O
Hippocampal	O
deficits	O
were	O
mapped	O
and	O
correlated	O
with	O
memory	O
performance	O
on	O
a	O
word-recall	O
test	O
(p	O
<	O
0.05).	O
MRI-based	O
maps	O
suggest	O
that	O
chronic	O
methamphetamine	Chemical
abuse	O
causes	O
a	O
selective	O
pattern	O
of	O
cerebral	O
deterioration	O
that	O
contributes	O
to	O
impaired	Disease
memory	Disease
performance	Disease
.	O
MA	Chemical
may	O
selectively	O
damage	O
the	O
medial	O
temporal	O
lobe	O
and,	O
consistent	O
with	O
metabolic	O
studies,	O
the	O
cingulate-limbic	O
cortex,	O
inducing	O
neuroadaptation,	O
neuropil	O
reduction,	O
or	O
cell	O
death.	O
Prominent	O
white-matter	O
hypertrophy	Disease
may	O
result	O
from	O
altered	O
myelination	O
and	O
adaptive	O
glial	O
changes,	O
including	O
gliosis	Disease
secondary	O
to	O
neuronal	Disease
damage	Disease
.	O
These	O
brain	O
substrates	O
may	O
help	O
account	O
for	O
the	O
symptoms	O
of	O
MA	Chemical
abuse,	O
providing	O
therapeutic	O
targets	O
for	O
drug-induced	O
brain	Disease
injury	Disease

Disruption	O
of	O
hepatic	O
lipid	O
homeostasis	O
in	O
mice	O
after	O
amiodarone	Chemical
treatment	O
is	O
associated	O
with	O
peroxisome	O
proliferator-activated	O
receptor-alpha	O
target	O
gene	O
activation.	O
Amiodarone	Chemical
,	O
an	O
efficacious	O
and	O
widely	O
used	O
antiarrhythmic	O
agent,	O
has	O
been	O
reported	O
to	O
cause	O
hepatotoxicity	Disease
in	O
some	O
patients.	O
To	O
gain	O
insight	O
into	O
the	O
mechanism	O
of	O
this	O
unwanted	O
effect,	O
mice	O
were	O
administered	O
various	O
doses	O
of	O
amiodarone	Chemical
and	O
examined	O
for	O
changes	O
in	O
hepatic	O
histology	O
and	O
gene	O
regulation.	O
Amiodarone	Chemical
induced	O
hepatomegaly	Disease
,	O
hepatocyte	O
microvesicular	O
lipid	O
accumulation,	O
and	O
a	O
significant	O
decrease	O
in	O
serum	O
triglycerides	Chemical
and	O
glucose	Chemical
.	O
Northern	O
blot	O
analysis	O
of	O
hepatic	O
RNA	O
revealed	O
a	O
dose-dependent	O
increase	O
in	O
the	O
expression	O
of	O
a	O
number	O
of	O
genes	O
critical	O
for	O
fatty	Chemical
acid	Chemical
oxidation,	O
lipoprotein	O
assembly,	O
and	O
lipid	O
transport.	O
Many	O
of	O
these	O
genes	O
are	O
regulated	O
by	O
the	O
peroxisome	O
proliferator-activated	O
receptor-alpha	O
(PPARalpha),	O
a	O
ligand-activated	O
nuclear	O
hormone	O
receptor	O
transcription	O
factor.	O
The	O
absence	O
of	O
induction	O
of	O
these	O
genes	O
as	O
well	O
as	O
hepatomegaly	Disease
in	O
PPARalpha	O
knockout	O
[PPARalpha-/-]	O
mice	O
indicated	O
that	O
the	O
effects	O
of	O
amiodarone	Chemical
were	O
dependent	O
upon	O
the	O
presence	O
of	O
a	O
functional	O
PPARalpha	O
gene.	O
Compared	O
to	O
wild-type	O
mice,	O
treatment	O
of	O
PPARalpha-/-	O
mice	O
with	O
amiodarone	Chemical
resulted	O
in	O
an	O
increased	O
rate	O
and	O
extent	O
of	O
total	O
body	O
weight	Disease
loss	Disease
.	O
The	O
inability	O
of	O
amiodarone	Chemical
to	O
directly	O
activate	O
either	O
human	O
or	O
mouse	O
PPARalpha	O
transiently	O
expressed	O
in	O
human	O
HepG2	O
hepatoma	Disease
cells	O
indicates	O
that	O
the	O
effects	O
of	O
amiodarone	Chemical
on	O
the	O
function	O
of	O
this	O
receptor	O
were	O
indirect.	O
Based	O
upon	O
these	O
results,	O
we	O
conclude	O
that	O
amiodarone	Chemical
disrupts	O
hepatic	O
lipid	O
homeostasis	O
and	O
that	O
the	O
increased	O
expression	O
of	O
PPARalpha	O
target	O
genes	O
is	O
secondary	O
to	O
this	O
toxic	O
effect.	O
These	O
results	O
provide	O
important	O
new	O
mechanistic	O
information	O
regarding	O
the	O
hepatotoxic	Disease
effects	O
of	O
amiodarone	Chemical
and	O
indicate	O
that	O
PPARalpha	O
protects	O
against	O
amiodarone	Chemical
-induced	O
hepatotoxicity	Disease

Safety	O
and	O
compliance	O
with	O
once-daily	O
niacin	Chemical
extended-release/lovastatin	Chemical
as	O
initial	O
therapy	O
in	O
the	O
Impact	O
of	O
Medical	O
Subspecialty	O
on	O
Patient	O
Compliance	O
to	O
Treatment	O
(IMPACT)	O
study.	O
Niacin	Chemical
extended-release/lovastatin	Chemical
is	O
a	O
new	O
combination	O
product	O
approved	O
for	O
treatment	O
of	O
primary	O
hypercholesterolemia	Disease
and	O
mixed	O
dyslipidemia	Disease
.	O
This	O
open-labeled,	O
multicenter	O
study	O
evaluated	O
the	O
safety	O
of	O
bedtime	O
niacin	Chemical
extended-release/lovastatin	Chemical
when	O
dosed	O
as	O
initial	O
therapy	O
and	O
patient	O
compliance	O
to	O
treatment	O
in	O
various	O
clinical	O
practice	O
settings.	O
A	O
total	O
of	O
4,499	O
patients	O
with	O
dyslipidemia	Disease
requiring	O
drug	O
intervention	O
was	O
enrolled	O
at	O
1,081	O
sites.	O
Patients	O
were	O
treated	O
with	O
1	O
tablet	O
(500	O
mg	O
of	O
niacin	Chemical
extended-release/20	O
mg	O
of	O
lovastatin	Chemical
)	O
once	O
nightly	O
for	O
4	O
weeks	O
and	O
then	O
2	O
tablets	O
for	O
8	O
weeks.	O
Patients	O
also	O
received	O
dietary	O
counseling,	O
educational	O
materials,	O
and	O
reminders	O
to	O
call	O
a	O
toll-free	O
number	O
that	O
provided	O
further	O
education	O
about	O
dyslipidemia	Disease
and	O
niacin	Chemical
extended-release/lovastatin	Chemical
.	O
Primary	O
end	O
points	O
were	O
study	O
compliance,	O
increases	O
in	O
liver	O
transaminases	O
to	O
>3	O
times	O
the	O
upper	O
limit	O
of	O
normal,	O
and	O
clinical	O
myopathy	Disease
.	O
Final	O
study	O
status	O
was	O
available	O
for	O
4,217	O
patients	O
(94%).	O
Compliance	O
to	O
niacin	Chemical
extended-release/lovastatin	Chemical
was	O
77%,	O
with	O
3,245	O
patients	O
completing	O
the	O
study.	O
Patients	O
in	O
the	O
southeast	O
and	O
those	O
enrolled	O
by	O
endocrinologists	O
had	O
the	O
lowest	O
compliance	O
and	O
highest	O
adverse	O
event	O
rates.	O
Flushing	Disease
was	O
the	O
most	O
common	O
adverse	O
event,	O
reported	O
by	O
18%	O
of	O
patients	O
and	O
leading	O
to	O
discontinuation	O
by	O
6%.	O
Incidence	O
of	O
increased	O
aspartate	Chemical
aminotransferase	O
and/or	O
alanine	Chemical
aminotransferase	O
>3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
was	O
<0.3%.	O
An	O
increase	O
of	O
creatine	Chemical
phosphokinase	O
to	O
>5	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
occurred	O
in	O
0.24%	O
of	O
patients,	O
and	O
no	O
cases	O
of	O
drug-induced	O
myopathy	Disease
were	O
observed.	O
Niacin	Chemical
extended-release/lovastatin	Chemical

Protective	O
effect	O
of	O
Terminalia	Chemical
chebula	Chemical
against	O
experimental	O
myocardial	Disease
injury	Disease
induced	O
by	O
isoproterenol	Chemical
.	O
Cardioprotective	O
effect	O
of	O
ethanolic	Chemical
extract	Chemical
of	Chemical
Terminalia	Chemical
chebula	Chemical
fruits	Chemical
(500	O
mg/kg	O
body	O
wt)	O
was	O
examined	O
in	O
isoproterenol	Chemical
(200	O
mg/kg	O
body	O
wt)	O
induced	O
myocardial	Disease
damage	Disease
in	O
rats.	O
In	O
isoproterenol	Chemical
administered	O
rats,	O
the	O
level	O
of	O
lipid	O
peroxides	Chemical
increased	O
significantly	O
in	O
the	O
serum	O
and	O
heart.	O
A	O
significant	O
decrease	O
was	O
observed	O
in	O
the	O
activity	O
of	O
the	O
myocardial	O
marker	O
enzymes	O
with	O
a	O
concomitant	O
increase	O
in	O
their	O
activity	O
in	O
serum.	O
Histopathological	O
examination	O
was	O
carried	O
out	O
to	O
confirm	O
the	O
myocardial	O
necrosis	Disease
.	O
T.	Chemical
chebula	Chemical
extract	Chemical
pretreatment	O
was	O
found	O
to	O
ameliorate	O
the	O
effect	O
of	O
isoproterenol	Chemical
on	O
lipid	O
peroxide	Chemical

A	O
case	O
of	O
postoperative	O
anxiety	Disease
due	O
to	O
low	O
dose	O
droperidol	Chemical
used	O
with	O
patient-controlled	O
analgesia.	O
A	O
multiparous	O
woman	O
in	O
good	O
psychological	O
health	O
underwent	O
urgent	O
caesarean	O
section	O
in	O
labour.	O
Postoperatively,	O
she	O
was	O
given	O
a	O
patient-controlled	O
analgesia	O
device	O
delivering	O
boluses	O
of	O
diamorphine	Chemical
0.5	O
mg	O
and	O
droperidol	Chemical
0.025	O
mg.	O
Whilst	O
using	O
the	O
device	O
she	O
gradually	O
became	O
anxious,	O
the	O
feeling	O
worsening	O
after	O
each	O
bolus.	O
The	O
diagnosis	O
of	O
droperidol	Chemical
-induced	O
psychological	Disease
disturbance	Disease
was	O
not	O
made	O
straight	O
away	O
although	O
on	O
subsequent	O
close	O
questioning	O
the	O
patient	O
gave	O
a	O
very	O
clear	O
history.	O
After	O
she	O
had	O
received	O
a	O
total	O
of	O
only	O
0.9	O
mg	O
droperidol	Chemical
,	O
a	O
syringe	O
containing	O
diamorphine	Chemical

Accurate	O
patient	O
history	O
contributes	O
to	O
differentiating	O
diabetes	Disease
insipidus	Disease
:	O
a	O
case	O
study.	O
This	O
case	O
study	O
highlights	O
the	O
important	O
contribution	O
of	O
nursing	O
in	O
obtaining	O
an	O
accurate	O
health	O
history.	O
The	O
case	O
discussed	O
herein	O
initially	O
appeared	O
to	O
be	O
neurogenic	Disease
diabetes	Disease
insipidus	Disease
(	O
DI	Disease
)	O
secondary	O
to	O
a	O
traumatic	Disease
brain	Disease
injury	Disease
.	O
The	O
nursing	O
staff,	O
by	O
reviewing	O
the	O
patient's	O
health	O
history	O
with	O
his	O
family,	O
discovered	O
a	O
history	O
of	O
polydipsia	Disease
and	O
long-standing	O
lithium	Chemical
use.	O
Lithium	Chemical
is	O
implicated	O
in	O
drug-induced	O
nephrogenic	Disease
DI	Disease
,	O
and	O
because	O
the	O
patient	O
had	O
not	O
received	O
lithium	Chemical
since	O
being	O
admitted	O
to	O
the	O
hospital,	O
his	O
treatment	O
changed	O
to	O
focus	O
on	O
nephrogenic	Disease
DI	Disease
.	O
By	O
combining	O
information	O
from	O
the	O
patient	O
history,	O
the	O
physical	O
examination,	O
and	O
radiologic	O
and	O
laboratory	O
studies,	O
the	O
critical	O
care	O
team	O
demonstrated	O
that	O
the	O
patient	O
had	O
been	O
self-treating	O
his	O
lithium	Chemical
-induced	O
nephrogenic	Disease
DI	Disease
and	O
developed	O
neurogenic	Disease
DI	Disease
secondary	O
to	O
brain	Disease
trauma	Disease
.	O
Thus	O
successful	O
treatment	O
required	O
that	O
nephrogenic	O
and	O
neurogenic	Disease
DI	Disease

Factors	O
contributing	O
to	O
ribavirin	Chemical
-induced	O
anemia	Disease
.	O
BACKGROUND	O
AND	O
AIM:	O
Interferon	Chemical
and	O
ribavirin	Chemical
combination	O
therapy	O
for	O
chronic	Disease
hepatitis	Disease
C	Disease
produces	O
hemolytic	Disease
anemia	Disease
.	O
This	O
study	O
was	O
conducted	O
to	O
identify	O
the	O
factors	O
contributing	O
to	O
ribavirin	Chemical
-induced	O
anemia	Disease
.	O
METHODS:	O
Eighty-eight	O
patients	O
with	O
chronic	Disease
hepatitis	Disease
C	Disease
who	O
received	O
interferon-alpha-2b	Chemical
at	O
a	O
dose	O
of	O
6	O
MU	O
administered	O
intramuscularly	O
for	O
24	O
weeks	O
in	O
combination	O
with	O
ribavirin	Chemical
administered	O
orally	O
at	O
a	O
dose	O
of	O
600	O
mg	O
or	O
800	O
mg	O
participated	O
in	O
the	O
study.	O
A	O
hemoglobin	O
concentration	O
of	O
<10	O
g/dL	O
was	O
defined	O
as	O
ribavirin	Chemical
-induced	O
anemia	Disease
.	O
RESULTS:	O
Ribavirin	Chemical
-induced	O
anemia	Disease
occurred	O
in	O
18	O
(20.5%)	O
patients	O
during	O
treatment.	O
A	O
2	O
g/dL	O
decrease	O
in	O
hemoglobin	O
concentrations	O
in	O
patients	O
with	O
anemia	Disease
was	O
observed	O
at	O
week	O
2	O
after	O
the	O
start	O
of	O
treatment.	O
The	O
hemoglobin	O
concentration	O
in	O
patients	O
with	O
>	O
or	O
=2	O
g/dL	O
decrease	O
at	O
week	O
2	O
was	O
observed	O
to	O
be	O
significantly	O
lower	O
even	O
after	O
week	O
2	O
than	O
in	O
patients	O
with	O
<2	O
g/dL	O
decrease	O
(P	O
<	O
0.01).	O
A	O
significant	O
relationship	O
was	O
observed	O
between	O
the	O
rate	O
of	O
reduction	O
of	O
hemoglobin	O
concentrations	O
at	O
week	O
2	O
and	O
the	O
severity	O
of	O
anemia	Disease
(P	O
<	O
0.01).	O
Such	O
factors	O
as	O
sex	O
(female),	O
age	O
(>	O
or	O
=60	O
years	O
old),	O
and	O
the	O
ribavirin	Chemical
dose	O
by	O
body	O
weight	O
(12	O
mg/kg	O
or	O
more)	O
were	O
significant	O
by	O
univariate	O
analysis.	O
CONCLUSIONS:	O
Careful	O
administration	O
is	O
necessary	O
in	O
patients	O
>	O
or	O
=60	O
years	O
old,	O
in	O
female	O
patients,	O
and	O
in	O
patients	O
receiving	O
a	O
ribavirin	Chemical

Oxidative	O
damage	O
precedes	O
nitrative	O
damage	O
in	O
adriamycin	Chemical
-induced	O
cardiac	O
mitochondrial	Disease
injury	Disease
.	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
if	O
elevated	O
reactive	O
oxygen	Chemical
(ROS)/	O
nitrogen	Chemical
species	O
(RNS)	O
reported	O
to	O
be	O
present	O
in	O
adriamycin	Chemical
(	O
ADR	Chemical
)-induced	O
cardiotoxicity	Disease
actually	O
resulted	O
in	O
cardiomyocyte	O
oxidative/nitrative	O
damage,	O
and	O
to	O
quantitatively	O
determine	O
the	O
time	O
course	O
and	O
subcellular	O
localization	O
of	O
these	O
postulated	O
damage	O
products	O
using	O
an	O
in	O
vivo	O
approach.	O
B6C3	O
mice	O
were	O
treated	O
with	O
a	O
single	O
dose	O
of	O
20	O
mg/kg	O
ADR	Chemical
.	O
Ultrastructural	O
damage	O
and	O
levels	O
of	O
4-hydroxy-2-nonenal	Chemical
(	O
4HNE	Chemical
)-protein	O
adducts	O
and	O
3-nitrotyrosine	Chemical
(	O
3NT	Chemical
)	O
were	O
analyzed.	O
Quantitative	O
ultrastructural	O
damage	O
using	O
computerized	O
image	O
techniques	O
showed	O
cardiomyocyte	O
injury	O
as	O
early	O
as	O
3	O
hours,	O
with	O
mitochondria	O
being	O
the	O
most	O
extensively	O
and	O
progressively	O
injured	O
subcellular	O
organelle.	O
Analysis	O
of	O
4HNE	Chemical
protein	O
adducts	O
by	O
immunogold	O
electron	O
microscopy	O
showed	O
appearance	O
of	O
4HNE	Chemical
protein	O
adducts	O
in	O
mitochondria	O
as	O
early	O
as	O
3	O
hours,	O
with	O
a	O
peak	O
at	O
6	O
hours	O
and	O
subsequent	O
decline	O
at	O
24	O
hours.	O
3NT	Chemical
levels	O
were	O
significantly	O
increased	O
in	O
all	O
subcellular	O
compartments	O
at	O
6	O
hours	O
and	O
subsequently	O
declined	O
at	O
24	O
hours.	O
Our	O
data	O
showed	O
ADR	Chemical
induced	O
4HNE	Chemical
-protein	O
adducts	O
in	O
mitochondria	O
at	O
the	O
same	O
time	O
point	O
as	O
when	O
mitochondrial	Disease
injury	Disease
initially	O
appeared.	O
These	O
results	O
document	O
for	O
the	O
first	O
time	O
in	O
vivo	O
that	O
mitochondrial	Disease
oxidative	Disease
damage	Disease
precedes	O
nitrative	O
damage.	O
The	O
progressive	O
nature	O
of	O
mitochondrial	Disease
injury	Disease

Sotalol	Chemical
-induced	O
coronary	Disease
spasm	Disease
in	O
a	O
patient	O
with	O
dilated	Disease
cardiomyopathy	Disease
associated	O
with	O
sustained	O
ventricular	Disease
tachycardia	Disease
.	O
A	O
54-year-old	O
man	O
with	O
severe	O
left	O
ventricular	Disease
dysfunction	Disease
due	O
to	O
dilated	Disease
cardiomyopathy	Disease
was	O
referred	O
to	O
our	O
hospital	O
for	O
symptomatic	O
incessant	O
sustained	O
ventricular	Disease
tachycardia	Disease
(	O
VT	Disease
).	O
After	O
the	O
administration	O
of	O
nifekalant	Chemical
hydrochloride	Chemical
,	O
sustained	O
VT	Disease
was	O
terminated.	O
An	O
alternate	O
class	O
III	O
agent,	O
sotalol	Chemical
,	O
was	O
also	O
effective	O
for	O
the	O
prevention	O
of	O
VT	Disease
.	O
However,	O
one	O
month	O
after	O
switching	O
over	O
nifekalant	Chemical
to	O
sotalol	Chemical
,	O
a	O
short	O
duration	O
of	O
ST	O
elevation	O
was	O
documented	O
in	O
ECG	O
monitoring	O
at	O
almost	O
the	O
same	O
time	O
for	O
three	O
consecutive	O
days.	O
ST	O
elevation	O
with	O
chest	O
discomfort	O
disappeared	O
since	O
he	O
began	O
taking	O
long-acting	O
diltiazem	Chemical
.	O
Coronary	Disease
vasospasm	Disease
may	O
be	O
induced	O
by	O
the	O
non-selective	O
beta-blocking	O
properties	O
of	O
sotalol	Chemical

Effects	O
of	O
the	O
antidepressant	O
trazodone	Chemical
,	O
a	O
5-HT	Chemical
2A/2C	O
receptor	O
antagonist,	O
on	O
dopamine	Chemical
-dependent	O
behaviors	O
in	O
rats.	O
RATIONALE:	O
5-Hydroxytryptamine	Chemical
,	O
via	O
stimulation	O
of	O
5-HT	Chemical
2C	O
receptors,	O
exerts	O
a	O
tonic	O
inhibitory	O
influence	O
on	O
dopaminergic	O
neurotransmission,	O
whereas	O
activation	O
of	O
5-HT	Chemical
2A	O
receptors	O
enhances	O
stimulated	O
DAergic	O
neurotransmission.	O
The	O
antidepressant	O
trazodone	Chemical
is	O
a	O
5-HT	Chemical
2A/2C	O
receptor	O
antagonist.	O
OBJECTIVES:	O
To	O
evaluate	O
the	O
effect	O
of	O
trazodone	Chemical
treatment	O
on	O
behaviors	O
dependent	O
on	O
the	O
functional	O
status	O
of	O
the	O
nigrostriatal	O
DAergic	O
system.	O
METHODS:	O
The	O
effect	O
of	O
pretreatment	O
with	O
trazodone	Chemical
on	O
dexamphetamine	Chemical
-	O
and	O
apomorphine	Chemical
-induced	O
oral	Disease
stereotypies	Disease
,	O
on	O
catalepsy	Disease
induced	O
by	O
haloperidol	Chemical
and	O
apomorphine	Chemical
(0.05	O
mg/kg,	O
i.p.),	O
on	O
ergometrine	Chemical
-induced	O
wet	O
dog	O
shake	O
(WDS)	O
behavior	O
and	O
fluoxetine	Chemical
-induced	O
penile	O
erections	O
was	O
studied	O
in	O
rats.	O
We	O
also	O
investigated	O
whether	O
trazodone	Chemical
induces	O
catalepsy	Disease
in	O
rats.	O
RESULTS:	O
Trazodone	Chemical
at	O
2.5-20	O
mg/kg	O
i.p.	O
did	O
not	O
induce	O
catalepsy	Disease
,	O
and	O
did	O
not	O
antagonize	O
apomorphine	Chemical
(1.5	O
and	O
3	O
mg/kg)	O
stereotypy	O
and	O
apomorphine	Chemical
(0.05	O
mg/kg)-induced	O
catalepsy	Disease
.	O
However,	O
pretreatment	O
with	O
5,	O
10	O
and	O
20	O
mg/kg	O
i.p.	O
trazodone	Chemical
enhanced	O
dexamphetamine	Chemical
stereotypy,	O
and	O
antagonized	O
haloperidol	Chemical
	O
catalepsy	Disease
,	O
ergometrine	Chemical
-induced	O
WDS	O
behavior	O
and	O
fluoxetine	Chemical
-induced	O
penile	O
erections.	O
Trazodone	Chemical
at	O
30,	O
40	O
and	O
50	O
mg/kg	O
i.p.	O
induced	O
catalepsy	Disease
and	O
antagonized	O
apomorphine	Chemical
and	O
dexamphetamine	Chemical
stereotypies.	O
CONCLUSIONS:	O
Our	O
results	O
indicate	O
that	O
trazodone	Chemical
at	O
2.5-20	O
mg/kg	O
does	O
not	O
block	O
pre-	O
and	O
postsynaptic	O
striatal	O
D2	O
DA	O
receptors,	O
while	O
at	O
30,	O
40	O
and	O
50	O
mg/kg	O
it	O
blocks	O
postsynaptic	O
striatal	O
D2	O
DA	O
receptors.	O
Furthermore,	O
at	O
5,	O
10	O
and	O
20	O
mg/kg,	O
trazodone	Chemical
blocks	O
5-HT	Chemical
2A	O
and	O
5-HT	Chemical
2C	O
receptors.	O
We	O
suggest	O
that	O
trazodone	Chemical
(5,	O
10	O
and	O
20	O
mg/kg),	O
by	O
blocking	O
the	O
5-HT	Chemical
2C	O
receptors,	O
releases	O
the	O
nigrostriatal	O
DAergic	O
neurons	O
from	O
tonic	O
inhibition	O
caused	O
by	O
5-HT	Chemical
,	O
and	O
thereby	O
potentiates	O
dexamphetamine	Chemical
stereotypy	O
and	O
antagonizes	O
haloperidol	Chemical
	O
catalepsy	Disease

Swallowing	Disease
abnormalities	Disease
and	O
dyskinesia	Disease
in	O
Parkinson's	Disease
disease	Disease
.	O
Gastrointestinal	Disease
abnormalities	Disease
in	O
Parkinson's	Disease
disease	Disease
(	O
PD	Disease
)	O
have	O
been	O
known	O
for	O
almost	O
two	O
centuries,	O
but	O
many	O
aspects	O
concerning	O
their	O
pathophysiology	O
have	O
not	O
been	O
completely	O
clarified.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
characterize	O
the	O
oropharyngeal	O
dynamics	O
in	O
PD	Disease
patients	O
with	O
and	O
without	O
levodopa	Chemical
-induced	O
dyskinesia	Disease
.	O
Fifteen	O
dyskinetic	Disease
,	O
12	O
nondyskinetic	O
patients,	O
and	O
a	O
control	O
group	O
were	O
included.	O
Patients	O
were	O
asked	O
about	O
dysphagia	Disease
and	O
evaluated	O
with	O
the	O
Unified	O
Parkinson's	Disease
Disease	Disease
Rating	O
Scale	O
Parts	O
II	O
and	O
III	O
and	O
the	O
Hoehn	O
and	O
Yahr	O
scale.	O
Deglutition	O
was	O
assessed	O
using	O
modified	O
barium	Chemical
swallow	O
with	O
videofluoroscopy.	O
Nondyskinetic	O
patients,	O
but	O
not	O
the	O
dyskinetic	Disease
ones,	O
showed	O
less	O
oropharyngeal	O
swallowing	O
efficiency	O
(OPSE)	O
for	O
liquid	O
food	O
than	O
controls	O
(Dunnett,	O
P	O
=	O
0.02).	O
Dyskinetic	Disease
patients	O
tended	O
to	O
have	O
a	O
greater	O
OPSE	O
than	O
nondyskinetic	O
(Dunnett,	O
P	O
=	O
0.06).	O
Patients	O
who	O
were	O
using	O
a	O
higher	O
dose	O
of	O
levodopa	Chemical
had	O
a	O
greater	O
OPSE	O
and	O
a	O
trend	O
toward	O
a	O
smaller	O
oral	O
transit	O
time	O
(Pearson's	O
correlation,	O
P	O
=	O
0.01	O
and	O
0.08,	O
respectively).	O
Neither	O
the	O
report	O
of	O
dysphagia	Disease
nor	O
any	O
of	O
the	O
PD	Disease
severity	O
parameters	O
correlated	O
to	O
the	O
videofluoroscopic	O
variables.	O
In	O
the	O
current	O
study,	O
dyskinetic	Disease
patients	O
performed	O
better	O
in	O
swallowing	O
function,	O
which	O
could	O
be	O
explained	O
on	O
the	O
basis	O
of	O
a	O
greater	O
levodopa	Chemical
dose.	O
Our	O
results	O
suggest	O
a	O
role	O
for	O
levodopa	Chemical
in	O
the	O
oral	O
phase	O
of	O
deglutition	O
and	O
confirm	O
that	O
dysphagia	Disease
is	O
not	O
a	O
good	O
predictor	O
of	O
deglutition	O
alterations	O
in	O
PD	Disease

Inhibition	O
of	O
nuclear	O
factor-kappaB	O
activation	O
attenuates	O
tubulointerstitial	Disease
nephritis	Disease
induced	O
by	O
gentamicin	Chemical
.	O
BACKGROUND:	O
Animals	O
treated	O
with	O
gentamicin	Chemical
can	O
show	O
residual	O
areas	O
of	O
interstitial	O
fibrosis	Disease
in	O
the	O
renal	O
cortex.	O
This	O
study	O
investigated	O
the	O
expression	O
of	O
nuclear	O
factor-kappaB	O
(NF-kappaB),	O
mitogen-activated	O
protein	O
(MAP)	O
kinases	O
and	O
macrophages	O
in	O
the	O
renal	O
cortex	O
and	O
structural	O
and	O
functional	O
renal	O
changes	O
of	O
rats	O
treated	O
with	O
gentamicin	Chemical
or	O
gentamicin	Chemical
+	O
pyrrolidine	Chemical
dithiocarbamate	Chemical
(	O
PDTC	Chemical
),	O
an	O
NF-kappaB	O
inhibitor.	O
METHODS:	O
38	O
female	O
Wistar	O
rats	O
were	O
injected	O
with	O
gentamicin	Chemical
,	O
40	O
mg/kg,	O
twice	O
a	O
day	O
for	O
9	O
days,	O
38	O
with	O
gentamicin	Chemical
+	O
PDTC	Chemical
,	O
and	O
28	O
with	O
0.15	O
M	O
NaCl	Chemical
solution.	O
The	O
animals	O
were	O
killed	O
5	O
and	O
30	O
days	O
after	O
these	O
injections	O
and	O
the	O
kidneys	O
were	O
removed	O
for	O
histological	O
and	O
immunohistochemical	O
studies.	O
The	O
results	O
of	O
the	O
immunohistochemical	O
studies	O
were	O
scored	O
according	O
to	O
the	O
extent	O
of	O
staining.	O
The	O
fractional	O
interstitial	O
area	O
was	O
determined	O
by	O
morphometry.	O
RESULTS:	O
Gentamicin	Chemical
-treated	O
rats	O
presented	O
a	O
transitory	O
increase	O
in	O
plasma	O
creatinine	Chemical
levels.	O
Increased	O
ED-1,	O
MAP	O
kinases	O
and	O
NF-kappaB	O
staining	O
were	O
also	O
observed	O
in	O
the	O
renal	O
cortex	O
from	O
all	O
gentamicin	Chemical
-treated	O
rats	O
compared	O
to	O
control	O
(p	O
<	O
0.05).	O
The	O
animals	O
killed	O
on	O
day	O
30	O
also	O
presented	O
fibrosis	Disease
in	O
the	O
renal	O
cortex	O
despite	O
the	O
recovery	O
of	O
renal	O
function.	O
Treatment	O
with	O
PDTC	Chemical
reduced	O
the	O
functional	O
and	O
structural	O
changes	O
induced	O
by	O
gentamicin	Chemical
.	O
CONCLUSIONS:	O
These	O
data	O
show	O
that	O
inhibition	O
of	O
NF-kappaB	O
activation	O
attenuates	O
tubulointerstitial	Disease
nephritis	Disease
induced	O
by	O
gentamicin	Chemical

Glucose	Chemical
metabolism	O
in	O
patients	O
with	O
schizophrenia	Disease
treated	O
with	O
atypical	O
antipsychotic	O
agents:	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	Chemical
tolerance	O
test	O
and	O
minimal	O
model	O
analysis.	O
BACKGROUND:	O
While	O
the	O
incidence	O
of	O
new-onset	O
diabetes	Disease
mellitus	Disease
may	O
be	O
increasing	O
in	O
patients	O
with	O
schizophrenia	Disease
treated	O
with	O
certain	O
atypical	O
antipsychotic	O
agents,	O
it	O
remains	O
unclear	O
whether	O
atypical	O
agents	O
are	O
directly	O
affecting	O
glucose	Chemical
metabolism	O
or	O
simply	O
increasing	O
known	O
risk	O
factors	O
for	O
diabetes	Disease
.	O
OBJECTIVE:	O
To	O
study	O
the	O
2	O
drugs	O
most	O
clearly	O
implicated	O
(	O
clozapine	Chemical
and	O
olanzapine	Chemical
)	O
and	O
risperidone	Chemical
using	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	Chemical
tolerance	O
test.	O
DESIGN:	O
A	O
cross-sectional	O
design	O
in	O
stable,	O
treated	O
patients	O
with	O
schizophrenia	Disease
evaluated	O
using	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	Chemical
tolerance	O
test	O
and	O
the	O
Bergman	O
minimal	O
model	O
analysis.	O
SETTING:	O
Subjects	O
were	O
recruited	O
from	O
an	O
urban	O
community	O
mental	O
health	O
clinic	O
and	O
were	O
studied	O
at	O
a	O
general	O
clinical	O
research	O
center.	O
Patients	O
Fifty	O
subjects	O
signed	O
informed	O
consent	O
and	O
41	O
underwent	O
the	O
frequently	O
sampled	O
intravenous	O
glucose	Chemical
tolerance	O
test.	O
Thirty-six	O
nonobese	O
subjects	O
with	O
schizophrenia	Disease
or	O
schizoaffective	Disease
disorder	Disease
,	O
matched	O
by	O
body	O
mass	O
index	O
and	O
treated	O
with	O
either	O
clozapine	Chemical
,	O
olanzapine	Chemical
,	O
or	O
risperidone	Chemical
,	O
were	O
included	O
in	O
the	O
analysis.	O
MAIN	O
OUTCOME	O
MEASURES:	O
Fasting	O
plasma	O
glucose	Chemical
and	O
fasting	O
serum	O
insulin	O
levels,	O
insulin	Disease
sensitivity	Disease
index,	O
homeostasis	O
model	O
assessment	O
of	O
insulin	Disease
resistance	Disease
,	O
and	O
glucose	Chemical
effectiveness.	O
RESULTS:	O
The	O
mean	O
+/-	O
SD	O
duration	O
of	O
treatment	O
with	O
the	O
identified	O
atypical	O
antipsychotic	O
agent	O
was	O
68.3	O
+/-	O
28.9	O
months	O
(	O
clozapine	Chemical
),	O
29.5	O
+/-	O
17.5	O
months	O
(	O
olanzapine	Chemical
),	O
and	O
40.9	O
+/-	O
33.7	O
(	O
risperidone	Chemical
).	O
Fasting	O
serum	O
insulin	O
concentrations	O
differed	O
among	O
groups	O
(F(33)	O
=	O
3.35;	O
P	O
=	O
.047)	O
(	O
clozapine	Chemical
>	O
olanzapine	Chemical
>	O
risperidone	Chemical
)	O
with	O
significant	O
differences	O
between	O
clozapine	Chemical
and	O
risperidone	Chemical
(t(33)	O
=	O
2.32;	O
P	O
=	O
.03)	O
and	O
olanzapine	Chemical
and	O
risperidone	Chemical
(t(33)	O
=	O
2.15;	O
P	O
=	O
.04).	O
There	O
was	O
a	O
significant	O
difference	O
in	O
insulin	Disease
sensitivity	Disease
index	O
among	O
groups	O
(F(33)	O
=	O
10.66;	O
P<.001)	O
(	O
clozapine	Chemical
<	O
olanzapine	Chemical
<	O
risperidone	Chemical
),	O
with	O
subjects	O
who	O
received	O
clozapine	Chemical
and	O
olanzapine	Chemical
exhibiting	O
significant	O
insulin	Disease
resistance	Disease
compared	O
with	O
subjects	O
who	O
were	O
treated	O
with	O
risperidone	Chemical
(	O
clozapine	Chemical
vs	O
risperidone	Chemical
,	O
t(33)	O
=	O
-4.29;	O
P<.001;	O
olanzapine	Chemical
vs	O
risperidone	Chemical
,	O
t(33)	O
=	O
-3.62;	O
P	O
=	O
.001	O
[P<.001]).	O
The	O
homeostasis	O
model	O
assessment	O
of	O
insulin	Disease
resistance	Disease
also	O
differed	O
significantly	O
among	O
groups	O
(F(33)	O
=	O
4.92;	O
P	O
=	O
.01)	O
(	O
clozapine	Chemical
>	O
olanzapine	Chemical
>	O
risperidone	Chemical
)	O
(	O
clozapine	Chemical
vs	O
risperidone	Chemical
,	O
t(33)	O
=	O
2.94;	O
P	O
=	O
.006;	O
olanzapine	Chemical
vs	O
risperidone	Chemical
,	O
t(33)	O
=	O
2.42;	O
P	O
=	O
.02).	O
There	O
was	O
a	O
significant	O
difference	O
among	O
groups	O
in	O
glucose	Chemical
effectiveness	O
(F(30)	O
=	O
4.18;	O
P	O
=	O
.02)	O
(	O
clozapine	Chemical
<	O
olanzapine	Chemical
<	O
risperidone	Chemical
)	O
with	O
significant	O
differences	O
between	O
clozapine	Chemical
and	O
risperidone	Chemical
(t(30)	O
=	O
-2.59;	O
P	O
=	O
.02)	O
and	O
olanzapine	Chemical
and	O
risperidone	Chemical
(t(30)	O
=	O
-2.34,	O
P	O
=	O
.03).	O
CONCLUSIONS:	O
Both	O
nonobese	O
clozapine	Chemical
-	O
and	O
olanzapine	Chemical
-treated	O
groups	O
displayed	O
significant	O
insulin	Disease
resistance	Disease
and	O
impairment	O
of	O
glucose	Chemical
effectiveness	O
compared	O
with	O
risperidone	Chemical
-treated	O
subjects.	O
Patients	O
taking	O
clozapine	Chemical
and	O
olanzapine	Chemical
must	O
be	O
examined	O
for	O
insulin	Disease
resistance	Disease

Focal	O
cerebral	Disease
ischemia	Disease
in	O
rats:	O
effect	O
of	O
phenylephrine	Chemical
-induced	O
hypertension	Disease
during	O
reperfusion.	O
After	O
180	O
min	O
of	O
temporary	O
middle	Disease
cerebral	Disease
artery	Disease
occlusion	Disease
in	O
spontaneously	O
hypertensive	Disease
rats,	O
the	O
effect	O
of	O
phenylephrine	Chemical
-induced	O
hypertension	Disease
on	O
ischemic	Disease
brain	Disease
injury	Disease
and	O
blood-brain	O
barrier	O
permeability	O
was	O
determined.	O
Blood	O
pressure	O
was	O
manipulated	O
by	O
one	O
of	O
the	O
following	O
schedules	O
during	O
120	O
min	O
of	O
reperfusion:	O
Control,	O
normotensive	O
reperfusion;	O
90/	O
hypertension	Disease
(90/	O
HTN	Disease
),	O
blood	O
pressure	O
was	O
increased	O
by	O
35	O
mm	O
Hg	O
during	O
the	O
initial	O
90	O
min	O
of	O
reperfusion	O
only;	O
15/	O
hypertension	Disease
(15/	O
HTN	Disease
),	O
normotensive	O
reperfusion	O
for	O
30	O
min	O
followed	O
by	O
15	O
min	O
of	O
hypertension	Disease
and	O
75	O
min	O
of	O
normotension.	O
Part	O
A,	O
for	O
eight	O
rats	O
in	O
each	O
group	O
brain	Disease
injury	Disease
was	O
evaluated	O
by	O
staining	O
tissue	O
using	O
2,3,5-triphenyltetrazolium	Chemical
chloride	Chemical
and	O
edema	Disease
was	O
evaluated	O
by	O
microgravimetry.	O
Part	O
B,	O
for	O
eight	O
different	O
rats	O
in	O
each	O
group	O
blood-brain	O
barrier	O
permeability	O
was	O
evaluated	O
by	O
measuring	O
the	O
amount	O
and	O
extent	O
of	O
extravasation	O
of	O
Evans	O
Blue	O
dye.	O
Brain	Disease
injury	Disease
(percentage	O
of	O
the	O
ischemic	Disease
hemisphere	Disease
)	O
was	O
less	O
in	O
the	O
15/	O
HTN	Disease
group	O
(16	O
+/-	O
6,	O
mean	O
+/-	O
SD)	O
versus	O
the	O
90/	O
HTN	Disease
group	O
(30	O
+/-	O
6),	O
which	O
was	O
in	O
turn	O
less	O
than	O
the	O
control	O
group	O
(42	O
+/-	O
5).	O
Specific	O
gravity	O
was	O
greater	O
in	O
the	O
15/	O
HTN	Disease
group	O
(1.043	O
+/-	O
0.002)	O
versus	O
the	O
90/	O
HTN	Disease
(1.036	O
+/-	O
0.003)	O
and	O
control	O
(1.037	O
+/-	O
0.003)	O
groups.	O
Evans	Chemical
Blue	Chemical
(mug	O
g-1	O
of	O
brain	O
tissue)	O
was	O
greater	O
in	O
the	O
90/	O
HTN	Disease
group	O
(24.4	O
+/-	O
6.0)	O
versus	O
the	O
control	O
group	O
(12.3	O
+/-	O
4.1),	O
which	O
was	O
in	O
turn	O
greater	O
than	O
the	O
15/	O
HTN	Disease
group	O
(7.3	O
+/-	O
3.2).	O
This	O
study	O
supports	O
a	O
hypothesis	O
that	O
during	O
reperfusion,	O
a	O
short	O
interval	O
of	O
hypertension	Disease
decreases	O
brain	Disease
injury	Disease
and	O
edema	Disease
;	O
and	O
that	O
sustained	O
hypertension	Disease
increases	O
the	O
risk	O
of	O
vasogenic	Disease
edema	Disease

People	O
aged	O
over	O
75	O
in	O
atrial	Disease
fibrillation	Disease
on	O
warfarin	Chemical
:	O
the	O
rate	O
of	O
major	O
hemorrhage	Disease
and	O
stroke	Disease
in	O
more	O
than	O
500	O
patient-years	O
of	O
follow-up.	O
OBJECTIVES:	O
To	O
determine	O
the	O
incidence	O
of	O
major	O
hemorrhage	Disease
and	O
stroke	Disease
in	O
people	O
aged	O
76	O
and	O
older	O
with	O
atrial	Disease
fibrillation	Disease
on	O
adjusted-dose	O
warfarin	Chemical
who	O
had	O
been	O
recently	O
been	O
admitted	O
to	O
hospital.	O
DESIGN:	O
A	O
retrospective	O
observational	O
cohort	O
study.	O
SETTING:	O
A	O
major	O
healthcare	O
network	O
involving	O
four	O
tertiary	O
hospitals.	O
PARTICIPANTS:	O
Two	O
hundred	O
thirty-five	O
patients	O
aged	O
76	O
and	O
older	O
admitted	O
to	O
a	O
major	O
healthcare	O
network	O
between	O
July	O
1,	O
2001,	O
and	O
June	O
30,	O
2002,	O
with	O
atrial	Disease
fibrillation	Disease
on	O
warfarin	Chemical
were	O
enrolled.	O
MEASUREMENTS:	O
Information	O
regarding	O
major	O
bleeding	Disease
episodes,	O
strokes	Disease
,	O
and	O
warfarin	Chemical
use	O
was	O
obtained	O
from	O
patients,	O
relatives,	O
primary	O
physicians,	O
and	O
medical	O
records.	O
RESULTS:	O
Two	O
hundred	O
twenty-eight	O
patients	O
(42%	O
men)	O
with	O
a	O
mean	O
age	O
of	O
81.1	O
(range	O
76-94)	O
were	O
included	O
in	O
the	O
analysis.	O
Total	O
follow-up	O
on	O
warfarin	Chemical
was	O
530	O
years	O
(mean	O
28	O
months).	O
There	O
were	O
53	O
major	O
hemorrhages	Disease
,	O
for	O
an	O
annual	O
rate	O
of	O
10.0%,	O
including	O
24	O
(45.3%)	O
life-threatening	O
and	O
five	O
(9.4%)	O
fatal	O
bleeds.	O
The	O
annual	O
stroke	Disease
rate	O
after	O
initiation	O
of	O
warfarin	Chemical
was	O
2.6%.	O
CONCLUSION:	O
The	O
rate	O
of	O
major	O
hemorrhage	Disease
was	O
high	O
in	O
this	O
old,	O
frail	O
group,	O
but	O
excluding	O
fatalities,	O
resulted	O
in	O
no	O
long-term	O
sequelae,	O
and	O
the	O
stroke	Disease
rate	O
on	O
warfarin	Chemical
was	O
low,	O
demonstrating	O
how	O
effective	O
warfarin	Chemical

Safety	O
of	O
celecoxib	Chemical
in	O
patients	O
with	O
adverse	O
skin	Disease
reactions	Disease
to	O
acetaminophen	Chemical
(	O
paracetamol	Chemical
)	O
and	O
nimesulide	Chemical
associated	O
or	O
not	O
with	O
common	O
non-steroidal	O
anti-inflammatory	O
drugs.	O
BACKGROUND:	O
Acetaminophen	Chemical
(	O
paracetamol	Chemical
--	O
P	Chemical
)	O
and	O
Nimesulide	Chemical
(	O
N	Chemical
)	O
are	O
widely	O
used	O
analgesic-antipyretic/anti-inflammatory	O
drugs.	O
The	O
rate	O
of	O
adverse	O
hypersensitivity	Disease
reactions	O
to	O
these	O
agents	O
is	O
generally	O
low.	O
On	O
the	O
contrary	O
non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
are	O
commonly	O
involved	O
in	O
such	O
reactions.	O
Celecoxib	Chemical
(	O
CE	Chemical
)	O
is	O
a	O
novel	O
drug,	O
with	O
high	O
selectivity	O
and	O
affinity	O
for	O
COX-2	O
enzyme.	O
OBJECTIVE:	O
We	O
evaluated	O
the	O
tolerability	O
of	O
CE	Chemical
in	O
a	O
group	O
of	O
patients	O
with	O
documented	O
history	O
of	O
adverse	O
cutaneous	Disease
reactions	Disease
to	O
P	Chemical
and	O
N	Chemical
associated	O
or	O
not	O
to	O
classic	O
NSAIDs.	O
METHODS:	O
We	O
studied	O
9	O
patients	O
with	O
hypersensitivity	Disease
to	O
P	Chemical
and	O
N	Chemical
with	O
or	O
without	O
associated	O
reactions	O
to	O
classic	O
NSAIDs.	O
The	O
diagnosis	O
of	O
P	Chemical
and	O
N	Chemical
-induced	O
skin	Disease
reactions	Disease
was	O
based	O
in	O
vivo	O
challenge.	O
The	O
placebo	O
was	O
blindly	O
administered	O
at	O
the	O
beginning	O
of	O
each	O
challenge.	O
After	O
three	O
days,	O
a	O
cumulative	O
dosage	O
of	O
200	O
mg	O
of	O
CE	Chemical
in	O
refracted	O
doses	O
were	O
given.	O
After	O
2-3	O
days,	O
a	O
single	O
dose	O
of	O
200	O
mg	O
was	O
administered.	O
All	O
patients	O
were	O
observed	O
for	O
6	O
hours	O
after	O
each	O
challenge,	O
and	O
controlled	O
again	O
after	O
24	O
hours	O
to	O
exclude	O
delayed	O
reactions.	O
The	O
challenge	O
was	O
considered	O
positive	O
if	O
one	O
or	O
more	O
of	O
the	O
following	O
appeared:	O
erythema	Disease
,	O
rush	O
or	O
urticaria	Disease
-	O
angioedema	Disease
.	O
RESULTS:	O
No	O
reaction	O
was	O
observed	O
with	O
placebo	O
and	O
eight	O
patients	O
(88.8%)	O
tolerated	O
CE	Chemical
.	O
Only	O
one	O
patient	O
developed	O
a	O
moderate	O
angioedema	Disease
of	O
the	O
lips.	O
CONCLUSION:	O
Only	O
one	O
hypersensitivity	Disease
reaction	O
to	O
CE	Chemical
was	O
documented	O
among	O
9	O
P	Chemical
and	O
N	Chemical
-highly	O
NSAIDs	O
intolerant	O
patients.	O
Thus,	O
we	O
conclude	O
that	O
CE	Chemical
is	O
a	O
reasonably	O
safe	O
alternative	O
to	O
be	O
used	O
in	O
subjects	O
who	O
do	O
not	O
tolerate	O
P	Chemical
and	O
N	Chemical

Case-control	O
study	O
of	O
regular	O
analgesic	O
and	O
nonsteroidal	O
anti-inflammatory	O
use	O
and	O
end-stage	Disease
renal	Disease
disease	Disease
.	O
BACKGROUND:	O
Studies	O
on	O
the	O
association	O
between	O
the	O
long-term	O
use	O
of	O
aspirin	Chemical
and	O
other	O
analgesic	O
and	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
and	O
end-stage	Disease
renal	Disease
disease	Disease
(	O
ESRD	Disease
)	O
have	O
given	O
conflicting	O
results.	O
In	O
order	O
to	O
examine	O
this	O
association,	O
a	O
case-control	O
study	O
with	O
incident	O
cases	O
of	O
ESRD	Disease
was	O
carried	O
out.	O
METHODS:	O
The	O
cases	O
were	O
all	O
patients	O
entering	O
the	O
local	O
dialysis	O
program	O
because	O
of	O
ESRD	Disease
in	O
the	O
study	O
area	O
between	O
June	O
1,	O
1995	O
and	O
November	O
30,	O
1997.	O
They	O
were	O
classified	O
according	O
to	O
the	O
underlying	O
disease,	O
which	O
had	O
presumably	O
led	O
them	O
to	O
ESRD	Disease
.	O
Controls	O
were	O
patients	O
admitted	O
to	O
the	O
same	O
hospitals	O
from	O
where	O
the	O
cases	O
arose,	O
also	O
matched	O
by	O
age	O
and	O
sex.	O
Odds	O
ratios	O
were	O
calculated	O
using	O
a	O
conditional	O
logistic	O
model,	O
including	O
potential	O
confounding	O
factors,	O
both	O
for	O
the	O
whole	O
study	O
population	O
and	O
for	O
the	O
various	O
underlying	O
diseases.	O
RESULTS:	O
Five	O
hundred	O
and	O
eighty-three	O
cases	O
and	O
1190	O
controls	O
were	O
included	O
in	O
the	O
analysis.	O
Long-term	O
use	O
of	O
any	O
analgesic	O
was	O
associated	O
with	O
an	O
overall	O
odds	O
ratio	O
of	O
1.22	O
(95%	O
CI,	O
0.89-1.66).	O
For	O
specific	O
groups	O
of	O
drugs,	O
the	O
risks	O
were	O
1.56	O
(1.05-2.30)	O
for	O
aspirin	Chemical
,	O
1.03	O
(0.60-1.76)	O
for	O
pyrazolones	Chemical
,	O
0.80	O
(0.39-1.63)	O
for	O
paracetamol	Chemical
,	O
and	O
0.94	O
(0.57-1.56)	O
for	O
nonaspirin	O
NSAIDs.	O
The	O
risk	O
of	O
ESRD	Disease
associated	O
with	O
aspirin	Chemical
was	O
related	O
to	O
the	O
cumulated	O
dose	O
and	O
duration	O
of	O
use,	O
and	O
it	O
was	O
particularly	O
high	O
among	O
the	O
subset	O
of	O
patients	O
with	O
vascular	O
nephropathy	Disease
as	O
underlying	O
disease	O
[2.35	O
(1.17-4.72)].	O
CONCLUSION:	O
Our	O
data	O
indicate	O
that	O
long-term	O
use	O
of	O
nonaspirin	O
analgesic	O
drugs	O
and	O
NSAIDs	O
is	O
not	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
ESRD	Disease
.	O
However,	O
the	O
chronic	O
use	O
of	O
aspirin	Chemical
may	O
increase	O
the	O
risk	O
of	O
ESRD	Disease

Two	O
cases	O
of	O
amisulpride	Chemical
	O
overdose	Disease
:	O
a	O
cause	O
for	O
prolonged	Disease
QT	Disease
syndrome	Disease
.	O
Two	O
cases	O
of	O
deliberate	O
self-	O
poisoning	Disease
with	O
5	O
g	O
and	O
3.6	O
g	O
of	O
amisulpride	Chemical
,	O
respectively,	O
are	O
reported.	O
In	O
both	O
cases,	O
QT	Disease
prolongation	Disease
and	O
hypocalcaemia	Disease
were	O
noted.	O
The	O
QT	Disease
prolongation	Disease
appeared	O
to	O
respond	O
to	O
administration	O
of	O
i.v.	O
calcium	Chemical
gluconate	Chemical

Growth-associated	O
protein	O
43	O
expression	O
in	O
hippocampal	O
molecular	O
layer	O
of	O
chronic	O
epileptic	Disease
rats	O
treated	O
with	O
cycloheximide	Chemical
.	O
PURPOSE:	O
GAP43	O
has	O
been	O
thought	O
to	O
be	O
linked	O
with	O
mossy	O
fiber	O
sprouting	O
(MFS)	O
in	O
various	O
experimental	O
models	O
of	O
epilepsy	Disease
.	O
To	O
investigate	O
how	O
GAP43	O
expression	O
(GAP43-ir)	O
correlates	O
with	O
MFS,	O
we	O
assessed	O
the	O
intensity	O
(densitometry)	O
and	O
extension	O
(width)	O
of	O
GAP43-ir	O
in	O
the	O
inner	O
molecular	O
layer	O
of	O
the	O
dentate	O
gyrus	O
(IML)	O
of	O
rats	O
subject	O
to	O
status	Disease
epilepticus	Disease
induced	O
by	O
pilocarpine	Chemical
(	O
Pilo	Chemical
),	O
previously	O
injected	O
or	O
not	O
with	O
cycloheximide	Chemical
(	O
CHX	Chemical
),	O
which	O
has	O
been	O
shown	O
to	O
inhibit	O
MFS.	O
METHODS:	O
CHX	Chemical
was	O
injected	O
before	O
the	O
Pilo	Chemical
injection	O
in	O
adult	O
Wistar	O
rats.	O
The	O
Pilo	Chemical
group	O
was	O
injected	O
with	O
the	O
same	O
drugs,	O
except	O
for	O
CHX	Chemical
.	O
Animals	O
were	O
killed	O
between	O
30	O
and	O
60	O
days	O
later,	O
and	O
brain	O
sections	O
were	O
processed	O
for	O
GAP43	O
immunohistochemistry.	O
RESULTS:	O
Densitometry	O
showed	O
no	O
significant	O
difference	O
regarding	O
GAP43-ir	O
in	O
the	O
IML	O
between	O
Pilo	Chemical
,	O
CHX	Chemical
+	O
Pilo	Chemical
,	O
and	O
control	O
groups.	O
However,	O
the	O
results	O
of	O
the	O
width	O
of	O
the	O
GAP43-ir	O
band	O
in	O
the	O
IML	O
showed	O
that	O
CHX	Chemical
+	O
Pilo	Chemical
and	O
control	O
animals	O
had	O
a	O
significantly	O
larger	O
band	O
(p	O
=	O
0.03)	O
as	O
compared	O
with	O
that	O
in	O
the	O
Pilo	Chemical
group.	O
CONCLUSIONS:	O
Our	O
current	O
finding	O
that	O
animals	O
in	O
the	O
CHX	Chemical
+	O
Pilo	Chemical
group	O
have	O
a	O
GAP43-ir	O
band	O
in	O
the	O
IML,	O
similar	O
to	O
that	O
of	O
controls,	O
reinforces	O
prior	O
data	O
on	O
the	O
blockade	O
of	O
MFS	O
in	O
these	O
animals.	O
The	O
change	O
in	O
GAP43-ir	O
present	O
in	O
Pilo	Chemical

Nicotine	Chemical
antagonizes	O
caffeine	Chemical
-	O
but	O
not	O
pentylenetetrazole	Chemical
-induced	O
anxiogenic	O
effect	O
in	O
mice.	O
RATIONALE:	O
Nicotine	Chemical
and	O
caffeine	Chemical
are	O
widely	O
consumed	O
licit	O
psychoactive	O
drugs	O
worldwide.	O
Epidemiological	O
studies	O
showed	O
that	O
they	O
were	O
generally	O
used	O
concurrently.	O
Although	O
some	O
studies	O
in	O
experimental	O
animals	O
indicate	O
clear	O
pharmacological	O
interactions	O
between	O
them,	O
no	O
studies	O
have	O
shown	O
a	O
specific	O
interaction	O
on	O
anxiety	Disease
responses.	O
OBJECTIVES:	O
The	O
present	O
study	O
investigates	O
the	O
effects	O
of	O
nicotine	Chemical
on	O
anxiety	Disease
induced	O
by	O
caffeine	Chemical
and	O
another	O
anxiogenic	O
drug,	O
pentylenetetrazole	Chemical
,	O
in	O
mice.	O
The	O
elevated	O
plus-maze	O
(EPM)	O
test	O
was	O
used	O
to	O
evaluate	O
the	O
effects	O
of	O
drugs	O
on	O
anxiety	Disease
.	O
METHODS:	O
Adult	O
male	O
Swiss	O
Webster	O
mice	O
(25-32	O
g)	O
were	O
given	O
nicotine	Chemical
(0.05-0.25	O
mg/kg	O
s.c.)	O
or	O
saline	O
10	O
min	O
before	O
caffeine	Chemical
(70	O
mg/kg	O
i.p.)	O
or	O
pentylenetetrazole	Chemical
(15	O
and	O
30	O
mg/kg	O
i.p.)	O
injections.	O
After	O
15	O
min,	O
mice	O
were	O
evaluated	O
for	O
their	O
open-	O
and	O
closed-arm	O
time	O
and	O
entries	O
on	O
the	O
EPM	O
for	O
a	O
10-min	O
session.	O
Locomotor	O
activity	O
was	O
recorded	O
for	O
individual	O
groups	O
by	O
using	O
the	O
same	O
treatment	O
protocol	O
with	O
the	O
EPM	O
test.	O
RESULTS:	O
Nicotine	Chemical
(0.05-0.25	O
mg/kg)	O
itself	O
did	O
not	O
produce	O
any	O
significant	O
effect	O
in	O
the	O
EPM	O
test,	O
whereas	O
caffeine	Chemical
(70	O
mg/kg)	O
and	O
pentylenetetrazole	Chemical
(30	O
mg/kg)	O
produced	O
an	O
anxiogenic	O
effect,	O
apparent	O
with	O
decreases	O
in	O
open-arm	O
time	O
and	O
entry.	O
Nicotine	Chemical
(0.25	O
mg/kg)	O
pretreatment	O
blocked	O
the	O
caffeine	Chemical
-	O
but	O
not	O
pentylenetetrazole	Chemical
-induced	O
anxiety	Disease
.	O
Administration	O
of	O
each	O
drug	O
and	O
their	O
combinations	O
did	O
not	O
produce	O
any	O
effect	O
on	O
locomotor	O
activity.	O
CONCLUSIONS:	O
Our	O
results	O
suggest	O
that	O
the	O
antagonistic	O
effect	O
of	O
nicotine	Chemical
on	O
caffeine	Chemical
-induced	O
anxiety	Disease
is	O
specific	O
to	O
caffeine	Chemical
,	O
instead	O
of	O
a	O
non-specific	O
anxiolytic	O
effect.	O
Thus,	O
it	O
may	O
extend	O
the	O
current	O
findings	O
on	O
the	O
interaction	O
between	O
nicotine	Chemical
and	O
caffeine	Chemical

Long	O
term	O
hormone	O
therapy	O
for	O
perimenopausal	O
and	O
postmenopausal	O
women.	O
BACKGROUND:	O
Hormone	O
therapy	O
(HT)	O
is	O
widely	O
used	O
for	O
controlling	O
menopausal	Disease
symptoms	Disease
.	O
It	O
has	O
also	O
been	O
used	O
for	O
the	O
management	O
and	O
prevention	O
of	O
cardiovascular	Disease
disease	Disease
,	O
osteoporosis	Disease
and	O
dementia	Disease
in	O
older	O
women	O
but	O
the	O
evidence	O
supporting	O
its	O
use	O
for	O
these	O
indications	O
is	O
largely	O
observational.	O
OBJECTIVES:	O
To	O
assess	O
the	O
effect	O
of	O
long-term	O
HT	O
on	O
mortality,	O
heart	Disease
disease	Disease
,	O
venous	Disease
thromboembolism	Disease
,	O
stroke	Disease
,	O
transient	Disease
ischaemic	Disease
attacks	Disease
,	O
breast	Disease
cancer	Disease
,	O
colorectal	Disease
cancer	Disease
,	O
ovarian	Disease
cancer	Disease
,	O
endometrial	Disease
cancer	Disease
,	O
gallbladder	Disease
disease	Disease
,	O
cognitive	O
function,	O
dementia	Disease
,	O
fractures	Disease
and	O
quality	O
of	O
life.	O
SEARCH	O
STRATEGY:	O
We	O
searched	O
the	O
following	O
databases	O
up	O
to	O
November	O
2004:	O
the	O
Cochrane	O
Menstrual	O
Disorders	O
and	O
Subfertility	O
Group	O
Trials	O
Register,	O
Cochrane	O
Central	O
Register	O
of	O
Controlled	O
Trials	O
(CENTRAL),	O
MEDLINE,	O
EMBASE,	O
Biological	O
Abstracts.	O
Relevant	O
non-indexed	O
journals	O
and	O
conference	O
abstracts	O
were	O
also	O
searched.	O
SELECTION	O
CRITERIA:	O
Randomised	O
double-blind	O
trials	O
of	O
HT	O
(	O
oestrogens	Chemical
with	O
or	O
without	O
progestogens	Chemical
)	O
versus	O
placebo,	O
taken	O
for	O
at	O
least	O
one	O
year	O
by	O
perimenopausal	O
or	O
postmenopausal	O
women.	O
DATA	O
COLLECTION	O
AND	O
ANALYSIS:	O
Fifteen	O
RCTs	O
were	O
included.	O
Trials	O
were	O
assessed	O
for	O
quality	O
and	O
two	O
review	O
authors	O
extracted	O
data	O
independently.	O
They	O
calculated	O
risk	O
ratios	O
for	O
dichotomous	O
outcomes	O
and	O
weighted	O
mean	O
differences	O
for	O
continuous	O
outcomes.	O
Clinical	O
heterogeneity	O
precluded	O
meta-analysis	O
for	O
most	O
outcomes.	O
MAIN	O
RESULTS:	O
All	O
the	O
statistically	O
significant	O
results	O
were	O
derived	O
from	O
the	O
two	O
biggest	O
trials.	O
In	O
relatively	O
healthy	O
women,	O
combined	O
continuous	O
HT	O
significantly	O
increased	O
the	O
risk	O
of	O
venous	Disease
thromboembolism	Disease
or	O
coronary	O
event	O
(after	O
one	O
year's	O
use),	O
stroke	Disease
(after	O
3	O
years),	O
breast	Disease
cancer	Disease
(after	O
5	O
years)	O
and	O
gallbladder	Disease
disease	Disease
.	O
Long-term	O
oestrogen	Chemical
-only	O
HT	O
also	O
significantly	O
increased	O
the	O
risk	O
of	O
stroke	Disease
and	O
gallbladder	Disease
disease	Disease
.	O
Overall,	O
the	O
only	O
statistically	O
significant	O
benefits	O
of	O
HT	O
were	O
a	O
decreased	O
incidence	O
of	O
fractures	Disease
and	O
colon	Disease
cancer	Disease
with	O
long-term	O
use.	O
Among	O
relatively	O
healthy	O
women	O
over	O
65	O
years	O
taking	O
continuous	O
combined	O
HT,	O
there	O
was	O
a	O
statistically	O
significant	O
increase	O
in	O
the	O
incidence	O
of	O
dementia	Disease
.	O
Among	O
women	O
with	O
cardiovascular	Disease
disease	Disease
,	O
long-term	O
use	O
of	O
combined	O
continuous	O
HT	O
significantly	O
increased	O
the	O
risk	O
of	O
venous	Disease
thromboembolism	Disease
.	O
No	O
trials	O
focussed	O
specifically	O
on	O
younger	O
women.	O
However,	O
one	O
trial	O
analysed	O
subgroups	O
of	O
2839	O
relatively	O
healthy	O
50	O
to	O
59	O
year-old	O
women	O
taking	O
combined	O
continuous	O
HT	O
and	O
1637	O
taking	O
oestrogen	Chemical
-only	O
HT,	O
versus	O
similar-sized	O
placebo	O
groups.	O
The	O
only	O
significantly	O
increased	O
risk	O
reported	O
was	O
for	O
venous	Disease
thromboembolism	Disease
in	O
women	O
taking	O
combined	O
continuous	O
HT;	O
their	O
absolute	O
risk	O
remained	O
very	O
low.	O
AUTHORS'	O
CONCLUSIONS:	O
HT	O
is	O
not	O
indicated	O
for	O
the	O
routine	O
management	O
of	O
chronic	Disease
disease	Disease

Drug-induced	Disease
liver	Disease
injury	Disease
:	O
an	O
analysis	O
of	O
461	O
incidences	O
submitted	O
to	O
the	O
Spanish	O
registry	O
over	O
a	O
10-year	O
period.	O
BACKGROUND	O
&	O
AIMS:	O
Progress	O
in	O
the	O
understanding	O
of	O
susceptibility	O
factors	O
to	O
drug-induced	Disease
liver	Disease
injury	Disease
(	O
DILI	Disease
)	O
and	O
outcome	O
predictability	O
are	O
hampered	O
by	O
the	O
lack	O
of	O
systematic	O
programs	O
to	O
detect	O
bona	O
fide	O
cases.	O
METHODS:	O
A	O
cooperative	O
network	O
was	O
created	O
in	O
1994	O
in	O
Spain	O
to	O
identify	O
all	O
suspicions	O
of	O
DILI	Disease
following	O
a	O
prospective	O
structured	O
report	O
form.	O
The	O
liver	Disease
damage	Disease
was	O
characterized	O
according	O
to	O
hepatocellular,	O
cholestatic	Disease
,	O
and	O
mixed	O
laboratory	O
criteria	O
and	O
to	O
histologic	O
criteria	O
when	O
available.	O
Further	O
evaluation	O
of	O
causality	O
assessment	O
was	O
centrally	O
performed.	O
RESULTS:	O
Since	O
April	O
1994	O
to	O
August	O
2004,	O
461	O
out	O
of	O
570	O
submitted	O
cases,	O
involving	O
505	O
drugs,	O
were	O
deemed	O
to	O
be	O
related	O
to	O
DILI	Disease
.	O
The	O
antiinfective	O
group	O
of	O
drugs	O
was	O
the	O
more	O
frequently	O
incriminated,	O
amoxicillin-clavulanate	Chemical
accounting	O
for	O
the	O
12.8%	O
of	O
the	O
whole	O
series.	O
The	O
hepatocellular	O
pattern	O
of	O
damage	O
was	O
the	O
most	O
common	O
(58%),	O
was	O
inversely	O
correlated	O
with	O
age	O
(P	O
<	O
.0001),	O
and	O
had	O
the	O
worst	O
outcome	O
(Cox	O
regression,	O
P	O
<	O
.034).	O
Indeed,	O
the	O
incidence	O
of	O
liver	O
transplantation	O
and	O
death	O
in	O
this	O
group	O
was	O
11.7%	O
if	O
patients	O
had	O
jaundice	Disease
at	O
presentation,	O
whereas	O
the	O
corresponding	O
figure	O
was	O
3.8%	O
in	O
nonjaundiced	O
patients	O
(P	O
<	O
.04).	O
Factors	O
associated	O
with	O
the	O
development	O
of	O
fulminant	Disease
hepatic	Disease
failure	Disease
were	O
female	O
sex	O
(OR	O
=	O
25;	O
95%	O
CI:	O
4.1-151;	O
P	O
<	O
.0001),	O
hepatocellular	O
damage	O
(OR	O
=	O
7.9;	O
95%	O
CI:	O
1.6-37;	O
P	O
<	O
.009),	O
and	O
higher	O
baseline	O
plasma	O
bilirubin	Chemical
value	O
(OR	O
=	O
1.15;	O
95%	O
CI:	O
1.09-1.22;	O
P	O
<	O
.0001).	O
CONCLUSIONS:	O
Patients	O
with	O
drug-induced	O
hepatocellular	O
jaundice	Disease
have	O
11.7%	O
chance	O
of	O
progressing	O
to	O
death	O
or	O
transplantation.	O
Amoxicillin-clavulanate	Chemical
stands	O
out	O
as	O
the	O
most	O
common	O
drug	O
related	O
to	O
DILI	Disease

Morphological	O
evaluation	O
of	O
the	O
effect	O
of	O
d-ribose	Chemical
on	O
adriamycin	Chemical
-evoked	O
cardiotoxicity	Disease
in	O
rats.	O
The	O
influence	O
of	O
d-ribose	Chemical
on	O
adriamycin	Chemical
-induced	O
myocardiopathy	Disease
in	O
rats	O
was	O
studied.	O
Adriamycin	Chemical
in	O
the	O
cumulative	O
dose	O
of	O
25	O
mg/kg	O
evoked	O
fully	O
developed	O
cardiac	Disease
toxicity	Disease
.	O
D-ribose	Chemical
in	O
the	O
multiple	O
doses	O
of	O
200	O
mg/kg	O
did	O
not	O
influence	O
ADR	Chemical
	O
cardiotoxicity	Disease

In	O
vivo	O
evidences	O
suggesting	O
the	O
role	O
of	O
oxidative	O
stress	O
in	O
pathogenesis	O
of	O
vancomycin	Chemical
-induced	O
nephrotoxicity	Disease
:	O
protection	O
by	O
erdosteine	Chemical
.	O
The	O
aims	O
of	O
this	O
study	O
were	O
to	O
examine	O
vancomycin	Chemical
(	O
VCM	Chemical
)-induced	O
oxidative	O
stress	O
that	O
promotes	O
production	O
of	O
reactive	O
oxygen	Chemical
species	O
(ROS)	O
and	O
to	O
investigate	O
the	O
role	O
of	O
erdosteine	Chemical
,	O
an	O
expectorant	O
agent,	O
which	O
has	O
also	O
antioxidant	O
properties,	O
on	O
kidney	O
tissue	O
against	O
the	O
possible	O
VCM	Chemical
-induced	O
renal	Disease
impairment	Disease
in	O
rats.	O
Rats	O
were	O
divided	O
into	O
three	O
groups:	O
sham,	O
VCM	Chemical
and	O
VCM	Chemical
plus	O
erdosteine	Chemical
.	O
VCM	Chemical
was	O
administrated	O
intraperitoneally	O
(i.p.)	O
with	O
200mgkg(-1)	O
twice	O
daily	O
for	O
7	O
days.	O
Erdosteine	Chemical
was	O
administered	O
orally.	O
VCM	Chemical
administration	O
to	O
control	O
rats	O
significantly	O
increased	O
renal	O
malondialdehyde	Chemical
(	O
MDA	Chemical
)	O
and	O
urinary	O
N-acetyl-beta-d-glucosaminidase	O
(NAG,	O
a	O
marker	O
of	O
renal	Disease
tubular	Disease
injury	Disease
)	O
excretion	O
but	O
decreased	O
superoxide	Chemical
dismutase	O
(SOD)	O
and	O
catalase	O
(CAT)	O
activities.	O
Erdosteine	Chemical
administration	O
with	O
VCM	Chemical
injections	O
caused	O
significantly	O
decreased	O
renal	O
MDA	Chemical
and	O
urinary	O
NAG	O
excretion,	O
and	O
increased	O
SOD	O
activity,	O
but	O
not	O
CAT	O
activity	O
in	O
renal	O
tissue	O
when	O
compared	O
with	O
VCM	Chemical
alone.	O
Erdosteine	Chemical
showed	O
histopathological	O
protection	O
against	O
VCM	Chemical
-induced	O
nephrotoxicity	Disease
.	O
There	O
were	O
a	O
significant	O
dilatation	O
of	O
tubular	O
lumens,	O
extensive	O
epithelial	O
cell	O
vacuolization,	O
atrophy	Disease
,	O
desquamation	Disease
,	O
and	O
necrosis	Disease
in	O
VCM	Chemical
-treated	O
rats	O
more	O
than	O
those	O
of	O
the	O
control	O
and	O
the	O
erdosteine	Chemical
groups.	O
Erdosteine	Chemical
caused	O
a	O
marked	O
reduction	O
in	O
the	O
extent	O
of	O
tubular	O
damage.	O
It	O
is	O
concluded	O
that	O
oxidative	O
tubular	O
damage	O
plays	O
an	O
important	O
role	O
in	O
the	O
VCM	Chemical
-induced	O
nephrotoxicity	Disease
and	O
the	O
modulation	O
of	O
oxidative	O
stress	O
with	O
erdosteine	Chemical
reduces	O
the	O
VCM	Chemical
-induced	O
kidney	Disease
damage	Disease

Does	O
domperidone	Chemical
potentiate	O
mirtazapine	Chemical
-associated	O
restless	Disease
legs	Disease
syndrome	Disease
?	O
There	O
is	O
now	O
evidence	O
to	O
suggest	O
a	O
central	O
role	O
for	O
the	O
dopaminergic	O
system	O
in	O
restless	Disease
legs	Disease
syndrome	Disease
(	O
RLS	Disease
).	O
For	O
example,	O
the	O
symptoms	O
of	O
RLS	Disease
can	O
be	O
dramatically	O
improved	O
by	O
levodopa	Chemical
and	O
dopamine	Chemical
agonists,	O
whereas	O
central	O
dopamine	Chemical
D2	O
receptor	O
antagonists	O
can	O
induce	O
or	O
aggravate	O
RLS	Disease
symptoms.	O
To	O
our	O
knowledge,	O
there	O
is	O
no	O
previous	O
report	O
regarding	O
whether	O
domperidone	Chemical
,	O
a	O
peripheral	O
dopamine	Chemical
D2	O
receptor	O
antagonist,	O
can	O
also	O
induce	O
or	O
aggravate	O
symptoms	O
of	O
RLS	Disease
.	O
Mirtazapine	Chemical
,	O
the	O
first	O
noradrenergic	O
and	O
specific	O
serotonergic	O
antidepressant	O
(NaSSA),	O
has	O
been	O
associated	O
with	O
RLS	Disease
in	O
several	O
recent	O
publications.	O
The	O
authors	O
report	O
here	O
a	O
depressed	O
patient	O
comorbid	O
with	O
postprandial	Disease
dyspepsia	Disease
who	O
developed	O
RLS	Disease
after	O
mirtazapine	Chemical
had	O
been	O
added	O
to	O
his	O
domperidone	Chemical
therapy.	O
Our	O
patient	O
started	O
to	O
have	O
symptoms	O
of	O
RLS	Disease
only	O
after	O
he	O
had	O
been	O
treated	O
with	O
mirtazapine	Chemical
,	O
and	O
his	O
RLS	Disease
symptoms	O
resolved	O
completely	O
upon	O
discontinuation	O
of	O
his	O
mirtazapine	Chemical
.	O
Such	O
a	O
temporal	O
relationship	O
between	O
the	O
use	O
of	O
mirtazapine	Chemical
and	O
the	O
symptoms	O
of	O
RLS	Disease
in	O
our	O
patient	O
did	O
not	O
support	O
a	O
potentiating	O
effect	O
of	O
domperione	Chemical
on	O
mirtazapine	Chemical
-associated	O
RLS	Disease
.	O
However,	O
physicians	O
should	O
be	O
aware	O
of	O
the	O
possibility	O
that	O
mirtazapine	Chemical
can	O
be	O
associated	O
with	O
RLS	Disease
in	O
some	O
individuals,	O
especially	O
those	O
receiving	O
concomitant	O
dopamine	Chemical

Antiandrogenic	O
therapy	O
can	O
cause	O
coronary	Disease
arterial	Disease
disease	Disease
.	O
AIM:	O
To	O
study	O
the	O
change	O
of	O
lipid	O
metabolism	O
by	O
antiandrogen	O
therapy	O
in	O
patients	O
with	O
prostate	Disease
cancer	Disease
.	O
MATERIALS	O
AND	O
METHODS:	O
We	O
studied	O
with	O
a	O
2.5	O
years	O
follow-up	O
the	O
changes	O
in	O
plasma	O
cholesterols	Chemical
(	O
C	Chemical
),	O
triglycerides	Chemical
(	O
TG	Chemical
),	O
lipoproteins	O
(LP),	O
and	O
apolipoproteins	O
(Apo)	O
B-100,	O
A-I,	O
and	O
A-II	O
pro	O
fi	O
les	O
in	O
24	O
patients	O
of	O
mean	O
age	O
60	O
years	O
with	O
low	O
risk	O
prostate	Disease
cancer	Disease
(stage:	O
T1cN0M0,	O
Gleason	O
score:	O
2-5)	O
during	O
treatment	O
with	O
cyproterone	Chemical
acetate	Chemical
(	O
CPA	Chemical
)	O
without	O
surgical	O
management	O
or	O
radiation	O
therapy.	O
RESULTS:	O
Significant	O
decreases	O
of	O
HDL-C,	O
Apo	O
A-I	O
and	O
Apo	O
A-II	O
and	O
an	O
increase	O
of	O
triglyceride	Chemical
levels	O
in	O
VLDL	O
were	O
induced	O
by	O
CPA	Chemical
.	O
After	O
a	O
period	O
of	O
2.5	O
years	O
on	O
CPA	Chemical
treatment,	O
four	O
patients	O
out	O
of	O
twenty-four	O
were	O
found	O
to	O
be	O
affected	O
by	O
coronary	Disease
heart	Disease
disease	Disease
.	O
CONCLUSIONS:	O
Ischaemic	O
coronary	Disease
arteriosclerosis	Disease
with	O
an	O
incidence	O
rate	O
of	O
16.6%	O
as	O
caused	O
by	O
prolonged	O
CPA	Chemical
therapy	O
is	O
mediated	O
through	O
changes	O
in	O
HDL	O
cholesterol	Chemical
,	O
Apo	O
A-I	O
and	O
Apo	O
A-II	O
pro	O
fi	O
les,	O
other	O
than	O
the	O
well-known	O
hyperglyceridemic	Disease
effect	Disease
caused	O
by	O
estrogen	Chemical

5-Fluorouracil	Chemical
	O
cardiotoxicity	Disease
induced	O
by	O
alpha-fluoro-beta-alanine	Chemical
.	O
Cardiotoxicity	Disease
is	O
a	O
rare	O
complication	O
occurring	O
during	O
5-fluorouracil	Chemical
(	O
5-FU	Chemical
)	O
treatment	O
for	O
malignancies	Disease
.	O
We	O
herein	O
report	O
the	O
case	O
of	O
a	O
70-year-old	O
man	O
with	O
5-FU	Chemical
-induced	O
cardiotoxicity	Disease
,	O
in	O
whom	O
a	O
high	O
serum	O
level	O
of	O
alpha-fluoro-beta-alanine	Chemical
(	O
FBAL	Chemical
)	O
was	O
observed.	O
The	O
patient,	O
who	O
had	O
unresectable	O
colon	Disease
cancer	Disease
metastases	O
to	O
the	O
liver	O
and	O
lung,	O
was	O
referred	O
to	O
us	O
for	O
chemotherapy	O
from	O
an	O
affiliated	O
hospital;	O
he	O
had	O
no	O
cardiac	O
history.	O
After	O
admission,	O
the	O
patient	O
received	O
a	O
continuous	O
intravenous	O
infusion	O
of	O
5-FU	Chemical
(1000	O
mg/day),	O
during	O
which	O
precordial	Disease
pain	Disease
with	O
right	Disease
bundle	Disease
branch	Disease
block	Disease
occurred	O
concomitantly	O
with	O
a	O
high	O
serum	O
FBAL	Chemical
concentration	O
of	O
1955	O
ng/ml.	O
Both	O
the	O
precordial	Disease
pain	Disease
and	O
the	O
electrocardiographic	O
changes	O
disappeared	O
spontaneously	O
after	O
the	O
discontinuation	O
of	O
5-FU	Chemical
.	O
As	O
the	O
precordial	Disease
pain	Disease
in	O
this	O
patient	O
was	O
considered	O
to	O
have	O
been	O
due	O
to	O
5-FU	Chemical
-induced	O
cardiotoxicity	Disease
,	O
the	O
administration	O
of	O
5-FU	Chemical
was	O
abandoned.	O
Instead,	O
oral	O
administration	O
of	O
S-1	O
(a	O
derivative	O
of	O
5-FU	Chemical
),	O
at	O
200	O
mg/day	O
twice	O
a	O
week,	O
was	O
instituted,	O
because	O
S-1	O
has	O
a	O
strong	O
inhibitory	O
effect	O
on	O
dihydropyrimidine	Chemical
dehydrogenase,	O
which	O
catalyzes	O
the	O
degradative	O
of	O
5-FU	Chemical
into	O
FBAL	Chemical
.	O
The	O
serum	O
FBAL	Chemical
concentration	O
subsequently	O
decreased	O
to	O
352	O
ng/ml,	O
the	O
same	O
as	O
the	O
value	O
measured	O
on	O
the	O
first	O
day	O
of	O
S-1	O
administration.	O
Thereafter,	O
no	O
cardiac	Disease
symptoms	Disease
were	O
observed.	O
The	O
patient	O
achieved	O
a	O
partial	O
response	O
6	O
months	O
after	O
the	O
initiation	O
of	O
the	O
S-1	O
treatment.	O
The	O
experience	O
of	O
this	O
case,	O
together	O
with	O
a	O
review	O
of	O
the	O
literature,	O
suggests	O
that	O
FBAL	Chemical
is	O
related	O
to	O
5-FU	Chemical
-induced	O
cardiotoxicity	Disease
.	O
S-1	O
may	O
be	O
administered	O
safely	O
to	O
patients	O
with	O
5-FU	Chemical
-induced	O
cardiotoxicity	Disease

The	O
influence	O
of	O
the	O
time	O
interval	O
between	O
monoHER	Chemical
and	O
doxorubicin	Chemical
administration	O
on	O
the	O
protection	O
against	O
doxorubicin	Chemical
-induced	O
cardiotoxicity	Disease
in	O
mice.	O
PURPOSE:	O
Despite	O
its	O
well-known	O
cardiotoxicity	Disease
,	O
the	O
anthracyclin	O
doxorubicin	Chemical
(	O
DOX	Chemical
)	O
continues	O
to	O
be	O
an	O
effective	O
and	O
widely	O
used	O
chemotherapeutic	O
agent.	O
DOX	Chemical
-induced	O
cardiac	Disease
damage	Disease
presumably	O
results	O
from	O
the	O
formation	O
of	O
free	O
radicals	O
by	O
DOX	Chemical
.	O
Reactive	O
oxygen	Chemical
species	O
particularly	O
affect	O
the	O
cardiac	O
myocytes	O
because	O
these	O
cells	O
seem	O
to	O
have	O
a	O
relatively	O
poor	O
antioxidant	O
defense	O
system.	O
The	O
semisynthetic	O
flavonoid	Chemical
	O
monohydroxyethylrutoside	Chemical
(	O
monoHER	Chemical
)	O
showed	O
cardioprotection	O
against	O
DOX	Chemical
-induced	O
cardiotoxicity	Disease
through	O
its	O
radical	O
scavenging	O
and	O
iron	Chemical
chelating	O
properties.	O
Because	O
of	O
the	O
relatively	O
short	O
final	O
half-life	O
of	O
monoHER	Chemical
(about	O
30	O
min),	O
it	O
is	O
expected	O
that	O
the	O
time	O
interval	O
between	O
monoHER	Chemical
and	O
DOX	Chemical
might	O
be	O
of	O
influence	O
on	O
the	O
cardioprotective	O
effect	O
of	O
monoHER	Chemical
.	O
Therefore,	O
the	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
this	O
possible	O
effect.	O
METHODS:	O
Six	O
groups	O
of	O
6	O
BALB/c	O
mice	O
were	O
treated	O
with	O
saline,	O
DOX	Chemical
alone	O
or	O
DOX	Chemical
(4	O
mg/kg	O
i.v.)	O
preceded	O
by	O
monoHER	Chemical
(500	O
mg/kg	O
i.p.)	O
with	O
an	O
interval	O
of	O
10,	O
30,	O
60	O
or	O
120	O
min.	O
After	O
a	O
6-week	O
treatment	O
period	O
and	O
additional	O
observation	O
for	O
2	O
weeks,	O
the	O
mice	O
were	O
sacrificed.	O
Their	O
cardiac	O
tissues	O
were	O
processed	O
for	O
light	O
microscopy,	O
after	O
which	O
cardiomyocyte	Disease
damage	Disease
was	O
evaluated	O
according	O
to	O
Billingham	O
(in	O
Cancer	Disease
Treat	O
Rep	O
62(6):865-872,	O
1978).	O
Microscopic	O
evaluation	O
revealed	O
that	O
treatment	O
with	O
DOX	Chemical
alone	O
induced	O
significant	O
cardiac	Disease
damage	Disease
in	O
comparison	O
to	O
the	O
saline	O
control	O
group	O
(P<0.001).	O
RESULTS:	O
The	O
number	O
of	O
damaged	O
cardiomyocytes	O
was	O
9.6-fold	O
(95%	O
CI	O
4.4-21.0)	O
higher	O
in	O
mice	O
treated	O
with	O
DOX	Chemical
alone	O
than	O
that	O
in	O
animals	O
of	O
the	O
control	O
group.	O
The	O
ratio	O
of	O
aberrant	O
cardiomyocytes	O
in	O
mice	O
treated	O
with	O
DOX	Chemical
preceded	O
by	O
monoHER	Chemical
and	O
those	O
in	O
mice	O
treated	O
with	O
saline	O
ranged	O
from	O
1.6	O
to	O
2.8	O
(mean	O
2.2,	O
95%	O
CI	O
1.2-4.1,	O
P=0.019).	O
The	O
mean	O
protective	O
effect	O
by	O
adding	O
monoHER	Chemical
before	O
DOX	Chemical
led	O
to	O
a	O
significant	O
4.4-fold	O
reduction	O
(P<0.001,	O
95%	O
CI	O
2.3-8.2)	O
of	O
abnormal	O
cardiomyocytes.	O
This	O
protective	O
effect	O
did	O
not	O
depend	O
on	O
the	O
time	O
interval	O
between	O
monoHER	Chemical
and	O
DOX	Chemical
administration	O
(P=0.345).	O
CONCLUSION:	O
The	O
results	O
indicate	O
that	O
in	O
an	O
outpatient	O
clinical	O
setting	O
monoHER	Chemical
may	O
be	O
administered	O
shortly	O
before	O
DOX	Chemical

Clinical	O
evaluation	O
of	O
adverse	O
effects	O
during	O
bepridil	Chemical
administration	O
for	O
atrial	Disease
fibrillation	Disease
and	Disease
flutter	Disease
.	O
BACKGROUND:	O
Bepridil	Chemical
hydrochloride	Chemical
(	O
Bpd	Chemical
)	O
has	O
attracted	O
attention	O
as	O
an	O
effective	O
drug	O
for	O
atrial	Disease
fibrillation	Disease
(	O
AF	Disease
)	O
and	O
atrial	Disease
flutter	Disease
(	O
AFL	Disease
).	O
However,	O
serious	O
adverse	O
effects,	O
including	O
torsade	Disease
de	Disease
pointes	Disease
(	O
Tdp	Disease
),	O
have	O
been	O
reported.	O
METHODS	O
AND	O
RESULTS:	O
Adverse	O
effects	O
of	O
Bpd	Chemical
requiring	O
discontinuation	O
of	O
treatment	O
were	O
evaluated.	O
Bpd	Chemical
was	O
administered	O
to	O
459	O
patients	O
(361	O
males,	O
63+/-12	O
years	O
old)	O
comprising	O
378	O
AF	Disease
and	O
81	O
AFL	Disease
cases.	O
Mean	O
left	O
ventricular	O
ejection	O
fraction	O
and	O
atrial	O
dimension	O
(LAD)	O
were	O
66+/-11%	O
and	O
40+/-6	O
mm,	O
respectively.	O
Adverse	O
effects	O
were	O
observed	O
in	O
19	O
patients	O
(4%)	O
during	O
an	O
average	O
follow-up	O
of	O
20	O
months.	O
There	O
was	O
marked	O
QT	Disease
prolongation	Disease
greater	O
than	O
0.55	O
s	O
in	O
13	O
patients,	O
bradycardia	Disease
less	O
than	O
40	O
beats/min	O
in	O
6	O
patients,	O
dizziness	Disease
and	O
general	O
fatigue	Disease
in	O
1	O
patient	O
each.	O
In	O
4	O
of	O
13	O
patients	O
with	O
QT	Disease
prolongation	Disease
,	O
Tdp	Disease
occurred.	O
The	O
major	O
triggering	O
factors	O
of	O
Tdp	Disease
were	O
hypokalemia	Disease
and	O
sudden	O
decrease	O
in	O
heart	O
rate.	O
There	O
were	O
no	O
differences	O
in	O
the	O
clinical	O
backgrounds	O
of	O
the	O
patients	O
with	O
and	O
without	O
Tdp	Disease
other	O
than	O
LAD	O
and	O
age,	O
which	O
were	O
larger	O
and	O
older	O
in	O
the	O
patients	O
with	O
Tdp	Disease
.	O
CONCLUSION:	O
Careful	O
observation	O
of	O
serum	O
potassium	Chemical
concentration	O
and	O
the	O
ECG	O
should	O
always	O
be	O
done	O
during	O
Bpd	Chemical

Enhanced	O
isoproterenol	Chemical
-induced	O
cardiac	Disease
hypertrophy	Disease
in	O
transgenic	O
rats	O
with	O
low	O
brain	O
angiotensinogen.	O
We	O
have	O
previously	O
shown	O
that	O
a	O
permanent	O
deficiency	O
in	O
the	O
brain	O
renin-	O
angiotensin	Chemical
system	O
(RAS)	O
may	O
increase	O
the	O
sensitivity	O
of	O
the	O
baroreflex	O
control	O
of	O
heart	O
rate.	O
In	O
this	O
study	O
we	O
aimed	O
at	O
studying	O
the	O
involvement	O
of	O
the	O
brain	O
RAS	O
in	O
the	O
cardiac	O
reactivity	O
to	O
the	O
beta-adrenoceptor	O
(beta-AR)	O
agonist	O
isoproterenol	Chemical
(	O
Iso	Chemical
).	O
Transgenic	O
rats	O
with	O
low	O
brain	O
angiotensinogen	O
(TGR)	O
were	O
used.	O
In	O
isolated	O
hearts,	O
Iso	Chemical
induced	O
a	O
significantly	O
greater	O
increase	O
in	O
left	O
ventricular	O
(LV)	O
pressure	O
and	O
maximal	O
contraction	O
(+dP/dt(max))	O
in	O
the	O
TGR	O
than	O
in	O
the	O
Sprague-Dawley	O
(SD)	O
rats.	O
LV	Disease
hypertrophy	Disease
induced	O
by	O
Iso	Chemical
treatment	O
was	O
significantly	O
higher	O
in	O
TGR	O
than	O
in	O
SD	O
rats	O
(in	O
g	O
LV	O
wt/100	O
g	O
body	O
wt,	O
0.28	O
+/-	O
0.004	O
vs.	O
0.24	O
+/-	O
0.004,	O
respectively).	O
The	O
greater	O
LV	Disease
hypertrophy	Disease
in	O
TGR	O
rats	O
was	O
associated	O
with	O
more	O
pronounced	O
downregulation	O
of	O
beta-AR	O
and	O
upregulation	O
of	O
LV	O
beta-AR	O
kinase-1	O
mRNA	O
levels	O
compared	O
with	O
those	O
in	O
SD	O
rats.	O
The	O
decrease	O
in	O
the	O
heart	O
rate	O
(HR)	O
induced	O
by	O
the	O
beta-AR	O
antagonist	O
metoprolol	Chemical
in	O
conscious	O
rats	O
was	O
significantly	O
attenuated	O
in	O
TGR	O
compared	O
with	O
SD	O
rats	O
(-9.9	O
+/-	O
1.7%	O
vs.	O
-18.1	O
+/-	O
1.5%),	O
whereas	O
the	O
effect	O
of	O
parasympathetic	O
blockade	O
by	O
atropine	Chemical
on	O
HR	O
was	O
similar	O
in	O
both	O
strains.	O
These	O
results	O
indicate	O
that	O
TGR	O
are	O
more	O
sensitive	O
to	O
beta-AR	O
agonist-induced	O
cardiac	Disease
inotropic	Disease
response	O
and	O
hypertrophy	Disease

Drug-induced	O
long	Disease
QT	Disease
syndrome	Disease
in	O
injection	O
drug	O
users	O
receiving	O
methadone	Chemical
:	O
high	O
frequency	O
in	O
hospitalized	O
patients	O
and	O
risk	O
factors.	O
BACKGROUND:	O
Drug-induced	O
long	Disease
QT	Disease
syndrome	Disease
is	O
a	O
serious	O
adverse	O
drug	O
reaction.	O
Methadone	Chemical
prolongs	O
the	O
QT	O
interval	O
in	O
vitro	O
in	O
a	O
dose-dependent	O
manner.	O
In	O
the	O
inpatient	O
setting,	O
the	O
frequency	O
of	O
QT	Disease
interval	Disease
prolongation	Disease
with	O
methadone	Chemical
treatment,	O
its	O
dose	O
dependence,	O
and	O
the	O
importance	O
of	O
cofactors	O
such	O
as	O
drug-drug	O
interactions	O
remain	O
unknown.	O
METHODS:	O
We	O
performed	O
a	O
systematic,	O
retrospective	O
study	O
comparing	O
active	O
or	O
former	O
intravenous	O
drug	O
users	O
receiving	O
methadone	Chemical
and	O
those	O
not	O
receiving	O
methadone	Chemical
among	O
all	O
patients	O
hospitalized	O
over	O
a	O
5-year	O
period	O
in	O
a	O
tertiary	O
care	O
hospital.	O
A	O
total	O
of	O
167	O
patients	O
receiving	O
methadone	Chemical
fulfilled	O
the	O
inclusion	O
criteria	O
and	O
were	O
compared	O
with	O
a	O
control	O
group	O
of	O
80	O
injection	O
drug	O
users	O
not	O
receiving	O
methadone	Chemical
.	O
In	O
addition	O
to	O
methadone	Chemical
dose,	O
15	O
demographic,	O
biological,	O
and	O
pharmacological	O
variables	O
were	O
considered	O
as	O
potential	O
risk	O
factors	O
for	O
QT	Disease
prolongation	Disease
.	O
RESULTS:	O
Among	O
167	O
methadone	Chemical
maintenance	O
patients,	O
the	O
prevalence	O
of	O
QTc	O
prolongation	O
to	O
0.50	O
second((1/2))	O
or	O
longer	O
was	O
16.2%	O
compared	O
with	O
0%	O
in	O
80	O
control	O
subjects.	O
Six	O
patients	O
(3.6%)	O
in	O
the	O
methadone	Chemical
group	O
presented	O
torsades	Disease
de	Disease
pointes	Disease
.	O
QTc	O
length	O
was	O
weakly	O
but	O
significantly	O
associated	O
with	O
methadone	Chemical
daily	O
dose	O
(Spearman	O
rank	O
correlation	O
coefficient,	O
0.20;	O
P<.01).	O
Multivariate	O
regression	O
analysis	O
allowed	O
attribution	O
of	O
31.8%	O
of	O
QTc	O
variability	O
to	O
methadone	Chemical
dose,	O
cytochrome	O
P-450	O
3A4	O
drug-drug	O
interactions,	O
hypokalemia	Disease
,	O
and	O
altered	O
liver	O
function.	O
CONCLUSIONS:	O
QT	Disease
interval	Disease
prolongation	Disease
in	O
methadone	Chemical
maintenance	O
patients	O
hospitalized	O
in	O
a	O
tertiary	O
care	O
center	O
is	O
a	O
frequent	O
finding.	O
Methadone	Chemical
dose,	O
presence	O
of	O
cytochrome	O
P-450	O
3A4	O
inhibitors,	O
potassium	Chemical
level,	O
and	O
liver	O
function	O
contribute	O
to	O
QT	Disease
prolongation	Disease
.	O
Long	Disease
QT	Disease
syndrome	Disease
can	O
occur	O
with	O
low	O
doses	O
of	O
methadone	Chemical

Mechanisms	O
of	O
hypertension	Disease
induced	O
by	O
nitric	Chemical
oxide	Chemical
(	O
NO	Chemical
)	O
deficiency:	O
focus	O
on	O
venous	O
function.	O
Loss	O
of	O
endothelial	O
cell-derived	O
nitric	Chemical
oxide	Chemical
(	O
NO	Chemical
)	O
in	O
hypertension	Disease
is	O
a	O
hallmark	O
of	O
arterial	Disease
dysfunction	Disease
.	O
Experimental	O
hypertension	Disease
created	O
by	O
the	O
removal	O
of	O
NO	Chemical
,	O
however,	O
involves	O
mechanisms	O
in	O
addition	O
to	O
decreased	O
arterial	O
vasodilator	O
activity.	O
These	O
include	O
augmented	O
endothelin-1	O
(ET-1)	O
release,	O
increased	O
sympathetic	O
nervous	O
system	O
activity,	O
and	O
elevated	O
tissue	O
oxidative	O
stress.	O
We	O
hypothesized	O
that	O
increased	O
venous	O
smooth	O
muscle	O
(venomotor)	O
tone	O
plays	O
a	O
role	O
in	O
Nomega-nitro-L-arginine	Chemical
(	O
LNNA	Chemical
)	O
hypertension	Disease
through	O
these	O
mechanisms.	O
Rats	O
were	O
treated	O
with	O
the	O
NO	Chemical
synthase	O
inhibitor	O
LNNA	Chemical
(0.5	O
g/L	O
in	O
drinking	O
water)	O
for	O
2	O
weeks.	O
Mean	O
arterial	O
pressure	O
of	O
conscious	O
rats	O
was	O
119	O
+/-	O
2	O
mm	O
Hg	O
in	O
control	O
and	O
194	O
+/-	O
5	O
mm	O
Hg	O
in	O
LNNA	Chemical
rats	O
(P<0.05).	O
Carotid	O
arteries	O
and	O
vena	O
cava	O
were	O
removed	O
for	O
measurement	O
of	O
isometric	O
contraction.	O
Maximal	O
contraction	O
to	O
norepinephrine	Chemical
was	O
modestly	O
reduced	O
in	O
arteries	O
from	O
LNNA	Chemical
compared	O
with	O
control	O
rats	O
whereas	O
the	O
maximum	O
contraction	O
to	O
ET-1	O
was	O
significantly	O
reduced	O
(54%	O
control).	O
Maximum	O
contraction	O
of	O
vena	O
cava	O
to	O
norepinephrine	Chemical
(37%	O
control)	O
also	O
was	O
reduced	O
but	O
no	O
change	O
in	O
response	O
to	O
ET-1	O
was	O
observed.	O
Mean	O
circulatory	O
filling	O
pressure,	O
an	O
in	O
vivo	O
measure	O
of	O
venomotor	O
tone,	O
was	O
not	O
elevated	O
in	O
LNNA	Chemical
	O
hypertension	Disease
at	O
1	O
or	O
2	O
weeks	O
after	O
LNNA	Chemical
.	O
The	O
superoxide	Chemical
scavenger	O
tempol	Chemical
(30,	O
100,	O
and	O
300	O
micromol	O
kg(-1),	O
IV)	O
did	O
not	O
change	O
arterial	O
pressure	O
in	O
control	O
rats	O
but	O
caused	O
a	O
dose-dependent	O
decrease	O
in	O
LNNA	Chemical
rats	O
(-18	O
+/-	O
8,	O
-26	O
+/-	O
15,	O
and	O
-54	O
+/-	O
11	O
mm	O
Hg).	O
Similarly,	O
ganglionic	O
blockade	O
with	O
hexamethonium	Chemical
caused	O
a	O
significantly	O
greater	O
fall	O
in	O
LNNA	Chemical
	O
hypertensive	Disease
rats	O
(76	O
+/-	O
9	O
mm	O
Hg)	O
compared	O
with	O
control	O
rats	O
(35	O
+/-	O
10	O
mm	O
Hg).	O
Carotid	O
arteries,	O
vena	O
cava,	O
and	O
sympathetic	O
ganglia	O
from	O
LNNA	Chemical
rats	O
had	O
higher	O
basal	O
levels	O
of	O
superoxide	Chemical
compared	O
with	O
those	O
from	O
control	O
rats.	O
These	O
data	O
suggest	O
that	O
while	O
NO	Chemical
deficiency	O
increases	O
oxidative	O
stress	O
and	O
sympathetic	O
activity	O
in	O
both	O
arterial	O
and	O
venous	O
vessels,	O
the	O
impact	O
on	O
veins	O
does	O
not	O
make	O
a	O
major	O
contribution	O
to	O
this	O
form	O
of	O
hypertension	Disease

Association	O
of	O
DRD2	O
polymorphisms	O
and	O
chlorpromazine	Chemical
-induced	O
extrapyramidal	Disease
syndrome	Disease
in	O
Chinese	O
schizophrenic	Disease
patients.	O
AIM:	O
Extrapyramidal	Disease
syndrome	Disease
(	O
EPS	Disease
)	O
is	O
most	O
commonly	O
affected	O
by	O
typical	O
antipsychotic	O
drugs	O
that	O
have	O
a	O
high	O
affinity	O
with	O
the	O
D2	O
receptor.	O
Recently,	O
many	O
research	O
groups	O
have	O
reported	O
on	O
the	O
positive	O
relationship	O
between	O
the	O
genetic	O
variations	O
in	O
the	O
DRD2	O
gene	O
and	O
the	O
therapeutic	O
response	O
in	O
schizophrenia	Disease
patients	O
as	O
a	O
result	O
of	O
the	O
role	O
of	O
variations	O
in	O
the	O
receptor	O
in	O
modulating	O
receptor	O
expression.	O
In	O
this	O
study,	O
we	O
evaluate	O
the	O
role	O
DRD2	O
plays	O
in	O
chlorpromazine	Chemical
-induced	O
EPS	Disease
in	O
schizophrenic	Disease
patients.	O
METHODS:	O
We	O
identified	O
seven	O
SNP(single	O
nucleotide	O
polymorphism)	O
(-141Cins>del,	O
TaqIB,	O
TaqID,	O
Ser311Cys,	O
rs6275,	O
rs6277	O
and	O
TaqIA)	O
in	O
the	O
DRD2	O
gene	O
in	O
146	O
schizophrenic	Disease
inpatients	O
(59	O
with	O
EPS	Disease
and	O
87	O
without	O
EPS	Disease
according	O
to	O
the	O
Simpson-Angus	O
Scale)	O
treated	O
with	O
chlorpromazine	Chemical
after	O
8	O
weeks.	O
The	O
alleles	O
of	O
all	O
loci	O
were	O
determined	O
by	O
PCR	O
(polymerase	O
chain	O
reaction).	O
RESULTS:	O
Polymorphisms	O
TaqID,	O
Ser311Cys	O
and	O
rs6277	O
were	O
not	O
polymorphic	O
in	O
the	O
population	O
recruited	O
in	O
the	O
present	O
study.	O
No	O
statistical	O
significance	O
was	O
found	O
in	O
the	O
allele	O
distribution	O
of	O
-141Cins>del,	O
TaqIB,	O
rs6275	O
and	O
TaqIA	O
or	O
in	O
the	O
estimated	O
haplotypes	O
(constituted	O
by	O
TaqIB,	O
rs6275	O
and	O
TaqIA)	O
in	O
linkage	O
disequilibrium	O
between	O
the	O
two	O
groups.	O
CONCLUSION:	O
Our	O
results	O
did	O
not	O
lend	O
strong	O
support	O
to	O
the	O
view	O
that	O
the	O
genetic	O
variation	O
of	O
the	O
DRD2	O
gene	O
plays	O
a	O
major	O
role	O
in	O
the	O
individually	O
variable	O
adverse	O
effect	O
induced	O
by	O
chlorpromazine	Chemical
,	O
at	O
least	O
in	O
Chinese	O
patients	O
with	O
schizophrenia	Disease
.	O
Our	O
results	O
confirmed	O
a	O
previous	O
study	O
on	O
the	O
relationship	O
between	O
DRD2	O
and	O
EPS	Disease

Physical	O
training	O
decreases	O
susceptibility	O
to	O
subsequent	O
pilocarpine	Chemical
-induced	O
seizures	Disease
in	O
the	O
rat.	O
Regular	O
motor	O
activity	O
has	O
many	O
benefits	O
for	O
mental	O
and	O
physical	O
condition	O
but	O
its	O
implications	O
for	O
epilepsy	Disease
are	O
still	O
controversial.	O
In	O
order	O
to	O
elucidate	O
this	O
problem,	O
we	O
have	O
studied	O
the	O
effect	O
of	O
long-term	O
physical	O
activity	O
on	O
susceptibility	O
to	O
subsequent	O
seizures	Disease
.	O
Male	O
Wistar	O
rats	O
were	O
subjected	O
to	O
repeated	O
training	O
sessions	O
in	O
a	O
treadmill	O
and	O
swimming	O
pool.	O
Thereafter,	O
seizures	Disease
were	O
induced	O
by	O
pilocarpine	Chemical
injections	O
in	O
trained	O
and	O
non-trained	O
control	O
groups.	O
During	O
the	O
acute	O
period	O
of	O
status	Disease
epilepticus	Disease
,	O
we	O
measured:	O
(1)	O
the	O
latency	O
of	O
the	O
first	O
motor	O
sign,	O
(2)	O
the	O
intensity	O
of	O
seizures	Disease
,	O
(3)	O
the	O
time	O
when	O
it	O
occurred	O
within	O
the	O
6-h	O
observation	O
period,	O
and	O
(4)	O
the	O
time	O
when	O
the	O
acute	O
period	O
ended.	O
All	O
these	O
behavioral	O
parameters	O
showed	O
statistically	O
significant	O
changes	O
suggesting	O
that	O
regular	O
physical	O
exercises	O
decrease	O
susceptibility	O
to	O
subsequently	O
induced	O
seizures	Disease
and	O
ameliorate	O
the	O
course	O
of	O
experimentally	O
induced	O
status	Disease
epilepticus	Disease

Tonic	O
dopaminergic	O
stimulation	O
impairs	Disease
associative	Disease
learning	Disease
in	O
healthy	O
subjects.	O
Endogenous	O
dopamine	Chemical
plays	O
a	O
central	O
role	O
in	O
salience	O
coding	O
during	O
associative	O
learning.	O
Administration	O
of	O
the	O
dopamine	Chemical
precursor	O
levodopa	Chemical
enhances	O
learning	O
in	O
healthy	O
subjects	O
and	O
stroke	Disease
patients.	O
Because	O
levodopa	Chemical
increases	O
both	O
phasic	O
and	O
tonic	O
dopaminergic	O
neurotransmission,	O
the	O
critical	O
mechanism	O
mediating	O
the	O
enhancement	O
of	O
learning	O
is	O
unresolved.	O
We	O
here	O
probed	O
how	O
selective	O
tonic	O
dopaminergic	O
stimulation	O
affects	O
associative	O
learning.	O
Forty	O
healthy	O
subjects	O
were	O
trained	O
in	O
a	O
novel	O
vocabulary	O
of	O
45	O
concrete	O
nouns	O
over	O
the	O
course	O
of	O
5	O
consecutive	O
training	O
days	O
in	O
a	O
prospective,	O
randomized,	O
double-blind,	O
placebo-controlled	O
design.	O
Subjects	O
received	O
the	O
tonically	O
stimulating	O
dopamine	Chemical
-receptor	O
agonist	O
pergolide	Chemical
(0.1	O
mg)	O
vs	O
placebo	O
120	O
min	O
before	O
training	O
on	O
each	O
training	O
day.	O
The	O
dopamine	Chemical
agonist	O
significantly	O
impaired	Disease
novel	Disease
word	Disease
learning	Disease
compared	O
to	O
placebo.	O
This	O
learning	O
decrement	O
persisted	O
up	O
to	O
the	O
last	O
follow-up	O
4	O
weeks	O
post-training.	O
Subjects	O
treated	O
with	O
pergolide	Chemical
also	O
showed	O
restricted	O
emotional	O
responses	O
compared	O
to	O
the	O
PLACEBO	O
group.	O
The	O
extent	O
of	O
'flattened'	O
affect	O
with	O
pergolide	Chemical
was	O
related	O
to	O
the	O
degree	O
of	O
learning	O
inhibition.	O
These	O
findings	O
suggest	O
that	O
tonic	O
occupation	O
of	O
dopamine	Chemical
receptors	O
impairs	O
learning	O
by	O
competition	O
with	O
phasic	O
dopamine	Chemical
signals.	O
Thus,	O
phasic	O
signaling	O
seems	O
to	O
be	O
the	O
critical	O
mechanism	O
by	O
which	O
dopamine	Chemical
enhances	O
associative	O
learning	O
in	O
healthy	O
subjects	O
and	O
stroke	Disease

Minocycline	Chemical
-induced	O
vasculitis	Disease
fulfilling	O
the	O
criteria	O
of	O
polyarteritis	Disease
nodosa	Disease
.	O
A	O
47-year-old	O
man	O
who	O
had	O
been	O
taking	O
minocycline	Chemical
for	O
palmoplantar	Disease
pustulosis	Disease
developed	O
fever	Disease
,	O
myalgias	Disease
,	O
polyneuropathy	Disease
,	O
and	O
testicular	Disease
pain	Disease
,	O
with	O
elevated	O
C-reactive	O
protein	O
(CRP).	O
Neither	O
myeloperoxidase-	O
nor	O
proteinase-3-antineutrophil	O
cytoplasmic	O
antibody	O
was	O
positive.	O
These	O
manifestations	O
met	O
the	O
American	O
College	O
of	O
Rheumatology	O
1990	O
criteria	O
for	O
the	O
classification	O
of	O
polyarteritis	Disease
nodosa	Disease
.	O
Stopping	O
minocycline	Chemical
led	O
to	O
amelioration	O
of	O
symptoms	O
and	O
normalization	O
of	O
CRP	O
level.	O
To	O
our	O
knowledge,	O
this	O
is	O
the	O
second	O
case	O
of	O
minocycline	Chemical
-induced	O
vasculitis	Disease
satisfying	O
the	O
criteria.	O
Differential	O
diagnosis	O
for	O
drug-induced	O
disease	O
is	O
invaluable	O
even	O
for	O
patients	O
with	O
classical	O
polyarteritis	Disease
nodosa	Disease

Intramuscular	O
hepatitis	Disease
B	Disease
immune	O
globulin	O
combined	O
with	O
lamivudine	Chemical
in	O
prevention	O
of	O
hepatitis	Disease
B	Disease
recurrence	O
after	O
liver	O
transplantation.	O
BACKGROUND:	O
Combined	O
hepatitis	Disease
B	Disease
immune	O
globulin	O
(HBIg)	O
and	O
lamivudine	Chemical
in	O
prophylaxis	O
of	O
the	O
recurrence	O
of	O
hepatitis	Disease
B	Disease
after	O
liver	O
transplantation	O
has	O
significantly	O
improved	O
the	O
survival	O
of	O
HBsAg	Chemical
positive	O
patients.	O
This	O
study	O
was	O
undertaken	O
to	O
evaluate	O
the	O
outcomes	O
of	O
liver	O
transplantation	O
for	O
patients	O
with	O
hepatitis	Disease
B	Disease
virus	O
(HBV).	O
METHODS:	O
A	O
retrospective	O
chart	O
analysis	O
and	O
a	O
review	O
of	O
the	O
organ	O
transplant	O
database	O
identified	O
51	O
patients	O
(43	O
men	O
and	O
8	O
women)	O
transplanted	O
for	O
benign	O
HBV-related	O
cirrhotic	Disease
diseases	Disease
between	O
June	O
2002	O
and	O
December	O
2004	O
who	O
had	O
survived	O
more	O
than	O
3	O
months.	O
HBIg	O
was	O
administered	O
intravenously	O
during	O
the	O
first	O
week	O
and	O
intramuscularly	O
thereafter.	O
RESULTS:	O
At	O
a	O
median	O
follow-up	O
of	O
14.1	O
months,	O
the	O
overall	O
recurrence	O
rate	O
in	O
the	O
51	O
patients	O
was	O
3.9%	O
(2/51).	O
The	O
overall	O
patient	O
survival	O
was	O
88.3%,	O
and	O
82.4%	O
after	O
1	O
and	O
2	O
years,	O
respectively.	O
A	O
daily	O
oral	O
dose	O
of	O
100	O
mg	O
lamivudine	Chemical
for	O
2	O
weeks	O
before	O
transplantation	O
for	O
10	O
patients	O
enabled	O
57.1%	O
(4/7)	O
and	O
62.5%	O
(5/8)	O
of	O
HBV-DNA	O
and	O
HBeAg	Chemical
positive	O
patients	O
respectively	O
to	O
convert	O
to	O
be	O
negative.	O
Intramuscular	O
HBIg	O
was	O
well	O
tolerated	O
in	O
all	O
patients.	O
CONCLUSION:	O
Lamivudine	Chemical

Anticonvulsant	O
effect	O
of	O
eslicarbazepine	Chemical
acetate	Chemical
(	O
BIA	Chemical
2-093	Chemical
)	O
on	O
seizures	Disease
induced	O
by	O
microperfusion	O
of	O
picrotoxin	Chemical
in	O
the	O
hippocampus	O
of	O
freely	O
moving	O
rats.	O
Eslicarbazepine	Chemical
acetate	Chemical
(	O
BIA	Chemical
2-093	Chemical
,	O
S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide	Chemical
)	O
is	O
a	O
novel	O
antiepileptic	O
drug,	O
now	O
in	O
Phase	O
III	O
clinical	O
trials,	O
designed	O
with	O
the	O
aim	O
of	O
improving	O
efficacy	O
and	O
safety	O
in	O
comparison	O
with	O
the	O
structurally	O
related	O
drugs	O
carbamazepine	Chemical
(	O
CBZ	Chemical
)	O
and	O
oxcarbazepine	Chemical
(	O
OXC	Chemical
).	O
We	O
have	O
studied	O
the	O
effects	O
of	O
oral	O
treatment	O
with	O
eslicarbazepine	Chemical
acetate	Chemical
on	O
a	O
whole-animal	O
model	O
in	O
which	O
partial	O
seizures	Disease
can	O
be	O
elicited	O
repeatedly	O
on	O
different	O
days	O
without	O
changes	O
in	O
threshold	O
or	O
seizure	Disease
patterns.	O
In	O
the	O
animals	O
treated	O
with	O
threshold	O
doses	O
of	O
picrotoxin	Chemical
,	O
the	O
average	O
number	O
of	O
seizures	Disease
was	O
2.3+/-1.2,	O
and	O
average	O
seizure	Disease
duration	O
was	O
39.5+/-8.4s.	O
Pre-treatment	O
with	O
a	O
dose	O
of	O
30	O
mg/kg	O
2h	O
before	O
picrotoxin	Chemical
microperfusion	O
prevented	O
seizures	Disease
in	O
the	O
75%	O
of	O
the	O
rats.	O
Lower	O
doses	O
(3	O
and	O
10mg/kg)	O
did	O
not	O
suppress	O
seizures	Disease
,	O
however,	O
after	O
administration	O
of	O
10mg/kg,	O
significant	O
reductions	O
in	O
seizures	Disease
duration	O
(24.3+/-6.8s)	O
and	O
seizure	Disease
number	O
(1.6+/-0.34)	O
were	O
found.	O
No	O
adverse	O
effects	O
of	O
eslicarbazepine	Chemical
acetate	Chemical

Acute	Disease
renal	Disease
failure	Disease
associated	O
with	O
prolonged	O
intake	O
of	O
slimming	O
pills	O
containing	O
anthraquinones	Chemical
.	O
Chinese	Chemical
herbal	Chemical
medicine	O
preparations	O
are	O
widely	O
available	O
and	O
often	O
regarded	O
by	O
the	O
public	O
as	O
natural	O
and	O
safe	O
remedies	O
for	O
a	O
variety	O
of	O
medical	O
conditions.	O
Nephropathy	Disease
caused	O
by	O
Chinese	Chemical
herbs	Chemical
has	O
previously	O
been	O
reported,	O
usually	O
involving	O
the	O
use	O
of	O
aristolochic	Chemical
acids	Chemical
.	O
We	O
report	O
a	O
23-year-old	O
woman	O
who	O
developed	O
acute	Disease
renal	Disease
failure	Disease
following	O
prolonged	O
use	O
of	O
a	O
proprietary	O
Chinese	Chemical
herbal	Chemical
slimming	O
pill	O
that	O
contained	O
anthraquinone	Chemical
derivatives,	O
extracted	O
from	O
Rhizoma	O
Rhei	O
(rhubarb).	O
The	O
renal	Disease
injury	Disease
was	O
probably	O
aggravated	O
by	O
the	O
concomitant	O
intake	O
of	O
a	O
non-steroidal	O
anti-inflammatory	O
drug,	O
diclofenac	Chemical
.	O
Renal	O
pathology	O
was	O
that	O
of	O
hypocellular	O
interstitial	O
fibrosis	Disease
.	O
Spontaneous	O
renal	O
recovery	O
occurred	O
upon	O
cessation	O
of	O
the	O
slimming	O
pills,	O
but	O
mild	O
interstitial	O
fibrosis	Disease
and	O
tubular	O
atrophy	Disease
was	O
still	O
evident	O
histologically	O
4	O
months	O
later.	O
Although	O
a	O
causal	O
relationship	O
between	O
the	O
use	O
of	O
an	O
anthraquinone	Chemical
-containing	O
herbal	O
agent	O
and	O
renal	Disease
injury	Disease
remains	O
to	O
be	O
proven,	O
phytotherapy-associated	O
interstitial	O
nephropathy	Disease
should	O
be	O
considered	O
in	O
patients	O
who	O
present	O
with	O
unexplained	O
renal	Disease
failure	Disease

Chloroacetaldehyde	Chemical
as	O
a	O
sulfhydryl	Chemical
reagent:	O
the	O
role	O
of	O
critical	O
thiol	Chemical
groups	O
in	O
ifosfamide	Chemical
	O
nephropathy	Disease
.	O
Chloroacetaldehyde	Chemical
(	O
CAA	Chemical
)	O
is	O
a	O
metabolite	O
of	O
the	O
alkylating	O
agent	O
ifosfamide	Chemical
(	O
IFO	Chemical
)	O
and	O
putatively	O
responsible	O
for	O
renal	Disease
damage	Disease
following	O
anti-	O
tumor	Disease
therapy	O
with	O
IFO	Chemical
.	O
Depletion	O
of	O
sulfhydryl	Chemical
(	O
SH	Chemical
)	O
groups	O
has	O
been	O
reported	O
from	O
cell	O
culture,	O
animal	O
and	O
clinical	O
studies.	O
In	O
this	O
work	O
the	O
effect	O
of	O
CAA	Chemical
on	O
human	O
proximal	O
tubule	O
cells	O
in	O
primary	O
culture	O
(hRPTEC)	O
was	O
investigated.	O
Toxicity	Disease
of	O
CAA	Chemical
was	O
determined	O
by	O
protein	O
content,	O
cell	O
number,	O
LDH	O
release,	O
trypan	Chemical
blue	Chemical
exclusion	O
assay	O
and	O
caspase-3	O
activity.	O
Free	O
thiols	Chemical
were	O
measured	O
by	O
the	O
method	O
of	O
Ellman.	O
CAA	Chemical
reduced	O
hRPTEC	O
cell	O
number	O
and	O
protein,	O
induced	O
a	O
loss	O
in	O
free	O
intracellular	O
thiols	Chemical
and	O
an	O
increase	O
in	O
necrosis	Disease
markers.	O
CAA	Chemical
but	O
not	O
acrolein	Chemical
inhibited	O
the	O
cysteine	Chemical
proteases	O
caspase-3,	O
caspase-8	O
and	O
cathepsin	O
B.	O
Caspase	O
activation	O
by	O
cisplatin	Chemical
was	O
inhibited	O
by	O
CAA	Chemical
.	O
In	O
cells	O
stained	O
with	O
fluorescent	O
dyes	O
targeting	O
lysosomes,	O
CAA	Chemical
induced	O
an	O
increase	O
in	O
lysosomal	O
size	O
and	O
lysosomal	O
leakage.	O
The	O
effects	O
of	O
CAA	Chemical
on	O
cysteine	Chemical
protease	O
activities	O
and	O
thiols	Chemical
could	O
be	O
reproduced	O
in	O
cell	O
lysate.	O
Acidification,	O
which	O
slowed	O
the	O
reaction	O
of	O
CAA	Chemical
with	O
thiol	Chemical
donors,	O
could	O
also	O
attenuate	O
effects	O
of	O
CAA	Chemical
on	O
necrosis	Disease
markers,	O
thiol	Chemical
depletion	O
and	O
cysteine	Chemical
protease	O
inhibition	O
in	O
living	O
cells.	O
Thus,	O
CAA	Chemical
directly	O
reacts	O
with	O
cellular	O
protein	O
and	O
non-protein	O
thiols	Chemical
,	O
mediating	O
its	O
toxicity	Disease
on	O
hRPTEC.	O
This	O
effect	O
can	O
be	O
reduced	O
by	O
acidification.	O
Therefore,	O
urinary	O
acidification	O
could	O
be	O
an	O
option	O
to	O
prevent	O
IFO	Chemical
	O
nephropathy	Disease

Stereological	O
methods	O
reveal	O
the	O
robust	O
size	O
and	O
stability	O
of	O
ectopic	O
hilar	O
granule	O
cells	O
after	O
pilocarpine	Chemical
-induced	O
status	Disease
epilepticus	Disease
in	O
the	O
adult	O
rat.	O
Following	O
status	Disease
epilepticus	Disease
in	O
the	O
rat,	O
dentate	O
granule	O
cell	O
neurogenesis	O
increases	O
greatly,	O
and	O
many	O
of	O
the	O
new	O
neurons	O
appear	O
to	O
develop	O
ectopically,	O
in	O
the	O
hilar	O
region	O
of	O
the	O
hippocampal	O
formation.	O
It	O
has	O
been	O
suggested	O
that	O
the	O
ectopic	O
hilar	O
granule	O
cells	O
could	O
contribute	O
to	O
the	O
spontaneous	O
seizures	Disease
that	O
ultimately	O
develop	O
after	O
status	Disease
epilepticus	Disease
.	O
However,	O
the	O
population	O
has	O
never	O
been	O
quantified,	O
so	O
it	O
is	O
unclear	O
whether	O
it	O
is	O
substantial	O
enough	O
to	O
have	O
a	O
strong	O
influence	O
on	O
epileptogenesis.	O
To	O
quantify	O
this	O
population,	O
the	O
total	O
number	O
of	O
ectopic	O
hilar	O
granule	O
cells	O
was	O
estimated	O
using	O
unbiased	O
stereology	O
at	O
different	O
times	O
after	O
pilocarpine	Chemical
-induced	O
status	Disease
epilepticus	Disease
.	O
The	O
number	O
of	O
hilar	O
neurons	O
immunoreactive	O
for	O
Prox-1,	O
a	O
granule-cell-specific	O
marker,	O
was	O
estimated	O
using	O
the	O
optical	O
fractionator	O
method.	O
The	O
results	O
indicate	O
that	O
the	O
size	O
of	O
the	O
hilar	O
ectopic	O
granule	O
cell	O
population	O
after	O
status	Disease
epilepticus	Disease
is	O
substantial,	O
and	O
stable	O
over	O
time.	O
Interestingly,	O
the	O
size	O
of	O
the	O
population	O
appears	O
to	O
be	O
correlated	O
with	O
the	O
frequency	O
of	O
behavioral	O
seizures	Disease
,	O
because	O
animals	O
with	O
more	O
ectopic	O
granule	O
cells	O
in	O
the	O
hilus	O
have	O
more	O
frequent	O
behavioral	O
seizures	Disease
.	O
The	O
hilar	O
ectopic	O
granule	O
cell	O
population	O
does	O
not	O
appear	O
to	O
vary	O
systematically	O
across	O
the	O
septotemporal	O
axis,	O
although	O
it	O
is	O
associated	O
with	O
an	O
increase	O
in	O
volume	O
of	O
the	O
hilus.	O
The	O
results	O
provide	O
new	O
insight	O
into	O
the	O
potential	O
role	O
of	O
ectopic	O
hilar	O
granule	O
cells	O
in	O
the	O
pilocarpine	Chemical
model	O
of	O
temporal	Disease
lobe	Disease
epilepsy	Disease

A	O
prospective,	O
open-label	O
trial	O
of	O
galantamine	Chemical
in	O
autistic	Disease
disorder	Disease
.	O
OBJECTIVE:	O
Post-mortem	O
studies	O
have	O
reported	O
abnormalities	O
of	O
the	O
cholinergic	O
system	O
in	O
autism	Disease
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
use	O
of	O
galantamine	Chemical
,	O
an	O
acetylcholinesterase	O
inhibitor	O
and	O
nicotinic	O
receptor	O
modulator,	O
in	O
the	O
treatment	O
of	O
interfering	O
behaviors	O
in	O
children	O
with	O
autism	Disease
.	O
METHODS:	O
Thirteen	O
medication-free	O
children	O
with	O
autism	Disease
(mean	O
age,	O
8.8	O
+/-	O
3.5	O
years)	O
participated	O
in	O
a	O
12-week,	O
open-label	O
trial	O
of	O
galantamine	Chemical
.	O
Patients	O
were	O
rated	O
monthly	O
by	O
parents	O
on	O
the	O
Aberrant	O
Behavior	O
Checklist	O
(ABC)	O
and	O
the	O
Conners'	O
Parent	O
Rating	O
Scale-Revised,	O
and	O
by	O
a	O
physician	O
using	O
the	O
Children's	O
Psychiatric	O
Rating	O
Scale	O
and	O
the	O
Clinical	O
Global	O
Impressions	O
scale.	O
RESULTS:	O
Patients	O
showed	O
a	O
significant	O
reduction	O
in	O
parent-rated	O
irritability	Disease
and	O
social	O
withdrawal	O
on	O
the	O
ABC	O
as	O
well	O
as	O
significant	O
improvements	O
in	O
emotional	O
lability	O
and	O
inattention	O
on	O
the	O
Conners'	O
Parent	O
Rating	O
Scale--Revised.	O
Similarly,	O
clinician	O
ratings	O
showed	O
reductions	O
in	O
the	O
anger	O
subscale	O
of	O
the	O
Children's	O
Psychiatric	O
Rating	O
Scale.	O
Eight	O
of	O
13	O
participants	O
were	O
rated	O
as	O
responders	O
on	O
the	O
basis	O
of	O
their	O
improvement	O
scores	O
on	O
the	O
Clinical	O
Global	O
Impressions	O
scale.	O
Overall,	O
galantamine	Chemical
was	O
well-tolerated,	O
with	O
no	O
significant	O
adverse	O
effects	O
apart	O
from	O
headaches	Disease
in	O
one	O
patient.	O
CONCLUSION:	O
In	O
this	O
open	O
trial,	O
galantamine	Chemical
was	O
well-tolerated	O
and	O
appeared	O
to	O
be	O
beneficial	O
for	O
the	O
treatment	O
of	O
interfering	O
behaviors	O
in	O
children	O
with	O
autism	Disease
,	O
particularly	O
aggression	Disease
,	O
behavioral	Disease
dyscontrol	Disease
,	O
and	O
inattention	Disease

Randomized	O
comparison	O
of	O
olanzapine	Chemical
versus	O
risperidone	Chemical
for	O
the	O
treatment	O
of	O
first-episode	O
schizophrenia	Disease
:	O
4-month	O
outcomes.	O
OBJECTIVE:	O
The	O
authors	O
compared	O
4-month	O
treatment	O
outcomes	O
for	O
olanzapine	Chemical
versus	O
risperidone	Chemical
in	O
patients	O
with	O
first-episode	O
schizophrenia	Disease
spectrum	O
disorders.	O
METHOD:	O
One	O
hundred	O
twelve	O
subjects	O
(70%	O
male;	O
mean	O
age=23.3	O
years	O
[SD	O
=	O
5.1])	O
with	O
first-episode	O
schizophrenia	Disease
(75%),	O
schizophreniform	Disease
disorder	Disease
(17%),	O
or	O
schizoaffective	Disease
disorder	Disease
(8%)	O
were	O
randomly	O
assigned	O
to	O
treatment	O
with	O
olanzapine	Chemical
(2.5-20	O
mg/day)	O
or	O
risperidone	Chemical
(1-6	O
mg/day).	O
RESULTS:	O
Response	O
rates	O
did	O
not	O
significantly	O
differ	O
between	O
olanzapine	Chemical
(43.7%,	O
95%	O
CI=28.8%-58.6%)	O
and	O
risperidone	Chemical
(54.3%,	O
95%	O
CI=39.9%-68.7%).	O
Among	O
those	O
responding	O
to	O
treatment,	O
more	O
subjects	O
in	O
the	O
olanzapine	Chemical
group	O
(40.9%,	O
95%	O
CI=16.8%-65.0%)	O
than	O
in	O
the	O
risperidone	Chemical
group	O
(18.9%,	O
95%	O
CI=0%-39.2%)	O
had	O
subsequent	O
ratings	O
not	O
meeting	O
response	O
criteria.	O
Negative	O
symptom	O
outcomes	O
and	O
measures	O
of	O
parkinsonism	Disease
and	O
akathisia	Disease
did	O
not	O
differ	O
between	O
medications.	O
Extrapyramidal	Disease
symptom	Disease
severity	O
scores	O
were	O
1.4	O
(95%	O
CI=1.2-1.6)	O
with	O
risperidone	Chemical
and	O
1.2	O
(95%	O
CI=1.0-1.4)	O
with	O
olanzapine	Chemical
.	O
Significantly	O
more	O
weight	Disease
gain	Disease
occurred	O
with	O
olanzapine	Chemical
than	O
with	O
risperidone	Chemical
:	O
the	O
increase	O
in	O
weight	O
at	O
4	O
months	O
relative	O
to	O
baseline	O
weight	O
was	O
17.3%	O
(95%	O
CI=14.2%-20.5%)	O
with	O
olanzapine	Chemical
and	O
11.3%	O
(95%	O
CI=8.4%-14.3%)	O
with	O
risperidone	Chemical
.	O
Body	O
mass	O
index	O
at	O
baseline	O
and	O
at	O
4	O
months	O
was	O
24.3	O
(95%	O
CI=22.8-25.7)	O
versus	O
28.2	O
(95%	O
CI=26.7-29.7)	O
with	O
olanzapine	Chemical
and	O
23.9	O
(95%	O
CI=22.5-25.3)	O
versus	O
26.7	O
(95%	O
CI=25.2-28.2)	O
with	O
risperidone	Chemical
.	O
CONCLUSIONS:	O
Clinical	O
outcomes	O
with	O
risperidone	Chemical
were	O
equal	O
to	O
those	O
with	O
olanzapine	Chemical
,	O
and	O
response	O
may	O
be	O
more	O
stable.	O
Olanzapine	Chemical
may	O
have	O
an	O
advantage	O
for	O
motor	O
side	O
effects.	O
Both	O
medications	O
caused	O
substantial	O
rapid	O
weight	Disease
gain	Disease
,	O
but	O
weight	Disease
gain	Disease
was	O
greater	O
with	O
olanzapine	Chemical

Early	O
paracentral	O
visual	Disease
field	Disease
loss	Disease
in	O
patients	O
taking	O
hydroxychloroquine	Chemical
.	O
OBJECTIVE:	O
To	O
review	O
the	O
natural	O
history	O
and	O
ocular	O
and	O
systemic	O
adverse	O
effects	O
of	O
patients	O
taking	O
hydroxychloroquine	Chemical
sulfate	Chemical
who	O
attended	O
an	O
ophthalmic	O
screening	O
program.	O
DESIGN:	O
Retrospective	O
study.	O
RESULTS:	O
Records	O
of	O
262	O
patients	O
who	O
were	O
taking	O
hydroxychloroquine	Chemical
and	O
screened	O
in	O
the	O
Department	O
of	O
Ophthalmology	O
were	O
reviewed.	O
Of	O
the	O
262	O
patients,	O
14	O
(18%)	O
of	O
76	O
who	O
had	O
stopped	O
treatment	O
at	O
the	O
time	O
of	O
the	O
study	O
experienced	O
documented	O
adverse	O
effects.	O
Systemic	O
adverse	O
effects	O
occurred	O
in	O
8	O
patients	O
(10.5%)	O
and	O
ocular	O
adverse	O
effects,	O
in	O
5	O
(6.5%).	O
Thirty-five	O
patients	O
(13.4%)	O
had	O
visual	Disease
field	Disease
abnormalities	Disease
,	O
which	O
were	O
attributed	O
to	O
hydroxychloroquine	Chemical
treatment	O
in	O
4	O
patients	O
(1.5%).	O
Three	O
of	O
the	O
4	O
patients	O
were	O
taking	O
less	O
than	O
6.5	O
mg/kg	O
per	O
day	O
and	O
all	O
patients	O
had	O
normal	O
renal	O
and	O
liver	O
function	O
test	O
results.	O
CONCLUSIONS:	O
The	O
current	O
study	O
used	O
a	O
protocol	O
of	O
visual	O
acuity	O
and	O
color	O
vision	O
assessment,	O
funduscopy,	O
and	O
Humphrey	O
10-2	O
visual	O
field	O
testing	O
and	O
shows	O
that	O
visual	Disease
field	Disease
defects	Disease
appeared	O
before	O
any	O
corresponding	O
changes	O
in	O
any	O
other	O
tested	O
clinical	O
parameters;	O
the	O
defects	O
were	O
reproducible	O
and	O
the	O
test	O
parameters	O
were	O
reliable.	O
Patients	O
taking	O
hydroxychloroquine	Chemical

Peri-operative	O
atrioventricular	Disease
block	Disease
as	O
a	O
result	O
of	O
chemotherapy	O
with	O
epirubicin	Chemical
and	O
paclitaxel	Chemical
.	O
A	O
47-year-old	O
woman	O
presented	O
for	O
mastectomy	O
and	O
immediate	O
latissimus	O
dorsi	O
flap	O
reconstruction	O
having	O
been	O
diagnosed	O
with	O
carcinoma	Disease
of	Disease
the	Disease
breast	Disease
6	O
months	O
previously.	O
In	O
the	O
preceding	O
months	O
she	O
had	O
received	O
neo-adjuvant	O
chemotherapy	O
with	O
epirubicin	Chemical
,	O
paclitaxel	Chemical
(	O
Taxol	Chemical
)	O
and	O
cyclophosphamide	Chemical
.	O
This	O
had	O
been	O
apparently	O
uncomplicated	O
and	O
she	O
had	O
maintained	O
a	O
remarkably	O
high	O
level	O
of	O
physical	O
activity.	O
She	O
was	O
found	O
to	O
be	O
bradycardic	Disease
at	O
pre-operative	O
assessment	O
but	O
had	O
no	O
cardiac	O
symptoms.	O
Second	O
degree	O
Mobitz	O
type	O
II	O
atrioventricular	Disease
block	Disease
was	O
diagnosed	O
on	O
electrocardiogram,	O
and	O
temporary	O
transvenous	O
ventricular	O
pacing	O
instituted	O
in	O
the	O
peri-operative	O
period.	O
We	O
discuss	O
how	O
evidence-based	O
guidelines	O
would	O
not	O
have	O
been	O
helpful	O
in	O
this	O
case,	O
and	O
how	O
chemotherapy	O
can	O
exhibit	O
substantial	O
cardiotoxicity	Disease

Risks	O
and	O
benefits	O
of	O
COX-2	Chemical
inhibitors	Chemical
vs	O
non-selective	O
NSAIDs:	O
does	O
their	O
cardiovascular	O
risk	O
exceed	O
their	O
gastrointestinal	O
benefit?	O
A	O
retrospective	O
cohort	O
study.	O
OBJECTIVES:	O
The	O
risk	O
of	O
acute	Disease
myocardial	Disease
infarction	Disease
(	O
AMI	Disease
)	O
with	O
COX-2	Chemical
inhibitors	Chemical
may	O
offset	O
their	O
gastrointestinal	O
(GI)	O
benefit	O
compared	O
with	O
non-selective	O
(NS)	O
non-steroidal	Chemical
anti-inflammatory	Chemical
drugs	Chemical
(NSAIDs).	O
We	O
aimed	O
to	O
compare	O
the	O
risks	O
of	O
hospitalization	O
for	O
AMI	Disease
and	O
GI	Disease
bleeding	Disease
among	O
elderly	O
patients	O
using	O
COX-2	Chemical
inhibitors	Chemical
,	O
NS-NSAIDs	O
and	O
acetaminophen	Chemical
.	O
METHODS:	O
We	O
conducted	O
a	O
retrospective	O
cohort	O
study	O
using	O
administrative	O
data	O
of	O
patients	O
>	O
or	O
=65	O
years	O
of	O
age	O
who	O
filled	O
a	O
prescription	O
for	O
NSAID	O
or	O
acetaminophen	Chemical
during	O
1999-2002.	O
Outcomes	O
were	O
compared	O
using	O
Cox	O
regression	O
models	O
with	O
time-dependent	O
exposures.	O
RESULTS:	O
Person-years	O
of	O
exposure	O
among	O
non-users	O
of	O
aspirin	Chemical
were:	O
75,761	O
to	O
acetaminophen	Chemical
,	O
42,671	O
to	O
rofecoxib	Chemical
65,860	O
to	O
celecoxib	Chemical
,	O
and	O
37,495	O
to	O
NS-NSAIDs.	O
Among	O
users	O
of	O
aspirin	Chemical
,	O
they	O
were:	O
14,671	O
to	O
rofecoxib	Chemical
,	O
22,875	O
to	O
celecoxib	Chemical
,	O
9,832	O
to	O
NS-NSAIDs	O
and	O
38,048	O
to	O
acetaminophen	Chemical
.	O
Among	O
non-users	O
of	O
aspirin	Chemical
,	O
the	O
adjusted	O
hazard	O
ratios	O
(95%	O
confidence	O
interval)	O
of	O
hospitalization	O
for	O
AMI	Disease
/GI	O
vs	O
the	O
acetaminophen	Chemical
(with	O
no	O
aspirin	Chemical
)	O
group	O
were:	O
rofecoxib	Chemical
1.27	O
(1.13,	O
1.42),	O
celecoxib	Chemical
0.93	O
(0.83,	O
1.03),	O
naproxen	Chemical
1.59	O
(1.31,	O
1.93),	O
diclofenac	Chemical
1.17	O
(0.99,	O
1.38)	O
and	O
ibuprofen	Chemical
1.05	O
(0.74,	O
1.51).	O
Among	O
users	O
of	O
aspirin	Chemical
,	O
they	O
were:	O
rofecoxib	Chemical
1.73	O
(1.52,	O
1.98),	O
celecoxib	Chemical
1.34	O
(1.19,	O
1.52),	O
ibuprofen	Chemical
1.51	O
(0.95,	O
2.41),	O
diclofenac	Chemical
1.69	O
(1.35,	O
2.10),	O
naproxen	Chemical
1.35	O
(0.97,	O
1.88)	O
and	O
acetaminophen	Chemical
1.29	O
(1.17,	O
1.42).	O
CONCLUSION:	O
Among	O
non-users	O
of	O
aspirin	Chemical
,	O
naproxen	Chemical
seemed	O
to	O
carry	O
the	O
highest	O
risk	O
for	O
AMI	Disease
/	O
GI	Disease
bleeding	Disease
.	O
The	O
AMI	Disease
/GI	O
toxicity	Disease
of	O
celecoxib	Chemical
was	O
similar	O
to	O
that	O
of	O
acetaminophen	Chemical
and	O
seemed	O
to	O
be	O
better	O
than	O
those	O
of	O
rofecoxib	Chemical
and	O
NS-NSAIDs.	O
Among	O
users	O
of	O
aspirin	Chemical
,	O
both	O
celecoxib	Chemical
and	O
naproxen	Chemical

Quinine	Chemical
-induced	O
arrhythmia	Disease
in	O
a	O
patient	O
with	O
severe	Disease
malaria	Disease
.	O
It	O
was	O
reported	O
that	O
there	O
was	O
a	O
case	O
of	O
severe	Disease
malaria	Disease
patient	O
with	O
jaundice	Disease
who	O
presented	O
with	O
arrhythmia	Disease
(	O
premature	Disease
ventricular	Disease
contraction	Disease
)	O
while	O
getting	O
quinine	Chemical
infusion	O
was	O
reported.	O
A	O
man,	O
25	O
years	O
old,	O
was	O
admitted	O
to	O
hospital	O
with	O
high	O
fever	Disease
,	O
chill	Disease
,	O
vomiting	Disease
,	O
jaundice	Disease
.	O
The	O
patient	O
was	O
fully	O
conscious,	O
blood	O
pressure	O
120/80	O
mmHg,	O
pulse	O
rate	O
100	O
x/minute,	O
regular.	O
On	O
admission,	O
laboratory	O
examination	O
showed	O
Plasmodium	O
falciparum	O
(++++),	O
total	O
bilirubin	Chemical
8.25	O
mg/dL,	O
conjugated	O
bilirubin	Chemical
4.36	O
mg/dL,	O
unconjugated	O
bilirubin	Chemical
3.89	O
mg/dL,	O
potassium	Chemical
3.52	O
meq/L	O
Patient	O
was	O
diagnosed	O
as	O
severe	Disease
malaria	Disease
with	O
jaundice	Disease
and	O
got	O
quinine	Chemical
infusion	O
in	O
dextrose	Chemical
5%	O
500	O
mg/8	O
hour.	O
On	O
the	O
second	O
day	O
the	O
patient	O
had	O
vomitus	Disease
,	O
diarrhea	Disease
,	O
tinnitus	Disease
,	O
loss	Disease
of	Disease
hearing	Disease
.	O
After	O
30	O
hours	O
of	O
quinine	Chemical
infusion	O
the	O
patient	O
felt	O
palpitation	Disease
and	O
electrocardiography	O
(ECG)	O
recording	O
showed	O
premature	Disease
ventricular	Disease
contraction	Disease
(	O
PVC	Disease
)	O
>	O
5	O
x/minute,	O
trigemini,	O
constant	O
type--	O
sinoatrial	Disease
block	Disease
,	O
positive	O
U	O
wave.	O
He	O
was	O
treated	O
with	O
lidocaine	Chemical
50	O
mg	O
intravenously	O
followed	O
by	O
infusion	O
1500	O
mg	O
in	O
dextrose	Chemical
5%/24	O
hour	O
and	O
potassium	Chemical
aspartate	Chemical
tablet.	O
Quinine	Chemical
infusion	O
was	O
discontinued	O
and	O
changed	O
with	O
sulfate	O
quinine	Chemical
tablets.	O
Three	O
hours	O
later	O
the	O
patient	O
felt	O
better,	O
the	O
frequency	O
of	O
PVC	Disease
reduced	O
to	O
4	O
-	O
5	O
x/minute	O
and	O
on	O
the	O
third	O
day	O
ECG	O
was	O
normal,	O
potassium	Chemical
level	O
was	O
3.34	O
meq/L.	O
He	O
was	O
discharged	O
on	O
7th	O
day	O
in	O
good	O
condition.	O
Quinine	Chemical
,	O
like	O
quinidine	Chemical
,	O
is	O
a	O
chincona	O
alkaloid	O
that	O
has	O
anti-	O
arrhythmic	Disease
property,	O
although	O
it	O
also	O
pro-	O
arrhythmic	Disease
that	O
can	O
cause	O
various	O
arrhythmias	Disease
,	O
including	O
severe	O
arrhythmia	Disease
such	O
as	O
multiple	O
PVC	Disease
.	O
Administration	O
of	O
parenteral	O
quinine	Chemical
must	O
be	O
done	O
carefully	O
and	O
with	O
good	O
observation	O
because	O
of	O
its	O
pro-	O
arrhythmic	Disease
effect,	O
especially	O
in	O
older	O
patients	O
who	O
have	O
heart	Disease
diseases	Disease
or	O
patients	O
with	O
electrolyte	Disease
disorder	Disease
(	O
hypokalemia	Disease
)	O
which	O
frequently	O
occurs	O
due	O
to	O
vomiting	Disease
and	O
or	O
diarrhea	Disease
in	O
malaria	Disease

Penicillamine	Chemical
-related	O
lichenoid	Disease
dermatitis	Disease
and	O
utility	O
of	O
zinc	Chemical
acetate	Chemical
in	O
a	O
Wilson	Disease
disease	Disease
patient	O
with	O
hepatic	O
presentation,	O
anxiety	Disease
and	O
SPECT	O
abnormalities.	O
Wilson's	Disease
disease	Disease
is	O
an	O
autosomal	O
recessive	O
disorder	O
of	O
hepatic	O
copper	Chemical
metabolism	O
with	O
consequent	O
copper	Chemical
accumulation	O
and	O
toxicity	Disease
in	O
many	O
tissues	O
and	O
consequent	O
hepatic,	Disease
neurologic	Disease
and	Disease
psychiatric	Disease
disorders	Disease
.	O
We	O
report	O
a	O
case	O
of	O
Wilson's	Disease
disease	Disease
with	O
chronic	Disease
liver	Disease
disease	Disease
;	O
moreover,	O
in	O
our	O
patient,	O
presenting	O
also	O
with	O
high	O
levels	O
of	O
state	O
anxiety	Disease
without	O
depression	Disease
,	O
99mTc-ECD-SPECT	O
showed	O
cortical	O
hypoperfusion	O
in	O
frontal	O
lobes,	O
more	O
marked	O
on	O
the	O
left	O
frontal	O
lobe.	O
During	O
the	O
follow-up	O
of	O
our	O
patient,	O
penicillamine	Chemical
was	O
interrupted	O
after	O
the	O
appearance	O
of	O
a	O
lichenoid	Disease
dermatitis	Disease
,	O
and	O
zinc	Chemical
acetate	Chemical
permitted	O
to	O
continue	O
the	O
successful	O
treatment	O
of	O
the	O
patient	O
without	O
side-effects.	O
In	O
our	O
case	O
the	O
therapy	O
with	O
zinc	Chemical
acetate	Chemical
represented	O
an	O
effective	O
treatment	O
for	O
a	O
Wilson's	Disease
disease	Disease
patient	O
in	O
which	O
penicillamine	Chemical
-related	O
side	O
effects	O
appeared.	O
The	O
safety	O
of	O
the	O
zinc	Chemical
acetate	Chemical
allowed	O
us	O
to	O
avoid	O
other	O
potentially	O
toxic	O
chelating	O
drugs;	O
this	O
observation	O
is	O
in	O
line	O
with	O
the	O
growing	O
evidence	O
on	O
the	O
efficacy	O
of	O
the	O
drug	O
in	O
the	O
treatment	O
of	O
Wilson's	Disease
disease	Disease
.	O
Since	O
most	O
of	O
Wilson's	Disease
disease	Disease
	O
penicillamine	Chemical
-treated	O
patients	O
do	O
not	O
seem	O
to	O
develop	O
this	O
skin	Disease
lesion	Disease
,	O
it	O
could	O
be	O
conceivable	O
that	O
a	O
specific	O
genetic	O
factor	O
is	O
involved	O
in	O
drug	O
response.	O
Further	O
studies	O
are	O
needed	O
for	O
a	O
better	O
clarification	O
of	O
Wilson's	Disease
disease	Disease
therapy,	O
and	O
in	O
particular	O
to	O
differentiate	O
specific	O
therapies	O
for	O
different	O
Wilson's	Disease
disease	Disease

A	O
dramatic	O
drop	Disease
in	Disease
blood	Disease
pressure	Disease
following	O
prehospital	O
GTN	Chemical
administration.	O
A	O
male	O
in	O
his	O
sixties	O
with	O
no	O
history	O
of	O
cardiac	O
chest	Disease
pain	Disease
awoke	O
with	O
chest	Disease
pain	Disease
following	O
an	O
afternoon	O
sleep.	O
The	O
patient	O
did	O
not	O
self	O
medicate.	O
The	O
patient's	O
observations	O
were	O
within	O
normal	O
limits,	O
he	O
was	O
administered	O
oxygen	Chemical
via	O
a	O
face	O
mask	O
and	O
glyceryl	Chemical
trinitrate	Chemical
(	O
GTN	Chemical
).	O
Several	O
minutes	O
after	O
the	O
GTN	Chemical
the	O
patient	O
experienced	O
a	O
sudden	O
drop	Disease
in	Disease
blood	Disease
pressure	Disease
and	O
heart	O
rate,	O
this	O
was	O
rectified	O
by	O
atropine	Chemical
sulphate	Chemical
and	O
a	O
fluid	O
challenge.	O
There	O
was	O
no	O
further	O
deterioration	O
in	O
the	O
patient's	O
condition	O
during	O
transport	O
to	O
hospital.	O
There	O
are	O
very	O
few	O
documented	O
case	O
like	O
this	O
in	O
the	O
prehospital	O
scientific	O
literature.	O
The	O
cause	O
appears	O
to	O
be	O
the	O
Bezold-Jarish	O
reflex,	O
stimulation	O
of	O
the	O
ventricular	O
walls	O
which	O
in	O
turn	O
decreases	O
sympathetic	O
outflow	O
from	O
the	O
vasomotor	O
centre.	O
Prehospital	O
care	O
providers	O
who	O
are	O
managing	O
any	O
patient	O
with	O
a	O
syncopal	Disease
episode	Disease

Acute	Disease
encephalopathy	Disease
and	O
cerebral	Disease
vasospasm	Disease
after	O
multiagent	O
chemotherapy	O
including	O
PEG-asparaginase	Chemical
and	O
intrathecal	O
cytarabine	Chemical
for	O
the	O
treatment	O
of	O
acute	Disease
lymphoblastic	Disease
leukemia	Disease
.	O
A	O
7-year-old	O
girl	O
with	O
an	O
unusual	O
reaction	O
to	O
induction	O
chemotherapy	O
for	O
precursor	O
B-cell	O
acute	Disease
lymphoblastic	Disease
leukemia	Disease
(	O
ALL	Disease
)	O
is	O
described.	O
The	O
patient	O
developed	O
acute	Disease
encephalopathy	Disease
evidenced	O
by	O
behavioral	O
changes,	O
aphasia	Disease
,	O
incontinence	Disease
,	O
visual	Disease
hallucinations	Disease
,	O
and	O
right-sided	O
weakness	Disease
with	O
diffuse	O
cerebral	Disease
vasospasm	Disease
on	O
magnetic	O
resonance	O
angiography	O
after	O
the	O
administration	O
of	O
intrathecal	O
cytarabine	Chemical
.	O
Vincristine	Chemical
,	O
dexamethasone	Chemical
,	O
and	O
polyethylene	Chemical
glycol-asparaginase	Chemical

Comparison	O
of	O
valsartan	Chemical
/	O
hydrochlorothiazide	Chemical
combination	O
therapy	O
at	O
doses	O
up	O
to	O
320/25	O
mg	O
versus	O
monotherapy:	O
a	O
double-blind,	O
placebo-controlled	O
study	O
followed	O
by	O
long-term	O
combination	O
therapy	O
in	O
hypertensive	Disease
adults.	O
BACKGROUND:	O
One	O
third	O
of	O
patients	O
treated	O
for	O
hypertension	Disease
attain	O
adequate	O
blood	O
pressure	O
(BP)	O
control,	O
and	O
multidrug	O
regimens	O
are	O
often	O
required.	O
Given	O
the	O
lifelong	O
nature	O
of	O
hypertension	Disease
,	O
there	O
is	O
a	O
need	O
to	O
evaluate	O
the	O
long-term	O
efficacy	O
and	O
tolerability	O
of	O
higher	O
doses	O
of	O
combination	O
anti-	O
hypertensive	Disease
therapies.	O
OBJECTIVE:	O
This	O
study	O
investigated	O
the	O
efficacy	O
and	O
tolerability	O
of	O
valsartan	Chemical
(	O
VAL	Chemical
)	O
or	O
hydrochlorothiazide	Chemical
(	O
HCTZ	Chemical
)-monotherapy	O
and	O
higher-dose	O
combinations	O
in	O
patients	O
with	O
essential	Disease
hypertension	Disease
.	O
METHODS:	O
The	O
first	O
part	O
of	O
this	O
study	O
was	O
an	O
8-week,	O
multicenter,	O
randomized,	O
double-blind,	O
placebo	O
controlled,	O
parallel-group	O
trial.	O
Patients	O
with	O
essential	Disease
hypertension	Disease
(mean	O
sitting	O
diastolic	O
BP	O
[MSDBP],	O
>	O
or	O
=95	O
mm	O
Hg	O
and	O
<110	O
mm	O
Hg)	O
were	O
randomized	O
to	O
1	O
of	O
8	O
treatment	O
groups:	O
VAL	Chemical
160	O
or	O
320	O
mg;	O
HCTZ	Chemical
12.5	O
or	O
25	O
mg;	O
VAL	Chemical
/	O
HCTZ	Chemical
160/12.5,	O
320/12.5,	O
or	O
320/25	O
mg;	O
or	O
placebo.	O
Mean	O
changes	O
in	O
MSDBP	O
and	O
mean	O
sitting	O
systolic	O
BP	O
(MSSBP)	O
were	O
analyzed	O
at	O
the	O
8-week	O
core	O
study	O
end	O
point.	O
VAL	Chemical
/	O
HCTZ	Chemical
320/12.5	O
and	O
320/25	O
mg	O
were	O
further	O
investigated	O
in	O
a	O
54-week,	O
open-label	O
extension.	O
Response	O
was	O
defined	O
as	O
MSDBP	O
<90	O
mm	O
Hg	O
or	O
a	O
>	O
or	O
=10	O
mm	O
Hg	O
decrease	O
compared	O
to	O
baseline.	O
Control	O
was	O
defined	O
as	O
MSDBP	O
<90	O
mm	O
Hg	O
compared	O
with	O
baseline.	O
Tolerability	O
was	O
assessed	O
by	O
monitoring	O
adverse	O
events	O
at	O
randomization	O
and	O
all	O
subsequent	O
study	O
visits	O
and	O
regular	O
evaluation	O
of	O
hematology	O
and	O
blood	O
chemistry.	O
RESULTS:	O
A	O
total	O
of	O
1346	O
patients	O
were	O
randomized	O
into	O
the	O
8-week	O
core	O
study	O
(734	O
men,	O
612	O
women;	O
924	O
white,	O
291	O
black,	O
23	O
Asian,	O
108	O
other;	O
mean	O
age,	O
52.7	O
years;	O
mean	O
weight,	O
92.6	O
kg).	O
All	O
active	O
treatments	O
were	O
associated	O
with	O
significantly	O
reduced	O
MSSBP	O
and	O
MSDBP	O
during	O
the	O
core	O
8-week	O
study,	O
with	O
each	O
monotherapy	O
significantly	O
contributing	O
to	O
the	O
overall	O
effect	O
of	O
combination	O
therapy	O
(	O
VAL	Chemical
and	O
HCTZ	Chemical
,	O
P	O
<	O
0.001).	O
Each	O
combination	O
was	O
associated	O
with	O
significantly	O
greater	O
reductions	O
in	O
MSSBP	O
and	O
MSDBP	O
compared	O
with	O
the	O
monotherapies	O
and	O
placebo	O
(all,	O
P	O
<	O
0.001).	O
The	O
mean	O
reduction	O
in	O
MSSBP/MSDBP	O
with	O
VAL	Chemical
/	O
HCTZ	Chemical
320/25	O
mg	O
was	O
24.7/16.6	O
mm	O
Hg,	O
compared	O
with	O
5.9/7.0	O
mm	O
Hg	O
with	O
placebo.	O
The	O
reduction	O
in	O
MSSBP	O
was	O
significantly	O
greater	O
with	O
VAL	Chemical
/	O
HCTZ	Chemical
320/25	O
mg	O
compared	O
with	O
VAL	Chemical
/	O
HCTZ	Chemical
160/12.5	O
mg	O
(P	O
<	O
0.002).	O
Rates	O
of	O
response	O
and	O
BP	O
control	O
were	O
significantly	O
higher	O
in	O
the	O
groups	O
that	O
received	O
combination	O
treatment	O
compared	O
with	O
those	O
that	O
received	O
monotherapy.	O
The	O
incidence	O
of	O
hypokalemia	Disease
was	O
lower	O
with	O
VAL	Chemical
/	O
HCTZ	Chemical
combinations	O
(1.8%-6.1%)	O
than	O
with	O
HCTZ	Chemical
monotherapies	O
(7.1%-13.3%).	O
The	O
majority	O
of	O
adverse	O
events	O
in	O
the	O
core	O
study	O
were	O
of	O
mild	O
to	O
moderate	O
severity.	O
The	O
efficacy	O
and	O
tolerability	O
of	O
VAL	Chemical
/	O
HCTZ	Chemical
combinations	O
were	O
maintained	O
during	O
the	O
extension	O
(797	O
patients).	O
CONCLUSIONS:	O
In	O
this	O
study	O
population,	O
combination	O
therapies	O
with	O
VAL	Chemical
/	O
HCTZ	Chemical
were	O
associated	O
with	O
significantly	O
greater	O
BP	O
reductions	O
compared	O
with	O
either	O
monotherapy,	O
were	O
well	O
tolerated,	O
and	O
were	O
associated	O
with	O
less	O
hypokalemia	Disease
than	O
HCTZ	Chemical

Succimer	Chemical
chelation	O
improves	O
learning,	O
attention,	O
and	O
arousal	O
regulation	O
in	O
lead	Chemical
-exposed	O
rats	O
but	O
produces	O
lasting	O
cognitive	Disease
impairment	Disease
in	O
the	O
absence	O
of	O
lead	Chemical
exposure.	O
BACKGROUND:	O
There	O
is	O
growing	O
pressure	O
for	O
clinicians	O
to	O
prescribe	O
chelation	O
therapy	O
at	O
only	O
slightly	O
elevated	O
blood	O
lead	Chemical
levels.	O
However,	O
very	O
few	O
studies	O
have	O
evaluated	O
whether	O
chelation	O
improves	O
cognitive	O
outcomes	O
in	O
Pb	Chemical
-exposed	O
children,	O
or	O
whether	O
these	O
agents	O
have	O
adverse	O
effects	O
that	O
may	O
affect	O
brain	O
development	O
in	O
the	O
absence	O
of	O
Pb	Chemical
exposure.	O
OBJECTIVES:	O
The	O
present	O
study	O
was	O
designed	O
to	O
answer	O
these	O
questions,	O
using	O
a	O
rodent	O
model	O
of	O
early	O
childhood	O
Pb	Chemical
exposure	O
and	O
treatment	O
with	O
succimer	Chemical
,	O
a	O
widely	O
used	O
chelating	O
agent	O
for	O
the	O
treatment	O
of	O
Pb	Disease
poisoning	Disease
.	O
RESULTS:	O
Pb	Chemical
exposure	O
produced	O
lasting	O
impairments	Disease
in	Disease
learning,	Disease
attention,	Disease
inhibitory	Disease
control,	Disease
and	Disease
arousal	Disease
regulation	Disease
,	O
paralleling	O
the	O
areas	O
of	O
dysfunction	O
seen	O
in	O
Pb	Chemical
-exposed	O
children.	O
Succimer	Chemical
treatment	O
of	O
the	O
Pb	Chemical
-exposed	O
rats	O
significantly	O
improved	O
learning,	O
attention,	O
and	O
arousal	O
regulation,	O
although	O
the	O
efficacy	O
of	O
the	O
treatment	O
varied	O
as	O
a	O
function	O
of	O
the	O
Pb	Chemical
exposure	O
level	O
and	O
the	O
specific	O
functional	O
deficit.	O
In	O
contrast,	O
succimer	Chemical
treatment	O
of	O
rats	O
not	O
previously	O
exposed	O
to	O
Pb	Chemical
produced	O
lasting	O
and	O
pervasive	O
cognitive	Disease
and	Disease
affective	Disease
dysfunction	Disease
comparable	O
in	O
magnitude	O
to	O
that	O
produced	O
by	O
the	O
higher	O
Pb	Chemical
exposure	O
regimen.	O
CONCLUSIONS:	O
These	O
are	O
the	O
first	O
data,	O
to	O
our	O
knowledge,	O
to	O
show	O
that	O
treatment	O
with	O
any	O
chelating	O
agent	O
can	O
alleviate	O
cognitive	Disease
deficits	Disease
due	O
to	O
Pb	Chemical
exposure.	O
These	O
findings	O
suggest	O
that	O
it	O
may	O
be	O
possible	O
to	O
identify	O
a	O
succimer	Chemical
treatment	O
protocol	O
that	O
improves	O
cognitive	O
outcomes	O
in	O
Pb	Chemical
-exposed	O
children.	O
However,	O
they	O
also	O
suggest	O
that	O
succimer	Chemical
treatment	O
should	O
be	O
strongly	O
discouraged	O
for	O
children	O
who	O
do	O
not	O
have	O
elevated	O
tissue	O
levels	O
of	O
Pb	Chemical

Caffeine	Chemical
challenge	O
test	O
in	O
panic	Disease
disorder	Disease
and	O
depression	Disease
with	O
panic	Disease
attacks	Disease
.	O
Our	O
aim	O
was	O
to	O
observe	O
if	O
patients	O
with	O
panic	Disease
disorder	Disease
(	O
PD	Disease
)	O
and	O
patients	O
with	O
major	Disease
depression	Disease
with	O
panic	Disease
attacks	Disease
(	O
MDP	Disease
)	O
(Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	Disease
Disorders	Disease
,	O
Fourth	O
Edition	O
criteria)	O
respond	O
in	O
a	O
similar	O
way	O
to	O
the	O
induction	O
of	O
panic	Disease
attacks	Disease
by	O
an	O
oral	O
caffeine	Chemical
challenge	O
test.	O
We	O
randomly	O
selected	O
29	O
patients	O
with	O
PD	Disease
,	O
27	O
with	O
MDP	Disease
,	O
25	O
with	O
major	Disease
depression	Disease
without	O
panic	Disease
attacks	Disease
(	O
MD	Disease
),	O
and	O
28	O
healthy	O
volunteers.	O
The	O
patients	O
had	O
no	O
psychotropic	O
drug	O
for	O
at	O
least	O
a	O
4-week	O
period.	O
In	O
a	O
randomized	O
double-blind	O
experiment	O
performed	O
in	O
2	O
occasions	O
7	O
days	O
apart,	O
480	O
mg	O
caffeine	Chemical
and	O
a	O
caffeine	Chemical
-free	O
(placebo)	O
solution	O
were	O
administered	O
in	O
a	O
coffee	O
form	O
and	O
anxiety	Disease
scales	O
were	O
applied	O
before	O
and	O
after	O
each	O
test.	O
A	O
total	O
of	O
58.6%	O
(n	O
=	O
17)	O
of	O
patients	O
with	O
PD	Disease
,	O
44.4%	O
(n	O
=	O
12)	O
of	O
patients	O
with	O
MDP	Disease
,	O
12.0%	O
(n	O
=	O
3)	O
of	O
patients	O
with	O
MD	Disease
,	O
and	O
7.1%	O
(n=	O
2)	O
of	O
control	O
subjects	O
had	O
a	O
panic	Disease
attack	Disease
after	O
the	O
480-mg	O
caffeine	Chemical
challenge	O
test	O
(chi(2)(3)	O
=	O
16.22,	O
P	O
=	O
.001).	O
The	O
patients	O
with	O
PD	Disease
and	O
MDP	Disease
were	O
more	O
sensitive	O
to	O
caffeine	Chemical
than	O
were	O
patients	O
with	O
MD	Disease
and	O
healthy	O
volunteers.	O
No	O
panic	Disease
attack	Disease
was	O
observed	O
after	O
the	O
caffeine	Chemical
-free	O
solution	O
intake.	O
The	O
patients	O
with	O
MD	Disease
had	O
a	O
lower	O
heart	O
rate	O
response	O
to	O
the	O
test	O
than	O
all	O
the	O
other	O
groups	O
(2-way	O
analysis	O
of	O
variance,	O
group	O
by	O
time	O
interaction	O
with	O
Greenhouse-Geisser	O
correction:	O
F(3,762)	O
=	O
2.85,	O
P	O
=	O
.026).	O
Our	O
data	O
suggest	O
that	O
there	O
is	O
an	O
association	O
between	O
panic	Disease
attacks	Disease
,	O
no	O
matter	O
if	O
associated	O
with	O
PD	Disease
or	O
MDP	Disease
,	O
and	O
hyperreactivity	O
to	O
an	O
oral	O
caffeine	Chemical

Mitral	O
annuloplasty	O
as	O
a	O
ventricular	O
restoration	O
method	O
for	O
the	O
failing	Disease
left	Disease
ventricle	Disease
:	O
a	O
pilot	O
study.	O
BACKGROUND	O
AND	O
AIM	O
OF	O
THE	O
STUDY:	O
Undersized	O
mitral	O
annuloplasty	O
(MAP)	O
is	O
effective	O
in	O
patients	O
with	O
dilated	Disease
cardiomyopathy	Disease
and	O
functional	O
mitral	Disease
regurgitation	Disease
(	O
MR	Disease
)	O
since,	O
as	O
well	O
as	O
addressing	O
the	O
MR	Disease
,	O
the	O
MAP	O
may	O
also	O
reshape	O
the	O
dilated	O
left	O
ventricular	O
(LV)	O
base.	O
However,	O
the	O
direct	O
benefits	O
of	O
this	O
possible	O
reshaping	O
on	O
LV	O
function	O
in	O
the	O
absence	O
of	O
underlying	O
MR	Disease
remain	O
incompletely	O
understood.	O
The	O
study	O
aim	O
was	O
to	O
identify	O
these	O
benefits	O
in	O
a	O
canine	O
model	O
of	O
acute	O
heart	Disease
failure	Disease
.	O
METHODS:	O
Six	O
dogs	O
underwent	O
MAP	O
with	O
a	O
prosthetic	O
band	O
on	O
the	O
posterior	O
mitral	O
annulus,	O
using	O
four	O
mattress	O
sutures.	O
The	O
sutures	O
were	O
passed	O
individually	O
through	O
four	O
tourniquets	O
and	O
exteriorized	O
untied	O
via	O
the	O
left	O
atriotomy.	O
Sonomicrometry	O
crystals	O
were	O
implanted	O
around	O
the	O
mitral	O
annulus	O
and	O
left	O
ventricle	O
to	O
measure	O
geometry	O
and	O
regional	O
function.	O
Acute	O
heart	Disease
failure	Disease
was	O
induced	O
by	O
propranolol	Chemical
and	O
volume	O
loading	O
after	O
weaning	O
from	O
cardiopulmonary	O
bypass;	O
an	O
absence	O
of	O
MR	Disease
was	O
confirmed	O
by	O
echocardiography.	O
MAP	O
was	O
accomplished	O
by	O
cinching	O
the	O
tourniquets.	O
Data	O
were	O
acquired	O
at	O
baseline,	O
after	O
induction	O
of	O
acute	O
heart	Disease
failure	Disease
,	O
and	O
after	O
MAP.	O
RESULTS:	O
MAP	O
decreased	O
mitral	O
annular	O
dimensions	O
in	O
both	O
commissure-commissure	O
and	O
septal-lateral	O
directions.	O
Concomitantly,	O
the	O
diastolic	O
diameter	O
of	O
the	O
LV	O
base	O
and	O
LV	O
sphericity	O
decreased	O
(i.e.,	O
improved)	O
from	O
37.4	O
+/-	O
9.3	O
to	O
35.9	O
+/-	O
10	O
mm	O
(p	O
=	O
0.063),	O
and	O
from	O
67.9	O
+/-	O
18.6%	O
to	O
65.3	O
+/-	O
18.9%	O
(p	O
=	O
0.016),	O
respectively.	O
Decreases	O
were	O
evident	O
in	O
both	O
LV	O
end-diastolic	O
pressure	O
(from	O
17	O
+/-	O
7	O
to	O
15	O
+/-	O
6	O
mmHg,	O
p	O
=	O
0.0480	O
and	O
Tau	O
(from	O
48	O
+/-	O
8	O
to	O
45	O
+/-	O
8	O
ms,	O
p	O
<0.01),	O
while	O
fractional	O
shortening	O
at	O
the	O
LV	O
base	O
increased	O
from	O
7.7	O
+/-	O
4.5%	O
to	O
9.4	O
+/-	O
4.5%	O
(p	O
=	O
0.045).	O
After	O
MAP,	O
increases	O
were	O
identified	O
in	O
both	O
cardiac	O
output	O
(from	O
1.54	O
+/-	O
0.57	O
to	O
1.65	O
+/-	O
0.57	O
1/min)	O
and	O
Emax	O
(from	O
1.86	O
+/-	O
0.9	O
to	O
2.41	O
+/-	O
1.31	O
mmHg/ml).	O
CONCLUSION:	O
The	O
data	O
acquired	O
suggest	O
that	O
isolated	O
MAP	O
may	O
have	O
certain	O
benefits	O
on	O
LV	O
dimension/function	O
in	O
acute	O
heart	Disease
failure	Disease
,	O
even	O
in	O
the	O
absence	O
of	O
MR	Disease
.	O
However,	O
further	O
investigations	O
are	O
warranted	O
in	O
a	O
model	O
of	O
chronic	O
heart	Disease
failure	Disease

Piperacillin/tazobactam	Chemical
-induced	O
seizure	Disease
rapidly	O
reversed	O
by	O
high	O
flux	O
hemodialysis	O
in	O
a	O
patient	O
on	O
peritoneal	O
dialysis.	O
Despite	O
popular	O
use	O
of	O
piperacillin	Chemical
,	O
the	O
dire	O
neurotoxicity	Disease
associated	O
with	O
piperacillin	Chemical
still	O
goes	O
unrecognized,	O
leading	O
to	O
a	O
delay	O
in	O
appropriate	O
management.	O
We	O
report	O
a	O
57-year-old	O
woman	O
with	O
end-stage	Disease
renal	Disease
disease	Disease
receiving	O
continuous	O
ambulatory	O
peritoneal	O
dialysis	O
(CAPD),	O
who	O
developed	O
slurred	O
speech,	O
tremor	Disease
,	O
bizarre	O
behavior,	O
progressive	O
mental	O
confusion	Disease
,	O
and	O
2	O
episodes	O
of	O
generalized	O
tonic-clonic	Disease
seizure	Disease
(	O
GTCS	Disease
)	O
after	O
5	O
doses	O
of	O
piperacillin/tazobactam	Chemical
(2	O
g/250	O
mg)	O
were	O
given	O
for	O
bronchiectasis	Disease
with	O
secondary	Disease
infection	Disease
.	O
The	O
laboratory	O
data	O
revealed	O
normal	O
plasma	O
electrolyte	O
and	O
ammonia	Chemical
levels	O
but	O
leukocytosis	Disease
.	O
Neurologic	O
examinations	O
showed	O
dysarthria	Disease
and	O
bilateral	O
Babinski	O
sign.	O
Computed	O
tomography	O
of	O
brain	O
and	O
electroencephalogram	O
were	O
unremarkable.	O
Despite	O
the	O
use	O
of	O
antiepileptic	O
agents,	O
another	O
GTCS	Disease
episode	O
recurred	O
after	O
the	O
sixth	O
dose	O
of	O
piperacillin/tazobactam	Chemical
.	O
Brain	O
magnetic	O
resonance	O
imaging	O
did	O
not	O
demonstrate	O
acute	O
infarction	Disease
and	O
organic	Disease
brain	Disease
lesions	Disease
.	O
Initiation	O
of	O
high-flux	O
hemodialysis	O
rapidly	O
reversed	O
the	O
neurologic	O
symptoms	O
within	O
4	O
hours.	O
Piperacillin	Chemical
-induced	O
encephalopathy	Disease
should	O
be	O
considered	O
in	O
any	O
uremic	Disease
patients	O
with	O
unexplained	O
neurological	O
manifestations.	O
CAPD	O
is	O
inefficient	O
in	O
removing	O
piperacillin	Chemical
,	O
whereas	O
hemodialysis	O
can	O
rapidly	O
terminate	O
the	O
piperacillin	Chemical
-induced	O
encephalopathy	Disease

Frequency	O
of	O
transient	O
ipsilateral	O
vocal	Disease
cord	Disease
paralysis	Disease
in	O
patients	O
undergoing	O
carotid	O
endarterectomy	O
under	O
local	O
anesthesia.	O
BACKGROUND:	O
Especially	O
because	O
of	O
improvements	O
in	O
clinical	O
neurologic	O
monitoring,	O
carotid	O
endarterectomy	O
done	O
under	O
local	O
anesthesia	O
has	O
become	O
the	O
technique	O
of	O
choice	O
in	O
several	O
centers.	O
Temporary	O
ipsilateral	O
vocal	Disease
nerve	Disease
palsies	Disease
due	O
to	O
local	O
anesthetics	O
have	O
been	O
described,	O
however.	O
Such	O
complications	O
are	O
most	O
important	O
in	O
situations	O
where	O
there	O
is	O
a	O
pre-existing	O
contralateral	O
paralysis	Disease
.	O
We	O
therefore	O
examined	O
the	O
effect	O
of	O
local	O
anesthesia	O
on	O
vocal	O
cord	O
function	O
to	O
better	O
understand	O
its	O
possible	O
consequences.	O
METHODS:	O
This	O
prospective	O
study	O
included	O
28	O
patients	O
undergoing	O
carotid	O
endarterectomy	O
under	O
local	O
anesthesia.	O
Vocal	O
cord	O
function	O
was	O
evaluated	O
before,	O
during,	O
and	O
after	O
surgery	O
(postoperative	O
day	O
1)	O
using	O
flexible	O
laryngoscopy.	O
Anesthesia	O
was	O
performed	O
by	O
injecting	O
20	O
to	O
40	O
mL	O
of	O
a	O
mixture	O
of	O
long-acting	O
(	O
ropivacaine	Chemical
)	O
and	O
short-acting	O
(	O
prilocaine	Chemical
)	O
anesthetic.	O
RESULTS:	O
All	O
patients	O
had	O
normal	O
vocal	O
cord	O
function	O
preoperatively.	O
Twelve	O
patients	O
(43%)	O
were	O
found	O
to	O
have	O
intraoperative	O
ipsilateral	O
vocal	Disease
cord	Disease
paralysis	Disease
.	O
It	O
resolved	O
in	O
all	O
cases	O
<	O
or	O
=24	O
hours.	O
There	O
were	O
no	O
significant	O
differences	O
in	O
operating	O
time	O
or	O
volume	O
or	O
frequency	O
of	O
anesthetic	O
administration	O
in	O
patients	O
with	O
temporary	O
vocal	Disease
cord	Disease
paralysis	Disease
compared	O
with	O
those	O
without.	O
CONCLUSION:	O
Local	O
anesthesia	O
led	O
to	O
temporary	O
ipsilateral	O
vocal	Disease
cord	Disease
paralysis	Disease
in	O
almost	O
half	O
of	O
these	O
patients.	O
Because	O
pre-existing	O
paralysis	Disease
is	O
of	O
a	O
relevant	O
frequency	O
(up	O
to	O
3%),	O
a	O
preoperative	O
evaluation	O
of	O
vocal	O
cord	O
function	O
before	O
carotid	O
endarterectomy	O
under	O
local	O
anesthesia	O
is	O
recommended	O
to	O
avoid	O
intraoperative	O
bilateral	O
paralysis	Disease
.	O
In	O
patients	O
with	O
preoperative	O
contralateral	O
vocal	Disease
cord	Disease
paralysis	Disease

Neuroprotective	O
effects	O
of	O
melatonin	Chemical
upon	O
the	O
offspring	O
cerebellar	O
cortex	O
in	O
the	O
rat	O
model	O
of	O
BCNU	Chemical
-induced	O
cortical	Disease
dysplasia	Disease
.	O
Cortical	Disease
dysplasia	Disease
is	O
a	O
malformation	O
characterized	O
by	O
defects	O
in	O
proliferation,	O
migration	O
and	O
maturation.	O
This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
alterations	O
in	O
offspring	O
rat	O
cerebellum	O
induced	O
by	O
maternal	O
exposure	O
to	O
carmustine	Chemical
-[	O
1,3-bis	Chemical
(2-chloroethyl)-1-nitrosoure	Chemical
]	O
(	O
BCNU	Chemical
)	O
and	O
to	O
investigate	O
the	O
effects	O
of	O
exogenous	O
melatonin	Chemical
upon	O
cerebellar	O
BCNU	Chemical
-induced	O
cortical	Disease
dysplasia	Disease
,	O
using	O
histological	O
and	O
biochemical	O
analyses.	O
Pregnant	O
Wistar	O
rats	O
were	O
assigned	O
to	O
five	O
groups:	O
intact-control,	O
saline-control,	O
melatonin	Chemical
-treated,	O
BCNU	Chemical
-exposed	O
and	O
BCNU	Chemical
-exposed	O
plus	O
melatonin	Chemical
.	O
Rats	O
were	O
exposed	O
to	O
BCNU	Chemical
on	O
embryonic	O
day	O
15	O
and	O
melatonin	Chemical
was	O
given	O
until	O
delivery.	O
Immuno/histochemistry	O
and	O
electron	O
microscopy	O
were	O
carried	O
out	O
on	O
the	O
offspring	O
cerebellum,	O
and	O
levels	O
of	O
malondialdehyde	Chemical
and	O
superoxide	Chemical
dismutase	O
were	O
determined.	O
Histopathologically,	O
typical	O
findings	O
were	O
observed	O
in	O
the	O
cerebella	O
from	O
the	O
control	O
groups,	O
but	O
the	O
findings	O
consistent	O
with	O
early	O
embryonic	O
development	O
were	O
noted	O
in	O
BCNU	Chemical
-exposed	O
cortical	Disease
dysplasia	Disease
group.	O
There	O
was	O
a	O
marked	O
increase	O
in	O
the	O
number	O
of	O
TUNEL	O
positive	O
cells	O
and	O
nestin	O
positive	O
cells	O
in	O
BCNU	Chemical
-exposed	O
group,	O
but	O
a	O
decreased	O
immunoreactivity	O
to	O
glial	O
fibrillary	O
acidic	O
protein,	O
synaptophysin	O
and	O
transforming	O
growth	O
factor	O
beta1	O
was	O
observed,	O
indicating	O
a	O
delayed	O
maturation,	O
and	O
melatonin	Chemical
significantly	O
reversed	O
these	O
changes.	O
Malondialdehyde	Chemical
level	O
in	O
BCNU	Chemical
-exposed	O
group	O
was	O
higher	O
than	O
those	O
in	O
control	O
groups	O
and	O
melatonin	Chemical
decreased	O
malondialdehyde	Chemical
levels	O
in	O
BCNU	Chemical
group	O
(P<0.01),	O
while	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
superoxide	Chemical
dismutase	O
levels	O
between	O
these	O
groups.	O
These	O
data	O
suggest	O
that	O
exposure	O
of	O
animals	O
to	O
BCNU	Chemical
during	O
pregnancy	O
leads	O
to	O
delayed	O
maturation	O
of	O
offspring	O
cerebellum	O
and	O
melatonin	Chemical
protects	O
the	O
cerebellum	O
against	O
the	O
effects	O
of	O
BCNU	Chemical

Myo-inositol-1-phosphate	Chemical
(	O
MIP	Chemical
)	O
synthase	O
inhibition:	O
in-vivo	O
study	O
in	O
rats.	O
Lithium	Chemical
and	O
valproate	Chemical
are	O
the	O
prototypic	O
mood	O
stabilizers	O
and	O
have	O
diverse	O
structures	O
and	O
targets.	O
Both	O
drugs	O
influence	O
inositol	Chemical
metabolism.	O
Lithium	Chemical
inhibits	O
IMPase	O
and	O
valproate	Chemical
inhibits	O
MIP	Chemical
synthase.	O
This	O
study	O
shows	O
that	O
MIP	Chemical
synthase	O
inhibition	O
does	O
not	O
replicate	O
or	O
augment	O
the	O
effects	O
of	O
lithium	Chemical
in	O
the	O
inositol	Chemical
sensitive	O
pilocarpine	Chemical
-induced	O
seizures	Disease
model.	O
This	O
lack	O
of	O
effects	O
may	O
stem	O
from	O
the	O
low	O
contribution	O
of	O
de-novo	O
synthesis	O
to	O
cellular	O
inositol	Chemical
supply	O
or	O
to	O
the	O
inhibition	O
of	O
the	O
de-novo	O
synthesis	O
by	O
lithium	Chemical

Non-steroidal	O
anti-inflammatory	O
drugs-associated	O
acute	O
interstitial	Disease
nephritis	Disease
with	O
granular	O
tubular	O
basement	O
membrane	O
deposits.	O
Acute	Disease
tubulo-interstitial	Disease
nephritis	Disease
(	O
ATIN	Disease
)	O
is	O
an	O
important	O
cause	O
of	O
acute	Disease
renal	Disease
failure	Disease
resulting	O
from	O
a	O
variety	O
of	O
insults,	O
including	O
immune	O
complex-mediated	O
tubulo-interstitial	Disease
injury	Disease
,	O
but	O
drugs	O
such	O
as	O
non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
are	O
a	O
far	O
more	O
frequent	O
cause.	O
Overall,	O
as	O
an	O
entity,	O
ATIN	Disease
remains	O
under-diagnosed,	O
as	O
symptoms	O
resolve	O
spontaneously	O
if	O
the	O
medication	O
is	O
stopped.	O
We	O
report	O
on	O
a	O
14-year-old	O
boy	O
who	O
developed	O
acute	Disease
renal	Disease
failure	Disease
2	O
weeks	O
after	O
aortic	O
valve	O
surgery.	O
He	O
was	O
put	O
on	O
aspirin	Chemical
following	O
surgery	O
and	O
took	O
ibuprofen	Chemical
for	O
fever	Disease
for	O
nearly	O
a	O
week	O
prior	O
to	O
presentation.	O
He	O
then	O
presented	O
to	O
the	O
emergency	O
department	O
feeling	O
quite	O
ill	O
and	O
was	O
found	O
to	O
have	O
a	O
blood	Chemical
urea	Chemical
nitrogen	Chemical
(	O
BUN	Chemical
)	O
concentration	O
of	O
of	O
147	O
mg/dl,	O
creatinine	Chemical
of	O
15.3	O
mg/dl	O
and	O
serum	O
potassium	Chemical
of	O
8.7	O
mEq/l.	O
Dialysis	O
was	O
immediately	O
initiated.	O
A	O
kidney	O
biopsy	O
showed	O
inflammatory	O
infiltrate	O
consistent	O
with	O
ATIN	Disease
.	O
However,	O
in	O
the	O
tubular	O
basement	O
membrane	O
(TBM),	O
very	O
intense	O
granular	O
deposits	O
of	O
polyclonal	O
IgG	O
and	O
C3	O
were	O
noted.	O
He	O
needed	O
dialysis	O
for	O
2	O
weeks	O
and	O
was	O
treated	O
successfully	O
with	O
steroids	Chemical
for	O
6	O
months.	O
His	O
renal	O
recovery	O
and	O
disappearance	O
of	O
proteinuria	Disease
took	O
a	O
year.	O
In	O
conclusion,	O
this	O
is	O
a	O
first	O
report	O
of	O
NSAIDs-associated	O
ATIN	Disease

Rifampicin	Chemical
-associated	O
segmental	O
necrotizing	O
glomerulonephritis	Disease
in	O
staphylococcal	Disease
endocarditis	Disease
.	O
Segmental	O
necrotising	O
glomerulonephritis	Disease
has	O
been	O
reported	O
as	O
complication	O
of	O
rifampicin	Chemical
therapy	O
in	O
patients	O
receiving	O
treatment	O
for	O
tuberculosis	Disease
.	O
Changing	O
epidemiology	O
of	O
infections	Disease
such	O
as	O
infective	Disease
endocarditis	Disease
(	O
IE	Disease
)	O
has	O
led	O
to	O
an	O
increase	O
in	O
the	O
use	O
of	O
rifampicin	Chemical
for	O
Staphylococcal	Disease
infections	Disease
.	O
We	O
describe	O
a	O
case	O
of	O
a	O
patient	O
with	O
Staphylococcal	Disease
IE	Disease
who	O
developed	O
acute	Disease
renal	Disease
failure	Disease
secondary	O
to	O
a	O
segmental	O
necrotising	O
glomerulonephritis	Disease
while	O
being	O
treated	O
with	O
rifampicin	Chemical
,	O
and	O
review	O
the	O
literature	O
regarding	O
this	O
complication	O
of	O
rifampicin	Chemical

Rate	O
of	O
YMDD	O
motif	O
mutants	O
in	O
lamivudine	Chemical
-untreated	O
Iranian	O
patients	O
with	O
chronic	Disease
hepatitis	Disease
B	Disease
virus	Disease
infection	Disease
.	O
BACKGROUND:	O
Lamivudine	Chemical
is	O
used	O
for	O
the	O
treatment	O
of	O
chronic	Disease
hepatitis	Disease
B	Disease
patients.	O
Recent	O
studies	O
show	O
that	O
the	O
YMDD	O
motif	O
mutants	O
(resistant	O
hepatitis	Disease
B	Disease
virus)	O
occur	O
as	O
natural	O
genome	O
variability	O
in	O
lamivudine	Chemical
-untreated	O
chronic	Disease
hepatitis	Disease
B	Disease
patients.	O
In	O
this	O
study	O
we	O
aimed	O
to	O
determine	O
the	O
rate	O
of	O
YMDD	O
motif	O
mutants	O
in	O
lamivudine	Chemical
-untreated	O
chronic	Disease
hepatitis	Disease
B	Disease
patients	O
in	O
Iran.	O
PATIENTS	O
AND	O
METHODS:	O
A	O
total	O
of	O
77	O
chronic	Disease
hepatitis	Disease
B	Disease
patients	O
who	O
had	O
not	O
been	O
treated	O
with	O
lamivudine	Chemical
were	O
included	O
in	O
the	O
study.	O
Serum	O
samples	O
from	O
patients	O
were	O
tested	O
by	O
polymerase	O
chain	O
reaction-restriction	O
fragment	O
length	O
polymorphism	O
(PCR-RFLP)	O
for	O
detection	O
of	O
YMDD	O
motif	O
mutants.	O
All	O
patients	O
were	O
also	O
tested	O
for	O
liver	O
enzymes,	O
anti-HCV,	O
HBeAg	Chemical
,	O
and	O
anti-HBe.	O
RESULTS:	O
Of	O
the	O
77	O
patients	O
enrolled	O
in	O
the	O
study,	O
73%	O
were	O
male	O
and	O
27%	O
were	O
female.	O
Mean	O
ALT	O
and	O
AST	O
levels	O
were	O
124.4+/-73.4	O
and	O
103.1+/-81	O
IU/l,	O
respectively.	O
HBeAg	Chemical
was	O
positive	O
in	O
40%	O
and	O
anti-HBe	O
in	O
60%	O
of	O
the	O
patients.	O
Anti-HCV	O
was	O
negative	O
in	O
all	O
of	O
them.	O
YMDD	O
motif	O
mutants	O
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
patients	O
despite	O
the	O
liver	O
enzyme	O
levels	O
and	O
the	O
presence	O
of	O
HBeAg	Chemical
or	O
anti-HBe.	O
CONCLUSION:	O
Although	O
the	O
natural	O
occurrence	O
of	O
YMDD	O
motif	O
mutants	O
in	O
lamivudine	Chemical
-untreated	O
patients	O
with	O
chronic	Disease
hepatitis	Disease
B	Disease
has	O
been	O
reported,	O
these	O
mutants	O
were	O
not	O
detected	O
in	O
Iranian	O
lamivudine	Chemical
-untreated	O
chronic	Disease
hepatitis	Disease
B	Disease

Branch	O
retinal	Disease
vein	Disease
occlusion	Disease
and	O
fluoxetine	Chemical
.	O
A	O
case	O
of	O
branch	O
retinal	Disease
vein	Disease
occlusion	Disease
associated	O
with	O
fluoxetine	Chemical
-induced	O
secondary	O
hypertension	Disease
is	O
described.	O
Although	O
an	O
infrequent	O
complication	O
of	O
selective	O
serotonin	Chemical
reuptake	O
inhibitor	O
therapy,	O
it	O
is	O
important	O
that	O
ophthalmologists	O
are	O
aware	O
that	O
these	O
agents	O
can	O
cause	O
hypertension	Disease

The	O
differential	O
effects	O
of	O
bupivacaine	Chemical
and	O
lidocaine	Chemical
on	O
prostaglandin	Chemical
E2	Chemical
release,	O
cyclooxygenase	O
gene	O
expression	O
and	O
pain	Disease
in	O
a	O
clinical	O
pain	Disease
model.	O
BACKGROUND:	O
In	O
addition	O
to	O
blocking	O
nociceptive	O
input	O
from	O
surgical	O
sites,	O
long-acting	O
local	O
anesthetics	O
might	O
directly	O
modulate	O
inflammation	Disease
.	O
In	O
the	O
present	O
study,	O
we	O
describe	O
the	O
proinflammatory	O
effects	O
of	O
bupivacaine	Chemical
on	O
local	O
prostaglandin	Chemical
E2	Chemical
(	O
PGE2	Chemical
)	O
production	O
and	O
cyclooxygenase	O
(COX)	O
gene	O
expression	O
that	O
increases	O
postoperative	Disease
pain	Disease
in	O
human	O
subjects.	O
METHODS:	O
Subjects	O
(n	O
=	O
114)	O
undergoing	O
extraction	O
of	O
impacted	O
third	O
molars	O
received	O
either	O
2%	O
lidocaine	Chemical
or	O
0.5%	O
bupivacaine	Chemical
before	O
surgery	O
and	O
either	O
rofecoxib	Chemical
50	O
mg	O
or	O
placebo	O
orally	O
90	O
min	O
before	O
surgery	O
and	O
for	O
the	O
following	O
48	O
h.	O
Oral	O
mucosal	O
biopsies	O
were	O
taken	O
before	O
surgery	O
and	O
48	O
h	O
after	O
surgery.	O
After	O
extraction,	O
a	O
microdialysis	O
probe	O
was	O
placed	O
at	O
the	O
surgical	O
site	O
for	O
PGE2	Chemical
and	O
thromboxane	Chemical
B2	Chemical
(	O
TXB2	Chemical
)	O
measurements.	O
RESULTS:	O
The	O
bupivacaine	Chemical
/	O
rofecoxib	Chemical
group	O
reported	O
significantly	O
less	O
pain	Disease
,	O
as	O
assessed	O
by	O
a	O
visual	O
analog	O
scale,	O
compared	O
with	O
the	O
other	O
three	O
treatment	O
groups	O
over	O
the	O
first	O
4	O
h.	O
However,	O
the	O
bupivacaine	Chemical
/placebo	O
group	O
reported	O
significantly	O
more	O
pain	Disease
at	O
24	O
h	O
and	O
PGE2	Chemical
levels	O
during	O
the	O
first	O
4	O
h	O
were	O
significantly	O
higher	O
than	O
the	O
other	O
three	O
treatment	O
groups.	O
Moreover,	O
bupivacaine	Chemical
significantly	O
increased	O
COX-2	O
gene	O
expression	O
at	O
48	O
h	O
as	O
compared	O
with	O
the	O
lidocaine	Chemical
/placebo	O
group.	O
Thromboxane	Chemical
levels	O
were	O
not	O
significantly	O
affected	O
by	O
any	O
of	O
the	O
treatments,	O
indicating	O
that	O
the	O
effects	O
seen	O
were	O
attributable	O
to	O
inhibition	O
of	O
COX-2,	O
but	O
not	O
COX-1.	O
CONCLUSIONS:	O
These	O
results	O
suggest	O
that	O
bupivacaine	Chemical
stimulates	O
COX-2	O
gene	O
expression	O
after	O
tissue	Disease
injury	Disease
,	O
which	O
is	O
associated	O
with	O
higher	O
PGE2	Chemical
production	O
and	O
pain	Disease

p75NTR	O
expression	O
in	O
rat	O
urinary	O
bladder	O
sensory	O
neurons	O
and	O
spinal	O
cord	O
with	O
cyclophosphamide	Chemical
-induced	O
cystitis	Disease
.	O
A	O
role	O
for	O
nerve	O
growth	O
factor	O
(NGF)	O
in	O
contributing	O
to	O
increased	O
voiding	O
frequency	O
and	O
altered	O
sensation	O
from	O
the	O
urinary	O
bladder	O
has	O
been	O
suggested.	O
Previous	O
studies	O
have	O
examined	O
the	O
expression	O
and	O
regulation	O
of	O
tyrosine	Chemical
kinase	O
receptors	O
(Trks)	O
in	O
micturition	O
reflexes	O
with	O
urinary	Disease
bladder	Disease
inflammation	Disease
.	O
The	O
present	O
studies	O
examine	O
the	O
expression	O
and	O
regulation	O
of	O
another	O
receptor	O
known	O
to	O
bind	O
NGF,	O
p75(NTR),	O
after	O
various	O
durations	O
of	O
bladder	Disease
inflammation	Disease
induced	O
by	O
cyclophosphamide	Chemical
(	O
CYP	Chemical
).	O
CYP	Chemical
-induced	O
cystitis	Disease
increased	O
(P	O
<	O
or	O
=	O
0.001)	O
p75(NTR)	O
expression	O
in	O
the	O
superficial	O
lateral	O
and	O
medial	O
dorsal	O
horn	O
in	O
L1-L2	O
and	O
L6-S1	O
spinal	O
segments.	O
The	O
number	O
of	O
p75(NTR)-immunoreactive	O
(-IR)	O
cells	O
in	O
the	O
lumbosacral	O
dorsal	O
root	O
ganglia	O
(DRG)	O
also	O
increased	O
(P	O
<	O
or	O
=	O
0.05)	O
with	O
CYP	Chemical
-induced	O
cystitis	Disease
(acute,	O
intermediate,	O
and	O
chronic).	O
Quantitative,	O
real-time	O
polymerase	O
chain	O
reaction	O
also	O
demonstrated	O
significant	O
increases	O
(P	O
<	O
or	O
=	O
0.01)	O
in	O
p75(NTR)	O
mRNA	O
in	O
DRG	O
with	O
intermediate	O
and	O
chronic	O
CYP	Chemical
-induced	O
cystitis	Disease
.	O
Retrograde	O
dye-tracing	O
techniques	O
with	O
Fastblue	O
were	O
used	O
to	O
identify	O
presumptive	O
bladder	O
afferent	O
cells	O
in	O
the	O
lumbosacral	O
DRG.	O
In	O
bladder	O
afferent	O
cells	O
in	O
DRG,	O
p75(NTR)-IR	O
was	O
also	O
increased	O
(P	O
<	O
or	O
=	O
0.01)	O
with	O
cystitis	Disease
.	O
In	O
addition	O
to	O
increases	O
in	O
p75(NTR)-IR	O
in	O
DRG	O
cell	O
bodies,	O
increases	O
(P	O
<	O
or	O
=	O
0.001)	O
in	O
pericellular	O
(encircling	O
DRG	O
cells)	O
p75(NTR)-IR	O
in	O
DRG	O
also	O
increased.	O
Confocal	O
analyses	O
demonstrated	O
that	O
pericellular	O
p75(NTR)-IR	O
was	O
not	O
colocalized	O
with	O
the	O
glial	O
marker,	O
glial	O
fibrillary	O
acidic	O
protein	O
(GFAP).	O
These	O
studies	O
demonstrate	O
that	O
p75(NTR)	O
expression	O
in	O
micturition	O
reflexes	O
is	O
present	O
constitutively	O
and	O
modified	O
by	O
bladder	Disease
inflammation	Disease

Azathioprine	Chemical
-induced	O
suicidal	O
erythrocyte	O
death.	O
BACKGROUND:	O
Azathioprine	Chemical
is	O
widely	O
used	O
as	O
an	O
immunosuppressive	O
drug.	O
The	O
side	O
effects	O
of	O
azathioprine	Chemical
include	O
anemia	Disease
,	O
which	O
has	O
been	O
attributed	O
to	O
bone	O
marrow	O
suppression.	O
Alternatively,	O
anemia	Disease
could	O
result	O
from	O
accelerated	O
suicidal	O
erythrocyte	O
death	O
or	O
eryptosis,	O
which	O
is	O
characterized	O
by	O
exposure	O
of	O
phosphatidylserine	Chemical
(	O
PS	Chemical
)	O
at	O
the	O
erythrocyte	O
surface	O
and	O
by	O
cell	O
shrinkage.	O
METHODS:	O
The	O
present	O
experiments	O
explored	O
whether	O
azathioprine	Chemical
influences	O
eryptosis.	O
According	O
to	O
annexin	O
V	O
binding,	O
erythrocytes	O
from	O
patients	O
indeed	O
showed	O
a	O
significant	O
increase	O
of	O
PS	Chemical
exposure	O
within	O
1	O
week	O
of	O
treatment	O
with	O
azathioprine	Chemical
.	O
In	O
a	O
second	O
series,	O
cytosolic	O
Ca	Chemical
2+	O
activity	O
(	O
Fluo3	Chemical
fluorescence),	O
cell	O
volume	O
(forward	O
scatter),	O
and	O
PS	Chemical
-exposure	O
(annexin	O
V	O
binding)	O
were	O
determined	O
by	O
FACS	O
analysis	O
in	O
erythrocytes	O
from	O
healthy	O
volunteers.	O
RESULTS:	O
Exposure	O
to	O
azathioprine	Chemical
(>	O
or	O
=2	O
microg/mL)	O
for	O
48	O
hours	O
increased	O
cytosolic	O
Ca	Chemical
2+	O
activity	O
and	O
annexin	O
V	O
binding	O
and	O
decreased	O
forward	O
scatter.	O
The	O
effect	O
of	O
azathioprine	Chemical
on	O
both	O
annexin	O
V	O
binding	O
and	O
forward	O
scatter	O
was	O
significantly	O
blunted	O
in	O
the	O
nominal	O
absence	O
of	O
extracellular	O
Ca	Chemical
2+.	O
CONCLUSIONS:	O
Azathioprine	Chemical
triggers	O
suicidal	O
erythrocyte	O
death,	O
an	O
effect	O
presumably	O
contributing	O
to	O
azathioprine	Chemical
-induced	O
anemia	Disease

Clinical	O
comparison	O
of	O
cardiorespiratory	O
effects	O
during	O
unilateral	O
and	O
conventional	O
spinal	O
anaesthesia.	O
BACKGROUND:	O
Spinal	O
anaesthesia	O
is	O
widely	O
employed	O
in	O
clinical	O
practice	O
but	O
has	O
the	O
main	O
drawback	O
of	O
post-spinal	O
block	O
hypotension	Disease
.	O
Efforts	O
must	O
therefore	O
continue	O
to	O
be	O
made	O
to	O
obviate	O
this	O
setback	O
OBJECTIVE:	O
To	O
evaluate	O
the	O
cardiovascular	O
and	O
respiratory	O
changes	O
during	O
unilateral	O
and	O
conventional	O
spinal	O
anaesthesia.	O
METHODS:	O
With	O
ethical	O
approval,	O
we	O
studied	O
74	O
American	O
Society	O
of	O
Anesthesiologists	O
(ASA),	O
physical	O
status	O
class	O
1	O
and	O
2	O
patients	O
scheduled	O
for	O
elective	O
unilateral	O
lower	O
limb	O
surgery.	O
Patients	O
were	O
randomly	O
allocated	O
into	O
one	O
of	O
two	O
groups:	O
lateral	O
and	O
conventional	O
spinal	O
anaesthesia	O
groups.	O
In	O
the	O
lateral	O
position	O
with	O
operative	O
side	O
down,	O
patients	O
recived	O
10	O
mg	O
(2mls)	O
of	O
0.5%	O
hyperbaric	O
bupivacaine	Chemical
through	O
a	O
25-gauge	O
spinal	O
needle.	O
Patients	O
in	O
the	O
unilateral	O
group	O
were	O
maintained	O
in	O
the	O
lateral	O
position	O
for	O
15	O
minutes	O
following	O
spinal	O
injection	O
while	O
those	O
in	O
the	O
conventional	O
group	O
were	O
turned	O
supine	O
immediately	O
after	O
injection.	O
Blood	O
pressure,	O
heart	O
rate,	O
respiratory	O
rate	O
and	O
oxygen	Chemical
saturation	O
were	O
monitored	O
over	O
1	O
hour.	O
RESULTS:	O
Three	O
patients	O
(8.1%)	O
in	O
the	O
unilateral	O
group	O
and	O
5	O
(13.5%)	O
in	O
the	O
conventional	O
group	O
developed	O
hypotension	Disease
,	O
P=	O
0.71.	O
Four	O
(10.8%)	O
patients	O
in	O
the	O
conventional	O
group	O
and	O
1	O
(2.7%)	O
in	O
the	O
unilateral	O
group,	O
P=	O
0.17	O
required	O
epinephrine	Chemical
infusion	O
to	O
treat	O
hypotension	Disease
.	O
Patients	O
in	O
the	O
conventional	O
group	O
had	O
statistically	O
significant	O
greater	O
fall	O
in	O
the	O
systolic	O
blood	O
pressures	O
at	O
15,	O
30	O
and	O
45	O
minutes	O
when	O
compared	O
to	O
the	O
baseline	O
(P=	O
0.003,	O
0.001	O
and	O
0.004).	O
The	O
mean	O
respiratory	O
rate	O
and	O
oxygen	Chemical
saturations	O
in	O
the	O
two	O
groups	O
were	O
similar.	O
CONCLUSION:	O
Compared	O
to	O
conventional	O
spinal	O
anaesthesia,	O
unilateral	O
spinal	O
anaesthesia	O
was	O
associated	O
with	O
fewer	O
cardiovascular	O
perturbations.	O
Also,	O
the	O
type	O
of	O
spinal	O
block	O
instituted	O
affected	O
neither	O
the	O
respiratory	O
rate	O
nor	O
the	O
arterial	O
oxygen	Chemical

Spectrum	O
of	O
adverse	O
events	O
after	O
generic	O
HAART	O
in	O
southern	O
Indian	O
HIV-infected	Disease
patients.	O
To	O
determine	O
the	O
incidence	O
of	O
clinically	O
significant	O
adverse	O
events	O
after	O
long-term,	O
fixed-dose,	O
generic	O
highly	O
active	O
antiretroviral	O
therapy	O
(HAART)	O
use	O
among	O
HIV-infected	Disease
individuals	O
in	O
South	O
India,	O
we	O
examined	O
the	O
experiences	O
of	O
3154	O
HIV-infected	Disease
individuals	O
who	O
received	O
a	O
minimum	O
of	O
3	O
months	O
of	O
generic	O
HAART	O
between	O
February	O
1996	O
and	O
December	O
2006	O
at	O
a	O
tertiary	O
HIV	O
care	O
referral	O
center	O
in	O
South	O
India.	O
The	O
most	O
common	O
regimens	O
were	O
3TC	Chemical
+	O
d4T	Chemical
+	O
nevirapine	Chemical
(	O
NVP	Chemical
)	O
(54.8%),	O
zidovudine	Chemical
(	O
AZT	Chemical
)	O
+	O
3TC	Chemical
+	O
NVP	Chemical
(14.5%),	O
3TC	Chemical
+	O
d4T	Chemical
+	O
efavirenz	Chemical
(	O
EFV	Chemical
)	O
(20.1%),	O
and	O
AZT	Chemical
+	O
3TC	Chemical
+	O
EFV	Chemical
(5.4%).	O
The	O
most	O
common	O
adverse	O
events	O
and	O
median	O
CD4	O
at	O
time	O
of	O
event	O
were	O
rash	Disease
(15.2%;	O
CD4,	O
285	O
cells/microL)	O
and	O
peripheral	Disease
neuropathy	Disease
(9.0%	O
and	O
348	O
cells/microL).	O
Clinically	O
significant	O
anemia	Disease
(hemoglobin	O
<7	O
g/dL)	O
was	O
observed	O
in	O
5.4%	O
of	O
patients	O
(CD4,	O
165	O
cells/microL)	O
and	O
hepatitis	Disease
(clinical	O
jaundice	Disease
with	O
alanine	Chemical
aminotransferase	O
>	O
5	O
times	O
upper	O
limits	O
of	O
normal)	O
in	O
3.5%	O
of	O
patients	O
(CD4,	O
260	O
cells/microL).	O
Women	O
were	O
significantly	O
more	O
likely	O
to	O
experience	O
lactic	Disease
acidosis	Disease
,	O
while	O
men	O
were	O
significantly	O
more	O
likely	O
to	O
experience	O
immune	Disease
reconstitution	Disease
syndrome	Disease
(p	O
<	O
0.05).	O
Among	O
the	O
patients	O
with	O
1	O
year	O
of	O
follow-up,	O
NVP	Chemical
therapy	O
was	O
significantly	O
associated	O
with	O
developing	O
rash	Disease
and	O
d4T	Chemical
therapy	O
with	O
developing	O
peripheral	Disease
neuropathy	Disease
(p	O
<	O
0.05).	O
Anemia	Disease
and	O
hepatitis	Disease
often	O
occur	O
within	O
12	O
weeks	O
of	O
initiating	O
generic	O
HAART.	O
Frequent	O
and	O
early	O
monitoring	O
for	O
these	O
toxicities	Disease

Thalidomide	Chemical
and	O
sensory	Disease
neurotoxicity	Disease
:	O
a	O
neurophysiological	O
study.	O
BACKGROUND:	O
Recent	O
studies	O
confirmed	O
a	O
high	O
incidence	O
of	O
sensory	Disease
axonal	Disease
neuropathy	Disease
in	O
patients	O
treated	O
with	O
different	O
doses	O
of	O
thalidomide	Chemical
.	O
The	O
study's	O
aims	O
were	O
to	O
measure	O
variations	O
in	O
sural	O
nerve	O
sensory	O
action	O
potential	O
(SAP)	O
amplitude	O
in	O
patients	O
with	O
refractory	O
cutaneous	Disease
lupus	Disease
erythematosus	Disease
(	O
CLE	Disease
)	O
treated	O
with	O
thalidomide	Chemical
and	O
use	O
these	O
findings	O
to	O
identify	O
the	O
neurotoxic	Disease
potential	O
of	O
thalidomide	Chemical
and	O
the	O
recovery	O
capacity	O
of	O
sensory	O
fibres	O
after	O
discontinuation	O
of	O
treatment.	O
PATIENTS	O
AND	O
METHODS:	O
Clinical	O
and	O
electrophysiological	O
data	O
in	O
12	O
female	O
patients	O
with	O
CLE	Disease
during	O
treatment	O
with	O
thalidomide	Chemical
and	O
up	O
to	O
47	O
months	O
after	O
discontinuation	O
of	O
treatment	O
were	O
analysed.	O
Sural	O
nerve	O
SAP	O
amplitude	O
reduction	O
>	O
or	O
=40%	O
was	O
the	O
criteria	O
for	O
discontinuing	O
therapy.	O
RESULTS:	O
During	O
treatment,	O
11	O
patients	O
showed	O
a	O
reduction	O
in	O
sural	O
nerve	O
SAP	O
amplitude	O
compared	O
to	O
baseline	O
values	O
(9	O
with	O
a	O
reduction	O
>	O
or	O
=50%	O
and	O
2	O
<50%).	O
One	O
patient	O
showed	O
no	O
changes	O
in	O
SAP	O
amplitude.	O
Five	O
patients	O
complained	O
of	O
paresthesias	Disease
and	O
leg	O
cramps	Disease
.	O
After	O
thalidomide	Chemical
treatment,	O
sural	O
SAP	O
amplitude	O
recovered	O
in	O
3	O
patients.	O
At	O
detection	O
of	O
reduction	O
in	O
sural	O
nerve	O
SAP	O
amplitude,	O
the	O
median	O
thalidomide	Chemical
cumulative	O
dose	O
was	O
21.4	O
g.	O
The	O
threshold	O
neurotoxic	Disease
dosage	O
is	O
lower	O
than	O
previously	O
reported.	O
CONCLUSIONS:	O
Sural	O
nerve	O
SAP	O
amplitude	O
reduction	O
is	O
a	O
reliable	O
and	O
sensitive	O
marker	O
of	O
degeneration	O
and	O
recovery	O
of	O
sensory	O
fibres.	O
This	O
electrophysiological	O
parameter	O
provides	O
information	O
about	O
subclinical	O
neurotoxic	Disease
potential	O
of	O
thalidomide	Chemical

Amiodarone	Chemical
-related	O
pulmonary	Disease
mass	Disease
and	O
unique	O
membranous	Disease
glomerulonephritis	Disease
in	O
a	O
patient	O
with	O
valvular	Disease
heart	Disease
disease	Disease
:	O
Diagnostic	O
pitfall	O
and	O
new	O
findings.	O
Amiodarone	Chemical
is	O
an	O
anti-	O
arrhythmic	Disease
drug	O
for	O
life-threatening	O
tachycardia	Disease
,	O
but	O
various	O
adverse	O
effects	O
have	O
been	O
reported.	O
Reported	O
herein	O
is	O
an	O
autopsy	O
case	O
of	O
valvular	Disease
heart	Disease
disease	Disease
,	O
in	O
a	O
patient	O
who	O
developed	O
a	O
lung	Disease
mass	Disease
(1.5	O
cm	O
in	O
diameter)	O
and	O
proteinuria	Disease
(2.76	O
g/day)	O
after	O
treatment	O
with	O
amiodarone	Chemical
for	O
a	O
long	O
time.	O
The	O
lung	Disease
mass	Disease
was	O
highly	O
suspected	O
to	O
be	O
lung	Disease
cancer	Disease
on	O
CT	O
and	O
positron	O
emission	O
tomography,	O
but	O
histologically	O
the	O
lesion	O
was	O
composed	O
of	O
lymphoplasmacytic	O
infiltrates	O
in	O
alveolar	O
walls	O
and	O
intra-alveolar	O
accumulation	O
of	O
foamy	O
macrophages	O
containing	O
characteristic	O
myelinoid	O
bodies,	O
indicating	O
that	O
it	O
was	O
an	O
amiodarone	Chemical
-related	O
lesion.	O
In	O
addition,	O
the	O
lung	O
tissue	O
had	O
unevenly	O
distributed	O
hemosiderin	Disease
deposition,	O
and	O
abnormally	O
tortuous	O
capillaries	O
were	O
seen	O
in	O
the	O
mass	O
and	O
in	O
heavily	O
hemosiderotic	Disease
lung	O
portions	O
outside	O
the	O
mass.	O
In	O
the	O
kidneys,	O
glomeruli	O
had	O
membrane	O
spikes,	O
prominent	O
swelling	O
of	O
podocytes	O
and	O
subepithelial	O
deposits,	O
which	O
were	O
sometimes	O
large	O
and	O
hump-like.	O
Autoimmune	Disease
diseases	Disease
,	O
viral	Disease
hepatitis	Disease
,	O
malignant	O
neoplasms	Disease
or	O
other	O
diseases	O
with	O
a	O
known	O
relationship	O
to	O
membranous	Disease
glomerulonephritis	Disease
were	O
not	O
found.	O
The	O
present	O
case	O
highlights	O
the	O
possibility	O
that	O
differential	O
diagnosis	O
between	O
an	O
amiodarone	Chemical
-related	O
pulmonary	Disease
lesion	Disease
and	O
a	O
neoplasm	Disease
can	O
be	O
very	O
difficult	O
radiologically,	O
and	O
suggests	O
that	O
membranous	Disease
glomerulonephritis	Disease
might	O
be	O
another	O
possible	O
complication	O
of	O
amiodarone	Chemical

Risk	O
of	O
coronary	Disease
artery	Disease
disease	Disease
associated	O
with	O
initial	O
sulphonylurea	Chemical
treatment	O
of	O
patients	O
with	O
type	Disease
2	Disease
diabetes	Disease
:	O
a	O
matched	O
case-control	O
study.	O
AIMS:	O
This	O
study	O
sought	O
to	O
assess	O
the	O
risk	O
of	O
developing	O
coronary	Disease
artery	Disease
disease	Disease
(	O
CAD	Disease
)	O
associated	O
with	O
initial	O
treatment	O
of	O
type	Disease
2	Disease
diabetes	Disease
with	O
different	O
sulphonylureas	Chemical
.	O
METHODS:	O
In	O
type	Disease
2	Disease
diabetic	Disease
patients,	O
cases	O
who	O
developed	O
CAD	Disease
were	O
compared	O
retrospectively	O
with	O
controls	O
that	O
did	O
not.	O
The	O
20-year	O
risk	O
of	O
CAD	Disease
at	O
diagnosis	O
of	O
diabetes	Disease
,	O
using	O
the	O
UKPDS	O
risk	O
engine,	O
was	O
used	O
to	O
match	O
cases	O
with	O
controls.	O
RESULTS:	O
The	O
76	O
cases	O
of	O
CAD	Disease
were	O
compared	O
with	O
152	O
controls.	O
The	O
hazard	O
of	O
developing	O
CAD	Disease
(95%	O
CI)	O
associated	O
with	O
initial	O
treatment	O
increased	O
by	O
2.4-fold	O
(1.3-4.3,	O
P=0.004)	O
with	O
glibenclamide	Chemical
;	O
2-fold	O
(0.9-4.6,	O
P=0.099)	O
with	O
glipizide	Chemical
;	O
2.9-fold	O
(1.6-5.1,	O
P=0.000)	O
with	O
either,	O
and	O
was	O
unchanged	O
with	O
metformin	Chemical
.	O
The	O
hazard	O
decreased	O
0.3-fold	O
(0.7-1.7,	O
P=0.385)	O
with	O
glimepiride	Chemical
,	O
0.4-fold	O
(0.7-1.3,	O
P=0.192)	O
with	O
gliclazide	Chemical
,	O
and	O
0.4-fold	O
(0.7-1.1,	O
P=0.09)	O
with	O
either.	O
CONCLUSIONS:	O
Initiating	O
treatment	O
of	O
type	Disease
2	Disease
diabetes	Disease
with	O
glibenclamide	Chemical
or	O
glipizide	Chemical
is	O
associated	O
with	O
increased	O
risk	O
of	O
CAD	Disease
in	O
comparison	O
to	O
gliclazide	Chemical
or	O
glimepiride	Chemical
.	O
If	O
confirmed,	O
this	O
may	O
be	O
important	O
because	O
most	O
Indian	O
patients	O
receive	O
the	O
cheaper	O
older	O
sulphonylureas	Chemical

Reduced	O
progression	O
of	O
adriamycin	Chemical
	O
nephropathy	Disease
in	O
spontaneously	O
hypertensive	Disease
rats	O
treated	O
by	O
losartan	Chemical
.	O
BACKGROUND:	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
antihypertensive	O
effects	O
of	O
angiotensin	Chemical
II	Chemical
type-1	O
receptor	O
blocker,	O
losartan	Chemical
,	O
and	O
its	O
potential	O
in	O
slowing	O
down	O
renal	Disease
disease	Disease
progression	O
in	O
spontaneously	O
hypertensive	Disease
rats	O
(SHR)	O
with	O
adriamycin	Chemical
(	O
ADR	Chemical
)	O
nephropathy	Disease
.	O
METHODS:	O
Six-month-old	O
female	O
SHR	O
were	O
randomly	O
selected	O
in	O
six	O
groups.	O
Two	O
control	O
groups	O
(SH(6),	O
SH(12))	O
received	O
vehicle.	O
Groups	O
ADR	Chemical
(6),	O
ADR	Chemical
+	O
LOS	Chemical
(6)	O
and	O
ADR	Chemical
(12),	O
and	O
ADR	Chemical
+	O
LOS	Chemical
(12)	O
received	O
ADR	Chemical
(2	O
mg/kg/b.w.	O
i.v.)	O
twice	O
in	O
a	O
3-week	O
interval.	O
Group	O
ADR	Chemical
+	O
LOS	Chemical
(6)	O
received	O
losartan	Chemical
(10	O
mg/kg/b.w./day	O
by	O
gavages)	O
for	O
6	O
weeks	O
and	O
group	O
ADR	Chemical
+	O
LOS	Chemical
(12)	O
for	O
12	O
weeks	O
after	O
second	O
injection	O
of	O
ADR	Chemical
.	O
Animals	O
were	O
killed	O
after	O
6	O
or	O
12	O
weeks,	O
respectively.	O
Haemodynamic	O
measurements	O
were	O
performed	O
on	O
anaesthetized	O
animals,	O
blood	O
and	O
urine	O
samples	O
were	O
taken	O
for	O
biochemical	O
analysis	O
and	O
the	O
left	O
kidney	O
was	O
processed	O
for	O
morphological	O
studies.	O
RESULTS:	O
Short-term	O
losartan	Chemical
treatment,	O
besides	O
antihypertensive	O
effect,	O
improved	O
glomerular	O
filtration	O
rate	O
and	O
ameliorated	O
glomerulosclerosis	Disease
resulting	O
in	O
decreased	O
proteinuria	Disease
.	O
Prolonged	O
treatment	O
with	O
losartan	Chemical
showed	O
further	O
reduction	O
of	O
glomerulosclerosis	Disease
associated	O
with	O
reduced	O
progression	O
of	O
tubular	O
atrophy	Disease
and	O
interstitial	Disease
fibrosis	Disease
,	O
thus	O
preventing	O
heavy	O
proteinuria	Disease
and	O
chronic	Disease
renal	Disease
failure	Disease
.	O
Losartan	Chemical
reduced	O
uraemia	Disease
and	O
increased	O
urea	Chemical
clearance	O
in	O
advanced	O
ADR	Chemical
	O
nephropathy	Disease
in	O
SHR.	O
Histological	O
examination	O
showed	O
that	O
losartan	Chemical
could	O
prevent	O
tubular	O
atrophy	Disease
,	O
interstitial	O
infiltration	O
and	O
fibrosis	Disease
in	O
ADR	Chemical
	O
nephropathy	Disease
.	O
CONCLUSION:	O
Losartan	Chemical
reduces	O
the	O
rate	O
of	O
progression	O
of	O
ADR	Chemical
-induced	O
focal	Disease
segmental	Disease
glomerulosclerosis	Disease
to	O
end-stage	Disease
renal	Disease
disease	Disease

The	O
risks	O
of	O
aprotinin	O
and	O
tranexamic	Chemical
acid	Chemical
in	O
cardiac	O
surgery:	O
a	O
one-year	O
follow-up	O
of	O
1188	O
consecutive	O
patients.	O
BACKGROUND:	O
Our	O
aim	O
was	O
to	O
investigate	O
postoperative	O
complications	O
and	O
mortality	O
after	O
administration	O
of	O
aprotinin	O
compared	O
to	O
tranexamic	Chemical
acid	Chemical
in	O
an	O
unselected,	O
consecutive	O
cohort.	O
METHODS:	O
Perioperative	O
data	O
from	O
consecutive	O
cardiac	O
surgery	O
patients	O
were	O
prospectively	O
collected	O
between	O
September	O
2005	O
and	O
June	O
2006	O
in	O
a	O
university-affiliated	O
clinic	O
(n	O
=	O
1188).	O
During	O
the	O
first	O
5	O
mo,	O
596	O
patients	O
received	O
aprotinin	O
(Group	O
A);	O
in	O
the	O
next	O
5	O
mo,	O
592	O
patients	O
were	O
treated	O
with	O
tranexamic	Chemical
acid	Chemical
(Group	O
T).	O
Except	O
for	O
antifibrinolytic	O
therapy,	O
the	O
anesthetic	O
and	O
surgical	O
protocols	O
remained	O
unchanged.	O
RESULTS:	O
The	O
pre-	O
and	O
intraoperative	O
variables	O
were	O
comparable	O
between	O
the	O
treatment	O
groups.	O
Postoperatively,	O
a	O
significantly	O
higher	O
incidence	O
of	O
seizures	Disease
was	O
found	O
in	O
Group	O
T	O
(4.6%	O
vs	O
1.2%,	O
P	O
<	O
0.001).	O
This	O
difference	O
was	O
also	O
significant	O
in	O
the	O
primary	O
valve	O
surgery	O
and	O
the	O
high	O
risk	O
surgery	O
subgroups	O
(7.9%	O
vs	O
1.2%,	O
P	O
=	O
0.003;	O
7.3%	O
vs	O
2.4%,	O
P	O
=	O
0.035,	O
respectively).	O
Persistent	O
atrial	O
fibrillation	O
(7.9%	O
vs	O
2.3%,	O
P	O
=	O
0.020)	O
and	O
renal	Disease
failure	Disease
(9.7%	O
vs	O
1.7%,	O
P	O
=	O
0.002)	O
were	O
also	O
more	O
common	O
in	O
Group	O
T,	O
in	O
the	O
primary	O
valve	O
surgery	O
subgroup.	O
On	O
the	O
contrary,	O
among	O
primary	O
coronary	O
artery	O
bypass	O
surgery	O
patients,	O
there	O
were	O
more	O
acute	O
myocardial	Disease
infarctions	Disease
and	O
renal	Disease
dysfunction	Disease
in	O
Group	O
A	O
(5.8%	O
vs	O
2.0%,	O
P	O
=	O
0.027;	O
22.5%	O
vs	O
15.2%,	O
P	O
=	O
0.036,	O
respectively).	O
The	O
1-yr	O
mortality	O
was	O
significantly	O
higher	O
after	O
aprotinin	O
treatment	O
in	O
the	O
high	O
risk	O
surgery	O
group	O
(17.7%	O
vs	O
9.8%,	O
P	O
=	O
0.034).	O
CONCLUSION:	O
Both	O
antifibrinolytic	O
drugs	O
bear	O
the	O
risk	O
of	O
adverse	O
outcome	O
depending	O
on	O
the	O
type	O
of	O
cardiac	O
surgery.	O
Administration	O
of	O
aprotinin	O
should	O
be	O
avoided	O
in	O
coronary	O
artery	O
bypass	O
graft	O
and	O
high	O
risk	O
patients,	O
whereas	O
administration	O
of	O
tranexamic	Chemical
acid	Chemical

The	O
biological	O
properties	O
of	O
the	O
optical	O
isomers	O
of	O
propranolol	Chemical
and	O
their	O
effects	O
on	O
cardiac	Disease
arrhythmias	Disease
.	O
1.	O
The	O
optical	O
isomers	O
of	O
propranolol	Chemical
have	O
been	O
compared	O
for	O
their	O
beta-blocking	O
and	O
antiarrhythmic	O
activities.2.	O
In	O
blocking	O
the	O
positive	O
inotropic	O
and	O
chronotropic	O
responses	O
to	O
isoprenaline	Chemical
,	O
(+)-	O
propranolol	Chemical
had	O
less	O
than	O
one	O
hundredth	O
the	O
potency	O
of	O
(-)-	O
propranolol	Chemical
.	O
At	O
dose	O
levels	O
of	O
(+)-	O
propranolol	Chemical
which	O
attenuated	O
the	O
responses	O
to	O
isoprenaline	Chemical
,	O
there	O
was	O
a	O
significant	O
prolongation	O
of	O
the	O
PR	O
interval	O
of	O
the	O
electrocardiogram.3.	O
The	O
metabolic	O
responses	O
to	O
isoprenaline	Chemical
in	O
dogs	O
(an	O
increase	O
in	O
circulating	O
glucose	Chemical
,	O
lactate	Chemical
and	O
free	O
fatty	Chemical
acids	Chemical
)	O
were	O
all	O
blocked	O
by	O
(-)-	O
propranolol	Chemical
.	O
(+)-	O
Propranolol	Chemical
had	O
no	O
effect	O
on	O
fatty	Chemical
acid	Chemical
mobilization	O
but	O
significantly	O
reduced	O
the	O
increments	O
in	O
both	O
lactate	Chemical
and	O
glucose	Chemical
.4.	O
Both	O
isomers	O
of	O
propranolol	Chemical
possessed	O
similar	O
depressant	O
potency	O
on	O
isolated	O
atrial	O
muscle	O
taken	O
from	O
guinea-pigs.5.	O
The	O
isomers	O
of	O
propranolol	Chemical
exhibited	O
similar	O
local	O
anaesthetic	O
potencies	O
on	O
an	O
isolated	O
frog	O
nerve	O
preparation	O
at	O
a	O
level	O
approximately	O
three	O
times	O
that	O
of	O
procaine	Chemical
.	O
The	O
racemic	O
compound	O
was	O
significantly	O
less	O
potent	O
than	O
either	O
isomer.6.	O
Both	O
isomers	O
of	O
propranolol	Chemical
were	O
capable	O
of	O
preventing	O
adrenaline	Chemical
-induced	O
cardiac	Disease
arrhythmias	Disease
in	O
cats	O
anaesthetized	O
with	O
halothane	Chemical
,	O
but	O
the	O
mean	O
dose	O
of	O
(-)-	O
propranolol	Chemical
was	O
0.09+/-0.02	O
mg/kg	O
whereas	O
that	O
of	O
(+)-	O
propranolol	Chemical
was	O
4.2+/-1.2	O
mg/kg.	O
At	O
the	O
effective	O
dose	O
level	O
of	O
(+)-	O
propranolol	Chemical
there	O
was	O
a	O
significant	O
prolongation	O
of	O
the	O
PR	O
interval	O
of	O
the	O
electrocardiogram.	O
Blockade	O
of	O
arrhythmias	Disease
with	O
both	O
isomers	O
was	O
surmountable	O
by	O
increasing	O
the	O
dose	O
of	O
adrenaline	Chemical
.7.	O
Both	O
isomers	O
of	O
propranolol	Chemical
were	O
also	O
capable	O
of	O
reversing	O
ventricular	Disease
tachycardia	Disease
caused	O
by	O
ouabain	Chemical
in	O
anaesthetized	O
cats	O
and	O
dogs.	O
The	O
dose	O
of	O
(-)-	O
propranolol	Chemical
was	O
significantly	O
smaller	O
than	O
that	O
of	O
(+)-	O
propranolol	Chemical

Topotecan	Chemical
in	O
combination	O
with	O
radiotherapy	O
in	O
unresectable	O
glioblastoma	Disease
:	O
a	O
phase	O
2	O
study.	O
Improving	O
glioblastoma	Disease
multiforme	Disease
(	O
GBM	Disease
)	O
treatment	O
with	O
radio-chemotherapy	O
remains	O
a	O
challenge.	O
Topotecan	Chemical
is	O
an	O
attractive	O
option	O
as	O
it	O
exhibits	O
growth	O
inhibition	O
of	O
human	O
glioma	Disease
as	O
well	O
as	O
brain	O
penetration.	O
The	O
present	O
study	O
assessed	O
the	O
combination	O
of	O
radiotherapy	O
(60	O
Gy/30	O
fractions/40	O
days)	O
and	O
topotecan	Chemical
(0.9	O
mg/m(2)/day	O
on	O
days	O
1-5	O
on	O
weeks	O
1,	O
3	O
and	O
5)	O
in	O
50	O
adults	O
with	O
histologically	O
proven	O
and	O
untreated	O
GBM	Disease
.	O
The	O
incidence	O
of	O
non-hematological	O
toxicities	Disease
was	O
low	O
and	O
grade	O
3-4	O
hematological	O
toxicities	Disease
were	O
reported	O
in	O
20	O
patients	O
(mainly	O
lymphopenia	Disease
and	O
neutropenia	Disease
).	O
Partial	O
response	O
and	O
stabilization	O
rates	O
were	O
2%	O
and	O
32%,	O
respectively,	O
with	O
an	O
overall	O
time	O
to	O
progression	O
of	O
12	O
weeks.	O
One-year	O
overall	O
survival	O
(OS)	O
rate	O
was	O
42%,	O
with	O
a	O
median	O
OS	O
of	O
40	O
weeks.	O
Topotecan	Chemical
in	O
combination	O
with	O
radiotherapy	O
was	O
well	O
tolerated.	O
However,	O
while	O
response	O
and	O
stabilization	O
concerned	O
one-third	O
of	O
the	O
patients,	O
the	O
study	O
did	O
not	O
show	O
increased	O
benefits	O
in	O
terms	O
of	O
survival	O
in	O
patients	O
with	O
unresectable	O
GBM	Disease

Long-term	O
lithium	Chemical
therapy	O
leading	O
to	O
hyperparathyroidism	Disease
:	O
a	O
case	O
report.	O
PURPOSE:	O
This	O
paper	O
reviews	O
the	O
effect	O
of	O
chronic	O
lithium	Chemical
therapy	O
on	O
serum	O
calcium	Chemical
level	O
and	O
parathyroid	O
glands,	O
its	O
pathogenesis,	O
and	O
treatment	O
options.	O
We	O
examined	O
the	O
case	O
of	O
a	O
lithium	Chemical
-treated	O
patient	O
who	O
had	O
recurrent	O
hypercalcemia	Disease
to	O
better	O
understand	O
the	O
disease	O
process.	O
CONCLUSION:	O
Primary	Disease
hyperparathyroidism	Disease
is	O
a	O
rare	O
but	O
potentially	O
life-threatening	O
side	O
effect	O
of	O
long-term	O
lithium	Chemical
therapy.	O
Careful	O
patient	O
selection	O
and	O
long-term	O
follow-up	O
can	O
reduce	O
morbidity.	O
PRACTICAL	O
IMPLICATIONS:	O
As	O
much	O
as	O
15%	O
of	O
lithium	Chemical
-treated	O
patients	O
become	O
hypercalcemic	Disease
.	O
By	O
routinely	O
monitoring	O
serum	O
calcium	Chemical

Comparison	O
of	O
laryngeal	O
mask	O
with	O
endotracheal	O
tube	O
for	O
anesthesia	O
in	O
endoscopic	O
sinus	O
surgery.	O
BACKGROUND:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
surgical	O
conditions,	O
including	O
the	O
amount	O
of	O
intraoperative	O
bleeding	Disease
as	O
well	O
as	O
intraoperative	O
blood	O
pressure,	O
during	O
functional	O
endoscopic	O
sinus	O
surgery	O
(FESS)	O
using	O
flexible	O
reinforced	O
laryngeal	O
mask	O
airway	O
(FRLMA)	O
versus	O
endotracheal	O
tube	O
(ETT)	O
in	O
maintaining	O
controlled	O
hypotension	Disease
anesthesia	O
induced	O
by	O
propofol	Chemical
-	O
remifentanil	Chemical
total	O
i.v.	O
anesthesia	O
(TIVA).	O
METHODS:	O
Sixty	O
normotensive	O
American	O
Society	O
of	O
Anesthesiologists	O
I-II	O
adult	O
patients	O
undergoing	O
FESS	O
under	O
controlled	O
hypotension	Disease
anesthesia	O
caused	O
by	O
propofol	Chemical
-	O
remifentanil	Chemical
-TIVA	O
were	O
randomly	O
assigned	O
into	O
two	O
groups:	O
group	O
I,	O
FRLMA;	O
group	O
II,	O
ETT.	O
Hemorrhage	Disease
was	O
measured	O
and	O
the	O
visibility	O
of	O
the	O
operative	O
field	O
was	O
evaluated	O
according	O
to	O
a	O
six-point	O
scale.	O
RESULTS:	O
Controlled	O
hypotension	Disease
was	O
achieved	O
within	O
a	O
shorter	O
period	O
using	O
laryngeal	O
mask	O
using	O
lower	O
rates	O
of	O
remifentanil	Chemical
infusion	O
and	O
lower	O
total	O
dose	O
of	O
remifentanil	Chemical
.	O
CONCLUSION:	O
In	O
summary,	O
our	O
results	O
indicate	O
that	O
airway	O
management	O
using	O
FRLMA	O
during	O
controlled	O
hypotension	Disease
anesthesia	O
provided	O
better	O
surgical	O
conditions	O
in	O
terms	O
of	O
quality	O
of	O
operative	O
field	O
and	O
blood	O
loss	O
and	O
allowed	O
for	O
convenient	O
induced	O
hypotension	Disease
with	O
low	O
doses	O
of	O
remifentanil	Chemical

Nonalcoholic	Disease
fatty	Disease
liver	Disease
disease	Disease
during	O
valproate	Chemical
therapy.	O
Valproic	Chemical
acid	Chemical
(	O
VPA	Chemical
)	O
is	O
effective	O
for	O
the	O
treatment	O
of	O
many	O
types	O
of	O
epilepsy	Disease
,	O
but	O
its	O
use	O
can	O
be	O
associated	O
with	O
an	O
increase	O
in	O
body	O
weight.	O
We	O
report	O
a	O
case	O
of	O
nonalcoholic	Disease
fatty	Disease
liver	Disease
disease	Disease
(	O
NAFLD	Disease
)	O
arising	O
in	O
a	O
child	O
who	O
developed	O
obesity	Disease
during	O
VPA	Chemical
treatment.	O
Laboratory	O
data	O
revealed	O
hyperinsulinemia	Disease
with	O
insulin	Disease
resistance	Disease
.	O
After	O
the	O
withdrawal	O
of	O
VPA	Chemical
therapy,	O
our	O
patient	O
showed	O
a	O
significant	O
weight	Disease
loss	Disease
,	O
a	O
decrease	O
of	O
body	O
mass	O
index,	O
and	O
normalization	O
of	O
metabolic	O
and	O
endocrine	O
parameters;	O
moreover,	O
ultrasound	O
measurements	O
showed	O
a	O
complete	O
normalization.	O
The	O
present	O
case	O
suggests	O
that	O
obesity	Disease
,	O
hyperinsulinemia	Disease
,	O
insulin	Disease
resistance	Disease
,	O
and	O
long-term	O
treatment	O
with	O
VPA	Chemical
may	O
be	O
all	O
associated	O
with	O
the	O
development	O
of	O
NAFLD	Disease
;	O
this	O
side	O
effect	O
is	O
reversible	O
after	O
VPA	Chemical

Carbimazole	Chemical
induced	O
ANCA	Disease
positive	Disease
vasculitis	Disease
.	O
Anti-thyroid	Chemical
drugs	Chemical
,	O
like	O
carbimazole	Chemical
and	O
propylthiouracil	Chemical
(	O
PTU	Chemical
)	O
are	O
commonly	O
prescribed	O
for	O
the	O
treatment	O
of	O
hyperthyroidism	Disease
.	O
One	O
should	O
be	O
aware	O
of	O
the	O
side	O
effects	O
of	O
antithyroid	Chemical
medications	Chemical
.	O
Antineutrophil	Disease
cytoplasmic	Disease
antibody	Disease
(ANCA)--associated	Disease
vasculitis	Disease
is	O
a	O
potentially	O
life-threatening	O
adverse	O
effect	O
of	O
antithyroidmedications	Chemical
.	O
We	O
report	O
a	O
patient	O
with	O
Graves'	Disease
disease	Disease
who	O
developed	O
ANCA	O
positive	O
carbimazole	Chemical
induced	O
vasculitis	Disease
.	O
The	O
episode	O
was	O
characterized	O
by	O
a	O
vasculitic	Disease
	O
skin	Disease
rash	Disease
associated	O
with	O
large	O
joint	O
arthritis	Disease
,	O
pyrexia	Disease
and	O
parotiditis	Disease
but	O
no	O
renal	O
or	O
pulmonary	O
involvement.	O
He	O
was	O
referred	O
to	O
us	O
for	O
neurological	O
evaluation	O
because	O
he	O
had	O
difficulty	O
in	O
getting	O
up	O
from	O
squatting	O
position	O
and	O
was	O
suspected	O
to	O
have	O
myositis	Disease
.	O
Carbimazole	Chemical
and	O
methimazole	Chemical
have	O
a	O
lower	O
incidence	O
of	O
reported	O
ANCA	O
positive	O
side	O
effects	O
than	O
PUT.	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
ANCA	O
positive	O
carbimazole	Chemical
induced	O
vasculitis	Disease

Aspirin	Chemical
for	O
the	O
primary	O
prevention	O
of	O
cardiovascular	O
events:	O
an	O
update	O
of	O
the	O
evidence	O
for	O
the	O
U.S.	O
Preventive	O
Services	O
Task	O
Force.	O
BACKGROUND:	O
Coronary	Disease
heart	Disease
disease	Disease
and	O
cerebrovascular	Disease
disease	Disease
are	O
leading	O
causes	O
of	O
death	O
in	O
the	O
United	O
States.	O
In	O
2002,	O
the	O
U.S.	O
Preventive	O
Services	O
Task	O
Force	O
(USPSTF)	O
strongly	O
recommended	O
that	O
clinicians	O
discuss	O
aspirin	Chemical
with	O
adults	O
who	O
are	O
at	O
increased	O
risk	O
for	O
coronary	Disease
heart	Disease
disease	Disease
.	O
PURPOSE:	O
To	O
determine	O
the	O
benefits	O
and	O
harms	O
of	O
taking	O
aspirin	Chemical
for	O
the	O
primary	O
prevention	O
of	O
myocardial	Disease
infarctions	Disease
,	O
strokes	Disease
,	O
and	O
death.	O
DATA	O
SOURCES:	O
MEDLINE	O
and	O
Cochrane	O
Library	O
(search	O
dates,	O
1	O
January	O
2001	O
to	O
28	O
August	O
2008),	O
recent	O
systematic	O
reviews,	O
reference	O
lists	O
of	O
retrieved	O
articles,	O
and	O
suggestions	O
from	O
experts.	O
STUDY	O
SELECTION:	O
English-language	O
randomized,	O
controlled	O
trials	O
(RCTs);	O
case-control	O
studies;	O
meta-analyses;	O
and	O
systematic	O
reviews	O
of	O
aspirin	Chemical
versus	O
control	O
for	O
the	O
primary	O
prevention	O
of	O
cardiovascular	Disease
disease	Disease
(	O
CVD	Disease
)	O
were	O
selected	O
to	O
answer	O
the	O
following	O
questions:	O
Does	O
aspirin	Chemical
decrease	O
coronary	O
heart	O
events,	O
strokes	Disease
,	O
death	O
from	O
coronary	O
heart	O
events	O
or	O
stroke	Disease
,	O
or	O
all-cause	O
mortality	O
in	O
adults	O
without	O
known	O
CVD	Disease
?	O
Does	O
aspirin	Chemical
increase	O
gastrointestinal	Disease
bleeding	Disease
or	O
hemorrhagic	Disease
strokes	Disease
?	O
DATA	O
EXTRACTION:	O
All	O
studies	O
were	O
reviewed,	O
abstracted,	O
and	O
rated	O
for	O
quality	O
by	O
using	O
predefined	O
USPSTF	O
criteria.	O
DATA	O
SYNTHESIS:	O
New	O
evidence	O
from	O
1	O
good-quality	O
RCT,	O
1	O
good-quality	O
meta-analysis,	O
and	O
2	O
fair-quality	O
subanalyses	O
of	O
RCTs	O
demonstrates	O
that	O
aspirin	Chemical
use	O
reduces	O
the	O
number	O
of	O
CVD	Disease
events	O
in	O
patients	O
without	O
known	O
CVD	Disease
.	O
Men	O
in	O
these	O
studies	O
experienced	O
fewer	O
myocardial	Disease
infarctions	Disease
and	O
women	O
experienced	O
fewer	O
ischemic	O
strokes	Disease
.	O
Aspirin	Chemical
does	O
not	O
seem	O
to	O
affect	O
CVD	Disease
mortality	O
or	O
all-cause	O
mortality	O
in	O
either	O
men	O
or	O
women.	O
The	O
use	O
of	O
aspirin	Chemical
for	O
primary	O
prevention	O
increases	O
the	O
risk	O
for	O
major	O
bleeding	Disease
events,	O
primarily	O
gastrointestinal	Disease
bleeding	Disease
events,	O
in	O
both	O
men	O
and	O
women.	O
Men	O
have	O
an	O
increased	O
risk	O
for	O
hemorrhagic	Disease
strokes	Disease
with	O
aspirin	Chemical
use.	O
A	O
new	O
RCT	O
and	O
meta-analysis	O
suggest	O
that	O
the	O
risk	O
for	O
hemorrhagic	Disease
strokes	Disease
in	O
women	O
is	O
not	O
statistically	O
significantly	O
increased.	O
LIMITATIONS:	O
New	O
evidence	O
on	O
aspirin	Chemical
for	O
the	O
primary	O
prevention	O
of	O
CVD	Disease
is	O
limited.	O
The	O
dose	O
of	O
aspirin	Chemical
used	O
in	O
the	O
RCTs	O
varied,	O
which	O
prevented	O
the	O
estimation	O
of	O
the	O
most	O
appropriate	O
dose	O
for	O
primary	O
prevention.	O
Several	O
of	O
the	O
RCTs	O
were	O
conducted	O
within	O
populations	O
of	O
health	O
professionals,	O
which	O
potentially	O
limits	O
generalizability.	O
CONCLUSION:	O
Aspirin	Chemical
reduces	O
the	O
risk	O
for	O
myocardial	Disease
infarction	Disease
in	O
men	O
and	O
strokes	Disease
in	O
women.	O
Aspirin	Chemical
use	O
increases	O
the	O
risk	O
for	O
serious	O
bleeding	Disease

Reducing	O
harm	O
associated	O
with	O
anticoagulation:	O
practical	O
considerations	O
of	O
argatroban	Chemical
therapy	O
in	O
heparin	Chemical
-induced	O
thrombocytopenia	Disease
.	O
Argatroban	Chemical
is	O
a	O
hepatically	O
metabolized,	O
direct	O
thrombin	O
inhibitor	O
used	O
for	O
prophylaxis	O
or	O
treatment	O
of	O
thrombosis	Disease
in	O
heparin	Chemical
-induced	O
thrombocytopenia	Disease
(	O
HIT	Disease
)	O
and	O
for	O
patients	O
with	O
or	O
at	O
risk	O
of	O
HIT	Disease
undergoing	O
percutaneous	O
coronary	O
intervention	O
(PCI).	O
The	O
objective	O
of	O
this	O
review	O
is	O
to	O
summarize	O
practical	O
considerations	O
of	O
argatroban	Chemical
therapy	O
in	O
HIT	Disease
.	O
The	O
US	O
FDA-recommended	O
argatroban	Chemical
dose	O
in	O
HIT	Disease
is	O
2	O
microg/kg/min	O
(reduced	O
in	O
patients	O
with	O
hepatic	Disease
impairment	Disease
and	O
in	O
paediatric	O
patients),	O
adjusted	O
to	O
achieve	O
activated	O
partial	O
thromboplastin	O
times	O
(aPTTs)	O
1.5-3	O
times	O
baseline	O
(not	O
>100	O
seconds).	O
Contemporary	O
experiences	O
indicate	O
that	O
reduced	O
doses	O
are	O
also	O
needed	O
in	O
patients	O
with	O
conditions	O
associated	O
with	O
hepatic	O
hypoperfusion,	O
e.g.	O
heart	Disease
failure	Disease
,	O
yet	O
are	O
unnecessary	O
for	O
renal	Disease
dysfunction	Disease
,	O
adult	O
age,	O
sex,	O
race/ethnicity	O
or	O
obesity	Disease
.	O
Argatroban	Chemical
0.5-1.2	O
microg/kg/min	O
typically	O
supports	O
therapeutic	O
aPTTs.	O
The	O
FDA-recommended	O
dose	O
during	O
PCI	O
is	O
25	O
microg/kg/min	O
(350	O
microg/kg	O
initial	O
bolus),	O
adjusted	O
to	O
achieve	O
activated	O
clotting	O
times	O
(ACTs)	O
of	O
300-450	O
sec.	O
For	O
PCI,	O
argatroban	Chemical
has	O
not	O
been	O
investigated	O
in	O
hepatically	O
impaired	O
patients;	O
dose	O
adjustment	O
is	O
unnecessary	O
for	O
adult	O
age,	O
sex,	O
race/ethnicity	O
or	O
obesity	Disease
,	O
and	O
lesser	O
doses	O
may	O
be	O
adequate	O
with	O
concurrent	O
glycoprotein	O
IIb/IIIa	O
inhibition.	O
Argatroban	Chemical
prolongs	O
the	O
International	O
Normalized	O
Ratio,	O
and	O
published	O
approaches	O
for	O
monitoring	O
the	O
argatroban	Chemical
-to-	O
warfarin	Chemical
transition	O
should	O
be	O
followed.	O
Major	O
bleeding	Disease
with	O
argatroban	Chemical
is	O
0-10%	O
in	O
the	O
non-interventional	O
setting	O
and	O
0-5.8%	O
periprocedurally.	O
Argatroban	Chemical
has	O
no	O
specific	O
antidote,	O
and	O
if	O
excessive	O
anticoagulation	O
occurs,	O
argatroban	Chemical
infusion	O
should	O
be	O
stopped	O
or	O
reduced.	O
Improved	O
familiarity	O
of	O
healthcare	O
professionals	O
with	O
argatroban	Chemical
therapy	O
in	O
HIT	Disease
,	O
including	O
in	O
special	O
populations	O
and	O
during	O
PCI,	O
may	O
facilitate	O
reduction	O
of	O
harm	O
associated	O
with	O
HIT	Disease
(e.g.	O
fewer	O
thromboses)	O
or	O
its	O
treatment	O
(e.g.	O
fewer	O
argatroban	Chemical

Rhabdomyolysis	Disease
and	O
brain	O
ischemic	Disease
stroke	Disease
in	O
a	O
heroin	Chemical
-dependent	O
male	O
under	O
methadone	Chemical
maintenance	O
therapy.	O
OBJECTIVE:	O
There	O
are	O
several	O
complications	O
associated	O
with	O
heroin	Disease
abuse	Disease
,	O
some	O
of	O
which	O
are	O
life-threatening.	O
Methadone	Chemical
may	O
aggravate	O
this	O
problem.	O
METHOD:	O
A	O
clinical	O
case	O
description.	O
RESULTS:	O
A	O
33-year-old	O
man	O
presented	O
with	O
rhabdomyolysis	Disease
and	O
cerebral	O
ischemic	Disease
stroke	Disease
after	O
intravenous	O
heroin	Chemical
.	O
He	O
had	O
used	O
heroin	Chemical
since	O
age	O
20,	O
and	O
had	O
used	O
150	O
mg	O
methadone	Chemical
daily	O
for	O
6	O
months.	O
He	O
was	O
found	O
unconsciousness	Disease
at	O
home	O
and	O
was	O
sent	O
to	O
our	O
hospital.	O
In	O
the	O
ER,	O
his	O
opiate	O
level	O
was	O
4497	O
ng/ml.	O
In	O
the	O
ICU,	O
we	O
found	O
rhabdomyolysis	Disease
,	O
acute	Disease
renal	Disease
failure	Disease
and	O
acute	O
respiratory	Disease
failure	Disease
.	O
After	O
transfer	O
to	O
an	O
internal	O
ward,	O
we	O
noted	O
aphasia	Disease
and	O
weakness	Disease
of	O
his	O
left	O
limbs.	O
After	O
MRI,	O
we	O
found	O
cerebral	Disease
ischemic	Disease
infarction	Disease
.	O
CONCLUSION:	O
Those	O
using	O
methadone	Chemical
and	O
heroin	Chemical
simultaneously	O
may	O
increase	O
risk	O
of	O
rhabdomyolysis	Disease
and	O
ischemic	Disease
stroke	Disease
.	O
Patients	O
under	O
methadone	Chemical
maintenance	O
therapy	O
should	O
be	O
warned	O
regarding	O
these	O
serious	O
adverse	O
events.	O
Hypotheses	O
of	O
heroin	Chemical
-related	O
rhabdomyolysis	Disease
and	O
stroke	Disease
in	O
heroin	Chemical

Increased	O
vulnerability	O
to	O
6-hydroxydopamine	Chemical
lesion	O
and	O
reduced	O
development	O
of	O
dyskinesias	Disease
in	O
mice	O
lacking	O
CB1	O
cannabinoid	O
receptors.	O
Motor	O
impairment,	O
dopamine	Chemical
(	O
DA	Chemical
)	O
neuronal	O
activity	O
and	O
proenkephalin	Chemical
(	O
PENK	Chemical
)	O
gene	O
expression	O
in	O
the	O
caudate-putamen	O
(CPu)	O
were	O
measured	O
in	O
6-OHDA	Chemical
-lesioned	O
and	O
treated	O
(	O
L-DOPA+benserazide	Chemical
)	O
CB1	O
KO	O
and	O
WT	O
mice.	O
A	O
lesion	O
induced	O
by	O
6-OHDA	Chemical
produced	O
more	O
severe	O
motor	O
deterioration	O
in	O
CB1	O
KO	O
mice	O
accompanied	O
by	O
more	O
loss	O
of	O
DA	Chemical
neurons	O
and	O
increased	O
PENK	Chemical
gene	O
expression	O
in	O
the	O
CPu.	O
Oxidative/nitrosative	O
and	O
neuroinflammatory	O
parameters	O
were	O
estimated	O
in	O
the	O
CPu	O
and	O
cingulate	O
cortex	O
(Cg).	O
CB1	O
KO	O
mice	O
exhibited	O
higher	O
MDA	Chemical
levels	O
and	O
iNOS	O
protein	O
expression	O
in	O
the	O
CPu	O
and	O
Cg	O
compared	O
to	O
WT	O
mice.	O
Treatment	O
with	O
L-DOPA+benserazide	Chemical
(12	O
weeks)	O
resulted	O
in	O
less	O
severe	O
dyskinesias	Disease
in	O
CB1	O
KO	O
than	O
in	O
WT	O
mice.	O
The	O
results	O
revealed	O
that	O
the	O
lack	O
of	O
cannabinoid	O
CB1	O
receptors	O
increased	O
the	O
severity	O
of	O
motor	O
impairment	O
and	O
DA	Chemical
lesion,	O
and	O
reduced	O
L-DOPA	Chemical
-induced	O
dyskinesias	Disease
.	O
These	O
results	O
suggest	O
that	O
activation	O
of	O
CB1	O
receptors	O
offers	O
neuroprotection	O
against	O
dopaminergic	O
lesion	O
and	O
the	O
development	O
of	O
L-DOPA	Chemical
-induced	O
dyskinesias	Disease

Animal	O
model	O
of	O
mania	Disease
induced	O
by	O
ouabain	Chemical
:	O
Evidence	O
of	O
oxidative	O
stress	O
in	O
submitochondrial	O
particles	O
of	O
the	O
rat	O
brain.	O
The	O
intracerebroventricular	O
(ICV)	O
administration	O
of	O
ouabain	Chemical
(a	O
Na	Chemical
(+)/	O
K	Chemical
(+)-ATPase	O
inhibitor)	O
in	O
rats	O
has	O
been	O
suggested	O
to	O
mimic	O
some	O
symptoms	O
of	O
human	O
bipolar	Disease
mania	Disease
.	O
Clinical	O
studies	O
have	O
shown	O
that	O
bipolar	Disease
disorder	Disease
may	O
be	O
related	O
to	O
mitochondrial	Disease
dysfunction	Disease
.	O
Herein,	O
we	O
investigated	O
the	O
behavioral	O
and	O
biochemical	O
effects	O
induced	O
by	O
the	O
ICV	O
administration	O
of	O
ouabain	Chemical
in	O
rats.	O
To	O
achieve	O
this	O
aim,	O
the	O
effects	O
of	O
ouabain	Chemical
injection	O
immediately	O
after	O
and	O
7	O
days	O
following	O
a	O
single	O
ICV	O
administration	O
(at	O
concentrations	O
of	O
10(-2)	O
and	O
10(-3)M)	O
on	O
locomotion	O
was	O
measured	O
using	O
the	O
open-field	O
test.	O
Additionally,	O
thiobarbituric	Chemical
acid	Chemical
reactive	O
substances	O
(TBARSs)	O
and	O
superoxide	Chemical
production	O
were	O
measured	O
in	O
submitochondrial	O
particles	O
of	O
the	O
prefrontal	O
cortex,	O
hippocampus,	O
striatum	O
and	O
amygdala.	O
Our	O
findings	O
demonstrated	O
that	O
ouabain	Chemical
at	O
10(-2)	O
and	O
10(-3)M	O
induced	O
hyperlocomotion	Disease
in	O
rats,	O
and	O
this	O
response	O
remained	O
up	O
to	O
7	O
days	O
following	O
a	O
single	O
ICV	O
injection.	O
In	O
addition,	O
we	O
observed	O
that	O
the	O
persistent	O
increase	O
in	O
the	O
rat	O
spontaneous	O
locomotion	O
is	O
associated	O
with	O
increased	O
TBARS	O
levels	O
and	O
superoxide	Chemical
generation	O
in	O
submitochondrial	O
particles	O
in	O
the	O
prefrontal	O
cortex,	O
striatum	O
and	O
amygdala.	O
In	O
conclusion,	O
ouabain	Chemical
-induced	O
mania	Disease
-like	O
behavior	O
may	O
provide	O
a	O
useful	O
animal	O
model	O
to	O
test	O
the	O
hypothesis	O
of	O
the	O
involvement	O
of	O
oxidative	O
stress	O
in	O
bipolar	Disease
disorder	Disease

Intraoperative	O
dialysis	O
during	O
liver	O
transplantation	O
with	O
citrate	Chemical
dialysate.	O
Liver	O
transplantation	O
for	O
acutely	O
ill	O
patients	O
with	O
fulminant	Disease
liver	Disease
failure	Disease
carries	O
high	O
intraoperative	O
and	O
immediate	O
postoperative	O
risks.	O
These	O
are	O
increased	O
with	O
the	O
presence	O
of	O
concomitant	O
acute	Disease
kidney	Disease
injury	Disease
(	O
AKI	Disease
)	O
and	O
intraoperative	O
dialysis	O
is	O
sometimes	O
required	O
to	O
allow	O
the	O
transplant	O
to	O
proceed.	O
The	O
derangements	O
in	O
the	O
procoagulant	O
and	O
anticoagulant	O
pathways	O
during	O
fulminant	Disease
liver	Disease
failure	Disease
can	O
lead	O
to	O
difficulties	O
with	O
anticoagulation	O
during	O
dialysis,	O
especially	O
when	O
continued	O
in	O
the	O
operating	O
room.	O
Systemic	O
anticoagulation	O
is	O
unsafe	O
and	O
regional	O
citrate	Chemical
anticoagulation	O
in	O
the	O
absence	O
of	O
a	O
functional	O
liver	O
carries	O
the	O
risk	O
of	O
citrate	Chemical
	O
toxicity	Disease
.	O
Citrate	Chemical
dialysate,	O
a	O
new	O
dialysate	O
with	O
citric	Chemical
acid	Chemical
can	O
be	O
used	O
for	O
anticoagulation	O
in	O
patients	O
who	O
cannot	O
tolerate	O
heparin	Chemical
or	O
regional	O
citrate	Chemical
.	O
We	O
report	O
a	O
case	O
of	O
a	O
40-year-old	O
female	O
with	O
acetaminophen	Chemical
-induced	O
fulminant	Disease
liver	Disease
failure	Disease
with	O
associated	O
AKI	Disease
who	O
underwent	O
intraoperative	O
dialytic	O
support	O
during	O
liver	O
transplantation	O
anticoagulated	O
with	O
citrate	Chemical
dialysate	O
during	O
the	O
entire	O
procedure.	O
The	O
patient	O
tolerated	O
the	O
procedure	O
well	O
without	O
any	O
signs	O
of	O
citrate	Chemical
	O
toxicity	Disease
and	O
maintained	O
adequate	O
anticoagulation	O
for	O
patency	O
of	O
the	O
dialysis	O
circuit.	O
Citrate	Chemical
dialysate	O
is	O
a	O
safe	O
alternative	O
for	O
intradialytic	O
support	O
of	O
liver	O
transplantation	O
in	O
fulminant	Disease
liver	Disease
failure	Disease

Delirium	Disease
in	O
a	O
patient	O
with	O
toxic	O
flecainide	Chemical
plasma	O
concentrations:	O
the	O
role	O
of	O
a	O
pharmacokinetic	O
drug	O
interaction	O
with	O
paroxetine	Chemical
.	O
OBJECTIVE:	O
To	O
describe	O
a	O
case	O
of	O
flecainide	Chemical
-induced	O
delirium	Disease
associated	O
with	O
a	O
pharmacokinetic	O
drug	O
interaction	O
with	O
paroxetine	Chemical
.	O
CASE	O
SUMMARY:	O
A	O
69-year-old	O
white	O
female	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
a	O
history	O
of	O
confusion	Disease
and	O
paranoia	Disease
over	O
the	O
past	O
several	O
days.	O
On	O
admission	O
the	O
patient	O
was	O
taking	O
carvedilol	Chemical
12	O
mg	O
twice	O
daily,	O
warfarin	Chemical
2	O
mg/day,	O
folic	Chemical
acid	Chemical
1	O
mg/day,	O
levothyroxine	Chemical
100	O
microg/day,	O
pantoprazole	Chemical
40	O
mg/day,	O
paroxetine	Chemical
40	O
mg/day,	O
and	O
flecainide	Chemical
100	O
mg	O
twice	O
daily.	O
Flecainide	Chemical
had	O
been	O
started	O
2	O
weeks	O
prior	O
for	O
atrial	Disease
fibrillation	Disease
.	O
Laboratory	O
test	O
findings	O
on	O
admission	O
were	O
notable	O
only	O
for	O
a	O
flecainide	Chemical
plasma	O
concentration	O
of	O
1360	O
microg/L	O
(reference	O
range	O
200-1000).	O
A	O
metabolic	O
drug	O
interaction	O
between	O
flecainide	Chemical
and	O
paroxetine	Chemical
,	O
which	O
the	O
patient	O
had	O
been	O
taking	O
for	O
more	O
than	O
5	O
years,	O
was	O
considered.	O
Paroxetine	Chemical
was	O
discontinued	O
and	O
the	O
dose	O
of	O
flecainide	Chemical
was	O
reduced	O
to	O
50	O
mg	O
twice	O
daily.	O
Her	O
delirium	Disease
resolved	O
3	O
days	O
later.	O
DISCUSSION:	O
Flecainide	Chemical
and	O
pharmacologically	O
similar	O
agents	O
that	O
interact	O
with	O
sodium	Chemical
channels	O
may	O
cause	O
delirium	Disease
in	O
susceptible	O
patients.	O
A	O
MEDLINE	O
search	O
(1966-January	O
2009)	O
revealed	O
one	O
in	O
vivo	O
pharmacokinetic	O
study	O
on	O
the	O
interaction	O
between	O
flecainide	Chemical
,	O
a	O
CYP2D6	O
substrate,	O
and	O
paroxetine	Chemical
,	O
a	O
CYP2D6	O
inhibitor,	O
as	O
well	O
as	O
3	O
case	O
reports	O
of	O
flecainide	Chemical
-induced	O
delirium	Disease
.	O
According	O
to	O
the	O
Naranjo	O
probability	O
scale,	O
flecainide	Chemical
was	O
the	O
probable	O
cause	O
of	O
the	O
patient's	O
delirium	Disease
;	O
the	O
Horn	O
Drug	O
Interaction	O
Probability	O
Scale	O
indicates	O
a	O
possible	O
pharmacokinetic	O
drug	O
interaction	O
between	O
flecainide	Chemical
and	O
paroxetine	Chemical
.	O
CONCLUSIONS:	O
Supratherapeutic	O
flecainide	Chemical
plasma	O
concentrations	O
may	O
cause	O
delirium	Disease
.	O
Because	O
toxicity	Disease
may	O
occur	O
when	O
flecainide	Chemical
is	O
prescribed	O
with	O
paroxetine	Chemical
and	O
other	O
potent	O
CYP2D6	O
inhibitors,	O
flecainide	Chemical

Efficacy	O
of	O
everolimus	Chemical
(	O
RAD001	Chemical
)	O
in	O
patients	O
with	O
advanced	O
NSCLC	Disease
previously	O
treated	O
with	O
chemotherapy	O
alone	O
or	O
with	O
chemotherapy	O
and	O
EGFR	O
inhibitors.	O
BACKGROUND:	O
Treatment	O
options	O
are	O
scarce	O
in	O
pretreated	O
advanced	O
non-small-cell	Disease
lung	Disease
cancer	Disease
(	O
NSCLC	Disease
)	O
patients.	O
RAD001	Chemical
,	O
an	O
oral	O
inhibitor	O
of	O
the	O
mammalian	O
target	O
of	O
rapamycin	Chemical
(mTOR),	O
has	O
shown	O
phase	O
I	O
efficacy	O
in	O
NSCLC	Disease
.	O
METHODS:	O
Stage	O
IIIb	O
or	O
IV	O
NSCLC	Disease
patients,	O
with	O
two	O
or	O
fewer	O
prior	O
chemotherapy	O
regimens,	O
one	O
platinum	Chemical
based	O
(stratum	O
1)	O
or	O
both	O
chemotherapy	O
and	O
epidermal	O
growth	O
factor	O
receptor	O
tyrosine	Chemical
kinase	O
inhibitors	O
(stratum	O
2),	O
received	O
RAD001	Chemical
10	O
mg/day	O
until	O
progression	O
or	O
unacceptable	O
toxicity	Disease
.	O
Primary	O
objective	O
was	O
overall	O
response	O
rate	O
(ORR).	O
Analyses	O
of	O
markers	O
associated	O
with	O
the	O
mTOR	O
pathway	O
were	O
carried	O
out	O
on	O
archival	O
tumor	Disease
from	O
a	O
subgroup	O
using	O
immunohistochemistry	O
(IHC)	O
and	O
direct	O
mutation	O
sequencing.	O
RESULTS:	O
Eighty-five	O
patients	O
were	O
enrolled,	O
42	O
in	O
stratum	O
1	O
and	O
43	O
in	O
stratum.	O
ORR	O
was	O
4.7%	O
(7.1%	O
stratum	O
1;	O
2.3%	O
stratum	O
2).	O
Overall	O
disease	O
control	O
rate	O
was	O
47.1%.	O
Median	O
progression-free	O
survivals	O
(PFSs)	O
were	O
2.6	O
(stratum	O
1)	O
and	O
2.7	O
months	O
(stratum	O
2).	O
Common	O
>	O
or	O
=grade	O
3	O
events	O
were	O
fatigue	Disease
,	O
dyspnea	Disease
,	O
stomatitis	Disease
,	O
anemia	Disease
,	O
and	O
thrombocytopenia	Disease
.	O
Pneumonitis	Disease
,	O
probably	O
or	O
possibly	O
related,	O
mainly	O
grade	O
1/2,	O
occurred	O
in	O
25%.	O
Cox	O
regression	O
analysis	O
of	O
IHC	O
scores	O
found	O
that	O
only	O
phospho	O
AKT	O
(pAKT)	O
was	O
a	O
significant	O
independent	O
predictor	O
of	O
worse	O
PFS.	O
CONCLUSIONS:	O
RAD001	Chemical
10	O
mg/day	O
was	O
well	O
tolerated,	O
showing	O
modest	O
clinical	O
activity	O
in	O
pretreated	O
NSCLC	Disease
.	O
Evaluation	O
of	O
RAD001	Chemical
plus	O
standard	O
therapy	O
for	O
metastatic	O
NSCLC	Disease

Posttransplant	O
anemia	Disease
:	O
the	O
role	O
of	O
sirolimus	Chemical
.	O
Posttransplant	O
anemia	Disease
is	O
a	O
common	O
problem	O
that	O
may	O
hinder	O
patients'	O
quality	O
of	O
life.	O
It	O
occurs	O
in	O
12	O
to	O
76%	O
of	O
patients,	O
and	O
is	O
most	O
common	O
in	O
the	O
immediate	O
posttransplant	O
period.	O
A	O
variety	O
of	O
factors	O
have	O
been	O
identified	O
that	O
increase	O
the	O
risk	O
of	O
posttransplant	O
anemia	Disease
,	O
of	O
which	O
the	O
level	O
of	O
renal	O
function	O
is	O
most	O
important.	O
Sirolimus	Chemical
,	O
a	O
mammalian	O
target	O
of	O
rapamycin	Chemical
inhibitor,	O
has	O
been	O
implicated	O
as	O
playing	O
a	O
special	O
role	O
in	O
posttransplant	O
anemia	Disease
.	O
This	O
review	O
considers	O
anemia	Disease
associated	O
with	O
sirolimus	Chemical

Coronary	O
computerized	O
tomography	O
angiography	O
for	O
rapid	O
discharge	O
of	O
low-risk	O
patients	O
with	O
cocaine	Chemical
-associated	O
chest	Disease
pain	Disease
.	O
BACKGROUND:	O
Most	O
patients	O
presenting	O
to	O
emergency	O
departments	O
(EDs)	O
with	O
cocaine	Chemical
-associated	O
chest	Disease
pain	Disease
are	O
admitted	O
for	O
at	O
least	O
12	O
hours	O
and	O
receive	O
a	O
"rule	O
out	O
acute	Disease
coronary	Disease
syndrome	Disease
"	O
protocol,	O
often	O
with	O
noninvasive	O
testing	O
prior	O
to	O
discharge.	O
In	O
patients	O
without	O
cocaine	Chemical
use,	O
coronary	O
computerized	O
tomography	O
angiography	O
(CTA)	O
has	O
been	O
shown	O
to	O
be	O
useful	O
for	O
identifying	O
a	O
group	O
of	O
patients	O
at	O
low	O
risk	O
for	O
cardiac	O
events	O
who	O
can	O
be	O
safely	O
discharged.	O
It	O
is	O
unclear	O
whether	O
a	O
coronary	O
CTA	O
strategy	O
would	O
be	O
efficacious	O
in	O
cocaine	Chemical
-associated	O
chest	Disease
pain	Disease
,	O
as	O
coronary	Disease
vasospasm	Disease
may	O
account	O
for	O
some	O
of	O
the	O
ischemia	Disease
.	O
We	O
studied	O
whether	O
a	O
negative	O
coronary	O
CTA	O
in	O
patients	O
with	O
cocaine	Chemical
-associated	O
chest	Disease
pain	Disease
could	O
identify	O
a	O
subset	O
safe	O
for	O
discharge.	O
METHODS:	O
We	O
prospectively	O
evaluated	O
the	O
safety	O
of	O
coronary	O
CTA	O
for	O
low-risk	O
patients	O
who	O
presented	O
to	O
the	O
ED	O
with	O
cocaineassociated	O
chest	Disease
pain	Disease
(self-reported	O
or	O
positive	O
urine	O
test).	O
Consecutive	O
patients	O
received	O
either	O
immediate	O
coronary	O
CTA	O
in	O
the	O
ED	O
(without	O
serial	O
markers)	O
or	O
underwent	O
coronary	O
CTA	O
after	O
a	O
brief	O
observation	O
period	O
with	O
serial	O
cardiac	O
marker	O
measurements.	O
Patients	O
with	O
negative	O
coronary	O
CTA	O
(maximal	O
stenosis	Disease
less	O
than	O
50%)	O
were	O
discharged.	O
The	O
main	O
outcome	O
was	O
30-day	O
cardiovascular	O
death	O
or	O
myocardial	Disease
infarction	Disease
.	O
RESULTS:	O
A	O
total	O
of	O
59	O
patients	O
with	O
cocaine	Chemical
-associated	O
chest	Disease
pain	Disease
were	O
evaluated.	O
Patients	O
had	O
a	O
mean	O
age	O
of	O
45.6	O
+/-	O
6.6	O
yrs	O
and	O
were	O
86%	O
black,	O
66%	O
male.	O
Seventy-nine	O
percent	O
had	O
a	O
normal	O
or	O
nonspecific	O
ECG	O
and	O
85%	O
had	O
a	O
TIMI	O
score	O
<2.	O
Twenty	O
patients	O
received	O
coronary	O
CTA	O
immediately	O
in	O
the	O
ED,	O
18	O
of	O
whom	O
were	O
discharged	O
following	O
CTA	O
(90%).	O
Thirty-nine	O
received	O
coronary	O
CTA	O
after	O
a	O
brief	O
observation	O
period,	O
with	O
37	O
discharged	O
home	O
following	O
CTA	O
(95%).	O
Six	O
patients	O
had	O
coronary	Disease
stenosis	Disease
>or=50%.	O
During	O
the	O
30-day	O
follow-up	O
period,	O
no	O
patients	O
died	O
of	O
a	O
cardiovascular	O
event	O
(0%;	O
95%	O
CI,	O
0-6.1%)	O
and	O
no	O
patient	O
sustained	O
a	O
nonfatal	O
myocardial	Disease
infarction	Disease
(0%;	O
95%	O
CI,	O
0-6.1%).	O
CONCLUSIONS:	O
Although	O
cocaine	Chemical
-associated	O
myocardial	Disease
ischemia	Disease
can	O
result	O
from	O
coronary	O
vasoconstriction,	O
patients	O
with	O
cocaine	Chemical
associated	O
chest	Disease
pain	Disease
,	O
a	O
non-	O
ischemic	Disease

Late	O
fulminant	O
posterior	Disease
reversible	Disease
encephalopathy	Disease
syndrome	Disease
after	O
liver	O
transplant.	O
OBJECTIVES:	O
Posterior	Disease
leukoencephalopathy	Disease
due	O
to	O
calcineurin-inhibitor-related	O
neurotoxicity	Disease
is	O
a	O
rare	O
but	O
severe	O
complication	O
that	O
results	O
from	O
treatment	O
with	O
immunosuppressive	O
agents	O
(primarily	O
those	O
administered	O
after	O
a	O
liver	O
or	O
kidney	O
transplant).	O
The	O
pathophysiologic	O
mechanisms	O
of	O
that	O
disorder	O
remain	O
unknown.	O
CASE:	O
We	O
report	O
the	O
case	O
of	O
a	O
46-year-old	O
woman	O
who	O
received	O
a	O
liver	O
transplant	O
in	O
our	O
center	O
as	O
treatment	O
for	O
alcoholic	Disease
cirrhosis	Disease
and	O
in	O
whom	O
either	O
a	O
fulminant	O
course	O
of	O
posterior	Disease
leukoencephalopathy	Disease
or	O
posterior	Disease
reversible	Disease
encephalopathy	Disease
syndrome	Disease
developed	O
110	O
days	O
after	O
transplant.	O
After	O
an	O
initially	O
uneventful	O
course	O
after	O
the	O
transplant,	O
the	O
patient	O
rapidly	O
fell	O
into	O
deep	O
coma.	O
RESULTS:	O
Cerebral	O
MRI	O
scan	O
showed	O
typical	O
signs	O
of	O
enhancement	O
in	O
the	O
pontine	O
and	O
posterior	O
regions.	O
Switching	O
the	O
immunosuppressive	O
regimen	O
from	O
tacrolimus	Chemical
to	O
cyclosporine	Chemical
did	O
not	O
improve	O
the	O
clinical	O
situation.	O
The	O
termination	O
of	O
treatment	O
with	O
any	O
calcineurin	O
inhibitor	O
resulted	O
in	O
a	O
complete	O
resolution	O
of	O
that	O
complication.	O
CONCLUSIONS:	O
Posterior	Disease
reversible	Disease
encephalopathy	Disease
syndrome	Disease

Prolonged	O
hypothermia	Disease
as	O
a	O
bridge	O
to	O
recovery	O
for	O
cerebral	Disease
edema	Disease
and	O
intracranial	Disease
hypertension	Disease
associated	O
with	O
fulminant	Disease
hepatic	Disease
failure	Disease
.	O
BACKGROUND:	O
To	O
review	O
evidence-based	O
treatment	O
options	O
in	O
patients	O
with	O
cerebral	Disease
edema	Disease
complicating	O
fulminant	Disease
hepatic	Disease
failure	Disease
(	O
FHF	Disease
)	O
and	O
discuss	O
the	O
potential	O
applications	O
of	O
hypothermia	Disease
.	O
METHOD:	O
Case-based	O
observations	O
from	O
a	O
medical	O
intensive	O
care	O
unit	O
(MICU)	O
in	O
a	O
tertiary	O
care	O
facility	O
in	O
a	O
27-year-old	O
female	O
with	O
FHF	Disease
from	O
acetaminophen	Chemical
and	O
resultant	O
cerebral	Disease
edema	Disease
.	O
RESULTS:	O
Our	O
patient	O
was	O
admitted	O
to	O
the	O
MICU	O
after	O
being	O
found	O
unresponsive	O
with	O
presumed	O
toxicity	Disease
from	O
acetaminophen	Chemical
which	O
was	O
ingested	O
over	O
a	O
2-day	O
period.	O
The	O
patient	O
had	O
depressed	O
of	O
mental	O
status	O
lasting	O
at	O
least	O
24	O
h	O
prior	O
to	O
admission.	O
Initial	O
evaluation	O
confirmed	O
FHF	Disease
from	O
acetaminophen	Chemical
and	O
cerebral	Disease
edema	Disease
.	O
The	O
patient	O
was	O
treated	O
with	O
hyperosmolar	O
therapy,	O
hyperventilation	Disease
,	O
sedation,	O
and	O
chemical	O
paralysis	Disease
.	O
Her	O
intracranial	O
pressure	O
remained	O
elevated	O
despite	O
maximal	O
medical	O
therapy.	O
We	O
then	O
initiated	O
therapeutic	O
hypothermia	Disease
which	O
was	O
continued	O
for	O
5	O
days.	O
At	O
re-warming,	O
patient	O
had	O
resolution	O
of	O
her	O
cerebral	Disease
edema	Disease
and	O
intracranial	Disease
hypertension	Disease
.	O
At	O
discharge,	O
she	O
had	O
complete	O
recovery	O
of	O
neurological	O
and	O
hepatic	O
functions.	O
CONCLUSION:	O
In	O
patients	O
with	O
FHF	Disease
and	O
cerebral	Disease
edema	Disease
from	O
acetaminophen	Chemical
	O
overdose	Disease
,	O
prolonged	O
therapeutic	O
hypothermia	Disease
could	O
potentially	O
be	O
used	O
as	O
a	O
life	O
saving	O
therapy	O
and	O
a	O
bridge	O
to	O
hepatic	O
and	O
neurological	O
recovery.	O
A	O
clinical	O
trial	O
of	O
hypothermia	Disease

Binasal	Disease
visual	Disease
field	Disease
defects	Disease
are	O
not	O
specific	O
to	O
vigabatrin	Chemical
.	O
This	O
study	O
investigated	O
the	O
visual	Disease
defects	Disease
associated	O
with	O
the	O
antiepileptic	O
drug	O
vigabatrin	Chemical
(	O
VGB	Chemical
).	O
Two	O
hundred	O
four	O
people	O
with	O
epilepsy	Disease
were	O
grouped	O
on	O
the	O
basis	O
of	O
antiepileptic	O
drug	O
therapy	O
(current,	O
previous,	O
or	O
no	O
exposure	O
to	O
VGB	Chemical
).	O
Groups	O
were	O
matched	O
with	O
respect	O
to	O
age,	O
gender,	O
and	O
seizure	Disease
frequency.	O
All	O
patients	O
underwent	O
objective	O
assessment	O
of	O
electrophysiological	O
function	O
(wide-field	O
multifocal	O
electroretinography)	O
and	O
conventional	O
visual	O
field	O
testing	O
(static	O
perimetry).	O
Bilateral	O
visual	O
field	O
constriction	O
was	O
observed	O
in	O
59%	O
of	O
patients	O
currently	O
taking	O
VGB	Chemical
,	O
43%	O
of	O
patients	O
who	O
previously	O
took	O
VGB	Chemical
,	O
and	O
24%	O
of	O
patients	O
with	O
no	O
exposure	O
to	O
VGB	Chemical
.	O
Assessment	O
of	O
retinal	O
function	O
revealed	O
abnormal	O
responses	O
in	O
48%	O
of	O
current	O
VGB	Chemical
users	O
and	O
22%	O
of	O
prior	O
VGB	Chemical
users,	O
but	O
in	O
none	O
of	O
the	O
patients	O
without	O
previous	O
exposure	O
to	O
VGB	Chemical
.	O
Bilateral	Disease
visual	Disease
field	Disease
abnormalities	Disease
are	O
common	O
in	O
the	O
treated	O
epilepsy	Disease
population,	O
irrespective	O
of	O
drug	O
history.	O
Assessment	O
by	O
conventional	O
static	O
perimetry	O
may	O
neither	O
be	O
sufficiently	O
sensitive	O
nor	O
specific	O
to	O
reliably	O
identify	O
retinal	Disease
toxicity	Disease
associated	O
with	O
VGB	Chemical

Smoking	O
of	O
crack	Chemical
cocaine	Chemical
as	O
a	O
risk	O
factor	O
for	O
HIV	Disease
infection	Disease
among	O
people	O
who	O
use	O
injection	O
drugs.	O
BACKGROUND:	O
Little	O
is	O
known	O
about	O
the	O
possible	O
role	O
that	O
smoking	O
crack	Chemical
cocaine	Chemical
has	O
on	O
the	O
incidence	O
of	O
HIV	Disease
infection	Disease
.	O
Given	O
the	O
increasing	O
use	O
of	O
crack	Chemical
cocaine	Chemical
,	O
we	O
sought	O
to	O
examine	O
whether	O
use	O
of	O
this	O
illicit	O
drug	O
has	O
become	O
a	O
risk	O
factor	O
for	O
HIV	Disease
infection	Disease
.	O
METHODS:	O
We	O
included	O
data	O
from	O
people	O
participating	O
in	O
the	O
Vancouver	O
Injection	O
Drug	O
Users	O
Study	O
who	O
reported	O
injecting	O
illicit	O
drugs	O
at	O
least	O
once	O
in	O
the	O
month	O
before	O
enrolment,	O
lived	O
in	O
the	O
greater	O
Vancouver	O
area,	O
were	O
HIV-negative	O
at	O
enrolment	O
and	O
completed	O
at	O
least	O
1	O
follow-up	O
study	O
visit.	O
To	O
determine	O
whether	O
the	O
risk	O
of	O
HIV	Disease
seroconversion	Disease
among	O
daily	O
smokers	O
of	O
crack	Chemical
cocaine	Chemical
changed	O
over	O
time,	O
we	O
used	O
Cox	O
proportional	O
hazards	O
regression	O
and	O
divided	O
the	O
study	O
into	O
3	O
periods:	O
May	O
1,	O
1996-Nov.	O
30,	O
1999	O
(period	O
1),	O
Dec.	O
1,	O
1999-Nov.	O
30,	O
2002	O
(period	O
2),	O
and	O
Dec.	O
1,	O
2002-Dec.	O
30,	O
2005	O
(period	O
3).	O
RESULTS:	O
Overall,	O
1048	O
eligible	O
injection	O
drug	O
users	O
were	O
included	O
in	O
our	O
study.	O
Of	O
these,	O
137	O
acquired	O
HIV	Disease
infection	Disease
during	O
follow-up.	O
The	O
mean	O
proportion	O
of	O
participants	O
who	O
reported	O
daily	O
smoking	O
of	O
crack	Chemical
cocaine	Chemical
increased	O
from	O
11.6%	O
in	O
period	O
1	O
to	O
39.7%	O
in	O
period	O
3.	O
After	O
adjusting	O
for	O
potential	O
confounders,	O
we	O
found	O
that	O
the	O
risk	O
of	O
HIV	Disease
seroconversion	Disease
among	O
participants	O
who	O
were	O
daily	O
smokers	O
of	O
crack	Chemical
cocaine	Chemical
increased	O
over	O
time	O
(period	O
1:	O
hazard	O
ratio	O
[HR]	O
1.03,	O
95%	O
confidence	O
interval	O
[CI]	O
0.57-1.85;	O
period	O
2:	O
HR	O
1.68,	O
95%	O
CI	O
1.01-2.80;	O
and	O
period	O
3:	O
HR	O
2.74,	O
95%	O
CI	O
1.06-7.11).	O
INTERPRETATION:	O
Smoking	O
of	O
crack	Chemical
cocaine	Chemical
was	O
found	O
to	O
be	O
an	O
independent	O
risk	O
factor	O
for	O
HIV	Disease
seroconversion	Disease
among	O
people	O
who	O
were	O
injection	O
drug	O
users.	O
This	O
finding	O
points	O
to	O
the	O
urgent	O
need	O
for	O
evidence-based	O
public	O
health	O
initiatives	O
targeted	O
at	O
people	O
who	O
smoke	O
crack	Chemical
cocaine	Chemical

Fluoxetine	Chemical
improves	O
the	O
memory	Disease
deficits	Disease
caused	O
by	O
the	O
chemotherapy	O
agent	O
5-fluorouracil	Chemical
.	O
Cancer	Disease
patients	O
who	O
have	O
been	O
treated	O
with	O
systemic	O
adjuvant	O
chemotherapy	O
have	O
described	O
experiencing	O
deteriorations	O
in	O
cognition.	O
A	O
widely	O
used	O
chemotherapeutic	O
agent,	O
5-fluorouracil	Chemical
(	O
5-FU	Chemical
),	O
readily	O
crosses	O
the	O
blood-brain	O
barrier	O
and	O
so	O
could	O
have	O
a	O
direct	O
effect	O
on	O
brain	O
function.	O
In	O
particular	O
this	O
anti	O
mitotic	O
drug	O
could	O
reduce	O
cell	O
proliferation	O
in	O
the	O
neurogenic	O
regions	O
of	O
the	O
adult	O
brain.	O
In	O
contrast	O
reports	O
indicate	O
that	O
hippocampal	O
dependent	O
neurogenesis	O
and	O
cognition	O
are	O
enhanced	O
by	O
the	O
SSRI	Chemical
antidepressant	O
Fluoxetine	Chemical
.	O
In	O
this	O
investigation	O
the	O
behavioural	O
effects	O
of	O
chronic	O
(two	O
week)	O
treatment	O
with	O
5-FU	Chemical
and	O
(three	O
weeks)	O
with	O
Fluoxetine	Chemical
either	O
separately	O
or	O
in	O
combination	O
with	O
5-FU	Chemical
were	O
tested	O
on	O
adult	O
Lister	O
hooded	O
rats.	O
Behavioural	O
effects	O
were	O
tested	O
using	O
a	O
context	O
dependent	O
conditioned	O
emotional	O
response	O
test	O
(CER)	O
which	O
showed	O
that	O
animals	O
treated	O
with	O
5-FU	Chemical
had	O
a	O
significant	O
reduction	O
in	O
freezing	O
time	O
compared	O
to	O
controls.	O
A	O
separate	O
group	O
of	O
animals	O
was	O
tested	O
using	O
a	O
hippocampal	O
dependent	O
spatial	O
working	O
memory	O
test,	O
the	O
object	O
location	O
recognition	O
test	O
(OLR).	O
Animals	O
treated	O
only	O
with	O
5-FU	Chemical
showed	O
significant	O
deficits	O
in	O
their	O
ability	O
to	O
carry	O
out	O
the	O
OLR	O
task	O
but	O
co	O
administration	O
of	O
Fluoxetine	Chemical
improved	O
their	O
performance.	O
5-FU	Chemical
chemotherapy	O
caused	O
a	O
significant	O
reduction	O
in	O
the	O
number	O
of	O
proliferating	O
cells	O
in	O
the	O
sub	O
granular	O
zone	O
of	O
the	O
dentate	O
gyrus	O
compared	O
to	O
controls.	O
This	O
reduction	O
was	O
eliminated	O
when	O
Fluoxetine	Chemical
was	O
co	O
administered	O
with	O
5-FU	Chemical
.	O
Fluoxetine	Chemical
on	O
its	O
own	O
had	O
no	O
effect	O
on	O
proliferating	O
cell	O
number	O
or	O
behaviour.	O
These	O
findings	O
suggest	O
that	O
5-FU	Chemical
can	O
negatively	O
affect	O
both	O
cell	O
proliferation	O
and	O
hippocampal	O
dependent	O
working	O
memory	O
and	O
that	O
these	O
deficits	O
can	O
be	O
reversed	O
by	O
the	O
simultaneous	O
administration	O
of	O
the	O
antidepressant	O
Fluoxetine	Chemical

Liver-specific	O
ablation	O
of	O
integrin-linked	O
kinase	O
in	O
mice	O
results	O
in	O
enhanced	O
and	O
prolonged	O
cell	O
proliferation	O
and	O
hepatomegaly	Disease
after	O
phenobarbital	Chemical
administration.	O
We	O
have	O
recently	O
demonstrated	O
that	O
disruption	O
of	O
extracellular	O
matrix	O
(ECM)/integrin	O
signaling	O
via	O
elimination	O
of	O
integrin-linked	O
kinase	O
(ILK)	O
in	O
hepatocytes	O
interferes	O
with	O
signals	O
leading	O
to	O
termination	O
of	O
liver	O
regeneration.	O
This	O
study	O
investigates	O
the	O
role	O
of	O
ILK	O
in	O
liver	O
enlargement	O
induced	O
by	O
phenobarbital	Chemical
(	O
PB	Chemical
).	O
Wild-type	O
(WT)	O
and	O
ILK:liver-/-	O
mice	O
were	O
given	O
PB	Chemical
(0.1%	O
in	O
drinking	O
water)	O
for	O
10	O
days.	O
Livers	O
were	O
harvested	O
on	O
2,	O
5,	O
and	O
10	O
days	O
during	O
PB	Chemical
administration.	O
In	O
the	O
hepatocyte-specific	O
ILK/liver-/-	O
mice,	O
the	O
liver:body	O
weight	O
ratio	O
was	O
more	O
than	O
double	O
as	O
compared	O
to	O
0	O
h	O
at	O
day	O
2	O
(2.5	O
times),	O
while	O
at	O
days	O
5	O
and	O
10,	O
it	O
was	O
enlarged	O
three	O
times.	O
In	O
the	O
WT	O
mice,	O
the	O
increase	O
was	O
as	O
expected	O
from	O
previous	O
literature	O
(1.8	O
times)	O
and	O
seems	O
to	O
have	O
leveled	O
off	O
after	O
day	O
2.	O
There	O
were	O
slightly	O
increased	O
proliferating	O
cell	O
nuclear	O
antigen-positive	O
cells	O
in	O
the	O
ILK/liver-/-	O
animals	O
at	O
day	O
2	O
as	O
compared	O
to	O
WT	O
after	O
PB	Chemical
administration.	O
In	O
the	O
WT	O
animals,	O
the	O
proliferative	O
response	O
had	O
come	O
back	O
to	O
normal	O
by	O
days	O
5	O
and	O
10.	O
Hepatocytes	O
of	O
the	O
ILK/liver-/-	O
mice	O
continued	O
to	O
proliferate	O
up	O
until	O
day	O
10.	O
ILK/liver-/-	O
mice	O
also	O
showed	O
increased	O
expression	O
of	O
key	O
genes	O
involved	O
in	O
hepatocyte	O
proliferation	O
at	O
different	O
time	O
points	O
during	O
PB	Chemical
administration.	O
In	O
summary,	O
ECM	O
proteins	O
communicate	O
with	O
the	O
signaling	O
machinery	O
of	O
dividing	O
cells	O
via	O
ILK	O
to	O
regulate	O
hepatocyte	O
proliferation	O
and	O
termination	O
of	O
the	O
proliferative	O
response.	O
Lack	O
of	O
ILK	O
in	O
the	O
hepatocytes	O
imparts	O
prolonged	O
proliferative	O
response	O
not	O
only	O
to	O
stimuli	O
related	O
to	O
liver	O
regeneration	O
but	O
also	O
to	O
xenobiotic	O
chemical	O
mitogens,	O
such	O
as	O
PB	Chemical

Decreased	O
Expression	O
of	O
Na	Chemical
/	O
K	Chemical
-ATPase,	O
NHE3,	O
NBC1,	O
AQP1	O
and	O
OAT	O
in	O
Gentamicin	Chemical
-induced	O
Nephropathy	Disease
.	O
The	O
present	O
study	O
was	O
aimed	O
to	O
determine	O
whether	O
there	O
is	O
an	O
altered	O
regulation	O
of	O
tubular	O
transporters	O
in	O
gentamicin	Chemical
-induced	O
nephropathy	Disease
.	O
Sprague-Dawley	O
male	O
rats	O
(200~250	O
g)	O
were	O
subcutaneously	O
injected	O
with	O
gentamicin	Chemical
(100	O
mg/kg	O
per	O
day)	O
for	O
7	O
days,	O
and	O
the	O
expression	O
of	O
tubular	O
transporters	O
was	O
determined	O
by	O
immunoblotting	O
and	O
immunohistochemistry.	O
The	O
mRNA	O
and	O
protein	O
expression	O
of	O
OAT	O
was	O
also	O
determined.	O
Gentamicin	Chemical
-treated	O
rats	O
exhibited	O
significantly	O
decreased	O
creatinine	Chemical
clearance	O
along	O
with	O
increased	O
plasma	O
creatinine	Chemical
levels.	O
Accordingly,	O
the	O
fractional	O
excretion	O
of	O
sodium	Chemical
increased.	O
Urine	O
volume	O
was	O
increased,	O
while	O
urine	O
osmolality	O
and	O
free	O
water	O
reabsorption	O
were	O
decreased.	O
Immunoblotting	O
and	O
immunohistochemistry	O
revealed	O
decreased	O
expression	O
of	O
Na	Chemical
(+)/	O
K	Chemical
(+)-ATPase,	O
NHE3,	O
NBC1,	O
and	O
AQP1	O
in	O
the	O
kidney	O
of	O
gentamicin	Chemical
-treated	O
rats.	O
The	O
expression	O
of	O
OAT1	O
and	O
OAT3	O
was	O
also	O
decreased.	O
Gentamicin	Chemical
-induced	O
nephropathy	Disease
may	O
at	O
least	O
in	O
part	O
be	O
causally	O
related	O
with	O
a	O
decreased	O
expression	O
of	O
Na	Chemical
(+)/	O
K	Chemical

Longitudinal	O
association	O
of	O
alcohol	Chemical
use	O
with	O
HIV	Disease
disease	Disease
progression	O
and	O
psychological	O
health	O
of	O
women	O
with	O
HIV.	O
We	O
evaluated	O
the	O
association	O
of	O
alcohol	Chemical
consumption	O
and	O
depression	Disease
,	O
and	O
their	O
effects	O
on	O
HIV	Disease
disease	Disease
progression	O
among	O
women	O
with	O
HIV.	O
The	O
study	O
included	O
871	O
women	O
with	O
HIV	O
who	O
were	O
recruited	O
from	O
1993-1995	O
in	O
four	O
US	O
cities.	O
The	O
participants	O
had	O
physical	O
examination,	O
medical	O
record	O
extraction,	O
and	O
venipuncture,	O
CD4+T-cell	O
counts	O
determination,	O
measurement	O
of	O
depression	Disease
symptoms	O
(using	O
the	O
self-report	O
Center	O
for	O
Epidemiological	O
Studies-	O
Depression	Disease
Scale),	O
and	O
alcohol	Chemical
use	O
assessment	O
at	O
enrollment,	O
and	O
semiannually	O
until	O
March	O
2000.	O
Multilevel	O
random	O
coefficient	O
ordinal	O
models	O
as	O
well	O
as	O
multilevel	O
models	O
with	O
joint	O
responses	O
were	O
used	O
in	O
the	O
analysis.	O
There	O
was	O
no	O
significant	O
association	O
between	O
level	O
of	O
alcohol	Chemical
use	O
and	O
CD4+	O
T-cell	O
counts.	O
When	O
participants	O
were	O
stratified	O
by	O
antiretroviral	O
therapy	O
(ART)	O
use,	O
the	O
association	O
between	O
alcohol	Chemical
and	O
CD4+	O
T-cell	O
did	O
not	O
reach	O
statistical	O
significance.	O
The	O
association	O
between	O
alcohol	Chemical
consumption	O
and	O
depression	Disease
was	O
significant	O
(p<0.001).	O
Depression	Disease
had	O
a	O
significant	O
negative	O
effect	O
on	O
CD4+	O
T-cell	O
counts	O
over	O
time	O
regardless	O
of	O
ART	O
use.	O
Our	O
findings	O
suggest	O
that	O
alcohol	Chemical
consumption	O
has	O
a	O
direct	O
association	O
with	O
depression	Disease
.	O
Moreover,	O
depression	Disease
is	O
associated	O
with	O
HIV	Disease
disease	Disease
progression.	O
Our	O
findings	O
have	O
implications	O
for	O
the	O
provision	O
of	O
alcohol	Chemical

Chemokine	O
CCL2	O
and	O
its	O
receptor	O
CCR2	O
are	O
increased	O
in	O
the	O
hippocampus	O
following	O
pilocarpine	Chemical
-induced	O
status	Disease
epilepticus	Disease
.	O
BACKGROUND:	O
Neuroinflammation	Disease
occurs	O
after	O
seizures	Disease
and	O
is	O
implicated	O
in	O
epileptogenesis.	O
CCR2	O
is	O
a	O
chemokine	O
receptor	O
for	O
CCL2	O
and	O
their	O
interaction	O
mediates	O
monocyte	O
infiltration	O
in	O
the	O
neuroinflammatory	Disease
cascade	O
triggered	O
in	O
different	O
brain	O
pathologies.	O
In	O
this	O
work	O
CCR2	O
and	O
CCL2	O
expression	O
were	O
examined	O
following	O
status	Disease
epilepticus	Disease
(	O
SE	Disease
)	O
induced	O
by	O
pilocarpine	Chemical
injection.	O
METHODS:	O
SE	Disease
was	O
induced	O
by	O
pilocarpine	Chemical
injection.	O
Control	O
rats	O
were	O
injected	O
with	O
saline	O
instead	O
of	O
pilocarpine	Chemical
.	O
Five	O
days	O
after	O
SE	Disease
,	O
CCR2	O
staining	O
in	O
neurons	O
and	O
glial	O
cells	O
was	O
examined	O
using	O
imunohistochemical	O
analyses.	O
The	O
number	O
of	O
CCR2	O
positive	O
cells	O
was	O
determined	O
using	O
stereology	O
probes	O
in	O
the	O
hippocampus.	O
CCL2	O
expression	O
in	O
the	O
hippocampus	O
was	O
examined	O
by	O
molecular	O
assay.	O
RESULTS:	O
Increased	O
CCR2	O
was	O
observed	O
in	O
the	O
hippocampus	O
after	O
SE	Disease
.	O
Seizures	Disease
also	O
resulted	O
in	O
alterations	O
to	O
the	O
cell	O
types	O
expressing	O
CCR2.	O
Increased	O
numbers	O
of	O
neurons	O
that	O
expressed	O
CCR2	O
was	O
observed	O
following	O
SE	Disease
.	O
Microglial	O
cells	O
were	O
more	O
closely	O
apposed	O
to	O
the	O
CCR2-labeled	O
cells	O
in	O
SE	Disease
rats.	O
In	O
addition,	O
rats	O
that	O
experienced	O
SE	Disease
exhibited	O
CCR2-labeling	O
in	O
populations	O
of	O
hypertrophied	Disease
astrocytes,	O
especially	O
in	O
CA1	O
and	O
dentate	O
gyrus.	O
These	O
CCR2+	O
astroctytes	O
were	O
not	O
observed	O
in	O
control	O
rats.	O
Examination	O
of	O
CCL2	O
expression	O
showed	O
that	O
it	O
was	O
elevated	O
in	O
the	O
hippocampus	O
following	O
SE	Disease
.	O
CONCLUSION:	O
The	O
data	O
show	O
that	O
CCR2	O
and	O
CCL2	O
are	O
up-regulated	O
in	O
the	O
hippocampus	O
after	O
pilocarpine	Chemical
-induced	O
SE	Disease
.	O
Seizures	Disease
also	O
result	O
in	O
changes	O
to	O
CCR2	O
receptor	O
expression	O
in	O
neurons	O
and	O
astrocytes.	O
These	O
changes	O
might	O
be	O
involved	O
in	O
detrimental	O
neuroplasticity	O
and	O
neuroinflammatory	Disease
changes	O
that	O
occur	O
following	O
seizures	Disease

Metallothionein	Chemical
induction	O
reduces	O
caspase-3	O
activity	O
and	O
TNFalpha	O
levels	O
with	O
preservation	O
of	O
cognitive	O
function	O
and	O
intact	O
hippocampal	O
neurons	O
in	O
carmustine	Chemical
-treated	O
rats.	O
Hippocampal	O
integrity	O
is	O
essential	O
for	O
cognitive	O
functions.	O
On	O
the	O
other	O
hand,	O
induction	O
of	O
metallothionein	Chemical
(	O
MT	Chemical
)	O
by	O
ZnSO(4)	Chemical
and	O
its	O
role	O
in	O
neuroprotection	O
has	O
been	O
documented.	O
The	O
present	O
study	O
aimed	O
to	O
explore	O
the	O
effect	O
of	O
MT	Chemical
induction	O
on	O
carmustine	Chemical
(	O
BCNU	Chemical
)-induced	O
hippocampal	O
cognitive	Disease
dysfunction	Disease
in	O
rats.	O
A	O
total	O
of	O
60	O
male	O
Wistar	O
albino	O
rats	O
were	O
randomly	O
divided	O
into	O
four	O
groups	O
(15/group):	O
The	O
control	O
group	O
injected	O
with	O
single	O
doses	O
of	O
normal	O
saline	O
(i.c.v)	O
followed	O
24	O
h	O
later	O
by	O
BCNU	Chemical
solvent	O
(i.v).	O
The	O
second	O
group	O
administered	O
ZnSO(4)	Chemical
(0.1	O
micromol/10	O
microl	O
normal	O
saline,	O
i.c.v,	O
once)	O
then	O
BCNU	Chemical
solvent	O
(i.v)	O
after	O
24	O
h.	O
Third	O
group	O
received	O
BCNU	Chemical
(20	O
mg/kg,	O
i.v,	O
once)	O
24	O
h	O
after	O
injection	O
with	O
normal	O
saline	O
(i.c.v).	O
Fourth	O
group	O
received	O
a	O
single	O
dose	O
of	O
ZnSO(4)	Chemical
(0.1	O
micromol/10	O
microl	O
normal	O
saline,	O
i.c.v)	O
then	O
BCNU	Chemical
(20	O
mg/kg,	O
i.v,	O
once)	O
after	O
24	O
h.	O
The	O
obtained	O
data	O
revealed	O
that	O
BCNU	Chemical
administration	O
resulted	O
in	O
deterioration	Disease
of	Disease
learning	Disease
and	Disease
short-term	Disease
memory	Disease
(STM),	O
as	O
measured	O
by	O
using	O
radial	O
arm	O
water	O
maze,	O
accompanied	O
with	O
decreased	O
hippocampal	O
glutathione	Chemical
reductase	O
(GR)	O
activity	O
and	O
reduced	O
glutathione	Chemical
(	O
GSH	Chemical
)	O
content.	O
Also,	O
BCNU	Chemical
administration	O
increased	O
serum	O
tumor	Disease
	O
necrosis	Disease
factor-alpha	O
(TNFalpha),	O
hippocampal	O
MT	Chemical
and	O
malondialdehyde	Chemical
(	O
MDA	Chemical
)	O
contents	O
as	O
well	O
as	O
caspase-3	O
activity	O
in	O
addition	O
to	O
histological	O
alterations.	O
ZnSO(4)	Chemical
pretreatment	O
counteracted	O
BCNU	Chemical
-induced	O
inhibition	O
of	O
GR	O
and	O
depletion	O
of	O
GSH	Chemical
and	O
resulted	O
in	O
significant	O
reduction	O
in	O
the	O
levels	O
of	O
MDA	Chemical
and	O
TNFalpha	O
as	O
well	O
as	O
the	O
activity	O
of	O
caspase-3.	O
The	O
histological	O
features	O
were	O
improved	O
in	O
hippocampus	O
of	O
rats	O
treated	O
with	O
ZnSO(4)	Chemical
+	O
BCNU	Chemical
compared	O
to	O
only	O
BCNU	Chemical
-treated	O
animals.	O
In	O
conclusion,	O
MT	Chemical
induction	O
halts	O
BCNU	Chemical
-induced	O
hippocampal	O
toxicity	Disease
as	O
it	O
prevented	O
GR	O
inhibition	O
and	O
GSH	Chemical
depletion	O
and	O
counteracted	O
the	O
increased	O
levels	O
of	O
TNFalpha,	O
MDA	Chemical

Fatal	O
carbamazepine	Chemical
induced	O
fulminant	Disease
eosinophilic	Disease
(	O
hypersensitivity	Disease
)	O
myocarditis	Disease
:	O
emphasis	O
on	O
anatomical	O
and	O
histological	O
characteristics,	O
mechanisms	O
and	O
genetics	O
of	O
drug	Disease
hypersensitivity	Disease
and	O
differential	O
diagnosis.	O
The	O
most	O
severe	O
adverse	O
reactions	O
to	O
carbamazepine	Chemical
have	O
been	O
observed	O
in	O
the	O
haemopoietic	O
system,	O
the	O
liver	O
and	O
the	O
cardiovascular	O
system.	O
A	O
frequently	O
fatal,	O
although	O
exceptionally	O
rare	O
side	O
effect	O
of	O
carbamazepine	Chemical
is	O
necrotizing	O
eosinophilic	O
(	O
hypersensitivity	Disease
)	O
myocarditis	Disease
.	O
We	O
report	O
a	O
case	O
of	O
hypersensitivity	Disease
	O
myocarditis	Disease
secondary	O
to	O
administration	O
of	O
carbamazepine	Chemical
.	O
Acute	O
hypersensitivity	Disease
	O
myocarditis	Disease
was	O
not	O
suspected	O
clinically,	O
and	O
the	O
diagnosis	O
was	O
made	O
post-mortem.	O
Histology	O
revealed	O
diffuse	O
infiltration	O
of	O
the	O
myocardium	O
by	O
eosinophils	O
and	O
lymphocytes	O
with	O
myocyte	O
damage.	O
Clinically,	O
death	O
was	O
due	O
to	O
cardiogenic	Disease
shock	Disease
.	O
To	O
best	O
of	O
our	O
knowledge	O
this	O
is	O
the	O
second	O
case	O
of	O
fatal	O
carbamazepine	Chemical
induced	O
myocarditis	Disease

Neuropsychiatric	O
behaviors	O
in	O
the	O
MPTP	Chemical
marmoset	O
model	O
of	O
Parkinson's	Disease
disease	Disease
.	O
OBJECTIVES:	O
Neuropsychiatric	O
symptoms	O
are	O
increasingly	O
recognised	O
as	O
a	O
significant	O
problem	O
in	O
patients	O
with	O
Parkinson's	Disease
disease	Disease
(	O
PD	Disease
).	O
These	O
symptoms	O
may	O
be	O
due	O
to	O
'sensitisation'	O
following	O
repeated	O
levodopa	Chemical
treatment	O
or	O
a	O
direct	O
effect	O
of	O
dopamine	Chemical
on	O
the	O
disease	O
state.	O
The	O
levodopa	Chemical
-treated	O
MPTP	Chemical
-lesioned	O
marmoset	O
was	O
used	O
as	O
a	O
model	O
of	O
neuropsychiatric	Disease
symptoms	Disease
in	O
PD	Disease
patients.	O
Here	O
we	O
compare	O
the	O
time	O
course	O
of	O
levodopa	Chemical
-induced	O
motor	O
fluctuations	O
and	O
neuropsychiatric-like	Disease
behaviors	Disease
to	O
determine	O
the	O
relationship	O
between	O
duration	O
of	O
treatment	O
and	O
onset	O
of	O
symptoms.	O
METHODS:	O
Marmosets	O
were	O
administered	O
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	Chemical
(2.0	O
mg/kg	O
s.c.)	O
for	O
five	O
days,	O
resulting	O
in	O
stable	O
parkinsonism	Disease
.	O
Levodopa	Chemical
(15	O
mg/kg	O
and	O
benserazide	Chemical
,	O
3.75	O
mg/kg)	O
p.o.	O
b.i.d,	O
was	O
administered	O
for	O
30	O
days.	O
Animals	O
were	O
evaluated	O
for	O
parkinsonian	Disease
disability	Disease
,	O
dyskinesia	Disease
and	O
on-time	O
(motor	O
fluctuations)	O
and	O
neuropsychiatric-like	Disease
behaviors	Disease
on	O
Day	O
0	O
(prior	O
to	O
levodopa	Chemical
)	O
and	O
on	O
Days	O
1,	O
7,	O
13,	O
27	O
and	O
30	O
of	O
treatment	O
using	O
post	O
hoc	O
DVD	O
analysis	O
by	O
a	O
trained	O
rater,	O
blind	O
to	O
the	O
treatment	O
day.	O
RESULTS:	O
The	O
neuropsychiatric-like	Disease
behavior	Disease
rating	O
scale	O
demonstrated	O
high	O
interrater	O
reliability	O
between	O
three	O
trained	O
raters	O
of	O
differing	O
professional	O
backgrounds.	O
As	O
anticipated,	O
animals	O
exhibited	O
a	O
progressive	O
increase	O
in	O
levodopa	Chemical
-induced	O
motor	O
fluctuations,	O
dyskinesia	Disease
and	O
wearing-off,	O
that	O
correlated	O
with	O
the	O
duration	O
of	O
levodopa	Chemical
therapy.	O
In	O
contrast,	O
levodopa	Chemical
-induced	O
neuropsychiatric-like	Disease
behaviors	Disease
were	O
present	O
on	O
Day	O
1	O
of	O
levodopa	Chemical
treatment	O
and	O
their	O
severity	O
did	O
not	O
correlate	O
with	O
duration	O
of	O
treatment.	O
CONCLUSIONS:	O
The	O
data	O
suggest	O
that	O
neuropsychiatric	Disease
disorders	Disease
in	O
PD	Disease
are	O
more	O
likely	O
an	O
interaction	O
between	O
levodopa	Chemical

Contrast	Chemical
medium	Chemical
	O
nephrotoxicity	Disease
after	O
renal	O
artery	O
and	O
coronary	O
angioplasty.	O
BACKGROUND:	O
Renal	Disease
dysfunction	Disease
induced	O
by	O
iodinated	O
contrast	Chemical
medium	Chemical
(	O
CM	Chemical
)	O
administration	O
can	O
minimize	O
the	O
benefit	O
of	O
the	O
interventional	O
procedure	O
in	O
patients	O
undergoing	O
renal	O
angioplasty	O
(PTRA).	O
PURPOSE:	O
To	O
compare	O
the	O
susceptibility	O
to	O
nephrotoxic	Disease
effect	O
of	O
CM	Chemical
in	O
patients	O
undergoing	O
PTRA	O
with	O
that	O
of	O
patients	O
submitted	O
to	O
percutaneous	O
coronary	O
intervention	O
(PCI).	O
MATERIAL	O
AND	O
METHODS:	O
A	O
total	O
of	O
33	O
patients	O
successfully	O
treated	O
with	O
PTRA	O
(PTRA	O
group,	O
mean	O
age	O
70+/-12	O
years,	O
23	O
female,	O
basal	O
creatinine	Chemical
1.46+/-0.79,	O
range	O
0.7-4.9	O
mg/dl)	O
were	O
compared	O
with	O
33	O
patients	O
undergoing	O
successful	O
PCI	O
(PCI	O
group),	O
matched	O
for	O
basal	O
creatinine	Chemical
(1.44+/-0.6,	O
range	O
0.7-3.4	O
mg/dl),	O
gender,	O
and	O
age.	O
In	O
both	O
groups	O
postprocedural	O
(48	O
h)	O
serum	O
creatinine	Chemical
was	O
measured.	O
RESULTS:	O
Postprocedural	O
creatinine	Chemical
level	O
decreased	O
nonsignificantly	O
in	O
the	O
PTRA	O
group	O
(1.46+/-0.8	O
vs.	O
1.34+/-0.5	O
mg/dl,	O
P=NS)	O
and	O
increased	O
significantly	O
in	O
the	O
PCI	O
group	O
(1.44+/-0.6	O
vs.	O
1.57+/-0.7	O
mg/dl,	O
P<0.02).	O
Changes	O
in	O
serum	O
creatinine	Chemical
after	O
intervention	O
(after-before)	O
were	O
significantly	O
different	O
between	O
the	O
PTRA	O
and	O
PCI	O
groups	O
(-0.12+/-0.5	O
vs.	O
0.13+/-0.3,	O
P=0.014).	O
This	O
difference	O
was	O
not	O
related	O
to	O
either	O
a	O
different	O
clinical	O
risk	O
profile	O
or	O
to	O
the	O
volume	O
of	O
CM	Chemical
administered.	O
CONCLUSION:	O
In	O
this	O
preliminary	O
study	O
patients	O
submitted	O
to	O
PTRA	O
showed	O
a	O
lower	O
susceptibility	O
to	O
renal	Disease
damage	Disease
induced	O
by	O
CM	Chemical
administration	O
than	O
PCI	O
patients.	O
The	O
effectiveness	O
of	O
PTRA	O
on	O
renal	O
function	O
seems	O
to	O
be	O
barely	O
influenced	O
by	O
CM	Chemical
	O
toxicity	Disease

Medical	O
and	O
psychiatric	O
outcomes	O
for	O
patients	O
transplanted	O
for	O
acetaminophen	Chemical
-induced	O
acute	Disease
liver	Disease
failure	Disease
:	O
a	O
case-control	O
study.	O
BACKGROUND:	O
Acetaminophen	Chemical
-induced	O
hepatotoxicity	Disease
is	O
the	O
most	O
common	O
cause	O
of	O
acute	Disease
liver	Disease
failure	Disease
(	O
ALF	Disease
)	O
in	O
the	O
UK.	O
Patients	O
often	O
consume	O
the	O
drug	O
with	O
suicidal	O
intent	O
or	O
with	O
a	O
background	O
of	O
substance	O
dependence.	O
AIMS	O
AND	O
METHODS:	O
We	O
compared	O
the	O
severity	O
of	O
pretransplant	O
illness,	O
psychiatric	O
co-morbidity,	O
medical	O
and	O
psychosocial	O
outcomes	O
of	O
all	O
patients	O
who	O
had	O
undergone	O
liver	O
transplantation	O
(LT)	O
emergently	O
between	O
1999-2004	O
for	O
acetaminophen	Chemical
-induced	O
ALF	Disease
(n=36)	O
with	O
age-	O
and	O
sex-matched	O
patients	O
undergoing	O
emergent	O
LT	O
for	O
non-	O
acetaminophen	Chemical
-induced	O
ALF	Disease
(n=35)	O
and	O
elective	O
LT	O
for	O
chronic	Disease
liver	Disease
disease	Disease
(	O
CLD	Disease
,	O
n=34).	O
RESULTS:	O
Acetaminophen	Chemical
-induced	O
ALF	Disease
patients	O
undergoing	O
LT	O
had	O
a	O
greater	O
severity	O
of	O
pre-LT	O
illness	O
reflected	O
by	O
higher	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
scores	O
and	O
requirement	O
for	O
organ	O
support	O
compared	O
with	O
the	O
other	O
two	O
groups.	O
Twenty	O
(56%)	O
acetaminophen	Chemical
-induced	O
ALF	Disease
patients	O
had	O
a	O
formal	O
psychiatric	O
diagnosis	O
before	O
LT	O
(non-	O
acetaminophen	Chemical
-induced	O
ALF	Disease
=0/35,	O
CLD	Disease
=2/34;	O
P<0.01	O
for	O
all)	O
and	O
nine	O
(25%)	O
had	O
a	O
previous	O
suicide	O
attempt.	O
During	O
follow-up	O
(median	O
5	O
years),	O
there	O
were	O
no	O
significant	O
differences	O
in	O
rejection	O
(acute	O
and	O
chronic),	O
graft	O
failure	O
or	O
survival	O
between	O
the	O
groups	O
(	O
acetaminophen	Chemical
-induced	O
ALF	Disease
1	O
year	O
87%,	O
5	O
years	O
75%;	O
non-	O
acetaminophen	Chemical
-induced	O
ALF	Disease
88%,	O
78%;	O
CLD	Disease
93%,	O
82%:	O
P>0.6	O
log	O
rank).	O
Two	O
acetaminophen	Chemical
-induced	O
ALF	Disease
patients	O
reattempted	O
suicide	O
post-LT	O
(one	O
died	O
8	O
years	O
post-LT).	O
CONCLUSIONS:	O
Despite	O
a	O
high	O
prevalence	O
of	O
psychiatric	O
disturbance,	O
outcomes	O
for	O
patients	O
transplanted	O
emergently	O
for	O
acetaminophen	Chemical
-induced	O
ALF	Disease
were	O
comparable	O
to	O
those	O
transplanted	O
for	O
non-	O
acetaminophen	Chemical
-induced	O
ALF	Disease
and	O
electively	O
for	O
CLD	Disease

Studies	O
of	O
synergy	O
between	O
morphine	Chemical
and	O
a	O
novel	O
sodium	Chemical
channel	O
blocker,	O
CNSB002	Chemical
,	O
in	O
rat	O
models	O
of	O
inflammatory	O
and	O
neuropathic	Disease
pain	Disease
.	O
OBJECTIVE:	O
This	O
study	O
determined	O
the	O
antihyperalgesic	O
effect	O
of	O
CNSB002	Chemical
,	O
a	O
sodium	Chemical
channel	O
blocker	O
with	O
antioxidant	O
properties	O
given	O
alone	O
and	O
in	O
combinations	O
with	O
morphine	Chemical
in	O
rat	O
models	O
of	O
inflammatory	O
and	O
neuropathic	Disease
pain	Disease
.	O
DESIGN:	O
Dose	O
response	O
curves	O
for	O
nonsedating	O
doses	O
of	O
morphine	Chemical
and	O
CNSB002	Chemical
given	O
intraperitoneally	O
alone	O
and	O
together	O
in	O
combinations	O
were	O
constructed	O
for	O
antihyperalgesic	O
effect	O
using	O
paw	O
withdrawal	O
from	O
noxious	O
heat	O
in	O
two	O
rat	O
pain	Disease
models:	O
carrageenan	Chemical
-induced	O
paw	O
inflammation	Disease
and	O
streptozotocin	Chemical
(	O
STZ	Chemical
)-induced	O
diabetic	Disease
neuropathy	Disease
.	O
RESULTS:	O
The	O
maximum	O
nonsedating	O
doses	O
were:	O
morphine	Chemical
,	O
3.2	O
mg/kg;	O
CNSB002	Chemical
10.0	O
mg/kg;	O
5.0	O
mg/kg	O
CNSB002	Chemical
with	O
morphine	Chemical
3.2	O
mg/kg	O
in	O
combination.	O
The	O
doses	O
calculated	O
to	O
cause	O
50%	O
reversal	O
of	O
hyperalgesia	Disease
(ED50)	O
were	O
7.54	O
(1.81)	O
and	O
4.83	O
(1.54)	O
in	O
the	O
carrageenan	Chemical
model	O
and	O
44.18	O
(1.37)	O
and	O
9.14	O
(1.24)	O
in	O
the	O
STZ	Chemical
-induced	O
neuropathy	Disease
model	O
for	O
CNSB002	Chemical
and	O
morphine	Chemical
,	O
respectively	O
(mg/kg;	O
mean,	O
SEM).	O
These	O
values	O
were	O
greater	O
than	O
the	O
maximum	O
nonsedating	O
doses.	O
The	O
ED50	O
values	O
for	O
morphine	Chemical
when	O
given	O
in	O
combination	O
with	O
CNSB002	Chemical
(5	O
mg/kg)	O
were	O
less	O
than	O
the	O
maximum	O
nonsedating	O
dose:	O
0.56	O
(1.55)	O
in	O
the	O
carrageenan	Chemical
model	O
and	O
1.37	O
(1.23)	O
in	O
the	O
neuropathy	Disease
model	O
(mg/kg;	O
mean,	O
SEM).	O
The	O
antinociception	O
after	O
morphine	Chemical
(3.2	O
mg/kg)	O
was	O
increased	O
by	O
co-administration	O
with	O
CNSB002	Chemical
from	O
28.0	O
and	O
31.7%	O
to	O
114.6	O
and	O
56.9%	O
reversal	O
of	O
hyperalgesia	Disease
in	O
the	O
inflammatory	O
and	O
neuropathic	Disease
models,	O
respectively	O
(P	O
<	O
0.01;	O
one-way	O
analysis	O
of	O
variance-significantly	O
greater	O
than	O
either	O
drug	O
given	O
alone).	O
CONCLUSIONS:	O
The	O
maximum	O
antihyperalgesic	O
effect	O
achievable	O
with	O
nonsedating	O
doses	O
of	O
morphine	Chemical
may	O
be	O
increased	O
significantly	O
when	O
the	O
drug	O
is	O
used	O
in	O
combination	O
with	O
CNSB002	Chemical

Heparin	Chemical
-induced	O
thrombocytopenia	Disease
:	O
a	O
practical	O
review.	O
Heparin	Chemical
-induced	O
thrombocytopenia	Disease
(	O
HIT	Disease
)	O
remains	O
under-recognized	O
despite	O
its	O
potentially	O
devastating	O
outcomes.	O
It	O
begins	O
when	O
heparin	Chemical
exposure	O
stimulates	O
the	O
formation	O
of	O
heparin	Chemical
-platelet	O
factor	O
4	O
antibodies,	O
which	O
in	O
turn	O
triggers	O
the	O
release	O
of	O
procoagulant	O
platelet	O
particles.	O
Thrombosis	Disease
and	O
thrombocytopenia	Disease
that	O
follow	O
comprise	O
the	O
2	O
hallmark	O
traits	O
of	O
HIT	Disease
,	O
with	O
the	O
former	O
largely	O
responsible	O
for	O
significant	O
vascular	O
complications.	O
The	O
prevalence	O
of	O
HIT	Disease
varies	O
among	O
several	O
subgroups,	O
with	O
greater	O
incidence	O
in	O
surgical	O
as	O
compared	O
with	O
medical	O
populations.	O
HIT	Disease
must	O
be	O
acknowledged	O
for	O
its	O
intense	O
predilection	O
for	O
thrombosis	Disease
and	O
suspected	O
whenever	O
thrombosis	Disease
occurs	O
after	O
heparin	Chemical
exposure.	O
Early	O
recognition	O
that	O
incorporates	O
the	O
clinical	O
and	O
serologic	O
clues	O
is	O
paramount	O
to	O
timely	O
institution	O
of	O
treatment,	O
as	O
its	O
delay	O
may	O
result	O
in	O
catastrophic	O
outcomes.	O
The	O
treatment	O
of	O
HIT	Disease
mandates	O
an	O
immediate	O
cessation	O
of	O
all	O
heparin	Chemical
exposure	O
and	O
the	O
institution	O
of	O
an	O
antithrombotic	O
therapy,	O
most	O
commonly	O
using	O
a	O
direct	Chemical
thrombin	Chemical
inhibitor	Chemical
.	O
Current	O
"diagnostic"	O
tests,	O
which	O
primarily	O
include	O
functional	O
and	O
antigenic	O
assays,	O
have	O
more	O
of	O
a	O
confirmatory	O
than	O
diagnostic	O
role	O
in	O
the	O
management	O
of	O
HIT	Disease
.	O
Special	O
attention	O
must	O
be	O
paid	O
to	O
cardiac	O
patients	O
who	O
are	O
often	O
exposed	O
to	O
heparin	Chemical
multiple	O
times	O
during	O
their	O
course	O
of	O
treatment.	O
Direct	Chemical
thrombin	Chemical
inhibitors	Chemical
are	O
appropriate,	O
evidence-based	O
alternatives	O
to	O
heparin	Chemical
in	O
patients	O
with	O
a	O
history	O
of	O
HIT	Disease
,	O
who	O
need	O
to	O
undergo	O
percutaneous	O
coronary	O
intervention.	O
As	O
heparin	Chemical
remains	O
one	O
of	O
the	O
most	O
frequently	O
used	O
medications	O
today	O
with	O
potential	O
for	O
HIT	Disease
with	O
every	O
heparin	Chemical
exposure,	O
a	O
close	O
vigilance	O
of	O
platelet	O
counts	O
must	O
be	O
practiced	O
whenever	O
heparin	Chemical

Abductor	O
paralysis	Disease
after	O
botox	Chemical
injection	O
for	O
adductor	Disease
spasmodic	Disease
dysphonia	Disease
.	O
OBJECTIVES/HYPOTHESIS:	O
Botulinum	O
toxin	O
(	O
Botox	Chemical
)	O
injections	O
into	O
the	O
thyroarytenoid	O
muscles	O
are	O
the	O
current	O
standard	O
of	O
care	O
for	O
adductor	Disease
spasmodic	Disease
dysphonia	Disease
(	O
ADSD	Disease
).	O
Reported	O
adverse	O
effects	O
include	O
a	O
period	O
of	O
breathiness,	O
throat	Disease
pain	Disease
,	O
and	O
difficulty	O
with	O
swallowing	O
liquids.	O
Here	O
we	O
report	O
multiple	O
cases	O
of	O
bilateral	O
abductor	O
paralysis	Disease
following	O
Botox	Chemical
injections	O
for	O
ADSD	Disease
,	O
a	O
complication	O
previously	O
unreported.	O
STUDY	O
DESIGN:	O
Retrospective	O
case	O
series.	O
METHODS:	O
Patients	O
that	O
received	O
Botox	Chemical
injections	O
for	O
spasmodic	Disease
dysphonia	Disease
between	O
January	O
2000	O
and	O
October	O
2009	O
were	O
evaluated.	O
Patients	O
with	O
ADSD	Disease
were	O
identified.	O
The	O
number	O
of	O
treatments	O
received	O
and	O
adverse	O
effects	O
were	O
noted.	O
For	O
patients	O
with	O
bilateral	O
abductor	O
paralysis	Disease
,	O
age,	O
sex,	O
paralytic	O
Botox	Chemical
dose,	O
prior	O
Botox	Chemical
dose,	O
and	O
course	O
following	O
paralysis	Disease
were	O
noted.	O
RESULTS:	O
From	O
a	O
database	O
of	O
452	O
patients	O
receiving	O
Botox	Chemical
,	O
352	O
patients	O
had	O
been	O
diagnosed	O
with	O
ADSD	Disease
.	O
Of	O
these	O
352	O
patients,	O
eight	O
patients	O
suffered	O
bilateral	O
abductor	O
paralysis	Disease
,	O
and	O
two	O
suffered	O
this	O
complication	O
twice.	O
All	O
affected	O
patients	O
were	O
females	O
over	O
the	O
age	O
of	O
50	O
years.	O
Most	O
patients	O
had	O
received	O
treatments	O
prior	O
to	O
abductor	O
paralysis	Disease
and	O
continued	O
receiving	O
after	O
paralysis	Disease
.	O
Seven	O
patients	O
recovered	O
after	O
a	O
brief	O
period	O
of	O
activity	O
restrictions,	O
and	O
one	O
underwent	O
a	O
tracheotomy.	O
The	O
incidence	O
of	O
abductor	O
paralysis	Disease
after	O
Botox	Chemical
injection	O
for	O
ADSD	Disease
was	O
0.34%.	O
CONCLUSIONS:	O
Bilateral	O
abductor	O
paralysis	Disease
is	O
a	O
rare	O
complication	O
of	O
Botox	Chemical
injections	O
for	O
ADSD	Disease
,	O
causing	O
difficulty	O
with	O
breathing	O
upon	O
exertion.	O
The	O
likely	O
mechanism	O
of	O
paralysis	Disease
is	O
diffusion	O
of	O
Botox	Chemical
around	O
the	O
muscular	O
process	O
of	O
the	O
arytenoid	O
to	O
the	O
posterior	O
cricoarytenoid	O
muscles.	O
The	O
paralysis	Disease

Mitochondrial	Disease
impairment	Disease
contributes	O
to	O
cocaine	Chemical
-induced	O
cardiac	Disease
dysfunction	Disease
:	O
Prevention	O
by	O
the	O
targeted	O
antioxidant	O
MitoQ	Chemical
.	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
assess	O
mitochondrial	O
function	O
and	O
ROS	O
production	O
in	O
an	O
experimental	O
model	O
of	O
cocaine	Chemical
-induced	O
cardiac	Disease
dysfunction	Disease
.	O
We	O
hypothesized	O
that	O
cocaine	Disease
abuse	Disease
may	O
lead	O
to	O
altered	O
mitochondrial	O
function	O
that	O
in	O
turn	O
may	O
cause	O
left	Disease
ventricular	Disease
dysfunction	Disease
.	O
Seven	O
days	O
of	O
cocaine	Chemical
administration	O
to	O
rats	O
led	O
to	O
an	O
increased	O
oxygen	Chemical
consumption	O
detected	O
in	O
cardiac	O
fibers,	O
specifically	O
through	O
complex	O
I	O
and	O
complex	O
III.	O
ROS	O
levels	O
were	O
increased,	O
specifically	O
in	O
interfibrillar	O
mitochondria.	O
In	O
parallel	O
there	O
was	O
a	O
decrease	O
in	O
ATP	Chemical
synthesis,	O
whereas	O
no	O
difference	O
was	O
observed	O
in	O
subsarcolemmal	O
mitochondria.	O
This	O
uncoupling	O
effect	O
on	O
oxidative	O
phosphorylation	O
was	O
not	O
detectable	O
after	O
short-term	O
exposure	O
to	O
cocaine	Chemical
,	O
suggesting	O
that	O
these	O
mitochondrial	Disease
abnormalities	Disease
were	O
a	O
late	O
rather	O
than	O
a	O
primary	O
event	O
in	O
the	O
pathological	O
response	O
to	O
cocaine	Chemical
.	O
MitoQ	Chemical
,	O
a	O
mitochondrial-targeted	O
antioxidant,	O
was	O
shown	O
to	O
completely	O
prevent	O
these	O
mitochondrial	Disease
abnormalities	Disease
as	O
well	O
as	O
cardiac	Disease
dysfunction	Disease
characterized	O
here	O
by	O
a	O
diastolic	Disease
dysfunction	Disease
studied	O
with	O
a	O
conductance	O
catheter	O
to	O
obtain	O
pressure-volume	O
data.	O
Taken	O
together,	O
these	O
results	O
extend	O
previous	O
studies	O
and	O
demonstrate	O
that	O
cocaine	Chemical
-induced	O
cardiac	Disease
dysfunction	Disease
may	O
be	O
due	O
to	O
a	O
mitochondrial	Disease
defect	Disease

Trimethoprim	Chemical
-induced	O
immune	O
hemolytic	Disease
anemia	Disease
in	O
a	O
pediatric	O
oncology	O
patient	O
presenting	O
as	O
an	O
acute	O
hemolytic	O
transfusion	O
reaction.	O
A	O
10-year-old	O
male	O
with	O
acute	Disease
leukemia	Disease
presented	O
with	O
post-chemotherapy	O
anemia	Disease
.	O
During	O
red	O
cell	O
transfusion,	O
he	O
developed	O
hemoglobinuria	Disease
.	O
Transfusion	O
reaction	O
workup	O
was	O
negative.	O
Drug-induced	O
immune	O
hemolytic	Disease
anemia	Disease
was	O
suspected	O
because	O
of	O
positive	O
direct	O
antiglobulin	O
test,	O
negative	O
eluate,	O
and	O
microspherocytes	O
on	O
smear	O
pre-	O
and	O
post-transfusion.	O
Drug	O
studies	O
using	O
the	O
indirect	O
antiglobulin	O
test	O
were	O
strongly	O
positive	O
with	O
trimethoprim	Chemical
and	O
trimethoprim-sulfamethoxazole	Chemical
but	O
negative	O
with	O
sulfamethoxazole	Chemical
.	O
The	O
patient	O
recovered	O
after	O
discontinuing	O
the	O
drug,	O
with	O
no	O
recurrence	O
in	O
2	O
years.	O
Other	O
causes	O
of	O
anemia	Disease
should	O
be	O
considered	O
in	O
patients	O
with	O
worse-than-expected	O
anemia	Disease
after	O
chemotherapy.	O
Furthermore,	O
hemolysis	Disease

Blockade	O
of	O
endothelial-mesenchymal	O
transition	O
by	O
a	O
Smad3	O
inhibitor	O
delays	O
the	O
early	O
development	O
of	O
streptozotocin	Chemical
-induced	O
diabetic	Disease
nephropathy	Disease
.	O
OBJECTIVE:	O
A	O
multicenter,	O
controlled	O
trial	O
showed	O
that	O
early	O
blockade	O
of	O
the	O
renin-	O
angiotensin	Chemical
system	O
in	O
patients	O
with	O
type	Disease
1	Disease
diabetes	Disease
and	O
normoalbuminuria	O
did	O
not	O
retard	O
the	O
progression	O
of	O
nephropathy	Disease
,	O
suggesting	O
that	O
other	O
mechanism(s)	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
early	O
diabetic	Disease
nephropathy	Disease
(	O
diabetic	Disease
nephropathy	Disease
).	O
We	O
have	O
previously	O
demonstrated	O
that	O
endothelial-mesenchymal-transition	O
(EndoMT)	O
contributes	O
to	O
the	O
early	O
development	O
of	O
renal	O
interstitial	O
fibrosis	Disease
independently	O
of	O
microalbuminuria	O
in	O
mice	O
with	O
streptozotocin	Chemical
(	O
STZ	Chemical
)-induced	O
diabetes	Disease
.	O
In	O
the	O
present	O
study,	O
we	O
hypothesized	O
that	O
blocking	O
EndoMT	O
reduces	O
the	O
early	O
development	O
of	O
diabetic	Disease
nephropathy	Disease
.	O
RESEARCH	O
DESIGN	O
AND	O
METHODS:	O
EndoMT	O
was	O
induced	O
in	O
a	O
mouse	O
pancreatic	O
microvascular	O
endothelial	O
cell	O
line	O
(MMEC)	O
in	O
the	O
presence	O
of	O
advanced	O
glycation	O
end	O
products	O
(AGEs)	O
and	O
in	O
the	O
endothelial	O
lineage-traceble	O
mouse	O
line	O
Tie2-Cre;Loxp-EGFP	O
by	O
administration	O
of	O
AGEs,	O
with	O
nonglycated	O
mouse	O
albumin	O
serving	O
as	O
a	O
control.	O
Phosphorylated	O
Smad3	O
was	O
detected	O
by	O
immunoprecipitation/Western	O
blotting	O
and	O
confocal	O
microscopy.	O
Blocking	O
studies	O
using	O
receptor	O
for	O
AGE	O
siRNA	O
and	O
a	O
specific	O
inhibitor	O
of	O
Smad3	O
(SIS3)	O
were	O
performed	O
in	O
MMECs	O
and	O
in	O
STZ	Chemical
-induced	O
diabetic	Disease
nephropathy	Disease
in	O
Tie2-Cre;Loxp-EGFP	O
mice.	O
RESULTS:	O
Confocal	O
microscopy	O
and	O
real-time	O
PCR	O
demonstrated	O
that	O
AGEs	O
induced	O
EndoMT	O
in	O
MMECs	O
and	O
in	O
Tie2-Cre;Loxp-EGFP	O
mice.	O
Immunoprecipitation/Western	O
blotting	O
showed	O
that	O
Smad3	O
was	O
activated	O
by	O
AGEs	O
but	O
was	O
inhibited	O
by	O
SIS3	O
in	O
MMECs	O
and	O
in	O
STZ	Chemical
-induced	O
diabetic	Disease
nephropathy	Disease
.	O
Confocal	O
microscopy	O
and	O
real-time	O
PCR	O
further	O
demonstrated	O
that	O
SIS3	O
abrogated	O
EndoMT,	O
reduced	O
renal	O
fibrosis	Disease
,	O
and	O
retarded	O
progression	O
of	O
nephropathy	Disease
.	O
CONCLUSIONS:	O
EndoMT	O
is	O
a	O
novel	O
pathway	O
leading	O
to	O
early	O
development	O
of	O
diabetic	Disease
nephropathy	Disease
.	O
Blockade	O
of	O
EndoMT	O
by	O
SIS3	O
may	O
provide	O
a	O
new	O
strategy	O
to	O
retard	O
the	O
progression	O
of	O
diabetic	Disease
nephropathy	Disease
and	O
other	O
diabetes	Disease
complications	Disease

Cytostatic	O
and	O
anti-angiogenic	O
effects	O
of	O
temsirolimus	Chemical
in	O
refractory	O
mantle	Disease
cell	Disease
lymphoma	Disease
.	O
Mantle	Disease
cell	Disease
lymphoma	Disease
(	O
MCL	Disease
)	O
is	O
a	O
rare	O
and	O
aggressive	O
type	O
of	O
B-cell	Disease
non-Hodgkin's	Disease
lymphoma	Disease
.	O
Patients	O
become	O
progressively	O
refractory	O
to	O
conventional	O
chemotherapy,	O
and	O
their	O
prognosis	O
is	O
poor.	O
However,	O
a	O
38%	O
remission	O
rate	O
has	O
been	O
recently	O
reported	O
in	O
refractory	O
MCL	Disease
treated	O
with	O
temsirolimus	Chemical
,	O
a	O
mTOR	O
inhibitor.Here	O
we	O
had	O
the	O
opportunity	O
to	O
study	O
a	O
case	O
of	O
refractory	O
MCL	Disease
who	O
had	O
tumor	Disease
regression	O
two	O
months	O
after	O
temsirolimus	Chemical
treatment,	O
and	O
a	O
progression-free	O
survival	O
of	O
10	O
months.	O
In	O
this	O
case,	O
lymph	O
node	O
biopsies	O
were	O
performed	O
before	O
and	O
six	O
months	O
after	O
temsirolimus	Chemical
therapy.	O
Comparison	O
of	O
the	O
two	O
biopsies	O
showed	O
that	O
temsirolimus	Chemical
inhibited	O
tumor	Disease
cell	O
proliferation	O
through	O
cell	O
cycle	O
arrest,	O
but	O
did	O
not	O
induce	O
any	O
change	O
in	O
the	O
number	O
of	O
apoptotic	O
tumor	Disease
cells.	O
Apart	O
from	O
this	O
cytostatic	O
effect,	O
temsirolimus	Chemical
had	O
an	O
antiangiogenic	O
effect	O
with	O
decrease	O
of	O
tumor	Disease
microvessel	O
density	O
and	O
of	O
VEGF	O
expression.	O
Moreover,	O
numerous	O
patchy,	O
well-limited	O
fibrotic	O
areas,	O
compatible	O
with	O
post-	O
necrotic	Disease
tissue	O
repair,	O
were	O
found	O
after	O
6-month	O
temsirolimus	Chemical
therapy.	O
Thus,	O
temsirolimus	Chemical
reduced	O
tumor	Disease
burden	O
through	O
associated	O
cytostatic	O
and	O
anti-angiogenic	O
effects.This	O
dual	O
effect	O
of	O
temsirolimus	Chemical
on	O
tumor	Disease
tissue	O
could	O
contribute	O
to	O
its	O
recently	O
reported	O
efficiency	O
in	O
refractory	O
MCL	Disease

Syncope	Disease
caused	O
by	O
hyperkalemia	Disease
during	O
use	O
of	O
a	O
combined	O
therapy	O
with	O
the	O
angiotensin	Chemical
-converting	O
enzyme	O
inhibitor	O
and	O
spironolactone	Chemical
.	O
A	O
76	O
year-old	O
woman	O
with	O
a	O
history	O
of	O
coronary	O
artery	O
bypass	O
grafting	O
and	O
prior	O
myocardial	Disease
infarction	Disease
was	O
transferred	O
to	O
the	O
emergency	O
room	O
with	O
loss	Disease
of	Disease
consciousness	Disease
due	O
to	O
marked	O
bradycardia	Disease
caused	O
by	O
hyperkalemia	Disease
.	O
The	O
concentration	O
of	O
serum	O
potassium	Chemical
was	O
high,	O
and	O
normal	O
sinus	O
rhythm	O
was	O
restored	O
after	O
correction	O
of	O
the	O
serum	O
potassium	Chemical
level.	O
The	O
cause	O
of	O
hyperkalemia	Disease
was	O
considered	O
to	O
be	O
several	O
doses	O
of	O
spiranolactone	Chemical
,	O
an	O
aldosterone	Chemical
antagonist,	O
in	O
addition	O
to	O
the	O
long-term	O
intake	O
of	O
ramipril	Chemical
,	O
an	O
ACE	O
inhibitor.	O
This	O
case	O
is	O
a	O
good	O
example	O
of	O
electrolyte	O
imbalance	O
causing	O
acute	O
life-threatening	O
cardiac	O
events.	O
Clinicians	O
should	O
be	O
alert	O
to	O
the	O
possibility	O
of	O
hyperkalemia	Disease
,	O
especially	O
in	O
elderly	O
patients	O
using	O
ACE/ARB	O
in	O
combination	O
with	O
potassium	Chemical
sparing	O
agents	O
and	O
who	O
have	O
mild	O
renal	Disease
disturbance	Disease

Diffuse	O
skeletal	O
pain	Disease
after	O
administration	O
of	O
alendronate	Chemical
.	O
BACKGROUND:	O
Osteoporosis	Disease
is	O
caused	O
by	O
bone	O
resorption	O
in	O
excess	O
of	O
bone	O
formation,	O
and	O
bisphosphonates	Chemical
,	O
are	O
used	O
to	O
inhibit	O
bone	O
resorption.	O
Alendronate	Chemical
,	O
a	O
biphosphonate	Chemical
,	O
is	O
effective	O
for	O
both	O
the	O
treatment	O
and	O
prevention	O
of	O
osteoporosis	Disease
in	O
postmenopausal	O
women.	O
Side	O
effects	O
are	O
relatively	O
few	O
and	O
prominently	O
gastrointestinal.	O
Musculoskeletal	Disease
pain	Disease
may	O
be	O
an	O
important	O
side	O
effect	O
in	O
these	O
patients.	O
We	O
presented	O
a	O
patient	O
admitted	O
to	O
our	O
out-patient	O
clinic	O
with	O
diffuse	O
skeletal	O
pain	Disease
after	O
three	O
consecutive	O
administration	O
of	O
alendronate	Chemical
.	O
CONCLUSION:	O
We	O
conclude	O
that	O
patients	O
with	O
osteoporosis	Disease
can	O
report	O
pain	Disease
,	O
and	O
bisphosphonate	Chemical
-related	O
pain	Disease
should	O
also	O
be	O
considered	O
before	O
ascribing	O
this	O
complaint	O
to	O
osteoporosis	Disease

Cerebrospinal	O
fluid	O
penetration	O
of	O
high-dose	O
daptomycin	Chemical
in	O
suspected	O
Staphylococcus	O
aureus	O
meningitis	Disease
.	O
OBJECTIVE:	O
To	O
report	O
a	O
case	O
of	O
methicillin	Chemical
-sensitive	O
Staphylococcus	O
aureus	O
(MSSA)	O
bacteremia	Disease
with	O
suspected	O
MSSA	O
meningitis	Disease
treated	O
with	O
high-dose	O
daptomycin	Chemical
assessed	O
with	O
concurrent	O
serum	O
and	O
cerebrospinal	O
fluid	O
(CSF)	O
concentrations.	O
CASE	O
SUMMARY:	O
A	O
54-year-old	O
male	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
generalized	O
weakness	Disease
and	O
presumed	O
health-care-associated	O
pneumonia	Disease
shown	O
on	O
chest	O
radiograph.	O
Treatment	O
was	O
empirically	O
initiated	O
with	O
vancomycin	Chemical
,	O
levofloxacin	Chemical
,	O
and	O
piperacillin	Chemical
/	O
tazobactam	Chemical
.	O
Blood	O
cultures	O
revealed	O
S.	O
aureus	O
susceptible	O
to	O
oxacillin	Chemical
.	O
Empiric	O
antibiotic	O
treatment	O
was	O
narrowed	O
to	O
nafcillin	Chemical
on	O
day	O
4.	O
On	O
day	O
8,	O
the	O
patient	O
developed	O
acute	Disease
renal	Disease
failure	Disease
(serum	O
creatinine	Chemical
1.9	O
mg/dL,	O
increased	O
from	O
1.2	O
mg/dL	O
the	O
previous	O
day	O
and	O
0.8	O
mg/dL	O
on	O
admission).	O
The	O
patient's	O
Glasgow	O
Coma	O
Score	O
was	O
3,	O
with	O
normal	O
findings	O
shown	O
on	O
computed	O
tomography	O
scan	O
of	O
the	O
head	O
72	O
hours	O
following	O
an	O
episode	O
of	O
cardiac	Disease
arrest	Disease
on	O
day	O
10.	O
The	O
patient	O
experienced	O
relapsing	O
MSSA	O
bacteremia	Disease
on	O
day	O
9,	O
increasing	O
the	O
suspicion	O
for	O
a	O
central	O
nervous	O
system	O
(CNS)	O
infection	Disease
.	O
Nafcillin	Chemical
was	O
discontinued	O
and	O
daptomycin	Chemical
9	O
mg/kg	O
daily	O
was	O
initiated	O
for	O
suspected	O
meningitis	Disease
and	O
was	O
continued	O
until	O
the	O
patient's	O
death	O
on	O
day	O
16.	O
Daptomycin	Chemical
serum	O
and	O
CSF	O
trough	O
concentrations	O
were	O
11.21	O
ug/mL	O
and	O
0.52	O
ug/mL,	O
respectively,	O
prior	O
to	O
the	O
third	O
dose.	O
Lumbar	O
puncture	O
results	O
were	O
inconclusive	O
and	O
no	O
further	O
blood	O
cultures	O
were	O
positive	O
for	O
MSSA.	O
Creatine	Chemical
kinase	O
levels	O
were	O
normal	O
prior	O
to	O
daptomycin	Chemical
therapy	O
and	O
were	O
not	O
reassessed.	O
DISCUSSION:	O
Daptomycin	Chemical
was	O
initiated	O
in	O
our	O
patient	O
secondary	O
to	O
possible	O
nafcillin	Chemical
-induced	O
acute	O
interstitial	Disease
nephritis	Disease
and	O
relapsing	O
bacteremia	Disease
.	O
At	O
a	O
dose	O
of	O
9	O
mg/kg,	O
resultant	O
penetration	O
of	O
5%	O
was	O
higher	O
than	O
in	O
previous	O
reports,	O
more	O
consistent	O
with	O
inflamed	O
meninges.	O
CONCLUSIONS:	O
High-dose	O
daptomycin	Chemical
may	O
be	O
an	O
alternative	O
option	O
for	O
MSSA	O
bacteremia	Disease
with	O
or	O
without	O
a	O
CNS	O
source	O
in	O
patients	O
who	O
have	O
failed	O
or	O
cannot	O
tolerate	O
standard	O
therapy.	O
Further	O
clinical	O
evaluation	O
in	O
patients	O
with	O
confirmed	O
meningitis	Disease

The	O
role	O
of	O
nitric	Chemical
oxide	Chemical
in	O
convulsions	Disease
induced	O
by	O
lindane	Chemical
in	O
rats.	O
Lindane	Chemical
is	O
an	O
organochloride	O
pesticide	O
and	O
scabicide.	O
It	O
evokes	O
convulsions	Disease
mainly	O
trough	O
the	O
blockage	O
of	O
GABA	Chemical
(A)	O
receptors.	O
Nitric	Chemical
oxide	Chemical
(	O
NO	Chemical
),	O
gaseous	O
neurotransmitter,	O
has	O
contradictor	O
role	O
in	O
epileptogenesis	O
due	O
to	O
opposite	O
effects	O
of	O
L-arginine	Chemical
,	O
precursor	O
of	O
NO	Chemical
syntheses	O
(NOS),	O
and	O
L-NAME	Chemical
(NOS	O
inhibitor)	O
observed	O
in	O
different	O
epilepsy	Disease
models.	O
The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
determine	O
the	O
effects	O
of	O
NO	Chemical
on	O
the	O
behavioral	O
and	O
EEG	O
characteristics	O
of	O
lindane	Chemical
-induced	O
epilepsy	Disease
in	O
male	O
Wistar	O
albino	O
rats.	O
The	O
administration	O
of	O
L-arginine	Chemical
(600,	O
800	O
and	O
1000	O
mg/kg,	O
i.p.)	O
in	O
dose-dependent	O
manner	O
significantly	O
increased	O
convulsion	Disease
incidence	O
and	O
severity	O
and	O
shortened	O
latency	O
time	O
to	O
first	O
convulsion	Disease
elicited	O
by	O
lower	O
lindane	Chemical
dose	O
(4	O
mg/kg,	O
i.p.).	O
On	O
the	O
contrary,	O
pretreatment	O
with	O
L-NAME	Chemical
(500,	O
700	O
and	O
900	O
mg/kg,	O
i.p.)	O
decreased	O
convulsion	Disease
incidence	O
and	O
severity	O
and	O
prolonged	O
latency	O
time	O
to	O
convulsion	Disease
following	O
injection	O
with	O
a	O
convulsive	Disease
dose	O
of	O
lindane	Chemical
(8	O
mg/kg,	O
i.p.).	O
EEG	O
analyses	O
showed	O
increase	O
of	O
number	O
and	O
duration	O
of	O
ictal	O
periods	O
in	O
EEG	O
of	O
rats	O
receiving	O
l-arginine	Chemical
prior	O
to	O
lindane	Chemical
and	O
decrease	O
of	O
this	O
number	O
in	O
rats	O
pretreated	O
with	O
L-NAME	Chemical
.	O
These	O
results	O
support	O
the	O
conclusion	O
that	O
NO	Chemical
plays	O
a	O
role	O
of	O
endogenous	O
convulsant	O
in	O
rat	O
model	O
of	O
lindane	Chemical
	O
seizures	Disease

Long-term	O
oral	O
galactose	Chemical
treatment	O
prevents	O
cognitive	Disease
deficits	Disease
in	O
male	O
Wistar	O
rats	O
treated	O
intracerebroventricularly	O
with	O
streptozotocin	Chemical
.	O
Basic	O
and	O
clinical	O
research	O
has	O
demonstrated	O
that	O
dementia	Disease
of	O
sporadic	O
Alzheimer's	Disease
disease	Disease
(sAD)	O
type	O
is	O
associated	O
with	O
dysfunction	O
of	O
the	O
insulin-receptor	O
(IR)	O
system	O
followed	O
by	O
decreased	O
glucose	Chemical
transport	O
via	O
glucose	Chemical
transporter	O
GLUT4	O
and	O
decreased	O
glucose	Chemical
metabolism	O
in	O
brain	O
cells.	O
An	O
alternative	O
source	O
of	O
energy	O
is	O
d-galactose	Chemical
(the	O
C-4-epimer	O
of	O
d-glucose	Chemical
)	O
which	O
is	O
transported	O
into	O
the	O
brain	O
by	O
insulin-independent	O
GLUT3	O
transporter	O
where	O
it	O
might	O
be	O
metabolized	O
to	O
glucose	Chemical
via	O
the	O
Leloir	O
pathway.	O
Exclusively	O
parenteral	O
daily	O
injections	O
of	O
galactose	Chemical
induce	O
memory	Disease
deterioration	Disease
in	O
rodents	O
and	O
are	O
used	O
to	O
generate	O
animal	O
aging	O
model,	O
but	O
the	O
effects	O
of	O
oral	O
galactose	Chemical
treatment	O
on	O
cognitive	O
functions	O
have	O
never	O
been	O
tested.	O
We	O
have	O
investigated	O
the	O
effects	O
of	O
continuous	O
daily	O
oral	O
galactose	Chemical
(200	O
mg/kg/day)	O
treatment	O
on	O
cognitive	Disease
deficits	Disease
in	O
streptozotocin	Chemical
-induced	O
(	O
STZ	Chemical
-icv)	O
rat	O
model	O
of	O
sAD,	O
tested	O
by	O
Morris	O
Water	O
Maze	O
and	O
Passive	O
Avoidance	O
test,	O
respectively.	O
One	O
month	O
of	O
oral	O
galactose	Chemical
treatment	O
initiated	O
immediately	O
after	O
the	O
STZ	Chemical
-icv	O
administration,	O
successfully	O
prevented	O
development	O
of	O
the	O
STZ	Chemical
-icv-induced	O
cognitive	Disease
deficits	Disease
.	O
Beneficial	O
effect	O
of	O
oral	O
galactose	Chemical
was	O
independent	O
of	O
the	O
rat	O
age	O
and	O
of	O
the	O
galactose	Chemical
dose	O
ranging	O
from	O
100	O
to	O
300	O
mg/kg/day.	O
Additionally,	O
oral	O
galactose	Chemical
administration	O
led	O
to	O
the	O
appearance	O
of	O
galactose	Chemical
in	O
the	O
blood.	O
The	O
increase	O
of	O
galactose	Chemical
concentration	O
in	O
the	O
cerebrospinal	O
fluid	O
was	O
several	O
times	O
lower	O
after	O
oral	O
than	O
after	O
parenteral	O
administration	O
of	O
the	O
same	O
galactose	Chemical
dose.	O
Oral	O
galactose	Chemical
exposure	O
might	O
have	O
beneficial	O
effects	O
on	O
learning	O
and	O
memory	O
ability	O
and	O
could	O
be	O
worth	O
investigating	O
for	O
improvement	O
of	O
cognitive	Disease
deficits	Disease
associated	O
with	O
glucose	Disease
hypometabolism	Disease
in	O
AD	Disease

